human leukaemic k562 cell line induce vitro undergo erythroid differentiation variety chemical compound include haemin butyric acid 5-azacytidine cytosine arabinoside differentiation k562 cell associate increase expression embryo-fetal globin gene zeta epsilon gamma globin gene therefore k562 cell line propose useful vitro model system determine therapeutic potential new differentiate compound well study molecular mechanism s regulate change expression embryonic fetal human globin gene inducer erythroid differentiation stimulate gamma-globin synthesis consider possible use experimental therapy haematological disease associate failure expression adult beta-globin gene paper demonstrate g c selective dna-binding drug chromomycin mithramycin powerful inducer erythroid differentiation k562 cell erythroid differentiation associate increase accumulation hb gower 1 hb portland b gamma-globin mrna 
order elucidate role dna topoisomerase ii topo ii subtype alpha beta drug target chemotherapy determine enzyme level k562 cell select resistance mitoxantrone k562/mxn daunorubicin k562/dnr idarubicin k562/ida 20 k562/ida 60 well topo ii-dna complex formation dna damage cytotoxicity induce topo ii interactive agent example etoposide teniposide mitoxantrone amsacrine compare parental cell topo iialpha/beta protein level k562/mxn k562/dnr k562/ida 20 60 line measure western blot 17/67 85/88 24/31 10/7 respectively dna damage determine dna unwind technique induce teniposide amsacrine correlate topo iialpha/beta protein level r2 = 0.8 / 0.9 p = 0.03 / 0.01 r2 = 0.8 / 0.9 p = 0.04 / 0.01 respectively topo ii-dna complex formation induce study drug correlate topo iibeta protein level r2-range 0.8-0.9 p-range 0.01-0.04 correlation topo iialpha weaker topo iialpha/beta protein level tend show inverse correlation cytotoxicity etoposide r2 = -0.9 / -0.7 p = 0.01 / 0.06 overall topo ii-dna complex formation correlate drug-induced dna damage r2 = 0.9 p = 0.0001 whilst cytotoxicity finding indicate topo ii isozyme target antitumor agent study potential clinical relevance prediction treatment efficacy play role tailor chemotherapy 
background combination paclitaxel cisplatin standard patient newly diagnose epithelial ovarian carcinoma role another taxane docetaxel currently study due milder nonhematologic toxicity carboplatin increasingly substitute cisplatin taxane-based combination purpose study compare combination carboplatin-paclitaxel carboplatin-docetaxel ovarian carcinoma vitro assess type interaction method sensitivity carboplatin concomitant use taxane carboplatin study 4 ovarian carcinoma cell line use 96-well plate clonogenic assay chemosensitivity express ic50 value i.e. drug concentration cause 50 inhibition clonogenic survival ic50 value obtain dose-response curve fitting datum linear quadratic equation synergism study area survival curve ratio auc ratio obtain numeric integration auc ratio survive fraction sf value administration taxane alone compare use student t test paired datum result ic50 value carboplatin 0.5-1.6 microgram/ml 3.2-fold difference individual cell line carboplatin administer concomitantly taxane either additive supra-additive growth inhibitory effect four ovarian carcinoma cell line supra-additive effect occur simultaneous exposure cell carboplatin test paclitaxel concentration three four cell line ut-oc-3 ut-oc-5 sk-ov-3 carboplatin-docetaxel combination supra-additive effect two highest docetaxel concentration two cell line ut-oc-4 ut-oc-5 highest docetaxel concentration two cell line ut-oc-3 sk-ov-3 conclusion carboplatin synergistic effect use paclitaxel docetaxel supra-additive effect achieve wider range paclitaxel concentration docetaxel concentration 
investigate capacity 1,25-dihydroxyvitamin d3 1,25 oh 2d3 all-trans-retinoic acid atra sensitize three breast cancer cell line cell killing effect paclitaxel taxol adriamycin two chemotherapeutic agent commonly use treatment breast cancer tissue culture colony assay 1,25 oh 2d3 atra synergistic inhibit clonogenicity mcf-7 t-47d cell express estrogen receptor vitamin d receptor retinoic acid receptor rar alpha beta gamma retinoid x receptor alpha beta gamma additive mda-mb-231 cell lack expression estrogen receptor raralpha rarbeta hormone use individually combination induce 40-50 cell death trypan blue exclusion assay dose-dependent manner concentration 10 -7 m mcf-7 t-47d cell modestly mda-mb-231 cell mcf-10 mcf-12 nontransformed mammary epithelial cell pretreat cancer cell line 1,25 oh 2d3 atra individually combination 3 day prior 1-h incubation paclitaxel adriamycin decrease ed50 inhibition colony formation cell death trypan blue 2 log paclitaxel 1 log adriamycin three cell line effect chemotherapy-induced mcf-12 cell death effect hormone synergistic chemotherapy agent breast cancer cell line generally higher concentration cell death take place apoptosis determine one potential reason greater potentiation effect paclitaxel adriamycin determine effect preincubation mcf-7 cell paclitaxel-induced phosphorylation bcl-2 pretreatment mcf-7 cell either 1,25 oh 2d3 atra increase phosphorylation bcl-2 variable concentration paclitaxel datum suggest pretreatment breast cancer 1,25 oh 2d3 atra lower threshold cell killing chemotherapy agent may provide novel treatment option disease 
earlier study laboratory show uricosuric agent probenecid pbcd will inhibit extrusion folate analogue tumor cell mediate plasma membrane atpase resemble canicular multispecific organic anion transporter/multidrug resistance-related protein mrp family atp binding cassette transporter inhibition outwardly direct membrane atpase show favorable impact upon cellular pharmacokinetic cytotoxicity efficacy methotrexate vivo extension earlier study focus murine ascite tumor now report parental co-administration pbcd will also enhance net intracellular accumulation vitro intracellular persistence vivo new folate analogue 10-propargyl-10-deazaaminopterin pdx tumor cell result marked enhancement efficacy pdx murine human lung neoplasm human prostate mammary neoplasm grow solid tumor mouse possible atpase target pbcd tumor express mrp-1 -4 -7 gene expression mrp-4 greatest case four mrp gene express variable extent tumor therapeutic enhancement pdx pbcd manifest tumor regression pdx alone growth inhibitory a549 nscl tumor substantial increase 3-4-fold overall regression and/or number complete regression lewis lx-1 lung pc-3 tsu-pr1 prostate mx-1 mammary tumor compare pdx alone also case pdx pbcd significant number mouse transplant lx-1 mx-1 tumor experience complete regression regrowth tumor view result clinical trial therapeutic modality appear warrant especially case new efficacious folate analogue also permeant canicular multispecific organic anion transporter/mrp-like plasma membrane atpase 
investigate whether low-dose anticancer agent increase sensitivity ovarian adenocarcinoma cell line skov3 lymphokine activate killer cell lak skov3 cell pretreat low dose anticancer agent taxol cis-diamminedichloroplatin cddp 5-fluorouracilum 5-fu 18 hour sensitivity skov3 lak detect four 51cr release assay percentage skov3 adhesion lak intercellular adhesion molecule-1 icam-1 expression skov3 detect improve grimm assay facs respectively pretreatment skov3 cell 1.5 micrograms/ml taxol 4 micrograms/ml cddp 25 micrograms/ml 5-fu without anticancer agent control 18 hour cytotoxicity interleukin-2 activate lak 29.7 45.9 37.2 28.5 respectively conjugation rate skov3 lak 20.1 26.1 24.9 18.7 respectively positive rate icam-1 expression 52.5 65.5 68.1 49.7 respectively cddp 5-fu increase icam-1 expression significantly sensitivity skov3 cell lak cell lysis well related icam-1 expression result indicate low dose anticancer agent increase sensitivity cancer cell lak cell useful clinical practice 
report trans retinoic acid atra enhance toxicity docetaxel du145 lncap prostate cancer cell nature interaction atra docetaxel highly synergistic docetaxel-induced apoptotic cell death associate phosphorylation hence inactivation bcl-2 atra enhance docetaxel-induced apoptosis combined treatment atra docetaxel result down-regulation bcl-2 docetaxel cause phosphorylation hence inactivation cdc2 kinase result ing g2/m arrest atra inhibit docetaxel-induced phosphorylation cdc2 result activation cdc2 kinase partial reversal g2/m arrest atra also inhibit docetaxel-induced activation mapk indicate effect docetaxel atra cdc2 phosphorylation dependent mapk conclude atra synergistically enhance docetaxel toxicity down-regulating bcl-2 expression partially reverse docetaxel-induced g2/m arrest inhibit docetaxel-induced cdc2 phosphorylation pathway dependent mapk 
death ligand cd95 ligand cd95l tumor necrosis factor-related apoptosis-inducing ligand/apo2 ligand trail/apo2l induce apoptosis radiochemotherapy-resistant human malignant glioma cell line death-signaling trail receptor 2 trail-r2 / death receptor dr 5 trail-r1 / dr4 express abundantly non-death-inducing decoy receptor trail-r3 / dcr1 trail-r4 / dcr2 12 human glioma cell line four 12 cell line trail/apo2l-sensitive absence protein synthesis inhibitor cycloheximide chx three 12 cell line still trail/apo2l-resistant presence chx trail-r2 expression predict sensitivity apoptosis coexposure trail/apo2l cytotoxic drug topotecan lomustine 1 2-chloroethyl -3-cyclohexyl-1-nitrosourea ccnu temozolomide result synergistic killing synergistic killing often observe cell line retain wild-type p53 activity u87mg ln-229 p53 mutant cell line ln-18 t98g u373mg drug exposure result enhance trail-r2 expression decrease trail-r4 expression u87mg cell ectopic expression dominant-negative p53 v135a abrogate drug-induced change trail-r2 trail-r4 expression effect synergy thus neither wild-type p53 function change trail receptor expression require synergy contrast synergy result possibly drug-induced cytochrome c release mitochondria serve amplifier trail/apo2l-mediated cascade caspase activation datum provide novel insight role trail/apo2l system malignant glioma illustrate trail/apo2l-based immunochemotherapy may effective therapeutic strategy lethal neoplasm 
antitumor cryptophycin synthetic derivative desipeptide cryptophycin isolate cyanobacterium nostoc sp. cryptophycin 52 currently clinical trial solid tumor prepare total synthesis four key fragment couple form final product mechanism anticancer activity cryptophycin associate destabilization microtubule induction bcl-2 phosphorylation lead apoptosis cryptophycin maintain activity ovarian breast carcinoma cell overexpress multidrug resistance efflux pump p-glycoprotein cryptophycin 52 demonstrate broad range antitumor activity murine human tumor human mx-1 breast carcinoma xenograft cryptophycin 55 produce greater-than additive tumor response combination 5-fluorouracil human non-small cell lung carcinoma human small cell carcinoma xenograft administration cryptophycin along gemcitabine cisplatin carboplatin result antitumor activity greater either agent alone cryptophycin appear additive fractionate radiation therapy human h460 non-small cell lung carcinoma human hct116 colon carcinoma cryptophycin result greater additive tumor response administer sequentially 5-fluorouracil irinotecan treatment animal bear intraperitoneal human ovcar-2 ovarian carcinoma cryptophycin 52 result survival time greater achieve docetaxel paclitaxel cryptophycin 52 currently early clinical testing 
purpose investigation compare antitumor activity series acyl derivative 4-demethylpenclomedine dm-pen major plasma metabolite penclomedine pen observe active antitumor agent vivo non-neurotoxic rat model dm-pen acyl derivative prepare dm-pen evaluate vivo human mx-1 breast tumor xenograft implant subcutaneously s.c. intracerebrally i.c. several derivative also evaluate human tumor xenograft murine p388 leukemia cell line several acyl derivative find superior dm-pen mx-1 human zr-75-1 breast tumor human u251 cns tumor p388 leukemia parent cell line line resistant cyclophosphamide carmustine 4-demethyl-4-methoxyacetylpenclomedine show inferior activity current clinical brain tumor drug glioma cell line superior activity temozolomide procarbazine derive mismatch repair-deficient cell line superior activity cyclophosphamide carmustine inferior activity temozolomide two ependymoma cell line implant s.c. propose mechanism activation action dm-pen acyl derivative support potential clinical superiority acyl derivative 
work three human cell line multidrug resistance mdr cause p-glycoprotein pgp overexpression cem vlb hl60 dnr lovo dx two cell line mdr associate multidrug related protein mrp lung resistance-related protein lrp overexpression name glc4 adr sw1573/2r120 test amifostine protection daunorubicin doxorubicin idarubicin mitoxantrone toxicity class anticancer agent choose commonly use first line treatment acute leukemia pgp lrp mrp overexpression often occur even onset 7-day incubation escalate dose anticancer agent without 15 minute preincubation amifostine active metabolite wr-1065 use conclusion none mdr positive negative cell line amifostine modify toxicity anticancer drug observation even wr-1065 metabolite give protection anthracycline toxicity strengthen datum provide confirmation vivo testing safety efficacy amifostine leukemia 
chemotherapy often use primary therapy metastatic cancer kill cell en masse however high dose chemotherapeutic drug cause toxicity nontarget organ gene therapy may provide better alternative chemotherapy targeting specific gene may reduce undesirable toxicity associate chemotherapy evaluate whether chemotherapeutic agent docetaxel paclitaxel may combine gene therapy create new therapeutic regimen metastatic androgen independent prostate cancer 2 androgen independent prostate cancer cell line pc-3 du 145 treat docetaxel paclitaxel three recombinant adenovirus contain p21waf-1 / cip1 p53 protein beta-galactosidase complementary dna control cytomegalovirus promoter use determine transgene expression evaluate western blot analysis beta-galactosidase activity vitro growth assay 3 h label e1 delete adenovirus dl312 use determine adenovirus uptake cell docetaxel paclitaxel enhance adenovirus mediated transgene expression docetaxel appear potent growth inhibitor vitro elevated transgene expression virus infected cell induce 2 drug produce increase cytomegalovirus promoter activity rather increase virus uptake potential synergy gene therapy docetaxel paclitaxel may important direction future therapy metastatic androgen independent prostate cancer 
therapy prostate cancer pc3 tumor-nude mouse model 90yttrium 90y dota-peptide-chl6 5.55 mbq 150 microci result durable response make radioimmunotherapy rit effective radiation-enhancing drug taxol paclitaxel taxotere docetaxel test synergy 90y-dota-peptide-chl6 nude mouse bear human prostate cancer pc3 xenograft treat 90y-dota-peptide-chl6 2.78 mbq 75 microci 24 hr paclitaxel 300 600 microg docetaxel 300 microg tumor size survival blood count pharmacokinetic monitor assess efficacy toxicity docetaxel plus rit 67 cure rate whereas mouse cure among rit alone chemotherapy alone untreated control paclitaxel 600 microg plus rit produce 100 response rate 20 cure average tumor volume reduce greater degree combined modality radioimmunotherapy cmrit group compare control anti-tumor response durable myelotoxicity combined modality group rit plus paclitaxel rit plus docetaxel similar group receive dose rit alone pc3-tumor nude mouse model addition paclitaxel docetaxel 90y-dota-peptide-chl6 dose clinically achievable human provide therapeutic synergy without increase excessive toxicity 
recent advance chemotherapy focus benefit high dose regimen increase dose intensity conventional chemotherapy however unacceptable cytotoxicity genotoxicity normal cell often impair proper management patient phosphoaminothiol wr-1065 active metabolite amifostine appear protect normal cell tissue cytotoxic exposure radiation chemotherapeutic agent nevertheless disagreement finding amifostine protection bleomycin-induced severe side effect suggest amifostine effectiveness bleomycin-induced genotoxicity normal leukocyte tumour line cell k562 study dna damage detect single cell gel electrophoresis comet assay technique able detect dna strand break alkali-labile site incomplete excision repair event individual cell appear ideal tool assess variability response different cell type vitro wr-2721 appear selectively protect healthy leukocyte k562 tumoral cell hand datum inter intra-individual sensitivity bleomycin amifostine suggest individual metabolic/genetic difference factor relate lifestyle may responsible response variability application comet assay appropriate clinical setting test sensitivity patient undergo chemotherapy appear possible 
establishment two new breast cancer cell line mxt mxt derive murine breast cancer model mxt-m-3 2 mc hormone-sensitive mxt-m-3 2 ovex mc hormone-insensitive describe characterization cell line perform investigation morphology steroid hormone receptor state growth kinetics drug response well cytogenetic analysis mxt contain estrogen receptor er 6.9 fmol/mg protein well progesterone receptor pgr 9.2 fmol/mg protein therefore inhibit tamoxifen tam mxt prove er pgr 23.4 fmol/mg protein expect resistant tam.the sensitivity mxt mxt pattern therapeutically establish anti-breast cancer drug cddp cisplatin jm-8 carboplatin dx adriamycin 5-fu 5-fluorouracil mtx methotrexate vlb vinblastine study use computerized kinetic chemosensitivity assay base quantification biomass staining cell crystal violet compound inhibition profile reflect cytostatic transient cytotoxic cytocidal drug effect well development resistance evaluate follow order activity find mtx vlb / = dx cddp / = 5-fu jm-8 test datum 5-fu vlb cddp tam mxt well mxt compare study er er human breast cancer cell line mcf-7 zr-75-1 t-47-d mda-mb-231 respectively reveal comparable inhibition profile sensitivity human murine breast cancer cell line indication result achieve combine vitro / vivo test use murine test model mxt mxt mxt-m-3 2 mc mxt-m-3 2 ovex mc relevant therapy human 
oxysterol compose large class natural substance endow number case marked antiproliferative cytotoxic activity consequence treatment combine 7beta-hydroxycholesterol 7beta-ohc xg-142 galactose-linked hydrosoluble derivative 7beta-ohc drug use cancer chemotherapy gamma radiation evaluate upon variety tumor cell line hep-g2 u937 k562 cell adriamycin-resistant variant k562 adr rdm4 proliferation assess uptiblue assay 3h thymidine incorporation test result indicate 7beta-ohc increase sensitivity tumor cell adriamycin vp-16 5-fu bleomycin various degree 7beta-ohc find reinforce susceptibility k562 adriamycin-resistant cell drug rdm4 cell enhance radiosensitivity 7beta-ohc also obtain whereas xg-142 less efficient provoke effect 
ability o 6 benzylguanine bg inactivate alkyltransferase agt potentiate antitumor efficacy 1,3-bis 2-chloroethyl -1-nitrosourea bcnu test clinical trial now example acquire resistance bg+bcnu clinical setting however hypothesize genetically unstable tumor might develop resistance combination repeat drug-exposure achieve therapeutic efficacy evaluate possibility treat three colon cancer cell line either proficient mismatch repair mmr sw480 mmr wild type deficient mmr hct116 hmlh1 mutant hct15 hmsh6 mutant three cycle bg+bcnu drug-treatment hct116 hct15 completely resistant bg-potentiated cytotoxicity bcnu two cell line acquire bg resistance result two de novo different mutation amino acid 165 agt 165-lysine k glutamic acid e k165e hct116 165-lysine asparagine n k165n hct15 k165-mutated agt markedly decrease enzymatic activity unstable agt protein remarkably resistant bg inactivation fish analysis show one copy mgmt gene exist hct116 cell status promoter methylation mgmt hct15 show one allele mgmt promoter aberrant methylation thus mgmt gene express agt either one copy hct116 unmethylated allele hct15 mutate exposure bg+bcnu two mmr-deficient cell line conversely mmr-proficient sw480 cell treat three cycle bg+bcnu maintain wt agt sensitivity bg-potentiated bcnu-cytotoxicity confirm k165-mutated agt protein responsible resistance bg+bcnu transfect k165e k165n mgmt cdna chinese hampster ovary cho cell transfect cho cell low agt activity increase ic 50 either bcnu temozolomide tmz compare parental cho cell bg potentiate cytotoxicity two alkylating agent concentration 200 microm contrast bg 25 microm sensitize cho-agt transfect wt mgmt cdna cell bcnu tmz-cytotoxicity 3-4 fold result suggest k165 agt mutant arise mmr-deficient tumor cell treatment chemotherapeutic agent resistant bg-inactivation active repair alkylate dna adduct 
establishment two new breast cancer cell line mxt mxt derive murine breast cancer model mxt-m-3,2 mc hormone-sensitive mxt-m-3,2 ovex mc hormone-insensitive describe characterization cell line perform investigation morphology steroid hormone receptor state growth kinetics drug response well cytogenetic analysis mxt contain estrogen receptor er 6.9 fmol/mg protein well progesterone receptor pgr 9.2 fmol/mg protein therefore inhibit tamoxifen tam mxt prove er pgr 23.4 fmol/mg protein expect resistant tam sensitivity mxt mxt pattern therapeutically establish anti-breast cancer drug cddp cisplatin jm-8 carboplatin dx adriamycin 5-fu 5-fluorouracil mtx methotrexate vlb vinblastine study use computerized kinetic chemosensitivity assay base quantification biomass staining cell crystal violet compound inhibition profile reflect cytostatic transient cytotoxic cytocidal drug effect well development resistance evaluate follow order activity find mtx vlb = dx cddp = 5-fu jm-8 test datum 5-fu vlb cddp tam mxt well mxt compare study er er human breast cancer cell line mcf-7 zr-75-1 t-47-d mda-mb-231 respectively reveal comparable inhibition profile sensitivity human murine breast cancer cell line indication result achieve combine vitro / vivo test use murine test model mxt mxt mxt-m-3,2 mc mxt-m-3,2 ovex mc relevant therapy human 
evaluate vitro effect paclitaxel docetaxel pc-3 du-145 prostate cancer cell line understand better downstream event drug-induced tumor cell death taxane treatment du-145 cell induce rapid cell death apoptosis pc-3 cell treatment achieve growth arrest follow extensive karyokinesis result multinucleation giant-cell formation delay cell death determine giant multinucleated cell able produce proliferate drug-resistant survivor first delineate kinetics drug activity cytotoxic dose range analysis line colorimetric cell viability assay demonstrate improve cytotoxicity taxane apply continuously select dose schedule docetaxel use induce giant multinucleated cell give rise docetaxel-resistant survivor remain sensitive paclitaxel chemotherapeutic growth morphology recover clone similar parental cell resistant phenotype clone determine immunofluorescence immunoblot associate transient expression beta-tubulin i.v. isoform independent p-glycoprotein bcl-2 bcl-xl resistant clone will useful model progression resistance taxane identify unknown clinically important molecular mechanism cell death resistance 
antitumor activity combination paclitaxel txl follow nedaplatin ndp sk-ov-3 human ovarian cancer evaluate also compare antitumor activity txl plus ndp txl plus carboplatin cbdca txl plus cisplatin cddp txl inject i.v. daily four day either ndp cbdca cddp inject i.v. txl treatment tumor-bearing mouse sequential administration txl prior ndp result enhance inhibition tumor growth comparison either txl ndp monotherapy combination txl plus ndp synergistic superior txl plus cddp txl plus cbdca therapy histological test demonstrate fraction brdu-incorporated cell tumor tissue significantly inhibit combination txl ndp result demonstrate antitumor efficacy txl ndp human ovarian cancer suggest clinical effectiveness combination txl ndp 
evaluate vitro inhibitory effect cis-diaminechloro 2 diethylamino ethyl 4-amino-benzoate n4 chlorideplatinum ii monohydrochloride monohydrate dpr colony formation granulocyte/macrophage cfu-gm peripheral blood progenitor cell represent method quantitate toxicity drug hematopoietic system human leukemic cell line result compare obtain expose cell cisplatin carboplatin datum show dpr significantly better cytotoxic activity cisplatin carboplatin hl60 k562 carboplatin molt 4 cell show 12 43 time less inhibitory effect cfu-gm cisplatin carboplatin respectively result suggest myelosuppressive activity dpr lower cisplatin carboplatin furthermore leukemic cell represent preferential target cytotoxic activity compare normal committed hemopoietic progenitor cell result speak favor better therapeutic index dpr platinum compound consider 
repopulation survive tumor cell course chemotherapy might lead effective drug resistance study inhibition repopulation hormone-responsive human breast cancer cell line selective estrogen receptor er modulator serm course chemotherapy hormone responsive breast cancer cell line mcf-7 t47d er cell line mda-231 treat either 4-hydroxy tamoxifen 4oht arzoxifene weekly course treatment 5-fluorouracil 5-fu methotrexate mtx clonogenic assay perform determine overall survival tumor cell treatment serm alone one three dose 5-fu mtx alone 5-fu mtx follow serm serm inhibit growth er cell mcf-7 t47d effect er-cell line mda-231 arzoxifene effective 4oht course treatment either 5-fu mtx repopulation er cell specifically inhibit serm whereas repopulation er mda-231 affect arzoxifene 4oht inhibit specifically repopulation er breast cancer cell course chemotherapy scheduling short-acting serm course chemotherapy potential improve therapeutic index 
combination topoisomerase topo inhibitor cpt-11 anti-epidermal growth factor receptor egfr agent gefitinib iressa zd1839 represent promising medical approach colorectal cancer patient report provide pre-clinical evidence optimal combination schedule ht-29 lovo human colon cancer cell line analyze different effect three different combination schedule sn-38 active cpt-11 metabolite gefitinib gefitinib gefitinib simultaneously gefitinib sn-38 cell growth cell cycle apoptosis expression/phosphorylation egfr topo step signal transduction pathway first determine ic 50 drug choose 5 day exposure gefitinib 0.6 3.8 microm lovo ht-29 cell respectively 1 day exposure sn-38 0.31 0.5 microm lovo ht-29 cell respectively different drug combination schedule test various concentration use equiactive concentration two drug cytotoxicity gefitinib sn-38 combination schedule concentration-dependent cell line-specific synergistic schedule gefitinib give sn-38 combination index ci 0.007 0.454 ht-29 lovo respectively analysis bio-molecular target show gefitinib able modulate sn-38 ability inhibit topo accumulate cell s-phase induce apoptosis interestingly sn-38 able activate egfr signal transduction pathway confirm preliminary clinical experience gefitinib cytotoxic drug seem gefitinib sn-38 represent best cytotoxic combination schedule biomolecular basis synergism remain completely elucidate 
selenite frequently use combination cancer chemotherapeutic agent reduce side effect however cytoprotective activity selenite may also reduce efficacy chemotherapeutic drug tumor cell study design examine effect selenite combine cytotoxic agent use clinical protocol e.g. doxorubicine docetaxel 5-fluorouracil 5-fu methotrexate mtx mafosphamide mitomycin c gemcitabine etoposide cisplatin irinotecan oxaliplatin proliferation various carcinoma cell type datum demonstrate selenite marked effect antiproliferative activity docetaxel doxorubicine 5-fu mtx mafosphamide mda-mb-231 breast cancer cell likewise consistent change observe a549 lung cancer cell proliferation selenite combine cisplatin etoposide gemcitabine mitomycin c. hand selenite potentiate cytotoxicity 5-fu oxaliplatin irinotecan hct116 colon cancer cell approx 1.1-fold 2.7-fold 2.6-fold respectively sw620 colon cancer cell selenite induce 1.5-fold 4.3-fold increase antiproliferative activity 5-fu oxaliplatin respectively whereas irinotecan show effect sw620 cell growth combination selenite result 23 inhibition result indicate selenite reduce antiproliferative activity chemotherapeutic agent vitro addition selenite able increase inhibitory activity docetaxel a549 lung cancer cell 5-fu oxaliplatin irinotecan hct116 sw620 colon cancer cell imply selenite potentially useful adjuvant chemotherapeutic agent 
three-dimensional 3-d culture system simulate tumor extracellular microenvironment may appropriate test cancer cell potential invasion tumor cell sensitivity anticancer drug human pc-3 prostate a549 colon ht-29 lung mcf-7 mda-mb231 breast cancer cell embedded grow collagen gel surround fibrin clot increase concentration cisplatin doxorubicin paclitaxel 5-fluorouracil comparatively evaluate ability inhibit tumor cell proliferation colony formation vitro cell except mda form colony collagen pc-3 a549 ht-29 cell massively invade fibrin form migratory front cell colony also form fibrin secondary tumor-like structure apart migratory front ht-29 cell aggressive regard mda cell particularly sensitive doxorubicin mcf-7 cell show sensitivity anticancer regimen test a549 cell tumor cell type greatest potential invasion sensitive mostly cisplatin pc-3 cell primarily sensitive cisplatin doxorubicin ht-29 cell sensitive fluorouracil doxorubicin 3-d collagen cell culture system use study cancer cell potential invasion relative sensitivity/resistance anticancer drug 
breast cancer resistance protein bcrp atp binding cassette transporter confer resistance series anticancer agent 7-ethyl-10-hydroxycamptothecin sn-38 topotecan mitoxantrone study evaluate possible interaction gefitinib selective epidermal growth factor receptor tyrosine kinase inhibitor bcrp bcrp-transduced human epidermoid carcinoma a431 a431/bcrp cell acquire cellular resistance gefitinib suggest bcrp one determinant gefitinib sensitivity certain sort cell next effect gefitinib bcrp-mediated drug resistance examine gefitinib reverse sn-38 resistance bcrp-transduced human myelogenous leukemia k562 k562/bcrp bcrp-transduced murine lymphocytic leukemia p388 p388/bcrp cell parental cell addition gefitinib sensitize human colon cancer ht-29 cell endogenously express bcrp sn-38 gefitinib increase intracellular accumulation topotecan k562/bcrp cell suppress atp-dependent transport estrone 3-sulfate substrate bcrp membrane vesicle k562/bcrp cell result suggest gefitinib may overcome bcrp-mediated drug resistance inhibit pump function bcrp furthermore p388/bcrp-transplanted mouse treat combination irinotecan gefitinib survive significantly longer treat irinotecan alone gefitinib alone conclusion gefitinib show interact bcrp bcrp expression certain sort cell suppose one determinant gefitinib sensitivity gefitinib inhibit transporter function bcrp reverse bcrp-mediated drug resistance vitro vivo 
sigma 1 receptor s1r represent unique drug-binding site distinct receptor examine s1r expression human breast cancer assess activity s1r ligand breast cancer cell line one-hundred nine breast specimen normal breast benign breast disease cancer examine immunohistochemistry rt-pcr six different cell line also evaluate s1r mrna overexpression detect 64 breast cancer compare normal breast tissue immunohistochemistry show positive epithelial cell staining 60 invasive 41 situ cancer 75 ductal hyperplasia 33 normal breast pattern expression diffuse invasive breast carcinoma compare condition p = 0.02 s1r expression neither prognostic predictive factor efficacy adjuvant chemotherapy study include 58 cancer patient therefore statistical power limit mda-mb-361 mda-mb-435 bt20 mcf7 cell express s1r protein western blot non-specific s1r ligand haloperidol reduce haloperidol progesterone produce dose-dependent inhibition growth high 10 microm concentration reduce haloperidol also show additive cytotoxic effect combine doxorubicin vinorelbine paclitaxel docetaxel vitro s1r-specific ligand skf 10047 demonstrate least growth inhibitory activity show interaction chemotherapy result demonstrate normal neoplastic breast epithelial cell cell line commonly express s1r high concentration haloperidol inhibit growth cell potentiate effect chemotherapy vitro 
background platelet-derived growth factor receptor pdfg-r tyrosine kinase express 88 primary prostate cancer 80 metastase tyrosine kinase inhibitor imatinib block pdgf signaling pathway inhibit pdgf-r autophosphorylation examine cytotoxic effect imatinib combination anticancer agent human prostate cancer cell line lncap pc-3 du 145 method cell expose imatinib drug simultaneously 5 day cell growth inhibition determine xtt assay cytotoxic effect combination evaluate inhibitory concentration 50 level isobologram result imatinib produce additive effect estramustine phosphate emp 4-hydroperoxy-cyclophosphamide three cell line combination etoposide imatinib produce additive effect two three cell line imatinib docetaxel produce antagonistic effect pc-3 additive antagonistic effect lncap du 145 cell conclusion simultaneous exposure imatinib emp effective hormone sensitive hormone insensitive cell line combination evaluate clinical trial contrast simultaneous exposure imatinib docetaxel little therapeutic efficacy although gap vitro study clinical trial present finding provide useful information establishment clinical protocol involve imatinib hormone-refractory prostate cancer 
platelet-derived growth factor receptor pdfg-r tyrosine kinase express 88 primary prostate cancer 80 metastase tyrosine kinase inhibitor imatinib block pdgf signaling pathway inhibit pdgf-r autophosphorylation examine cytotoxic effect imatinib combination anticancer agent human prostate cancer cell line lncap pc-3 du 145 cell expose imatinib drug simultaneously 5 day cell growth inhibition determine xtt assay cytotoxic effect combination evaluate inhibitory concentration 50 level isobologram imatinib produce additive effect estramustine phosphate emp 4-hydroperoxy-cyclophosphamide three cell line combination etoposide imatinib produce additive effect two three cell line imatinib docetaxel produce antagonistic effect pc-3 additive antagonistic effect lncap du 145 cell simultaneous exposure imatinib emp effective hormone sensitive hormone insensitive cell line combination evaluate clinical trial contrast simultaneous exposure imatinib docetaxel little therapeutic efficacy although gap vitro study clinical trial present finding provide useful information establishment clinical protocol involve imatinib hormone-refractory prostate cancer 
gefitinib iressa zd1839 orally active selective epidermal growth factor receptor tyrosine kinase inhibitor single agent clinically effective non-small cell lung cancer although gefitinib combine various cytotoxic agent report enhance cytotoxicity vitro mouse model mechanism remain undetermined explore mechanism topoisomerase inhibitor focus efflux pump breast cancer resistance protein bcrp/abcg2 examine whether gefitinib restore drug sensitivity multidrug-resistant cancer cell overexpress bcrp use pc-6 human small cell lung cancer cell multidrug-resistant pc-6 / sn2-5h cell select sn-38 active metabolite irinotecan bcrp-overexpressing mcf-7 / mx cell select mitoxantrone bcrp cdna transfectant mcf-7 / clone 8 cell drug sensitivity anticancer drug determine tetrazolium dye assay intracellular topotecan accumulation facscan topotecan transport study use plasma membrane vesicle pc-6 / sn2-5h cell resistant pc-6 / sn2-5h cell overexpress bcrp epidermal growth factor receptor mrna ten micromole gefitinib reverse topotecan sn-38 mitoxantrone resistance increase intracellular topotecan accumulation resistant cell parental cell furthermore gefitinib inhibit topotecan transport vesicle k value 1.01 / 0.09 micromol/l dixon plot analysis indicate direct inhibition bcrp gefitinib however gefitinib transport vesicle high-performance liquid chromatography method result indicate gefitinib reverse bcrp-mediated drug resistance direct inhibition competitive inhibition bcrp substrate combination gefitinib topoisomerase inhibitor clinically effective cancer express bcrp 
study focus aromatase cytochrome p450 cyp19 expression ovarian epithelial normal cancer cell tissue aromatase mrna expression analyze real-time pcr ovarian epithelial cancer cell line human ovarian surface epithelial hose cell primary culture ovarian tissue specimen n = 94 include normal ovary ovarian cyst cancer aromatase mrna find express hose cell bg1 peo4 peo14 skov3 nih ovcar-3 ovarian cancer cell line correlation analysis aromatase expression perform accord clinical histological biological parameter aromatase expression ovarian tissue specimen higher normal ovary cyst cancer p 0.0001 use laser capture microdissection normal postmenopausal ovary aromatase find predominantly express epithelial cell compare stromal component use immunohistochemistry ihc aromatase also detect epithelium component inverse correlation aromatase eralpha expression ovarian tissue p 0.001 r = -0.34 cancer group significant difference aromatase expression observe accord tumor histotype grade stage survival aromatase activity evaluate ovarian epithelial cancer oec cell line tritiated water assay effect third-generation aromatase inhibitor ai aromatase activity growth study letrozole exemestane able completely inhibit aromatase activity bg1 peo14 cell line interestingly ai show antiproliferative effect estrogen responsive bg1 cell line co-express aromatase eralpha aromatase expression find ovarian epithelial normal tissue ovarian epithelial cancer cell tissue finding raise possibility tumor may respond estrogen provide basis ascertain antimitogenic effect ai subgroup ovarian epithelial cancer 
examine effect aerosolized celecoxib selective cyclooxygenase-2 cox-2 inhibitor vitro cytotoxicity apoptotic response docetaxel human lung carcinoma cell line a549 h460 metered dose inhaler mdi formulation celecoxib prepare evaluate medication delivery aerodynamic property vitro cytotoxicity aerosolized celecoxib-mdi alone combination docetaxel assess use six-stage viable impactor previously establish method induction apoptosis evaluate morphologic examination acridine orange hoechst staining dna fragmentation furthermore attempt identify molecular target involve anticancer mechanism celecoxib docetaxel examine effect expression array marker involve cox-2 dependent independent pathway celecoxib-mdi medication delivery 231.3 microg/shot mass median aerodynamic diameter mmad 1.4 microm gsd = 1.9 respirable fraction 50.7 celecoxib-mdi 2 shot combination docetaxel cell kill high 81.3 67.7 a549 h460 cell respectively hoechst acridine orange staining show enhance induction apoptosis a549 h460 cell expose aerosolized celecoxib docetaxel confirm dna fragmentation western blot analysis show significant reduction cpla2 expression a549 h460 cell treat combination celecoxib docetaxel cox-2 independent pathway significant increase expression ppar-gamma p53 whereas pro-caspase-3 expression significantly decrease may contribute enhance apoptotic response observe combination treatment result suggest aerosolized celecoxib significantly enhance vitro cytotoxicity apoptotic response docetaxel a549 h460 cell enhance activity mediate via alteration expression various molecular target involve apoptosis 
develop evaluate injectable controlled release delivery system phosphorothioate antisense oligonucleotide aso base complex aso chitosan disperse biodegradable polymeric paste intratumoral treatment solid tumor clusterin aso complex chitosan particle incorporate paste base 60:40 blend methoxy-poly ethylene glycol mepeg triblock copolymer poly d l lactic acid-co-caprolactone peg d l lactic acid-co-caprolactone vitro release profile clusterin aso phosphate-buffered saline 37 degree c obtain sink condition assay anionic exchange high-performance liquid chromatography vivo efficacy study carry human prostate pc-3 lncap tumor grow subcutaneously mouse paste formulation clusterin aso without paclitaxel docetaxel inject intratumorally tumor volume serum prostate specific antigen psa level measure control release clusterin aso obtain several week rate extent aso release proportional ratio aso chitosan paste treatment mouse bear pc-3 tumor clusterin aso plus paclitaxel docetaxel paste reduce mean tumor volume greater 50 4 week treatment mouse bear lncap tumor clusterin aso plus paclitaxel reduce mean tumor volume serum psa level 50 70 respectively complexation clusterin aso chitosan incorporation polymeric paste paclitaxel docetaxel produce vitro control release aso vivo efficacy 4 week follow single intratumoral injection solid human prostate tumor mouse 
gefitinib iressa selective epidermal growth factor receptor tyrosine kinase inhibitor use treatment lung cancer recently discover inhibit breast cancer resistance protein atp-binding cassette transporter p-glycoprotein pgp also pump multiple type drug cell use energy generate atp confer multidrug resistance cancer cell study design examine whether gefitinib inhibit function pgp use multidrug resistant pc-6 / ptx lung cancer mcf-7 / adr breast cancer cell overexpress pgp measure drug sensitivity drug-efflux function tetrazolium assay flowcytometry respectively addition drug-stimulated atpase activity pgp measure use insect membrane express human pgp epidermal growth factor receptor express mcf-7 / adr pc-6 / ptx cell overexpression pgp confer resistance gefitinib cell type however clinically achievable level gefitinib moderately reverse pgp-mediated resistance paclitaxel docetaxel pgp overexpress cell addition gefitinib increase intracellular accumulation pgp substrate rhodamine-123 resistant cell activate atpase preparation pure pgp-expressing membrane finding suggest gefitinib directly interact pgp inhibit function gefitinib may clinically inhibit excretion pgp substrate drug include anticancer agent drug-interaction therefore consider 
study investigate effect highly selective cyclooxygenase-2 cox-2 inhibitor celecoxib cytotoxicity docetaxel nude mouse bear a549 tumor xenograft elucidate molecular mechanism antitumor effect combination female nu/nu mouse xenograft s.c. a549 tumor treat either celecoxib 150 mg/kg/day docetaxel 10 mg/kg combination tumor tissue quantify induction apoptosis intratumor levels/expressions prostaglandin e2 pge2 15 deoxy prostaglandin j2 15-d pgj2 microsomal prostaglandin e synthase mpges cytoplasmic phospholipase a2 cpla2 combination celecoxib docetaxel significantly inhibit tumor growth p 0.03 compare celecoxib docetaxel alone decrease level pge2 10-fold increase 15-d pgj2 level 4-fold compare control combination also enhance peroxisome proliferator-activated receptor ppar gamma expression decrease expression cpla2 mpges vascular endothelial growth factor vegf effect expression cox-1 cox-2 tumor tissue tunel staining tumor tissue show marked increase apoptosis combination group compare celecoxib docetaxel-treated group associate increase intratumor p53 expression conclusion combination celecoxib docetaxel produce greater antitumor effect s.c. a549 tumor compare celecoxib docetaxel alone effect associate concomitant alteration intratumor level pge2 15-d pgj2 
resistance tumor classic taxane paclitaxel docetaxel present problem chemotherapy thus new taxane higher antitumor activity resistant tumor synthesize study compare cytotoxicity transport paclitaxel docetaxel novel taxane sb-t-1103 sb-t-1214 sb-t-1216 adriamycin-sensitive mda-mb-435 resistant nci/adr-res human breast cancer cell cell line examine differ adriamycin transport suggest different expression abc membrane transporter reverse transcription-polymerase chain reaction reveal nci/adr-res cell express high level p-glycoprotein mrna absent mda-mb-435 cell opposite true mrp2 mrna cell line share differently express eight abc transporter lrp nci/adr-res cell 1,000-fold resistant paclitaxel 600-fold resistant docetaxel mtt assay mda-mb-435 cell almost equally sensitive sb-t-1103 sb-t-1214 sb-t-1216 comply fact nci/adr-res cell absorb almost 20-fold less 14c paclitaxel 7-fold less docetaxel almost equal amount sb-t-1103 sb-t-1214 sb-t-1216 mda-mb-435 cell verapamil increase uptake 14c paclitaxel nci/adr-res cell 7-fold decrease efflux 2.5-fold contrast weakly influence uptake increase efflux mda-mb-435 cell sb-t-1103 sb-t-1216 influence transport paclitaxel sb-t-1214 decrease 14c paclitaxel uptake cell line indicate inhibition uptake suggest novel taxane inhibitor p-glycoprotein however novel taxane exert much higher activity resistant tumor cell classic taxane seem potential drug therapy taxane-resistant tumor 
cancer chemotherapeutic strategy commonly require multiple agent however use multiple agent contribute add toxicity result poor treatment outcome thus combination chemotherapy must optimize increase tumor response time lower toxicity chemotherapeutic agent know induce nuclear factor kappab nf-kappab activity tumor cell result lower cell killing drug resistance contrast genistein show inhibit activity nf-kappab growth various cancer cell without cause systemic toxicity therefore investigate whether inactivation nf-kappab genistein treatment various cancer cell chemotherapeutic agent lead better tumor cell killing test vitro study use gene transfection also animal study pc-3 prostate mda-mb-231 breast h460 lung bxpc-3 pancreas cancer cell pretreat 15 30 micromol/l genistein 24 hour expose low dose chemotherapeutic agent additional 48 72 hour find 15 30 micromol/l genistein combine 100 500 nmol/l cisplatin 0.5 2 nmol/l docetaxel 50 ng/ml doxorubicin result significantly greater inhibition cell growth induction apoptosis compare either agent alone moreover find nf-kappab activity significantly increase within 2 hour cisplatin docetaxel treatment nf-kappab induce activity agent completely abrogate cell pretreat genistein result also support first time animal experiment p65 cdna transfection p65 small interfere rna study clearly show specific target nf-kappab affect vivo collectively result clearly suggest genistein pretreatment inactivate nf-kappab may contribute increase growth inhibition apoptosis induce cisplatin docetaxel doxorubicin prostate breast lung pancreatic cancer cell thesis result warrant carefully design clinical study investigate combination soy isoflavone commonly use chemotherapeutic agent treatment human cancer 
aim study contribute understanding mechanism responsible resistance breast cancer cell taxane cell cycle characteristic dna fragmentation p53 p21 waf1/cip1 expression caspase-3 caspase-9 activity cytochrome c release mitochondria cell death induction taxane paclitaxel docetaxel highly-sensitive mda-mb-435 highly-resistant nci-adr-res human breast cancer cell compare approximately 300-fold higher concentration taxane require induce death resistant nci-adr-res cell sensitive mda-mb-435 cell cell death induce taxane sensitive resistant cell precede accumulation cell g2/m-phase neither cell type produce dna fragmentation dna ladder typical regular apoptosis p53 p21 waf1/cip1 level change sensitive resistant cell cell death induction taxane activity executioner caspase-3 increase significantly 2 2.5-fold similarly activity caspase-9 increase significantly 2 3.5-fold cell type however cytochrome c find release mitochondria cytosol resistant nci-adr-res cell sensitive mda-mb-435 cell death induce taxane study breast cancer cell characterize apoptosis-like death include caspase-3 caspase-9 activation oligonucleosomal dna fragmentation however mechanism death induction taxane sensitive mda-mb-435 cell resistant nci-adr-res cell differ cytochrome c release mitochondria resistant sensitive cell 
recent datum show epidermal growth factor receptor egfr inhibitor zd1839 alone combination chemotherapeutic agent androgen-independent prostate cancer aipc produce promising result clinical setting effective regimen involve novel stronger inhibitor egfr better combination need anti-tumor activity pd168393 irreversible egfr inhibitor without chemotherapeutic agent treatment aipc investigate vitro result androgen-independent cell line pc-3 du145 express higher level egfr androgen-dependent mda pca 2b androgen-responsive lncap cell western blotting du145 much sensitive pd168393 zd1839 mda pca 2b pd168393 zd1839 significantly potentiate paclitaxel cytotoxicity du145 mtt assay median-effect analysis combination pd168393 zd1839 cytotoxic agent include docetaxel 5-fluorouracil however either additive antagonistic compare paclitaxel alone pd168393 significantly enhance paclitaxel-induced dna fragmentation sub-g1 fraction accumulation mitochondrial membrane dysfunction cytochrome c release caspase-3 activation eventually apoptosis molecular event accompany bad up-regulation p53 p21waf1/cip1 induction erk1/2 inactivation inhibition egfr phosphorylation presence pd168393 effect involve significant alteration akt1/2 stat3 signaling pathway conclusion combination paclitaxel pd168393 produce profound synergistic growth inhibition aipc cell combine pd168393 paclitaxel may clinical benefit warrant investigation 
direct delivery chemotherapeutic agent lung increase drug concentration exposure period lung tumour objective study formulate docetaxel doc metered dose inhaler mdi assess aerodynamic characteristic evaluate effect celecoxib cxb cyclooxygenase-2 cox-2 inhibitor in-vitro cytotoxicity apoptotic response aerosolized doc human lung adenocarcinoma cell line a549 stable solution-type mdi formulation develop 0.25 doc 15 w/w ethyl alcohol use hfa 134a propellant formulation evaluate medication delivery mass median aerodynamic diameter mmad geometric standard deviation gsd percent throat deposition respirable mass respirable fraction six-stage viable impactor use assess in-vitro cytotoxicity doc-mdi alone combination cxb induction apoptosis a549 cell doc non-aerosolized aerosolized combination cxb evaluate established technique caspase-3 estimation terminal deoxynucleotidyl transferase-mediated nick end labelling tunel staining influence different treatment expression cox-2 peroxisome proliferator-activated receptor-gamma ppar-gamma a549 cell study rt-pcr doc-mdi formulation mmad 1.58 microm gsd = 3.2 medication delivery 80 microg/shot doc-mdi one shot combination cxb 10 microg ml -1 cell kill 80 determine in-vitro cytotoxicity assay specific caspase-3 activity a549 cell treat doc 0.01 microg ml -1 cxb 10.0 microg ml -1 combination 4 time higher cxb untreated control group respectively tunel staining show significant apoptosis a549 cell treat aerosolized doc alone combination cxb compare cxb untreated cell rt-pcr experiment show similar expression cox-2 control treated group ppar-gamma expression increase combination treatment 0.01 microg ml -1 doc 10 microg ml -1 cxb compare control untreated doc 0.01 microg ml -1 cxb 10 microg ml -1 treatment result indicate potential inhalation delivery doc treatment lung cancer 
sorafenib tosylate sorafenib bay 43-9006 nexavar multi-kinase inhibitor target tumor cell proliferation angiogenesis study evaluate efficacy tolerability combination sorafenib plus agent use treat non-small cell lung cancer nsclc use preclinical model disease intravenous iv vinorelbine interperitoneal ip cisplatin administer intermittently q4d x 3 combination sorafenib administer orally po daily 9 day start day standard agent study sorafenib gefitinib agent administer po daily 10 day start day treatment study initiate establish sc tumor study conduct duplicate efficacy assess delay tumor growth specify size tgd vinorelbine 6.7 mg/kg sorafenib 40 mg/kg produce tgd 2.4 7.8 day respectively nci-h460 nsclc model combination therapy produce 10.0-day tgd increase toxicity combination therapy nci-h23 nsclc model highest evaluate dose level sorafenib plus cisplatin well tolerate produce tgd equivalent produce cisplatin alone lower dose level agent produce approximately additive tgd combination therapy a549 nsclc model sorafenib gefitinib produce tgd equivalent produce sorafenib alone toxicity tumor growth mda-mb-231 mammary tumor model contain mutation signal transduction protein downstream egf receptor target gefitinib also inhibit sorafenib gefitinib concurrent administration sorafenib vinorelbine cisplatin gefitinib least efficacious individual agent alone well tolerate result support inclusion sorafenib clinical trial nsclc employ combination cytotoxic cytostatic agent 
determine vivo anti-tumor effect aerosolized celecoxib cxb combination i.v docetaxel doc compare anti-tumor effect oral cxb combine i.v doc human orthotopic non-small cell lung cancer nsclc xenograft model female nu/nu mouse implant orthotopic tumor inject a549 cell lung parenchyma seven day tumor implantation mouse treat aerosolized cxb 30 min exposure/day 5 mg/ml solution i.v doc 10 mg/kg effect compare oral cxb 150 mg/kg/day i.v doc 10 mg/kg 28 day small-animal nose inhalation chamber ch technologies westwood nj utilize aerosol exposure therapeutic activity cxb aerosol/oral doc estimate difference lung weight tumor area animal body weight lung tumor sample isolate mouse analyze pge2 level enzyme immunoassay eia b expression fas factor viii immunohistochemistry c il-8 expression use eia kit d mrna expression caspase-3 real-time pcr mouse treat cxb aerosol/oral doc show significant reduction p 0.001 lung weight tumor area compare cxb doc treatment cxb aerosol/oral doc show increase apoptosis mediate via increase fas caspase-3 p 0.001 expression compare untreated control combination treatment show antiangiogenic effect demonstrate reduce expression factor viii il-8 p 0.001 pge2 p 0.001 lung tumor compare untreated control aerosolized cxb significantly lower therapeutic dose 4.56 mg/kg/day demonstrate comparable anti-tumor efficacy orally administer cxb 150 mg/kg/day cxb formulate effectively deliver via aerosolization treat orthotopic lung tumor combination i.v doc cxb administer aerosol produce therapeutic effect oral cxb lower therapeutic dose thus show promise treatment lung cancer 
selective er downregulator fulvestrant currently approve second line endocrine therapy onset resistance prior antiestrogen therapy postmenopausal breast cancer patient resistance antihormonal therapy common therefore anticipate fulvestrant-resistance will occur well current study undertake investigate underlie molecular change fulvestrant-resistance find new therapeutic target agent fulvestrant-resistant breast cancer cell develop unique fulvestrant-resistant cell line mcf-7 / f derive mcf-7 estrogen receptor alpha eralpha positive human breast cancer cell culture 1 microm fulvestrant contain medium approximately 18 month mcf-7 / f cell become irreversibly eralpha negative withdrawal fulvestrant alter eralpha-negative phenotype determine real-time pcr western blot analysis ere-luciferase transfection assay mcf-7 / f cell grow hormone-independent manner interestingly mcf-7 / f cell overexpress epidermal growth factor receptor egfr breast cancer resistant protein bcrp gefitinib specific egfr tyrosine kinase inhibitor preferentially inhibit growth mcf-7 / f cell relative mcf-7 cell inhibit mapk44/42 akt phosphorylation mcf-7 / f cell become less sensitive chemotherapeutic agent mitoxantrone moreover fumitremorgin c specific bcrp inhibitor significantly increase efficacy mitoxantrone mcf-7 / f cell gefitinib increase inhibitory effect mitoxantrone cell growth similarly fumitremorgin c increase inhibitory effect gefitinib cell growth suggest bidirectional crosstalk egfr bcrp importantly result provide molecular basis use gefitinib bcrp inhibitor chemotherapeutic agent combination therapy approach fulvestrant-resistant breast cancer 
chronic myeloid leukemia cml cause reciprocal translocation chromosome 9 22 form bcr-abl constitutively activate tyrosine kinase imatinib mesylate selective inhibitor bcr-abl represent current frontline therapy cml however emerge evidence suggest drug resistance imatinib may limit long-term success improve treatment option dasatinib bms-354825 develop novel oral multi-targeted kinase inhibitor bcr-abl src family kinase date dasatinib show promising anti-leukemic activity preclinical model cml phase i/ii clinical study patient imatinib-resistant imatinib-intolerant disease pharmacokinetic pharmacodynamic biomarker dasatinib investigate k562 human cml xenograft grow s.c. severe combined immunodeficient mouse tumoral level phospho-bcr-abl/phospho-crkl determine western blot follow single oral administration dasatinib preclinical efficacious dose 1.25 2.5 mg/kg tumoral phospho-bcr-abl/phospho-crkl maximally inhibit approximately 3 hour recover basal level 24 hour time course extent inhibition correlate plasma level dasatinib mouse pharmacokinetic/biomarker modeling predict plasma concentration dasatinib require inhibit 90 phospho-bcr-abl vivo 10.9 ng/ml mouse 14.6 ng/ml human within range concentration achieve cml patient respond dasatinib treatment clinic phospho-bcr-abl/phospho-crkl likely useful clinical biomarker assessment bcr-abl kinase inhibition dasatinib 
evaluate clonogenic assay bleomycin a6 find highly active establish human cancer cell line derive colon cancer ht-29 cecum cancer hce-8693 human cancer cell serially transplant nude mouse tolerable dosage level bleomycin a6 exert remarkable growth inhibition human colon cancer ht-29 cecum cancer hce-8693 xenograft approximately 90 inhibition histopathological change find organ treated animal compare basis equitoxic dose 1/9 ld50 bleomycin a6 exert much stronger growth inhibition colon cancer ht-29 xenograft nude mouse 5-fluorouracil mitomycin c inhibition rate 82 12 53 respectively extensive necrosis find tumor treat bleomycin a6 treat mitomycin c 5-fluorouracil ratio value non-necrotic tumor tissue whole tumor tissue bleomycin a6 mitomycin c 5-fluorouracil 0.33 0.65 0.57 respectively observation indicate bleomycin a6 potent antitumor agent colon cancer xenograft may useful human colon cancer chemotherapy 
dasatinib atp-competitive multi-targeted src abl kinase inhibitor bind bcr-abl active inactive conformation clinical standpoint dasatinib particularly attractive show induce hematologic cytogenetic response imatinib-resistant chronic myeloid leukemia patient fact combination imatinib dasatinib show additive/synergistic growth inhibition wild-type p210 bcr-abl-expressing cell reason abl kinase inhibitor might induce different molecular pathway address question use dna microarray identify gene whose transcription alter imatinib dasatinib k562 cell culture imatinib dasatinib 16 h gene expression datum obtain three independent microarray hybridization almost imatinib dasatinib-responsive gene appear similarly increase decrease k562 cell however small subset gene identify selectively alter expression either imatinib dasatinib distinct gene selectively modulate dasatinib cyclin-dependent kinase 2 cdk2 cdk8 maximal reduction 5-fold microarray screen assess functional importance dasatinib regulate gene use rna interference determine whether reduction cdk2 cdk8 affect growth inhibition k562 tf-1bcr-abl cell pretreat cdk2 cdk8 small interfere rna show additive growth inhibition imatinib dasatinib finding demonstrate additive/synergistic growth inhibition imatinib dasatinib may mediate part cdk2 cdk8 
interaction mek1/2 inhibitor dual abl/src kinase inhibitor dasatinib bms-354825 examine chronic myeloid leukemia cml cell line primary specimen cotreatment k562 lama cell subtoxic marginally toxic concentration pd184352 u0126 dasatinib synergistically potentiate mitochondrial damage caspase activation apoptosis similar interaction observe cd34 cell one cml patient-derived normal human cd34 bone marrow cell specimen interaction associate multiple perturbation survival signaling pathway include inactivation bcr/abl stat5 erk1/2 down-regulation bcl-x l mcl-1 dephosphorylation/activation bim also associate bax/bak conformational change mitochondrial dysfunction caspase activation bim knockdown shrna suppress bax bak conformational change protected cell dasatinib/pd184352 lethality conversely k562 cell ectopically express mcl-1 bcl-x l significantly less susceptible dasatinib/pd184352 toxicity notably dasatinib/pd184352 regimen active leukemic cell exhibit various form imatinib mesylate resistance include bcr/abl overexpression lyn activation several bcr/abl kinase domain mutation eg e255k m351t t315i together finding suggest strategy combine dasatanib mek1/2 inhibitor warrant investigation bcr/abl malignancy particularly setting imatinib mesylate-resistant disease 
sixteen different taxoid conjugate prepare link various anticancer compound include camptothecin cpt epipodophyllotoxin ep colchicine col glycyrrhetinic acid ga 2 7-position paclitaxel txl 1 ester imine amine amide bond newly synthesize conjugate evaluate cytotoxic activity replication several human tumor cell line among txl-cpt conjugate 8-10 potent txl human prostate carcinoma cell line pc-3 ed 50 = 14.8 3.1 19.4 nm compare 55.5 nm conjugate 10 also 8-fold active txl ln-cap prostate cancer cell line compound also possess anti-angiogenesis ability well lower inhibitory effect normal cell line mrc-5 thus conjugate 8-10 possible antitumor drug candidate particularly prostate cancer 
epidermal growth factor receptor egfr hedgehog cascade provide critical role prostate cancer progression contribute resistance clinical therapy disease relapse therefore evaluate first time antiproliferative cytotoxic effect induce combination selective inhibitor egfr tyrosine kinase smoothen hedgehog signaling element gefitinib cyclopamine current chemotherapeutic drug use clinic docetaxel metastatic prostate cancer cell line immunohistochemical analysis reveal sonic hedgehog shh expression enhance 39 primary prostatic adenocarcinoma gleason score 4-10 compare corresponding normal tissue prostate gland 32 prostate cancer patient confocal microscopy western blot analysis also indicate high expression level shh egfr metastatic lncap du145 pc3 cell moreover result reveal drug alone combination lower concentration inhibit growth egf plus shh-stimulated serum-stimulated androgen-responsive lncap-c33 androgen-independent lncap-c81 du145 pc3 cell importantly combined docetaxel gefitinib cyclopamine also cause higher rate apoptotic death prostate cancer cell compare individual agent cytotoxic effect induce drug pc3 cell seem mediate part cellular ceramide production activation caspase cascade via mitochondrial pathway release cytochrome c cytosol additionally combined agent effective suppress invasiveness pc3 cell matrigel vitro single drug finding indicate combine use inhibitor egf-egfr hedgehog signaling docetaxel represent promising strategy treatment patient metastatic androgen-independent prostate cancer 
dasatinib bms-354825 novel oral potent multi-targeted kinase inhibitor bcr-abl src family kinase sfk promising cancer therapeutic agent preclinical datum indicate dasatinib 325-fold potent imatinib cell express wild-type bcr-abl dasatinib active 18 19 bcr-abl mutation know cause imatinib resistance phase clinical datum show dasatinib well tolerate highly effective treatment imatinib-resistant/imatinib-intolerant chronic myelogenous leukemia cml philadelphia chromosome-positive acute lymphoblastic leukemia however molecular mechanism action dasatinib fully understand study confirm dasatinib inhibit tyrosine phosphorylation sfk include src hck lyn k562 human cml cell significantly downstream signal transducer activator transcription 5 stat5 signaling also block dasatinib show decrease level phosphorylate stat5 stat5 dna-binding activity addition dasatinib down-regulate expression stat5 target gene include bcl-x mcl-1 cyclin d1 consistent result blockade stat5 signaling dasatinib accompany inhibition cell proliferation induction apoptosis surprisingly stat5 dna-binding activity enhance increase cell density associate resistance apoptosis dasatinib finding indicate inhibition stat5 signaling downstream bcr-abl/sfks contribute action dasatinib conversely increase cell density up-regulate stat5 activation confer resistance dasatinib moreover level phosphorylate stat5 cml cell represent mechanistically relevant biomarker monitoring inhibition bcr-abl signaling dasatinib cml patient use convenient immunocytochemical assay 
evaluate preclinical pharmacokinetic antitumor efficacy novel orally bioavailable poly adp-ribose polymerase parp inhibitor abt-888 vitro potency determine parp-1 parp-2 enzyme assay vivo efficacy evaluate syngeneic xenograft model combination temozolomide platinum cyclophosphamide ionize radiation abt-888 potent inhibitor parp-1 parp-2 k s 5.2 2.9 nmol/l respectively compound good oral bioavailability cross blood-brain barrier abt-888 strongly potentiate temozolomide b16f10 s.c. murine melanoma model parp inhibition dramatically increase efficacy temozolomide abt-888 dose low 3.1 mg/kg/d maximal efficacy achieve 25 mg/kg/d 9l orthotopic rat glioma model temozolomide alone exhibit minimal efficacy whereas abt-888 combine temozolomide significantly slow tumor progression mx-1 breast xenograft model brca1 deletion brca2 mutation abt-888 potentiate cisplatin carboplatin cyclophosphamide cause regression established tumor whereas comparable dose cytotoxic agent alone modest tumor inhibition exhibit finally abt-888 potentiate radiation 2 gy/d x 10 hct-116 colon carcinoma model model abt-888 display single-agent activity abt-888 potent inhibitor parp good oral bioavailability cross blood-brain barrier potentiate temozolomide platinum cyclophosphamide radiation syngeneic xenograft tumor model broad spectrum chemopotentiation radiopotentiation make compound attractive candidate clinical evaluation 
physiological molecular finding indicate over-expression protein dysregulation neo-angiogenesis progression advanced prostate cancer aim study test novel rational therapeutic approach combine docetaxel egfr-targeting agent cetuximab anti-angiogenic agent sunitinib sutent mouse bear well-established pc3 prostate tumor mean tumor volume/treatment group approximately 250 mm 3 treat every week vehicle alone control sunitinib 40 mg/kg/day 5 days/week 3 week 0.2 ml p.o. cetuximab 0.2 mg/kg/day 5 days/week 3 week 0.2 ml i.p. docetaxel 10 mg/kg 1 day/week 3 week 0.2 ml i.p. drug administer single-agent demonstrate comparable moderate effect tumor growth approximately 50 inhibition end 3-week dosing schedule compute combination ratio cr value tumor growth determine day 61 68 75 cell implantation indicate supra-additive effect sunitinib-docetaxel 1.53 1.15 1.47 respectively sunitinib-cetuximab combination 1.2 1.32 1.14 respectively suggest additive effect sunitinib-cetuximab-docetaxel combination cr = 1 effect tumor growth accompany parallel diminution tumor cell proliferation ki 67 tumor vascularization von willebrandt factor significantly higher pro-apoptotic effect caspase-3 cleavage observe sunitinib-docetaxel sunitinib-docetaxel-cetuximab compare condition supra-additive anti-tumor effect observe sunitinib-docetaxel combination might support innovative strategy management advanced prostate cancer 
positron emission tomography pet suggest early monitoring treatment response assume effective anticancer treatment induce metabolic change precede morphology alteration change growth aim study introduce multicellular tumour spheroid mt study effect anticancer drug suggest appropriate pet tracer study mts breast cancer cell line mcf7 expose doxorubicin paclitaxel docetaxel tamoxifen imatinib 7 day growth pattern study 3 5 day pet tracer study effect growth compute use semi-automated size determination method sasdm effect uptake pet tracer 18f 3 deoxy-3 fluorothymidine flt 1-11c acetate ace 11c choline cho 11c methionine met 2 18f fluoro-2-deoxyglucose fdg calculate form uptake/viable volume mts end drug exposure finally uptake relate effect growth rate drug paclitaxel docetaxel doxorubicin give severe growth inhibition correlate well inhibition flt uptake flt compare ace cho met fdg higher sensitivity monitor therapy effect sasdm provide effective user-friendly time-saving accurate method record growth pattern mts also calculate effect drug pet tracer uptake study demonstrate use mts sasdm combination pet tracer promising approach probe select pet tracer treatment monitoring anticancer drug hopefully apply optimisation breast cancer treatment 
describe chemical proteomic approach profile interaction small molecule hundred endogenously express protein kinase purine-binding protein subproteome capture immobilize nonselective kinase inhibitor kinobead bind protein quantify parallel mass spectrometry use isobaric tag relative absolute quantification itraq measure competition affinity matrix assess binding drug target cell lysate cell map drug-induced change phosphorylation state capture proteome also analyze signaling pathway downstream target kinase quantitative profiling drug imatinib gleevec dasatinib sprycel bosutinib k562 cell confirm known target include abl src family kinase identify receptor tyrosine kinase ddr1 oxidoreductase nqo2 novel target imatinib datum suggest approach valuable tool drug discovery 
basic fibroblast growth factor bfgf multifunctional protein one important growth factor cutaneous melanoma development progression hypothesize high bfgf expression might responsible chemoresistance advanced melanoma m14 human melanoma cell express low level bfgf successfully transfect vector encode either 18 kda isoform protein bfgf m14 cell bfgf-overexpressing clone similar growth rate vitro overexpression 18 kda isoform protein bfgf result respectively 2.9 6.9-fold resistance temozolomide o6-alkylguanine-dna-alkyltransferase agt protein level highly elevated specific inhibition agt o6-benzylguanine completely reverse resistance 18 kda clone partially clone overexpress isoform methylation-specific pcr show least 18 kda overexpress clone increase agt expression result demethylation o6-methylguanine-dna-methyltransferase promoter parental m14 cell demethylating agent 5-azacytidine generate agt expression result temozolomide resistance overexpression isoform protein bfgf 18 kda isoform alone result 2.9-fold resistance cisplatin reverse o6-benzylguanine expression level mismatch repair protein msh2 msh6 mlh1 decrease likely exclude defective mismatch repair system cause cisplatin resistance change sensitivity docetaxel doxorubicin conclusion bfgf overexpression result resistance temozolomide mediate demethylation o6-methylguanine-dna-methyltransferase promoter 
previously report microtubule-stabilizing agent docetaxel induce formation fragile acentrosomal spindle pole structurally related paclitaxel present study examine whether microtubule-stabilizing agent epothilone b structurally similar affect centrosome/spindle pole architecture.we investigate mitotic process epothilone b-treated human mda-mb-435 cell centrosome spindle pole mitotic micro-tubule simultaneously visualize gfp-aurora kinase fluorescence microscopy metaphase cell indicate several chromosome misalign away metaphase plate treat ic 50 concentration epothilone b 4.5 2 nm respectively suggest microtubule dynamics impaired interestingly epothilone b induce formation acentro-somal spindle pole effect observe epothilone a. live-cell imaging show aster-like structure ectopically arise around nuclear envelope onset mitosis epothilone b-treated cell one aster become acentrosomal spindle pole aster-like structure also arise presence epothilone merge centro-some-derived spindle pole prometaphase completely disappear metaphase result indicate centro-some/spindle pole integrity strongly affect epothilone b greatly affect epothilone finding show two epothilone cause different cellular response equipotent concentration suggest different mechanism activity cell 
previous work show methylseleninic acid msea sensitize hormone refractory prostate cancer hrpca cell apoptosis induce paclitaxel taxol enhance multiple caspase study aim determine general applicability sensitization effect taxane drug vitro b establish enhancement paclitaxel efficacy msea vivo c investigate bcl-xl survivin molecular target msea augment apoptosis du145 pc-3 hrpca cell line use evaluate vitro apoptosis effect paclitaxel docetaxel combination msea molecular mechanism du145 xenograft growth athymic nude mouse use evaluate vivo efficacy paclitaxel combination msea tumor sample use examine bcl-xl survivin protein abundance msea combination paclitaxel docetaxel exert greater additive apoptosis effect du145 pc-3 cell nude mouse paclitaxel msea combination inhibit growth du145 subcutaneous xenograft equivalent efficacy four-time higher dose paclitaxel alone msea decrease basal paclitaxel-induced expression bcl-xl survivin vitro vivo ectopic expression bcl-xl survivin attenuate msea/paclitaxel-induced apoptosis msea enhance efficacy paclitaxel hrpca vitro vivo least part down-regulate basal paclitaxel-induced expression bcl-xl survivin increase caspase-mediated apoptosis msea may novel agent improve taxane combination therapy 
characterize change secretory clusterin sclu expression prostate cancer cell treatment docetaxel determine whether sclu knockdown re-introduce chemosensitivity docetaxel-resistant androgen-independent human prostate cancer model tissue microarray construct 84 radical prostatectomy rp specimen multicentre phase ii trial neoadjuvant combined androgen ablation docetaxel cuog-p01a assess change expression cytoprotective chaperone sclu human prostate cancer cell line pc-3 repeatedly expose docetaxel chemotherapy vitro docetaxel-resistant cell subline pc-3dr develop analyse sclu level significantly higher rp specimen treat neoadjuvant combined androgen ablation docetaxel untreated specimen similarly sclu expression increase 2.5-fold newly develop docetaxel-refractory pc-3dr cell line compare parental pc-3 cell dose-dependent sequence-specific decrease sclu level pc-3dr cell use ogx-011 antisense oligonucleotide human sclu ogx-011 small-interference rna chemosensitize pc-3dr cell docetaxel mitoxantrone vitro apoptotic rate pc-3dr cell significantly increase ogx-011 combine docetaxel vivo growth pc-3dr xenograft nude mouse synergistically inhibit ogx-011 combine paclitaxel mitoxantrone 76 44 compare mismatch control respectively present finding indicate target knockdown sclu enhance effect cytotoxic chemotherapy docetaxel-refractory cell provide preclinical proof principle clinical trial test ogx-011 second-line chemotherapy regimen patient docetaxel-refractory prostate cancer 
result present study reveal first time possibility use combination mitoxantrone gefitinib cyclopamine inhibit growth epidermal growth factor egf sonic hedgehog shhnp serum-stimulated androgen-sensitive lncap-c33 androgen-independent ai lncap-c81 du145 pc3 prostate cancer pc cell supra-additive anti-proliferative effect drug mediate via blockade pc3 cell g 1 g 2 m phase cell cycle importantly combination mitoxantrone plus gefitinib and/or cyclopamine also cause higher rate apoptotic death pc cell include enriched fraction cd44 high pc3 cell subpopulation compare individual agent bi-combination drug cytotoxic effect induce mitoxantrone gefitinib cyclopamine pc3 cell appear least partly mediate depolarization mitochondrial membrane release cytochrome c cytosol hydrogen peroxide production activation caspase cascade finding indicate simultaneous blockade egf-egfr sonic hedgehog tumorigenic signaling cascade may represent promising strategy improve efficacy current mitoxantrone-based therapy incurable ai metastatic pc clinic 
despite promising result clinical study abl kinase inhibitor challenging problem remain t315i mutation neither nilotinib dasatinib show significant activity present study investigate activity novel aurora kinase inhibitor ve-465 leukemia cell express wild-type bcr-abl t315i mutant form bcr-abl observe dose-dependent reduction level bcr-abl autophosphorylation ve-465-treated cell exposure combination ve-465 imatinib exert enhance apoptotic effect k562 cell combined treatment ve-465 imatinib cause attenuation level phospho-akt c-myc k562 cell isobologram indicate synergistic effect simultaneous exposure ve-465 imatinib k562 cell assess vivo efficacy ve-465 athymic nude mouse inject intravenously baf3 cell express wild-type bcr-abl t315i mutant form vehicle-treated mouse die condition resemble acute leukemia 28 day however nearly mouse treat ve-465 75 mg/kg twice daily intraperitoneally 14 day survive 56 day histopathological analysis vehicle-treated mouse reveal infiltration spleen contrast histopathological analysis organ ve-465-treated mouse demonstrate normal tissue architecture take together present study show ve-465 exhibit desirable therapeutic index reduce vivo growth t315i mutant form wild-type bcr-abl-expressing cell efficacious manner 
aim study evaluate activity antiangiogenic agent su-11248 sunitinib malate sutent alone combination docetaxel end animal bear du-145 human hormone-refractory prostate cancer hrpc xenograft treat sunitinib 40 mg/kg daily p.o. docetaxel 10 30 mg/kg/week i.v. combination sunitinib 40 mg/kg daily docetaxel 10 mg/kg/week vehicle alone end 3-week dosing schedule single-agent treatment induce tumor regression 59 49 75 sunitinib docetaxel 10mg/kg docetaxel 30 mg/kg respectively combination sunitinib low-dose 10mg/kg docetaxel produce tumor regression comparable obtain high-dose 30 mg/kg docetaxel tolerability higher indicate mouse weight sunitinib docetaxel inhibit tumor regrowth initial treatment alternate drug result suggest sunitinib alone combination low-dose docetaxel may role treatment hrpc 
management hormone-refractory prostate cancer hrpc still remain important challenge daily oncology practice docetaxel prove first line treatment choice all-trans retinoic acid atra potently inhibit growth prostate cancer cell vitro combination various anticancer agent result increase cytotoxicity base datum aim examine synergistic/additive cytotoxic apoptotic effect combination docetaxel atra hormone drug refractory human du-145 prostate cancer cell furthermore search underlying mechanism apoptosis demonstrate apoptosis-related gene xtt cell proliferation assay use show cytotoxicity verify apoptosis dna fragmentation elisa assay caspase 3/7 activity measurement use detect mechanism apoptosis induce docetaxel-atra combination oligogearray consist 112 apoptosis related gene use result reveal docetaxel atra synergistically cytotoxic apoptotic du-145 cell dose time dependent manner also show study apoptosis induce du-145 prostate carcinoma cell significant cytotoxicity matter agent apply first find docetaxel-atra combination significantly downregulate survivin birc5 myeloid cell leukemia-1 mcl-1 lymphotoxin beta-receptor ltbetar gene three pivotal role regulation apoptosis cell cycle progression conclusion strongly suggest docetaxel atra combination good candidate challenging era daily oncologic practice also combination docetaxel atra might allow reduction docetaxel dose way may diminish docetaxel adverse effect maintain therapeutic effect patient hrpc 
although dual src-family kinase/bcr/abl inhibitor dasatinib bms-354825 provide therapeutic advantage imatinib-resistant cell mechanism dasatinib resistance fully know use tf-1 bcr/abl cell introduce bcr/abl gene leukemia cell line tf-1 k562 establish dasatinib bms-r imatinib-resistant im-r cell characterize chronic myelogenous leukemia drug-resistant cell examine intracellular signaling ic 50 dasatinib 0.75 nmol/l tf-1 bcr/abl 1 nmol/l k562 7.5 nmol/l tf-1 bcr/abl im-r 10 nmol/l k562 im-r 15 micromol/l tf-1 bcr/abl bms-r 25 micromol/l k562 bms-r number bcr/abl copy resistant cell line parental cell line fluorescence situ hybridization analysis mutation abl kinase find protein level bcr/abl reduce dasatinib-resistant cell line bcr/abl protein increase treatment ubiquitin inhibitor src kinase lck well mitogen-activated protein kinase akt activate p21 waf phosphatase tensin homologue reduce k562 bms-r cell removal dasatinib culture medium k562 bms-r cell lead apoptosis activate caspase 3 poly adp-ribose polymerase result suggest expression protein activation signature identify study provide insight mechanism resistance dasatinib imatinib may therapeutic chronic myelogenous leukemia value clinically 
lapatinib active atp-binding site tyrosine kinase associate human epidermal growth factor receptor her-1 erbb1 her-2 conceivable lapatinib may inhibit function atp-binding cassette abc transporter bind atp-binding site aim study investigate ability lapatinib reverse tumor multidrug resistance mdr due overexpression abc subfamily b member 1 abcb1 abc subfamily g member 2 abcg2 transporter result show lapatinib significantly enhance sensitivity abcb1 abcg2 substrate cell express transporter although small synergetic effect observe combine lapatinib conventional chemotherapeutic agent parental sensitive mcf-7 s1 cell lapatinib alone however significantly alter sensitivity non-abcb1 non-abcg2 substrate sensitive resistant cell additionally lapatinib significantly increase accumulation doxorubicin mitoxantrone abcb1 abcg2-overexpressing cell inhibit transport methotrexate e 2 17betag abcg2 furthermore lapatinib stimulate atpase activity abcb1 abcg2 inhibit photolabeling abcb1 abcg2 125 iodoarylazidoprazosin concentration-dependent manner however lapatinib affect expression transporter mrna protein level importantly lapatinib also strongly enhance effect paclitaxel inhibition growth abcb1-overexpressing kbv200 cell xenograft nude mouse overall conclude lapatinib reverse abcb1 abcg2-mediated mdr directly inhibit transport function finding may useful cancer combinational therapy lapatinib clinic 
object cancer progenitor-like cell isolate hoechst 33342 dye efflux term side population sp study variety cancer include malignant brain tumor study author investigate nature sp phenotype 2 glioma cell line u87mg t98g response temozolomide role several adenosine triphosphate-binding cassette abc multidrug transporter express sp cell particular abcg2 also examine method use fluorescence-activated cell sorting cell separate sp non-sp fraction analyze progenitor cell-like property immunofluorescence staining quantitative real-time polymerase chain reaction ability reform glioma mass immune-compromised mouse response sp cell temozolomide investigate cellular molecular level small interfere rna knockdown use examine specific role abcg2 transporter cell tumorigenic potential measure use soft agar clonogenic assay result side population cell characterize presence progenitor cell-like property increase expression nestin musashi-1 abcg2 observe addition sp cell able reconstitute cellular heterogeneity cell also invasive non-sp cell possess tumorigenic capacity temozolomide treatment increase number sp cell correspond progenitor-like cell concurrent elevated expression several abc transporter conclusion knockdown abcg2 transporter abrogate sp cell response temozolomide upregulation several abc drug transporter gene propose account chemoresistance 
observe sensitivity pc-3 cell line transfect pci-neo-sncg plasmid cisplatin ddp 5-fluorouracil 5-fu adriamycin adm vincristine vcr paclitaxel tax explore influence sncg expression effectiveness anti-tumor drug plasmid pci-neo pci-neo-sncg transfect hormone-independent prostate cancer cell line pc-3 rt-pcr adopt examine expression sncg pc-3 cell line mtt method employ detect suppressive effect different anti-tumor drug ddp adm 5-fu vcr tax cell line transfect pci-neo pci-neo-sncg flow cytometry use analyze cell cycle apoptosis transfect cell treat tax 5 anti-tumor drug suppress growth cell line transfect plasmid pci-neo pci-neo-sncg time-dependant manner comparison growth-suppressing effect different anti-tumor drug pc-3 cell line show significant difference group transfect pci-neo pci-neo-sncg ddp 5-fu adm vcr p 0.05 rate suppression tax latter cell line significantly lower former p 0.01 compare pci-neo-sncg plasmid transfect cell line treat tax 48 hour transfect pci-neo plasmid exhibit significantly larger proportion cell remain g2-m stage p 0.01 smaller proportion g0-g1 s stage p 0.01 significantly higher expression caspase-3 p 0.01 significant reduction growth-suppressing effect tax sncg-transfected pc-3 cell line suggest expression sncg may restrain effect tax finding provide evidence guide individual chemotherapy prostate cancer 
taxane first line drug treat prostate cancer recurrence failure anti-androgen therapy need make taxane effective since provide palliative benefit exploit endoplasmic reticulum er stress death signaling enhance drug efficacy delineate human pc-3 cell use model hormone refractory prostate cancer thapsigargin methylseleninic acid msa examine sensitizer thapsigargin classic er stress inducer activity msa induce er stress recently study group efficacy single drug various combination evaluate measure apoptosis cell death elisa kit thapsigargin increase cell killing potency paclitaxel docetaxel 10 12-fold msa cause 5 8-fold increase since thapsigargin use clinically toxicity follow-up experiment msa test hypothesis threshold level er stress crucial chemotherapeutic sensitization three different approach design dampen severity er stress induce msa examine lower er stress consistently attenuate efficacy msa/taxane gadd153 pro-apoptotic transcription factor upregulate er stress knock gadd153 sirna also reduce cell killing effect msa/taxane intrinsic extrinsic apoptotic pathway involve sensitization mechanism study support idea marshal er stress apoptotic response conducive chemotherapeutic sensitization 
carboplatin lower nephro neurotoxicity better penetration brain tissue cisplatin carboplatin comparable cytotoxicity glioma cell might therapeutic advantage treatment malignant glioma use assay colony-forming efficiency compare cytotoxicity two drug human glioma cell line sf-126 sf-188 u87-mg u251-mg experiment design product vitro drug concentration c time t encompass range value c x t ultrafilterable platinum plasma fraction determine pharmacokinetic study man vitro stability drug evaluate measure cytotoxicity aged drug microculture tetrazolium assay cisplatin carboplatin stable 2-h treatment cytotoxic activity drug clinically achievable level drug exposure order magnitude result conjunction lower nephro neurotoxicity carboplatin higher platinum level brain tissue treatment carboplatin encouraging result carboplatin clinical treatment brain tumor demonstrate study suggest carboplatin might preferable cisplatin treatment patient malignant glioma 
study evaluate mechanistic difference pralatrexate methotrexate pemetrex inhibition dihydrofolate reductase dhfr quantify use recombinant human dhfr cellular uptake folylpolyglutamate synthetase fpgs activity determine use radiolabele pralatrexate methotrexate pemetrex nci-h460 non-small cell lung cancer nsclc cell tumor growth inhibition tgi assess use mv522 nci-h460 human nsclc xenograft apparent k value dhfr inhibition 45 26 200 nm pralatrexate methotrexate pemetrex respectively significantly greater percentage radiolabele pralatrexate enter cell polyglutamylatate relative methotrexate pemetrex vivo pralatrexate show superior anti-tumor activity nsclc model effective dose-dependent tgi rapidly grow nci-h460 xenograft pralatrexate demonstrate distinct mechanistic anti-tumor activity profile relative methotrexate pemetrex pralatrexate exhibit enhance cellular uptake increase polyglutamylation correlate increase tgi nsclc xenograft model 
dynamic instability microtubule cell one key target anticancer therapeutics microtubule-disrupting agent vinca alkaloid microtubule-stabilizing agent taxane important antitumor agent bone marrow toxicity human tumor xenograft activity three tubulin-binding compound vincristine paclitaxel tasidotin compare mouse human bone marrow subject colony-forming cfu-gm assay 5-log concentration range culture vivo range tasidotin dose compare vincristine paclitaxel docetaxel efficacy several human tumor xenograft ic 90 concentration vincristine paclitaxel mouse cfu-gm 30 27 nm human cfu-gm 3 9 nm give mouse human differential ten threefold tasidotin produce ic 90 s 300 nm mouse 65 nm human cfu-gm thus 4.6-fold differential species vivo tasidotin result dose-dependent increase tumor growth delay rl lymphoma rpmi 8226 multiple myeloma mx-1 breast carcinoma model vincristine tasidotin also effective tumor pc-3 prostate carcinoma responsive full-dose paclitaxel docetaxel tasidotin generate dose dependent effect bring together bone marrow toxicity datum pharmacokinetic parameter human tumor xenograft efficacy provide valuable information translation preclinical finding clinic 
phosphorylation histone h2ax sensitive marker dna damage particularly dna double strand break use multiparameter cytometry explore effect etoposide temozolomide tmz three glioblastoma cell line different p53 status a172 t98g ykg-1 normal human astrocyte nha correlate drug-induced phosphorylate h2ax gammah2ax cell cycle phase induction apoptosis etoposide induce gammah2ax phase cell cycle three glioblastoma line lead arrest t98g ykg-1 cell s g 2 / m. nha cell arrest g 1 evidence gammah2ax induction a172 respond rise gammah2ax throughout phase cycle arrest late s g 2 / m-phase appearance senescence feature induction p53 p21 waf1/cip1 p16 ink4a beta-galactosidase accompany morphological change typical senescence t98g cell show presence gammah2ax s phase evidence cell cycle arrest modest degree arrest g 1 see ykg-1 cell rise gammah2ax frequency apoptotic cell four tmz-treated cell culture relatively low conceivable cell extensive dna damage reproductively dead datum show neither status p53 wild-type vs. mutate inhibit pifithrin-alpha expression o 6 methylguanine-dna methyltransferase significantly affect cell response tmz diversity response tmz individual glioblastoma line datum suggest better understanding mechanism treatment may customize individual patient 
search potent anticancer agent 15 nitric oxide donate thalidomide analogue 6a 6b 8a-8e 13a-13h design synthesize cytotoxicity compound evaluate vitro three human tumor cell line hepg2 a549 pc-3 result indicate 13a-13d exhibit notable anticancer activity comparable stronger 5-fluorouracil 5-fu structure-activity relationship also discuss base experimental datum obtain generally cytotoxic activity target compound closely related type donor length spacer connect donor also appear important bioactivity 
previously demonstrate abl kinase highly active invasive breast cancer cell line contribute survival response nutrient deprivation invasion proliferation determine whether abl kinase inhibitor sti571 gleevec imatinib mesylate sensitize breast cancer cell chemotherapeutic agent treat three breast cancer cell line bt-549 mda-mb-231 mda-mb-468 active abl kinase sti571 combination several conventional chemotherapeutic drug frequently use treat breast cancer assess effect cell viability proliferation apoptosis find sti571 synergistic effect cisplatin bt-549 extent mda-mb-468 cell synergize camptothecin use alternate dosing regimen mda-mb-231 cell sti571 synergistically sensitize mda-mb-468 cell paclitaxel high dose 5-fluorouracil significantly sti571 increase ability cisplatin inhibit constitutive activation pi3k/akt bt-549 cell synergize camptothecin increase stability ikappab mda-mb-231 cell mda-mb-468 cell camptothecin 5-fluorouracil inhibit sti571-dependent activation stat3 cell line/drug combination sti571 additive antagonistic effect indicate ability sti571 sensitize breast cancer cell chemotherapeutic agent cell type-dependent significantly unlike cisplatin paclitaxel camptothecin mechloroethamine strongly antagonistic sti571 effect cell line-dependent take together datum indicate cellular milieu govern response breast cancer cell sti571/chemotherapeutic combination regimen suggest treatment combination require individualization 
chronic myelogenous leukemia cml result translocation chromosome 9 22 generate bcr/abl fusion protein characterize uncontrolled proliferation immature white blood cell imatinib molecularly target anticancer agent use widely treatment cml show significant activity chronic accelerated phase much less blast crisis phase resistance imatinib especially blast crisis phase recognize major problem treatment cml patient docetaxel show arrest cell g2/m phase cell cycle make cell sensitive chemo radiotherapy study aim increase chemosensitivity human k562 cml cell imatinib combination docetaxel take together result show combination imatinib docetaxel decrease cellular proliferation increase apoptosis human k562 chronic myeloid leukemia cell compare agent alone imatinib docetaxel induce apoptosis caspase-3 enzyme activity mitochondrial membrane potential 
epidermal growth factor receptor tyrosine kinase inhibitor egfr-tki inhibit function certain adenosine triphosphate atp bind cassette transporter include p-glycoprotein/abcb1 breast cancer resistance protein bcrp / abcg2 previously report antagonistic activity gefitinib towards bcrp now analyze effect erlotinib another egfr-tki p-glycoprotein bcrp gefitinib erlotinib effectively reverse bcrp-mediated resistance sn-38 7-ethyl-10-hydroxycamptothecin mitoxantrone contrast find erlotinib effectively suppress p-glycoprotein-mediated resistance vincristine paclitaxel suppress resistance mitoxantrone doxorubicin conversely erlotinib appear enhance p-glycoprotein-mediated resistance mitoxantrone k562/mdr cell bidirectional activity erlotinib observe verapamil typical p-glycoprotein inhibitor flow cytometric analysis show erlotinib co-treatment restore intracellular accumulation mitoxantrone k562 cell express bcrp cell express p-glycoprotein consistently erlotinib inhibit mitoxantrone efflux k562/mdr cell although vincristine efflux k562/mdr cell mitoxantrone efflux k562/bcrp cell intravesicular transport assay show erlotinib inhibit p-glycoprotein-mediated vincristine transport bcrp-mediated estrone 3-sulfate transport intriguingly lineweaver-burk plot suggest inhibitory mode erlotinib mixed type p-glycoprotein-mediated vincristine transport whereas competitive type bcrp-mediated estrone 3-sulfate transport collectively observation indicate pharmacological activity erlotinib p-glycoprotein-mediated drug resistance dependent upon transporter substrate finding will useful understand pharmacological interaction erlotinib use combinational chemotherapy 
investigate interaction epidermal growth factor receptor egfr inhibit tyrosine kinase inhibitor tki p-gp-mediated drug resistance test three tki lapatinib gefitinib erlotinib direct atpase assay non-small cell lung cancer ncslc cell line define low level growth factor receptor expression three tki potentiate action known p-gp substrate cytotoxic drug therapeutically-relevant concentration however detailed analysis reveal interaction lapatinib p-gp distinct gefitinib erlotinib characterise direct inhibition stimulate p-gp atpase activity lapatinib prove potent p-gp modulator tki examine drug transport study p-gp-over-expressing a549-taxol cell line show lapatinib erlotinib capable increase docetaxel accumulation clinically achievable concentration combination study p-gp substrate chemotherapeutic agent demonstrate three tki significant potential augment cytotoxic activity p-gp-positive malignancy however interestingly agent also potentiate toxicity epirubicin non-p-gp resistant parental cell observation suggest combination lapatinib taxane anthracycline warrant clinical investigation nsclc examine beneficial detrimental interaction may result 
glioma common primary brain tumor poor prognosis temozolomide use thalidomide treat glioma investigate synergistic mechanism two drug vitro human malignant glioma cell u251-mg culture assign four group different treatment 3 day temozolomide group 100 micromol/l thalidomide group 100 microg/l temozolomide 100 micromol/l plus thalidomide group 100 microg/l control group mtt assay apply evaluate cell viability cell cycle analyze flow cytometry ultra-structural feature autophagosome observe electron microscope acridine orange monodansylcadaverine adopt label autophagosome flow cytometry apply quantification autophagosome expression autophagy-associated protein detect western blotting proliferation tumor cell obviously suppress temozolomide thalidomide treatment either drug use alone p = 0.000 day combination treatment induce cell cycle arrest g0/g1 phase typical autophagic ultra-structural character find combined treatment thalidomide promote autophagy induce temozolomide autophagy-associated proteins-microtubule associate protein 1 light chain 3 map1lc3 beclin1 significantly up-regulate combined treatment temozolomide use alone map1lc3 p = 0.000 beclin1 p = 0.004 expression level phosphatase tensin homolog delete chromosome ten pten promote autophagy suppress pi3k/akt/mtor signaling pathway elevated thalidomide thalidomide group p = 0.000 combined group p = 0.002 thalidomide enhance cytotoxicity temozolomide promote autophagy induce temozolomide contribute up-regulation pten thalidomide expression autophagy associate protein-map1lc3 beclin1 enhance lead reinforce autophagy combined treatment temozolomide thalidomide vitro 
triphenyltin iv complex composition ph 3 snl 1 h n 1 ph 3 snl 2 h n 2 l 1 h = 2 e -2 3-formyl-4-hydroxyphenyl -1-diazenyl benzoate l 2 h = 2 e -2 4-hydroxy-5-methylphenyl -1-diazenyl benzoate synthesize characterize spectroscopic 1 h 13 c 119 sn nmr ir 119 sn mössbauer technique combination elemental analysis molecular structure geometry complex 1 2 fully optimize use quantum mechanical method pm3 complex 1 2 find exhibit stronger cytotoxic activity vitro across panel human tumour cell line viz. a498 evsa-t h226 igrov m19 mel mcf-7 widr test compound 1 2 exhibit comparable result compound find far superior ccdp cisplatin 5-fu 5-fluorouracil eto etoposide across panel cell line activity pronounced a498 22 fold h226 33 fold cell line compare ccdp a498 13 fold h226 39 fold mcf-7 33 fold cell line compare eto test compound even 23 fold active magnitude term id 50 value least h226 cell line compare mtx methotrexate mechanistic role cytotoxic activity test compound 1 2 discuss relation theoretical result docking study key enzyme ribonucleotide reductase thymidylate synthase thymidylate phosphorylase topoisomerase ii 
many established cancer therapy involve dna-damaging chemotherapy radiotherapy gain dna repair capacity tumor represent common mechanism use cancer cell survive dna-damaging therapy poly adp-ribose polymerase-1 parp-1 nuclear enzyme activate dna damage play critical role base excision repair inhibition parp represent attractive approach treatment cancer previously describe discovery characterization potent parp inhibitor abt-888 abt-888 potentiate activity dna-damaging agent temozolomide tmz variety preclinical model report generation hct116 cell resistant treatment tmz abt-888 hct116r cell hct116r cell exhibit decrease h2ax phosphorylation response treatment tmz abt-888 relative parental hct116 cell microarray western blot study indicate hct116r cell decrease parp-1 elevated rad51 expression level hct116r cell dependent rad51 proliferation survival show inhibition proliferation induction apoptosis upon treatment rad51 small interfere rna addition hct116r cell resistant radiation parental hct116 cell study suggest cancer cell upregulate homologous recombination dna repair pathway compensate loss base excision repair may account observe resistance treatment tmz abt-888 
plant use drug century however limited research great potential source new therapeutic agent purpose study evaluate physalis peruviana cytotoxic activity cell line ht-29 pc-3 k-562 vero ht-29 cell line pc-3 k-562 vero expose four concentration p. peruviana ethanolic leave stem extract also different concentration cisplatin 5-fluorouracil 5-fu use positive control find rate growth within 48 hour determine inhibitory concentration 50 ic50 use linear regression analysis index selectivity sample p. peruviana ethanolic leave stem extract show cytotoxic activity ic50 g/ml leaf stem 0.35 r = -0.95 p 0.025 0.37 r = 0.90 p 0.05 ht-29 0.87 r = -0.98 p 0.01 1.01 r = -0.95 p 0.025 pc-3 0.02 r = -0.98 p 0.01 0.03 r = -0.98 p 0.01 k-562 4.9 r = -0.95 p 0.025 6.2 r = -0.98 p 0.01 vero ic50 antineoplastic cisplatin 4.2 r = -0.96 p 0.025 10.3 r = -0.97 p 0.025 0.15 r = -0.98 p = 0.01 1.1 r = 0.98 p = 0.01 5-fu 2.3 r = -0.97 p 0.025 17.9 r = -0.95 p 0.025 0.15 r = -0.98 p = 0.01 1.1 r = -0.94 p = 0.05 ht-29 pc-3 k562 vero respectively leaf stem extract selectivity index 5.6 245 tumor cell line evaluate contrast cisplatin 5-fu show value 0.11 7.3 p. peruviana leave steam ethanolic extract cytotoxic cisplatin 5 fu line ht-29 pc-3 k562 furthermore p. peruviana cytotoxic effect less cisplatin 5-fu vero control cell line 
gateway clinical trial guide recent clinical trial current literature congress datum follow table retrieve clinical trial knowledge area prous science integrity drug discovery development portal http://integrity.prous.com issue focus follow selection drug aav1/serca2a abacavir sulfate/lamivudine adalimumab aliskiren fumarate ambrisentan aripiprazole at-7519 atazanavir sulfate atomoxetine hydrochloride azacitidine azelnidipine besifloxacin hydrochloride bevacizumab bioabsorbable everolimus-eluting coronary stent bortezomib bosentan budesonide/formoterol fumarate caiv-t carisbamate casopitant mesylate certolizumab pegol cetuximab ciclesonide ciprofloxacin/dexamethasone ctce-9908 dalcetrapib darunavir deferasirox desloratadine disitertide drotrecogin alfa activate dta-h19 duloxetine hydrochloride dutasteride ecogramostim efalizumab emtricitabine eribulin mesilate escitalopram oxalate eszopiclone eur-1008 everolimus-eluting coronary stent exenatide fampridine fluticasone furoate formoterol fumarate/fluticasone propionate fosamprenavir calcium fulvestrant gabapentin enacarbil gs-7904l hpv-6 / 11/16/18 human secretin hydralazine hydrochloride/isosorbide dinitrate imatinib mesylate imexon inalimarev/falimarev indacaterol indacaterol maleate inhalable human insulin insulin detemir insulin glargine ixabepilone l-alanosine lapatinib ditosylate lenalidomide levocetirizine dihydrochloride liraglutide lisdexamfetamine mesilate lopinavir loratadine/montelukast sodium lutropin alfa menzb mepolizumab micafungin sodium morphine hydrochloride nabiximols nikkomycin z olmesartan medoxomil omalizumab paclitaxel-eluting stent pegfilgrastim peginterferon alfa-2a peginterferon alfa-2b perifosine pf-489791 plitidepsin posaconazole pregabalin qax-576 raltegravir potassium ramelteon rasagiline mesilate recombinant human relaxin h2 rhgad65 rivaroxaban rosuvastatin calcium rotigotine saxagliptin sch-530348 sirolimus-eluting stent slit-amikacin sorafenib sotrastaurin sr-16234 sulforaphane tadalafil tanespimycin tapentadol hydrochloride teriparatide tesofensine tiotropium bromide tipifarnib tirapazamine tmc-207 tocilizumab tolvaptan tosedostat treprostinil sodium ustekinumab varespladib methyl vicriviroc vildagliptin vildagliptin/metformin hydrochloride volociximab voriconazole ziconotide ziprasidone hydrochloride 
endothelin-1 et-1 endothelin receptor etar contribute development progression breast carcinoma modulate cell proliferation angiogenesis anti-apoptosis investigate antitumoral effect specific etar antagonist zd4054 breast cancer cell xenograft assess antitumoral efficacy combination zd4054 aromatase inhibitor fulvestrant gene expression change assess quantitative real-time pcr cell proliferation measure use alamarblue migration invasion assay perform use modify boyden chamber evaluate antitumoral efficacy zd4054 vivo different breast cancer model employ use nude mouse xenograft zd4054 reduce et-1 etar expression mcf-7 mda-mb-231 mda-mb-468 breast cancer cell concentration-dependent manner zd4054 inhibit invasion 37.1 p = 0.022 combination zd4054 either anastrozole letrozole produce significant reduction migration aromatase-overexpressing mcf-7aro cell p 0.05 combination zd4054 fulvestrant reduce mcf-7 cell migration invasion 36.0 p = 0.027 56.7 p 0.001 respectively effect significantly exceed see either compound alone regard tumor volume reduction vivo zd4054 10 mg/kg equipotent fulvestrant 200 mg/kg exhibit additive effect anastrozole 0.5 mg/kg datum first indicate selective etar antagonism zd4054 display antitumoral activity breast cancer cell vitro vivo datum strongly support rationale clinical use zd4054 combination endocrine therapy 
physically load paclitaxel ptx onto carbon nanotube cnt achieve immersion poly ethylene glycol peg graft-single walled cnt peg-g-swnt peg-graft-multi-walled cnt peg-g-mwnt saturated solution ptx methanol load load capacity ld 26 w/w 36 w/w peg-g-swnt peg-g-mwnt respectively ptx contents ptx load peg-g-swnt ptx loaded peg-g-mwnt still good dispersity aqueous solution individual cnt observe tem image ptx release peg-g-cnt several time faster free ptx still sustained profile less 40 ptx release 40 day ph 7 5 vitro cytotoxicity sample evaluate hela cell mcf-7 cell peg-g-swnt peg-g-mwnt show low cytotoxicity cell insignificant effect cell proliferation rate however ptx load peg-g-swnt ptx loaded peg-g-mwnt show high efficacy kill hela cell mcf-7 cell reflect ic 50 lower free ptx therefore ptx load peg-g-cnt promise cancer therapeutics carbon nanotube poly ethylene glycol drug delivery cancer therapy nanomedicine 
chronic myeloid leukemia cml bcr/abl-mediated oncogenic signaling target bcr/abl-inhibitor imatinib nilotinib dasatinib however agent may also affect anti-tumor immunity analyze effect 3 bcr/abl-inhibitor natural killer nk cell reactivity exposure cml cell k562 meg-01 pharmacological concentration imatinib nilotinib dasatinib diminish expression ligand activate immunoreceptor nkg2d similar extent result comparably reduce nk cell cytotoxicity ifn-gamma production direct effect nk cell response k562 primary cml cell well activate cytokine study dasatinib find abrogate nk cytotoxicity cytokine production nilotinib alter cytotoxicity high level impaired nk cytokine production imatinib direct influence nk cell reactivity note nilotinib bcr/abl-inhibitor increase cell death within preferentially cytokine-secreting cd56 bright cd16 nk cell subset may least part serve explain effect nilotinib nk cytokine production analysis nk cell signaling reveal dasatinib inhibit proximal signaling event lead decrease phosphorylation pi3k erk crucial nk cell reactivity imatinib nilotinib contrast show relevant effect nk cell pi3k erk activity light potential role nk cell immunesurveillance residual leukemia future combinatory immunotherapeutic approach datum indicate choice dosing suitable bcr/abl-inhibitor give patient require careful consideration 
background alkylating agent dacarbazine dtic use treatment melanoma decade use monotherapy cancer moderate response rate achieve recently clinical use temozolomide tmz become commonly use analog dtic-related oral agent greater bioavailability ability cross blood brain barrier response rate achieve tmz also unsatisfactory great interest identify compound use combination therapy previously demonstrate bioflavonoid quercetin qct promote p53-mediated response sensitize melanoma dtic demonstrate qct also sensitize cell tmz propose mechanism involve modulation truncate p53 family member deltanp73 method db-1 melanoma p53 wildtype sk mel 28 p53 mutant cell line treat tmz 400 microm 48 hr follow qct 75 microm 24 hr cell death determine annexin v-fitc staining immunocytochemical analysis carry determine protein translocation result treatment tmz db-1 cell demonstrate increase phosphorylation ataxia telangiectasia mutate atm p53 however cell resistant tmz-induced apoptosis resistance associate increase nuclear localization deltanp73 qct treatment combination tmz abolish drug insensitivity cause additive induction apoptosis compare either treatment alone treatment qct cause redistribution deltanp73 cytoplasm nucleus associate increase p53 transcriptional activity knockdown deltanp73 restore parp cleavage tmz treat cell confirm anti-apoptotic role response treatment predominantly p53 mediate p53 mutant sk mel 28 cell show significant enhancement apoptosis conclusion study demonstrate qct sensitize cell tmz mechanism sensitization involve modulation p53 family member 
serine/threonine kinase akt lie critical signaling node downstream phosphatidylinositol-3-kinase important promote cell survival inhibit apoptosis akt inhibitor may particularly useful cancer increase akt signaling associate reduce sensitivity cytotoxic agent receptor tyrosine kinase inhibitor evaluate effect novel allosteric akt inhibitor mk-2206 combination several anticancer agent vitro mk-2206 synergistically inhibit cell proliferation human cancer cell line combination molecular target agent erlotinib epidermal growth factor receptor inhibitor lapatinib dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor complementary inhibition erlotinib-insensitive akt phosphorylation mk-2206 one mechanism synergism synergistic effect find even erlotinib-insensitive cell line mk-2206 also show synergistic response combination cytotoxic agent topoisomerase inhibitor doxorubicin camptothecin antimetabolite gemcitabine 5-fluorouracil anti-microtubule agent docetaxel dna cross-linker carboplatin lung nci-h460 ovarian a2780 tumor cell synergy docetaxel depend treatment sequence schedule mk-2206 dose docetaxel effective mk-2206 suppress akt phosphorylation induce carboplatin gemcitabine vivo mk-2206 combination agent exert significantly potent tumor inhibitory activity agent monotherapy setting finding suggest akt inhibition may augment efficacy exist cancer therapeutics thus mk-2206 promising agent treat cancer patient receive cytotoxic and/or molecular target agent 
bevacizumab bvz vascular endothelial growth factor vegf target humanised monoclonal antibody provide clinical benefit combination docetaxel dxl microtubule-stabilising agent treatment metastatic breast prostate cancer since vegf receptor express tumour cell hypothesise bvz addition impact neo-vascularisation impact tumour cell enhance dxl activity hence study effect dxl bvz metastatic breast mda mb-231 prostate pc3 cancer cell line bvz alone decrease cell proliferation combination dxl bvz enhance anti-proliferative activity dxl anti-angiogenic factor sunitinib sorafenib gefitinib enhance anti-proliferative effect dxl qpcr experiment show dxl significantly increase vegf vegf receptor 2 vegf-r2 mrna level activation vegf vegf-r2 promoter demonstrate enhance mrna level partly due transcriptional activation elisa assay show dxl induce accumulation cytoplasmic vegf decrease extracellular level 39 mda 48 pc3 cell surface localisation vegf-r2 increase dxl alone decrease combined treatment dxl plus bvz abnormal expression vegf-r2 also show breast prostate tumour sample reinforce result obtain cellular model conclusion dxl bvz combination decrease extracellular vegf vegf-r2 level plasma membrane thereby block important growth/survival loop thus combined therapeutic impact bvz dxl observe clinical trial associate enhance anti-proliferative activity inhibition vascular network 
present preclinical study design evaluate new combination therapy comprise aromatase inhibitor anastrozole ana oral fluoropyrimidine uft s-1 estrogen receptor er positive human breast cancer cell line mcf-7 / arom 14 stably transfect cdna human aromatase mcf-7 / arom 14 cell show high aromatase activity notably able grow presence testosterone estradiol e 2 vitro ana 5-fluorouracil 5-fu inhibit cell growth concentration 0.005-10 0.2-5 mum respectively combination drug additively inhibit cell growth growth mcf-7 / arom 14 tumor significantly inhibit ana s-1 uft vivo combination ana s-1 uft administer use 21-day consecutive metronomic-like regimen significantly enhance antitumor efficacy suppress tumor growth 2-4 time longer monotherapy investigate mechanism s-1 enhance antitumor activity ana protein mrna expression level er-alpha tumor tissue treatment s-1 ana typical chemotherapeutic agent doxorubicin adm paclitaxel txl analyze protein mrna expression level er-alpha tumor tissue markedly decrease treatment s-1 s-1 ana treatment either adm txl reduce er-alpha level s-1 treatment might contribute increase antitumor activity ana reduce er-alpha-induced growth signaling addition decrease estrogen production induce ana base result combination ana s-1 might yield greater benefit chemotherapeutic agent postmenopausal woman er-positive breast cancer 
purpose cancer cell survival invasion metastasis depend cancer cell proliferation tumor-induced angiogenesis evaluate efficacy combination sorafenib erlotinib cetuximab experimental design sorafenib erlotinib cetuximab alone combination test vitro panel non-small cell lung cancer nsclc colorectal cancer cell line vivo h1299 tumor xenograft result epidermal growth factor receptor egfr ligand mrna express nsclc colorectal cancer cell line variable level range 0.4 8.1-fold compare geo colorectal cancer cell lung cancer cell highest level vascular endothelial growth factor vegf b c vegf receptor compare colorectal cancer cell combine treatment sorafenib erlotinib cetuximab produce combination index value 0.02 0.5 suggest significant synergistic activity inhibit soft agar colony formation cancer cell line accompany marked blockade mitogen-activated protein kinase akt signal vitro migration h1299 cell express high level vegf ligand receptor inhibit treatment sorafenib effect significantly increase combination anti-egfr drug nude mouse bear established human h1299 xenograft treatment combination sorafenib erlotinib cetuximab cause significant tumor growth delay result 70 90 day increase mouse median overall survival compare single-agent sorafenib treatment conclusion combination treatment sorafenib erlotinib cetuximab synergistic antitumor effect human colorectal lung cancer cell 
angiogenesis inhibitor may enhance effect low dose metronomic chemotherapy however wide range novel angiogenesis inhibitor must test combination oral chemotherapy agent assess anti-endothelial anti-cancer effect preliminary testing suit high throughput vitro model rather clinical trial aim establish vitro model test anti-endothelial anti-cancer effect multi-kinase inhibitor sorafenib use single agent combination oral chemotherapy agent use low concentration micro-vascular endothelial cell 3 cancer cell line utilise extended treatment strategy 96 h employ order mimic continuous low dose anti-angiogenic chemotherapy regimen sorafenib significantly enhance anti-endothelial effect low dose etoposide paclitaxel temozolomide sorafenib also significantly enhance anti-cancer effect low dose etoposide paclitaxel temozolomide sk-mel-2 melanoma cell produce additive effect inhibition cell growth case combination appear promising vivo pre-clinical study view testing melanoma patient continuous dosing strategy due vitro additive inhibitory effect growth see endothelial cancer cell 
investigate second-generation tyrosine kinase inhibitor dasatinib nilotinib potential overcome resistance imatinib-resistant k562 cell line evaluate whether rapamycin mammalian target rapamycin mtor inhibitor bortezomib proteasome inhibitor increase imatinib sensitivity resistant cell line cell line include k562 chronic myeloid leukaemia blast crisis k562r imatinib-resistant k562 expose dasatinib nilotinib rapamycin bortezomib rapamycin plus imatinib cell proliferation measure 3 4 5-dimethylthia-zol-2-yl -2 5-diphenyl tetrazolium bromide mtt assay mtor signaling pathway assess western blotting dasatinib nilotinib bortezomib inhibit proliferation k562 k562r cell line nm concentration resistance k562r due duplication autophosphorylation wild-type bcr-abl overcome dasatinib nilotinib sensitive bortezomib rapamycin partially inhibit proliferation k562 k562r cell line rapamycin plus imatinib inhibitory effect proliferation k562 k562r cell line k562r due duplication autophosphorylation wild-type bcr-abl induce imatinib still partially resistant dasatinib nilotinib overcome incremental dosing rapamycin enhance imatinib sensitivity blockade ubiquitin-proteasome pathway effective overcome resistance k562r imatinib-resistant cell line 
explore activity dasatinib alone combination paclitaxel carboplatin ovarian cancer cell determine dasatinib activity predict base evaluation src pathway microarray analysis perform igrov1 ovcar3 a2780 skov3 ovarian cancer cell status genomic src signature pathway determine cell treat carboplatin paclitaxel dasatinib individually combination pre post-treatment phospho-src psrc src protein expression determine dose-response curve construct drug interaction assess combination index ci method src protein expression level reflect src pathway genomic signature cell line lowest skov3 highest igrov1 pathway expression intermediate expression ovcar3 a2780 dasatinib treatment cause loss psrc cell line 50 growth inhibition igrov1 70 nm ovcar3 34 nm a2780 4.1 μm skov3 530 nm dasatinib combine cytotoxic yield synergistic effect ci = 0.46 0.79 cell line except skov3 dasatinib combination standard chemotherapeutic agent appear interact synergistic manner ovarian cancer cell line research need evaluate tumor cell characteristic predict response dasatinib 
beta cyclodextrin β-cd base nanosponge synthesize paclitaxel inclusion complex nanosponge prepare use technique inclusion complex formation paclitaxel nanosponge complex evaluate release nanosponge complex also evaluate use dsc ftir nmr technique confirmation inclusion complex formation paclitaxel nanosponge particle size morphology paclitaxel nanosponge complex estimate use sem tem dynamic light scattering technique particle size find range 400 600 nm cytotoxic efficacy paclitaxel nanosponge complex determine mcf-7 cell paclitaxel nanosponge complex find cytotoxic effective cell line 
paclitaxel show potent efficacy wide spectrum cancer clinical treatment however chemotherapy paclitaxel limit due serious allergic reaction patient cause cremophor el multidrug resistance many type tumor restricted permeability across intestinal barrier functional paclitaxel nanomicelle develop overcome obstacle evaluation perform breast cancer mcf-7 resistant mcf-7 / adr cell mcf-7 mcf-7 / adr tumor spheroid caco-2 cell manolayer evert gut sac xenografted resistant mcf-7 / adr cancer nude mouse functional paclitaxel nanomicelle approximately 15 nm diameter significantly increase intracellular uptake paclitaxel selectively accumulate mitochondria endoplasmic reticulum treatment show strong inhibitory effect mcf-7 mcf-7 / adr cell able penetrate deeply central region mcf-7 mcf-7 / adr spheroid result significant reduction size spheroid tem observation show intact functional paclitaxel nanomicelle transport across caco-2 cell manolayer everted gut sac significant antitumor efficacy xenografted resistant mcf-7 / adr cancer mouse evidence oral administration comparable intravenous administration functional paclitaxel nanomicelle provide strategy oral administration paclitaxel increase solubility paclitaxel overcome multidrug resistant cancer 
tra-8 monoclonal antibody death receptor 5 induce apoptosis various cancer cell however degree sensitivity vary highly sensitive resistant previously show resistance tra-8 reverse use chemotherapeutic agent mechanism underlie sensitization fully understand examine combination tra-8 doxorubicin bortezomib breast cancer cell tra-8-resistant bt-474 t47d cell chemotherapy agent synergistically sensitize cell tra-8 cytotoxicity enhance activation apoptosis show cleavage caspase parp reduce bid increase proapoptotic bcl-2 protein increase mitochondrial membrane depolarization doxorubicin bortezomib combine tra-8 also reduce bcl-xl x-linked inhibitor apoptosis xiap treat cell furthermore target protein pharmacologic modulator at-101 bh3i-2 at-406 produce sensitization tra-8 tra-8 combine at-101 bh3i-2 inhibitor antiapoptotic bcl-2 protein produce synergistic cytotoxicity zr-75-1 bt-474 t47d cell iap-targeting compound at-406 synergistic tra-8 bt-474 cell lesser extent t47d cell activation intrinsic apoptotic pathway common mechanism associate sensitization tra-8-resistant breast cancer cell line collectively study show bcl-2 iap family protein involve tra-8 chemotherapy resistance via modulation intrinsic apoptotic pathway targeting protein novel agent sensitize tra-8-resistant breast cancer cell suggest approach may represent potent therapeutic strategy treatment breast cancer 
temozolomide tmz preferred chemotherapeutic agent treatment glioma follow surgical resection and/or radiation resistance tmz attribute efficient repair and/or tolerance tmz-induced dna lesion majority tmz-induced dna base adduct repair base excision repair ber pathway therefore modulation pathway enhance drug sensitivity n-methylpurine dna glycosylase mpg initiate ber remove tmz-induced n3-methyladenine n7-methylguanine base lesion leave abasic site ap site dna processing ber use human glioma cell line ln428 t98g report potentiation tmz via ber inhibition methoxyamine mx parp inhibitor pj34 abt-888 depletion knockdown parg greatly enhance over-expression ber initiate enzyme mpg also show methoxyamine-induced potentiation tmz mpg express glioma cell abrogate elevated-expression rate-limiting ber enzyme dna polymerase beta polbeta suggest cell proficient ber readily repair ap site presence mx. depletion polbeta increase parp inhibitor-induced potentiation mpg over-expressing glioma cell suggest expression polbeta modulate cytotoxic effect combine increase repair initiation ber inhibition study demonstrate mpg overexpression together inhibition ber sensitize glioma cell alkylating agent tmz polbeta-dependent manner suggest expression level mpg polbeta might use predict effectiveness mx parp-mediated potentiation tmz cancer treatment 
optimal scheduling chemotherapy molecular-targeted agent important maximize clinical benefit compare effect concurrent sequential administration docetaxel multi-target inhibitor sunitinib malate tumor cell xenograft study several mechanism involve drug interaction provide experimental datum support clinical use non-small cell lung cancer nsclc human umbilical vein endothelial cell huvec nci-h460 human non-small lung carcinoma cell nci-h460 xenograft treat docetaxel sunitinib malate use concurrent sequential treatment schedule cell proliferation detect 3 4,5-dimethylthiazol-2-yl -5 3-carboxymethoxyphenyl -2 4-sulfophenyl 2h-tetrazolium mts assay cell cycle analysis conduct use flow cytometry extracellular signal-regulated kinase erk1/2 phosphorylation evaluate immunoblot analysis effect xenograft assess tumor growth delay significant difference cell proliferation cell cycle distribution nci-h460 cell concurrent treatment first sequential treatment docetaxel sunitinib malate effect inhibit erk1/2 phosphorylation sequential treatment docetaxel eliminate inhibitory activity sunitinib malate erk1/2 phosphorylation concurrent treatment nci-h460 xenograft first sequential treatment show superior effect concurrent treatment inhibit tumor growth combined treatment sunitinib malate docetaxel greater therapeutic effect monotherapy first sequential scheduling effective concurrent scheduling partly due effect docetaxel receptor tyrosine kinase rtk signaling pathway 
study aim develop chitosan couple lipid nanoparticle ch-ptx-lip immunomodulatory activity chitosan chemotherapeutic effect paclitaxel synergistically enhance efficacy novel drug delivery system particle size zeta potential entrapment efficiency ee ch-ptx-lip find 113.3 / 4.5 nm pdi 0.38 35.7 / 2.9 mv 96.4 / 1.8 respectively morphological evaluation particle tem show circular bilayer structure along outer polymer layer ch-ptx-lip show significantly enhance cytotoxicity p 0.05 compare market formulation ptx solution ptx-lip evaluate in-vitro mtt assay mcf-7 cell line improve efficacy lower dose drug new strategy cancer minimum side effect shorter treatment duration 
glioblastoma multiforme gbm brain tumour characterise remarkably high chemoresistance infiltrate capability date chemotherapy temozolomide contribute poorly improve survival rate patient one important mechanism chemoresistance come activity certain protein atp-binding cassette superfamily extrude antitumour drug metabolite cell identify increase expression multiple drug resistance-associated protein 1 mrp1 glioblastoma multiforme biopsy t98g g44 cell line activity transporter also confirm measure extrusion fluorescent substrate cfda sensitivity gbm cell low upon exposure temozolomide vincristine etoposide decrease cell viability 20 see therapeutic concentration drug however combined exposure vincristine etoposide inhibitor mrp1 efficiently decrease cell viability 80 conclude chemosensitization cell inhibitor mrp1 activity might efficient tool treatment human gbm 
mechanism cell death apoptosis necrosis determine morphologically dna gel electrophoresis 3 human leukaemic t-cell line ccrf-cem f2 ccrf-hsb molt .4 treatment cytotoxic drug include one hormone dexamethasone dxm dna damaging agent melphalan cisplatin bleomycin mitomycin c mithramycin inhibitor dna synthesis aphidicolin cytosine arabinoside ara-c methotrexate mtx 5-fluoro-2 deoxyuridine fudr 5-fluorouracil 5-fu metabolic inhibitor bromo-2 deoxy-2 uridine budr actinomycin d 5-azacytidine 5-ac cycloheximide vincristine etoposide adriamycin cell death assess morphologically apoptotic cell death apparent three cell line 48 hour drug treatment however distinct pattern dna breakdown observe cell line smear dna agarose gel see ccrf-cem f2 5-fu mithramycin treatment whilst ccrf-hsb cell show similar dna profile 5-fu mtx treatment drug treatment molt .4 cell produce necrotic pattern dna degradation cycloheximide inhibitor protein synthesis reduce dna fragmentation ccrf-cem f2 cell treat dxm mtx fudr indicate protein synthesis require cytotoxicity apoptosis however extent dna fragmentation cause 5-fu significantly affect cycloheximide result indicate least morphological electrophoretic criterion use avoid differ conclusion mode cell death 
20 patient chronic myeloid leukemia cml respond treatment imatinib either initially acquire resistance study development cml drug resistance vitro experimental system comprise cell line different resistance level establish expose k562 cell increase concentration imatinib dasatinib anticancer agent mrna level bcr abl1 gene involve drug transport redistribution abcb1 abcc1 abcc3 abcg2 mvp slc22a1 measure abl1 kinase domain sequence result exclude bcr abl1 overexpression mutation relevant resistance mechanism study transporter overexpress majority resistant cell line expression pattern dynamic vary resistance level chronic drug exposure study efflux transporter may important role initial stage resistance prolonged exposure higher dose drug mechanism might take place 
three currently identify secondary resistance mechanism observe patient chronic myeloid leukemia cml receive tyrosine kinase inhibitor tki bcr-abl kinase domain kd mutation increase bcr-abl expression overexpression drug-efflux protein abcb1 abcg2 investigate interplay three mode resistance three cml blast crisis cell line k562 abcb1-overexpressing variant k562 dox ku812 culture gradually increase concentration imatinib 2 μm dasatinib 200 nm eight imatinib two dasatinib-resistant cell line establish two imatinib-resistant k562 line increase bcr-abl expression apparent mode resistance however dasatinib-resistant k562 culture generate observe gradually increase bcr-abl expression peak prior identification t315i mutation bcr-abl overexpression follow mutation development observe 4/10 cell line different kd mutation contrast three imatinib-resistant k562 dox line exhibit increase abcb1 expression tki-resistant cell line generate increase ic 50 dose drug require reduce phosphorylation adaptor protein p-crkl 50 imatinib dasatinib nilotinib regardless tki use induce resistance suggest currently available tki share susceptibility drug resistance 
ataxia telangiectasia mutate rad3-related kinase atr key role signalling stall replication fork dna damage cell cycle checkpoint dna repair long recognise important target cancer therapy inhibitor prove elusive nu6027 originally develop cdk2 inhibitor potentiate cisplatin cdk2-independent manner postulate may inhibit atr cellular atr kinase activity determine chk1 phosphorylation human fibroblast inducible dominant-negative atr-kinase dead expression human breast cancer mcf7 cell cell cycle effect chemo radiopotentiation nu6027 determine mcf7 cell role mismatch repair p53 determine isogenically match ovarian cancer a2780 cell nu6027 potent inhibitor cellular atr activity ic 50 = 6.7 μm enhance hydroxyurea cisplatin cytotoxicity atr-dependent manner nu6027 attenuate g2/m arrest follow dna damage inhibit rad51 focus formation increase cytotoxicity major class dna-damaging anticancer cytotoxic therapy antimitotic paclitaxel a2780 cell sensitisation cisplatin greatest cell functional p53 mismatch repair mmr sensitisation temozolomide greatest p53 mutant cell functional mmr importantly nu6027 synthetically lethal dna single-strand break repair impaired either poly adp-ribose polymerase parp inhibition defect xrcc1 nu6027 inhibit atr impair g2/m arrest homologous recombination thus increase sensitivity dna-damaging agent parp inhibitor provide proof concept datum clinical development atr inhibitor 
epidermal growth factor receptor egfr frequently overexpress colorectal cancer therefore attractive target treatment zegfr 1907 2 newly develop dimeric affibody molecule high affinity extracellular part egfr study evaluate cytotoxic effect zegfr 1907 2 combination external radiation possible inhibitory effect egfr signalling pathway colon cancer cell line ht-29 hct116 effect compare egfr antibody cetuximab tyrosine kinase inhibitor erlotinib sunitinib cell line genotypically different respect e.g. kras braf mutational status recently show clinical significance therapeutic effect cell line express approximately 100,000-150,000 egfr per cell differ radiation response hct116 sf2 = 0.28 ht-29 sf2 = 0.70 exposure zegfr 1907 2 produce small significant reduction survival hct116 affect ht-29 cell similar result obtain exposure egf egfr antibody cetuximab egfr tyrosine kinase target inhibitor erlotinib multi-tyrosine kinase inhibitor sunitinib reduce survival cell line however none drug significant radiosensitizing effect combination radiation akt erk central protein egfr downstream signalling cellular response ionize radiation activation akt ser 473 erk thr202/tyr204 radiation dose time-dependent however activation egfr clearly affect radiation neither zegfr 1907 2 drug able completely inactivate akt erk contrary erlotinib stimulate akt phosphorylation cell line hct116 cell erk activate overall result illustrate complexity response radiation drug cell differential phenotypic status 
assess role novel second-line treatment nonsmall cell lung cancer nsclc systematic review literature meta-analysis phase iii randomize clinical trial rct independently perform 3 author trial compare novel treatment every-3-week docetaxel 3wd design noninferiority trial include analysis one-year survival rate sr primary end point quality life safety represent secondary end point four rct meet selection criterion outcome 3355 patient analyze pooled analysis heterogeneity document primary analysis either include trial analyze separately gefitinib chemotherapeutic alternative 3wd cumulative odds ratio 0.927 p = 0.313 1-year sr 0.889 p = 0.323 chemotherapeutic alternative 3wd 0.953 p = 0.616 gefitinib experimental arm show significant advantage quality life cumulative analysis odds ratio = 1.623 p = 0.01 subgroup patient treat gefitinib odds ratio = 1.962 p 0.001 better safety profile experimental arm observe cumulative analysis subgroup alternative chemotherapy gefitinib noninferiority trial demonstrate noninferiority pemetrexed oral topotecan gefitinib 1-year sr primary end point improvement overall survival remain modest improvement quality life safety secondary end point represent main value treatment whose aim mainly palliative 
imatinib mesylate gleevec sti571 specific inhibitor bcr/abl fusion tyrosine kinase exhibit potent antileukemic effect chronic myelogenous leukemia bcr/abl-positive k562 bcr/abl-negative hl-60 human leukemia cell use investigate effect pri-2191 calcitriol analog biological effect imatinib combine anticancer drug result show pri-2191 enhance antiproliferative effect imatinib hl-60 cell two agent together apply either docetaxel cisplatin idarubicin antiproliferative effect still enhance moreover interaction chemotherapy agent antagonistic additive pri-2191 even shift synergism effect correlate accumulation hl-60 cell g0/g1 phase cell cycle decrease percentage cell g2/m s stage ternary combination use pri-2191 influence apoptosis induce imatinib alone ternary combination chemotherapy agent use result may suggest stronger antiproliferative effect combined treatment pri-2191 hl-60 cell relate cell cycle arrest rather induction apoptosis 
series novel self-assembled hyaluronic acid derivative ha-c 18 graft hydrophobic octadecyl moiety dual target folic acid-conjugated ha-c 18 fa-ha-c 18 synthesize increase degree substitution octadecyl group 12.7 19.3 critical micellar concentration ha-c 18 copolymer decrease 37.3 10.0 μg/ml paclitaxel ptx successfully encapsulate hydrophobic core ha-c 18 fa-ha-c 18 micelle encapsulation efficiency high 97.3 physicochemical property polymeric micelle measure dls tem dsc moreover vitro release behavior ptx investigate dialysis bag method ptx release micelle near zero-order sustained manner vitro antitumor activity test suggest ptx-loaded ha-c 18 fa-ha-c 18 micelle exhibit significantly higher cytotoxic activity mcf-7 a549 cell compare taxol lower ptx concentration cellular uptake experiment conduct quantitative assay ptx cellular accumulation confocal laser scanning microscopy imaging coumarin-6 label ha-c 18 fa-ha-c 18 micelle folate receptor overexpress mcf-7 cell folate cd44 receptor competitive inhibition study perform fluorescence microscopy imaging suggest intracellular delivery ha-c 18 fa-ha-c 18 micelle efficiently take via cd44 receptor-mediated endocytosis folate receptor-mediated endocytosis enhance internalize amount fa-ha-c 18 micelle mcf-7 cell compare ha-c 18 micelle internalization pathway ptx-loaded ha-c 18 fa-ha-c 18 micelle might include clathrin-mediated endocytosis caveolae-mediated endocytosis macropinocytosis therefore present study suggest ha-c 18 fa-ha-c 18 copolymer biodegradable biocompatible cell-specific targetable nanostructure carrier promising nanosystem cellular intracellular target delivery hydrophobic anticancer drug 
spite good research drug delivery bone targeting remain largely unexplored even bone disease seldom cure just poor distribution drug bone site zoledronate zol strong affinity towards bone utility bone metastasis management make perfect ligand bone targeting recent study reveal zol combination docetaxel show significant synergism management bone metastasis result clear zol-conjugated plga nanoparticle np show cellular uptake pegylate plga np change cellular uptake route vitro study mcf-7 bo2 cell line reveal zol anchor plga-peg np show enhance cell cytotoxicity increase cell cycle arrest apoptotic activity plga-peg-zol np find block mevalonate pathway increase accumulation apoptotic metabolite apppi vivo animal study use technetium-99m radiolabeling show prolong blood circulation half-life reduce liver uptake significantly higher retention zol tag np bone site enhance tumor retention conclude target ability zol enhance strong affinity bone enhance endocytosis zol anchor plga-peg np 
treatment non small cell lung cancer nsclc colorectal cancer crc substantially change last year introduction epidermal growth factor receptor egfr inhibitor clinical practice understanding mechanism regulate cell sensitivity drug necessary optimal use.an vitro model acquire resistance two tyrosine kinase inhibitor tki target egfr erlotinib gefitinib tki target egfr vegfr vandetanib develop continuously treat human nsclc cell line calu-3 human crc cell line hct116 escalate dose drug mtt western blot analysis migration invasion anchorage-independent colony form assay conduct vitro experiment established xenograft athymic nude mouse perform vivo sensitive wild type wt tki-resistant calu-3 hct116 cell lines.as compare wt calu-3 hct116 human cancer cell tki-resistant cell line show significant increase level activate phosphorylate akt mapk survivin consider role ras raf downstream signal egfr vegfr pathway treat resistant cell sorafenib inhibitor c-raf b-raf c-kit flt-3 ret vegfr-2 vegfr-3 pdgfr-β sorafenib reduce activation mek mapk cause inhibition cell proliferation invasion migration anchorage-independent growth vitro tumor growth vivo tki-resistant calu-3 hct116 cell lines.these datum suggest resistance egfr inhibitor predominantly drive ras/raf/mapk pathway overcome treatment sorafenib 
exosome microvesicle endocytic origin release normal tumor cell play important role cell-to-cell communication angiogenesis show regulate progression chronic myeloid leukemia cml mechanism happen elucidate isolate characterize exosome k562 cml cell evaluate effect human umbilical endothelial cell huvec fluorescent-labeled exosome internalize huvec tubular differentiation matrigel exosome localization perinuclear early differentiation move peripherally cell undergo elongation connection exosome move within nanotubular structure connect remodel endothelial cell stimulate angiotube formation serum/growth factor-limited medium control double total cumulative tube length p = 0.003 treatment k562 cell two clinically active tyrosine kinase inhibitor imatinib dasatinib reduce total exosome release p 0.009 equivalent concentration drug-treated exosome induce similar extent tubular differentiation however dasatinib treatment huvec markedly inhibit huvec response drug control cml exosome p 0.002 vivo mouse matrigel plug model angiogenesis induce k562 exosome abrogate oral dasatinib treatment p 0.01 k562 exosome induce dasatinib-sensitive src phosphorylation activation downstream src pathway protein huvec imatinib minimally active exosome stimulation huvec cell differentiation signaling thus cml cell-derived exosome induce angiogenic activity huvec cell inhibitory effect dasatinib exosome production vascular differentiation signaling reveal key role src leukemia microenvironment 
paper report design synthesis new family compound phostine belong 1,2 oxaphosphinane family twenty-six compound screen antiproliferative activity large panel nci cancer cell line easy synthesis low ec 50 value 500 nm c6 rat glioma cell line compound 3.1 select biological study moreover specific biological effect 3.1 glioblastoma phylogenetic cluster nci dependent stereochemistry within cluster 3.1 higher antiproliferative activity temozolomide potent paclitaxel sf295 snb75 cell line constrast paclitaxel vincristine 3.1 devoid astrocyte toxicity original activity spectrum 3.1 nci cancer cell line panel allow development family use association exist drug open new therapeutic perspective 
glioblastoma multiforme gbm common intracranial tumor dismal prognosis although temozolomide tmz base chemotherapy follow neurosurgery prove effective patient benefit clinically tmz resistance give protein expression o 6 methylguanine-dna-methyltransferase mgmt important determinant tmz resistance great effort make suppress regulate mgmt-related transcription factor study present demonstrate resveratrol natural polyphenol able reverse tmz resistance glioblastoma t98g cell relatively high mgmt activity datum show combination treatment tmz resveratrol result enhance antitumor potential tmz decrease 50 inhibit concentration ic50 tmz increase induction apoptosis tmz-resistant t98g cell hoechst 33258 staining reveal increase apoptotic morphology chromatin aggregation nuclear cytoplasmic condensation cell receive combination treatment western blot analysis manifest significant decrease intracellular content nuclear translocation nf-κb increase cleavage caspase-3 cell expose combination treatment compare cell treat tmz alone addition recombinant expression nf-κb subunit p65 remarkably promote nuclear translocation nf-κb abolish tmz-resistance reversal induce combination treatment suggest underlie nf-κb-dependent mechanism study improve knowledge mechanism tmz resistance suggest novel strategy tmz-based chemotherapy glioblastoma patient 
elafin report abundantly express human epithelial ovarian carcinoma eoc however function poorly understand evaluate role elafin modulate sensitivity human eoc cell chemotherapeutic drug elafin expression determine elisa 9 establish human eoc cell line lentivirus encode elafin-specific shrna use down-regulate elafin expression ovcar3 ov433 cell plasmid encode elafin use ectopically express elafin elafin-negative skov3 cell sensitivity cisplatin genotoxic agent paclitaxel inhibitor microtubule depolymerization examine ovcar3 ov433 skov3 subline cell viability determine mtt assay apoptosis annexin v/7-aad staining caspase activation fluorimetric assay knockdown elafin gene decrease cisplatin ic50 least 2-fold ovcar3 ovcar433 cell p 0.01 affect paclitaxel ic50 sensitivity genotoxic agent carboplatin cyclophosphamide 5-fluorouracil also increase silence expression elafin apoptosis caspase-3 activation significantly augmented cisplatin-treated ovcar3 cell silence elafin overexpression elafin skov3 cell make resistant cisplatin decrease cisplatin-induced apoptosis caspase activation p 0.01 expression elafin decrease sensitivity human eoc cell several genotoxic agent may important implication predict response patient eoc chemotherapy clinic 
prostate cancer major problem worldwide affect man age forty-five vernonia guineensis benth asteraceae root decoction use folk medicine cameroon treat number ailment include prostate cancer aim study provide preliminary validation use vernonia guineensis benth extract treat prostate cancer evaluate vitro activity crude extract isolate molecule prostate cancer cell line effect angiogenesis essential growth metastase prostate cancer aqueous dichloromethane methanol extract vernonia guineensis benth tuber test activity three prostate cancer cell line pc-3 du-145 at3b-1 dichloromethane extract subject bioactivity guide fractionation anti-proliferation clonogenic antiangiogenic activity crude extract isolate compound test wst-1 assay use anti-proliferation activity meanwhile standard clonogenic test rat ring aorta assay carry determine clonogenic antiangiogenic activity test product respectively aqueous methanol extract vernonia guineensis benth demonstrate weak activity prostate cancer cell line vitro ic 50 100 μg/ml dichloromethane extract potent ic 50 56.233 ± 3.630 μg/ml 67.316 ± 2.452 μg/ml du-145 pc-3 cell line respectively activity guide fractionation extract yield pentaisovalerylsucrose 1 isolate first time natural source best knowledge compound 1 demonstrate vitro activity human prostate cancer cell line pc-3 du-145 ic 50 5.701 ± 0.142 μm 4.275 ± 0.710 μm respectively ic 50 compound 5.763 ± 0.425 μm at3b-1 rat prostate cancer cell line express p-glycoprotein link drug resistance metastatic cancer compare compound 1 paclitaxel docetaxel active at3b-1 2.641 ± 1.253 μm 0.613 ± 0.251 μm paclitaxel show ic 50 value 0.004 ± 0.002 μm 0.003 ± 0.001 μm du-145 pc-3 prostate cancer cell line respectively docetaxel show ic 50 value 0.002 ± 0.001 μm 0.004 ± 0.001 μm du-145 pc-3 prostate cancer cell line respectively vitro anti-prostate cancer antiangiogenic activity vernonia guineensis benth extract isolate compound support use tuber plant treatment prostate cancer 
high-linear energy transfer radiation offer superior biophysical property conventional radiotherapy may great potential treat radioresistant tumor glioblastoma however little pre-clinical datum exist effect high-let radiation glioblastoma cell line concomitant application chemotherapy study investigate vitro effect temozolomide combination low-energy proton α particle cell survival dna damage repair cell growth examine four human glioblastoma cell line ln18 t98g u87 u373 treatment either x ray proton let 12.91 kev/μm α particle let 99.26 kev/μm without concurrent temozolomide clinically-relevant dose 25 50 μm relative biological effectiveness 10 survival rbe 10 increase let increase 1.17 1.06 proton 1.84 1.68 α particle ln18 u87 cell line respectively temozolomide administration increase cell killing o 6 methylguanine dna methyltransferase-methylated u87 u373 cell line contrast temozolomide provide therapeutic enhancement methylguanine dna methyltransferase-unmethylated ln18 t98g cell line addition residual number γ-h2ax focus 24 h treatment radiation concomitant temozolomide find lower equal expect dna damage either individual treatment kinetics focus disappearance x-ray proton irradiation follow similar time course whereas loss γ-h2ax focus α particle irradiation occur slower rate low-let radiation half-life 12.51-16.87 h combination temozolomide different radiation type cause additive rather synergistic cytotoxicity nevertheless particle therapy combine chemotherapy may offer promising alternative additional benefit superior biophysical property also possible new fractionation schedule design exploit change dna repair kinetics mgmt-methylated cell respond high-let radiation 
transport protein iron transferrin trigger cellular endocytosis bind receptor tfr cell membrane use property conjugate transferrin onto surface biodegradable polymeric micelle construct amphiphilic block copolymer core micelle either label near-infrared dye nir conjugate chemotherapeutic drug paclitaxel ptx study biodistribution antitumor effect nude mouse bear subcutaneous tfr-overexpressing cancer dls tem show size tf-conjugated tf-free micelle range 85-110 nm confocal laser scanning microscopy flow cytometry experiment indicate uptake efficiency micelle tfr-overexpressing cell enhance tf conjugation semiquantitative analysis nir signal collect tumor site show maximum accumulation achieve 28 h m nir group 22 h tf-m nir group area intensity curve tf-m nir group m nir group finally tumor inhibition effect target micelle study gastric carcinoma model overexpress tfr analysis tumor volume observation h&e stain tumor section show tf-m ptx best antitumor effect compare control group saline ptx m ptx result study demonstrate potential application tf-conjugated polymeric micelle treatment tfr-overexpressing cancer 
sorafenib sunitinib multi-kinase inhibitor antitumor activity patient advanced renal cell carcinoma rcc several study evaluate effect sorafenib/sunitinib combination chemotherapeutic agent different type tumor however study address activity fluorinate pyrimidine combination sorafenib/sunitinib study examine potential combination therapy 5fu sorafenib/sunitinib human rcc cell line three human rcc cell line achn caki-1 caki-2 use assess sensitivity 5-fluorouracil 5fu sorafenib sunitinib alone combination use vitro cell survival assay caki-2 cell demonstrate significantly higher resistance 5fu sorafenib compare achn caki-1 additive antitumor effect combination therapy observe vitro study tendency positive correlation sensitivity sunitinib platelet-derived growth factor beta pdgfr-beta expression level examine reverse transcription polymerase chain reaction caki-1 xenograft model prepare inoculate cell subcutaneously nude mouse divide randomly six group control 5fu 8 mg/kg/day intraperitoneally sorafenib 15 mg/kg/day orally sunitinib 20 mg/kg/day orally 5fu sorafenib sunitinib treatment administer 5 day week tumor growth monitor 42 day follow inoculation cell synergistic antitumor effect combination therapy observe vivo study resected tumor evaluate use ki-67 labeling index microvessel density ki-67 labeling index microvessel density decrease tumor treat combination therapy compare treat sorafenib/sunitinib alone finding suggest combination therapy 5fu sorafenib/sunitinib may effective therapeutic modality advanced rcc patient 
previously hypothesize small molecule selectively accumulate cancer cell might participate non-immunological antitumor surveillance mechanism demonstrate earlier mixture experimentally select substance active mixture l-arginine l-histidine l-methionine l-phenylalanine l-tyrosine l-tryptophan l-ascorbate d-biotin pyridoxine riboflavin adenine l malate possess selective toxic effect vitro variety tumor cell line show selectively induce apoptosis cancer cell vitro explore vivo significance earlier finding examine antitumor effect colon 26 murine colorectal adenocarcinoma b16 murine melanoma mxt murine mammary carcinoma s180 murine sarcoma p388 murine lymphoid leukemia hl-60 human promyeloid leukemia pc-3 human prostate carcinoma ht-29 human colon carcinoma tumor model treatment tumor bearing mouse inhibit growth tumor investigate inhibitory effect range 40 69 comparable antitumor effect 5-fluorouracil cisplatin colon-26 tumor model combined treatment 5-fluorouracil cisplatin result enhance tumor growth inhibitory effect induced apoptosis mitochondrial pathway induce g1 arrest pc-3 cell increase number apoptotic cell pc-3 xenograft finding suggest might offer interesting perspective treatment cancer combination treatment may offer hope effective cancer therapy 
cellax pegylate carboxymethylcellulose conjugate docetaxel dtx condense 120-nm nanoparticle compare approve clinical taxane nanoformulation abraxane ® mouse model cellax increase systemic exposure taxane 37 × compare abraxane improve delivery specificity cellax uptake selective tumor liver spleen 203 × increase tumor accumulation compare abraxane concentration release dtx cellax treated tumor well ic50 least 10 d paclitaxel release abraxane undetectable 24h s.c. pc3 prostate b16f10 melanoma model cellax exhibit enhance efficacy better tolerate compare abraxane orthotopic 4t1 breast tumor model cellax reduce incidence lung metastasis 40 metastasic incidence tissue mouse treat abraxane display increase lung metastasic incidence 85 metastase detect bone liver spleen kidney result confirm cellax effective drug delivery strategy compare approve taxane nanomedicine 
study combination therapy use oral fluoropyrimidine tegafur-gimeracil-oteracil s-1 several target agent antibody evaluate first effect tyrosine kinase inhibitor erlotinib hydrochloride sorafenib tosilate sunitinib malate human non-small cell lung cancer nsclc breast cancer colorectal cancer evaluate vivo effect combination s-1 target antibody bevacizumab cetuximab human colorectal cancer also evaluate vivo s-1 epidermal growth factor receptor egfr tyrosine kinase inhibitor erlotinib show significant inhibition growth human nsclc lu-99 pc-9 cell line antitumor activity combination s-1 erlotinib lu-99 pc-9 cancer cell line significantly superior either monotherapy p 0.05 combination therapy use multi-tyrosine kinase inhibitor sorafenib sunitinib s-1 breast cancer mx-1 cell line nsclc nci-h460 cell line significantly superior either monotherapy p 0.01 combination anti-vascular endothelial growth factor antibody bevacizumab anti-egfr antibody cetuximab s-1 human colorectal cancer col-1 km20c bevacizumab dld-1 cetuximab cell line 5-fluorouracil 5-fu resistant cell line km12c/5-fu significantly superior either monotherapy p 0.01 particular growth col-1 cell completely inhibit combination s-1 bevacizumab toxic mortality significant difference body weight change animal treat s-1 combine target agent mono-therapy observe therefore treatment appear well-tolerated preclinical finding indicate combination therapy s-1 target agent promising treatment option 
initiate preclinical study order analyze impact sorafenib single treatment versus combination treatment human colorectal cancer effect increase sorafenib dose proliferation apoptosis migration activation signal cascade analyze vitro effect sorafenib single treatment versus 5-fluorouracil 5-fu single treatment combination therapy vivo proliferation target cytokine receptor/ligand expression analyze human colon cancer xenograft mouse model use ht29 tumor cell vitro sw480 ht29 cell line sensitive sorafenib compare caco2 sw620 cell line independent mutation status k-ras raf pten pi3k effect migration marginal distinct difference caspase activation see combination strategy beneficial setting sorafenib 5-fu irinotecan disadvantageous sorafenib oxaliplatin depend chemotherapeutic drug cell line choose sensitive cell line reveal downregulation akt weak expression level gadd45β resistant cell line pp53 gadd45β level decrease upon sorafenib exposure vivo combination treatment sorafenib 5-fu equally effective respective monotherapy concern tumor proliferation interestingly treatment either sorafenib 5-fu result significant decrease vegfr1 pdgfrβ expression intensity colorectal cancer sensitivity towards sorafenib exist seem similarly effective 5-fu monotherapy combination therapy contrast show additional effect 
several study implicate lung cancer progression govern interaction estrogen receptor er epidermal growth factor receptor egfr signaling pathway combine targeting egfr er may synergistic effect lung cancer treatment aim study explore potential utility inhibit two pathway combination anastrozole gefitinib non-small cell lung cancer nsclc cell line expression level er er-α er-β lung cancer cell line a549 h460 spc-a-1 h1299 normal bronchus epithelial cell beas-2b detect use real-time pcr western blot immunocytochemistry use locate er-α er-β cell line highest er expression level cell treat anastrozole gefitinib alone combination cell proliferation inhibition detect cck8 assay cell cycle apoptosis effect detect flow cytometry expression level phosphorylated-egfr p-egfr erk phosphorylated-erk p-erk akt phosphorylated-akt p-akt detect western blot among cell line expression level er a549 cell highest a549 cell line er-α mainly localized cytoplasm whereas er-β mainly localized cytoplasm lesser degree nucleus combination two drug increase proliferation inhibition rate 24h 48 h 72 h 37.66 ± 1.02 63.41 ± 2.02 70.50 ± 0.86 respectively closely associate elevation g0/g1 phase fraction p 0.05 apoptosis rate a549 cell treat anastrozole gefitinib alone combination 10.72 ± 1.12 17.40 ± 1.28 23.02 ± 2.32 respectively p 0.05 synergistic effect combination therapy accompany reduction p-egfr p-erk p-akt expression compare individual treatment result study suggest combination anastrozole gefitinib compare either drug alone maximally inhibit cell proliferation induce apoptosis affect downstream signaling pathway study support functional interaction er egfr pathway lung cancer provide clinically exploitable strategy non-small cell lung cancer patient 
pecam-1 cd31 immunoreceptor tyrosine-based inhibitory motif itim contain surface glycoprotein express various hematopoietic cell well endothelial cell pecam-1 show play role regulation adhesion migration apoptosis bcr/abl fusion tyrosine kinase express chronic myeloid leukemia philadelphia-positive ph acute lymphoblastic leukemia cell inhibition clinically use tyrosine kinase inhibitor imatinib dasatinib induce apoptosis cell present study demonstrate pecam-1 tyrosine phospho-rylated itim motif various bcr/abl-expressing cell include primary leukemia cell study use imatinib dasatinib well transient expression experiment 293t cell reveal pecam-1 phosphorylate directly bcr/abl enhance imatinib-resistant e255k t315i mutation partly src family tyrosine kinase include lyn activate dependently independently bcr/abl also demonstrate use substrate trapping mutant shp2 tyrosine phosphorylated pecam-1 bind shp2 major substrate tyrosine phosphatase bcr/abl-expressing cell overexpression pecam-1 bcr/abl-expressing cell include k562 human leukemia cell enhance cell adhesion partially inhibit imatinib-induced apoptosis involve mitochondria depolarization caspase-3 cleavage least partly itim-independent manner datum suggest pecam-1 may play role regulation apoptosis well adhesion bcr/abl-expressing cell modulate imatinib sensitivity possible candidate therapeutic target ph leukemia 
purpose compare efficacy safety epidermal growth factor receptor tyrosine kinase inhibitor monotherapy efgr-tki gefitinib erlotinib standard second-line chemotherapy single agent docetaxel pemetrex previously treat advanced non-small-cell lung cancer nsclc method systematically search randomize clinical trial compare egfr-tki monotherapy standard second-line chemotherapy previously treat advanced nsclc end point overall survival os progression-free survival pfs overall response rate orr 1-year survival rate 1-year sr grade 3 4 toxicity pooled hazard ratio hr risk ratio rr corresponding 95 confidence interval ci calculate employ fix random-effects model depend heterogeneity include trial result eight randomize controlled trial totally 3218 patient eligible meta-analysis result show egfr-tki comparable standard second-line chemotherapy advanced nsclc term overall survival hr 1.00 95 ci 0.92-1.10 p = 0.943 progression-free survival hr 0.90 95 ci 0.75-1.08 p = 0.258 1-year-survival rate rr 0.97 95 ci 0.87-1.08 p = 0.619 overall response rate higher patient receive egfr-tki rr 1.50 95 ci 1.22-1.83 p = 0.000 sub-group analysis demonstrate egfr-tki monotherapy significantly improve pfs hr 0.73 95 ci 0.55-0.97 p = 0.03 orr rr 1.96 95 ci 1.46-2.63 p = 0.000 east asian patient translate increase os 1-year sr. furthermore fewer incidence grade 3 4 neutropenia febrile neutropenia neurotoxicity egfr-tki monotherapy group exclude grade 3 4 rash conclusion intervention comparable efficacy second-line treatment patient advanced nsclc egfr-tki monotherapy associate less toxicity better tolerability moreover datum also demonstrate egfr tki monotherapy tend effective east asian patient term pfs orr compare standard second-line chemotherapy result help inform decision patient management design future trial 
evaluation in-vivo anticancer activity aerosolized celecoxib encapsulate nanolipidcarriers cxb-nlc single therapeutic agent combine intravenously administer docetaxel doc non-small cell lung cancer cxb-nlc prepare high-pressure homogenization characterize physicochemical characteristic metastatic a549 tumor model nu/nu mouse use evaluate response aerosolized cxb-nlc doc isolate lung tumor sample analyze dna fragmentation cleave caspase-3 immunohistochemistry b apoptotic angiogenic protein marker western blot c global proteomic alteration isobaric labeling quantitative proteomic method d toxicity study nlc particle size cxb-nlc 217 ± 20 nm entrapment efficiency 90 cxb-nlc doc alone combination show 25 ± 4 37 ± 5 67 ± 4 reduction tumor size respectively compare control proteomic analysis combination treatment reveal significantly decrease expression multiple pro-survival pro-metastasis protein well tumor invasion marker expression s100 family protein s100a6 s100p decrease 2.5 1.6 fold combination therapy cxb-nlc doc show significant reduction tumor growth confirm proteomic analysis 
study aim investigate cabazitaxel efficacy model docetaxel-resistant prostate cancer cell evaluate involvement atp-cassette binding protein 4 abcc4 regard multidrug resistance docetaxel cabazitaxel sensitivity measure pc3 r3327-matlylu mll cell line use sulforhodamine b srb assay abcc4 expression examine western blotting functional involvement drug sensitivity block mk571 inhibitor docetaxel-resistant mll cell 4.5-fold compare cabazitaxel p 0.001 show express high level abcc4 non-resistant pc3 cell detectable abcc4 expression functional inhibition abcc4 mll cell result two-fold decrease effective concentration docetaxel effect toxicity cabazitaxel cabazitaxel show improve therapeutic efficacy docetaxel abcc4-expressing prostate cancer cell abcc4 appear important determinant docetaxel resistance since inhibition almost completely reverse resistance 
β-elemene originally derive plant recently investigate new anticancer agent purpose study explore efficacy mechanism action combine use β-elemene plus taxane antitumor therapeutic strategy ovarian cancer carcinoma interaction β-elemene paclitaxel docetaxel produce additive moderately synergistic effect platinum-resistant ovarian cancer cell line a2780/cp70 parental cell line a2780 show moderately synergistic activity pc-3 prostate cancer cell addition co-administration β-elemene taxane low-micromolar concentration dramatically increase rate micronucleus formation percentage mitotic arrest ovarian cancer cell line compare treatment either agent alone highest synergy towards ovarian cancer cell observe β-elemene plus docetaxel consistent datum treatment a2780/cp70 cell β-elemene plus taxane strikingly reduce cell viability increase cell apoptosis assess annexin v binding moreover β-elemene plus docetaxel induce elevated level caspase-9 p53 protein a2780/cp70 cell combination β-elemene plus taxane cause marked cell-cycle arrest g2/m phase cell one possible mechanism account enhance cytotoxic efficacy combination treatment β-elemene-induced increase taxane influx cancer cell observation indicate combination therapy β-elemene taxane synergistic antitumor activity ovarian prostate carcinoma vitro promising new therapeutic combination warrant pre-clinical exploration treatment chemoresistant ovarian cancer type tumor 
poly adp-ribose polymerase play critical role recognition repair dna single-strand break double-strand break dsb abt-888 orally available inhibitor enzyme study seek evaluate use abt-888 combine chemotherapy radiation therapy rt colorectal carcinoma model rt clonogenic assay perform hct116 ht29 cell treat 5-fluorouracil irinotecan oxaliplatin without abt survive fraction 2 gy dose-modifying factor 10 survival analyze synergism assess isobologram analysis combination therapy γh2ax neutral comet assay perform assess effect therapy dsb formation/repair vivo assessment make use hct116 cell xenograft mouse model tumor growth delay measure volume 500 mm 3 line radiosensitize abt alone abt increase chemotherapy dose-modifying factor 1.6 1.8 range combination synergistic combination index 0.9 abt treatment significantly increase dsb rt γh2ax 69 vs 43 p = .017 delay repair find tumor growth delay 7.22 day rt 11.90 day rt abt 13.5 day oxaliplatin rt abt 14.17 day 5-fluorouracil rt abt 23.81 day irinotecan rt abt abt-888 radiosensitize similar higher level compare classic chemotherapy act synergistically chemotherapy enhance rt effect vivo confirmation result indicate potential role combine use exist chemoradiation regimen 
purpose taxane important chemotherapeutic agent proven efficacy human cancer use limit resistance development report preclinical characteristic cabazitaxel xrp6258 semisynthetic taxane develop overcome taxane resistance experimental design cabazitaxel effect purify tubulin taxane-sensitive chemotherapy-resistant tumor cell evaluate vitro antitumor activity pharmacokinetic intravenously administer cabazitaxel assess tumor-bearing mouse result vitro cabazitaxel stabilize microtubule effectively docetaxel 10-fold potent docetaxel chemotherapy-resistant tumor cell ic50 range cabazitaxel 0.013-0.414 mumol/l docetaxel 0.17-4.01 mumol/l active concentration cabazitaxel cell line achieve easily maintain 96 hour tumor mouse bear ma16/c tumor treat cabazitaxel 40 mg/kg cabazitaxel exhibit antitumor efficacy broad spectrum murine human tumor melanoma b16 colon c51 c38 hct 116 ht-29 mammary ma17/a ma16/c pancreas p03 mia paca-2 prostate du 145 lung a549 nci-h460 gastric n87 head neck sr475 kidney caki-1 particular note cabazitaxel active tumor poorly sensitive innately resistant docetaxel lewis lung pancreas p02 colon hct-8 gastric gxf-209 mammary uiso bca-1 acquire docetaxel resistance melanoma b16/txt conclusion cabazitaxel active docetaxel docetaxel-sensitive tumor model potent docetaxel tumor model innate acquire resistance taxane chemotherapy study basis subsequent clinical evaluation 
glycogen synthase kinase 3beta gsk3beta serine/threonine protein kinase involve human cancer include glioblastoma previously demonstrate gsk3beta inhibition enhance temozolomide effect glioma cell report investigate molecular mechanism sensitization glioblastoma cell temozolomide gsk3beta inhibition focus o 6 methylguanine dna methyltransferase mgmt gene silencing glioblastoma tissue patient treat gsk3beta-inhibiting drug subject immunohistochemistry methylation-specific pcr assay human glioblastoma cell line t98g u138 u251 u87 treat small-molecule gsk3beta inhibitor ar-a014418 gsk3beta-specific small interfere rna combined effect temozolomide ar-a014418 cell proliferation determine alamarblue assay isobologram method mgmt promoter methylation estimate methylation-specific pcr methylight assay mgmt gene expression evaluate real-time quantitative reverse transcriptase-pcr c-myc dna cytosine-5 methyltransferase 3a binding mgmt promoter estimate chromatin immunoprecipitation assay gsk3beta inhibition decrease phosphorylation glycogen synthase reduce mgmt expression increase mgmt promoter methylation clinical tumor glioblastoma cell line gsk3beta inhibition decrease cell viability enhance temozolomide effect downregulate mgmt expression relevant change methylation level mgmt promoter show first time c-myc bind mgmt promoter consequent recruitment dna cytosine-5 methyltransferase 3a regulate level mgmt promoter methylation result study suggest gsk3beta inhibition enhance temozolomide effect silencing mgmt expression via c-myc-mediated promoter methylation 
evidence grow beneficial role selective estrogen receptor modulator serm prostate disease caffeic acid phenethyl ester cape promising component propolis possess serm activity study aim investigate modulatory impact cape docetaxel doc paclitaxel ptx cytotoxicity prostate cancer cell explore possible underlying mechanism chemomodulation cape significantly increase doc ptx potency pc-3 du-145 lncap prostate cancer cell combination index calculation show synergistic interaction cape/doc cape/ptx cotreatment test cell line subsequent mechanistic study pc-3 cell indicate cyclin d1 c-myc significantly reduce combined treatment group concurrent increase p27kip dna-ploidy analysis indicate significant increase percentage cell pre-g1 cape/doc cape/ptx cotreatment decrease bcl-2 / bax ratio together increase caspase-3 activity protein abundance observe group estrogen receptor-β er-β downstream tumor suppressor forkhead box o1 level significantly elevated cape combination group compare doc ptx-alone er-α insulin-like growth factor-1 receptor protein abundance reduce group cape significantly reduce akt erk er-α ser-167 phosphorylation pc-3 cell cape-induced inhibition akt phosphorylation prominent 1.7-fold higher cell express er-α pc-3 compare lncap conclusion cape enhance antiproliferative cytotoxic effect doc ptx prostate cancer cell least partly attribute cape augmentation doc ptx proapoptotic effect addition cape-induced alteration er-α er-β abundance 
glioblastoma gbm highly lethal primary brain tumour treatment malignant glioma remain ineffective extremely resistant chemotherapeutic application furthermore combination therapy cancer treatment become popular generate synergistic anticancer effect reduce individual drug-related toxicity associate side effect currently magnetic nanoparticle mnp base drug delivery system attract much attention owing intrinsic magnetic property drug loading capacity present study mnp base drug delivery approach co-delivering potent chemotherapeutic drug curcumin herbal drug temozolomide dna methylating agent implement dual drug load mnp formulation evaluate two-dimensional 2-d monolayer culture three-dimensional 3-d tumour spheroid culture t-98g cell understand therapeutic discrepancy dual drug load mnp formulation demonstrate higher cytotoxic effect single drug load mnp formulation compare corresponding native drug 2-d 3-d culture combination index ci analysis reveal synergistic mode action dual drug load mnp formulation confirm cell death induction assay mediate acridine orange ao / propidium iodide pi staining illustrate higher efficacy formulation towards gbm therapy 
examine antiproliferative effect combination docetaxel sorafenib apply representative non-small cell lung cancer cell line a549 cell either wild type acquire resistance docetaxel a549/d aim study evaluate synergistic effect combination treatment cell growth inhibition elucidate involve molecular mechanism a549 cell acquire resistance docetaxel establish continuous exposure docetaxel examine effect different combinatorial treatment cell proliferation cell cycle distribution addition effect combinatorial treatment proliferative apoptotic signalling pathway study result show synergistic effect present a549 cell treat docetaxel follow sorafenib a549/d cell treat reverse sequence furthermore suggest synergistic effect a549/d cell cause inhibit p-gp function alter balance growth apoptotic signalling pathway datum suggest potential role sorafenib chemosensitize docetaxel-resistant cancer cell study also provide molecular evidence apply different therapeutic strategy patient different genetic proteomic profile 
zebrafish-based chemical screening recently emerge rapid efficient method identify important compound modulate specific biological process test therapeutic efficacy disease model include cancer leukemia ablation leukemia stem cell lsc necessary permanently eradicate leukemia cell population however small number lsc leukemia cell population use xenotransplantation study vivo difficulty functionally pathophysiologically replicate clinical condition cell culture experiment vitro progress drug discovery lsc inhibitor painfully slow study develop novel phenotype-based vivo screening method use lsc xenotransplant zebrafish aldehyde dehydrogenase-positive aldh cell purify chronic myelogenous leukemia k562 cell tag fluorescent protein kusabira-orange implant young zebrafish 48 hour post-fertilization twenty-four hour transplantation animal treat one eight different therapeutic agent imatinib dasatinib parthenolide tdzd-8 arsenic trioxide niclosamide salinomycin thioridazine cancer cell proliferation cell migration determine high-content imaging eight compound test except imatinib dasatinib selectively inhibit aldh cell proliferation zebrafish addition anti-lsc agent suppress tumor cell migration lsc-xenotransplant approach offer simple rapid reliable vivo screening system facilitate phenotype-driven discovery drug effective suppress lsc 
recent study indicate complex relationship exist autophagy apoptosis study investigate regulatory relationship autophagy apoptosis colorectal cancer cell utilize molecular biochemical approach study human colorectal carcinoma hct116 cx-1 cell treat two chemotherapeutic agents-oxaliplatin induce apoptosis bortezomib trigger apoptosis autophagy combinatorial treatment oxaliplatin bortezomib cause synergistic induction apoptosis mediate increase caspase activation combinational treatment oxaliplatin bortezomib promote jnk-bcl-xl-bax pathway modulate synergistic effect mitochondria-dependent apoptotic pathway jnk signaling lead bcl-xl phosphorylation serine 62 oligomerization bax alteration mitochondrial membrane potential subsequent cytochrome c release overexpression dominant-negative mutant bcl-xl s62a dominant-positive mutant bcl-xl s62d suppress cytochrome c release synergistic death effect interestingly bcl-xl also affect autophagy alteration interaction beclin-1 beclin-1 dissociate bcl-xl initiate autophagy treatment oxaliplatin bortezomib however activate caspase 8 cleave beclin-1 suppress beclin-1-associated autophagy enhance apoptosis combinatorial treatment oxaliplatin bortezomib-induced beclin-1 cleavage abolish beclin-1 double mutant d133aa/d149a knock-in hct116 cell restore autophagy-promoting function beclin-1 suppress apoptosis induce combination therapy addition combinatorial treatment significantly inhibit colorectal cancer xenograft tumor growth understanding molecular mechanism crosstalk apoptosis autophagy will support application combinatorial treatment colorectal cancer 
modest up-regulation either her-ligand receptor implicate acquire endocrine resistance azd8931 dual tyrosine kinase inhibitor tki epithelial growth factor receptor egfr / her2 show effectively block ligand-dependent signaling tki lapatinib gefitinib therefore examine effect azd8931 er-positive/her2-negative breast cancer cell acquire resistance tamoxifen ligand up-regulation associate pathway activation rna-seq ligand profiling level receptor signaling western blotting conduct er mcf7 t47d parental cell tam-resistant derivative tamre vitro cell growth apoptosis ligand-stimulated signaling measure response endocrine tki study vivo transplantable mcf7/tamres xenograft treat tamoxifen fulvestrant either alone combination azd8931 azd8931 minimally enhance endocrine sensitivity mcf7 parental cell show greater effect t47d parental model azd8931 combine either tamoxifen fulvestrant inhibit cell growth lapatinib t47d tamres cell also significantly though modestly potent mcf7 tamres cell tamres model azd8931 significantly inhibit cell proliferation induce apoptosis ligand-stimulated condition azd8931 potently inhibit signaling lapatinib gefitinib azd8931 also significantly delay growth mcf7 tamre xenograft presence tamoxifen fulvestrant strongest inhibition achieve fulvestrant azd8931 combination though tumor regression observe study provide evidence azd8931 greater inhibitory efficacy tamoxifen-resistant setting endocrine therapy naïve setting absence tumor regression however suggest additional escape pathway contribute resistant growth will need target fully circumvent tamoxifen resistance 
signaling phosphatidylinositol-3 kinase pi3k / akt pathway aberrantly activate 50 carcinoma inhibit apoptosis contribute drug resistance accordingly several akt inhibitor currently undergo preclinical early clinical testing examine effect akt inhibition activity multiple widely use class antineoplastic agent human cancer cell line treat akt inhibitor a-443654 2s -1 1h-indol-3-yl -3 5 3-methyl-2h-indazol-5-yl pyridin-3-yl oxypropan-2-amine atp-competitive mk-2206 8 4 1-aminocyclobutyl phenyl -9-phenyl-2h 1,2,4 triazolo 3,4-f 1,6 naphthyridin-3-one dihydrochloride allosteric inhibitor small interfere rna sirna target phosphoinositide-dependent kinase 1 pdk1 along cisplatin melphalan camptothecin etoposide assay colony formation surprisingly different result observe akt inhibitor combine different drug synergistic effect observe multiple cell line independent pi3k pathway status a-443654 mk-2206 combine dna cross-linking agent cisplatin melphalan contrast effect akt inhibitor combination camptothecin etoposide complicate hct116 dld1 cell harbor activate pi3kca mutation a-443654 broad concentration range enhance effect camptothecin etoposide contrast cell line lack activate pi3kca mutation partial inhibition akt signaling synergize camptothecin etoposide higher a-443654 mk-2206 concentration 80 inhibition akt signaling pdk1 sirna antagonize topoisomerase poison diminish dna synthesis process contribute effective dna damage killing agent result indicate effect combine inhibitor pi3k/akt pathway certain class chemotherapeutic agent might complicated previously recognize 
tyrosine-kinase inhibitor tki chemotherapy different pharmacological mechanism therefore combine administration tki chemotherapy agent may synergy research aim explore cytotoxic interaction gefitinib docetaxel different concentration non-small-cell lung cancer cell line furthermore mechanism underlie cytotoxic synergism nci-h1650 epidermal growth factor receptor egfr mutation kras wild-type nci-h292 egfr wild-type kras wild-type a549 egfr wild-type kras mutation cell line treat docetaxel and/or gefitinib cytotoxic interaction cell cycle distribution cell signal pathway analyze respectively cytotoxic interaction docetaxel gefitinib dose-dependent sequence-dependent three cell line docetaxel follow gefitinib treatment optimum regimen regardless mutation status egfr kras kras mutation egfr wild-type predict insensitive gefitinib docetaxel combined treatment well gefitinib alone g1 arrest inconsistently associate combination index ci however apoptosis induction schedule-dependent explain synergism completely mitogen-activated protein kinase mapk phosphorylation ratio also schedule-dependent positively correlate ci cytotoxic interaction docetaxel gefitinib sequence-dependent regardless mutation status egfr kras cell characteristic apoptosis induction mapk phosphorylation cell cycle change may explain molecular mechanism synergism 
environmentally sensitive hydrogel gain considerable attention recent year one promising drug delivery system present study two new formulation ph temperature stimuli-responsive nanogel ng base poly-n-isopropylacrylamide nipa n-hydroxyethyl acrylamide heaa tert-butyl 2-acrylamidoethyl carbamate 2aaecm synthesize evaluate passive targeting paclitaxel ptx nanogel prepare microemulsion polymerization method use n-methylenebis acrylamide nmba crosslink agent tem image dls result show nanosized spherical hydrogel ftir spectrum confirm synthesis nanogel radical polymerization among vinyl group monomer ptx load capacity encapsulation efficiency vitro release analyze hplc cumulative release profile ptx-loaded nanohydrogel within 144h show faster drug release acid ph ph 5 similar observe lysosome compartment whereas fewer ptx amount release ng ph similar plasma level cellular uptake assay reveal rapid penetration intracellular accumulation nanogel mcf7 hela t47d cell 48h incubation mtt assay show cell viability dependence concentration time incubation finally ptx effect cell viability show g2/m cell arrest use ptx-loaded ng pure ptx 
development cancer therapeutics partially depend upon selection appropriate animal model therefore improvement model selection beneficial forty-nine human tumor xenograft vivo passage 1 4 10 subject cdna microarray analysis yield dataset 823 affymetrix hg-u133 plus 2.0 array illustrate mining strategy support therapeutic study transcript expression determine 1 relative model 2 successive vivo passage 3 vitro vivo transition ranking model accord relative transcript expression vivo potential improve initial model selection example combine p53 tumor expression datum mutational status guide selection tumor therapeutic study agent p53 status purportedly affect efficacy e.g. mk-1775 utility monitoring change gene expression extend vivo tumor passage illustrate focused study drug resistance mediator receptor tyrosine kinase noteworthy observation include significant decline hct-15 colon xenograft abcb1 transporter expression increase expression kinase kit a549 serial passage trend predict sensitivity agent paclitaxel abcb1 substrate imatinib c-kit inhibitor alter extended passage give gene expression result indicate model undergo profound change vivo passage general metric stability generate model rank accordingly lastly change occur transition vitro vivo growth may important consequence therapeutic study since target identify vitro under-represented tumor cell adapt vivo growth comprehensive list mouse transcript capable cross-hybridize human probe set hg-u133 plus 2.0 array generate removal murine artifact follow pairwise analysis vitro cell respective passage 1 xenograft go analysis illustrate complex interplay model host microenvironment study provide strategy aid selection xenograft model therapeutic study datum highlight dynamic nature xenograft model emphasize importance maintain passage consistency throughout experiment 
high electric field apply plasma membrane affect organization lipid molecule generate transient hydrophilic electropore application cell membrane electroporation combination cytotoxic drug increase drug transport cell approach know electrochemotherapy ect work show new datum concern influence electrochemical reaction cisplatin 5-fluorouracil 5-fu cancer ovarian cell resistant standard therapy cisplatin comparison ect effect human primary fibroblast investigate effect electroporation electrochemotherapy 5-fu cisplatin human ovarian clear-cell carcinoma cell line ovbh-1 epithelial ovarian carcinoma cell line skov-3 resistant cisplatin typically use ovarian cancer control cell human gingival fibroblast hgf primary culture use electropermeabilization efficiency determine facs analysis iodide propidium efficiency electrochemotherapy evaluate viability assay cytotoxic effect dependent electroporation parameter drug concentration electroporation alone insignificantly decrease cell proliferation ovbh-1 line skov-3 line sensitive electrical field electrochemotherapy cisplatin 5-fu show promising effect ovarian cell line recovery normal cell reveal 72 hour 
role quercetin ovarian cancer treatment remain controversial mechanism unknown aim study investigate therapeutic effect quercetin combination cisplatin anti-neoplastic drug ovarian cancer cell vitro vivo along molecular mechanism action quercetin treatment various concentration examine combination cisplatin taxol pirarubicin 5-fu human epithelial ovarian cancer c13 skov3 cell cck8 assay annexin v assay cell viability apoptosis analysis immunofluorescence assay dcfda staining realtime pcr use reactive oxygen species ros induce injury detection endogenous antioxidant enzyme expression athymic balb/c-nu nude mouse inject c13 cell obtain xenograft model vivo study immunohistochemical analysis carry evaluate ros-induced injury sod1 activity xenograft tumor contrary pro-apoptotic effect high concentration 40 µm-100 µm quercetin low concentration 5 µm-30 µm quercetin result vary degree attenuation cytotoxicity cisplatin treatment combine cisplatin similar anti-apoptotic effect observe quercetin combine anti-neoplastic agent taxol pirarubicin 5-fluorouracil 5-fu low concentration quercetin observe suppress ros-induced injury reduce intracellular ros level increase expression endogenous antioxidant enzyme suggest ros-mediated mechanism attenuate anti-neoplastic drug xenogeneic model quercetin lead substantial reduction therapeutic efficacy cisplatin along enhance endogenous antioxidant enzyme expression reduce ros-induced damage xenograft tumor tissue take together datum suggest quercetin low concentration attenuate therapeutic effect cisplatin anti-neoplastic drug ovarian cancer cell reduce ros damage quercetin supplementation ovarian cancer treatment may detrimentally affect therapeutic response 
nuclear factor kappa-light-chain-enhancer activate b cell nf-κb signaling pathway activate cell expose various stimulus include originate cell surface nucleus activate nf-κb signaling think enhance cell survival response stimulus include chemotherapy radiation present effort determine anticancer drug preferentially activate nf-κb colon cancer cell nf-κb reporter cell establish treat 5-fluorouracil 5-fu dna/rna damaging oxaliplatin dna damaging camptothecin ctp topoisomerase inhibitor phleomycin radiomimetic erlotinib egfr inhibitor activation nf-κb assess immunofluorescence p65 translocation luciferase assay downstream target nf-κb activation ciap2 bcl-xl evaluate immunoblotting elisa cxcl8 il-6 culture supernatant gene expression analysis colon cancer cell respond variably different class therapeutic agent agent initiate variable response among different cell type cpt activate nf-κb sw480 colon cancer cell dose-dependent manner hct116 cell either wild-type deficient p53 sw480 colon cancer cell nf-κb activation cpt accompany secretion cytokine cxcl8 up-regulation anti-apoptotic gene ciap2 bcl-xl contrary treatment hct116 cell cpt result up-regulation cxcr2 receptor cxcl8 without increase cytokine level sw480 cell nf-κb reporter activity cytokine secretion inhibit sm-7368 nf-κb inhibitor result show response cancer therapeutic agent nf-κb activation vary cellular make drug-induced nf-κb activation may functionally uncouple anti-apoptotic outcome find stimulus cancer cell heterogeneous tumor tissue may therapeutic pressure release soluble factor paracrine activity neighboring cell express cognate receptor 
abnormality phosphatidylinositol 3-kinase pi3k / akt signaling pathway commonly observe human cancer contribute chemotherapy resistance combination therapy involve use molecular target agent traditional cytotoxic drug may represent promising strategy lower resistance enhance cytotoxicity demonstrate efficacy akt inhibitor mk-2206 increase cytotoxic effect either paclitaxel taxol cisplatin ovarian cancer cell line skov3 constitutively active akt es2 inactive akt sequential treatment taxol cisplatin follow mk-2206 induce synergistic inhibition cell proliferation effectively promote cell death either inhibit phosphorylation akt downstream effector 4e-bp1 p70s6k skov3 cell restore p53 level downregulate taxol cisplatin treatment es2 cell combination treatment also downregulate pro-survival protein bcl-2 skov3 es2 cell may contribute cell death addition discover taxol/mk -2206 cisplatin/mk -2206 combination treatment result significant enhancement intracellular reactive oxygen species ros induce mk-2206 skov3 es2 cell however mk-2206-induced growth inhibition reverse ros scavenger es2 cell mk-2206 also suppress dna repair particularly skov3 cell take together result demonstrate akt inhibitor mk-2206 enhance efficacy cytotoxic agent akt-active akt-inactive ovarian cancer cell different mechanism 
series malonate mal platinum ii complex general formula pt mal l 2 l = 5,7-dimethyl-1,2,4-triazolo 1,5-a pyrimidine dmtp 1 7-isobutyl-5-methyl-1,2,4-triazolo 1,5-a pyrimidine ibmtp 2 5,7-ditertbutyl-1,2,4-triazolo 1,5-a pyrimidine dbtp 3 prepare characterize use multinuclear 1 h 13 c 15 n 195 pt nmr ir electrospray ionization mass spectrometry esims furthermore crystal structure pt mal dmtp 2 ∙ 4h2o 1a pt mal dbtp 2 ∙ chcl3 3a determine use single-crystal x-ray diffraction spectroscopic characterization unambiguously confirm square-planar geometry pt ii two monodentate n3-bonded 5,7-disubstituted-1,2,4-triazolo 1,5-a pyrimidine one o-chelating malonate antiproliferative activity compound human cell line t47d cisplatin-resistant human ductal breast epithelial tumor cell line a549 lung adenocarcinoma epithelial cell line mouse cell line 4t1 mouse breast tumor model assess use vitro screening assay compound 2 3 exhibit substantial antigrowth property t47d cell whereas 3 exhibit ic50 value lower cisplatin carboplatin 4t1 cell line additionally compound 2 3 capable arrest cell cycle a549 cell g0/g1 phase whereas cisplatin carboplatin arrest cell g2/m phase indicate difference mechanism suppression tumor cell growth finally quest low toxicity platinum drug vitro antiproliferative activity normal mouse fibroblast cell balb/3t3 evaluate inhibition balb/3t3 cell proliferation evaluate pt ii complex increase order 1 2 << carboplatin << 3 cisplatin 
merm1/wbscr22 novel metastasis promoter show involve tumor metastasis viability apoptosis best knowledge currently study suggest possible correlation expression merm1/wbscr22 tumor cell chemosensitivity antitumor agent present study two human non-small cell lung cancer cell line h1299 h460 use investigate whether merm1/wbscr22 affect chemosensitivity antitumor agent include cisplatin cddp doxorubicin adm paclitaxel ptx mitomycin mmc 7-ethyl-10-hydroxycamptothecin sn-38 active metabolite camptothecin 5-fluorouracil 5-fu merm1/wbscr22 knockdown cell line h1299-shrna h460-shrna negative control cell line h1299-nc h460-nc establish stable transfection efficiency merm1/wbscr22 knockdown confirm western blotting immunofluorescence microscopy quantitative polymerase chain reaction result demonstrate shrna-mediated knockdown merm1/wbscr22 affect cell proliferation vitro vivo h460 cell harbor wild type p53 markedly sensitive six antitumor agent compare p53-null h1299 cell downregulation merm1/wbscr22 affect h1299 sensitivity six antitumor agent whereas attenuate h460 sensitivity sn-38 5-fu without significant alteration p53 mrna protein level identify reduce h460 sensitivity sn-38 confirm vivo sn-38 demonstrate significant tumor growth inhibitory activity h460 h460‑nc tumor xenograft model marginally suppress h460-shrna xenograft tumor growth furthermore cddp 4 10 15 µg/ml resistant human non-small lung cancer cell a549 a549-cddpr-4 10 15 express significant amount merm1/wbscr22 protein compare parental a549 cell conclusion shrna-mediated knockdown merm1/wbscr22 attenuate h460 sensitivity sn-38 5-fu suggest merm1/wbscr22 involve chemosensitivity sn-38 5-fu h460 cell direct correlation p53 expression level altered chemosensitivity identify 
alternative pathway vegf hepatocyte growth factor hgf/c-met emerge key player tumor angiogenesis resistance anti-vegf therapy aim study assess effect combination strategy target vegf c-met pathway clear cell renal cell carcinoma ccrcc model male scid mouse 8/group implant 786-o tumor piece treat either selective vegf receptor tyrosine kinase inhibitor axitinib 36 mg/kg 2 × / day c-met inhibitor crizotinib 25 mg/kg 1 × / day combination test drug combination human ccrcc patient-derived xenograft rp-r-01 vegf-targeted therapy-sensitive resistant model evaluate resistant phenotype establish rp-r-01 sunitinib-resistant model continuous sunitinib treatment 60 mg/kg 1 × / day rp-r-01-bearing mouse treatment single-agent crizotinib reduce tumor vascularization fail inhibit tumor growth either model despite also significant increase c-met expression phosphorylation sunitinib-resistant tumor contrast axitinib treatment effective inhibit angiogenesis tumor growth model antitumor effect significantly increase combined treatment crizotinib independently c-met expression combination treatment also induce prolonged survival significant tumor growth inhibition 786-o human rcc model overall result support rationale clinical testing combined vegf hgf/c-met pathway blockade treatment ccrcc first second-line setting 
main problem oncology development drug-resistance plant-derived lignan establish cancer therapy e.g. semisynthetic epipodophyllotoxin etoposide teniposide activity unfortunately hamper atp-binding cassette abc efflux transporter p-glycoprotein investigate bisphenolic honokiol derive magnolia officinalis p-glycoprotein-overexpressing cem/adr5000 cell cross-resistant honokiol mda-mb-231 brcp cell transfect another abc-transporter bcrp reveal 3-fold resistance drug resistance mechanism analyze study tumor suppressor tp53 epidermal growth factor receptor egfr hct116 p53 / reveal resistance honokiol egfr-transfected u87.mg egfr cell collateral sensitive compare wild-type cell degree resistance 0.34 gain insight possible mode collateral sensitivity perform silico molecular docking study honokiol egfr egfr-related downstream signal protein honokiol bind comparable binding energy egfr -7.30 ± 0.01 kcal/mol control drug erlotinib -7.50 ± 0.30 kcal/mol gefitinib -8.30 ± 0.10 kcal/mol similar binding affinity akt mek1 mek2 stat3 mtor calculate honokiol range -9.0 ± 0.01 7.40 ± 0.01 kcal/mol compare corresponding control inhibitor compound signal transducer indicate collateral sensitivity egfr-transfectant cell towards honokiol may due bind egfr downstream signal transducer compare hierarchical cluster analysis microarray-based transcriptomic mrna expression datum 59 tumor cell line reveal specific gene expression profile predict sensitivity resistance towards honokiol 
synthesis new series 1,3,4-oxadiazole derivative possess sulfonamide moiety describe vitro antiproliferative activity nci-58 human cancer cell line nine different cancer type test compound 1k p-methoxybenzenesulfonamido moiety show highest mean inhibition value 58 cell line panel 10 μm concentration show broad-spectrum antiproliferative activity many cell line different cancer type instance compound 1k inhibit growth t-47d breast cancer cell line 90.47 10 μm inhibit growth sr leukemia sk-mel-5 melanoma mda-mb-468 breast cancer cell line 80 test concentration compound 1k show superior activity paclitaxel gefitinib sensitive cell line 
recent clinical trial show sequential combination epidermal growth factor receptor tyrosine kinase inhibitor egfr-tki chemotherapy prolong pfs and/or os advanced non-small cell lung cancer nsclc patient egfr mutation aim present study assess optimal combination sequence explore possible mechanism pc-9 cell a549 cell lung adenocarcinoma cell mutant wide-type egfr respectively treat docetaxel/gefitinib alone different combination schedule egfr k-ras gene status determine qpcr-hrm technique cell proliferation detect mtt assay expression phosphorylation egfr erk akt igf-1r detect western blot cell cycle distribution observe flow cytometry sequential administration docetaxel follow gefitinib d → g induce significant synergistic effect cell line combination index 0.9 reverse sequence g → d result antagonistic interaction cell line ci 1.1 whereas concurrent administration d+g show additive 0.9 ci 1.1 synergistic effect pc-9 cell antagonistic-additive effect a549 cell mechanism study show docetaxel-induced phosphorylation egfr erk repress subsequently use gefitinib concurrent exposure gefitinib gefitinib-repressed phosphorylation egfr erk reverse neither concurrent subsequent administration docetaxel d+g reinforce inhibition phosphorylation igf-1r pc-9 cell cytotoxic drug follow egfr-tki may optimal combination antiproliferative effect egfr-mutant nsclc cell phosphorylation egfr erk might contribute effect 
cancer cell characterize complex network interrelated compensatory signaling drive multiple kinase reduce sensitivity target therapy therefore strategy direct inhibit two kinase require robustly block growth refractory tumour cell report novel strategy promote sustained inhibition two oncogenic kinase kin-1 kin-2 design molecule k1-k2 term combi-molecule induce tandem blockade kin-1 kin-2 intact structure hydrolyze two inhibitor k1 k2 direct kin-1 kin-2 respectively choose target egfr kin-1 c-src kin-2 two tyrosine kinase know synergize promote tumour growth progression variation k1-k2 linker lead al776 first optimize egfr-c-src target prototype show al776 block egfr c-src intact structure use vitro kinase assay ic50 egfr = 0.12 μm ic50 c-src = 3 nm b release k1 al621 nanomolar egfr inhibitor k2 dasatinib clinically approve abl/c-src inhibitor hydrolytic cleavage vitro vivo c robustly inhibit phosphorylation egfr c-src 0.25-1 μm cell d induce 2-4 fold stronger growth inhibition gefitinib dasatinib apoptosis concentration low 1 μm e block motility invasion sub-micromolar dose highly invasive 4t1 mda-mb-231 cell despite size mw = 1032 al776 block phosphorylation egfr c-src 4t1 tumour vivo now term new target model consist design kinase inhibitor k1-k2 target kin-1 kin-2 release two inhibitor k1 k2 latter kinase type iii combi-targeting 
cancer treatment resistance tyrosine kinase inhibitor tki occur switch another tki often consider reasonable option previously report resistance sunitinib may cause increase lysosomal sequestration lead increase intracellular lysosomal storage thereby inactivity study effect several tki development cross resistance tki resistance induce continuous exposure cancer cell line increase tki concentration 3-4 month cross resistance evaluate use mtt cell proliferation assay intracellular tki concentration measure use lc-ms/ms western blotting use detect lysosome-associated membrane protein-1 -2 lamp1/2 expression previously generate sunitinib-resistant sun renal cancer cell 786-o colorectal cancer cell ht-29 find cross-resistant pazopanib erlotinib lapatinib sorafenib exposure 786-o ht-29 cell sorafenib pazopanib erlotinib 3-4 month induce drug resistance pazopanib erlotinib sorafenib intracellular drug accumulation find increase pazopanib erlotinib sorafenib-exposed cell lysosomal capacity reflect lamp1/2 expression find increase resistant cell addition transient cross-resistance mtor inhibitor everolimus detect datum indicate tumor cell develop cross resistance tki resistance include increase intracellular drug accumulation accompany increase lysosomal storage transient cross resistance find occur several tki test everolimus indicate switching tki mtor inhibitor may attractive therapeutic option 
underlying mechanism lead antiestrogen resistance estrogen-receptor α er positive breast cancer still poorly understand aim study therefore identify biomarker novel treatment antiestrogen resistant breast cancer perform kinase inhibitor screen antiestrogen responsive t47d breast cancer cell t47d-derived tamoxifen fulvestrant resistant cell line find dasatinib broad-spectrum kinase inhibitor inhibit growth antiestrogen resistant cell compare parental t47d cell furthermore western blot analysis show increase expression phosphorylation src resistant cell dasatinib inhibit phosphorylation src also signaling via akt erk cell line immunoprecipitation reveal src er complex parental t47d cell fulvestrant resistant cell src form complex human epidermal growth factor receptor 1 her2 neither receptor er co-precipitate src tamoxifen resistant cell line compare treatment dasatinib alone combined treatment dasatinib fulvestrant stronger inhibitory effect tamoxifen resistant cell growth whereas dasatinib combination tamoxifen additive inhibitory effect fulvestrant resistant growth perform immunohistochemical staining 268 primary tumor breast cancer patient receive tamoxifen first line endocrine treatment find membrane expression src tumor cell significant associate reduce disease-free overall survival conclusion src identify target treatment antiestrogen resistant t47d breast cancer cell tamoxifen resistant t47d cell combined treatment dasatinib fulvestrant superior treatment dasatinib alone src located membrane potential new biomarker reduce benefit tamoxifen 
patient highly malignant glioblastoma short median survival time mainly due aggressive relapse therapeutic treatment beside achieve progressive character via epithelial-to-mesenchymal transition emt however comprehensive investigation emt paired primary-recurrent glioblastoma pair presently available thus present study examine expression profile different emt-marker 17 match primary recurrent glioblastoma qpcr double-immunofluorescence staining identify emt marker express cell type additionally analyze influence temozolomide emt marker expression vitro comparison primary tumor expression β-catenin p 0.05 snail1 p 0.05 snail2/slug p 0.05 biglycan p 0.05 twist1 p 0.01 downregulate recurrence whereas l1cam show upregulation p 0.05 qpcr expression desmoplakin vimentin fibronectin tgf-β1 receptor tgf-βr1 tgf-βr2 almost unchanged compare individual pair five different 'em t group within glioblastoma collective identify accord regulation mrna expression gfap desmoplakin snail1 snail2 twist1 vimentin additionally double-staining emt marker combination cell specific marker glial fibrillary acidic protein cd11b von willebrand factor reveal emt marker express complex pattern three cellular type possible source temozolomide treatment significantly induce mrna expression nearly investigate emt marker t98g glioma cell thus emt seem involve glioma progression complex way require individualized analysis influence commonly use therapeutic option glioma therapy 
docetaxel use first-line chemotherapy castration-resistant prostate cancer crpc docetaxel resistance occur part owe induction p-glycoprotein p-gp encode multidrug resistance protein 1 mdr1 gene recently develop taxane-cabazitaxel-has poor affinity p-gp thereby effective docetaxel-resistant crpc recently demonstrate exosome body fluid serve diagnostic marker contain protein rna specific cell derive study aim investigate p-gp blood exosome marker diagnose docetaxel resistance select taxoid patient crpc exosome isolate differential centrifugation docetaxel-resistant prostate cancer pc-3 cell pc-3r parental pc-3 cell serum patient silencing p-gp perform small interfere rna transfection protein expression examine western blot analysis viability cell treat docetaxel cabazitaxel determine water soluble tetrazolium salt wst assay level p-gp higher exosome well cell lysate pc-3r cell pc-3 cell cabazitaxel effectively kill pc-3r cell mdr1 knockdown improve sensitivity pc-3r cell docetaxel cabazitaxel p-gp level blood exosome relatively higher clinically docetaxel-resistant patient therapy-naïve patient result suggest detection p-gp blood exosome involve resistance docetaxel cabazitaxel useful diagnose docetaxel resistance select appropriate taxoid patient crpc-docetaxel cabazitaxel 
investigate effect chemoradiotherapy pp2 temozolomide tmz malignant glioma cell use clonogenic assay vivo brain tumor model effect pp2 radiosensitivity u251 t98g cell investigate use clonogenic assay expression e-cadherin matrix metalloproteinase 2 mmp2 ephrin type-a receptor 2 epha2 vascular endothelial growth factor vegf measure western blotting accumulation γh2ax focus 6 hour radiotherapy measure pp2 treatment effect pp2 migration invasion vasculogenic mimicry formation vmf u251 cell evaluate orthotopical brain tumor model u251 cell pp2 inject intraperitoneally without oral tmz whole brain radiotherapy bioluminescence image take visualize vivo tumor immunohistochemical staining vegf cd31 epha2 hypoxia-inducible factor 1a perform pp2 increase radiosensitivity u251 t98g cell without decrease survival normal human astrocyte chemoradiotherapy pp2 tmz result increase accumulation γh2ax focus pp2 induce overexpression e-cadherin suppression mmp2 vegf epha2 pp2 also compromise invasion migration vmf u251 cell brain tumor chemoradiotherapy pp2 tmz decrease tumor volume best statistically significantly compare chemoradiotherapy tmz expression vegf cd31 suppress pp2-treated tumor pp2 enhance radiosensitivity malignant glioma cell suppress invasion migration u251 cell chemoradiotherapy pp2 tmz result non-significant tumor volume decrease 
cutaneous squamous cell carcinoma keratoacanthoma commonly occur patient treat braf inhibitor investigate effect braf inhibitor vemurafenib normal immortalize human hacat keratinocyte explore mechanism hyperproliferative cutaneous neoplasia associate use braf inhibitor vemurafenib induce increase viable cell number braf wild-type cell line sk-mel-2 hacat braf mutant cell line sk-mel-24 g361 hacat keratinocyte low concentration 2 mumol/l vemurafenib increase cell proliferation activate mitogen-activated protein kinase kinase/extracellular signal-regulated kinase craf-dependent manner invasiveness hacat cell matrigel assay significantly increase upon cultivation cell 2 mumol/l vemurafenib 24 h. gelatin zymography reverse transcription polymerase chain reaction western blot result reveal 2 mumol/l vemurafenib treatment increase matrix metalloproteinase mmp -2 mmp-9 expression activity hacat cell result offer additional insight complex mechanism paradoxical mitogen-activated protein kinase signaling involve hyperproliferative cutaneous neoplasia arise braf inhibition suggest possible role mmp tumor progression invasion 
although target therapy improve clinical outcome cancer treatment tumor resistance target drug often detect late cause mortality cse1l secrete tumor phosphorylation regulate erk1/2 erk1/2 located downstream various growth factor receptor kinase target target drug serum phospho-cse1l may marker monitor efficacy target therapy use mouse tumor xenograft model study assay serum phosphorylate cse1l early detect efficacy target drug phosphorylation status cse1l vemurafenib sorafenib treat tumor cell assay immunoblot antibody phosphorylate cse1l ras activation increase phospho-cse1l expression b16f10 melanoma cell vemurafenib sorafenib treatment significantly reduce total cse1l level however inhibit erk1/2 cse1l phosphorylation a375 melanoma cell ht-29 colorectal cancer cell melanoma xenograft model serum phospho-cse1l level decline 5 day vemurafenib/sunitinib treatment 3 day sorafenib/lapatinib treatment ht-29 colon cancer xenograft model vemurafenib/sunitinib sorafenib/lapatinib treatment result tumor regression result indicate serum phospho-cse1l useful early detect efficacy target therapy initial treatment monitor emerge secondary drug resistance facilitate timely therapeutic decision making 
mtt assay less degree mts xtt wst widely exploit approach measure cell viability/drug cytotoxicity mtt reduction occur throughout cell significantly affect number factor include metabolic energy perturbation change activity oxidoreductase endo / exocytosis intracellular trafficking over/underestimation cell viability mtt assay may due adaptive metabolic mitochondrial reprogramming cell subject drug treatment-mediated stress inhibitor off-target effect previously imatinib rottlerin ursolic acid verapamil resveratrol genistein nanoparticle polypeptide show interfere mtt reduction rate result inconsistent result mtt assay alternative assay test under/overestimation viability mtt assay compare result derive mtt assay trypan blue exclusion assay treatment glioblastoma u251 t98g c6 cell three widely use inhibitor known direct side effect energy metabolic homeostasis temozolomide tmz dna-methylating agent temsirolimus tem inhibitor mtor kinase u0126 inhibitor mek1/2 kinase inhibitor apply shortly ic50 evaluate study long study focus drug resistance acquisition show over/underestimation cell viability mtt assay significance depend cell line time point viability measurement experimental parameter furthermore provide comprehensive survey factor account mtt assay avoid result misinterpretation supplementation tetrazolium salt-based assay non-metabolic assay recommend 
combination high dose oral lapatinib lapa her2 tyrosine kinase inhibitor intravenous paclitaxel ptx exhibit clinical survival advantage compare ptx alone her2 positive breast cancer however localized delivery system high regional drug level may greatly decrease dose drug lead higher safety lower cost attempt imitate fast slow exposure two drug clinic use incorporate ptx nanoparticle lapa microparticle thermosensitive hydrogel pl-gel peritumoral injection use ptx-gel plus lapa-oral p-gel l-oral control visually study vitro vivo ptx/did lapa/dir hybrid crystal prepare vitro vivo study demonstrate fast short-term release ptx well slow long-term release lapa pl-gel synergistic effect find lapa ptx cell line overexpress her2 p-gp mechanism relate lapa-induced inhibition p-gp expression g2/m phase arrest ptx uptake ptx tumor cell dose lapa pl-gel group less 5 p-gel l-oral group pl-gel demonstrate significant tumor suppression similar p-gel l-oral group show longer mouse survival time besides pl-gel achieve steady lapa accumulation tumor reveal significantly less toxicity compare p-gel l-oral group summarize localized co-delivery system good synergistic effect lapa ptx might offer potential strategy her2 p-gp positive breast cancer 
cabazitaxel approve second-line treatment docetaxel-refractory metastatic castration-resistant prostate cancer however median time progression cabazitaxel 2.8 month aim determine whether dna methylation play role cabazitaxel resistance du145 cell resistant docetaxel cabaxitaxel du145 10drcr generate cell resistant 10 nm docetaxel du145 10dr effect pre-treatment 5-azacytidine determine regard cabazitaxel sensitivity gene expression profiling carried-out du145 10dr du145 10drcr du145 10drcr treat 5-azacytidine pre-treatment cell 5-azacytidine result enhance sensitivity cabazitaxel gene expression profiling identify subset gene may regulate dna methylation result indicate dna methylation pro-apoptotic cell-cycle regulatory gene may contribute cabazitaxel resistance pre-treatment 5-azacytidine may restore sensitivity cabazitaxel prostate cancer cell 
evofosfamide th-302 hypoxia-activated prodrug cytotoxin bromo-isophosphoramide hypoxic condition br-ipm release alkylate dna ifosfamide chloro-isophosphoramide prodrug activate hepatic cytochrome p450 enzyme compound use treatment cancer ifosfamide approve fda evofosfamide currently late stage clinical development purpose study compare efficacy safety profile evofosfamide ifosfamide preclinical non-small cell lung cancer h460 xenograft model immunocompetent cd-1 mouse h460 tumor-bearing immunocompromised nude mouse use investigate safety profile efficacy evofosfamide ifosfamide alone combination docetaxel sunitinib compare ectopic intrapleural othortopic h460 xenograft model animal expose ambient air different oxygen concentration breathing condition equal body weight loss level evofosfamide show greater comparable efficacy ectopic orthotopic h460 xenograft model evofosfamide ifosfamide exhibit controlled oxygen concentration breathing condition-dependent antitumor activity however equal body weight loss level ifosfamide yield severe hematologic toxicity compare evofosfamide monotherapy combination docetaxel equal hematoxicity level evofosfamide show superior antitumor activity result indicate evofosfamide show superior comparable efficacy favorable safety profile compare ifosfamide preclinical human lung carcinoma model finding consistent multiple clinical trial evofosfamide single agent combination therapy demonstrate anti-tumor activity safety profile without severe myelosuppression 
majority prostate cancer pca death occur due metastatic spread tumor cell distant organ currently lack effective therapy tumor cell spread outside prostate therefore imperative rapidly develop therapeutics inhibit metastatic spread tumor cell gain cell motility invasive property first step metastasis inhibit motility one potentially inhibit metastasis use drug reposition strategy develop cell-based multi-parameter primary screening assay identify drug inhibit migratory invasive property metastatic pc-3 pca cell follow completion primary screening assay 33 drug identify fda approve drug library either inhibit migration cytotoxic pc-3 cell base datum obtain subsequent validation study mitoxantrone hydrochloride simvastatin fluvastatin vandetanib identify strong candidate inhibit migration invasion pc-3 cell without significantly affect cell viability employ drug reposition strategy instead de novo drug discovery development strategy identify drug candidate potential rapidly translate clinic management man aggressive form pca 
chronic myeloid leukemia cml patient relapse imatinib due acquire abl1 kinase domain mutation successfully treat second-generation abl1-tyrosine kinase inhibitor abl-tki dasatinib nilotinib ponatinib however ~ 40 relapsed patient uncharacterized bcr-abl1 kinase-independent mechanism resistance identify mechanism resistance potential treatment option generate abl-tki-resistant k562 cell prolonged sequential exposure imatinib dasatinib dual-resistant k562 cell lack bcr-abl1 kinase domain mutation acquire genomic aberration characterize next-generation sequencing copy number analysis proteomic show dual-resistant cell elevated level foxo1 phospho-erk bcl-2 dasatinib longer inhibit substrate pi3k/akt pathway contrast parental cell resistant cell sensitive growth inhibition apoptosis induce class pi3k inhibitor gdc-0941 pictilisib also induce foxo1 nuclear translocation foxo1 elevated subset primary specimen relapse cml patient lack bcr-abl1 kinase domain mutation sample responsive gdc-0941 treatment ex vivo conclude elevated foxo1 contribute bcr-abl1 kinase-independent resistance experience cml patient pi3k inhibition couple bcr-abl1 inhibition may represent novel therapeutic approach 
although dasatinib effective imatinib mesylate imt resistant chronic myeloid leukemia cml patient underlie mechanism effectiveness eliminate imatinib-resistant cell partially understand study investigate effect dasatinib signaling mechanism driving-resistance imatinib-resistant cml cell line k562 k562r imt compare k562 control cell exsomal release phosphoinositide 3-kinase pi3k / protein kinase b akt / mammalian target rapamycin mtor signaling autophagic activity increase significantly k562r imt cell mtor-independent beclin-1 / vps34 signaling show involve exosomal release cell find notch1 activation-mediated reduction phosphatase tensin homolog pten responsible increase akt/mtor activity k562r imt cell treatment notch1 γ-secretase inhibitor prevent activation akt/mtor addition suppression mtor activity rapamycin decrease level activity p70s6k induce upregulation p53 caspase 3 lead increase apoptosis k562r imt cell inhibition autophagy spautin-1 beclin-1 knockdown decrease exosomal release affect apoptosis k562r imt cell summary k562r imt cell dasatinib promote apoptosis downregulation akt/mtor activity prevent exosomal release inhibit autophagy downregulate expression beclin-1 vps34 finding reveal distinct dasatinib-induced mechanism apoptotic response exosomal release imatinib-resistant cml cell 
cisplatin paclitaxel consider backbone chemotherapy lung adenocarcinoma agent show pleiotropic effect cell death however precise mechanism remain unclear present study report phosphorylate caspase-8 tyrosine 380 p-casp8 characterize biomarker chemoresistance tp regimen cisplatin paclitaxel patient resectable lung adenocarcinoma significantly poorer 5-year disease-free survival dfs overall survival os cisplatin kill lung adenocarcinoma cell regardless c-src-induced caspase-8 phosphorylation tyrosine 380 subsequently identify novel mechanism paclitaxel induce necroptosis lung adenocarcinoma cell dependent upon p-casp8 receptor-interacting protein kinase 1 ripk1 ripk3 moreover dasatinib c-src inhibitor dephosphorylate caspase-8 facilitate necroptosis rather apoptosis paclitaxel-treated p-casp8-expressing lung adenocarcinoma cell datum study reveal previously unrecognized role p-casp8 positive effector initiation necroptosis negative effector repression interaction ripk1 ripk3 moreover outcome support need clinical study goal evaluate efficacy dasatinib plus paclitaxel treatment lung adenocarcinoma 
abcb1 p-glycoprotein implicate multidrug-resistance phenotype include resistance toward anticancer drug tyrosine kinase inhibitor tki purpose study evaluate vitro influence abcb1 1199g snp abcb1 transport activity toward select tki imatinib nilotinib dasatinib currently use chronic myelogenous leukemia two different cell line hek293 k562 stably transfect abcb1 1199g wild-type abcb1 1199a variant allele impact polymorphism accumulation antiproliferative effect imatinib nilotinib dasatinib evaluate k562 model expression asn400 variant protein associate lower antiproliferative effect imatinib nilotinib dasatinib compare ser400 wild-type protein moreover hek293 cell imatinib nilotinib intracellular accumulation lower variant compare wild-type model imatinib nilotinib dasatinib transport efficiently abcb1 variant asn400 compare wild-type ser400 protein impact abcb1 1199g snp tki response investigate chronic myelogenous leukemia patient 
background derivative d-glucosamine d-galactosamine represent important family cell surface glycan component fluorinate analog find use metabolic inhibitor complex glycan biosynthesis probe study protein-carbohydrate interaction work focus synthesis acetylate 3-deoxy-3-fluoro 4-deoxy-4-fluoro 3,4-dideoxy-3,4-difluoro analog d-glucosamine d-galactosamine via 1,6-anhydrohexopyranose chemistry moreover cytotoxicity target compound towards select cancer cell determine result introduction fluorine c-3 achieve reaction 1,6-anhydro-2-azido-2-deoxy-4-o-benzyl-beta-d-glucopyranose 4-fluoro analog dast retention configuration reaction discuss fluorine c-4 install reaction 1,6:2,3-dianhydro-beta-d-talopyranose dast fluoridolysis 1,6:3,4-dianhydro-2-azido-beta-d-galactopyranose khf2 amino group introduce mask azide synthesis 1-o-deacetylated 3-fluoro 4-fluoro analog acetylate d-galactosamine inhibit proliferation human prostate cancer cell line pc-3 cisplatin 5-fluorouracil ic50 28 3 mum 54 5 mum respectively conclusion complete series acetylate 3-fluoro 4-fluoro 3,4-difluoro analog d-glucosamine d-galactosamine now accessible 1,6-anhydrohexopyranose chemistry intermediate fluorinate 1,6-anhydro-2-azido-hexopyranose potential synthon oligosaccharide assembly 
overexpression abcb1 also call p-glycoprotein confer resistance multiple anticancer drug include tyrosine kinase inhibitor tki several abcb1 single nucleotide polymorphism affect transporter activity common abcb1 variant 1236c t 2677g t 3435c t associate clinical response imatinib chronic myelogenous leukaemia cml study evaluate impact polymorphism anti-proliferative effect intracellular accumulation tki imatinib nilotinib dasatinib ponatinib transfect hek293 k562 cell abcb1 overexpression increase resistance cell doxorubicin vinblastine tki imatinib anti-proliferative effect accumulation decrease larger extent cell express abcb1 wild-type protein compare 1236t-2677t-3435t variant relatively control cell contrast abcb1 polymorphism influence activity nilotinib dasatinib ponatinib much lesser extent conclusion datum suggest wild-type abcb1 export imatinib efficiently 1236t-2677t-3435t variant protein provide molecular basis report association abcb1 polymorphism response imatinib cml result also point weaker impact abcb1 polymorphism activity nilotinib dasatinib ponatinib 
background allogeneic hematopoietic stem cell transplantation hsct potentially curative variety hematological malignancy graft-v host disease gvhd remain life-threatening complication standard treatment high-dose hd corticosteroid steroid-refractory sr gvhd associate poor prognosis present second-line treatment ill-defined include number agent novel insight pathophysiology acute gvhd agvhd highlight relevant role host inflammatory response govern several kinase family include janus kinase jak 1/2 ruxolitinib jak1/2 inhibitor approve intermediate-2 / high-risk myelofibrosis recently employ sr-gvhd encouraging overall response rate clinical experience however remain limited case presentation 51-year-old male refractory anemia excess blast type-2 undergo myeloablative allogeneic hsct 9/10 hla-matched unrelated donor conditioning busulfan cyclophosphamide gvhd prophylaxis consist cyclosporine methotrexate thymoglobulin cd34 cells/kg infuse 8.69 x 10 6 kg day 29 patient develop overall grade iv agvhd biopsy proven stage iv gastrointestinal gi gvhd refractory hd corticosteroid patient condition rapidly deteriorate become critical despite addition mycophenolate mofetil budesonide day 33 ruxolitinib start day 39 patient clinical condition gradually improve complete resolution agvhd also confirm histology day 54 conclusion 5 month hsct patient well continuous hematological complete remission without flare gvhd ruxolitinib discontinue day 156 ruxolitinib feasible effective sr-agvhd though large prospective clinical trial warrant 
proteasome inhibition attractive approach anticancer therapy doxorubicin dox widely use treatment number cancer include breast cancer however development dox resistance largely limit clinical application one possible mechanism dox-resistance dox might induce activation nf-kappab case proteasome inhibitor inhibit activation nf-kappab block inhibitory factor kappab ikappab degradation carfilzomib second-generation proteasome inhibitor overcome bortezomib resistance lessen side-effect currently effect carfilzomib breast cancer cell proliferation remain unclear study exploit role carfilzomib seven breast cancer cell line mcf7 t-47d mda-mb-361 hcc1954 mda-mb-468 mda-mb-231 bt-549 represent major molecular subtype breast cancer find carfilzomib alone cytotoxic effect breast cancer cell increase dox-induced cytotoxic effect apoptosis combination enhance dox-induced jnk phosphorylation inhibit dox-induced ikappabalpha degradation result suggest carfilzomib potent antitumor effect breast cancer vitro sensitize breast cancer cell dox treatment dox combination carfilzomib may effective feasible therapeutic option clinical trial treat breast cancer 
evaluate effect fractionate irradiation fi tumor cell sensitivity ionize radiation ir antineoplastic drug examine potential early growth response-1 egr-1 inhibition sensitize tumor cell ir pc3 hepg2 cell subject 10 time γ-ray 2 gy survive cell name pc3/r hepg2/r respectively cell sensitivity irradiation chemotherapeutic drug include cisplatin pt doxorubicin dox mitomycin c mmc 5-fluorouracil 5-fu identify colony formation assay mmt method respectively quantitative real-time polymerase chain reaction rt-qpcr analysis utilize compare difference gene expression radioresistant cell parental cell small interfere rna system implement inhibit endogenous egr-1 expression radiation-resistant cell western blot employ identify possible mechanism egr-1 regulate cell radiosensitivity fi induce cross-resistant ir mmc tumor cell along reduction ovarian cancer-2 / disabled homolog 2 doc-2 / dab2 interactive protein dab2ip expression egr-1 gene upregulate fi-treated cell hand downregulation egr-1 gene expression sensitize radioresistant cell ir accompany dab2ip overexpression stat3 inactivation addition nf-κb inhibitor bay11-7082 enhance resistant cell radiosensitivity chemosensitivity conventionally fi higher risk form acquire radioresistance arr vitro egr-1 gene-targeted drug design effective strategy overcome dab2ip-dysregulation-induced arr tumor patient 
endocrine therapy use estrogen receptor-alpha er-alpha antagonist attenuate horm2one-driven cell proliferation major treatment modality breast cancer exploit dna repair deficiency associate endocrine therapy investigate functional physical interaction er-alpha o6-methylguanine dna methyltransferase mgmt unique dna repair protein confer tumor resistance various anticancer alkylating agent er-alpha positive breast cancer cell line mcf-7 t47d er negative cell line mdamb-468 mdamb-231 establish inhibitor er-alpha mgmt namely ici-182,780 faslodex o6-benzylguanine respectively use study mgmt er interaction mgmt gene promoter find harbor one full two half estrogen-responsive element ere two antioxidant-responsive element mgmt expression upregulate estrogen downregulate tamoxifen western blot promoter-linked reporter assay similarly transient stable transfection nrf-2 nuclear factor-erythroid 2-related factor-2 increase level mgmt protein activity 3 4-fold reflect novel regulatory node drug-resistance determinant different er-alpha antagonist test pure anti-estrogen fulvestrant potent inhibit mgmt activity dose time er-alpha dependent manner similar o6-benzylguanine interestingly fulvestrant exposure lead degradation er-alpha mgmt protein o6-benzylguanine also induce specific loss er-alpha mgmt protein mcf-7 t47d breast cancer cell similar kinetics immunoprecipitation reveal specific association er-alpha mgmt protein breast cancer cell furthermore silencing mgmt gene expression trigger decrease level mgmt er-alpha protein involvement proteasome drug-induced degradation protein also demonstrate fulvestrant enhance cytotoxicity mgmt-targeted alkylating agent namely temozolomide bcnu 3 4-fold er-alpha positive cell er-negative cell conclude mgmt er-alpha protein exist complex co-target ubiquitin-conjugation subsequent proteasomal degradation finding offer clear rationale combine alkylating agent endocrine therapy 
recurrent triple-negative breast cancer tnbc need new therapeutic target src homology region 2 domain-containing phosphatase-1 shp-1 act tumor suppressor dephosphorylate oncogenic kinase one major target shp-1 stat3 highly activate tnbc study test sorafenib analogue sc-60 lack angiokinase inhibition activity act shp-1 agonist tnbc cell sc-60 inhibit proliferation induce apoptosis dephosphorylate stat3 dose time-dependent manner tnbc cell mda-mb-231 mda-mb-468 hcc1937 contrast ectopic expression stat3 rescue anticancer effect induce sc-60 sc-60 also increase shp-1 activity effect inhibit n-sh2 domain dn1 delete shp-1 point mutation d61a imply shp-1 major target sc-60 tnbc use sc-60 combination docetaxel synergize anticancer effect induce sc-60 shp-1 / stat3 pathway tnbc cell importantly sc-60 also display significant antitumor effect mda-mb-468 xenograft model modulate shp-1 / stat3 axis indicate anticancer potential sc-60 tnbc treatment targeting shp-1 / p-stat3 potential combination shp-1 agonist chemotherapeutic docetaxel feasible therapeutic strategy tnbc 
glioblastoma multiforme gbm among lethal human tumor frequently occur malignant primary brain tumor adult current standard care soc gbm initial surgical resection follow treatment combination temozolomide tmz ionize radiation ir however gbm dismal prognosis survivor compromise quality life owing adverse effect radiation gbm characterize overt activity phosphoinositide 3-kinase pi3k signaling pathway gdc-0941 highly specific pi3k inhibitor promising anti-tumor activity human solid tumor evaluate phase ii clinical trial treatment breast non-squamous cell lung cancer hypothesize gdc-0941 may act antitumor agent potentiate effect tmz ir study gdc-0941 alone induce cytotoxicity pro-apoptotic effect moreover combine standard gbm therapy tmz ir suppress cell viability show enhance pro-apoptotic effect augment autophagy response attenuate migratory/invasive capacity three glioma cell line protein microarray analysis show treatment tmz+gdc -0941 ir induce higher level p53 glycogen synthase kinase 3-beta gsk3-β expression shg44gbm cell induce treatment verify cell line western blot analysis furthermore combination tmz gdc-0941 without ir reduce level p-akt o6-methylguanine dna methyltransferase mgmt t98g cell result study suggest combination tmz ir gdc-0941 promising choice future treatment gbm 
prostate cancer pca associate chronic prostate inflammation result activation stress pro-survival pathway contribute disease progression chemoresistance stress oncoprotein lens epithelium-derived growth factor p75 ledgf/p75 also know dfs70 autoantigen promote cellular survival environmental stressor include oxidative stress radiation cytotoxic drug furthermore ledgf/p75 overexpression pca cancer associate feature tumor aggressiveness include resistance cell death chemotherapy report endogenous level ledgf/p75 upregulate metastatic castration resistant prostate cancer mcrpc cell select resistance taxane drug docetaxel dtx cell also show resistance taxane cabazitaxel cbz paclitaxel ptx classical inducer apoptosis trail silencing ledgf/p75 effectively sensitize taxane-resistant pc3 du145 cell dtx cbz evidence significant decrease clonogenic potential trail induce apoptotic blebbing caspase-3 processing apoptotic ledgf/p75 cleavage lead inactivation taxane-resistant sensitive pc3 du145 cell treatment dtx cbz fail robustly induce signature apoptotic event observation suggest taxane induce caspase-dependent independent cell death mcrpc cell maintain structural integrity ledgf/p75 critical role promote taxane-resistance result establish ledgf/p75 stress oncoprotein play important role taxane-resistance mcrpc cell possibly antagonize drug-induced caspase-independent cell death 
azd1775 small molecule wee1 inhibitor use combination dna-damaging agent cause premature mitosis cell death p53-mutated cancer cell seek determine mechanism action azd1775 combination chemotherapeutic agent light recent finding azd1775 cause double-stranded dna ds-dna break azd1775 significantly improve cytotoxicity 5-fu p53-mutated colorectal cancer cell line ht29 cell decrease ic50 9.3 mum 3.5 mum flow cytometry show significant increase mitotic marker phh3 3.4 vs. 56.2 ds-dna break marker gammah2ax 5.1 vs. 50.7 combination therapy compare 5-fu alone combination therapy also increase amount caspase-3 dependent apoptosis compare 5-fu alone 4 vs. 13 addition exogenous nucleoside combination therapy significantly rescue increase ds-dna break caspase-3 dependent apoptosis almost level 5-fu monotherapy conclusion azd1775 enhance 5-fu cytotoxicity increase ds-dna break premature mitosis p53-mutated colorectal cancer cell finding important designer future clinical trial consider optimal timing duration azd1775 treatment 
chronic myeloid leukemia cml hematopoietic malignancy cause constitutive activation bcr-abl tyrosine kinase bcr-abl inhibitor imatinib second-generation tyrosine kinase inhibitor dasatinib nilotinib remarkable efficacy cml treatment however gene mutation-mediated drug resistance remain critical problem among point mutation bcr-abl t315i mutation confer resistance bcr-abl inhibitor previously synthesize compound 1-methyl-1h-indol-5-yl 3,4,5-trimethoxy-phenyl methanone mpt0b002 novel microtubule inhibitor study evaluate effect proliferation cell cycle apoptosis k562 cml cell baf3 cell express either wild-type bcr-abl baf3/p210 t315i-mutated bcr-abl baf3/t315i mpt0b002 inhibit cell viability dose-dependent manner cell affect proliferation human umbilical vein endothelial cell disrupt tubulin polymerization arrest cell cycle g2/m phase treatment mpt0b002 induce apoptosis induction associate increase level cleave caspase-3 cleave parp furthermore mpt0b002 downregulate bcr-abl bcr-abl-t315i mrna expression protein level downstream signaling pathway take together finding suggest mpt0b002 may consider promising compound downregulate wild type bcr-abl also t315i mutant overcome bcr-abl-t315i mutation-mediated resistance cml cell 
background ovarian cancer lead cause death gynecological cancer 6th cause woman cancer death developed country late stage detection peritoneal dissemination acquisition resistance carboplatin main reason explain poor prognosis strengthen need alternative treatment improve management ovarian cancer and/or sensitize tumor platinum salt epidermal growth factor receptor egfr hepatocyte growth factor receptor met cellular src kinase c-src crucial kinase imply ovarian tumor growth survival invasion resistance carboplatin expression increase advanced ovarian cancer correlate poor prognosis despite clear potential inhibit protein ovarian cancer single agent combination carboplatin treatment need target kinase tandem capacity trigger compensatory pathway synergize promote drug resistance method target egfr c-src met individually combination carboplatin use gefitinib dasatinib crizotinib respectively panel carboplatin-sensitive ovcar-3 igrov-1 a2780 carboplatin-resistant cell skov-3 efo-21 study ability potent combination induce apoptosis regulate migration invasion modulate activation proliferation survival protein result crizotinib dasatinib gefitinib alone combination carboplatin show cell-specific cytotoxic synergy ovarian cancer cell dasatinib plus gefitinib combination synergistic ovcar-3 skov-3 igrov-1 cell high concentration combination unable induce apoptosis suppress cell migration invasion activation egfr erk c-src akt compare single treatment conclusion combine carboplatin kinase inhibitor lead synergistic interaction cell-specific manner unlike platinum-based combination mix dasatinib gefitinib lead cytotoxic activity inhibition cell migration invasion thus dasatinib gefitinib combination present anti-tumour property superior platinum-based combination indicate may well represent promising new treatment modality test clinic 
ovarian cancer lead cause death gynecological cancer 6th cause woman cancer death developed country late stage detection peritoneal dissemination acquisition resistance carboplatin main reason explain poor prognosis strengthen need alternative treatment improve management ovarian cancer and/or sensitize tumor platinum salt epidermal growth factor receptor egfr hepatocyte growth factor receptor met cellular src kinase c-src crucial kinase imply ovarian tumor growth survival invasion resistance carboplatin expression increase advanced ovarian cancer correlate poor prognosis despite clear potential inhibit protein ovarian cancer single agent combination carboplatin treatment need target kinase tandem capacity trigger compensatory pathway synergize promote drug resistance target egfr c-src met individually combination carboplatin use gefitinib dasatinib crizotinib respectively panel carboplatin-sensitive ovcar-3 igrov-1 a2780 carboplatin-resistant cell skov-3 efo-21 study ability potent combination induce apoptosis regulate migration invasion modulate activation proliferation survival protein crizotinib dasatinib gefitinib alone combination carboplatin show cell-specific cytotoxic synergy ovarian cancer cell dasatinib plus gefitinib combination synergistic ovcar-3 skov-3 igrov-1 cell high concentration combination unable induce apoptosis suppress cell migration invasion activation egfr erk c-src akt compare single treatment combine carboplatin kinase inhibitor lead synergistic interaction cell-specific manner unlike platinum-based combination mix dasatinib gefitinib lead cytotoxic activity inhibition cell migration invasion thus dasatinib gefitinib combination present anti-tumour property superior platinum-based combination indicate may well represent promising new treatment modality test clinic 
docetaxel one primary drug use treat castration resistant prostate cancer crpc unfortunately time patient invariably develop resistance docetaxel therapy disease will continue progress mechanism resistance develop still incompletely understand study seek determine involvement mirna specifically mir-181a docetaxel resistance crpc real-time pcr use measure mir-181a expression parental docetaxel resistant c4-2b du145 cell taxr du145-dtxr mir-181a expression modulate parental docetaxel resistant cell transfect mir-181a mimic antisense respectively follow transfection cell number determine 48 h without docetaxel cross resistance cabazitaxel induce mir-181a also determine western blot use determine abcb1 protein expression rhodamine assay use assess activity phospho-p53 expression assess western blot apoptosis measure elisa c4-2b taxr pc3 cell inhibit overexpress mir-181a expression without docetaxel mir-181a significantly overexpress taxr du145-dtxr cell compare parental cell overexpression mir-181a parental cell confer docetaxel cabazitaxel resistance knockdown mir-181a taxr cell re-sensitize treatment docetaxel cabazitaxel mir-181a observe impact abcb1 expression activity protein previously demonstrate highly involve docetaxel resistance knockdown mir-181a taxr cell induce phospho-p53 expression furthermore mir-181a knockdown alone induce apoptosis taxr cell enhance addition dtx overexpression mir-181a prostate cancer cell contribute resistance docetaxel cabazitaxel inhibition mir-181a expression restore treatment response due part modulation p53 phosphorylation apoptosis 
glioma aggressive brain tumor high resistance chemotherapy therefore aim present study investigate effectiveness sorafenib temozolomide elimination human glioma cell apoptosis autophagy moggccm anaplastic astrocytoma t98g glioblastoma multiforme cell line incubate sorafenib and/or temozolomide use experiment cell morphology er stress apoptosis autophagy necrosis analyze microscopically apoptosis mitochondrial membrane potential assess flow cytometry beclin1 lc3 p62 hsp27 hsp72 level analyze immunoblotting activity caspase 3 8 9 evaluate fluorometrically expression hsp block transfection specific sirna moggccm cell temozolomide frequently induce autophagy accompany decrease p62 increase beclin1 lc3ii level sorafenib initiate mainly apoptosis additional incubation temozolomide synergistically potentiate pro-apoptotic property sorafenib mediate caspase-independent way t98g cell effect analyze drug program cell death induction different moggccm cell sorafenib induce autophagy temozolomide initiate mainly apoptosis simultaneous drug application apoptosis dominate suggest synergistic action drug inhibition hsp27 hsp72 expression increase sensitivity cell line er stress lesser extent induction apoptosis autophagy sorafenib temozolomide apply combination potent apoptosis inducer t98g moggccm cell er stress precede elimination blocking hsp expression greater impact er stress rather apoptosis induction 
jak protein link survival proliferation multiple myeloma mm cell therefore jak inhibition therapeutic strategy mm evaluate jak1 jak2 expression mm patient effect jak/stat pathway inhibition apoptosis cell cycle gene protein expression rpmi-8226 u266 mm cell line 57 patient present overexpression jak2 27 jak1 treatment ruxolitinib bortezomib rpmi-8226 u266 present 50 cell late apoptosis reduction anti-apoptotic gene expression higher number cell subg0 phase co-culture stromal cell protect rpmi-8226 cell apoptosis reverse lenalidomide addition combination ruxolitinib bortezomib lenalidomide induce 72 cell death equivalent bortezomib lenalidomide dexamethasone combination use clinical practice many jak/stat pathway gene treatment expression reduce mainly rpmi-8226 insignificant change u266 scenario jak/stat pathway pose new therapeutic target exploit since constitutively active contribute survival mm tumor cell 
chemotherapeutic drug resistance tumor cell hypoxic condition cause inhibition apoptosis autophagy drug efflux via adenosine triphosphate atp dependent transporter activation among factor demonstrate disrupt glyceraldehyde-3-phosphate dehydrogenase gapdh expression reduce autophagy atp level tumor cell test whether gapdh knockdown sufficient overcome drug resistance nanocarrier asymmetry-membrane liposome design encapsulate gapdh-sirna low dose paclitaxel ptx liposome prepare use novel cryogenic inner-outer dual reverse phase emulsion liposome manufacturing technology obtain high loading sirna result dynamic light scattering dls indicate liposome average hydrodynamic diameter 250.5 nm polydispersity index pdi 0.210 confirm transmission electron microscope tem image vitro test sirna liposome present high specificity suppression gapdh expression significant synergy cytotoxicity co-delivery ptx tumor cell hela mcf-7 hypoxic condition moreover vivo study hela tumor xenograft model use female balb/c nude mouse demonstrate liposome increase concentration drug tumor time also successfully boost chemotherapeutic efficacy ptx synergistic therapy gapdh-sirna tumor cell appear lose resistance ptx therapy become sensitive ptx gapdh-sirna simultaneously administer long-circulating liposome consequently novel delivery gapdh-sirna use nanotargeted liposome provide useful potential tool overcome multidrug resistant mdr tumor present bright prospect compare traditional chemotherapeutic strategy clinic cancer therapy 
advancement research add several new therapy castration-resistant prostate cancer crpc greatly augment ability treat patient however crpc remain incurable disease due development therapeutic resistance existence cross-resistance available therapy understand interplay different treatment will lead improve sequencing creation combination overcome resistance prolong survival whether exist cross-resistance docetaxel next-generation taxane cabazitaxel poorly understand study use c4-2b du145 derive docetaxel-resistant cell line test response cabazitaxel result demonstrate docetaxel resistance confer cross-resistance cabazitaxel show increase abcb1 expression responsible cross-resistance cabazitaxel inhibition abcb1 function small-molecule inhibitor elacridar resensitize taxane-resistant cell treatment addition antiandrogen bicalutamide enzalutamide previously demonstrate able resensitize taxane-resistant cell docetaxel inhibition abcb1 atpase activity also able resensitize resistant cell cabazitaxel treatment finally show resensitization use antiandrogen far effective combination cabazitaxel docetaxel collectively result address key concern field include cross-resistance taxane highlight mechanism cabazitaxel resistance involve abcb1 furthermore preclinical study suggest potential use combination antiandrogen cabazitaxel increase effect treat advanced crpc mol cancer ther 16 10 2257-66 © 2017 aacr 
cytochrome p450 2j2 cyp2j2 expression elevated breast tumour know protective cytotoxic agent may use cancer chemotherapy study evaluate mechanism mda-mb-468 breast cancer cell stably express cyp2j2 mda-2j2 cell protect kill anti-cancer agent paclitaxel compare control cell caspase-3 / 7 activation paclitaxel lower mda-2j2 cell cell proliferation colony formation follow paclitaxel treatment increase basal lipid peroxidation lower mda-2j2 cell control cell paclitaxel-mediated increase peroxidation attenuate mitochondrial complex iii inhibitor antimycin modulate basal paclitaxel-activated reactive oxygen species ros formation control cell paclitaxel-activated ros production also modulate nadph oxidase inhibitor diphenyleneiodonium paclitaxel increase formation protein adduct reactive aldehyde 4-hydroxynonenal produce lipid peroxidation adduct formation attenuate mda-2j2 cell aldh1a1 expression activity strongly upregulate mda-2j2 cell attribute cyp2j2-derived 14,15-epoxyeicosatrienoic acid 14,15-eet 8,9 11,12-eet regioisomer activate aldh1a1 expression silencing aldh1a1 restore sensitivity mda-2j2 cell paclitaxel indicate pronounced decrease proliferation greater increase caspase activity formation ros level comparable control cell similar finding observe doxorubicin sorafenib staurosporine also promote ros-mediated cell death attenuate mda-2j2 cell reverse aldh1a1 gene silencing finding implicate aldh1a1 important gene activate mda-mb-468-derived cell contain high level cyp2j2 aldh1a1 modulate production ros anti-cancer agent paclitaxel diminish efficacy future approach adapt information facilitate targeting aldh1a1 promote efficacy ros-generating cytotoxic agent enhance treatment breast cancer 
numerous datum suggest increase cancer stem cell csc tumor mass reason failure conventional therapy resistance cd44 / cd24 cell putative cancer stem cell subpopulation prostate cancer trail tumor necrosis factor-related apoptosis-inducing ligand activator apoptosis tumor cell however tumor trail-resistant cancer cell re-sensitize trail induce apoptosis combination trail taxane aim work analyze enhancement anticancer effect trail paclitaxel cabazitaxel docetaxel whole population pc3 du145 prostate cancer cell also cd44 / cd24 prostate cancer stem cell examine apoptotic effect trail taxane use flow cytometry annexin-v-pe staining co-treatment taxane trail enhance significantly apoptosis cd44 / cd24 cell pc3 cell line du145 cell discover also taxane increase expression death receptor trail-r2 pc3 prostate cancer cell result study show treatment paclitaxel cabazitaxel docetaxel able enhance apoptosis induce trail even prostate cancer stem cell 
anti-cancer activity intravenous anesthetic drug propofol demonstrate various type cancer chronic myeloid leukemia cml systematically examine effect propofol combination bcr-abl tyrosine kinase inhibitor tki cml cell line patient progenitor cell mouse xenograft model analyze propofol underlie mechanism focus survival pathway cml cell show propofol alone active inhibit proliferation induce apoptosis kbm-7 ku812 k562 cell act synergistically imatinib dasatinib vitro cell culture system vivo xenograft model addition propofol effective induce apoptosis inhibit colony formation cml cd34 progenitor cell normal bone marrow nbm counterpart combination propofol dasatinib significantly eliminate cml cd34 without affect nbm cd34 cell demonstrate propofol suppress phosphorylation akt mtor s6 4ebp1 k562 overexpression constitutively active akt significantly reverse inhibitory effect propofol k562 confirm propofol act cml cell via inhibition akt/mtor interestingly level p-akt p-mtor p-s6 lower cell treat combination propofol imatinib cell treat propofol imatinib alone suggest propofol augment bcr-abl tki inhibitory effect via suppress akt/mtor pathway work show propofol repurpose cml treatment finding highlight therapeutic value akt/mtor overcome resistance bcr-abl tki treatment cml 
breast cancer common invasive cancer among woman currently model use therapy selection often poor predictor therapeutic response take month set assay report introduce microfluidic organoplate ® platform extracellular matrix ecm embedded tumor culture perfusion initial study design investigate feasibility adapt technology therapy selection triple negative breast cancer cell line mda-mb-453 mda-mb-231 hcc1937 select base different brca1 p53 status seed platform evaluate seed density ecm composition matrigel ® bme2rgf collagen biomechanical perfusion vs static condition expose cell series anti-cancer drug paclitaxel olaparib cisplatin compare response 2d culture finally generate cisplatin dose response 3d culture breast cancer cell derive 2 pdx model microfluidic platform allow simultaneous culture 96 perfused micro tissue use limited amount material enable drug screening patient-derived material 3d cell culture viability improve constant perfusion medium furthermore drug response triple negative breast cancer cell attenuate culture 3d differ observe 2d substrate investigate use high-throughput organ-on-a-chip platform select therapy result raise possibility use technology personalized medicine support selection appropriate drug predict response therapy real time fashion 
remotely control localized drug delivery highly desirable potentially minimize systemic toxicity induce administration typically hydrophobic chemotherapy drug conventional means nanoparticle-based drug delivery system provide highly promising approach localized drug delivery emerge field interest cancer treatment demonstrate near-ir light-triggered release two drug molecule dna-based protein-based host conjugate near-infrared-absorbing au nanoshell sio2 core au shell form light-responsive drug delivery complex show depend upon drug molecule type host molecule laser illumination method continuous wave pulsed laser vitro light-triggered release achieve type nanoparticle-based complex two breast cancer drug docetaxel her2-targeted lapatinib deliver mda-mb-231 skbr3 overexpress her2 breast cancer cell compare release noncancerous raw 264.7 macrophage cell continuous wave laser-induced release docetaxel nanoshell-based dna host complex show increase cell death also coincide nonspecific cell death photothermal heating use femtosecond pulsed laser lapatinib release nanoshell-based human serum albumin protein host complex result increase cancerous cell death noncancerous control cell unaffected method provide spatially temporally localized drug-release strategy facilitate high local concentration chemotherapy drug deliverable specific treatment site specific time window potential greatly minimize side effect 
claudin tight junctional protein regulate paracellular permeability ion small molecule claudin-2 highly express human lung adenocarcinoma cell involve up-regulation cell proliferation however effect claudin-2 cellular sensitivity anticancer agent clarify cytotoxicity anticancer agent cisplatin gefitinib doxorubicin dxr increase claudin-2 knockdown a549 cell claudin-2 knockdown also significantly decrease expression level multidrug resistance-associated protein/abcc2 expression level drug efflux transporter unchanged intracellular accumulation 5-chloromethylfluorescein diacetate cmfda dxr substrate abcc2 increase claudin-2 knockdown whereas efflux decrease mk-571 inhibitor abcc2 enhance cytotoxicity anticancer agent claudin-2 knockdown decrease level p-c-jun nuclear sp1 sp600125 inhibitor c-jun mithramycin inhibitor sp1 decrease level abcc2 promoter activity abcc2 decrease claudin-2 knockdown sp600125 mithramycin treatment suggest claudin-2 involve up-regulation abcc2 expression transcriptional level claudin-2 knockdown increase paracellular permeability dxr 2d monolayer culture model addition accumulation dxr spheroid enhance claudin-2 knockdown result reduction cell viability suggest claudin-2 may novel therapeutic target lung adenocarcinoma claudin-2 knockdown increase accumulation anticancer agent cancer cell spheroid 
new series 4,6-disubstituted 2 4 dimethylamino styryl quinoline 4a,b-9a b synthesize reaction 2 4 dimethylamino styryl -6-substituted quinoline-4-carboxylic acid 3a b thiosemicarbazide p-hydroxybenzaldehyde ethylcyanoacetate 2,4-pentandione addition antitumour activity synthesize compound 3a,b-9a b study via mtt assay two cancer cell line hepg2 hct116 furthermore epidermal growth factor receptor egfr inhibition use potent antitumour compound 3a 3b 4a 4b 8a evaluate interpretation result show clearly derivative 3a 4a 4b exhibit highest antitumour activity test cell line hepg2 hct116 ic50 range 7.7-14.2 µg/ml comparison reference drug 5-fluorouracil ic50 = 7.9 5.3 µg/ml respectively afatinib ic50 = 5.4 11.4 µg/ml respectively vitro egfr screening show compound 3a 3b 4a 4b 8a exhibit moderate inhibition towards egfr ic50 value micromolar level ic50 range 16.01-1.11 µm compare reference drug sorafenib ic50 = 1.14 µm erlotinib ic50 = 0.1 µm molecular docking perform study mode interaction compound 3a 4b egfr kinase 
numerous vitro vivo study demonstrate calcitriol 1,25 oh 2d3 different vitamin d analog possess antineoplastic activity regulate proliferation differentiation apoptosis well angiogenesis vitamin d compound show exert synergistic effect use combination different agent use anticancer therapy different cancer model aim study evaluate mechanism cooperation vitamin d compound 1,24 oh 2d3 pri‑2191 1,25 oh 2d3 tyrosine kinase inhibitor imatinib sunitinib together cytostatic cisplatin docetaxel a549 non-small cell lung cancer model cytotoxic effect test compound use different combination evaluate a549 lung cancer cell well human lung microvascular endothelial cell hlmec effect combination cell cycle cell death also determine addition change expression protein involve cell cycle regulation angiogenesis action vitamin d analyze moreover effect 1,24 oh 2d3 anticancer activity sunitinib sunitinib combination docetaxel examine a549 lung cancer model vivo experiment aim evaluate cytotoxicity combination test agent reveal imatinib sunitinib together cisplatin docetaxel exert potent anti-proliferative effect vitro a549 lung cancer cell hlmec however 1,24 oh 2d3 1,25 oh 2d3 enhance cytotoxic effect endothelial cell among test agent sunitinib cisplatin decrease secretion vascular endothelial growth factor vegf ‑ a549 lung cancer cell decrease vegf‑a level follow incubation cisplatin correlate higher p53 protein expression correlation observe follow treatment a549 cell sunitinib sunitinib together docetaxel 1,24 oh 2d3 exhibit potent anticancer activity a549 lung cancer model compare double combination treatment compound alone observe anticancer activity may result influence test agent process tumor angiogenesis example downregulation vegf‑a expression tumor also induction cell death inside tumor 
new series 1-phenyl-3 4 pyridin-3-yl phenyl urea derivative synthesize subject vitro antiproliferative screening national cancer institute nci -60 human cancer cell line nine different cancer type fourteen compound 5a-n synthesize three different solvent exposure moiety 4-hydroxylmethylpiperidinyl trimethoxyphenyloxy 4-hydroxyethylpiperazine attach core structure substituent different pi sigma value add terminal phenyl group compound 5a-e 4-hydroxymethylpiperidine moiety show broad-spectrum antiproliferative activity higher mean percentage inhibition value 60-cell line panel 10 microm concentration compound 5a elicit lethal rather inhibition effect sk-mel-5 melanoma cell line 786-0 a498 rxf 393 renal cancer cell line mda-mb-468 breast cancer cell line two compound 5a 5d show promising mean growth inhibition thus test five-dose mode determine median inhibitory concentration ic50 value datum reveal urea compound 5a 5d active derivative significant efficacy superior potency paclitaxel 21 different cancer cell line belong particularly renal cancer melanoma cell line moreover 5a 5d superior potency gefitinib 38 34 cancer cell line respectively particularly colon cancer breast cancer melanoma cell line 
new series 1-phenyl-3 4 pyridin-3-yl phenyl urea derivative synthesize subject vitro antiproliferative screening national cancer institute nci -60 human cancer cell line nine different cancer type fourteen compound 5a-n synthesize three different solvent exposure moiety 4-hydroxylmethylpiperidinyl trimethoxyphenyloxy 4-hydroxyethylpiperazine attach core structure substituent different π σ value add terminal phenyl group compound 5a-e 4-hydroxymethylpiperidine moiety show broad-spectrum antiproliferative activity higher mean percentage inhibition value 60-cell line panel 10 µm concentration compound 5a elicit lethal rather inhibition effect sk-mel-5 melanoma cell line 786-0 a498 rxf 393 renal cancer cell line mda-mb-468 breast cancer cell line two compound 5a 5d show promising mean growth inhibition thus test five-dose mode determine median inhibitory concentration ic50 value datum reveal urea compound 5a 5d active derivative significant efficacy superior potency paclitaxel 21 different cancer cell line belong particularly renal cancer melanoma cell line moreover 5a 5d superior potency gefitinib 38 34 cancer cell line respectively particularly colon cancer breast cancer melanoma cell line 
background vitro test allow establish experimental variable however vitro result extrapolate vivo test consider three-dimensional 3d culture one best way portray vivo system cell type possible carry assay great clinical relevance analysis screening action resistance antitumor drug objective thus objective present study compare 2d 3d cell culture form conclude suitable model preclinical vitro drug testing method evaluate proliferation genetic expression chemoresistance prostate tumor cell line pc 3 lncap du145 prostate tumor cell line pc-3 lncap du145 treat antineoplastic drug paclitaxel docetaxel evaluate cytotoxicity cell proliferation gene expression assay 2d magnetic 3d bioprint culture result lower cell proliferation rate resistance paclitaxel docetaxel altered gene expression profile show 3d cell culture compare 2d counterpart conclusion 3d cell culture exhibit similar behavior vivo system promising reliable tool development new drug 
background taxane chemotherapy represent major therapeutic alternative symptomatic mcrpc docetaxel commonly prescribe taxane mcrpc cabazitaxel approve patient unresponsive docetaxel still mcrpc remain incurable patient often experience severe side effect recently firstana trial first demonstrate absence superiority overall survival cabazitaxel docetaxel mcrpc patient inversely different toxicity report suggest cabazitaxel may provide first line treatment option patient urge deeper characterization cabazitaxel mechanism action well re-evaluation cabazitaxel conventional dose schedule study goal therefore evaluate anti-tumor efficacy various cabazitaxel regimen deliver monotherapy combination pedf known anti-angiogenic anti-neoplastic agent method crpc cell undergo taxane treatment evaluate cell proliferation migration death apoptosis use crystal violet staining chemotaxis cell cycle tunel assay vitro datum corroborate cl1 crpc xenograft mouse receive intermittent metronomic low-doses cabazitaxel pedf result find cabazitaxel inhibit proliferation crpc cell higher efficacy docetaxel vitro expect high-dose taxanes block cell mitosis surprisingly low-dose cabazitaxel induce cell death docetaxel mainly apoptosis vivo intermittent cabazitaxel lead disease stabilization combine pedf unexpectedly low-dose cabazitaxel delay tumor growth severe toxicity dose test result show pedf low-dose cabazitaxel combination inhibit migration tumor cell increase tumoricidal activity macrophage toward prostate tumor cell conclusion finding highlight great promise cabazitaxel drug predict possible move cabazitaxel forward within therapeutic sequence prostate cancer 
resistance docetaxel major clinical problem castration‑resistant prostate cancer crpc previously report combined inhibition epidermal growth factor receptor egfr cyclooxygenase‑2 cox‑2 lead increase antitumor activity docetaxel crpc present study explore efﬁcacy combination egfr inhibition gefitinib cox‑2 inhibition celecoxib potential treatment docetaxel‑resistant crpc establish two docetaxel‑resistant prostate cancer cell line pc3/dr du145/dr culture pc3 du145 cell docetaxel dose‑escalating manner egfr cox‑2 protein expression level determine effect gefitinib celecoxib cell proliferation apoptosis invasion vitro vivo evaluate vitro change bcl‑2 foxm1 abcb1 expression analyze expression ki‑67 cleaved‑caspase‑3 also examine du145/dr tumor tissue enhance expression egfr cox‑2 observe docetaxel‑resistant crpc relative parental cell line mtt clone formation fluorescence‑activated cell sorting facs analysis demonstrate gefitinib celecoxib combination decrease cell viability enhance rate apoptosis compare either drug use alone additionally combination treatment superior inhibit cell invasion induce significant decrease bcl‑2 foxm1 abcb1 expression level furthermore gefitinib‑celecoxib combination inhibit du145/dr tumor growth greater extent either treatment use individually expression ki‑67 reduce whereas cleaved‑caspase‑3 protein expression increase tumor combination therapy group conclusion combined inhibition egfr cox‑2 gefitinib celecoxib may overcome docetaxel resistance human crpc ﬁndings provide molecular basis clinical application novel combination therapy docetaxel‑resistant crpc 
co-delivery chemotherapy drug vegf sirna sivegf control tumor growth research hotspot improve cancer treatment current system co-deliver sivegf chemo drug tumor cell simultaneously although effective system flow abnormal blood vessel around tumor cell vascular niche pvn play important role metastasis deterioration tumor thus custom-synthesize triblock copolymer poly epsilon-caprolactone polyethyleneglycol-poly l-histidine pcl-peg-phis previously synthesize folate-peg-phis construct target multifunctional polymer micelle ptx/sivegf-cpps/tmpm sequentially deliver sivegf-cpps disulfide bond-linked sivegf cell-penetrating peptide paclitaxel ptx sequential delivery vesicle show anticipated three-layered tem structure dual-convertible surface charge particle size-reversible feature tumor environment ph 6.5 guarantee sequential release sivegf-cpp ptx tumor extracellular environment tumor cell respectively mimic vivo tumor environment double cell model employ co-culture huvec mcf-7 cell improve cell endocytosis efficiency vegf gene silence efficacy vitro anti-proliferation activity achieve vivo study mcf-7 tumor-bearing female nude mouse also indicate sequential delivery vesicle lead significant induction tumor cell apoptosis loss vegf expression destruction tumor blood vessel pvn neovascularization sequential delivery vesicle show potential effective co-delivery platform sivegf chemo drug improve cancer therapy efficacy 
triple-negative breast cancer tnbc insensitive endocrine therapy target therapy human epidermal growth factor receptor-2 her2 estrogen receptor er progesterone receptor pr new target new target therapeutic drug tnbc desperately need study confirm dcc-2036 inhibit proliferation invasion migration epithelial-mesenchymal transition emt tnbc cell well induced apoptosis moreover antiproliferative activity dcc-2036 efficient clinical drug addition combination dcc-2036 cisplatin lapatinib synergistic effect tnbc cell mechanistically dcc-2036 target axl/met especially axl regulate downstream pi3k/akt-nfkappab signaling exert antitumor effect tnbc dcc-2036 also inhibit growth metastasis xenografted mda-mb-231 cell axl/met-high tnbc cell mda-mb-468 cell axl-low tnbc cell nsg mouse vivo furthermore dcc-2036 significantly inhibit tumor growth invasion axl/met-high tnbc pdx tumor axl/met-low tnbc pdx tumor result highlight role axl/met cancer growth metastasis verify critical target dcc-2036 axl met especially axl addition significant toxicity dcc-2036 even high dosage therefore dcc-2036 may potential compound treat tnbc especially tumor axl/met overexpression 
malignant glioma aggressive primary neoplasm originate glial cell brain spine notable resistance standard treatment option carry study aim shed light sensitization resveratrol temozolomide tmz glioma wnt signaling pathway initially glioma cell line strong resistance tmz select 3 4,5-dimethylthiazol-2-yl -2,5-diphenyltetrazolium bromide mtt assay glioma cell subject resveratrol tmz wnt signaling pathway inhibitor activator cell survival rate inhibitory concentration half maximum value detect mtt apoptosis flow cytometry terminal deoxynucleotidyl transferase-mediated dutp nick-end labeling staining vitro proliferation hang drop method beta-catenin translocation nucleus top/fop-flash assay expression wnt signaling pathway-related apoptosis-related factor determine western blot analysis nude mouse glioma xenograft establish detect tumorigenic ability glioma cell line t98g u138 highly resistant tmz select subsequent experiment resveratrol increase efficacy tmz restrain cell proliferation tumor growth promote cell apoptosis glioma cell resveratrol inhibit wnt2 beta-catenin expression yet elevated gsk-3beta expression moreover wnt signaling pathway participate sensitivity enhancing resveratrol tmz via regulate o 6 methylguanine-dna methyltransferase mgmt expression resveratrol sensitize tmz-induced glioma cell apoptosis repress activation wnt signaling pathway downregulate mgmt expression may confer new thought chemotherapy glioma 
background co-delivery all-trans-retinoic acid atra paclitaxel ptx effective strategy cancer therapy however many previous report atra conjugate co-delivery system atra release slower ptx total drug release atra far lower ptx purpose design prepare ph redox dual responsive drug delivery system da-ss-np co-delivery atra ptx cancer therapy surface charge da-ss-np change negative positive tumor slightly acidic microenvironment drug quickly release da-ss-np intracellular high concentration glutathione gsh method da-ss-nps construct encapsulate ptx hydrophobic core polymer micelle polymer synthesize conjugate atra 2,3-dimethylmalefic anhydride dma side chain cystamine dihydrochloride cys modify peg-b-pasp name da-ss-np surface charge da-ss-np different ph condition detect drug release also measure different concentration gsh therapeutic effect da-ss-np investigate human lung cancer a549 cell a549 tumor-bearing mouse result zeta potential da-ss-np -16.3 mv ph 7.4 change 16 mv ph 6.5 cell uptake experiment show da-ss-np internalize a549 cell ph 6.5 ph 7.4 addition presence 10 mm gsh ph 7.4 75 -85 atra release da-ss-np within 48 h less 20 atra release without gsh vivo antitumor efficiency show da-ss-np affectively inhibite tumor compare control group conclusion charge-reversal gsh-responsive da-ss-np provide excellent platform potential tumor therapy 
tumor-targeting micelle delivery paclitaxel ptx develop base folic acid alpha-tocopherol succinate conjugate hyaluronic acid fa-ha-tos conjugate fa-ha-tos synthesize esterification reaction characterize proton nuclear magnetic resonance 1h nmr fourier transform infrare ft-ir analysis conjugate self-assemble nanosized micelle aqueous medium critical micellar concentration cmc 1.12 x 10-2 mg/ml fa-ha-tos micelle demonstrate high drug loading entrapment efficiency ptx respective value 21.37 90.48 physicochemical property micelle measure dls tem xrd moreover vitro vivo evaluation perform demonstrate superior antitumor activity ptx-loaded micelle suggest fa-ha-tos micelle system represent promising nanocarrier target delivery ptx 
conventional cytotoxic drug preferentially eliminate differentiate cancer cell spare relatively resistant stem-like cancer cell capable initiate recurrence due cancer cell plasticity stem-like phenotype also acquire cancer cell refractory treatment cytotoxic drug investigate whether drug inhibit receptor tyrosine kinase use target human colon cancer cell initiate cancer regrowth follow conventional cytotoxic treatment moderately differentiate cell line ht-29 poorly differentiate cell line hct-116 expose 5-fluorouracil 5-fu cell resist exposure 5-fu subsequently treat imatinib sunitinib drug reduce clonogenicity 5-fu-refractory cell normoxic hypoxic culture condition expression numerous stemness-related gene upregulate cancer cell follow exposure 5-fu remain high level 5-fu-refractory cell undergo renewal normoxia decrease spontaneously hypoxia imatinib downregulate expression stemness-related gene cell undergo renewal normoxia combination imatinib pri-2191 analogue 1,25-dihydroxyvitamin d3 downregulate stemness-related gene hct-116 / 5-fu cell efficiently imatinib alone synthetic analogue 1,25-dihydroxyvitamin d2 pri-1906 abolish effect imatinib gene expression hct-116 / 5-fu cell undergo renewal normoxia sunitinib promote shift phenotype ht-29 / 5-fu cell undergo renewal toward stem-like one suggest phenotype shift toward stemness induce sequential sunitinib treatment follow 5-fu treatment increase risk cancer recurrence contrast sunitinib imatinib use interfere cancer regrowth conventional chemotherapy downregulate expression stemness-related gene residual colon cancer cell capable initiate cancer recurrence finding suggest imatinib also combine vitamin d analogue pri-2191 prevent recurrence efficiently imatinib alone compensate vitamin d deficiency result imatinib treatment 
multidrug resistance mdr remain one major reason inefficiency many chemotherapeutic agent cancer therapy study d-alpha-tocopheryl polyethylene glycol 1000 succinate tpgs polylysine-deoxycholic acid copolymer pll-da co-modified cationic liposome coating hyaluronic acid ha construct co-delivery paclitaxel ptx chemosensitize agent sorafenib sor treat mdr cancer multifunctional liposome ha-tpd-cl-ptx / sor present good stability rat plasma capable reverse surface zeta potential acidic condition presence haase additionally experimental result confirm pll-da copolymer facilitate endo-lysosomal escape liposome vitro study demonstrate ha-tpd-cl-ptx / sor significantly enhance drug accumulation resistant mcf-7 / mdr cell inhibit p-gp efflux effectively inhibit growth tumor cell furthermore liposome show enhance anticancer activity vivo tumor growth inhibition rate 78.52 summary ha-tpd-cl-ptx / sor exhibit great potential effective therapy resistant cancer combine chemotherapeutic agent promising nano-carrier reverse mdr improve effectiveness chemotherapy 
therapy glioblastoma gbm show high percentage failure associate survival glioma stem cell gsc repopulate treated tumour force differentiation gsc promising new approach cancer treatment erythropoietin-producing hepatocellular eph receptor drive tumourigenicity stemness gbm test glpg1790 first small molecule inhibition activity versus inhibitor various eph receptor kinase preclinical gbm model use vitro vivo assay glpg1790 rapidly persistently inhibit ephrin-a1-mediated phosphorylation tyr588 ser897 completely block epha2 receptor signalling similarly compound block ephrin b2-mediated epha3 ephb4 tyrosine phosphorylation result anti-glioma effect glpg1790 down-modulate expression mesenchymal marker cd44 sox2 nestin octamer-binding transcription factor 3/4 oct3/4 nanog cd90 cd105 up-regulate glial fibrillary acidic protein gfap pro-neural/neuronal marker betaiii tubulin neurofilament glpg1790 reduce tumour growth vivo effect larger compare radiation therapy rt u251 t98g xenograft smaller temozolomide tmz u251 u87mg cell model contrast glpg1790 show effect higher radiotherapy rt similar temozolomide tmz orthotopic u87mg cscs-5 model term disease-free survival dfs overall survival os experiment necessary study possible interaction radio chemotherapy glpg1790 demonstrate anti-tumor effect regulate differentiative status glioma initiate cell gic quality tumor microenvironment translate efficacy aggressive gbm mouse model significant common molecular target radio chemo therapy support combination use glpg1790 ameliorative antiglioma therapy 
arecoline primary alkaloid betel nut know risk factor oral submucosal fibrosis oral cancer lung cancer severe type carcinoma high cell motility difficult treat however detailed mechanism correlation arecoline lung cancer fully understand investigate effect arecoline migration lung cancer cell line potential mechanism muscarinic acetylcholine receptor 3 machr3 trigger egfr/src/fak pathway result indicate different concentration arecoline treatment 10 microm 20 microm 40 microm significantly increase cell migration ability a549 cl1-0 cell promote formation filamentous actin f-actin cytoskeleton crucial element cell migration however migration h460 cl1-5 h520 cell line higher migration ability affect arecoline treatment egfr/c-src/fak pathway responsible cell migration activate arecoline treatment decrease expression level e-cadherin epithelial marker observe arecoline-treated cell line blockade egfr/c-src/fak pathway inhibitor egfr gefitinib c-src dasatinib significantly prevent arecoline-promoted migration a549 cell gefitinib dasatinib treatment significantly disrupt arecoline-induced localization phospho-y576-fak focal adhesion a549 cell interestingly arecoline-promoted migration a549 cell block specific machr3 inhibitor 4-damp neutralize antibody matrix metalloproteinase mmp7 matrilysin take together finding suggest machr3 might play essential role arecoline-promoted egfr/c-src/fak activation migration a549 lung cancer cell line 
aim study evaluate effect related pharmacological mechanism switch schedule antiangiogenic chemotherapeutic drug beyond progression first-line treatment colorectal cancer preclinical model vivo study perform nude mouse subcutaneously transplant colon cancer cell treatment include drug combination switch chemotherapeutic i.e. irinotecan 5-fluorouracil and/or antiangiogenic drug i.e. anti-vegf antibody sunitinib time tumor progression proliferation assay also achieve vitro different colon cancer cell line expose sn-38 sunitinib alone combination abcg2 gene expression perform real-time pcr sn-38 intracellular concentration measure switch combined treatment time tumor progression chemotherapeutic irinotecan 5-fluoruracil antiangiogenic drug anti-vegf antibody sunitinib drug induce new response immunohistochemistry stromal pdgf-c plgf sd1-alpha tie-2 vegfr-2 show statistical difference tumor time relapse switch therapy moreover combination sn-38 sunitinib cause synergism colon cancer cell significant inhibition abcg2 gene expression increase sn-38 intracellular concentration observation may clinical relevance suggest switch single chemotherapeutic antiangiogenic drug beyond progression disease obtain new tumor response due modulation angiogenic factor direct effect tumor cell possible variation intracellular drug concentration 
find better strategy enhance cytotoxic effect paclitaxel ptx lapatinib lap breast cancer cell analyze efficacy novel delivery system contain polylactide-co-poly ethylene glycol pla-peg filomicelle 100 nm length spherical micelle approximately 20 nm diameter 1h nmr measurement confirm incorporation ptx lap micelle analysis drug release mechanism reveal diffusion-controlled release lap anomalous transport ptx drug content analysis lyophilize micelle micellar solution show good storage stability least 6 week blank micelle lap-loaded micelle free lap affect mcf-7 breast cancer cell proliferation suggest cytotoxicity ptx ptx/lap-loaded micelle binary mixture free ptx lap solely cause ptx ptx/lap-loaded micelle show greater toxicity compare binary mixture ptx lap 48 h 72 h. free ptx alone induce p-gp activity study show feasibility use lap ptx combination overcome mdr mcf-7 cell particularly co-load micelle suggest ptx/lap micelle applicable therapy her-2-positive also her-2-negative breast cancer 
present study tri-layer nanofiber synthesize via triaxial electrospinning process control sustained delivery doxorubicin dox paclitaxel ptx 5 fluorouracil 5-fu anticancer drug nanofiber 5-fu molecule incorporate core solution chitosan/polyvinyl alcohol cs/pva fabricate cs/pva/5-fu inner layer nanofiber intermediate layer prepare poly lactic acid / chitosan pla/cs nanofiber dox ptx molecule initially load g-c3n4 nanosheet follow incorporate pla/cs solution fabricate outer layer nanofiber synthesize nanosheet nanofiber characterize use xrd sem tem uv-vis analysis pla/pva/cs / fu/g-c 3n4/dox/ptx single layer nanofiber also synthesize via electrospinning method drug load efficiency degradation rate anticancer drug release profile single layer tri-layer nanofiber investigate various intermediate shell layer thickness pharmacokinetic study perform understand drug release mechanism nanofiber cell viability cell attachment drug loaded single layer tri-layer nanofiber toward mcf-7 breast cancer cell examine achieve optimum nanofibrous formulation breast cancer treatment obtain result reveal high activity tri-layer nanofiber breast cancer cell kill 
experiment perform ascertain whether cytotoxic effect various anticancer drug five human genitourinary malignant cell line enhance recombinant gamma-type interferon cell use follow hela cell uterine cervix cancer ht-1376 ej cell bladder cancer achn cell renal cancer pc-3 cell prostatic cancer effect drug study colony formation assay follow drug use two metabolic antagonist cytosine arabinoside ara-c 5-fluorouracil 5-fu three antibiotic adriamycin adm mitomycin c mmc peplomycin pep two alkylating agent nimustine hydrochloride acnu melphalan one vinca alkaloid vincristine vcr one drug cisplatin cddp interferon use preparation recombinant gamma-type interferon pep show synergistically enhance cytotoxic effect hela ej ht-1376 achn cell concomitant application gamma-ifn synergistic cytotoxicity also detect hela ej achn combined treatment adm gamma-ifn similar enhance cytotoxicity demonstrate ht-1376 pc-3 5-fu treatment gamma-ifn mmc show enhance cytotoxicity achn cell presence gamma-ifn cytotoxic effect pep cell increase lower concentration gamma-ifn compare drug dna rna protein synthesis examine hela cell follow combined exposure pep gamma-ifn combined therapy find produce specific decrease dna synthesis yield significant inhibition intracellular rna protein synthesis 
background lung cancer often rank one prevalent malignancy world one challenging aspect treat late-stage lung cancer patient development drug resistance conventional chemo target therapeutic agent tumor-associated microphage tam show promote survival distant metastasis lung cancer cell method study investigate tam modulate potential cisplatin-resistant non-small cell lung cancer nsclc cell line a549r h460r use bioinformatic approach immunoblotting immunofluorescence staining migration invasion colony lung sphere formation xenograft tumorigenecity assay result study first demonstrate elevated expression oncogenic stemenss marker src notch1 macrophage inhibitory factor mif cd155 trained cisplatin cddp resistant a549 h460 cell a549r h460r cell co-culture tam a549r h460r cell promote m2-polarization tam addition a549r h460r cell show increase self-renewal ability form tumor sphere higher frequency compare parental counterpart increase mif secretion a549r h460r cell suppress multiple kinase inhibitor dasatinib result decrease oncogenic network src cd155 mif expression similarly dasatinib treatment reduce m2 polarization tam suppress self-renewal ability a549r h460r cell conclusion summary cisplatin resistant lung cancer cell show increase self-renewal ability also promote m2 polarization tam via secretion mif finding link increase src-associated signaling dasatinib treatment significantly reverse phenomenon thus kinase inhibitor dasatinib may potential treat cisplatin-resistant lung cancer target tumor tumor microenvironment 
three-dimensional 3d culture potential increase predictive value pre-clinical drug research bridge gap towards anticipate clinical outcome propose treatment however implementation advanced drug-discovery program still infancy due lack reproducibility low time cost effectiveness hct116 sw620 dld1 cell cell line distinct mutation grade origin co-culture fibroblast endothelial cell ec 3d spheroid clinically relevant drug i.e. 5-fluorouracil 5-fu regorafenib erlotinib administer individually crc cell culture study establish robust low-cost reproducible short-term 3d culture system address various complexity colorectal carcinoma crc microenvironment observe dose-dependent increase erlotinib sensitivity 3d co culture compare 2d culture furthermore compare drug combination efficacy drug-drug interaction administer 2d 3d 3d co-culture observe synergistic/additive drug-drug interaction drug combination administer low dose shift towards additive antagonistic apply higher dose metastatic crc cell addition fibroblast various ratio ec increase resistance drug combination sw620 dld1 cell hct116 retreatment sw620 3d co-culture low-dose 3-drug combination active 88 inhibition relative control 5-fu treatment high dose 100 mum moreover 3d 3d co-culture respond variably drug combination treatment also signalling pathway differently regulate probably due influence fibroblast ec cancer cell short-term 3d co-culture system develop powerful platform screening combination therapy understand signalling 3d co-culture versus 3d culture response 3d model upon drug treatment might beneficial design anti-cancer therapy 
temozolomide alkylating agent use first line treatment glioblastoma however chemoresistance temozolomide common glioma patient addition likely many unknown mechanism anti-tumor effect temozolomide know alkylating agent sulfur mustard activate cytosolic phospholipase a2 cpla2 release arachidonic acid suppress tumor present study perform elucidate involvement cpla2 anti-tumor mechanism temozolomide three glioblastoma cell line gl261 u251mg t98g perform several evaluation include cell viability cell migration apoptosis study temozolomide-induced anti-tumor effect evaluate tumor size murine orthotropic glioblastoma model oral administration temozolomide finally investigate phosphorylation cpla2 gl261 cell treat temozolomide clarify whether phosphorylation cpla2 affect cell growth temozolomide suppress cell growth cell migration glioblastoma cell vitro show anti-tumor effect murine orthotopic glioblastoma model vivo furthermore temozolomide increase phosphorylation cpla2 associate suppression cell growth however mgmt high-expressing glioblastoma t98g cell temozolomide suppress cell growth cause phosphorylation cpla2 finding indicate temozolomide suppress cell growth partly phosphorylation cpla2 glioblastoma cell addition temozolomide cause phosphorylation cpla2 mgmt high-expressing glioblastoma t98g cell phosphorylation cpla2 may cause dna alkylation temozolomide 
background glioblastoma common aggressive brain tumour adult median overall survival 14 month standard therapy radiation therapy ir temozolomide tmz novel multimodal treatment approach combine checkpoint kinase 1 chk1 inhibitor sar-020106 sar disrupt homologue recombination standard dna damage inducer ir tmz epigenetic/cytotoxic drug decitabine 5-aza-2 deoxycitidine 5-aza-dc different vitro glioblastoma model monitor evaluate impaired dna damage repair may chemo/radiosensitize tumour cell method human p53-mutated p53-mut wildtype p53-wt glioblastoma cell line p53-mut ln405 t98g p53-wt a172 dbtrg primary glioblastoma cell p53-mut p0297 p53-wt p0306 treat sar combine tmz 5-aza-dc and/or ir analyse induction apoptosis annexinv sub-g1 assay cell cycle distribution nuclear pi staining dna damage alkaline comet gh2a.x assay proliferation inhibition brdu assay reproductive survival clonogenic assay potential tumour stem cell nestinpos/gfapneg fluorescence staining potential treatment-induced neurotoxicity evaluate nestin-positive neural progenitor cell murine entorhinal-hippocampal slice culture model result sar show radiosensitizing effect induction apoptosis reduction long-term survival p53-mut p53-wt glioblastoma cell line primary cell p53-mut cell effect accompany abrogation ir-induced g2/m arrest enhancement ir-induced dna damage sar treatment also tmz 5-aza-dc act radioadditively albeit lesser extent multimodal treatment achieve effective reduction clonogenicity test cell line affect ratio nestinpos/gfapneg cell neurotoxic effect detect number nestin-positive neural progenitor cell remain unchanged multimodal treatment conclusion chk1 inhibitor sar-020106 potent sensitizer dna damage-induced cell death glioblastoma therapy strongly reduce clonogenicity tumour cell selectively enhance p53-mut cell death may provide stronger response tumour defective non-homologous end join nhej result suggest multimodal therapy involve dna damage inducer dna repair inhibitor might effective anti-tumour strategy low risk neurotoxicity 
background prostate cancer pca remain second lead cause cancer-related death among man taxanes docetaxel cabazitaxel utilize standard treatment regimen chemotherapy naive castration-resistant pca however tumor often develop resistance taxane chemotherapeutic highlight need identify additional therapeutic target fatty acid-binding protein 5 fabp5 intracellular lipid carrier whose expression upregulate metastatic pca increase cell growth invasion tumor formation assess whether fabp5 inhibitor synergize semi-synthetic taxane induce cytotoxicity vitro attenuate tumor growth vivo method pc3 du-145 22rv1 pca cell incubate fabp5 inhibitor stony brook fatty acid-binding protein inhibitor 102 sbfi-102 sbfi-103 presence absence docetaxel cabazitaxel cytotoxicity evaluate use 3 4,5-dimethylthiazol-2-yl -2,5 diphenyl tetrazolium bromide assay cytotoxicity sbfi-102 sbfi-103 also evaluate noncancerous cell vivo study pc3 cell subcutaneously implant balb/c nude mouse subsequently treat fabp5 inhibitor docetaxel combination result sbfi-102 sbfi-103 produce cytotoxicity pca cell coincubation pca cell fabp5 inhibitor docetaxel cabazitaxel produce synergistic cytotoxic effect vitro treatment mouse fabp5 inhibitor reduce tumor growth combination fabp5 inhibitor submaximal dose docetaxel reduce tumor growth larger extent treatment drug alone conclusion fabp5 inhibitor increase cytotoxic tumor-suppressive effect taxane pca cell ability drug synergize permit efficacious antitumor activity allow dosage docetaxel cabazitaxel lower potentially decrease taxane-resistance 
significance phenotypic plasticity afford epithelial-mesenchymal transition emt cancer progression drug resistance remain fully elucidate clinic evaluate epithelial-mesenchymal phenotypic characteristic across range tumor histology use validate high resolution digital microscopic immunofluorescence assay ifa incorporate beta-catenin detection cellular morphology delineate carcinoma cell stromal fibroblast quantitate individual co-localized expression epithelial marker e-cadherin e mesenchymal marker vimentin v subcellular resolution emt ifa report discovery beta-catenin cancer cell co-express e-cadherin vimentin core needle biopsy patient various advanced metastatic carcinoma wherein cell transition strongly epithelial strongly mesenchymal-like phenotype treatment carcinoma model anticancer drug differ mechanism action tyrosine kinase inhibitor pazopanib mkn45 gastric carcinoma xenograft combination tubulin-targeting agent paclitaxel bcr-abl inhibitor nilotinib mda-mb-468 breast cancer xenograft cause change tumor epithelial-mesenchymal character moreover appearance partial-emt mesenchymal-like carcinoma cell mda-mb-468 tumor treat paclitaxel-nilotinib combination result upregulation cancer stem cell csc marker susceptibility fak inhibitor metastatic prostate cancer patient treat parp inhibitor talazoparib exhibit similar csc marker upregulation therefore phenotypic plasticity confer carcinoma cell emt allow rapid adaptation cytotoxic molecularly-targeted therapy create form acquire drug resistance transient nature 
triple-negative breast cancer tnbc lack specific target therapy option evolve highly chemo-resistant tumor metastasize multiple organ simultaneously previously show tnbc maintain activate wnt10b-driven network drive metastasis pharmacologic inhibition icg-001 decrease beta-catenin-mediated proliferation multiple tnbc cell line tnbc patient-derived xenograft pdx derive cell line vitro icg-001 effective combination conventional cytotoxic chemotherapeutic cisplatin doxorubicin decrease proliferation mda-mb-231 cell contrast tnbc pdx-derived cell doxorubicin plus icg-001 synergistic pair cisplatin effective mechanistically cytotoxicity induce doxorubicin cisplatin icg-001 associate increase cleavage parp-1 pdx cell vivo mda-mb-231 tnbc pdx orthotopic primary tumor initiate de novo simultaneous multi-organ metastase include bone metastase wnt monotherapy block multi-organ metastase measure luciferase imaging histology loss expression wnt10b/beta-catenin direct target hmga2 ezh2 axin2 myc pcna ccnd1 transcriptionally active beta-catenin snail vimentin vitro vivo primary tumor mechanistically explain loss multi-organ metastase wnt monotherapy induce vegfa expression tumor model system whereas increase cd31 observe mda-mb-231 tumor moreover wnt-inhibition sensitize anticancer response tnbc pdx model doxorubicin prevent simultaneous metastase liver ovary well bone datum demonstrate wnt-inhibition sensitize tnbc anthracycline treat multi-organ metastase tnbc 
new series 1,2,3-triazole-chalcone hybrid synthesize screen vitro panel 60 human cancer cell line accord nci usa protocol compound 4d 3 4-dimethoxyphenyl chalcone moiety potent derivative inhibit growth rpmi-8226 sr leukemia cell line 99.73 94.95 10 mum respectively also inhibit growth m14 melanoma k-562 leukemia mcf7 breast cancer cell line 80 test concentration 4d show ic50 value less 1 mum six type tumor cell high selectivity index reach 104 fold mcf7 compound 4d show superior activity methotrexate gefitinib sensitive leukemia cell line addition higher comparable activity rest sensitive cell line flow cytometry analysis rpmi-8226 cell reveal compound 4d cause cell cycle arrest g2/m phase induce apoptosis dose dependant manner mechanistic evaluation refer apoptosis induction trigger mitochondrial apoptotic pathway induce ros accumulation increase bax/bcl -2 ratio activation caspase 3 7 9 
drug resistance present serious difficulty cancer treatment combination paclitaxel ptx lapatinib lapa show potential multiple drug resistant cancer clinic almost impossible deliver two drug tumor time best proportion simple co-administration respective current formualtion different pharmacokinetic profile composite nanocrystal ptx lapa cnc design ratio 2:1 w/w intracellular ratio best synergistic efficacy drug-resistant cancer cell line mcf-7 / adr cnc prepare use bottom-up method achieve nearly spherical appearance narrow size distribution 95.1 2.1 nm nanocrystal stabilization polyethylene glycol peg coating introduce cnc via polydopamine pda coating order get pegylate composite nanocrystal cnc@pda-peg nanoscale size 170.5 1.4 nm considerable drug loading ptx 21.33 1.48 lapa 10.95 1.24 good stability least 4 day plasma-containing buffer differential scanning calorimeter dsc xrd datum indicate different crystalline state cnc well cnc@pda-peg comparison bulk drug vitro release datum show ptx lapa gradually completely release cnc@pda-peg 3 day drug release bulk drug cnc 30 cnc@pda-peg also show negligible hemolysis vitro cellular uptake experiment mcf-7 / adr cell line show nanocrystal enter cell complete form endocytosis release drug cell cnc@pda-peg inhibit growth drug-resistant cell effectively unmodified version cnc summary pegylate ptx lapa composite nanocrystal show potential treament drug-resistant tumor simultaneously deliver two drug tumor cell best proportion 
objective glutamatergic signaling significantly promote proliferation migration invasion glioblastoma gbm riluzole metabotropic glutamate receptor 1 inhibitor reportedly suppress gbm growth however effect combine riluzole primary gbm chemotherapeutic agent temozolomide tmz unknown study aim investigate efficacy combinatorial therapy tmz/riluzole gbm vitro vivo method three gbm cell line t98g human o6-methylguanine dna methyltransferase mgmt positive u87mg human mgmt negative gl261 murine mgmt positive treat tmz riluzole combination author perform cell viability assay follow isobologram analysis evaluate effect combinatorial treatment gbm cell line test effect riluzole mgmt dna repair enzyme cause chemoresistance tmz quantitative real-time reverse transcription polymerase chain reaction t98g cell furthermore evaluate efficacy combinatorial tmz/riluzole treatment orthotopic mouse allograft model mgmt-positive gbm use c57bl/6 j mouse gl261 cell result riluzole display significant time dose-dependent growth-inhibitory effect gbm cell line assess independently riluzole enhance antitumor effect tmz synergistically mgmt-positive mgmt-negative gbm cell line riluzole singularly suppress mgmt expression significantly suppress tmz-induced mgmt upregulation p 0.01 furthermore combinatorial tmz/riluzole treatment significantly suppress tumor growth intracranial mgmt-positive gbm model p 0.05 conclusion riluzole attenuate tmz-induced mgmt upregulation enhance antitumor effect tmz mgmt-positive gbm therefore combinatorial tmz/riluzole treatment potentially promising novel therapeutic regimen mgmt-positive gbm 
tyrosine kinase inhibitor tki induce autophagy many type cancer cell previously report gefitinib gef imatinib ima induce autophagy epidermal growth factor receptor egfr knock-out a549 non-bcr-abl-expressing leukemia cell line respectively evidence suggest tki-induced autophagy independent original target molecule present study compare autophagy-inducing ability various tki regardless target quantitative autophagy flux assay establish stable clone express gfp-lc3-mcherry-lc3deltag plasmid a549 pc-9 cal 27 cell line assess autophagy inducibility monitor fluorescent ratio gfp-lc3 mcherry-lc3deltag use incucyte live cell imaging system exposure tki viz gef osimertinib osi lapatinib lap lenvatinib len sorafenib sor ima dasatinib das tivantinib tiv among tki das gef sor exhibit prominent autophagy induction a549 pc-9 cell cal 27 cell ima sor len gef tiv osi exhibit autophagy induction presence azithromycin azm show inhibitory effect autophagy flux tki prominent autophagy inducibility exhibit enhance cytotoxicity via non-apoptotic cell death relative effect tki alone therefore autophagy inducibility tki differ context cancer cell however induce appear cytoprotective function thus block tki-induced autophagy azm may improve therapeutic effect tki cancer cell 
simple environmentally friendly microwave-assisted protocol develop synthesis 3,5-bis styryl pyrazole 2a-l allow rapid generation screening anti-proliferative activity pc3 prostate cancer cell line two analogue 2a 2l gi50 value low micromolar range select biological evaluation apoptosis cell cycle analysis effect tubulin microtubule 3,5-bis 1e -2 2,6-dichlorophenyl ethenyl -1 h-pyrazole 2l induce cell death pc3 cell even removal compound compound bind tubulin kd 0.4 -0.1 mum inhibit tubulin polymerization vitro effect polymerization bacterial cell division protein ftsz homolog tubulin addition pyrazole 2l competitive paclitaxel bind tubulin vinblastine crocin colchicine treatment pyrazole 2l result microtubule depolymerization pc3 cell 3,5-bi styryl pyrazole thus warrant investigation lead compound treatment castration-resistant prostate cancer crpc significance statement taxane paclitaxel docetaxel cabazitaxel important component prostate cancer chemotherapy regimen oral administration hamper low highly variable oral bioavailability example mean oral bioavailability paclitaxel 10 result poor absorption due poor solubility high first-pass metabolism efficient efflux p-glycoprotein abundant gastrointestinal tract new chemical entity nce treatment prostate cancer thus require ideally much simpler structurally complex taxane report facile synthesis extensive investigation mechanism action bis styryl pyrazole demonstrate potential lead compound treatment prostate cancer 
background enrichment cancer stem cell-like cell csc consider responsible tumor progression initial response epidermal growth factor receptor egfr tyrosine kinase inhibitor egfr-tki patient non-small cell lung adenocarcinoma nsclc/adc csc aldh1a1bright / cd44high expression contribute tki resistance nsclc/adc cell all-trans retinoic acid atra show potential target therapy csc due ability inhibit aldh1a1 activity therefore investigate whether atra circumvent resistance improve response gefitinib nsclc/adc cell method treatment nsclc/adc a549 h1650 cell gefitinib enrich gefitinib survive cell gsc expression aldh1a1 cd44 ic50 value gefitinib determine flow cytometry fcm crystal violet assay gsc atra-treated gsc respectively use deab positive control direct inhibitory effect atra aldh1a1 activity determine aldefluor assay result gsc show higher expression aldh1a1 cd44 ic50 value gefitinib respective parental cell suggest gefitinib lead propagation csc-enriched gefitinib-resistant cell treatment atra find significantly reduce increase expression aldh1a1 cd44 ic50 value gefitinib a549gsc h1650gsc cell atra directly inhibit active aldh1a1 compare deab conclusion finding suggest combination treatment atra prevent gefitinib-induced enrichment aldh1a1bright/cd44high csc enhance gefitinib-induced growth inhibition nsclc/adc cell 
glioblastoma malignant brain tumor exhibit highly aggressive proliferation invasion capacity despite treatment aggressive surgical resection adjuvant therapy include temozolomide radiation therapy patient prognosis remain poor lenalidomide derivative thalidomide know immunomodulatory agent use treat hematopoietic malignancy numerous study reveal antitumor effect lenalidomide hematopoietic cell glioma cell present study aim demonstrate antitumor effect lenalidomide malignant glioma cell line growth inhibition malignant glioma cell a-172 am-38 t98g u-138mg u-251mg yh-13 lenalidomide assess use coulter counter mechanism antitumor effect lenalidomide examine employ fluorescence-activated cell sorter western blot analysis quantitative real-time reverse transcriptional polymerase chain reaction rt-qpcr malignant glioma cell line a-172 am-38 result reveal number malignant glioma cell decrease concentration-dependent manner lenalidomide dna flow cytometric analysis demonstrate increase ratio cell g0/g1 phase follow lenalidomide treatment western blot analysis rt-qpcr reveal p53 activation expression p21 increase glioma cell treat lenalidomide western blot analysis reveal cleavage parp occur however increase expression bax protein cleavage caspase-9 cleavage caspase-3 confirm analysis facs also support conclusion little apoptosis induction occur follow lenalidomide treatment malignant glioma cell line conclusion lenalidomide exert antitumor effect glioma cell due alteration cell cycle distribution 
recent year coumarin bioactive compound identify posess anticancer property therefore aim present study investigate first time efficacy osthole umbelliferone esculin 4-hydroxycoumarin alone combination temozolomide elimination deadly brain tumor anaplastic astrocytoma aa glioblastoma multiforme gbm cell via program death result indicate osthole umbelliferone esculin 4-hydroxycoumarin initiate mainly apoptosis t98g moggccm cell osthole effective also initiate autophagy small percentage cell population co-incubation temozolomide increase pro-apoptotic potential natural compound decrease level autophagy t98g cell apoptosis associate reduce mitochondrial membrane potential activation caspase 3 inhibition bcl-2 expression presence bcl-2 / beclin 1 blocking bcl-2 expression result promotion apoptosis autophagy moggccm t98g line also sensitize astrocytoma cell gbm combined osthole tmz treatment correlate reduce level beclin 1 increase expression caspase 3 osthole tmz alone combination inhibit migratory phenotype gbm aa cell summary result indicate osthole effectively eliminate glioma cell via apoptosis correlate bcl-2 / beclin 1 complex formation consider anti-migratory effect osthole temozolomide display antiglioma potential need extensive study 
order develop potential anticancer agent stimulate apoptosis novel 3,4-isoxazolediamide 4,5,6,7-tetrahydro-isoxazolo 4,5-c pyridine derivative synthetize original structure geldanamycin radicicol know natural heat shock protein hsp inhibitor deeply modify exhibit several drawback poor solubility hepatotoxicity intrinsic chemical instability deprivation vivo activity novel class synthetic compound contain isoxazole nucleus exhibit potent selective inhibition hsp90 previous study biological assay focus vitro antiproliferative effect pro-apoptotic activity human erythroleukemic k562 cell model system refer tumor cell grow suspension glioblastoma u251-mg glioblastoma temozolomide tmz resistant t98g cell line two model system refer tumor cell grow attach flask perform almost isoxazole derivative demonstrate significant antiproliferative pro-apoptotic activity show induction early late apoptosis k562 cell different effect observe glioma u251-mg t98g cell depend structure analogue antiproliferative pro-apoptotic activity k562 cell associate activation erythroid differentiation program present study demonstrate 3,4-isoxazolediamide 4,5,6,7-tetrahydro-isoxazolo 4,5-c pyridine derivative consider vivo study focus development anticancer drug act least partially via activation apoptosis 
establishment clinically relevant model tumor metastasis drug testing major challenge cancer research report physiologically relevant assay enable quantitative analysis metastatic capacity tumor cell follow implantation chorioallantoic membrane cam engraftment 103 non-small cell lung cancer nsclc prostate cancer pca cell line sufficient primary tumor metastasis formation standard 2d-imaging well 3d optical tomography imaging use detection fluorescent metastatic focus chick embryo h2228 h1975-initiated metastase confirm genomic analysis quantify inhibitory effect docetaxel lncap cisplatin a549 h1299-initiated metastatic growth cam assay also mimic sensitivity alk-rearranged h2228 egfr-mutated h1975 nsclc cell tyrosine kinase inhibitor crizotinib gefitinib respectively well sensitivity lncap cell androgen-dependent enzalutamide therapy assay suggest reconstitute bone metastatic tropism pca cell show cam chick embryo model may powerful preclinical platform testing targeting metastatic capacity cancer cell 
prostate cancer common malignant tumor bone metastasis still ideal treatment bone metastasis prostate cancer study ph gsh dual sensitive calcium phosphate-polymer hybrid nanoparticle dtx@cap / hp prepare co-deliver zoledronate zol docetaxel dtx treat bone metastasis prostate cancer dtx@cap / hp exhibit high bone binding affinity release dtx zol acidic high gsh concentration environment large amount dtx@cap / hp uptaken pc-3 cell acidic medium neutral medium dtx@cap / hp obviously reduce pc-3 cell proliferation bone lesion in-vitro 3d model bone metastase prostate cancer besides dtx@cap / hp also exhibit stronger anti bone metastase prostate cancer activity vivo compare dose dtx+zol result co-delivery dtx zol bone metastase prostate cancer dtx@cap / hp synergistic effect dtx zol dtx@cap / hp great potential treatment bone metastase prostate cancer 
background tyrosine kinase inhibitor tki inhibit phosphorylation signaling protein tki often show large variation clinic due poor pharmacology possibly lead resistance compare gut absorption inhibitor epidermal growth factor receptor erlotinib gefitinib afatinib alk-cmet crizotinib pdgfr/bcr-abl dasatinib multikinase inhibitor sunitinib sorafenib clinical sample measure disposition compound within various blood compartment method use optimize caco2 gut epithelial model characterize 20 microm tki absorption apical/basolateral transfer consider represent gut/blood transfer drug measure use lc-ms/ms result sorafenib sunitinib show highest apical/basolateral transfer papp 14.1 7.7 x 10-6 cm/s respectively follow dasatinib 3.4 afatinib 1.5 gefitinib 0.38 erlotinib 0.13 crizotinib n.d. however net absorption dasatinib afatinib crizotinib erlotinib highly negative efflux ratio 5 neutral/negative sorafenib 0.86 gefitinib 1.0 sunitinib 1.6 high negative absorption may result resistance poor exposure tissue drug accumulation tki end transfer period b detectable erlotinib low afatinib 0.45 pmol/mug protein follow gefitinib 0.79 dasatinib 1.1 sorafenib 1.65 crizotinib 2.11 highest sunitinib 11.9 similar pattern find accumulation drug colon cell line widr ht29 clinical sample drug accumulate consistently red blood cell blood plasma ratio 3 sorafenib 30 erlotinib conclusion tki consistently poorly absorb accumulation red blood cell seem compensate 
study aim design novel amphiphilic carrier base schizophyllan spg exopolysacharide drug delivery stearic acid sa use esterification spg two degree substitution sa-spg0.5 sa-spg1 h nmr ftir spectroscopy verify succesfull esterification spg polymeric micelle easily self-assemble nanomicelle ultrasound method fluorescence spectroscopy show critical micelle concentration cmc sa-spg0.5 sa-spg1 micelle 0.068 mg/ml 0.027 mg/ml respectively dls analysis show nanomicelle range 156 175 nm sem tem image show nanomicelle mostly spherical paclitaxel ptx drug model successfully load sa-spg nanomicelle three different drug/polymer weight ratio 0.1 0.2 0.3 highest encapsulation efficiency 75 obtain ptx/sa-spg weight ratio 0.1 vitro release ptx sa-spg micelle represent sustained release profile 144 h. mtt assay show ptx-loaded sa-spg nanomicelle higher cytotoxicity mcf-7 cell free ptx result reveal synthesize sa-spg nanomicelle promising potential new carrier efficient delivery hydrophobic drug 
angiogenesis inhibitor o chloroacetyl-carbamoyl fumagillol tnp-470 show antitumor activity three human cancer xenograft system tnp-470 potently inhibit tumor growth hormone-independent prostate cancer pc-3 cell breast cancer mda-mb-231 cell dose dependently weekly s.c. dose 50-200 mg/kg maximum inhibition 96 88 tumor growth 4 12 respective control experiment combination therapy chemotherapeutic agent combination tnp-470 100 mg/kg cisplatin 5 mg/kg show additive antitumor effect treat versus control 38 22 5 pc-3 carcinoma 5-fluorouracil adriamycin alone significantly inhibit mda-mb-231 tumor growth treat versus control 131 64 respectively tnp-470 also inhibit tumor growth widr colon cancer although inhibition less marked treated versus control 39 observe hormone-independent cancer use study vitro study cell line test considerably insensitive tnp-470 monolayer culture 50 inhibitory concentration approximately 5 micrograms/ml whereas tnp-470 inhibit anchorage-independent growth pc-3 mda-mb-231 cell 50 inhibitory concentration 0.05 470 ng/ml respectively inhibitory activity tnp-470 anchorage-independent growth correlate well vivo antitumor activity among cell line test thus inhibitory action may partly contribute potent antitumor activity angiogenesis inhibitor tnp-470 least case pc-3 mda-mb-231 result suggest hormone-independent prostate breast cancer may appropriate target disease tnp-470 clinical trial 
suramin show antitumour activity vitro vivo plasma level higher 200 microm however excessive toxicity therefore attempt improve antitumour effect suramin vitro combine several antitumour agent mcf-7 mammary carcinoma pc3 prostate cancer cell line expose continuously suramin agent 6 day sulphorhodamine b srb assay use assessment growth inhibition dose-response interaction evaluate use median-effect analysis chou talalay computer programme mcf-7 cell line combination suramin plus doxorubicin dxr cisplatin cddp 5-fluorouracil 5-fu tumour necrosis factor tnf result synergistic growth inhibition whilst combination miltefosine hpc antagonistic pc-3 cell line suramin plus cddp tnf synergistic whilst combination dxr 5-fu hpc antagonistic test combination interferon-alpha ifn-alpha interferon-gamma ifn-gamma combination ifn-alpha ifn-gamma synergistic synergistic effect suramin dxr schedule dependent pretreatment addition dxr day 1 suramin day 2-5 additive ic50 level cell line addition dxr day 5 effective simultaneous exposure find synergistic effect combination suramin cddp tnf cell line addition combination dxr 5-fu synergistic mcf-7 sequential administration dxr-suramin suramin-dxr increase growth inhibition 
investigate ability 5 dimethyltriazeno imidazole-4-carboxamide dtic decarbazine analogue temozolomide deplete cell tumor o6-alkylguanine-dna alkyltransferase agt enhance antitumor effect 1,3-bis 2-chloroethyl -1-nitrosourea bcnu human colon cancer ht29 cell survival decrease almost 1 log treat 500 microm temozolomide prior 150 microm bcnu administration maximal tolerate dose dtic 300 mg/kg nude mouse carry ht29 xenograft result complete depletion agt activity tumor 4 h 16 h. administration 150 mg/kg dtic cause 76 reduction agt activity 4 h 28 reduction 16 h maximally tolerate dose dtic bcnu alone combination use treat nude mouse bear ht29 xenograft difference tumor growth occur animal treat either bcnu alone 50 mg/kg dtic alone 300 mg/kg dtic 150 mg/kg follow bcnu 12.5 mg/kg bcnu 25 mg/kg follow dtic 150 mg/kg datum suggest methylating agent dtic may toxic use combination bcnu deplete tumor alkyltransferase level effectively increase therapeutic index bcnu 
cell mutator phenotype tolerant methylate damage n-methylnitrosourea n-methyl-n nitro-n-nitrosoguanine exhibit replication repair error recently find mutant mismatch repair mmr however resistance cell line defect clinically use chemotherapeutic agent relationship resistance expression o6-alkylguanine-dna alkyltransferase agt repair dna damage cause methylate agent demonstrate compare resistance methylating agent temozolomide tmz chloroethylating agent 1,3-bis 2-chloroethyl -1-nitrosourea bcnu without agt inhibition 06-bg several colorectal carcinoma cell line two cell line know microsatellite instability replication repair error-positive high level agt well mutation one two mmr gene hmlh1 hct116 gtbp hct15 cell line sw480 wild-type mmr gene high agt hct116 ch3 previously transduce chromosome 3 carry wild-type hmlh1 thus correct mmr phenotype sw480 exhibit expect sensitivity tmz bcnu marked potentiation cytotoxicity o6-bg contrast hct15 hct116 markedly resistant tmz sensitize o6-bg-mediated inhibition agt whereas sensitivity pattern hct116 ch3 cell similar sw480 cell line sensitize bcnu o6-bg thus tumor cell defect mmr appear particularly resistant methylating agent manner override dependence agt inhibition o6-bg however cell use agt resistance chloroethylating agent provide alternative strategy alkylate agent therapy 
breast cancer cell overexpress her-2 / neu resistant chemotherapeutic agent paclitaxel taxol docetaxel taxotere overexpress her-2 / neu previous work show adenovirus type 5 e1a repress her-2 / neu expression transcriptional level first demonstrate paclitaxel sensitivity correlate her-2 / neu expression level panel mouse fibroblast express different level her-2 / neu downregulation her-2 / neu expression e1a sensitize cell paclitaxel test whether e1a sensitize her-2 / neu-overexpressing human breast cancer cell paclitaxel e1a-mediated her-2 / neu repression adenoviral vector use transfer e1a gene two human breast cancer cell line mda-mb-453 mda-mb-361 overexpress her-2 / neu e1a delivery observe her-2 / neu expression level reduce cell treat paclitaxel cell proliferation assay show synergistic growth inhibition effect e1a paclitaxel synergistic effect also confirm soft agar colony-formation assay breast cancer cell line express low level her-2 / neu mda-mb-435 mda-mb-231 cell show synergistic growth inhibition effect treat protocol thus conclude adenovirus type 5 e1a gene sensitize paclitaxel-resistant her-2 / neu-overexpressing breast cancer cell drug repress her-2 / neu expression turn may important implication development novel therapy combine chemotherapy gene therapy 
parental igrov-1 human ovarian adenocarcinoma cell line intermittently expose increase concentration cisplatin obtain resistant subline stable resistant subline resistance factor 8.4 develop 9 month 28 passage denote igrov cddp high correlation coefficient 0.97 find log cell survival dna-adduct peak level process resistance development igrov cddp strongly cross-resistant carboplatin doxorubicin moderately cross-resistant etoposide docetaxel topotecan minor resistance 5-fluorouracil observe whereas igrov cddp cross-resistant methotrexate intracellular accumulation cisplatin 65 lower igrov cddp compare parental igrov-1 37 degree c normal condition coincubation cisplatin na / k atpase inhibitor ouabain result pronounced decrease platinum accumulation igrov-1 44 decrease igrov cddp 26 decrease energy-depleting condition accumulation cisplatin parental cell line approximately 60 lower observe normal energy i.e. atp rich culture condition contrast accumulation igrov cddp affect atp-depletion appear significant difference intracellular accumulation platinum resistant sensitive cell condition energy deprivation uptake study 0 degree c conclusion abrogation energy-dependent accumulation igrov cddp seem major mechanism resistance cisplatin cell line 
study seek evaluate biochemical cellular pharmacokinetic property cytotoxicity antitumor efficacy new analogue 10-deaza-aminopterin pdx human tumor study conduct group human tumor cell line culture examine pdx folate analogue permeant mediated membrane transport inhibitor dihdrofolate reductase substrate folylpolyglutamate synthetase analogue examine cytotoxicity follow 3-h pulse exposure experiment provide value ic50 study analogue conduct nude mouse bear subcutaneously implant human tumor treatment mouse initiate 4 day implantation tumor use schedule administration one dose per day 5 day tumor measure 6 day cessation therapy compare control assessment response ccrf-cem cell system pdx 2 3-fold less effective inhibitor dihydrofolate reductase aminopterin amt methotrexate mtx edatrexate edx much effective permeant one-carbon reduce folate transport inward pdx amt approximately equal edx mtx substrate folylpolyglutamate synthetase pdx amt edx mtx predict result pdx 15 40-fold cytotoxic mtx 3 4-fold cytotoxic highly potent edx follow 3-h pulse exposure culture ccrf-cem cell cell panel three human breast two human nonsmall-cell nsc lung cancer relative difference show therapeutic efficacy three analogue equitoxic dose study human mx-1 lx-1 tumor human a549 nsc lung tumor xenograft nude mouse schedule qd x 5 give 3-4 day posttransplant mtx minimally active modest tumor growth delay three tumor edx highly active 25-35 complete regression 5-10 cure mx-1 lx-1 tumor modestly active regression a549 tumor contrast pdx even active 75-85 complete regression 25-30 cure edx mx-1 lx-1 tumor highly active 30 complete regression 20 cure a549 tumor study show significantly enhance antitumor property pdx compare mtx edx base upon result clinical trial pdx patient metastatic breast nsc lung cancer appear warrant 
platinum agent frequently combine ifosfamide mesna originally coadminister protect ifosfamide side effect might also react platinum agent combination malignant glioma cell incubate cisplatin carboplatin mesna cell number measure count mtt-test cell free solution mesna turn mtt blue farmazan product mesna effect cell cell-line specific penetrate u87 cell without effect growth reduce cell number c6 t98g cell alter u251 cell concentration cisplatin killing 50 cell 7 x 10 -7 c6 9.7 x 10 -6 t98g 1.2 x 10 -5 u251 2.4 x 10 -4 u87 cell effect carboplatin require 3-10 time higher concentration mesna protect cell line cytotoxicity platinum agent clinical study specify detail infusion schedule mesna platinum agent 
present treatment colon cancer base 5-fluorouracil 5-fu despite promising result combine leucovorin levamisole 5-fu 5-year survival rate patient advanced colon cancer increase significantly colon tumor vitro show previously elevated requirement methionine suggest new therapeutic target study target methionine dependence colon tumor effect recombinant methioninase rmetase alone combination cisplatin cddp vitro result demonstrate cddp rmetase act synergistically human colon cancer cell line sw 620 combination index ci 0.45 well human colon cancer cell line colo 205 ci 0.7 human colon cancer line hct 15 ht 29 colo 205 sw 620 grow nude mouse treat rmetase determine effective dose depletion tumor methionine rmetase 15 units/g/day 5 day deplete tumor methionine four tumor type approximately 30 untreated control rmetase alone arrest growth hct 15 ht29 nude mouse 1 week treatment termination colo 205 sw 620 partially arrest rmetase however cddp combination rmetase result tumor regression colo 205 growth arrest sw 620 nude mouse ratio treat control group t c tumor weight colo 205 8 cddp give day-5 follow treatment day 5-9 rmetase treatment schedule result two six animal detectable tumor experiment terminate day 16 sw620 resistant cddp alone partially sensitive rmetase alone however sw 620 treat rmetase days-5 -9 cddp day-5 tumor growth arrest result demonstrate rmetase use simultaneously combination cddp significant antitumor efficacy colon cancer vitro vivo datum suggest novel promising therapeutic approach target elevated methionine dependence colon cancer 
beta-hydroxy-beta-methylglutaryl coa reductase inhibitor hri inhibit isoprenylation several member ras superfamily protein therefore important cellular effect include reduction proliferation increase apoptosis significant toxicity high dose preclude use hri monotherapy cancer therefore study whether combination hri lovastatin standard chemotherapeutic agent augment apoptosis colon cancer cell colon cancer cell line sw480 hct116 lovo ht29 lovastatin induce apoptosis differ sensitivity pretreatment lovastatin significantly increase apoptosis induce 5-fluorouracil 5-fu cisplatin four cell line lovastatin treatment result decrease expression antiapoptotic protein bcl-2 increase expression proapoptotic protein bax addition geranylgeranylpyrophospate 10 microm prevent lovastatin-induced augmentation 5-fu cisplatin-induced apoptosis mevalonate 100 microm partially effective whereas cotreatment farnesyl pyrophosphate 100 microm effect datum imply lovastatin act inhibit geranylgeranylation farnesylation target protein s datum suggest lovastatin may potentially combine 5-fu cisplatin chemotherapy colon cancer 
study design evaluate combination docetaxel taxotere carboplatin radiopotentiation vitro h460 human lung carcinoma cell treat docetaxel paclitaxel 1 h rinsed 24 h cell treat carboplatin 1 h irradiated colony form ability assese use various dose docetaxel 100 microm carboplatin dose enhancement ratio d.e.r. drug 1.26 25 nm docetaxel use various dose radiation radiation d.e.r. 1.41 three agent combine normalization combine drug effect radiation d.e.r. 1.55 similar value obtain use paclitaxel agent significant redistribution cell radiosensitive g2/m phase observe use dose paclitaxel 750 nm also cause radiation enhancement however equally cytotoxic dose docetaxel 25 nm result cell cycle redistribution phenomenon observe higher dose study show combination docetaxel carboplatin enhance effect radiation vitro effectively either drug seperately addition datum show mechanism radiopotentiation docetaxel probably involve g2/m block h460 cell 
development therapy-induced drug resistance still one important therapeutic limitation nevertheless integrate view molecular mechanism underlie resistance development general miss order shed light network resistance development establish drug-resistant doxorubicin dx methotrexate mtx cisplatin cispt vincristine vin derivative six tumour cell line jurkat u937 hl60 dohh-2 k562 arh77 haematopoetic origin differential gene expression drug-sensitive parental cell line drug-resistant derivative thereof analyse suppressive subtractive hybridisation dot blot screening differential expression sequencing clone pcr fragment differential expression confirm northern blot analysis attempt discriminate differentially express gene related one investigate drug cdna various resistant subline doxorubicin methotrexate cisplatin-resistant jurkat cell pool compare sensitive parental cell line addition cdna resistant derivative different haematopoetic tumour cell line pool compare pooled cdna corresponding sensitive haematopoetic cell line eliminate cell line cell line variation relate drug resistance result screening following gene show higher least 2-fold exclusive expression drug-resistant variant serglycin sorcin bmpg bone marrow proteoglycan gene pti-1 prostate-tumour-inducing gene 1 addition elevated expression hsp90 previously find group upregulate drug-resistant colon carcinoma cell line lovo h67p find overexpress drug-resistant hl60 cell 
scheduling antifolate antitumor agent include new multitargeted autofolate ly231514 mta 5-fluorouracil explore human mx-1 breast carcinoma human h460 calu-6 non-small cell lung carcinoma xenograft assess antitumor activity toxicity body weight loss administration antifolate methotrexate mta ly309887 6 h prior administration 5-fluorouracil result additive growth delay mx-1 tumor antifolate methotrexate ly309887 greater-than-additive tumor growth delay tgd antifolate mta h460 tumor effective regimen 14-day course mta ly309887 along 5-fluorouracil administer final 5 day addition simultaneous combination mta administer daily 5 day 2 week administration gemcitabine result greater-than-additive h460 tgd mta additive fractionate radiation therapy h460 tumor drug administer prior radiation fraction mta administer along paclitaxel produce greater-than-additive h460 tgd additive response along vinorelbine carboplatin calu-6 non-small cell lung carcinoma xenograft mta administer combination cisplatin oxaliplatin highly effective whereas mta administer combination cyclophosphamide gemcitabine doxorubicin produce additive response administration mta along paclitaxel doxorubicin result additive mx-1 tgd thus mta appear especially effective combination therapy include 5-fluorouracil antitumor platinum complex 
although numerous chemotherapeutic regimen evaluate patient hormone-refractory prostate cancer none improve survival testosterone-repressed prostate message-2 trpm-2 highly up-regulate androgen withdrawal androgen-independent progression prostate cancer show inhibit apoptosis induce various kind stimulus objective study test whether antisense oligodeoxynucleotide odn target trpm-2 enhance chemosensitivity human androgen-independent prostate cancer pc-3 cell vitro vivo initially potency 10 odn target various region trpm-2 mrna evaluate odn target trpm-2 translation initiation site odn 2 find potent sequence inhibit trpm-2 expression pc-3 cell despite significant dose-dependent sequence-specific suppression trpm-2 expression odn 2 effect growth pc-3 cell vitro vivo however pretreatment pc-3 cell odn 2 significantly enhance chemosensitivity taxol paclitaxel mitoxantrone vitro characteristic apoptotic dna laddering cleavage poly adp-ribose polymerase observe combined treatment odn 2 plus paclitaxel mitoxantrone either agent alone vivo administration odn 2 plus either paclitaxel mitoxantrone significantly decrease pc-3 tumor volume 80 60 respectively compare mismatch control odn plus either paclitaxel mitoxantrone addition terminal deoxynucleotidyl transferase-mediated nick end labeling staining reveal increase apoptotic cell tumor treat odn 2 plus paclitaxel mitoxantrone finding confirm trpm-2 overexpression confer resistance cytotoxic chemotherapy prostate cancer cell illustrate potential utility combined treatment trpm-2 odn plus chemotherapeutic agent patient hormone-refractory prostate cancer 
growth inhibitory effect paclitaxel docetaxel newly develop taxane idn5109 idn5111 idn5127 assess peripheral blood pb cd34 maintain liquid culture three human cancer cell line mda-mb231 mcf-7 adrr cem vblr concomitantly dna analysis also perform unfractionated peripheral blood progenitor cell pbpc toxicity also assess clonogenic assay cytotoxic effect induce taxane toward pbpc measure clonogenic assay correlate find multidrug resistance mdr positive cell line idn5109 idn5111 idn5127 docetaxel paclitaxel establish therapeutic index ti antitumor activity mdr-positive cell toxicity toward pbpc paclitaxel idn5109 determine ti show best value mdr-negative mdr-positive cell respectively ranking cytotoxic effect observe pb cd34 correlate obtain clonogenic assay cancer cell idn5127 idn5109 docetaxel idn5111 remarkably dna analysis docetaxel induce maximal cell cycle blocking activity newly develop taxane idn5109 idn5111 endowed profile anticancer activity mdr-bearing cell toxicity toward hematopoietic progenitor better docetaxel however mechanism s underlie toxicity toward hematopoietic progenitor least part different docetaxel likely dependent interaction p-glycoprotein function pb cd34 cell 
antitumor activity cryptophycin 52 c52 cryptophycin 55 c55 sequential simultaneous combination treatment regimen human tumor xenograft model explore antitumor activity c52 c55 compare alone sequential combination gemcitabine paclitaxel four lung cancer model h460 calu-6 nsclc sw2 h82 small cell lung carcinoma combination c52 follow gemcitabine additive three tumor greater-than-additive fourth combination c55 follow gemcitabine additive three tumor less-than-additive fourth combination c52 follow paclitaxel greater-than-additive one tumor additive one tumor less-than-additive two tumor combination c55 follow paclitaxel greater-than-additive two tumor less-than-additive two tumor simultaneous combination c52 c55 fractionate radiation therapy assess h460 nsclc tumor cryptophycin produce tumor response additive along radiation therapy hct116 colon carcinoma use compare antitumor activity simultaneous sequential combination 5-fluorouracil irinotecan c52 c52 produce greater-than-additive tumor response administer either simultaneously sequentially 5-fluorouracil iriniotecan finally administer animal bear intraperitoneal ovcar-3 ovarian carcinoma c52 docetaxel paclitaxel result mean survival time 123 80 85 day compare 72 day untreated control combination carboplatin c52 docetaxel paclitaxel result mean survival time 140 105 135 day cryptophycin potential useful chemotherapeutic agent wide variety clinical combination regimen 
purpose present study investigate impact use peripheral blood progenitor cell pbpc induction autologous graft-versus-host disease gvhd patient advanced breast cancer 14 woman stage iiib 36 woman stage iv breast cancer receive cyclosporine csa 2.5 mg kg-1 i.v. daily d 0-28 interferon-gamma ifng 0.025 mg/m2 s.c. qod d7-28 follow pbpc-t / bone marrow transplantation bmt precede high-dose chemotherapy consist cyclophosphamide 6 g/m2 thiotepa 800 mg/m2 histologically prove = grade ii cutaneous gvhd induce in18/50 36 patient independent source haematopoietic support vitro study show post-transplant 76 patient develop auto-cytotoxicity pre-transplant pha-lymphoblast significant correlation occurrence gvhd = grade ii cytolysis observe nk cell-line k562 t47d breast cancer cell-line median follow-up 2 1/2 year overall survival os 58 disease-free survival dfs 26 independent development gvhd similar observe study high-dose chemotherapy advanced breast cancer therefore remain unclear whether induction autologous gvhd occurrence auto-cytotoxic lymphocyte result anti-tumour effect group patient 
5-fluorouracil 5-fu use chemotherapeutic drug colorectal cancer escherichia coli uracil phosphoribosyltransferase uprt pyrimidine salvage enzyme convert 5-fu 5-fluorouridine monophosphate 5-fump initial step 5-fu activation investigate effect adenoviral-mediated transfer e. coli uprt gene human colon cancer cell 5-fu metabolism 5-fu chemosensitivity three cell line use ht29 km12 sw1116 intracellular level 5-fluorodeoxyuridine monophosphate 5-fdump 5-fu incorporate rna 5-fu treatment cell infect adenovirus contain uprt gene adca-uprt significantly higher non-infected cell accompany marked inhibition thymidylate synthase ts cell line furthermore ht29 km12 sw1116 infect adca-uprt respectively 13.1 30.2 70.5-fold sensitive 5-fu non-infected cell importantly treatment adca-uprt 5-fu effectively inhibit growth ht29-xenografted subcutaneous tumour nude mouse therefore adca-uprt/5-fu treatment potential enhance action 5-fu dna rna level treatment augment sensitivity human colon cancer cell 5-fu vitro vivo conclude adenoviral-mediated transfer e. coli uprt gene colon cancer cell achieve biochemical modulation 5-fu provide new approach treatment colorectal cancer 
base previously publish hollow-fibre assay mainly use early vivo anticancer drug screening want develop extended hollow-fibre model antitumour activity haematological toxicity pharmacokinetic study animal breast cancer cell line mda-mb-231 mcf-7 culture semipermeable hollow fibre fibre implant subcutaneously immunocompetent male sprague dawley rat rat treat 5-fluorouracil 5-fu 125 mg/kg epirubicin epi 10 mg/kg cyclophosphamide cp 120 mg/kg intraperitoneally new cyanoguanidine chs 828 375 mg/kg 75 mg/kg x 5 orally vehicle 6 day fibre retrieve cell density evaluate haematological parameter monitor two four sample per animal draw determine pharmacokinetic parameter nonmem drug treatment generally low effect tumour cell standard drug 5-fu epi cp cp exert statistically significant antiproliferative effect chs 828 minor effect single dose divide five daily dose pronounced effect cell line 5-fu epi cp cause marked decrease leucocyte platelet haemoglobin chs 828 seem affect parameter pharmacokinetic 5-fu epi accordance previously establish pharmacokinetic model pharmacokinetic cp chs 828 describe one-compartment model study illustrate possibility measure antitumour effect haematological toxicity pharmacokinetic animal use hollow-fibre model 
investigate potential genetic change underlie progression human hormone-resistant prostate cancer relate chromosomal alteration du 145 cell line subline isolate form metastasis orthotopic model tumorigenicity metastasis chemoresistance 15 mouse 1 x 10 5 du 145 cell inject dorsal prostate result paraaortic lymphnode metastasis isolate subline du 145 mn1 inject 15 nude mouse sulforhodamine b srb assay use analyze cell doubling time ic 50 cisplatin 5-fluorouracil cell line cytogenetic characterization perform conventional karyotype analysis fluorescence situ hybridization fish orthotopic implantation du 145 cell tumorigenicity 100 whereas 2 mouse reveal lymphnode metastase contrast take rate implantation du 145 mn1 100 lymphnode metastase 7 mouse srb assay reveal 8-fold increase ic 50 cisplatin 2.5-fold increase 5-fu du 145 mn1 compare du 145 cell gain chromosome 8 two copy chromosome 17 du 145 mn1 cell compare parental cell line emergence 9 q10 addition two normal chromosome 9 homologue du 145 mn1 cell line confirm fish use chromosome 9-specific painting probe summary clonal evolution chromosomal change follow repeat orthotopic implantation may assist locate gene involve progression chemoresistance human hormone-resistant prostate cancer 
preclinical study roswell park cancer institute minderman cao rustum unpublished result show combination sn-38 5-fu hct-8 human colon carcinoma cell vitro synergistic best interaction occur drug add sequentially sn-38 first vivo study use hct-8 tumor xenograft implant s.c. nude athymic mouse demonstrate superior efficacy sequential i.v. administration cpt-11 24 hr 5-fu basis study group begin evaluate effect rfs2000 9-nitro-20 s camptothecin 9-nc combination series antitumor agent use panel human tumor cell line include a121 ovarian cancer hct-8 colon cancer h-460 nsclc ht-1080 fibrosarcoma mcf7 mammary cancer find 2-hr exposure 9-nc result id50 value 1.0 microm whereas continuous exposure drug result id50 value 1.0 nm tumor growth inhibitory activity 5-fu gemcitabine paclitaxel determine comparison combination agent evaluate 9-nc use human hct-8 colon tumor cell line concurrent sequential combination 9-nc 5-fu region concentration-effect surface local synergy local antagonism however sequential combination 9nc sn-38 follow 5-fu 24 hr later appear highly synergistic high dose-effect level i.e. id90 suggest sequential drug administration may efficacious high effect level order drug addition important overall result similar find earlier rustum group cpt11 sn-38 5-fu suggest sequential combination 9-nc camptothecin analogue follow 5-fu potential treatment cancer man 
inhibition purine de novo synthesis enhancement 6-mercaptopurine 6mp bioavailability high-dose methotrexate hdm may increase incorporation dna 6-thioguanine nucleotide 6tgn cytoxic metabolite 6mp thus coadministration 6mp increase myelotoxicity follow hdm twenty-one child standard risk sr 25 intermediate risk ir acute lymphoblastic leukemia study consolidation therapy receive either three course hdm 2 week interval without concurrent oral 6mp sr-all four course hdm give 2 week interval 25 mg/m2 oral 6mp daily ir-all first year maintenance oral 6mp 75 mg/m2/day oral mtx 20 mg/m2/week receive five course hdm 8 week interval case hdm consist 5,000 mg mtx/m2 give 24 h intraspinal mtx leucovorin rescue erythrocyte level 6tgn e-6tgn methotrexate e-mtx average measure every second week maintenance therapy sr consolidation 6mp 0 mg ir consolidation 6mp 25 mg/m2 sr/ir maintenance therapy 6mp 75 mg/m2 compare white cell absolute neutrophil count anc nadir lymphocyte count nadir thrombocyte count nadir hemoglobin nadir hdm decrease significantly increase dose oral 6mp three percent hdm course give without oral 6mp sr consolidation follow anc nadir 0.5 x 10 9 / l compare 50 hdm course give sr/ir maintenance therapy similarly 13 hdm course give sr-all consolidation induce thrombocyte count nadir 100 x 10 9 / l compare 58 hdm course give maintenance therapy best-fit model predict anc nadir follow hdm maintenance therapy include dose 6mp prior hdm beta = -0.017 p = 0.001 average anc level maintenance therapy beta = 0.82 p = 0.004 e-6tgn beta = -0.0029 p = 0.02 best-fit model predict thrombocyte nadir follow hdm maintenance therapy include mplate beta = 0.0057 p = 0.046 conclusion study indicate reduction dose concurrently give oral 6mp one way reduce risk significant myelotoxicity follow hdm maintenance therapy childhood 
potentiation cytotoxic activity 5-fluorouracil fura folinic acid 5-hco-h4folate due elevation methylene tetrahydrofolate ch2-h4folate level increase stability ternary complex thymidylate synthase ts fluorodeoxyuridine monophosphate ch2-h4folate inactivate ts methionine deprivation result production tetrahydrofolate h4folate subsequently ch2-h4folate methyl tetrahydrofolate consequence induction methionine synthesis hypothesize efficacy fura augment combination high-concentration 5-hco-h4folate recombinant methioninase rmetase methionine-cleaving enzyme study vitro perform cell line ccrf-cem cytotoxic synergism fura rmetase fura 5-hco-h4folate rmetase demonstrate combination index throughout broad concentration range fura rmetase subcytotoxic concentration rmetase reduce ic50 fura factor 3.6 factor 7.5 absence presence 5-hco-h4folate respectively 5-hco-h4folate increase intracellular concentration ch2-h4folate h4folate baseline level concentration folate change exposure rmetase level free ts cell treat fura 5-hco-h4folate fura rmetase lower cell expose fura alone decrease ts still pronounced cell treat fura 5-hco-h4folate rmetase synergism describe study will basis exploration combination fluoropyrimidine folate rmetase 
purpose study human pharmacokinetic vitro cytotoxicity apomine p.o. administer nonmyelosuppressive agent selectively inhibit cell proliferation induce tumor cell apoptosis farnesoid x receptor experimental design seven solid cancer patient participate ongoing phase study apomine receive start dose level 125 mg/m 2 / day x 14 day every 3 week undergo pharmacokinetic study day 14 first course plasma concentration apomine assay hewlett packard gas chromatograph use nitrogen phosphorus detector hp-5 15m x 0.32-mm column fresh human ovarian cancer tumor sample obtain initial exploratory laparotomy 35 chemotherapy-naive advanced stage epithelial ovarian cancer patient tumor sample test sensitivity apomine carboplatin cisplatin paclitaxel topotecan use vitro clonogenic 3 h thymidine end point assay result pharmacokinetic analysis reveal mean apomine plasma c max 16.4 / 9.1 microg/ml 29.1 microm mean plasma auc 0 -- 12 h 173.4 / 105 microg h/ml 308 microm h mean t 1/2 24 -- 192 h 156.2 / 42.9 h vitro assay result show 63 91 ovarian cancer sensitive i.e. 70 inhibition tumor cell growth apomine concentration 10 20 microm sensitivity rate 91 carboplatin 270 microm 88 cisplatin 33 microm 41 paclitaxel 5.9 microm 85 topotecan 2.2 microm conclusion vitro assay result take together preliminary plasma pharmacokinetic datum suggest apomine clinically active 125 mg/m 2 dose level 
enzyme protein farnesyltransferase catalyze first step posttranslational modification ras number polypeptide emerge important target development anticancer agent sch66336 one first farnesyltransferase inhibitor undergo clinical testing present study examine effect combine sch66336 several class antineoplastic drug various human tumor cell line flow cytometry indicate sch66336 effect cell cycle distribution treated cell nonetheless colony-forming assay reveal antiproliferative effect sch66336 5-fluorouracil less additive contrast effect sch66336 melphalan additive moreover combination sch66336 cisplatin produce antiproliferative effect additive synergistic broad range clinically achievable concentration a549 non-small cell lung cancer cell t98g human glioblastoma cell less additive mcf-7 breast hct116 colon bxpc-3 pancreatic adenocarcinoma cell examination effect drug sequencing a549 cell reveal synergism cell expose sch66336 cisplatin antagonism drug administer opposite order additive synergistic effect result enhance apoptosis sch66336 cisplatin combination additional study fail show effect sch66336 formation removal platinum-dna adduct raise possibility sch66336 affect survival cisplatin-treated cell downstream dna lesion observation suggest sch66336 exhibit additive synergistic effect combine cisplatin sequence cell line-dependent fashion additional preclinical clinical study combination appear warrant 
integration chemotherapy radiation standard practice management locally advanced inoperable nsclc assess biological interaction third generation chemotherapeutic agent radiation non-small cell lung cancer nsclc vitro test number different drug paclitaxel docetaxel gemcitabine topotecan sn-38 cisplatin combine radiation lung cancer cell line cellular chemosensitivity determine use semi-automated colorimetric mtt assay 48 72 96 h exposure increase drug concentration 0.001-100 microm radiation dose 100-400 cgy cell line use adenocarcinoma adk a-549 squamous-cell carcinoma scc lx-1 cell pre-treat anticancer agent 24 12 0 h irradiation cytofluorimetric cell cycle analysis perform significant s-phase block g 2 / m block see gemcitabine topotecan paclitaxel pre-treatment respectively apoptosis see paclitaxel exposure a-549 cell line despite similar pattern cell-kinetic change induce chemotherapy pre-treatment cell line adenocarcinoma a-549 cell line radiosensitize anticancer agent test whereas synergism observe lx-1 squamous carcinoma cell line expose gemcitabine sn-38 topotecan cisplatin paclitaxel despite favourable cell cycle effect find synergistic radiotherapy experimental model conclusion observe synergism appear dose timing-independent seem relate histological subtype present scc favourable perturbation cell cycle evident new agent test cell type sufficient produce synergism radiation 
dna mismatch repair mmr efficient system detection repair mismatched unpaired basis dna deficiency mmr commonly find hereditary sporadic colorectal cancer well cancer tissue fluorinate thymidine analogue action might generate lesion recognizable mmr widely use treatment colorectal cancer investigate role mmr cellular response 5-fluorouracil 5-fluoro-2 deoxyuridine fdurd human mlh1 mmr-deficient hct116 colon cancer cell 18-fold resistant 7.5 microm 5-fluorouracil continuous treatment 17-fold resistant 7.5 microm fdurd clonogenic survival assay compare genetically match mlh1 mmr-proficient hct116 3-6 cell likewise murine mlh1 mmr-deficient ct-5 cell 3-fold resistant 2-h pulse 10 microm fdurd mlh1 mmr-proficient me-10 counterpart decrease cytotoxicity mmr-deficient cell treatment various methylating agent base analogue well report believe reflect tolerance dna damage synchronize hct116 3-6 cell treat low dose fdurd 2-fold greater g 2 cell cycle arrest compare mmr-deficient hct116 cell asynchronous me-10 cell demonstrate 4-fold greater g 2 arrest fdurd treatment compare ct-5 cell enhance g 2 arrest mmr-proficient cell response agent report believe allow time dna repair g 2 cell cycle arrest determine propidium iodide staining result mitotic arrest rather true g 2 arrest indicate elevated cyclin b1 level lack staining mitotic protein monoclonal antibody 2 additionally p53 gadd45 level induce fdurd-treated hct116 3-6 cell dna double-strand break dsb formation 2-fold higher mmr-proficient hct116 3-6 cell fdurd treatment determine pulsed-field gel electrophoresis formation dsb result enhance apoptosis mmr-proficient cell fdurd-mediated cytotoxicity cause dna-directed rna-directed effect administration excess thymidine uridine prevent cytotoxicity cell cycle arrest dsb formation hmlh1-dependent response fluoropyrimidine treatment may involve action p53 formation dsb clearly clinical relevance use class drug treatment tumor mmr deficiency 
death ligand cd95 ligand cd95l tumor necrosis factor-related apoptosis-inducing ligand/apo2 ligand trail/apo2l induce apoptosis radiochemotherapy-resistant human malignant glioma cell line death-signaling trail receptor 2 trail-r2 / death receptor dr 5 trail-r1 / dr4 express abundantly non-death-inducing decoy receptor trail-r3 / dcr1 trail-r4 / dcr2 12 human glioma cell line four 12 cell line trail/apo2l-sensitive absence protein synthesis inhibitor cycloheximide chx three 12 cell line still trail/apo2l-resistant presence chx trail-r2 expression predict sensitivity apoptosis coexposure trail/apo2l cytotoxic drug topotecan lomustine 1 2-chloroethyl -3-cyclohexyl-1-nitrosourea ccnu temozolomide result synergistic killing synergistic killing often observe cell line retain wild-type p53 activity u87mg ln-229 p53 mutant cell line ln-18 t98g u373mg drug exposure result enhance trail-r2 expression decrease trail-r4 expression u87mg cell ectopic expression dominant-negative p53 v135a abrogate drug-induced change trail-r2 trail-r4 expression effect synergy thus neither wild-type p53 function change trail receptor expression require synergy contrast synergy result possibly drug-induced cytochrome c release mitochondria serve amplifier trail/apo2l-mediated cascade caspase activation datum provide novel insight role trail/apo2l system malignant glioma illustrate trail/apo2l-based immunochemotherapy may effective therapeutic strategy lethal neoplasm 
antitumor cryptophycin synthetic derivative desipeptide cryptophycin isolate cyanobacterium nostoc sp. cryptophycin 52 currently clinical trial solid tumor prepare total synthesis four key fragment couple form final product mechanism anticancer activity cryptophycin associate destabilization microtubule induction bcl-2 phosphorylation lead apoptosis cryptophycin maintain activity ovarian breast carcinoma cell overexpress multidrug resistance efflux pump p-glycoprotein cryptophycin 52 demonstrate broad range antitumor activity murine human tumor human mx-1 breast carcinoma xenograft cryptophycin 55 produce greater-than additive tumor response combination 5-fluorouracil human non-small cell lung carcinoma human small cell carcinoma xenograft administration cryptophycin along gemcitabine cisplatin carboplatin result antitumor activity greater either agent alone cryptophycin appear additive fractionate radiation therapy human h460 non-small cell lung carcinoma human hct116 colon carcinoma cryptophycin result greater additive tumor response administer sequentially 5-fluorouracil irinotecan treatment animal bear intraperitoneal human ovcar-2 ovarian carcinoma cryptophycin 52 result survival time greater achieve docetaxel paclitaxel cryptophycin 52 currently early clinical testing 
purpose investigation compare antitumor activity series acyl derivative 4-demethylpenclomedine dm-pen major plasma metabolite penclomedine pen observe active antitumor agent vivo non-neurotoxic rat model dm-pen acyl derivative prepare dm-pen evaluate vivo human mx-1 breast tumor xenograft implant subcutaneously s.c. intracerebrally i.c. several derivative also evaluate human tumor xenograft murine p388 leukemia cell line several acyl derivative find superior dm-pen mx-1 human zr-75-1 breast tumor human u251 cns tumor p388 leukemia parent cell line line resistant cyclophosphamide carmustine 4-demethyl-4-methoxyacetylpenclomedine show inferior activity current clinical brain tumor drug glioma cell line superior activity temozolomide procarbazine derive mismatch repair-deficient cell line superior activity cyclophosphamide carmustine inferior activity temozolomide two ependymoma cell line implant s.c. propose mechanism activation action dm-pen acyl derivative support potential clinical superiority acyl derivative 
purpose study analyze drug interaction paclitaxel ptx epirubicin epi carboplatin cbdca gemcitabine gem vinorelbine vin human breast cancer cell compare cytotoxic activity drug combination primary breast cancer sample experiment intend identify active agent combination ptx provide preclinical rational future clinical investigation breast cancer multiple drug effect/combination index ci isobologram analysis apply combination ptx either cbdca epi gem vin mcf-7 mda-mb-231 sk-br-3 human breast cancer cell line drug concentration limit range achievable human vivo drug apply simultaneously fix molar ratio drug combination interaction assess multiple effect level ic10-ic90 additionally cytotoxic activity combination assess tumor sample 50 primary breast cancer patient utilize atp-tumorchemosensitivity assay atp-tca drug interaction show strongly dose-related human breast cancer cell line investigate clinically relevant concentration cbdca/ptx demonstrate synergistic mcf-7 additive mda-mb-231 sk-br-3 interaction epi/ptx show additive sk-br-3 mcf-7 antagonistic mda-mb-231 interaction gem/ptx vin/ptx however demonstrate antagonism multiple dose effect level clinically relevant drug concentration three cell line test plasma peak concentration epi/ptx cbdca/ptx gem/ptx vin/ptx achieve = 90 tumor growth inhibition 93 86 63 50 respectively primary breast cancer sample investigate atp-tca cumulative dose-response plot primary breast cancer tumor cell respond vitro = 90 growth inhibition show strong dose dependence epi/ptx cbdca/ptx conclusion current datum indicate favorable drug interaction cbdca/ptx clinically relevant drug concentration breast cancer cell demonstrate superior vitro cytotoxicity epi/ptx cbdca/ptx compare gem/ptx vin/ptx primary breast cancer culture 
sequence-specific combination purine analog fludarabine 6-mercaptopurine 6-mp administer prior cytosine arabinoside ara-c show abrogate ara-c resistance human leukemia cell vitro patient relapse acute myeloid lymphoblastic leukemia two-drug combination 6-mp plus ara-c result greater cytotoxicity achieve either ara-c 6-mp alone preclinical investigation show addition peg-asparaginase peg-asnase combination 6-mp plus ara-c 6-mp ara-c peg-asnase result 15.6-fold synergism achieve two-drug regimen due increase dna damage lead apoptotic cell death since intravenous preparation 6-mp longer available since oral 6-thioguanine 6-tg provide higher level intracellular thioguanine nucleotide isotoxic dose oral 6-mp investigate potential drug synergism 6-tg plus ara-c plus peg-asnase tgap myeloid hl60/s hl60/sn3 u937 lymphoblastic cem/0 cem / ara-c/b cem/ara-c/i molt-4 leukemia cell line cem clone molt-4 hl60/sn3 cell line express functional measurable p53 protein cell line mtt trypan blue dye exclusion assay use determine drug cytotoxicity addition cellular apoptosis cellular p53 p21/waf -1 bcl-2 protein concentration determine facs analysis elisa assay sequential exposure 6-tg 24 h plus ara-c 24 h plus peg-asnase 24 h produce 1.3 18.3-fold drug synergism two-drug combination 6-tg plus ara-c molecular mechanism synergism due fact three-drug combination capable downregulate bcl-2 oncoprotein level cell line even p53 absent study strongly demonstrate tgap regimen highly synergistic p53-null p53-expressing leukemia cell line conclude combination regimen collaterally sensitive ara-c evaluation investigational phase trial relapsed leukemia patient warrant 
isis 3521 g3139 20 18-mer phosphorothioate oligonucleotide respectively target protein kinase c pkc alpha bcl-2 mrna treatment t24 bladder pc3 prostate carcinoma cell full-length 3 truncation mutant isis 3521 cause down-regulation pkc-alpha protein mrna however level 15-mer shorter down-regulation mrna expression longer observe diminution cellular viability measure 3 4,5-dimethylthiazol-2-yl 2,5-diphenyl tetrazolium bromide assay response increase concentration paclitaxel observe shorter oligomer observation indicate pkc-alpha protein expression down-regulate rnase h-dependent independent mechanism also down-regulation pkc-alpha insufficient chemosensitize cell g3139 down-regulate bcl-2 protein mrna expression also down-regulate pkc-alpha protein mrna expression pkc-betai epsilon zeta however down-regulation pkc-alpha bcl-2 link carrier eufectin 5 employ bcl-2 down-regulate t24 pc3 cell 50 nm oligonucleotide concentration 100 nm bcl-2 pkc-alpha expression down-regulate concentration chemosensitization paclitaxel carboplatin observe contrast down-regulation bcl-2 seem link rela p65 however also sufficient chemosensitization even though lead loss expression gene putative control nuclear factor-kappab detachment cell plastic surface result underscore complexity intracellular requirement initiation chemosensitization anti-neoplastic agent 
agent use endocrine therapy patient breast cancer change markedly past decade tamoxifen remain anti-oestrogen choice replace oestrogen receptor down-regulator ici 182780 fix ring triphenylethylene arzoxifene previously serm iii soon whilst aminoglutethimide 4-oh androstenedione aromatase inhibitor choice replace non-steroidal anastrozole letrozole steroidal exemestane inhibitor high potency low side effect profile previously often use treatment progestogen megestrol acetate medroxyprogesterone acetate androgen now rarely use confine fourth fifth line treatment lhrh agonist goserelin remain treatment choice pre-menopausal patient advanced breast cancer although recent randomised trial indicate response time progression survival advantage combination goserelin tamoxifen compare goserelin alone newer treatment lead question concern optimum sequence agent use advanced breast cancer neo-adjuvant adjuvant therapy relation surgery two trial anastrozole compare tamoxifen one trial letrozole compare tamoxifen indicate new triazole aromatase inhibitor significant advantage anti-oestrogen respect time progression survival similarly triazole aromatase inhibitor give faster complete response compare tamoxifen use post-menopausal woman surgery major research question remain respect aromatase inhibitor use adjuvant therapy anastrozole test alone combination tamoxifen compare tamoxifen so-called atac trial 9000 patient randomise important study result will available late-2001 similar study compare letrozole tamoxifen start recently auspices breast international group importantly trial also compare sequence tamoxifen follow letrozole vice versa similar trial exemestane give 2-3 year tamoxifen compare 5 year tamoxifen recruit well study compare letrozole placebo 5 year 5 year adjuvant tamoxifen study may show aromatase inhibitor superior tamoxifen sequence preferable.ici 182780 cause complete oestrogen receptor down-regulation lead lack agonist activity drug two trial ici 182780 compare anastrozole advanced disease will report later year comparison tamoxifen next year arzoxifene serm iii test tamoxifen study likely result new anti-oestrogen introduce clinic endocrine treatment deprive tumour cell oestradiol vitro experiment mcf-7 cell indicate tumour cell adapt grow response low oestrogen concentration tissue -- culture medium importantly cell show apoptose response high oestrogen concentration recent clinical trial demonstrate high response rate stilboestrol give median four previous oestrogen deprive endocrine therapy datum newer treatment available indicate need re-think general approach endocrine therapy endocrine prevention 
paclitaxel able cause cell death induction apoptosis cell death characteristic docetaxel yet describe detail investigate four unselected human ovarian cancer cell line sensitivity 1 hr exposure docetaxel calculate concentration inhibit 50 ic 50 90 ic 90 cell growth cell line a2780 h134 igrov-1 wild-type p53 ovcar-3 mutant mt p53 a2780 sensitive ovcar-3 least sensitive equitoxic drug concentration represent ic 90 value 25-510nm apply 1 hr measure cell cycle distribution dna degradation count apoptotic cell body cell multifragmented nucleus various time-point drug exposure h134 igrov-1 ovcar-3 show continued mitotic block least 72 hr prolonged presence cell multifragmented nucleus high percentage apoptosis calculate 48 hr later time-point contrast a2780 cell accumulate s-phase cell cycle apoptosis hardly present change expression level p53 p21/waf1 bax bcl-2 predictive docetaxel-induced apoptosis caspase-3 activation occur cell accumulation g2/m phase start early 8 hr ovcar-3 prolonged bcl-2 phosphorylation evident ovcar-3 visible 24 hr h134 igrov-1 phenomenon occur a2780 mitogen-activated protein kinase pathway jnks/sapks c-jun n-terminal kinases/stress-activated protein kinase jnk1/2 extracellular response kinase erk1/2 p38 seem directly involve bcl-2 phosphorylation apoptosis conclude docetaxel able activate caspase-3 induce bcl-2 phosphorylation apoptosis cell show prolonged g2/m arrest cell may also die caspase-3-independent cell death mechanism 
selective estrogen receptor modulator serm agent prevention osteoporosis postmenopausal woman raloxifene ral decrease high-dose methotrexate mtx cytotoxicity mcf-7 breast cancer cell ral give least 24 hour prior mtx resultant interaction antagonistic however breast cancer cell expose ral 24 hour mtx interaction ral mtx antagonistic proliferation cell expose 10 microm ral 10 microm mtx alone combination ral 24 hour prior mtx follow order mtx ral 24 hour prior mtx ral mtx administration 24 hour prior ral follow inhibitory effect growth cell mtx 24 hour prior ral = mtx ral 24 hour prior mtx ral control drug exposure determine antagonistic interaction ral mtx function sequence time cell expose ral 24 hour 36 hour prior mtx exposure percentage control rate 43.48 / 3.90 54.43 / 2.93 respectively 24 hour 36 hour exposure ral prior mtx growth rate 24 h 36 h exposure mtx alone 30.30 / 0.61 33.11 / 2.27 control rate respectively study suggest interaction ral mtx sequence-dependent b ral antagonize effect mtx ral administration precede mtx c ral antagonism mtx function time 
use combination chemotherapy accept standard human malignancy little attention pay drug interaction combination drug may synergistic additive antagonistic cytotoxic activity study evaluate combination agent docetaxel one active agent human breast cancer use median effect model look synergy antagonism vitro potential predictor clinical outcome three human breast cancer cell line mcf7/wt mcf7/adr multiply drug resistant bt474 grow confluence plate 96 well dish incubate combination drug 72h cytotoxic effect measure mtt assay median effect analysis use calculate combination index ci value less 1 indicate synergism 1 additive effect greater 1 antagonism potentially useful combination clinical study identify include docetaxel vinorelbine docetaxel dexrazoxane docetaxel cis-retinoic acid docetaxel disulfiram either doxorubicin epirubicin docetaxel dexrazoxane epirubicin 
chronic myelogenous leukemia cml characterize molecular aberration fusion bcr-abl gene encode aberrant tyrosine kinase activity crucial pathogenesis cml vitro inhibition bcr-abl protein tyrosine kinase activity tyrosine kinase inhibitor imatinib mesylate sti571 formerly cgp57148b successfully suppress proliferation/survival bcr-abl positive clone clinical study hematologic cytogenetic remission achieve patient chronic phase cml accelerate blastic phase cml sti571 appear less effective current study author test combination sti571 cytarabine homoharringtonine hht drug documented activity cml single agent combination study vitro effect proliferation bcr-abl positive cell line kbm5 kbm7 3 4,5-dimethylthiazol-2yl -2,5 diphenyl-tetrazolium bromide assay primary patient-derived bcr-abl cell clonogenic assay vitro additive synergistic antagonistic effect cytarabine hht sti571 investigate computer-assisted analysis use calcusyn software sti571 consistently suppress bcr-abl positive cell proliferation dose-effect correlation model system use sti571/cytarabine sti571/hht combination effective inhibit kbm5 kbm7 cell growth drug single agent result also verify primary cml-derived clonogenic cell semisolid culture experimental system study document additive synergistic effect sti571 plus cytarabine hht support future use sti571 combination clinical trial patient philadelphia chromosome-positive leukemia 
antiproliferative effect 111 in-dtpa-hegf breast cancer cell express high level egfr compare chemotherapeutic agent gamma-radiation mda-mb-468 cell culture 111 in-dtpa-hegf 30 mbq/microg 1.8 x 10 5 mbq/micromol dtpa-hegf methotrexate doxorubicin paclitaxel 5-fluorouracil cell growth measure colorimetrically ic 50 111in-dtpa-hegf 70 pm 11 kbq/ml versus 500 pm dtpa-hegf ic 50 paclitaxel methotrexate doxorubicin 5-fluorouracil 6 nm 15 nm 20 nm 4 microm respectively 111 in-dtpa-hegf 70 pm 11 kbq/ml deliver approx. 6 gy breast cancer cell produce growth inhibition equivalent 4 gy gamma-radiation conclude 111 in-dtpa-hegf exhibit potent antiproliferative effect towards breast cancer cell concentration much lower chemotherapeutic agent equivalent produce several gy high dose rate gamma-radiation 
dx-8951f exatecan mesylate 1s ,9 s -1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1h ,12 h-benzo de pyrano 3 ,4 6,7 indolizino 1,2-b quinoline-10-13 9h ,15 h dione methanesulfonate dihydrate new water-soluble derivative camptothecin determine activity dx-8951f experimental human colon cancer ovarian cancer tumor type sensitive camptothecin use mtt assay dx-8951f potent sn-38 four five human colon cancer cell line three four human ovarian cancer cell line p 0.05 dx-8951f considerably potent topotecan cell line test p 0.05 prolonged exposure dx-8951f result greater increase inhibition cell proliferation compare obtain sn-38 topotecan p 0.05 overexpression pgp mrp1 lrp affect vitro activity dx-8951f dx-8951f administer daily x 5 weekly x 2 result growth inhibition 50 two human colon cancer xenograft grow s.c. nude mouse three human ovarian cancer xenograft however 50 growth inhibition observe schedule ovcar-3 human ovarian cancer model dx-8951f show considerably greater activity topotecan p 0.01 dx-8951f combine cisplatin paclitaxel indicate presence pharmacological interaction ovcar-3 xenograft combination clearly effective dx-8951f alone number complete remission increase substantially conclusion study show dx-8951f highly potent vitro highly effective experimental human ovarian cancer vivo prolonged exposure dx-8951f vitro greatly increase antiproliferative effect may rationale test continuous infusion schedule clinic addition cisplatin paclitaxel improve vivo antitumor effect dx-8951f 
protein kinase b/akt describe central mediator anti-apoptotic signal transduce pi3 kinase although role akt suppression apoptosis well elucidate potential function akt tumorigenesis chemoresistance less intensively document study describe construction novel form constitutively active akt1 rely deletion pleckstrin homology domain insertion c-terminal farnesylation sequence stable cell line generate mcf10a mammary epithelial cell a549 human nsclc cell express constitutively active akt1 enigneered mcf10a cell render resistant towards apoptosis result loss cellular substrate attachment anoikis investigate chemosensitivity a549 cell express farnesylate akt vs control cell profoundly decrease sensitivity towards mitoxantrone cisplatin observe cell express farnesylate akt significant difference sensitivity however observe upon treatment cell cycle specific chemotherapeutic agent like paclitaxel datum suggest akt central mediator suppression anoikis modulation chemotherapy-induced apoptosis therefore represent promising target small molecule inhibitor shift apoptotic threshold cancer cell treatment standard chemotherapy 
1 increase lipophilicity strategy often use improve compound cellular uptake retention may also convert substrate atp-dependent transporter p-glycoprotein multidrug resistance-associated protein mrp1 involve cellular efflux drug tris-lipidation compound convenient way modify drug lipophilicity generate array derivative diverse property 2 determine effect tris-lipidation drug cytoxicity multidrug resistant cell various glycyl-tris-mono gtp1 di gtp2 tri-palmitate gtp3 derivative prepare cancer chemotherapeutic drug chlorambucil methotrexate anti-hiv drug azt cytotoxicity derivative parent compound determine cem/vlb 100 cell increase p-glycoprotein expression cem/e1000 cell overexpress mrp1 parent drug-sensitive ccrf-cem cell 3 increase lipophilicity azt increase cytotoxicity sensitive ccrf-cem parental cell line decrease cytotoxicity observe methotrexate derivative chlorambucil derivative increase gtp1 decrease gtp2 cytotoxicity occur ccrf-cem cell exception azt-gtp1 gtp1 gtp2 derivative chlorambucil methotrexate azt decrease cytotoxicity p-glycoprotein-expressing cem/vlb 100 cell chlorambucil-gtp1 methotrexate-gtp2 methotrexate-gtp3 compound decrease cytotoxicity mrp1-overexpressing cem/e1000 cell 4 number palmitate residue position derivatisation type linkage may affect p-glycoprotein mrp1 substrate property 5 tris-lipidation may therefore provide useful way manipulate pharmacokinetic property drug 
improve poor efficacy 10 chemotherapy patient hormone-refractory prostate cancer investigate possible cytotoxic effect carmustine/beta-glucan combination prostatic cancer pc-3 cell focus glutathione-dependent detoxifying enzyme glyoxalase gly-i carmustine bcnu anticancer agent putative inhibitor gly-i beta-glucan unique nontoxic polysaccharide extract maitake mushroom cytotoxic effect bcnu anticancer agent beta-glucan pc-3 cell assess cell-viability testing gly-i activity measure use spectrophotometric method bcnu 5-fluorouracil 5-fu methotrexate mtx capable induce approximately 50 reduction cell viability 72 hour etoposide cisplatin mitomycin c ineffective combination bcnu 50 micro mol beta-glucan 60 micro g/ml exhibit enhance cytotoxicity approximate 90 cell viability reduction little improvement see combination 5-fu mtx beta-glucon gly-i assay reveal profound approximately 90 cell death accompany approximate 80 reduction gly-i activity 6 hour study demonstrate sensitize cytotoxic effect bcnu beta-glucan pc-3 cell associate drastic approximately 80 inactivation gly-i therefore bcnu/beta-glucan combination may help improve current treatment efficacy target gly-i appear critically involve prostate cancer viability 
novel tricyclic benzimidazole carboxamide poly adp-ribose polymerase-1 parp-1 inhibitor synthesize several compound find powerful chemopotentiator temozolomide topotecan a549 lovo cell line vitro inhibition parp-1 confirm direct measurement nad depletion adp-ribose polymer formation cause chemically induce dna damage 
background methotrexate mtx follow 6-mercaptopurine 6mp one best know combination treatment childhood acute lymphoblastic leukaemia tiazofurin tf 6-thioguanine tg also use chemotherapy agent treatment malignancy examine induction apoptosis combination drug gain insight efficacy treatment malignancy method induction apoptosis examine molt-4 human malignant acute lymphoblastic t-cell line cell expose increase drug concentration various exposure time annexin v/fitc propidium iodide pi use marker apoptosis cell death annexin v/fitc positive pi positive cell detect flow-cytometric analysis result sequential 24-h exposure mtx 0.005-0.02 micro mol follow 6mp 1-10 micro mol 24-h exposure tf 5-20 micro mol follow tg 0.5-2 micro mol show additive induction apoptosis compare single-drug exposure simultaneous administration drug show additive effect apoptosis conclusion result study indicate sequential administration mtx 6mp tf tg may essential therapeutic success treatment leukaemia 
assess effect downregulation type 1 insulin-like growth factor receptor igf1r chemosensitivity prostate cancer cell igf1r overexpress prostate cancer compare benign prostatic epithelium igf1r expression commonly persist androgen-independent metastatic disease level comparable primary human androgen-independent du145 prostate cancer cell transfect igf1r antisense oligonucleotide antisense rna transfect culture treat cisplatin mitoxantrone paclitaxel vehicle control survival measure use clonogenic assay antisense strategy suppress igf1r protein level 30-50 control culture associate 1.5-2-fold enhancement sensitivity cisplatin mitoxantrone paclitaxel increase cisplatin-induced apoptosis approach potential development clinical treatment advanced prostate cancer chemoresistant tumour 
determine role p53 protein cellular effect amifostine use molecularly engineer hct116 colon cancer cell p53 gene inactivate target homologous recombination p53 protein degrade high-level expression papillomavirus e6 protein amifostine induce g1 arrest protect paclitaxel toxicity p53-proficient p53-deficient cell absence p53 protein amifostine enhance cytotoxicity paclitaxel addition treatment hct116 cell amifostine alone result apoptotic cell death compare p53-deficient cell p53-proficient cell exhibit low-level resistance amifostine-induced apoptosis amifostine induce expression p53 protein p53-proficient cell expression p21 protein p53-proficient deficient cell finding indicate amifostine-induced g1 arrest cytoprotection mediate via pathway dependent p53 protein amifostine-induced expression p21 protein sufficient sustain g1 arrest mediate cytoprotection addition finding identify p53 protein mechanism resistance amifostine-induced apoptosis.british 
recent study demonstrate resistance cancer cell tumor necrosis factor-related apoptosis-inducing ligand trail reverse various chemotherapeutic agent present study investigate role akt apoptosis resistance trail chemotherapeutic agents-induced trail sensitization human renal cell carcinoma cell apoptosis assay western blot analysis reveal apoptosis resistance trail correlate well level akt phosphorylation ser 473 rather protein expression level trail receptor dr4 dr5 apoptosis sensitivity trail trail-resistant skrc-49 trail-sensitive caki-1 cell alter modulation akt activity increase protein expression cellular fadd-like il-1beta-converting enzyme-like inhibitory protein cflip paclitaxel 5 100 nm cisplatin 10 microm etoposide 1 10 microm promote trail-induced apoptosis skrc-49 cell mediate increase trail receptor expression chemotherapeutic agents-induced akt inactivation ceramide formation derive sphingomyelin hydrolysis note low concentration 5 nm paclitaxel promote ceramide formation trail-induced apoptosis predominantly skrc-49 cell normal renal proximal tubular epithelial cell result may provide novel therapeutic modality selective killing renal cell carcinoma minimal toxicity normal renal cell 
purpose temozolomide tmz oral alkylating agent good penetration blood-brain barrier show efficacy treatment malignant brain tumor ribonucleotide reductase rr rate-limiting enzyme dna synthesis seem complementary target combination chemotherapy brain tumor trimidox tx didox dx two recently synthesize specific inhibitor rr combination tmz tx dx basis synergistic chemotherapy protocol test study method effect single drug tmz dx tx combination tmz/dx tmz/tx evaluate human malignant glioma cell line u87mg t98g lnz308 wt1119 latter experiment carry presence absence wild-type p53 protein express control tetracycline-responsive transgene system cytotoxicity evaluate mtt assay isobologram combination index ci method chou-talalay use evaluate interaction drug result drug demonstrate cytotoxicity brain tumor cell synergistic cytotoxic effect ci 1 tmz tx dx different dose level demonstrate examine cell line instance however drug combination result additive even antagonistic effect toxicity single agent synergy combination correlate wild-type p53 expression tumor cell conclusion tumor toxicity tmz single agent may modify combination novel rr inhibitor dx tx synergistically enhance case depend combination ratio dose drug give degree effect combination may drastically reduce 
poly adp-ribose polymerase 1 parp-1 nuclear zinc finger dna-binding protein implicate repair dna damage inhibition parp-1 genetic knockout cause cell become hypersensitive various chemotherapeutic agent test chemopotentiate ability parp-1 inhibitor cep-6800 use combination temozolomide tmz irinotecan camptothecin sn38 cisplatin u251mg glioblastoma ht29 colon carcinoma calu-6 non-small cell lung carcinoma xenograft cell line respectively exposure tumor cell tmz camptothecin sn38 cisplatin presence cep-6800 significantly increase onset magnitude dna damage duration cell effect repair onset duration fraction cell arrest g 2 / m boundary addition vivo biochemical efficacy study cep-6800 show able attenuate irinotecan tmz-induced poly adp-ribose accumulation lovo ht29 xenograft respectively treatment cep 6800 30 mg/kg tmz 17 34 mg/kg result 100 complete regression u251mg tumor day 28 versus 60 complete regression cause tmz alone cep-6800 30 mg/kg combination irinotecan 10 mg/kg result 60 inhibition ht29 tumor growth versus irinotecan alone day 33 combination therapy cisplatin 5 mg/kg cep-6800 30 mg/kg cause 35 reduction calu-6 tumor growth versus cisplatin alone day 28 datum suggest cep-6800 use chemopotentiating agent variety clinically effective chemotherapeutic agent 
purpose mismatch repair mmr system play major role mediate cytotoxicity clastogenicity agent generate o 6 methylguanine dna loss mmr also associate tumor cell resistance cytotoxic effect 6-thioguanine cisplatin hypersensitivity n 2-chloroethyl n cyclohexyl n-nitrosourea ccnu aim present investigation elucidate role play mmr system generation chromosomal damage cell expose 6-thioguanine cisplatin ccnu method mmr-proficient cell line tk6 hct116/3 -6 mmr-deficient counterpart mt1 hct116 treat 6-thioguanine cisplatin ccnu analyze cell growth inhibition chromosomal damage control similar experiment perform methylating agent temozolomide result cytotoxicity chromosomal aberration sister chromatid exchange induce 6-thioguanine temozolomide significantly reduce mmr-deficient cell line respect mmr-proficient counterpart contrast although confer protection cytotoxicity loss mmr affect cytogenetic damage induce cisplatin ccnu produce comparable level cytotoxicity chromosomal aberration sister chromatid exchange mmr-proficient mmr-deficient cell line conclusion mmr system involve generation chromosomal damage cell expose 6-thioguanine system play relevant role generation chromosomal damage cell treat cddp confer protection clastogenic effect ccnu least cell line investigate 
isothermal microcalorimetry use order continuously monitor quantitatively assess action two antineoplastic drug methotrexate mtx 6-thioguanine 6-tg human t-lymphoma cell line ccrf-cem result mtx compare datum experiment mtx-resistant subline cem/mtx slope power-time curve drug injection relative obtain unperturbed growth use construct dose-response curve normal cell line characterize d50 value i.e. dose produce half maximal response 0.05 microm mtx 0.38 microm 6-tg mtx-resistant subline d50 value 8 microm mtx comparison continuous power-time curve show inhibitory effect 6-tg faster mtx 
nuclear enzyme poly adp-ribose polymerase parp-1 facilitate dna repair therefore attractive target anticancer chemo radio-potentiation novel benzimidazole-4-carboxamide bz1-6 tricyclic lactam indole ti1-5 parp-1 k value 10 nm identify whole cell parp-1 inhibition intrinsic cell growth inhibition chemopotentiation cytotoxic agent temozolomide tm topotecan tp evaluate lovo human colon carcinoma cell acute toxicity inhibitor investigate parp-1 null wild-type mouse tissue distribution vivo chemopotentiation activity determine nude mouse bear lovo xenograft nontoxic concentration 0.4 micro m parp-1 inhibitor potentiate tm-induced growth inhibition 1.0-5.3-fold tp-induced inhibition 1.0-2.1-fold concentration parp-1 inhibitor alone inhibit cell growth 50 range 8 94 micro m. maximum potentiation tm activity achieve nongrowth inhibitory concentration / = 1 micro m potent parp-1 inhibitor bz5 ti4 whole cell parp-1 inhibition bz3 bz5 bz6 ti1 ti4 confirm attenuation dna damage-induced nad depletion select inhibitor ti1 ti3 ti4 contrast benchmark compound pd128763 cause mild hypothermia parp-1 null wild-type mouse excellent distribution bz5 ti1 ti3 tumor tissue observe ti3 enhance tm antitumor activity vivo study identify potent nontoxic parp-1 inhibitor structural modification promote aqueous solubility tolerability tissue distribution compound important lead development clinically viable parp-1 inhibitor 
taxane paclitaxel docetaxel anticancer agent use clinical trial ovarian carcinoma breast lung head/neck cancer paclitaxel insoluble water generally formulate use cremophor el docetaxel soluble water formulate use tween 80 ethanol tween 80 albeit less toxic cremophor el may responsible toxic effect eliminate vehicle improve drug antitumor efficacy taxane incorporate liposome compare formulation stability biodistribution pharmacokinetic docetaxel conventional pegylated liposome several formulation examine docetaxel-liposome compose epc/pg/chol 9:1:2 epc/pg/dspe-peg 2000/chol 9:1:2:0.7 effective conventional pegylate docetaxel-liposome stable 4 degree c 15 day whereas presence serum 37 degree c less stable ic50 value docetaxel-liposome evaluate ht-29 igrov1 cell line remain high pharmacokinetic biodistribution evaluate balb/c mouse i.v. injection 14c docetaxel formulate tween 80 3h-labeled conventional pegylated liposome t 1/2 beta low docetaxel 52.3 min rise 260 min conventional docetaxel-liposome 665 min pegylate docetaxel liposome biodistribution study confirm pharmacokinetic 
carmethizole hydrochloride 1-methyl-2-methylthio-4,5-bis hydroxymethyl imidazole-4 5 bis n-methylcarbamate hydrochloride nsc 602,668 hereafter call carmethizole new antitumor drug show relatively broad activity initial evaluation several murine tumor human tumor xenograft vivo present study design address question carmethizole activity establish disease activity different treatment schedule extent cross-resistance established drug human mx-1 mammary carcinoma human nci-h82 small-cell lung carcinoma human lox amelanotic melanoma xenograft athymic mouse use determine drug activity establish disease nci-h82 lung-tumor xenograft athymic mouse use explore schedule dependence series drug-resistant murine leukemia provide vivo cross-resistance profile inject i.p. carmethizole exhibit antitumor activity advanced-stage s.c. mx-1 mammary s.c. nci-h82 lung i.p. lox melanoma xenograft effective establish disease mx-1 lox early-stage disease datum available early-stage nci-h82 therapeutic effect carmethizole route-dependent evidence similar delay observe tumor growth follow i.p. i.v. administration use split-dose schedule single day instead one bolus injection yield increase total dose deliver result increase delay tumor growth murine leukemia resistant vincristine vcr amsacrine amsa methotrexate mtx cross-resistant carmethizole however murine leukemia resistant doxorubicin adr melphalan l-pam cisplatin ddpt 1-beta-d-ara-binofuranosylcytosine ara-c 5-fluorouracil 5-fu cross-resistant carmethizole suggest patient previously treat agent might less likely respond carmethizole opportunity develop resistance compound anticipate information derive study may useful design clinical trial carmethizole may stimulate additional basic research mechanism action new agent 
increase response rate study patient colon cancer indicate cytotoxic effect fluorouracil 5-fu potentiate leucovorin lv methotrexate mtx however preliminary study use sequential combination mtx lv 5-fu show additional potentiation hypothesize lack additional cell kill combination due competition lv mtx cellular uptake reduce folate polyglutamylation test possibility compare cytotoxicity drug combination contain mtx drug combination contain trimetrexate tmtx antifolate compete lv uptake polyglutamylation human lymphocytic leukemia ccrf-cem cell expose mtx tmtx 24 hour 5-fu last 4 hour antifolate exposure lv administer 30 minute 5-fu 20 hour exposure tmtx mtx intracellular level phosphoribosyl pyrophosphate elevated similar degree level decrease 30-minute exposure lv additional cell kill observe lv add mtx/5-fu combination cytotoxicity enhance lv add tmtx/5-fu combination study support hypothesis lack additional cell kill high-dose lv add mtx/5-fu combination may due competition mtx lv cellular uptake and/or competition mtx polyglutamate polyglutamylation reduce folate inasmuch tmtx compete lv reduce folate uptake polyglutamylation synergy obtain combination tmtx plus 5-fu high-dose lv support hypothesis 
cyclophosphamide cyc epirubicin epi 5-fluorouracil 5fu commonly use cytotoxic drug treatment breast cancer efficacy drug induction caspase cpp-32 pro-apoptotic p21 waf-1 anti-apoptotic bcl-2 protein test vitro breast cancer cell line mda-mb-231 mcf-7 cell proliferation rate level cpp-32 p21 waf-1 bcl-2 measure 3 6 12 24 h. mda-mb-231 three drug cause significant inhibition cell growth cyc produce significant induction cpp-32 3-6 h mcf-7 mda-mb-231 mcf-7 respectively epi induce cpp-32 significant level 12-24 h 6-12 h 5fu create induction mda-mb-231 3 h mcf-7 3-12 h level expression p21 waf-1 bcl-2 test group significantly different respective control group case mda-mb-231 regression analysis reveal change cpp-32 level p21 waf-1 level significant positive relationship likelihood mechanism cell death implicate antitumor effect drug beyond activation cpp-32 p21 waf-1 describe paper 
irofulven 6-hydroxymethylacylfulvene mgi-114 nsc 683863 semisynthetic derivative illudin s natural product obtain omphalotus mushroom irofulven demonstrate potent activity broad range solid tumor cellular xenograft model show promising activity clinical trial guide clinical use irofulven present study use mtt viability assay examine cytotoxic effect obtain combine irofulven two anticancer agent cisplatin 5-fluorouracil 5-fu study carry ht-29 hct-116 colorectal a2780 ovarian carcinoma cell well irofulven ht-29 / if2 hct-116 / if27 cisplatin-resistant a2780/cp70 variant combination show strong sequence specificity simultaneous exposure cisplatin irofulven least additive four cell line include cisplatin-resistant a2780/cp70 ovarian cell exhibit multifactorial resistance phenotype cisplatin follow irofulven additive parental hct-116 a2780 cell whereas irofulven follow cisplatin antagonistic cellular model simultaneous exposure 5-fu irofulven least additive six cell line 5-fu follow irofulven additive parental ht-29 a2780 cell synergistic irofulven-resistant hct-116 cell line irofulven follow 5-fu synergistic two ovarian cell line additive two parental colon cell line study demonstrate simultaneous exposure irofulven cisplatin least additive cell line whereas simultaneous exposure irofulven 5-fu additive synergistic cell line test include irofulven cisplatin-resistant variant enhance cytotoxicity irofulven combination cisplatin 5-fu support clinical application regimen 
breast cancer resistance protein bcrp/abcg2 atp-binding cassette half-transporter confer resistance mitoxantrone camptothecin derivative topotecan irinotecan novobiocin coumermycin antibiotic know enhance anticancer drug sensitivity cancer cell vitro vivo mechanism remain undetermined focus drug efflux pump examine whether novobiocin reverse drug resistance multidrug-resistant cell highly express bcrp explore reversal mechanism intracellular drug accumulation measure flow cytometry topotecan transport study use plasma membrane vesicle perform use pc-6 / sn2-5h2 small cell lung cancer mcf-7 / mx breast cancer cell select sn-38 active irinotecan metabolite mitoxantrone respectively bcrp cdna transfectant mcf-7 / clone 8 cell cell express high level bcrp mrna known transporter compare parental pc-6 cell pc-6 / sn2-5h2 cell 141 173 57.2-fold resistant topotecan sn-38 mitoxantrone respectively novobiocin 60 microm decrease degree resistance approximately 26-fold pc-6 / sn2-5h2 cell similarly reverse resistance mcf-7 / mx mcf-7 / clone 8 un-selected nci-h460 cell highly express bcrp furthermore novobiocin increase intracellular topotecan accumulation cell inhibit topotecan transport membrane vesicle pc-6 / sn2-5h2 cell effect novobiocin assay observe parental pc-6 mcf-7 cell kinetic parameter transport study indicate novobiocin inhibitor bcrp result competitive inhibition bcrp-mediated topotecan transport finding suggest novobiocin effectively overcome bcrp-mediated drug resistance acceptable concentration 
relation p53 expression human colon cancer cell line induction apoptosis anticancer drug examine experimentally hct116 wild-type p53 expression 5-fluorouracil 5-fu combination cisplatinum cddp increase sub g1 dna content proportion apoptotic cell however solitary administration drug alter neither alternatively sw480 mutant-type p53 expression combined administration solitary administration anticancer drug show minimal effect sub g1 dna content proportion apoptotic cell result indicate type p53 expression might play important role determination response low-dose cddp 5-fu therapy colon cancer patient 
tamoxifen one effective treatment breast cancer ability antagonize estrogen-dependent growth bind estrogen receptor er inhibit proliferation breast epithelial cell however tamoxifen estrogenic agonist effect tissue bone endometrium due liganded er activate target gene different type cell several novel anti-estrogen compound develop reduce agonist profile breast gynaecological tissue compound offer potential enhance efficacy reduce toxicity compare tamoxifen advanced breast cancer clinical datum exist two group agent selective estrogen receptor modulator serm divide tamoxifen-like e.g. toremifene droloxifene idoxifene fix ring compound e.g. raloxifene arzoxifene em-800 selective estrogen receptor down-regulator serd e.g. fulvestrant ici 182780 sr 16234 zk 191703 also term pure anti-estrogen phase ii trial tamoxifen-resistant metastatic breast cancer serm show low objective response rate range 0-15 suggest cross resistance tamoxifen randomize phase iii trial toremifene idoxifene 1500 patient show significant difference compare tamoxifen fewer clinical datum exist fixed ring serm remain unclear whether clinical advantage exist fixed ring serm tamoxifen first-line therapy main advantage serm tamoxifen raloxifene probably remain early-stage disease adjuvant therapy prevention fulvestrant serd high affinity estrogen receptor er compare tamoxifen none agonist activity serd fulvestrant enter clinic new agent show promising clinical activity treatment advanced breast cancer recently publish phase iii study show fulvestrant least effective third-generation aromatase inhibitor anastrozole patient whose disease relapse progress prior endocrine therapy surprisingly however phase iii trial versus tamoxifen first-line therapy advanced breast cancer fulvestrant attain requirement equivalence tamoxifen term time-to-treatment failure inferior 5.9 versus 7.8 month fulvestrant tamoxifen respectively p = 0.029 future clinical study will evaluate fulvestrant neoadjuvant setting together optimal sequencing relation tamoxifen endocrine therapy advanced disease 
temozolomide tmz dna alkylating agent currently use adjuvant treatment anaplastic astrocytoma use manage glioblastoma multiforme halt lack therapeutic effect due cell resistance note o6-alkylguanine-dna alkyltranferase agt dna repair enzyme limit efficacy tmz study author investigate ability o6-benzylguanine bg agt inhibitor sensitize glioblastoma cell line resistant tmz effect tmz alone 100 microg exposure bg 50 microg assess two glioblastoma cell line u373-mg t98g respectively sensitive resistant tmz cell viability assess use trypan blue cell cycle analysis fluorescence-activated cell sorter apoptosis autophagy terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling tunel acridine orange staining respectively furthermore involvement autophagy marker microtubule-associated light chain 3 lc3 assess temozolomide suppress growth cause cell cycle arrest g2-m phase u373-mg cell t98g cell exposure bg prior tmz result significant decrease cell viability well cell cycle arrest g2-m phase t98g cell p 0.05 although apoptosis detect tunel staining program cell death type ii autophagy detect exposure bg tmz t98g cell result indicate inhibition agt bg render previously resistant glioma cell sensitive tmz treatment mechanism cell demise follow bg-tmz treatment seem autophagy apoptosis combination therapy involve tmz agt inhibitor may effective strategy treat resistant glioma 
poly adp-ribose polymerase-1 parp-1 facilitate repair dna strand break inhibit parp-1 increase cytotoxicity dna-damaging chemotherapy radiation therapy vitro classical parp-1 inhibitor limit clinical utility investigate whether ag14361 novel potent parp-1 inhibitor inhibition constant 5 nm enhance effect chemotherapy radiation therapy human cancer cell culture xenograft effect ag14361 antitumor activity dna alkylating agent temozolomide topoisomerase poison topotecan irinotecan x-irradiation gamma-radiation investigate human cancer cell line a549 lovo sw620 proliferation survival assay xenograft mouse tumor volume determination specificity ag14361 parp-1 investigate microarray analysis antiproliferation acute toxicity assay parp-1 / parp-1 / cell mouse intraperitoneal administration concentration ag14361 determine mouse plasma tissue effect parp-1 activity determine tumor homogenate statistical test two-sided ag14361 0.4 micro m affect cancer cell gene expression growth increase antiproliferative activity temozolomide e.g. lovo cell 5.5-fold 95 confidence interval ci = 4.9-fold 5.9-fold p = .004 topotecan e.g. lovo cell 1.6-fold 95 ci = 1.3-fold 1.9-fold p = .002 inhibit recovery potentially lethal gamma-radiation damage lovo cell 73 95 ci = 48 98 vivo nontoxic dose ag14361 increase delay lovo xenograft growth induce irinotecan x-irradiation temozolomide two threefold combination ag14361 temozolomide cause complete regression sw620 xenograft tumor ag14361 retain xenograft parp-1 activity inhibit 75 least 4 hour ag14361 knowledge first high-potency parp-1 inhibitor specificity vivo activity enhance chemotherapy radiation therapy human cancer 
attempt study whole protein expression alteration tumer cell become multidrug-resistant may provide useful information new drug target identification adriamycin-resistant variant human leukemia cell line k562 k562/adr develop vitro continuous exposure adrimycin mtt assay use determine ic50 k562/adr cell adriamycin adr cisplatin ddp 5-fluorouracil 5-fu vincristin vcr total protein k562 k562/adr separate two-dimensional gel electrophoresis visualize silver staining protein significant expression alteration select peptide mass fingerprint pmf obtain matrix-assisted laser desorption/ionization time fly mass spectrometry maldi-tof-ms pmf use search ncbinr database automs-fit software result show k562/adr cell demonstrate cross-resistance antineoplastic drug ic50 k562/adr cell adr ddp 5-fu vdr much higher k562 protein differentially express two cell line identify cell cycle-related protein zinc finger protein 165 etc. protein involve cell cycling transcription regulation whose expression alteration may contribute multidrug resistant phenotype k562/adr cell 
irofulven 6-hydroxymethylacylfulvene hmaf mgi 114 novel antitumor agent currently undergo clinical trial hormone-refractory prostate cancer report examine efficacy irofulven alone combination mitoxantrone docetaxel androgen-independent prostate cancer cell line elucidate activity irofulven monotherapy combination pc-3 du-145 cell line utilize cellular viability assessment tumor growth inhibition study viability assay irofulven mitoxantrone show additive synergistic activity furthermore irofulven mitoxantrone combination exhibit enhance antitumor activity pc-3 du-145 xenograft additive combination effect also observe irofulven docetaxel test pc-3 xenograft curative activity 8/10 cr observe du-145 xenograft study demonstrate irofulven display strong activity monotherapy combination mitoxantrone docetaxel androgen-independent prostate cancer vitro vivo thus support clinical investigation irofulven hormone-refractory prostate cancer 
apoptosis target cell important index assessment efficacy cancer chemotherapy previously establish new experimental technique cancer cell distribute thin collagen gel one two cell layer culture anti-cancer drug cell stain fluorescent hoechst 33258 ho photograph hematoxylin eosin h&e photograph result show cell death pattern determine combine observation ho h&e stain cell without necessity judge apoptosis electron microscopy 5-fluorouracil 5-fu cisplatin cddp important anti-cancer drug treatment variety cancer 5-fu cddp alone show significant effect treatment gastric colon cancer addition show combination 5-fu plus cddp fp therapy produce synergism greater 5-fu cddp alone gastrointestinal cancer study evaluate efficacy toxicity fp therapy gastric cancer cell line mkn45 mkn28 katoiii colon cancer cell line hct116 colo320 examine relationship response fp therapy apoptosis additionally perform transfection normal p53 gene p53 mutant mkn28 cell analyze impact p53 gene sensitivity test wild-type p53 mkn45 hct116 colo320 cell undergo significantly p 0.01 apoptosis mkn28 katoiii cell possess p53 mutant deficient-type respectively fp therapy transfection p53 mkn28 cell result significantly p 0.01 higher apoptotic index result conclude p53 pathway allow induction apoptosis gastrointestinal cancer fp therapy treatment identification p53 type patient cancer use predict success fp therapy 
raf-1 protein serine/threonine kinase play important role cell proliferation cell survival previously describe novel cationic liposome-entrapped formulation raf antisense oligodeoxyribonucleotide lerafaon use radiosensitizer aim study examine effect combination lerafaon chemotherapeutic agent growth human prostate pc-3 pancreatic tumor xenograft athymic mouse aspc-1 colo 357 pc-3 tumor-bearing mouse administration combination lerafaon i.v. 25 mg/kg/dose x10/16 cisplatin i.v. 11.0 mg/kg/dose x3 epirubicin epi i.v. 9.0 mg/kg/dose x3 mitoxantrone mto i.v. 2.5 mg/kg/dose x3 lead enhance tumor growth inhibition compare single agent lerafaon cisplatin versus cisplatin p 0.0002 n = 8 lerafaon epi versus epi p 0.0001 n = 6 lerafaon mto versus mto p 0.05 n = 5 prostate pancreatic tumor-bearing mouse combination lerafaon i.v. 25 mg/kg/dose x10/13 docetaxel taxotere i.v. 5 7.5 10 mg/kg/dose x2/4 lead tumor regression enhance growth inhibition compare single agent pc-3 lerafaon taxotere versus taxotere p 0.02 n = 7 aspc-1 lerafaon taxotere versus taxotere p 0.03 n = 5 colo 357 lerafaon taxotere versus taxotere p 0.04 n = 7 combination lerafaon i.v. 25 mg/kg/dose x10/13 gemcitabine i.v. 75 mg/kg/dose x4/6 also cause significant tumor growth inhibition two pancreatic carcinoma model study aspc-1 lerafaon gemcitabine versus gemcitabine p 0.0001 n = 7 colo 357 lerafaon gemcitabine versus gemcitabine p 0.002 n = 5 lerafaon treatment i.v. 25 mg/kg/dose x10 cause inhibition raf-1 protein expression tumor tissue around 25-60 n = 4-7 interestingly taxotere treatment per se also lead decrease steady state level raf-1 protein pc-3 aspc-1 tumor tissue i.v. 10 mg/kg/dose x1 7.5 mg/kg/dose x2 around 25-80 n = 2/6 present study demonstrate enhance tumor growth inhibition regression response combination chemotherapeutic drug lerafaon datum provide proof-of-principle clinical use lerafaon combination chemotherapy cancer treatment 
selective cyclooxygenase-2 cox-2 inhibitor find induce anti-proliferative apoptotic activity many cancer cell however interaction cox-2 inhibitor chemotherapeutic agent remain determine investigate interactive effect selective cox-2 inhibitor etodolac combination 5-fluorouracil 5-fu sn-38 active metabolite irinotecan colon cancer cell line ht29 sw620 simultaneous sequential administration schedule isobologram analysis demonstrate etodolac combination 5-fu sn-38 accord simultaneous schedule result additive effect however synergism achieve sequential schedule apoptosis induction cell line also significantly increase sequential treatment etodolac follow either 5-fu sn-38 compare simultaneous treatment etodolac either 5-fu sn-38 study suggest apoptosis-inducing synergism result administration etodolac either 5-fu sn-38 sequentially simultaneously 
study effect icrf-154 combination 11 anticancer agent four human leukaemia cell line cell incubate 3 day presence two drug icrf-154 one cell growth inhibition determine mtt assay effect drug combination id50 level analyse use isobologram method steel lymphoblastic leukaemia cell line molt-3 hsb b-all supra-additive effect observe icrf-154 combination amsacrine bleomycin doxorubicin etoposide additive effect observe combination cisplatin cpt-11 cytosine arabinoside 5-fluorouracil mitomycin c vincristine sub-additive protective effect observe combination methotrexate erythroleukaemia cell line k-562 drug show supra-additive effect icrf-154 sub-additive protective effect observe icrf-154 combination cisplatin methotrexate drug show additive effect icrf-154 result indicate combined effect icrf-154 agent vary depend cell line lymphoid malignancy icrf-154 advantageous administer simultaneously many anticancer agent agent amsacrine bleomycin doxorubicin etoposide suitable methotrexate least suitable combined treatment 
angiogenesis propose possible target anticancer treatment either inhibition production angiogenic factor inhibition endothelial cell proliferation impact preoperative chemoendocrine therapy unknown regulation angiogenic factor recent report suggest anticancer drug antiangiogenic activity expression two angiogenic factor vegf angiopoetin-1 quantify different concentration doxorubicin docetaxel tamoxifen exemestane letrozol mcf-7 t47d cell low-drug concentration lead increase vegf-a gene transcription whereas high 10-fold increase drug concentration suppress gene expression similar cell reaction observe vegf protein smaller variety extent modulation incubation mcf-7 cell different drug show similar dose-dependent modulation angiopoietin-1 gene expression enhancement low-drug concentration treatment breast cancer cell follow preoperative protocol show dose-dependent expression vegf angiopoetin-1 high-drug concentration follow decrease secretion factor whereas low concentration induce up-regulation vegf angiopoietin 1 
several new 4 3,3-dimethyltriazeno -5-benzamidopyrazole derivative prepare react 4-diazo-5-benzamidopyrazole derivative dimethylamine compound test 10 microm vitro antileukemic activity k562 human chronic myelogenous leukemia raji human burkitt limphoma cell line dacarbazine methotrexate use comparative purpose 3-methyl-4 3,3-dimethyltriazeno -5 substitute benzamido pyrazole bear pyrazole nucleus free 1 position result active 1 substitute phenyl -3-methyl-4 3,3-dimethyltriazeno -5-benzamidopyrazole dacarbazine 10 microm show activity test observe difference among dacarbazine active 4-triazenopyrazole migth explain admit last compound differently dacarbazine follow mechanism action base cytochrome p-450 induce demethylation active compound 2d show growth inhibition value 97.8 99.4 k562 raji cell line respectively methotrexate inhibition value 0.2 microm cell line 86.7 75.1 respectively 
cell-kinetics biochemical pharmacology simultaneous sequential combination treatment 0.02 microm methotrexate mtx 2 microm 6-mercaptopurine 6mp study molt-4 malignant t-lymphoblast result compare datum earlier study separate treatment antimetabolite synergistic effect combination treatment demonstrate base inhibition purine de novo synthesis agent dna rna synthesis incorporation 6-thioguanine nucleotide dna rna inhibition cell growth clonal growth synergistic effect combination treatment mtx 6mp will available malignant lymphoblast will absent normal bone marrow cell normal lymphocyte activity purine de novo synthesis cell absent low base synergistic effect mtx 6mp good penetration agent cerebrospinal fluid dutch childhood leukemia study group presently perform randomized study protocol m bfm/dclsg-all -90 protocol compare result 4 time two week 24 hr intravenous administration mtx 5 g/m2 versus intravenous mtx immediately follow 24 hr intravenous administration 6mp 1.3 g/m2 pharmacokinetic intracellular biochemical pharmacology 6mp lymphocyte will study compare intravenous administration low dose oral administration 
2-methoxyestradiol 2me endogenous estradiol metabolite act antiproliferative various tumor cell line independent hormone receptor status investigate whether combination 2me various chemotherapeutic endocrine compound may result additive effect proliferation human breast cancer cell breast cancer cell line mcf-7 receptor-positive bm receptor-negative mcf-7 line transfect aromatase gene use cell line incubate concentration range 0.8 microm 25 microm 2me alone equimolar combination follow compound epirubicine daunorubicine paclitaxel docetaxel carboplatin vinorelbine 5-fluorouracil mafosfamide 4-oh tamoxifen effect letrozole 2me alone equimolar combination test concentration range 0.6 1 microm proliferation measure 4 day use atp-chemosensitivity test mcf-7 cell 2me combination 4oh-tamoxifen epirubicine docetaxel 5-fluoprouracil mafosfamide carboplatin lead additive effect bm cell 2me combine 4oh-tamoxifen daunorubicine mafosfamide show additive action letrozole 2me nearly similar effective inhibition aromatase gene additive effect find 2me display antiproliferative action various human breast cancer cell addition 2me able increase antiproliferative property certain antihormone cytostatic substance furthermore 2me exhibit similar property compare letrozole inhibit aromatase activity since 2me well tolerate recently conduct phase ii trial patient refractory metastatic breast cancer combination 2me chemotherapeutic antihormone may offer new clinically relevant treatment regimen 
selenite frequently use combination cancer chemotherapeutic agent reduce side effect however cytoprotective activity selenite may also reduce efficacy chemotherapeutic drug tumor cell study design examine effect selenite combine cytotoxic agent use clinical protocol e.g. doxorubicine docetaxel 5-fluorouracil 5-fu methotrexate mtx mafosphamide mitomycin c gemcitabine etoposide cisplatin irinotecan oxaliplatin proliferation various carcinoma cell type datum demonstrate selenite marked effect antiproliferative activity docetaxel doxorubicine 5-fu mtx mafosphamide mda-mb-231 breast cancer cell likewise consistent change observe a549 lung cancer cell proliferation selenite combine cisplatin etoposide gemcitabine mitomycin c. hand selenite potentiate cytotoxicity 5-fu oxaliplatin irinotecan hct116 colon cancer cell approx 1.1-fold 2.7-fold 2.6-fold respectively sw620 colon cancer cell selenite induce 1.5-fold 4.3-fold increase antiproliferative activity 5-fu oxaliplatin respectively whereas irinotecan show effect sw620 cell growth combination selenite result 23 inhibition result indicate selenite reduce antiproliferative activity chemotherapeutic agent vitro addition selenite able increase inhibitory activity docetaxel a549 lung cancer cell 5-fu oxaliplatin irinotecan hct116 sw620 colon cancer cell imply selenite potentially useful adjuvant chemotherapeutic agent 
combination 5-fluorouracil 5-fu plus cisplatin cddp fp treatment possess synergistic cytotoxicity colon cancer molecular mechanism chemotherapeutic agent induce apoptosis clarify identify apoptosis-related gene p53 bcl-2 previously establish new experimental technique cancer cell distribute thin collagen gel 1 2 cell layer additionally evaluate efficacy toxicity fp treatment gastric colon cancer cell line examine relationship response fp treatment apoptosis result report transfection normal p53 gene p53 mutant analyze impact p53 gene sensitivity test study examine induced apoptosis colon cancer cell line status p53 expression response treatment hct116 colo320 sw480 dld1 5-fu alone cddp alone fp treatment flow cytometric analysis transfection sw480 dld1 cell perform compare chemosensitivity naturally occur mutant-type p53 sw480 dld1 cell neo-transfected sw480 dld1 cell transfect sw480 dld1 cell appreciable apoptosis induce hct116 colo320 p53 wild-type sw480 dld1 cell p53 mutant-type transfect sw480 dld1 cell undergo significantly apoptosis p lt 0.001 naturally occur mutant-type p53 sw480 dld1 cell p53 expression may induce apoptosis fp treatment patient p53 wild-type may better candidate fp therapy patient p53 mutant-type colon cancer therefore think p53 may also effective colon cancer fp therapy 
conventional preclinical investigation strongly recommend combine interferon-alpha ifn-alpha 13-cis retinoic acid 13-cra isotretinoin treatment renal cell carcinoma rcc however recent randomize controlled trial drug combination ultimately fail demonstrate increase tumor-specific survival patient metastatic rcc mrcc all-trans retinoic acid atra tretinoin suggest provide stronger antineoplastic property 13-cra different tumor present study aim compare atra 13-cra 0.1 1 10 100 nm alone combination ifn-alpha 5 400 5,000 25,000 250,000 iu/ml 5-fluorouracil 5-fu 0.1 1 10 100 microg/ml multicellular tumor spheroid human rcc cell sn12c treat order facilitate prediction model system atra decrease mean volume sn12c spheroid 10-20 13-cra retinoid lead super-additive growth inhibition combination ifn-alpha 5-fu however scenario superior effect atra compare 13-cra although statistically significant impressive 10 atra provide slightly stronger direct antineoplastic effect human renal cancer cell 13-cra act synergistically ifn-alpha however atra seem suitable treatment patient mrcc 13-cra 
mutant form p53 tumor suppressor document exert novel oncogenic function include increase tumorigenicity metastatic potential genomic instability therapy resistance tumor cell latter suggest cause primarily inhibition apoptosis part activation gene mutant p53 whose product counteract drug activity recently describe context dutpase may confer resistance fluoropyrimidine drug 5-fluorouracil 5-fu report finding call question existence direct anti-apoptotic effect mutant p53 wild-type p53-negative human fibroblast saos-2 h1299 hct116 tumor cell treat adriamycin etoposide cisplatin 5-fu fail show apoptosis resistance retrovirally bulk-infected express p53 mutant 175h 273h level observe naturally mutant p53-producing tumor cell furthermore dutpase gene expression stimulate mutant p53 instead cellular event involve dna synthesis interpret combined available datum suggest much anti-apoptotic effect mutant p53 indirect secondary dna-damaging and/or repair-interfering effect protein 
background activation nuclear factor-kappab nf-kappab inhibit chemotherapy-induced apoptosis cancer cell line inhibition nf-kappab adenoviral delivery ikappabalpha superrepressor ad.ikappabalpha-sr potentiate 5-fluorouracil 5-fu irinotecan chemotherapy gastric cancer cell study design nci-n87 ags human gastric cancer cell study chemotherapy-induced nf-kappab activation assess use luciferase reporter assay inhibition nf-kappab assess luciferase reporter assay electrophoretic mobility shift assay cell pretreat 1 hour ad.ikappabalpha 25 moi incubate 5-fu active metabolite irinotecan sn-38 cell growth assess cell proliferation assay induction apoptosis determine flow cytometry caspase 3/7 assay result 5-fu sn-38 significantly induce nf-kappab activation measure luciferase reporter assay p 0.001 ad.ikappabalpha-sr treatment inhibit nf-kappab binding demonstrate electrophoretic mobility shift assay luciferase reporter assay ags cell pretreatment ad.ikappabalpha-sr follow 5-fu 0.005 mmol/l sn-38 10 ng/ml lead increase growth inhibition 13 59 respectively p 0.001 similarly growth inhibition nci cell significantly increase pretreatment ad.ikappabalpha follow 5-fu 0.001 mmol/l sn-38 0.5 ng/ml p 0.001 cell line ad.ikappabalpha-sr enhance apoptosis flow cytometry caspase 3/7 assay compare chemotherapy alone conclusion nf-kappab activate human gastric cancer response chemotherapy may result inducible chemoresistance inhibition nf-kappab ad.ikappabalpha-sr enhance antitumor effect chemotherapy potential novel antineoplastic strategy 
lentiviral vector capable efficiently transduce nondividing slowly divide cell include hematopoietic stem cell result stable integration sustained transgene expression construct human immunodeficiency virus type 1-based self-inactivating lentiviral vector express either wild-type o6-benzylguanine o6-beg resistant mutant form human o6-alkylguanine-dna methyltransferase mgmt dna-o6-methylguanine protein l-cysteine s-methyltransferase ec 2.1.1.63 transduce k562 granulocyte colony-stimulating factor-mobilized human peripheral blood cd34 cell transduction k562 cell express high level mgmt determine western blot immunocytochemistry biochemical assay colony-forming survival assay show significant protection o6-beg plus 1,3-bis 2-chloroethyl nitrosourea bcnu temozolomide tmz toxicity similarly single transduction cd34 cell result 13 14-fold increase level mgmt expression comparison non-transduced cell mutant mgmtp140k-transduced cd34 cell show significant resistance combined toxicity o6-beg either tmz bcnu approximately 9-fold increase survival colony-forming cell indicate ic50 value o6-beg plus tmz treatment approximately 5-fold increase case o6-beg plus bcnu treatment result show lentivirus-mediated expression mgmtp140k efficiently protect hematopoietic compartment combined toxicity o6-beg plus tmz bcnu 
three-dimensional 3-d culture system simulate tumor extracellular microenvironment may appropriate test cancer cell potential invasion tumor cell sensitivity anticancer drug human pc-3 prostate a549 colon ht-29 lung mcf-7 mda-mb231 breast cancer cell embedded grow collagen gel surround fibrin clot increase concentration cisplatin doxorubicin paclitaxel 5-fluorouracil comparatively evaluate ability inhibit tumor cell proliferation colony formation vitro cell except mda form colony collagen pc-3 a549 ht-29 cell massively invade fibrin form migratory front cell colony also form fibrin secondary tumor-like structure apart migratory front ht-29 cell aggressive regard mda cell particularly sensitive doxorubicin mcf-7 cell show sensitivity anticancer regimen test a549 cell tumor cell type greatest potential invasion sensitive mostly cisplatin pc-3 cell primarily sensitive cisplatin doxorubicin ht-29 cell sensitive fluorouracil doxorubicin 3-d collagen cell culture system use study cancer cell potential invasion relative sensitivity/resistance anticancer drug 
pemetrexed novel multitargeted antifolate significant clinical activity variety tumor study schedule-dependent cytotoxic effect pemetrex combination paclitaxel vitro improve understanding combination might use clinically human lung cancer a549 cell breast cancer mcf7 ovarian cancer pa1 colon cancer widr cell expose pemetrexed paclitaxel vitro cell growth inhibition 5 day determine effect drug combination analyze isobologram method steel peckham simultaneous exposure pemetrexed paclitaxel 24 h produce antagonistic effect a549 pa1 cell additive/antagonistic effect mcf7 cell additive effect widr cell pemetrex 24 h follow paclitaxel 24 h produce synergistic effect a549 mcf7 cell additive effect pa1 widr cell reverse sequence produce additive effect four cell line cell cycle analysis support observation finding suggest simultaneous administration pemetrexed paclitaxel suboptimal optimal schedule pemetrex combination paclitaxel sequential administration pemetrexed follow paclitaxel schedule assess clinical trial treatment solid tumor 
background commonly use antineoplastic drug cytotoxic toward normally oxygenate tumor cell toward hypoxic tumor cell purpose method examine ability sr-4233 new cytotoxic agent overcome resistance hypoxic tumor cell antitumor alkylating agent test cytotoxic effect sr-4233 alone combination vary dose cisplatin cddp cyclophosphamide cpm carmustine bcnu melphalan l-pam tumor cell bone marrow cell isolate c3h/fej mouse bear fsaiic fibrosarcoma result sr-4233 alone give tumor cell killing limit sr-4233 administer just single-dose treatment cddp cpm bcnu l-pam however marked dose enhancement lead increase cytotoxic effect tumor cell bone marrow cell observe similar experiment tumor cell subpopulation select hoechst 33342 dye diffusion confirm cytotoxicity bright oxygenate dim hypoxic cell increase combine alkylate agent sr-4233 enhancement effect relatively greater subpopulation dim cell delay growth tumor animal treat combination sr-4233 cddp cpm l-pam 1.6-fold 5.3-fold greater animal treat alkylate agent alone conclusion result suggest sr-4233 may potential improve clinical efficacy commonly use antitumor alkylating agent 
compound zhu-xiang herbal extract contain ginseng carthamus tinctorius use treat mda-mb-231 breast cancer cell normal human mammary gland cell line inhibition cell proliferation zhu-xiang epirubicin 5-fluorouracil cyclophosphamide determine wst-1 assay apoptotic effect study flow cytometry analysis dna strand break apoptag peroxidase situ apoptosis kit tunel assay proliferation index well cell cycle progression also evaluate flow cytometry use ki-67 propidium iodide respectively marker zhu-xiang show significantly inhibition cell proliferation inhibition dose dependent inhibitory effect zhu-xiang significantly greater commonly use cytotoxic drug inhibitory effect result induction apoptosis concentration time-dependent dna histogram indicate compound cause accumulation cell mainly s phase viability cell breast solid tumour measure atp bioluminescence assay determine drug-induced cytotoxicity zhu-xiang three different concentration zhu-xiang exhibit ability inhibit proliferation solid tumour zhu-xiang useful anti-cancer compound breast cancer 
combination therapy include antisense oligonucleotide odn traditional chemotherapeutic agent offer potential benefit increase effectiveness chemotherapeutic reduce effective dosage simultaneously reduce toxicity previously report antisense odn specific transform growth factor-alpha tgf-alpha binding site epidermal growth factor receptor egfr mr1 mr2 respectively effective pc-3 vitro vivo prostate cancer model series evaluate antisense odn various combination treatment cycle paclitaxel taxol cyclophosphamide cytoxan mitoxantrone carboplatin cisplatin oxaliplatin order identify synergistic effects.we find either odn simultaneously administer taxol synergistic activity note however sequentially administer series 1 d apart pretreatment odn direct tgf-alpha 6.64 microm follow taxol 5 nm significantly p 0.001 greater activity agent similarly administer reverse order simultaneously cytoxan administer sequence odn significantly increase growth inhibition obtain compare cytoxan administer alone 1 d treatment pc-3 cell cytoxan follow next day mr1 significantly effective p 0.0001 reverse order pretreatment mr1 follow cytoxan also result significant additional inhibition p = 0.0004 similarly sequence mr2 follow cytoxan also significantly effective p = 0.0014 cytoxan treatment alone mitoxantrone administer combination therapy odn mitoxantrone mr1 significantly inhibitory combination mr1 mr2 odn p = 0.006 also mitoxantrone administer alone p = 0.0012 mitoxantrone administer mr1 significantly different mitoxantrone give combination mr2 although mitoxantrone mr2 statistically p = 00015 inhibitory mitoxantrone alone combination barely effective p = 0.04 mr1 odn administer alone 
previous study laboratory indicate expression mlh1 dna mismatch repair mmr gene necessary restore cytotoxicity efficient g 2 arrest hct116 human colon cancer cell well mlh1 / murine embryonic fibroblast treatment 5-fluoro-2 deoxyuridine fdurd show identical phenomenon occur expression msh2 major mmr gene restore hec59 human endometrial carcinoma cell present adenovirus e1a-immortalized msh2 / compare isogenic msh2 / murine embryonic stem cell mmr status little effect cellular response i.e. g 2 arrest lethality thymidylate synthase inhibitor tomudex greater level 3 h fdurd incorporation dna find mmr-deficient cell conclude differential fdurd cytotoxicity mmr-competent mmr-deficient cell mediate level dna incorporation analysis atpase activation suggest hmsh2-hmsh6 heterodimer recognize fdurd moiety base 5-fluorouracil fu dna mispair guanine pair adenine furthermore analysis incorporated fdurd use methyl-cpg-binding domain 4 glycosylase indicate misincorporate fu gua dna mmr-deficient hct116 cell datum provide first demonstration mmr specifically detect fu gua first round dna replication signal sustained g 2 arrest lethality 
human glioblastoma deadly brain tumor often treat combination drug new alkylating agent temozolomide tmz recently find efficacious clinical trial glioblastoma steroid dexamethasone dxm often use concomitantly supportive therapy treat cerebral edema however possible modulatory effect steroid efficacy tmz yet evaluate experimentally study examine whether dxm provide synergistic antagonistic effect tmz-induced apoptosis human glioblastoma t98g cell t98g cell pretreat various dose dxm follow tmz cell viability assess trypan blue dye exclusion test wright staining tdt-mediated dutp nick-end labeling tunel assay use evaluate apoptotic cell death base morphological biochemical dna fragmentation feature respectively biochemical feature apoptotic death upregulation bax bcl-2 ratio calpain activity caspase-3 activity assess western blot analysis significant number t98g cell commit apoptosis treatment 200 microm tmz however pretreatment 100 microm 200 microm dxm protect t98g cell tmz-induced apoptosis concomitantly decrease bax bcl-2 ratio calpain activity caspase-3 activity experimental result indicate dxm work antagonistic agent combination tmz therefore investigation strongly imply combination dxm tmz may counteractive treat human glioblastoma 
2-methoxyestradiol 2-meo-e 2 well-known nonpolar endogenous metabolite 17beta-estradiol strong antiproliferative apoptotic antiangiogenic action vitro vivo pharmacologic concentration determine present study whether 2-meo-e 2 enhance anticancer action paclitaxel vinorelbine two commonly use microtubule-disrupting agent several human breast cancer cell line include estrogen receptor-positive mcf-7 t-47d cell receptor-negative mda-mb-435s mda-mb-231 cell 2-meo-e 2 combination paclitaxel vinorelbine exhibit synergistic anticancer effect human breast cancer cell vitro synergistic effect pronounced drug use relatively low concentration additional experiment use female athymic balb/c nu/nu mouse show p.o. administration 2-meo-e 2 30 mg/kg body weight week 6 week markedly enhance activity paclitaxel vinorelbine growth estrogen receptor-negative mda-mb-231 human breast cancer xenograft animal contrast combination 2-meo-e 2 5-fluorouracil partial additive effect growth cell line culture synergistic effect observe interestingly doxorubicin use combination 2-meo-e 2 antiproliferative effect 2-meo-e 2 somewhat antagonize doxorubicin present high concentration result show 2-meo-e 2 nontoxic subtoxic dose selectively enhance effect certain microtubule-disrupting agent paclitaxel vinorelbine growth receptor-negative human breast cancer cell culture also athymic nude mouse 
investigate new drug combination potential clinical value treatment hormone-refractory prostate cancer combination paclitaxel carboplatin mitoxantrone combination three drug compound target important pathway cancer progression 13-cis-retinoic acid chelerythrine assess drug combination incubate 72 h steroid-free condition two androgen-independent cell line du145 pc3 cytotoxicity assay perform use resazurin hoescht 33342 synergism antagonism measure combination index calculate combination median-effect method six compound exhibit cytotoxic effect test alone paclitaxel exhibit highest 13-cis-retinoic acid lowest effect cell line paclitaxel demonstrate synergism additivity 13-cis-retinoic acid cell line whereas antagonistic effect observe test combination carboplatin chelerythrine show additive effect mitoxantrone cell line paclitaxel pc3 cell result suggest combination paclitaxel 13-cis-retinoic acid chelerythrine mitoxantrone paclitaxel may clinical value treatment hormone-refractory prostate cancer 
selective inhibition repopulation survive tumor cell course chemotherapy might improve outcome treatment potential target inhibit repopulation mammalian target rapamycin pathway pten-negative tumor cell particularly sensitive inhibition pathway study rapamycin analogue cci-779 alone chemotherapy inhibitor proliferation human prostate cancer cell line pc-3 du145 pten phospho-akt/pkb status effect cci-779 phosphorylation ribosomal protein s6 evaluate immunostaining and/or western blotting expression phospho-akt/pkb pten mutant pc-3 cell xenograft higher pten wild-type du145 cell phosphorylation s6 inhibit cci-779 cell line culture cell treat weekly mitoxantrone docetaxel two cycle cci-779 vehicle give course growth clonogenic survival cell line inhibit dose-dependent manner cci-779 minimal effect cci-779 give course chemotherapy cci-779 inhibit growth xenograft derive cell line greater effect pc-3 du145 tumor cci-779 cause mild myelosuppression activity mitoxantrone docetaxel limit cci-779 give course chemotherapy increase growth delay pc-3 xenograft result suggest repopulation pten-negative cancer cell course chemotherapy might inhibit cci-779 
gefitinib iressa selective epidermal growth factor receptor tyrosine kinase inhibitor use treatment lung cancer recently discover inhibit breast cancer resistance protein atp-binding cassette transporter p-glycoprotein pgp also pump multiple type drug cell use energy generate atp confer multidrug resistance cancer cell study design examine whether gefitinib inhibit function pgp use multidrug resistant pc-6 / ptx lung cancer mcf-7 / adr breast cancer cell overexpress pgp measure drug sensitivity drug-efflux function tetrazolium assay flowcytometry respectively addition drug-stimulated atpase activity pgp measure use insect membrane express human pgp epidermal growth factor receptor express mcf-7 / adr pc-6 / ptx cell overexpression pgp confer resistance gefitinib cell type however clinically achievable level gefitinib moderately reverse pgp-mediated resistance paclitaxel docetaxel pgp overexpress cell addition gefitinib increase intracellular accumulation pgp substrate rhodamine-123 resistant cell activate atpase preparation pure pgp-expressing membrane finding suggest gefitinib directly interact pgp inhibit function gefitinib may clinically inhibit excretion pgp substrate drug include anticancer agent drug-interaction therefore consider 
folate analogue bgc9331 new thymidylate synthase ts inhibitor show broad spectrum cyto-toxic activity several human solid tumor include colorectal cancer study investigate anticancer activity bgc9331 either alone combine 5-fluorouracil 5-fu mta multi-target antifolate oxali-platin sn-38 active metabolite topoisomerase inhibitor cpt-11 antiproliferative activity drug bgc9331-based combination investigate ht-29 human colorectal cancer cell line ht-29 / 5-fu counterpart select resistance 5-fu bgc9331 combine mta sn-38 induce synergistic response ht-29 cell treatment ht-29 cell either bgc9331 sn-38 increase caspase-3 activity percentage apoptotic cell 3 13 drug also augment proteolytic cleavage rho-kinase rock-1 attenuate caspase-3 pathway inhibitor z-devd-fmk bgc9331 combine sn-38 increase percentage apoptotic cell 25 inhibit cell cycle progression cell proliferation 65 accompany proteolytic activation rock-1 caspase-3-dependent independent mechanism show caspase-3-deficient mcf-7 breast cancer cell encouraging result warrant preclinical investigation clinical trial use bgc9331 combine sn-38 / cpt-11 treatment patient advanced colorectal gastric cancer 
resistance tumor classic taxane paclitaxel docetaxel present problem chemotherapy thus new taxane higher antitumor activity resistant tumor synthesize study compare cytotoxicity transport paclitaxel docetaxel novel taxane sb-t-1103 sb-t-1214 sb-t-1216 adriamycin-sensitive mda-mb-435 resistant nci/adr-res human breast cancer cell cell line examine differ adriamycin transport suggest different expression abc membrane transporter reverse transcription-polymerase chain reaction reveal nci/adr-res cell express high level p-glycoprotein mrna absent mda-mb-435 cell opposite true mrp2 mrna cell line share differently express eight abc transporter lrp nci/adr-res cell 1,000-fold resistant paclitaxel 600-fold resistant docetaxel mtt assay mda-mb-435 cell almost equally sensitive sb-t-1103 sb-t-1214 sb-t-1216 comply fact nci/adr-res cell absorb almost 20-fold less 14c paclitaxel 7-fold less docetaxel almost equal amount sb-t-1103 sb-t-1214 sb-t-1216 mda-mb-435 cell verapamil increase uptake 14c paclitaxel nci/adr-res cell 7-fold decrease efflux 2.5-fold contrast weakly influence uptake increase efflux mda-mb-435 cell sb-t-1103 sb-t-1216 influence transport paclitaxel sb-t-1214 decrease 14c paclitaxel uptake cell line indicate inhibition uptake suggest novel taxane inhibitor p-glycoprotein however novel taxane exert much higher activity resistant tumor cell classic taxane seem potential drug therapy taxane-resistant tumor 
erosion ulceration intestinal epithelium hallmark inflammatory bowel disease ibd intestinal epithelial cell migration restitution proliferation pivotal mechanism healing epithelial defect mucosal injury addition rate apoptosis epithelial cell may modulate intestinal wound healing purine antagonist azathioprine aza 6-mercaptopurine 6-mp widely use drug treatment ibd present study hitherto unknown effect aza well metabolite 6-mp 6-thioguanine 6-tg repair mechanism apoptosis intestinal epithelia analyse intestinal epithelial cell line human caco-2 t-84 ht-29 cell rat iec-6 cell incubate aza 6-mp 6-tg 24 h final concentration 0.1-10 microm migration caco-2 iec-6 cell analyse vitro restitution assay caco-2 iec-6 cell proliferation evaluate measurement 3h thymidine incorporation dna apoptosis caco-2 t-84 ht-29 iec-6 cell assess histone elisa 4 6 diamidino-2 phenylindole-dihydrochloride staining well flow cytometric analysis annexin v/propidium iodide pi stain cell cell cycle progression evaluate pi staining flow cytometry epithelial restitution significantly affect substance test however proliferation intestinal epithelial cell inhibit dose-dependent manner maximal effect 92 aza 6-mp well 6-tg ht-29 cell purine antagonist-effected inhibition cell proliferation explain cell cycle arrest g2 phase contrast aza 6-mp 6-tg induce cell cycle arrest caco-2 t-84 iec-6 cell aza 6-mp well 6-tg induce apoptosis non-transformed iec-6 cell line human caco-2 t-84 ht-29 cell summary aza metabolite exert significant effect intestinal epithelial restitution however profoundly inhibit intestinal epithelial cell growth via various mechanism cause g2 cell cycle arrest ht-29 cell induce apoptosis iec-6 cell dose-dependently inhibit intestinal epithelial proliferation 
clinical study show oxaliplatin novel platinum derivative potent chemotherapeutic agent colorectal cancer combine 5-fluorouracil leucovorin although toxic activity base covalent adduct platinum dna actual biological behavior mostly unknown effort explore mechanism tumor susceptibility oxaliplatin examine cytotoxic effect oxaliplatin colorectal cancer cell line reference p53 gene status although p53 gene status clearly predict sensitivity oxaliplatin p53 wild-type cell include hct116 sensitive hct116 p53 / find resistant oxaliplatin oxaliplatin cause strong p21waf1/cip1 induction g0-g1 arrest p53 wild-type cell whereas cisplatin induce g0-g1 arrest assay use p53 wild p21waf1/cip1 null hct116 cell reveal oxaliplatin show g0-g1 arrest reduce growth-inhibitory effect suggest p21waf1/cip1 may key element oxaliplatin-treated p53 wild-type cell although hct116 dna mismatch repair-deficient mismatch repair-proficient hct116 ch3 cell line display similar response regard p21waf1/cip1-mediated growth inhibition g0-g1 arrest p53 mutant cell hand oxaliplatin cause abrupt transition g1 s phase eventually result g2-m arrest abrupt entry s phase associate loss p21waf1/cip1 protein via proteasome-mediated degradation finding suggest p21waf1/cip1 play role oxaliplatin-mediated cell cycle growth control p53-dependent independent pathway 
third-generation non-steroidal aromatase inhibitor ai challenging tamoxifen treatment choice early advanced breast cancer postmenopausal woman estrogen receptor er positive disease however patient initially respond ai eventually develop resistance treatment experience disease progression establish optimal endocrine therapy follow ai resistance essential understand mechanism contribute loss response datum vitro model suggest acquire ai resistance due enhance sensitization low estrogen level long-term estrogen deprivation lted cross-talk er various growth-factor-receptor signaling pathway include human epidermal growth factor receptor 2 insulin-like growth factor pathway may also implicate therefore endocrine therapy abolish estrogen signaling via removal er effective patient ai-resistant disease fulvestrant faslodex new er antagonist agonist effect bind block degrade er due unique mode action lack cross-resistance exist treatment fulvestrant effective therapeutic agent use sequential endocrine regimen fulvestrant establish efficacy tamoxifen-resistant disease grow body evidence demonstrate efficacy patient ai-resistant disease preclinical model mcf-7 cell undergo lted refractory tamoxifen sensitive fulvestrant suggest fulvestrant appropriate choice follow ai resistance steroidal ai exemestane also option non-steroidal ai-resistant disease clinical trial underway compare fulvestrant exemestane appropriate therapy follow onset ai resistance 
aim study contribute understanding mechanism responsible resistance breast cancer cell taxane cell cycle characteristic dna fragmentation p53 p21 waf1/cip1 expression caspase-3 caspase-9 activity cytochrome c release mitochondria cell death induction taxane paclitaxel docetaxel highly-sensitive mda-mb-435 highly-resistant nci-adr-res human breast cancer cell compare approximately 300-fold higher concentration taxane require induce death resistant nci-adr-res cell sensitive mda-mb-435 cell cell death induce taxane sensitive resistant cell precede accumulation cell g2/m-phase neither cell type produce dna fragmentation dna ladder typical regular apoptosis p53 p21 waf1/cip1 level change sensitive resistant cell cell death induction taxane activity executioner caspase-3 increase significantly 2 2.5-fold similarly activity caspase-9 increase significantly 2 3.5-fold cell type however cytochrome c find release mitochondria cytosol resistant nci-adr-res cell sensitive mda-mb-435 cell death induce taxane study breast cancer cell characterize apoptosis-like death include caspase-3 caspase-9 activation oligonucleosomal dna fragmentation however mechanism death induction taxane sensitive mda-mb-435 cell resistant nci-adr-res cell differ cytochrome c release mitochondria resistant sensitive cell 
purpose perform phase ii study evaluate combination imatinib mesylate adenosine triphosphate mimetic tyrosine kinase inhibitor plus hydroxyurea ribonucleotide reductase inhibitor patient recurrent glioblastoma multiforme gbm patient method patient gbm recurrence receive imatinib mesylate plus hydroxyurea 500 mg twice day orally continuous daily schedule imatinib mesylate dose 500 mg twice day patient enzyme-inducing antiepileptic drug eiaed 400 mg day eiaed assessment perform every 28 day primary end point 6-month progression-free survival pfs result thirty-three patient enrol progressive disease prior radiotherapy least temozolomide-based chemotherapy median follow-up 58 week 27 patient progression-free 6 month median pfs 14.4 week three patient 9 achieve radiographic response 14 42 achieve stable disease cox regression analysis identify concurrent eiaed use one prior progression independent positive prognostic factor pfs common toxicity include grade 3 neutropenia 16 thrombocytopenia 6 edema 6 grade 4 5 event concurrent eiaed use lower imatinib mesylate exposure imatinib mesylate clearance decrease day 28 compare day 1 patient suggest effect hydroxyurea conclusion imatinib mesylate plus hydroxyurea well tolerate associate durable antitumor activity patient recurrent gbm 
interaction cisplatin cddp irradiation potential significance combined modality treatment cancer previous datum indicate follow vitro exposure x-irradiation certain tumour cell express resistance cddp identify parameter associate cddp resistance human ovarian carcinoma cell line sk-ov-3 / p pre-expose fractionate x-irradiation total dose 50 gy vitro resultant subline sk-ov-3 / dkr-10 prove 2-fold resistant cddp acute x-irradiation consistent unaltered dihydrofolate reductase thymidylate synthase activity sk-ov-3 / dxr-10 cell neither cross-resistant methotrexate 5-fluorouracil verapamil 6.6 microm significantly p less 0.05 enhance cddp-induced cytotoxicity resistant dxr-10 subline parental cell total glutathione level significantly p less 0.01 lower resistant subline bso pretreatment fail influence cytotoxicity whilst related enzyme activity consistently modify sk-ov-3 / dxr-10 cell resistance cell associate significantly decrease cisplatin uptake p less 0.002 immediately follow drug exposure total platination level dna quantitate immunochemically higher p less 0.05 resistant subline indicative increase tolerance dna damage 18 h post-treatment incubation parental cell line appear proficient removal intrastrand adduct pt-ag deficient remove major adduct pt-gg difunctional pt gmp 2 lesion whilst dxr-10 resistant subline appear proficient removal four pt-dna adduct dna polymerase alpha beta activity however comparable cell line datum implicate enhance repair increase tolerance dna damage mechanism resistance cddp result vitro exposure human ovarian carcinoma cell line fractionate x-irradiation 
p140k-mgmt g156a-mgmt gene encode two o 6 benzylguanine-resistant o 6 alkylguanine dna alkyltransferase protein confer high degree o 6 benzylguanine 1,3-bis 2-chloroethyl -1-nitrosourea bcnu o 6 benzylguanine temozolomide resistance primary hematopoietic cell study directly compare three o 6 benzylguanine-resistant mgmt gene ability protect human erythroleukemia cell line k562 use direct competitive selection strategy identify mutation confer greatest degree protection o 6 benzylguanine either bcnu temozolomide mfg retroviral vector plasmid mutant g156a-mgmt ed 50 o 6 benzylguanine 60 micromol/l p140k-mgmt mgmt-2 s152h a154g y158h g160s l162v mgmt-3 c150y a154g y158f l162p k165r mgmt-5 n157t y158h a170s ed 50 benzylguanine 1,000 micromol/l mixed virus produce phoenix cell transduce k562 cell stringent selection use high dose o 6 benzylguanine 800 micromol/l temozolomide 1,000 micromol/l bcnu 20 micromol/l administer twice follow regrowth survive clone isolate mgmt transgene sequence none mutant lose selection use temozolomide enrichment factor greatest p140k-mgmt 1.7-fold use bcnu selection greatest enrichment observe mgmt-2 1.5-fold g156a-mgmt least o 6 benzylguanine-resistant mgmt gene mutant test lose selection select optimal mutant mgmt useful drug resistance gene may depend whether methylating chloroethylating agent use drug selection 
mechanism resistance thiopurine 6-mercaptopurine 6-mp 6-thioguanine 6-tg investigate human leukemia cell line develop two 6-mp 6-tg-resistant cell line human t-lymphoblastic cell line molt-4 prolonged exposure drug resistant cell highly cross resistant 6-mp 6-tg exhibit marked reduction cellular uptake 6-mp 70 80 respectively significant modification activity hypoxanthine-guanine phosphoribosyl transferase thiopurine methyltransferase inosine monophosphate dehydrogenase observe real-time pcr concentrative nucleoside transporter 3 cnt3 equilibrative nucleoside transporter 2 ent2 resistant cell show substantial reduction expression messenger rna small interfere rna design silence cnt3 ent2 gene down-regulate expression gene leukemia cell decrease accompany reduction transport 6-mp 47 21 respectively well cytocidal effect 30 21 respectively take together result show cnt3 ent2 play key role transport 6-mp 6-tg leukemia cell clinical point view determination cnt3 ent2 level leukemia cell may useful predict efficacy thiopurine treatment 
celecoxib specific cyclooxygenase-2 cox-2 inhibitor show possess antitumor activity variety cancer cell however antitumor activity celecoxib hematopoietic tumor especially chronic myeloid leukemia cml well establish study design investigate effect celecoxib growth apoptosis human cml cell line k562 cell primary cml cell examine synergistic action celecoxib hydroxyurea imatinib k562 cell proliferation apoptosis celecoxib significantly inhibit growth k562 primary cml cell induced apoptosis dose-dependent fashion ic50 celecoxib 46 microm inhibition k562 cell proliferation effect celecoxib growth inhibition accompany downregulation cyclin d1 cyclin e p-rb expression upregulation p16 ink4a p27kip expression g1-s phase arrest cell cycle pro-apoptotic effect celecoxib determine mediate caspase-3 activation k562 cell pretreat devd-fmk specific inhibitor caspase apoptotic activity celecoxib part abrogate importantly demonstrate first time k562 cell cox-2-positive mrna protein level note follow observation detect cox-2 mrna k562 cell reverse transcription-pcr rt-pcr protein expression western blot analysis ii cox-2 expression k562 cell stimulate il-1beta specific induce agent cox-2 expression iii primary cml cell cml patient bone marrow also exhibit cox-2 protein expression furthermore cox-2 expression downregulate higher dose celecoxib 80-160 microm suggest cox-2-dependent mechanism involve drug effect growth inhibition induction apoptosis addition synergistic effect observe cell expose low-dose celecoxib 40 microm hydroxyurea 10 mm combination celecoxib 40 microm imatinib 0.2 microm finding provide basis uncover mechanism celecoxib antitumor effect develop new therapeutic strategy treat cml 
metronomic antiangiogenic chemotherapy prolonged administration relatively low drug dose close regular interval significant break mainly study preclinical level use single chemotherapeutic drug frequently combination target antiangiogenic drug almost always evaluate primary localized tumor test doublet combination metronomic chemotherapy treatment use two oral drug uft 5-fluorouracil 5-fu prodrug administer gavage cyclophosphamide efficacy toxicity new mouse model advanced terminal metastatic human breast cancer optimal biological dose drug first determine effect level circulate endothelial progenitor cell surrogate marker angiogenesis assess 15 mg/kg uft 20 mg/kg cyclophosphamide combination treatment evaluate mouse advanced metastatic disease use serially select metastatic variant mda-mb-231 breast cancer-cell line 231/lm2 4 uft cyclophosphamide treatment show modest survival advantage whereas combination two result remarkable prolongation survival evidence overt toxicity despite 140 day continuous therapy significant proportion mouse survive year contrast striking therapeutic effect combination treatment observe test primary orthotopic tumor conclude combination oral low-dose daily metronomic chemotherapy use cyclophosphamide uft superior monotherapy seem safe highly effective experimental antimetastatic therapy case advanced metastatic breast cancer 
fk973 11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1 11-diazatetracyclo 7.4.1.0.0 tetradeca-2 4 6-trien-6 9-diyl diacetate analogue mitomycin c mmc test human oral squamous cancer cell line 9-22 hsc-2 hsc-3 breast adenocarcinoma cell line mcf-7 bt-20 breast ductal carcinoma cell line t-47d use mtt assay fk973 show cytotoxic effect six test cell line much wider effective dose range mmc adriamycin adm cisplatin cddp fk973 potent four drug test growth three squamous cancer cell line derive oral cavity however breast cancer cell line fk973 less potent mmc adm. fk973 time dose dependent combination effect fk973 5-fluorouracil 5fu cddp synthetical may promising candidate treatment oral breast cancer 
sorafenib tosylate sorafenib bay 43-9006 nexavar multi-kinase inhibitor target tumor cell proliferation angiogenesis study evaluate efficacy tolerability combination sorafenib plus agent use treat non-small cell lung cancer nsclc use preclinical model disease intravenous iv vinorelbine interperitoneal ip cisplatin administer intermittently q4d x 3 combination sorafenib administer orally po daily 9 day start day standard agent study sorafenib gefitinib agent administer po daily 10 day start day treatment study initiate establish sc tumor study conduct duplicate efficacy assess delay tumor growth specify size tgd vinorelbine 6.7 mg/kg sorafenib 40 mg/kg produce tgd 2.4 7.8 day respectively nci-h460 nsclc model combination therapy produce 10.0-day tgd increase toxicity combination therapy nci-h23 nsclc model highest evaluate dose level sorafenib plus cisplatin well tolerate produce tgd equivalent produce cisplatin alone lower dose level agent produce approximately additive tgd combination therapy a549 nsclc model sorafenib gefitinib produce tgd equivalent produce sorafenib alone toxicity tumor growth mda-mb-231 mammary tumor model contain mutation signal transduction protein downstream egf receptor target gefitinib also inhibit sorafenib gefitinib concurrent administration sorafenib vinorelbine cisplatin gefitinib least efficacious individual agent alone well tolerate result support inclusion sorafenib clinical trial nsclc employ combination cytotoxic cytostatic agent 
p14 arf tumor suppressor protein regulate p53 interfere mdm2-p53 interaction p14 arf activate response oncogenic stimulus little know response endogenous p14 arf different type cellular stress dna damage azidothymidine azt test several clinical trial enhancer anticancer chemotherapy however knowledge relationship azt cellular pathway e.g. p53 pathway limited study show azt cisplatin cddp docetaxel dtx induce unique molecular response ovcar-3 ovarian carcinoma cell carry mutate p53 a2780 ovarian carcinoma mcf-7 breast carcinoma cell wild type p53 drug cause similar p53 response find endogenous p14 arf protein ovcar-3 cell down-regulate dtx induce azt short cddp pulse treatment ht-29 colon carcinoma cell mutate p53 treatment down-regulate p14 arf protein cddp azt increase expression p14arf mrna ovcar-3 cell difference cell death induce drug explain difference protein mrna expression increase level either c-myc h-ras oncoprotein see ovcar-3 cell azt cddp-treatment result suggest p14 arf respond dna damage without oncogene activation cell line without functional p53 
selective estrogen receptor modulator raloxifene ral use treat prevent osteoporosis investigation use treatment prevention breast cancer ral combination antimetabolite methotrexate mtx 5-fluorouracil 5-fu extensively study ral antimetabolite target different phase cell cycle exhibit different mechanism action clinical toxicity effect sequence administration growth inhibition mcf-7 human breast cancer cell investigate mcf-7 human breast cancer cell expose vehicle alone 10 microm mtx 1 microm 5-fu 10 microm ral 10 microm ral 24 hour prior 1 microm 5-fu follow 2 hour later 10 microm mtx 1 microm 5-fu 2 hour prior 10 microm mtx follow 24 hour later 10 microm ral cell evaluate viability proliferation retinoblastoma rb protein cell cycle regulator phosphorylate allow progression cell g1 s-phase use marker determine effect early ral late ral cellular progression molecular level early ral administration exhibit cell viability 66.83 / 6.17 control however late ral administration exhibit cell viability 39.40 / 17.03 control late ral cytotoxic combination ral alone early ral finding manual cell counting also support cell flow cytometric analysis western blot datum late ral combination 5-fu mtx due greater cytotoxicity desirable combination treat breast cancer ral alone 
increase evidence suggest adjuvant systemic chemotherapy necessary survival breast cancer patient antitumor agent effective use combination drug exhibit different mechanism action use alone previous study laboratory show raloxifene ral attenuation 5-fluorouracil/methotrexate 5-fu/mtx cytotoxicity breast cancer cell sequence-dependent aim evaluate combination ral 5-fu mtx determine effective regime cellular mechanism action mitigate mtx cytotoxicity human bone marrow cell sequence-dependent interaction among mtx 5-fu ral proliferation viability human bone marrow hs-5 cell determine mtt assay trypan blue dye exclusion assay expose cell mtx 5-fu ral alone ral 24 h prior 5-fu follow 2 h later mtx 5-fu 2 h prior mtx follow 24 h later ral control cell untreated growth rate mcf-7 early ral 68 / 3.07 late ral 37 / 2.05 control rate whereas bone marrow drug combination exhibit significant protection mtx cytotoxity early ral combination yield 81 / 3.77 late 54 / 2.74 control finding support cell flow cytometry western blot analysis sequence-dependent administration ral combination 5-fu/mtx may maximum antineoplastic activity breast cancer time provide protection human bone marrow 
methylmercaptopurine riboside mempr cellular metabolite 6-mercaptopurine 6-mp potent inhibitor de novo purine synthesis dnps human molt4 t-lymphoblastic leukaemia cell acquire resistance 6-mp 6-thioguanine 6-tg consequence defective transport exhibit enhance sensitivity mempr hplc-based analysis transport mempr reveal normal uptake compound thiopurine-resistant cell subline suggest route transport distinct 6-mp 6-tg study wild-type parental leukemic cell show adenosine dipyridamole nitrobenzylthioinosine inhibit uptake mempr significant extent whereas na ion influence process transfection leukemic cell small interference rna molecule target gene encode first member family equiliberative nucleoside transporter ent1 strongly reduce initial rate mempr transport resistant cell line exhibit 30-52 reduction p 0.005 level mrna encode several protein involve de novo purine synthesis i.e. aminoimidazole carboxamide ribonucleotide formyltransferase glycinamide ribonucleotide transformylase guanine monophosphate synthetase consequently rate de novo purine synthesis resistant subline decrease 50 furthermore level ribonucleoside triphosphate cell significantly lower non-resistant parental cell combination reduce rate de novo purine synthesis together low level ribonucleoside triphosphate explain enhance sensitivity thiopurine-resistant cell line mempr manner mempr bypass mechanism resistance thiopurine even cytotoxic towards resistant towards wild-type cell 
fk228 novel antitumor depsipeptide inhibit histone deacetylase restore expression gene aberrantly suppress cancer cell agent show broad antitumor activity preclinical study currently phase i/ii evaluation wide spectrum action reasonable consider combination anticancer drug clinical application study cytotoxic interaction fk228 combination conventional antileukemic agent use human promyelocytic leukemia hl60 philadelphia chromosome-positive ph chronic myelogenous leukemia ku-812 t-cell lymphoblastic leukemia molt3 burkitt lymphoma raji cell line combination fk228 imatinib ph leukemia ku812 k562 tcc-s cell line use cell expose simultaneously fk228 agent 4 day cell growth inhibition determine use 3 4,5-dimethylthiazol-2-yl -2,5-diphenyltetrazolium bromide mtt assay use isobologram method steel peckham evaluate cytotoxic interaction concentration drug produce 80 cell growth inhibition ic 80 fk228 show additive effect cytarabine carboplatin doxorubicin etoposide 4-hydroperoxy-cyclophosphamide 6-mercaptopurine sn-38 active metabolite irinotecan cell line study fk228 methotrexate vincristine show antagonistic effect three one four cell line respectively fk228 additive imatinib three ph leukemia cell finding suggest fk228 promising candidate combine anticancer agent except methotrexate vincristine produce suboptimal effect 
study undertake characterize preclinical cytotoxic interaction human malignancy multikinase inhibitor sorafenib bay 43-9006 proteasome inhibitor bortezomib mg132 multiple tumor cell line vary histiotype include a549 lung adenocarcinoma 786-o renal cell carcinoma hela cervical carcinoma mda-mb-231 breast k562 chronic myelogenous leukemia jurkat acute t-cell leukemia mec-2 b-chronic lymphocytic leukemia u251 d37 glioma well cell derive primary human glioma tumor likely clinically relevant model treat sorafenib bortezomib alone combination sorafenib bortezomib synergistically induce marked increase mitochondrial injury apoptosis reflect cytochrome c release caspase-3 cleavage poly adp-ribose polymerase degradation broad range solid tumor leukemia cell line finding accompany several biochemical change include decrease phosphorylation vascular endothelial growth factor receptor-2 platelet-derived growth factor receptor-beta akt increase phosphorylation stress-related c-jun nh2-terminal kinase jnk inhibition akt require synergism constitutively active akt protect cell apoptosis induce combination alternatively jnk inhibitor sp600125 also protect cell apoptosis induce combination indicate inhibition akt activation jnk require synergism finding show sorafenib interact synergistically bortezomib induce apoptosis broad spectrum neoplastic cell line show important role akt jnk pathway mediate synergism clinical development combination seem warrant 
clinical treatment solid tumor docetaxel flavopiridol 5-fluorouracil 5-fu often encounter undesirable side effect drug resistance study aim evaluate potential role combination therapy docetaxel flavopiridol 5-fu modulate chemosensitivity better understand might use clinically hct116 colon cancer cell treat docetaxel flavopiridol 5-fu several different administrative schedule vitro either sequentially simultaneously cell survival measure mtt assay activity caspase-3 determine caspase-3 assay soft agar colony assay use test colony formation hct116 cell soft agar also establish xenograft model extend vitro observation vivo system maximum cytotoxicity find human colon cancer hct116 cell treat docetaxel 1 h follow flavopiridol 24 h 5-fu another 24 h sequential combination therapy inhibit tumor cell growth strongly compare combination therapy also significantly reduce colony formation soft agar augment apoptosis hct116 cell sequencing docetaxel follow 1 h later flavopiridol follow 24 h later 5-fu xenograft model also result delay tumor growth higher survival rate result highlight importance administrative schedule combine docetaxel flavopiridol 5-fu provide rationale explanation development clinical trial 
order better understand mechanism resistance thiopurine study two subline molt4 t-lymphoblastic leukemia cell line resistant 6-mercaptopurine 6-mp 6-thioguanine 6-tg find underlie mechanism resistance resistant cell line markedly reduction initial transport 6-mp 3 5-fold respectively 6-mp 6-tg-resistant cell significant alteration activity hypoxanthine-guanine phosphoribosyl transferase thiopurine methyltransferase inosine monophosphate dehydrogenase key enzyme involve metabolism thiopurine detect conclude defect initial transport thiopurine cell may well explain resistance drug 
renal cell carcinoma common neoplasm occur kidney largely resistant current chemotherapy understand mechanism involve renal carcinoma cell death may lead novel effective therapy cak -1 renal cancer cell use phosphatidylserine externalization marker apoptosis anti-cancer drug 5-fluorouracil 5-fu pro-drug doxifluridine dox floxuridine flox proceed via caspase-dependent mechanism contrast phosphatidylserine externalization produce staurosporine renal cancer cell line cak -1 a-498 proceeds via caspase-independent mechanism pan caspase inhibitor n-benzyloxycabonyl-val-ala-asp-fluoromethylketone zvad ameliorate annexin v binding cell shrinkage change nuclear morphology subsequent experiment conduct determine mediator phosphatidylserine externalization use annexin v binding caspase inhibit prior treatment a-498 cell cathepsin b ca74 methyl ester cathespsin d pepstatin calpain inhibitor calpeptin e64d presence absence zvad ameliorate annexin v binding endonuclease inhibitor aurintricarboxylic acid ata phospholipase 2 inhibitor bromoenol lactone bel protein synthesis inhibitor cycloheximide ch chloride channel blocker niflumic acid nfa 5-nitro-2 3-phenylpropylamino benzoic acid nppb effect staurosporine-induced annexin v binding a-498 cell either presence absence zvad also modulate sphingomyelin de novo pathway ceramide synthesis find amelioration staurosporine-induced annexin v binding a-498 cell either presence absence zvad result indicate 5-fu dox flox induce externalization phosphatidylserine apoptosis cak -1 renal cancer cell primarily caspase-dependent mechanism externalization phosphatidylserine apoptosis produce staurosporine renal cancer cell line a-498 independent many common signaling pathway know involve process 
purpose experiment assess synergistic activity silibinin chemotherapy agent clinical use prostate cancer silybin-phytosome commercially available formulation contain silibinin recently study phase clinical trial silibinin dose use present study clinically achievable base preliminary phase datum du145 pc-3 lncap prostate cancer cell seed 96-well plate triplicate twenty-four hour later silibinin 10 20 40 microm either mitoxantrone docetaxel add designate well seventy-two hour post-treatment cell viability determine tetrazolium-based assay combination index ci determination synergistic effect calculate value 0.9 indicate synergy value 1.1 antagonism apoptosis also assess use luminescent assay 72 hr treatment media alone silibinin mitoxantrone silibinin plus mitoxantrone silibinin show synergistic effect mitoxantrone measure reduction cell viability ci value range 0.413 2.650 combination silibinin mitoxantrone contrast treatment docetaxel silibinin show little synergy ci value 0.898-4.469 concordance finding addition silibinin increase level apoptosis compare mitoxantrone alone particularly pc-3 cell combination silibinin mitoxantrone exhibit pattern synergy reduce cell viability increase apoptosis datum important planning future clinical application silibinin 
study evaluate cytotoxic effect imexon nsc-714597 tumor cell combine broad panel chemotherapeutic drug sulforhodamine b srb 3 4,5-dimethylthiazol-2-yl -2,5-diphenyltetrazolium bromide mtt cytotoxicity assay use analyze degree growth inhibition combination study a375 human malignant melanoma rpmi 8226 human multiple myeloma cell line respectively cell continuously expose drug constant molar ratio 4-5 day combination effect analyze use median effect method statistical significance infer 95 confidence interval combination interaction c.i. value particular two-drug combination include 1.0 additivity synergy infer c.i. value 1.0 antagonism ci value 1.0 imexon synergistic combine dna-binding agent cisplatin dacarbazine melphalan pyrimidine-based antimetabolite cytarabine fluorouracil gemcitabine cell line antagonistic combination imexon include methotrexate topoisomerase topo ii topo ii inhibitor irinotecan doxorubicin mitoxantrone etoposide docetaxel synergistic imexon cell line whereas paclitaxel fludarabine show mixed result dexamethasone proteasome inhibitor bortezomib show synergy myeloma cell additivity melanoma cell vinca alkaloid vinorelbine multi-targeted antifol pemetrex additive imexon cell line consistent synergy see imexon alkylating agent may relate sulfhydryl-lowering effect imexon render cell sensitive electrophilic species alkylator marked synergy note pyrimidine-based antimetabolite unexpected may relate induction cell cycle arrest s-phase strong antagonism note imexon topoisomerase ii inhibitor may due effect imexon increase oxidant level know antagonize cytotoxic effect topoisomerase poison contrast synergy see bortezomib myeloma cell may relate increase reactive oxygen species ros drug result suggest combination imexon alkylating agent pyrimidine-based antimetabolite rational pursue therapeutic study vivo 
background current 3rd edition italian society nephrology guideline draw summarize evidence key intervention issue basis systematic review sr randomize trial rct rct datum present guideline evidence intervention idiopathic membranous nephropathy mn present method sr rct rct intervention mn identify refer cochrane library renal health library search 2005 update result three sr 18 rct available address issue methodological quality available rct suboptimal accord current methodological standard patient mn nephrotic syndrome normal renal function methylprednisolone chlorambucil cyclophosphamide 6 month alternately increase probability nephritic syndrome remission evidence sr long-term renal protection evidence rct drug acth cyclosporine associate nephrotic syndrome remission evidence significant effect renal function evidence rct patient impaired renal function association corticosteroid cytotoxic agent prove cause short-term delay renal damage progression even though benefit counterbalance complication evidence rct conclusion patient mn nephrotic syndrome normal renal function current available evidence support hypothesis primary intervention association corticosteroid cytotoxic agent secondary therapeutic choice include acth cyclosporine study necessary test new immunosuppressive agent mycophenolate mofetil 
poly adp-ribose polymerase parp -1 ec 2.4.2.30 nuclear enzyme promote base excision repair dna break inhibition parp-1 enhance efficacy dna alkylating agent topoisomerase poison ionize radiation aim identify parp inhibitor clinical trial panel 42 potent parp inhibitor k 1.4-15.1 nmol/l base quinazolinone benzimidazole tricyclic benzimidazole tricyclic indole tricyclic indole-1-one core structure evaluate chemosensitization temozolomide topotecan use lovo sw620 human colorectal cell vitro radiosensitization measure use lovo cell enhancement antitumor activity temozolomide evaluate mouse bear sw620 xenograft excellent chemopotentiation radiopotentiation observe vitro 17 compound cause greater temozolomide topotecan sensitization benchmark inhibitor ag14361 10 compound potent radiosensitizer ag14361 tumor-bearing mouse none compound toxic give alone antitumor activity parp inhibitor-temozolomide combination unrelated toxicity compound potent chemosensitizer vivo ag14361 also potent vitro validate vitro assay prescreen study identify compound ag14447 parp inhibitor outstanding vivo chemosensitization potency tolerable dose least 10 time potent initial lead ag14361 phosphate salt ag14447 ag014699 improve aqueous solubility select clinical trial 
antitumour effect retinoid attribute influence cell proliferation differentiation apoptosis angiogenesis effort develop useful agent breast cancer therapy evaluate effect four representative retinoic acid metabolism block agent ramba vn/14 -1 vn/50 -1 vn/66 -1 vn/69 -1 growth inhibition oestrogen receptor positive er ve mcf-7 t-47d oestrogen receptor negative er ve mda-mb-231 human breast cancer cell additionally investigate biological effects/molecular mechanism s underlie growth inhibitory property well antitumour efficacy mcf-7 mcf-7ca tumour xenograft nude mouse also assess effect combine vn/14 -1 all-trans-retinoic acid atra mcf-7 tumour xenograft er ve cell line sensitive ic 50 value 3.0 609 nm ramba er ve mda-mb-231 cell line ic 50 = 5.6-24.0 microm retinoic acid metabolism block agent induce cell differentiation determine increase expression cytokeratin 8/18 oestrogen receptor-alpha er-alpha similar atra also induce apoptosis via activation caspase 9 cell cycle analysis indicate ramba arrest cell g1 g2/m phase cause significant downregulation 80 cyclin d1 protein vivo growth mcf-7 mammary tumour dose-dependently significantly inhibit 92.6 p 0.0005 vn/14 -1 combination vn/14 -1 atra also inhibit mcf-7 breast tumour growth vivo 120 compare single agent p 0.025 vn/14 -1 also effective prevent formation mcf-7ca tumour significantly inhibit growth established mcf-7ca tumour effective clinically use aromatase inhibitor anastrozole letrozole decrease cyclin d1 upregulation cytokeratin bad bax vn/14 -1 may responsible efficacy compound inhibit breast cancer cell growth vitro vivo result suggest ramba especially vn/14 -1 may useful novel therapy breast cancer 
aim investigate combined chemotherapeutic effect celecoxib use 5-fu vitro method two human colon cancer cell line hct-15 ht-29 treat 5-fu celecoxib alone combination effect drug evaluate use mtt 3 4 5-dimethylthiazol-2-yl -2 5-diphenyltetrazolium bromide assay flow cytometry western blotting result 5-fu celecoxib show dose-dependent cytotoxic effect treat 10 -3 mol/l 5-fu ic 50 celecoxib concentration range 10 -8 mol/l 10 -4 mol/l celecoxib cell show reduce cytotoxic effect 5-fu 10 -3 mol/l alone flow cytometry show celecoxib attenuate 5-fu induce accumulation cell subg1 phase western blot analysis caspase-3 poly adp-ribose polymerase parp cleavage show celecoxib attenuate 5-fu induced apoptosis western blot analysis cell cycle molecule show g2/m arrest might possible cause 5-fu induce apoptosis celecoxib attenuate 5-fu induced apoptosis via blocking cell cycle progression g2/m phase cause accumulation cell g1/s phase conclusion find celecoxib attenuate cytotoxic effect 5-fu celecoxib might act via inhibition cell cycle progression thus prevent apoptosis induce 5-fu 
paclitaxel 5-fluorouracil use treat hormone-refractory prostate cancer success vitro datum suggest combined cytotoxicity may sequence dependent thus explore combined effect 2 agent vitro vivo combined cytotoxicity paclitaxel 5-fluorouracil possible schedule dependence study vitro use pc-3 du145 cell microculture tetrazolium assay 23 patient hormone-refractory prostate cancer treat regimen t-hdfl paclitaxel 90 mg/m2 intravenously 1 hour day 1 8 5-fluorouracil 2000 mg/m2 leucovorin 300 mg/m2 intravenous 24-hour infusion day 2 9 repeat every 21 day allow percentage bone marrow irradiation 50 significant synergistic cytotoxicity see paclitaxel give 24 hour 5-fluorouracil t-hdfl regimen 11 52 21 evaluable patient = 50 reduction prostate-specific antigen last 6 week 7 patient measurable disease 2 partial response median overall survival 14.1 month grade iii/iv leukopenia occur 2 patient treatment-related death toxicity well tolerate combined cytotoxicity paclitaxel 5-fluorouracil schedule dependent feasible administer weekly paclitaxel high-dose 5-fluorouracil infusion patient hormone-refractory prostate cancer finding may serve important rationale future trial design 
majority chronic phase chronic myeloid leukemia cml patient treat tyrosine kinase inhibitor tki imatinib mesylate maintain durable response drug however patient relapse withdrawal imatinib advanced stage patient often develop drug resistance cml consider hematopoietic stem cell cancer postulate inherent protective mechanism lead relapse patient atp binding-cassette transporter abcb1 mdr-1 p-glycoprotein abcg2 highly express primitive hematopoietic stem cell hsc show interact tki herein demonstrate dose-dependent reversible inhibition abcg2-mediated hoechst 33342 dye efflux primary human murine hsc imatinib nilotinib amn107 novel aminopyrimidine inhibitor bcr-abl abcg2-transduced k562 cell protect imatinib nilotinib-mediated cell death downregulation p-crkl moreover photoaffinity labeling reveal interaction tki abcg2 substrate binding site compete binding 125 iaap also stimulate transporter atpase activity therefore evidence suggest role abc transporter resistance tki primitive hsc cml stem cell provide rationale tki resistance overcome vivo 
important challenge better understand mechanism tyrosine kinase inhibitors-induced apoptosis cml cell thus investigate apoptosis modulate extracellular factor apoptosis induce imatinib nilotinib determine bcr-abl expressing cell line primary cml cd34 cell molecule induce apoptosis bcr-abl expressing cell apoptosis inhibit protein synthesis inhibition k562 cml cd34 cell k562 80 inhibition bcr-abl auto-phosphorylation either imatinib nilotinib induce two fold increase bim-el expression induction apoptosis 48 h. bim accumulation precede apoptosis induction completely abolish depletion bim use shrna however anti-proliferative effect imatinib preserve bim-depleted cell k562 cell culture cytokine contain medium pro-apoptotic effect nilotinib decrease 68 relate decrease bim-el dephosphorylation accumulation similarly presence combination cytokine inhibit 88 nil 39 ima-induced apoptosis primary cml cd34 cell conclusion nilotinib imatinib induce apoptosis bim accumulation independently cell cycle arrest however pro-apoptotic effect molecule attenuate presence cytokine growth factor particularly concern nilotinib thus bcr-abl inhibition restore cytokine dependence sufficient induce apoptosis signaling pathway activate 
effect multikinase inhibitor sorafenib bay 43-9006 agent show previously induce apoptosis human leukemia cell inhibition myeloid cell leukemia-1 mcl-1 translation examine bcr/abl leukemia cell resistant imatinib mesylate administer pharmacologically relevant concentration 10-15 microm sorafenib potently induce apoptosis imatinib mesylate-resistant cell express high level bcr/abl cell exhibit bcr/abl-independent lyn-dependent form resistance cd34 cell obtain imatinib-resistant patient addition ba/f3 cell express mutation render resistant e.g. e255k m351t dasatinib nilotinib t315i remain fully sensitive sorafenib induction apoptosis sorafenib associate rapid pronounced down-regulation mcl-1 diminish signal transducer activator transcription stat 5 phosphorylation reporter activity modest delay inactivation bcr/abl downstream target crkl moreover transfection constitutively active stat5 construct partially significantly protected cell sorafenib lethality ba/f3 cell express bcr/abl mutation sensitive sorafenib-induced mcl-1 down-regulation dephosphorylation stat5 eukaryotic initiation factor 4e wild-type cell finally stable knockdown bcl-2-interacting mediator cell death bim short hairpin rna k562 cell significantly diminish sorafenib lethality argue strongly functional role proapoptotic bcl-2 family member lethality agent together finding suggest sorafenib effectively induce apoptosis highly imatinib-resistant chronic myelogenous leukemia cell likely inhibit down-regulating target i.e. stat5 mcl-1 downstream independent bcr/abl 
effort improve cytotoxicity clinically use anticancer alkylating agent topoisomerase ii inhibitory drug u73-975 mitoxantrone add cell culture expose cddp carboplatin bcnu melphalan thiotepa mcf-7 human breast cancer cell line mcf-7 / cp cddp resistant subline u73-975 mitoxantrone potent cytotoxic agent ic50 0.002 microm 0.006 microm u73-975 respectively 0.8 microm 0.1 microm mitoxantrone respectively evaluate isobologram analysis addition either u73-975 mitoxantrone 1 h exposure cddp result greater-than-additive killing mcf-7 parent cell u73-975 also greater-than-additive cytotoxicity cddp mcf-7 / cp line mitoxantrone cddp additive cytotoxicity cell case carboplatin addition u73-975 mitoxantrone treatment drug result greater-than-additive cell killing mcf-7 parental cell line mcf-7 / cp cell line combination additive cell killing addition u73-975 treatment bcnu result additive cytotoxicity cell line however combination mitoxantrone bcnu result greater-than-additive cell killing parental cddp resistant cell line either u73-975 mitoxantrone add treatment melphalan greater-than-additive cytotoxicity result cell line except low melphalan concentration mcf-7 / cp cell line finally addition either modulator treatment thiotepa mcf-7 cell line produce variable interaction depend thiotepa concentration mcf-7 / cp cell line either modulator combination thiotepa cause greater-than-additive cell killing result indicate addition topoisomerase ii inhibitory drug may substantially increase cytotoxicity alkylating agent vivo experiment necessary however ascertain whether therapeutic gain achievable 
lipogenic enzyme fatty acid synthase fasn differentially overexpress hyperactivate biologically aggressive subset breast carcinoma minimally normal adult tissue render interesting target anti-neoplastic therapy development previously report fasn blockade induce synergistic chemosensitization breast cancer cell microtubule interfere agent mia docetaxel paclitaxel vinorelbine upon pharmacological inhibition fasn activity use natural antibiotic cerulenin 2s ,3 r -2,3-epoxy-4-oxo-7e ,10 e-dodecadienamide evaluate role fasn-catalyzed endogenous fatty acid biogenesis sensitivity sk-br3 mcf-7 mda-mb-231 breast cancer cell line anti-metabolite 5-fluorouracil 5-fu cell expose simultaneously cerulenin 5-fu sequentially 5-fu follow cerulenin cerulenin follow 5-fu cell viability determine mtt assay increase 5-fu-induced cell growth inhibition measure divide 5-fu ic30 ic50 value i.e. 30 50 inhibitory concentration respectively obtain absence cerulenin presence co-exposure cerulenin enhance 5-fu efficacy 20 81 58-time sk-br3 mcf-7 mda-mb-231 cell respectively pre-treatment cerulenin follow addition 5-fu increase 5-fu efficacy 31 87 126-time sk-br3 mcf-7 mda-mb-231 cell respectively pre-treatment 5-fu follow addition cerulenin augment 5-fu efficacy 107 20 18-time sk-br3 mcf-7 mda-mb-231 cell respectively isobologram transformation multiple dose-response analysis perform detect vitro synergy conclude nature interaction cerulenin 5-fu individual breast cancer cell line generally exhibit sequence-dependency thus synergism mainly observe breast cancer cell expose 5-fu prior cerulenin moderate synergism additive interaction obtain either chemical fasn blocker precede 5-fu drug concurrently administer note antagonist interaction occur upon schedule combined treatment cerulenin 5-fu current finding reveal schedule-dependent synergistic interaction 5-fu cerulenin represent best knowledge first evidence fasn-catalyzed de novo fa biogenesis play key role regulate breast cancer cell response antimetabolite-based therapy 
order develop model liver metastasis human gastrointestinal cancer cell examine potential 10 human colon stomach cancer cell line ht-29 widr hct-116 hct-15 hcc-2998 mkn7 mkn28 mkn45 mkn74 st-4 form liver metastase nude mouse among cell line hct-116 cell consistently form gross liver metastase inject spleen nude mouse contrast human colon stomach cancer cell produce little liver metastasis order analyze high metastatic potential hct-116 cell adhesion potential compare hct-116 cell colon cancer cell line hct-116 cell show efficient adhesion fibronectin fn cell furthermore fn enhance haptotaxis hct-116 cell colon cancer cell high adhesion potential fn enhance haptotaxis may contribute least part high metastatic potential hct-116 assess value newly develop model liver metastasis compare ability four anticancer drug fluorouracil doxifluridine paclitaxel irinotecan inhibit formation liver metastase paclitaxel irinotecan show strong inhibition liver metastasis fluorouracil doxifluridine show slight inhibition therefore model metastasis may useful screen anti-liver metastatic reagent result indicate hct-116 liver-metastasis model useful analyze molecular mechanism liver metastasis evaluate new anti-liver metastatic drug 
currently quantitative semiquantitative assay minimal residual disease detection include fluorescence situ hybridisation multiparameter flow cytometric immunophenotyping real-time quantitative polymerase chain reaction rq-pcr develop new approach detect hybrid breakpoint cluster region abelson proto-oncogene bcr-abl transcript inside suspension cell use situ rt-pcr light upon extension lux primer follow rapid quantitative analysis flow cytometry cellular permeabilization fixation single cell suspension neoplastic mrna reverse transcribe amplify pcr lux primer result demonstrate strong positive yellow-green signal observe 99-100 cell k562 cell line red nucleus detect nb4 cell line normal control technique utilise study 12 patient chronic myeloid leukemia result compare bcr-abl fusion mrna rt-pcr bcr-abl fusion gene interphase cell fluorescence situ hybridization fish five diagnose patient 90-98 cell strongly positive four patient include three patient treat interferon-alpha hydroxyurea one patient treat imatinib mesylate 26-82.5 positive cell three patient treat imatinib mesylate negative situ rt-pcr result demonstrate complete concordance result i-fish rt-pcr fluorescence signal detectable 1/10 4 cell become negative threshold flow cytometry result present study suggest 1 lux primer use efficiently detect bcr-abl fusion mrna in-cell rt-pcr 2 novel technique specific sensitive way detect fusion gene potential clinical usefulness 
aromatase inhibitor ai evaluate long-term adjuvant therapy chemopreventive breast cancer however concern bone mineral density loss estrogen-free environment unlike nonsteroidal ai steroidal ai exemestane may exert beneficial effect bone primary metabolite 17-hydroexemestane investigate 17-hydroexemestane observe bind estrogen receptor alpha eralpha weakly androgen receptor ar strongly next evaluate 17-hydroexemestane mcf-7 t47d breast cancer cell attribute dependency effect er ar use antiestrogen fulvestrant antiandrogen bicalutamide 17-hydroexemestane induce proliferation stimulate cell cycle progression regulated transcription high sub-micromolar micromolar concentration er cell line ar low nanomolar concentration selectively t47d cell response cell type high low concentration non-aromatizable synthetic androgen r1881 parallel 17-hydroexemestane 17-hydroexemestane down-regulate eralpha protein level high concentration cell type-specific manner similarly 17beta-estradiol increase ar protein accumulation low concentration cell type similarly r1881 computer docking indicate 17beta-oh group 17-hydroexemestane relative 17-keto group exemestane contribute significantly intermolecular interaction energy toward bind ar eralpha molecular modeling also indicate 17-hydroexemestane interact eralpha ar selective recognition motif employ 17beta-estradiol r1881 respectively conclude 17-hydroexemestane exert biological effect androgen result may important implication long-term maintenance patient ai 
resistance toward imatinib bcr/abl tyrosine kinase inhibitor remain increase clinical problem treatment advanced stage chronic myeloid leukemia cml recently identify heat shock protein 32 hsp32 / heme oxygenase-1 ho-1 bcr/abl-dependent survival molecule cml cell show silencing hsp32/ho -1 cml cell sirna approach result induction apoptosis moreover target hsp32/ho -1 either pegylate zinc protoporphyrine peg-znpp styrene maleic acid-micelle-encapsulated znpp sma-znpp result growth inhibition bcr/abl-transformed cell effect peg-znpp sma-znpp demonstrable ba/f3 cell carry various imatinib-resistant mutant bcr/abl include t315i mutant exhibit resistance clinically available bcr/abl tyrosine kinase inhibitor growth-inhibitory effect peg-znpp sma-znpp also observe cml-derived human cell line k562 ku812 well primary leukemic cell obtain patient freshly diagnose cml imatinib-resistant cml finally hsp32/ho -1-targeting compound find synergize either imatinib nilotinib produce growth inhibition imatinib-resistant k562 cell ba/f3 cell harbor t315i mutant bcr/abl summary datum show ho-1 promising novel target imatinib-resistant cml 
folylpolyglutamyl synthase fpgs convert intracellular folate antifolate polyglutamate polyglutamylate folate antifolate retain cell longer better substrate monoglutamate counterpart enzyme involve one-carbon transfer fpgs modulation affect chemosensitivity cancer cell antifolate methotrexate 5-fluorouracil 5fu alter polyglutamylation antifolate specific target intracellular folate cofactor however effect may counterbalance fpgs modulation-induced change polyglutamylation intracellular folate cofactor total intracellular folate pool generate vitro model fpgs overexpression inhibition breast cancer cell stably transfect human mda-mb-435 breast cancer cell sense fpgs cdna fpgs-targeted small interfere rna respectively investigate effect fpgs modulation chemosensitivity 5fu methotrexate fpgs modulation-induced change polyglutamylation antifolate folate cofactor intracellular folate pool affect chemosensitivity breast cancer cell pemetrexed trimetrexate whose cytotoxic effect depend polyglutamylation respectively predictable manner however effect fpgs modulation chemosensitivity breast cancer cell 5fu methotrexate seem highly complex depend polyglutamylation specific target intracellular folate cofactor methotrexate respectively also total intracellular folate pool polyglutamylation intracellular folate cofactor whether fpgs modulation may important clinical determinant chemosensitivity breast cancer cell 5fu methotrexate-based chemotherapy need exploration 
granulosa cell tumor ovary gct represent approximately 5 malignant ovarian tumor surgery remain primary modality therapy treatment option advanced disease limit molecular pathogenesis gct know likely involve activation tyrosine kinase-mediated cell signaling pathway recent case report patient advanced recurrent gct respond tyrosine kinase inhibitor imatinib mesylate prompt explore role therapy gct expression imatinib-sensitive tyrosine kinase c-kit c-abl pdgfr-alpha pdgfr-beta determine use rt-pcr panel gct activate mutation c-kit pdgfr-alpha also seek functional response examine two human-derived gct cell line four kinase express level lower observe pre-menopausal ovarian sample mutation c-kit pdgfr-alpha find cell line respond imatinib second generation tyrosine kinase inhibitor nilotinib dose-dependent decrease cell proliferation viability response parallel imatinib-sensitive k562 cell line approximately 240 approximately 1000-fold higher concentration imatinib nilotinib respectively study suggest human gct general unlikely respond imatinib nilotinib therapy response cell line high concentration imply off-target effect suggest tyrosine kinase inhibitor appropriate specificity may represent therapeutic option gct 
aim study investigate antiproliferative effect c-1311 symadex member imidazoacridinone family human colorectal cancer cell vitro screen c-1311 lead prominent growth inhibition ht29 hct116 colo205 cell line compare oxaliplatin cpt-11 dfur 5-fu capecitabine gi 50 value c-1311 range 0.12 0.83 microm tgi concentration result total growth inhibition 6 13-fold lower agent hollow fiber assay vivo c-1311 cause 77 growth inhibition ht29 intraperitoneal site compare paclitaxel 17 growth inhibition subcutaneous site c-1311 produce 57 growth inhibition paclitaxel show cell growth inhibition effect unique cytotoxicity profile c-1311 warrant investigation support clinical development colon cancer patient symadex c-1311 currently phase 2 clinical trial 
author report previous study nk012 7-ethyl-10-hydroxy-camptothecin sn-38 release nano-system exhibit high antitumor activity human colorectal cancer xenograft study conduct investigate advantage nk012 irinotecan hydrochloride cpt-11 administer combination 5-fluorouracil 5fu cytotoxic effect nk012 sn-38 active metabolite cpt-11 administer combination 5fu evaluate vitro human colorectal cancer cell line ht-29 combination index method effect drug combination also evaluate vivo use mouse bear ht-29 hct-116 cell drug administer i.v. 3 time week nk012 10 mg/kg cpt11 50 mg/kg give 24 hr 5fu 50 mg/kg cell cycle analysis ht-29 tumor administer nk012 cpt-11 vivo perform flow cytometry nk012 exert synergistic activity 5fu compare sn-38 therapeutic effect nk012/5fu significantly superior cpt-11 / 5fu ht-29 tumor p = 0.0004 whereas significant difference antitumor effect hct-116 tumor observe 2-drug combination p = 0.2230 cell-cycle analysis show nk012 cpt-11 tend cause accumulation cell s phase although effect pronounced maintain prolonged period nk012 cpt-11 optimal therapeutic synergy observe nk012 5fu therefore regimen consider hold promise clinical benefit especially patient colorectal cancer 
accumulate evidence mammalian target rapamycin mtor activate pathway play important role cell growth survival bcr-abl-transformed cell previously show mtor/p70 s6 kinase p70 s6k pathway constitutively activate bcr-abl transform cell inhibition bcr-abl kinase activity imatinib mesylate abrogate activation now provide evidence existence novel regulatory mechanism bcr-abl promote cell proliferation involve p70 s6k-mediated suppression expression program cell death 4 pdcd4 tumor suppressor protein act inhibitor cap-dependent translation block translation initiation factor eif4a datum also establish second generation bcr-abl kinase inhibitor block activation p70 s6k downstream engagement s6 ribosomal protein bcr-abl transform cell moreover pdcd4 protein expression up-regulate inhibition bcr-abl kinase k562 cell baf3/bcr-abl transfectant suggest mechanism generation proapoptotic effect inhibitor knockdown pdcd4 expression result reversal suppressive effect nilotinib imatinib mesylate leukemic progenitor colony formation suggest important role protein generation antileukemic response altogether study identify novel mechanism bcr-abl may promote leukemic cell growth involve sequential engagement mtor/p70 s6k pathway downstream suppression pdcd4 expression 
human glioma-derived cell line find vary ability incorporate radiosensitizer 5-bromo-2 deoxyuridine brdurd dna one cell doubling u-251 cell line best incorporator brdurd whereas u-118 d-54 demonstrate poor incorporation respective c50 brdurd concentration require 50 maximum amount brdurd incorporation dna value 2.8 6-fold greater u-251 p less 0.001 modulation radiosensitizer uptake dna achieve use thymidylate synthase inhibitor 5-fluorouracil 5-fluoro-2 deoxyuridine fdurd incorporation u-251 cell increase slightly presence fluoropyrimidine brdurd concentration require 50 maximum amount brdurd incorporation dna change p less 0.001 1.8 / 0.11 microm sd absence modulator 1.1 / 0.09 1.1 / 0.16 microm presence 10 microm 5-fluorouracil 5 nm fdurd respectively d-54 cell line worst incorporator brdurd find extensive amount brdurd dna following biomodulation c50 absence modulation 7.3 / 1.3 microm reduce p less 0.001 0.62 / 0.04 0.32 / 0.13 microm respectively presence 10 microm 5-fluorouracil 5 nm fdurd represent 12 22-fold reduction concentration radiosensitizer require achieve level brdurd incorporation dna furthermore enhancement brdurd dna incorporation see presence fluoropyrimidine observe clinically achievable concentration degree radiosensitization solely dependent upon amount brdurd incorporate dna d-54 cell grow presence 0.18 microm brdurd plus 5 nm fdurd 2.8 microm brdurd alone yield similar level brdurd incorporation dna radiosensitization though 15-fold lower brdurd concentration use presence fdurd combine use radiosensitizer fluoropyrimidine may overcome poor incorporation brdurd dna may exist among resistant subpopulation cell within malignant glioma 
introduction patupilone microtubule stabilizer mts currently clinical development evaluate anti-cancer activity vitro vivo comparison paclitaxel describe pharmacokinetic pk patupilone tumor-bearing nude mouse rat method potency vitro patupilone two mts paclitaxel ixabepilone determine use human colon carcinoma cell line low hct-116 ht-29 rko high hct-15 p-glycoprotein expression p-gp well two multi-drug resistance mdr model cell pair mcf7/adr kb-8511 cell respective drug-sensitive parental counterpart pk patupilone investigate nude mouse bear hct-15 ht-29 xenograft rat bear s.c. pancreatic ca20498 tumor a15 glioma tumor anti-cancer activity vivo compare paclitaxel use three different human tumor colon model retention efficacy patupilone compare small large ht-29 xenograft whose vascularity determine non-invasive magnetic resonance imaging result patupilone highly potent vitro four different colon carcinoma cell line include show multi-drug-resistance contrast paclitaxel ixabepilone display significantly reduce activity markedly increase resistance factor rat mouse single i.v. bolus injection patupilone 1.5-4 mg/kg rapidly distribute plasma tissue slowly eliminate muscle liver small intestine show longer retention tumor brain apparent elimination 24 h. patupilone show significant activity three human colon tumor model vivo unlike paclitaxel activity low p-gp express tumor ht-29 tumor patupilone activity retention independent tumor size blood volume flow conclusion high potency patupilone affect p-gp expression either vitro vivo favorable pk independent tumor vascularity suggest show significant activity colorectal cancer indication high p-gp expression may compromise taxane activity 
characterize change secretory clusterin sclu expression prostate cancer cell treatment docetaxel determine whether sclu knockdown re-introduce chemosensitivity docetaxel-resistant androgen-independent human prostate cancer model tissue microarray construct 84 radical prostatectomy rp specimen multicentre phase ii trial neoadjuvant combined androgen ablation docetaxel cuog-p01a assess change expression cytoprotective chaperone sclu human prostate cancer cell line pc-3 repeatedly expose docetaxel chemotherapy vitro docetaxel-resistant cell subline pc-3dr develop analyse sclu level significantly higher rp specimen treat neoadjuvant combined androgen ablation docetaxel untreated specimen similarly sclu expression increase 2.5-fold newly develop docetaxel-refractory pc-3dr cell line compare parental pc-3 cell dose-dependent sequence-specific decrease sclu level pc-3dr cell use ogx-011 antisense oligonucleotide human sclu ogx-011 small-interference rna chemosensitize pc-3dr cell docetaxel mitoxantrone vitro apoptotic rate pc-3dr cell significantly increase ogx-011 combine docetaxel vivo growth pc-3dr xenograft nude mouse synergistically inhibit ogx-011 combine paclitaxel mitoxantrone 76 44 compare mismatch control respectively present finding indicate target knockdown sclu enhance effect cytotoxic chemotherapy docetaxel-refractory cell provide preclinical proof principle clinical trial test ogx-011 second-line chemotherapy regimen patient docetaxel-refractory prostate cancer 
imatinib resistance chronic myeloid leukemia primarily cause re-establishment abl kinase new inhibitor may efficacious evaluate 3 new agent 2 new k562 variant im-r1 im-r2 cell develop 7 27-fold greater resistance respectively parental k562 cell variant possess bcr-abl gene amplification along elevated level transcript protein greater bcr-abl gene amplification observe im-r2 cell im-r1 cell consistent higher mrna protein level bcr-abl ultimately correlate greater resistance im-r2 cell mutation abl kinase domain detect either variant despite absence lyn overexpression src kinase inhibitor cgp76030 show positive cooperability inhibit cell growth k562 cell also 2 variant might augmented inhibition erk1/2 phosphorylation new abl kinase inhibitor nilotinib 10-fold potent inhibit growth k562 cell nilotinib inhibit growth im-r1 im-r2 cell potently k562 cell combination nilotinib cgp76030 show little additivity potency nilotinib mask efficacy cgp76030 new dual abl/lyn inhibitor inno-406 formerly ns-187 slightly potent nilotinib inhibit growth 3 cell line bcr-abl gene amplification occur blast crisis inhibitor might overcome resistance patient leukemia 
phenotypic functional difference cell initiate human breast tumor cancer stem cell comprise tumor bulk difficult study use primary tumor tissue embark study hypothesize breast cancer cell line contain analogous hierarchical differentiation program find primary breast tumor eight human breast cell line human mammary epithelial cell mcf10a mcf7 sum149 sum159 sum1315 mda.mb .231 cell analyze use flow cytometry cd44 cd24 epithelial-specific antigen esa expression limit dilution orthotopic injection use evaluate tumor initiation serial colony-forming unit reconstitution tumorsphere assay perform assess self-renewal differentiation pulse-chase bromodeoxyuridine 5-bromo-2-deoxyuridine brdu labeling use examine cell cycle label-retention cancer stem cell cell treat paclitaxel 5-fluorouracil test selective resistance chemotherapy gene expression profile chemotherapy examine percentage cd44 / cd24 cell within cell line correlate tumorigenicity 100 cell form tumor sort cd44 / cd24 / low/esa furthermore cd44 / cd24 / esa cell self-renew reconstitute parental cell line retain brdu label preferentially survive chemotherapy datum validate use cancer cell line model development testing novel therapeutics aim eradicate cancer stem cell 
bortezomib velcade r proteasome inhibitor approve fda treatment multiple myeloma mm effective use hamper peripheral neurotoxicity unexplained etiology since proteasome inhibitor alter protein degradation speculate protein regulate microtubule mt stability may affect treatment examine mt polymerization cell compare distribution tubulin polymerize p soluble s fraction observe increase mt polymerization follow treatment sy5y kcnr neuroblastoma hcn2 8226 mm cell use five proteasome inhibitor baseline proportion total alpha-tubulin p fraction range approximately 41-68 increase approximately 55-99 treatment increase acetylate alpha-tubulin post-translational marker stabilize mt observe neural cell line hcn1a hcn2 sustain 144 hour proteasome inhibitor remove cell cycle analysis three cell line treatment show approximately 50-75 increase g 2 m phase immunofluorescent localization study proteasome inhibitor treat cell reveal microtubule bundle contrast paclitaxel treat suggest mt stabilization via mechanism direct drug binding examine level microtubule associate protein observe 1.4-3.7 fold increase microtubule associate protein map2 hcn2 cell follow treatment proteasome inhibitor datum provide plausible explanation neurotoxicity observe clinically raise possibility microtubule stabilization contribute cytotoxicity 
despite promising result clinical study abl kinase inhibitor challenging problem remain t315i mutation neither nilotinib dasatinib show significant activity present study investigate activity novel aurora kinase inhibitor ve-465 leukemia cell express wild-type bcr-abl t315i mutant form bcr-abl observe dose-dependent reduction level bcr-abl autophosphorylation ve-465-treated cell exposure combination ve-465 imatinib exert enhance apoptotic effect k562 cell combined treatment ve-465 imatinib cause attenuation level phospho-akt c-myc k562 cell isobologram indicate synergistic effect simultaneous exposure ve-465 imatinib k562 cell assess vivo efficacy ve-465 athymic nude mouse inject intravenously baf3 cell express wild-type bcr-abl t315i mutant form vehicle-treated mouse die condition resemble acute leukemia 28 day however nearly mouse treat ve-465 75 mg/kg twice daily intraperitoneally 14 day survive 56 day histopathological analysis vehicle-treated mouse reveal infiltration spleen contrast histopathological analysis organ ve-465-treated mouse demonstrate normal tissue architecture take together present study show ve-465 exhibit desirable therapeutic index reduce vivo growth t315i mutant form wild-type bcr-abl-expressing cell efficacious manner 
acetazolomide acz dexamethasone dxm alleviate vasogenic edema inflammation glioblastoma patient temozolomide tmz use treat glioblastoma compare modulatory effect acz dxm tmz mediated apoptosis human glioblastoma t98g u87mg cell cell treat drug s 6 h leave drug-free medium 48 h. although acz dxm alone induce apoptosis tmz alone induce significant amount apoptosis interestingly acz pretreatment enhance apoptosis dxm pretreatment decrease apoptosis result suggest combination chemotherapy acz tmz may control inflammation enhance apoptosis glioblastoma 
background currently docetaxel use treat hormone-refractory metastatic prostate cancer docetaxel inhibit microtubule formation also downregulate expression bcl-2 known antiapoptotic oncogene furthermore 26s proteasome inhibitor bortezomib downregulate bcl-2 expression previously demonstrate overexpression bcl-2 render cell resistant radiation therapy study investigate whether treat human prostate cancer cell docetaxel bortezomib modulate bcl-2 expression whether modulation render bcl-2-overexpressing cell susceptible radiation method pc-3-bcl-2 pc-3-neo human prostate cancer cell treat docetaxel and/or bortezomib addition irradiation analyze vitro proliferation clonogenic survival cell cycle phase distribution expression bcl-2 bcl-xl protein result docetaxel bortezomib alone significant cytotoxic effect addition docetaxel bortezomib radiation result g2m phase arrest pc-3-bcl-2 whereas docetaxel radiation pc-3-neo cell cell line sensitize radiation killing effect treat combination docetaxel bortezomib treat either agent alone furthermore docetaxel bortezomib-treated cell exhibit marked change expression bcl-2 bcl-xl conclusion first study demonstrate docetaxel bortezomib combination effectively sensitize bcl-2-overexpressing human prostate cancer cell radiation effect modulate expression key member bcl-2 family together finding warrant evaluation combination docetaxel bortezomib prostate cancer 
doxorubicin dna-damaging drug commonly use treatment cancer patient doxorubicin cause cytotoxic cytostatic effect also inhibit metastasis formation tgfbeta1 transform growth factor-beta1 cytokine often up-regulate human cancer promote metastasis formation study influence doxorubicin tgfbeta signaling tumor cell demonstrate doxorubicin inhibit tgfbeta-signaling human lung adenocarcinoma a549 cell namely block tgfbeta1-induced activation smad3-responsive caga 12 luc reporter affect c-myc-luc reporter effect observe early 1-3 h treat cell doxorubicin drug cisplatin methotrexate alter activation caga 12 luc reporter condition besides 1 h action doxorubicin abrogate tgfbeta-induced translocation smad3-protein cytoplasm nucleus down-regulation expression smad2 smad3 smad4 protein up-regulation inhibitory smad7 protein upon doxorubicin treatment find 12-24 h doxorubicin treatment phosphorylation smad2/3 protein also affect doxorubicin summarize find human tumor cell treatment doxorubicin result inhibition tgfbeta-signaling early 1 h later 12 h stage drug action inhibition new potential mechanism doxorubicin action towards tumor cell 
increase 2 deoxy-2 18f fluoro-d-glucose fdg uptake commonly use marker positron emission tomography oncology however proliferation tracer 3 deoxy-3 18f fluorothymidine flt might specific cancer 3 deoxy-3 18f fluorothymidine uptake dependent thymidine kinase 1 tk activity effect chemotherapeutic agent unknown aim study characterise fdg flt uptake mechanism vitro exposure chemotherapeutic agent effect 5-fluorouracil 5-fu doxorubicin paclitaxel fdg flt uptake measure mda mb231 human breast cancer cell relation cell cycle distribution expression enzyme activity tk-1 ic50 concentration 5-fu result accumulation g1 phase doxorubicin paclitaxel induce g2/m accumulation compare untreated cell 5-fu doxorubicin increase tk-1 level 300 72 h 5-fu decrease fdg uptake 50 flt uptake 54 whereas doxorubicin increase fdg flt uptake 71 173 respectively paclitaxel increase fdg uptake 100 48 h whereas flt uptake hardly change conclusion various chemotherapeutic agent commonly use treatment breast cancer different effect time course uptake fdg flt vitro might implication interpretation clinical finding 
recent phase ii randomised trial colorectal cancer fail demonstrate advantage celecoxib combine standard chemotherapy author even report addition celecoxib irinotecan oxaliplatin colon cancer result inferior response rate observation lead hypothesis pharmacokinetic interaction celecoxib chemotherapeutic drug aim study investigate induction celecoxib multidrug resistance protein mrp1 mrp2 mrp4 mrp5 involve transport irinotecan 5-fu widr colo-205 cell treat celecoxib clinically relevant concentration viability assay perform treat cell chemotherapy alone chemotherapy plus celecoxib expression mrp1 mrp2 mrp4 mrp5 analyse rt-pcr western blot analysis sub cellular localization mrp4 mrp5 investigate cryoimmunoelectron microscopy cell line celecoxib induce mrp4 mrp5 over-expression rna protein level induction mrp1 mrp2 observe treated cell compare control cryoimmunoelectron microscopy show increase mrp4 mrp5 immunolabeling celecoxib treat cell cytoplasmic level along plasma membrane finding suggest low response rate observe clinical trial use celecoxib add 5-fluorouracil irinotecan may reflect celecoxib-mediated extrusion chemotherapeutic drug cancer cell regulation atp-binding cassette protein finding together result clinical trial may suggest combine use celecoxib drug substrate mrp4/mrp5 avoid 
dna damage checkpoint pathway activate cell halt cell cycle thus ensure repair induce cell death better investigate role checkpoint kinase 1 chk1 cellular response different anticancer agent chk1 knock hct-116 cell line p53-deficient subline use small interfere rna sirna chk1 abrogate transient transfection specific sirna stable tetracycline-inducible chk1 sirna clone obtain transfect cell plasmid express two sirna chk1 validate inducible system translate vivo setting transplant inducible clone nude mouse transient chk1 down-regulation sensitize hct-116 cell p53 / p53 wild-type counterpart dna-damaging agent 5-fluorouracil 5-fu doxorubicin etoposide treatment modification taxol ps341 cytotoxic activity inhibition chk1 protein level inducible clone induction doxycycline correlate increase cisplatin 5-fu activity effect evident p53-deficient background clone transplant nude mouse clear chk1 down-regulation show tumor sample mouse give tetracycline drinking water immunohistochemical detection chk1 protein importantly increase 5-fu antitumor activity find tumor double chk1 p53 silencing finding corroborate fact chk1 protein molecular target inhibit tumor defective g1 checkpoint increase selectivity anticancer treatment 
overview present approach inhibition de novo salvage pathway pyrimidine purine metabolism 1 combination acivicin inhibitor de novo biosynthesis dipyridamole transport inhibitor provide synergistic cytotoxicity hepatoma colon carcinoma cell 2 azt competitive inhibitor salvage enzyme thymidine kinase 5-fu mtx provide synergistic cytotoxicity hepatoma 3924a human colon carcinoma ht-29 cell azt methotrexate yield synergistic cytotoxicity thymidine hypoxanthine together provide protection action drug 3 observation significant rat hepatoma 3924a human cell line ht-29 hl-60 k562 thymidine kinase activity 16 67-fold higher dtmp synthase therefore inhibition dtmp synthase activity alone may provide poor response salvage pathway circumvent block 4 leukemic patient treat tiazofurin inhibitor imp dehydrogenase rate-limiting enzyme gtp biosynthesis allopurinol inhibit gprt activity raise plasma hypoxanthine level synergistic therapeutic result obtain response sensitive patient entail decrease imp dehydrogenase activity gtp concentration leukemic cell down-regulation ras myc oncogene down-regulation ras oncogene tiazofurin decrease gtp concentration now show k562 hl-60 hepatoma cell patient chronic granulocytic leukemia blast crisis tiazofurin may useful study selective depression expression ras oncogene 5 27 consecutive patient 50 respond positively tiazofurin treatment group 10 12 patient 83 chronic granulocytic leukemia blast crisis respond tiazofurin treatment 
therapy prostate cancer base fas cd95 modulation active development preclinical stage use immortalize cell line address clinical applicability potential 11 culture primary prostate cancer cell kill fas-mediated apoptosis investigate addition effect chemotherapeutic agent mitoxantrone docetaxel killing determine apoptosis induce patient-derived primary prostate cancer cell use effector cell engineer recombinant lentivirus infection express fas ligand fasl measure 51cr release assay culture prostate cell find undergo fas-mediated killing cytotoxicity range 12 87 6 h cell significantly sensitive fasl-mediated killing pc-3 cell basal expression fas expression five inhibitor apoptosis c-flip survivin cellular inhibitor apoptosis protein 1 2 bcl-2 find correlate susceptibility fas-mediated killing mitoxantrone docetaxel able induce fas receptor expression primary prostate cancer cell translate 1.5 3-fold enhancement apoptosis mediate fasl whereas mitoxantrone increase fas-induced apoptotic response culture prostate cell test docetaxel pretreatment find preferentially enhance killing bcl-2-expressing cell finding show culture primary prostate cancer cell sensitive fas-mediated apoptosis furthermore incidence apoptosis find improve combine fas-mediated therapy standard chemotherapeutic agent finding may significant implication prostate cancer therapy 
alteration chemosensitivity associate transformation rat 3y1 fibroblast compare among various agent include either adenovirus type 12 ad12-3y1 e1a region adenovirus type 12 e1a-3y1 mouse polyoma virus py-3y1 simian virus 40 sv-3y1 rous avian sarcoma virus sr-3y1 plasmid dna carry v-ha-ras oncogene hr-3y1 n-methyl-n nitro-n-nitrosoguanidine ng-3y1 untransformed 3y1 fibroblast use semiautomated non-clonogenic mtt assay ic50 value compare drug cell line among different cell line untransformed 3y1 cell resistant cisplatin cddp adriamycin adm carboquone cq bleomycin blm mitomycin c mmc 4-hydroperoxy cyclophosphamide 4-hp-cpa hand e1a-3y1 cell resistant vincristine vcr ng-3y1 ad12-3y1 resistant 5-fluorouracil 5-fu untransformed 3y1 cell transform line display cross-resistance drug dissociation chemosensitivity ad12-3y1 e1a-3y1 adm vcr 5-fu recognize result suggest transform agent may alter chemosensitivity anticancer drug 
signal pathway inhibitor spi design act synergistically conventional cytotoxic drug control cancer progression objective study evaluate effect various spi alone combination cisplatin three different non-small cell lung cancer nsclc cell line cell line a549 201t 273t represent nsclc treat 72 h presence absence inhibitor pi3k ly-294002 tocris bioscience ellisville mo bcl-2 gossypol sigma-aldrich st. louis mo cox-2 ns-398 sigma-aldrich celecoxib pfizer mapk u0126 sigma-aldrich egfr iressa astrazeneca macclesfield united kingdom alone combination 10 30 mum cisplatin sigma-aldrich 18 possible regimen cell line mtt assay trevigen gaithersburg md use measure cytotoxicity controls represent cell either pure culture medium monotherapy regimen control culture medium corresponding dose cisplatin combination regimen control unpaired t-test use classify response therapy highly sensitive p 0.01 sensitive 0.01 = p 0.05 resistant p = 0.05 concordance define similar response category cell line concordance rate 50 three cell line spi use monotherapy combination regimen concordance rate 33 a549 273t 17 a549 201t 75 273t 201t 273t cell susceptible therapy 11 61 highly sensitive response whereas a549 cell least susceptible 14 78 resistant response substantial degree variability nsclc cell line response spi alone combination cisplatin 
explore sensitivity ovarian cancer cell line skov3 paclitaxel proteasome inhibitor bortezomib combination methyl thiazolyl tetrazolium mtt assay apply examine cell viability treatment annexin v-propidium iodide apoptosis detection kit use determine apoptosis rate different group western blot assay use evaluate expression level phosphorylate protein kinase b akt glycogen synthase kinase-3 beta gsk-3beta mtt assay cell viability ratio combination group serial time point 12 24 36 48 72 hour 65.2 / 5.8 58.3 / 14.4 35.3 / 5.0 19.2 / 1.5 11.4 / 2.5 significantly lower paclitaxel group p 0.05 drug treatment apoptosis rate paclitaxel group bortezomib group combination group 14.7 / 0.5 15.1 / 0.8 20.5 / 0.7 respectively rate combination group significantly higher non-treated group paclitaxel group p 0.05 western blot assay show change expression level phosphorylate akt gsk-3beta decrease significantly paclitaxel bortezomib combination treatment 3.2 / 0.8 19.3 / 0.4 p 0.05 lethal effect paclitaxel tumor cell increase significantly combination proteasome inhibitor bortezomib akt/gsk -3 beta signaling pathway play important role molecular mechanism combination treatment 
previous study group show expression level orc6 highly elevated colorectal cancer patient specimen induction orc6 associate 5-fluorouracil 5-fu treatment goal study investigate molecular cellular impact orc6 colon cancer study use hct116 wt-p53 hct116 null-p53 colon cancer cell line model system investigate impact orc6 cell proliferation chemosensitivity pathway involve orc6 demonstrate regulation orc6 sensitize colon cancer cell 5-fu cisplatin cis-pt treatment decrease orc6 expression hct-116 wt-p53 cell rna interference trigger cell cycle arrest g1 phase prolonged inhibition orc6 expression result multinucleated cell hct-116 wt-p53 cell line western immunoblot analysis show regulation orc6 induce p21 expression hct-116 wt-p53 cell induction p21 mediate increase level phosphorylate p53 ser-15 contrast elevated expression p21 hct-116 null-p53 cell orc6 regulation also increase expression dna damaging repair protein gadd45beta reduce expression level jnk1 orc6 may potential novel target future anti cancer therapeutic development colon cancer 
background present study explore efficacy toxicity combine new non-toxic cancer treatment modality term tumor treat fields ttfield chemotherapeutic treatment in-vitro in-vivo pilot clinical trial method cell proliferation culture study human breast carcinoma mda-mb-231 human glioma u-118 cell line expose ttfield paclitaxel doxorubicin cyclophosphamide dacarbazine dtic separately combination addition study effect combine chemotherapy ttfield animal tumor model pilot clinical trial recurrent newly diagnose gbm patient result efficacy ttfields-chemotherapy combination in-vitro find additive tendency towards synergism drug cell line test combination index = 1 sensitivity chemotherapeutic treatment increase 1-3 order magnitude adjuvant ttfields therapy dose reduction index 23 1316 similar finding see animal tumor model finally 20 gbm patient treat ttfield median duration 1 year ttfields related systemic toxicity observe patient increase temozolomide toxicity see patient receive combined treatment newly diagnose gbm patient combine ttfield temozolomide treatment lead progression free survival 155 week overall survival 39 month conclusion result indicate combine chemotherapeutic cancer treatment ttfield may increase chemotherapeutic efficacy sensitivity without increase treatment related toxicity 
notch signaling implicate colon cancer tumorigenesis protect cell apoptosis induce prosurvival target hypothesize inhibition notch signaling gamma-secretase inhibitor gsi may enhance chemosensitivity colon cancer cell first show notch-1 receptor well downstream target hes-1 up-regulate colon cancer progression similar gene involve chemoresistance report chemotherapy induce notch-1 oxaliplatin 5-fluorouracil 5-fu sn-38 active metabolite irinotecan induce notch-1 intracellular domain nicd protein activate hes-1 induction nicd oxaliplatin cause increase activity expression gamma-secretase complex suppression protein subunit nicastrin small interfere rna sirna prevent nicd induction oxaliplatin subsequent inhibition notch-1 signaling sulfonamide gsi gsi34 prevent induction nicd chemotherapy blunt hes-1 activation block activation notch signaling gsi34 sensitize cell chemotherapy synergistic oxaliplatin 5-fu sn-38 chemosensitization mediate notch-1 inhibition notch-1 sirna enhance chemosensitivity whereas overexpression nicd increase chemoresistance down-regulation notch signaling also prevent induction prosurvival pathway notably phosphoinositide kinase-3 / akt oxaliplatin summary colon cancer cell may up-regulate notch-1 protective mechanism response chemotherapy therefore combine gsis chemotherapy may represent novel approach treat metastatic colon cancer mitigate development chemoresistance 
p21 waf1 p21 describe cyclin-dependent kinase inhibitor p21 activity subsequently describe include ability inhibit apoptosis model comparative work human colon cancer isogenic cell line hct116 hct116p21 / lead proposal p21 protect colon cancer cell apoptosis genotoxic drug ask whether p21 also protect cell death induce non-genotoxic drug tyrosine kinase inhibitor find p21-deficient cell dramatically sensitive towards imatinib gefitinib parental cell interestingly hct116p21 / also show higher basal activity protein kinase c-abl c-src akt generate hct116p21 / subline inducible p21 expression find p21 rescue hypersensitivity imatinib moreover down-regulation p21 enforce c-myc expression p21 sirna sensitize parental hct116 cell find hct116p21 / cell p53 show higher stability higher transcriptional activity phosphorylation serine associate p53 activity furthermore silencing p53 sirna inactivation p53 dominant negative mutant rescue hypersensitive response kinase inhibitor 5-fluorouracil adriamycin hct116p21 / cell consistently hct116p53 / cell resistant imatinib parental cell suggest imatinib activity partly dependent p53 colon cancer cell conclude high p53 activity rather p21 deficiency mechanism responsible hypersensitivity drug hct116p21 / cell therefore role p21 apoptosis hct116 colon cancer cell re-evaluate 
imatinib effective first-line therapy chronic myelogenous leukemia cml act target tyrosine kinase activity bcr-abl overcome resistance second-generation inhibitor bcr-abl develop among nilotinib potent bcr-abl imatinib effective many imatinib-resistant bcr-abl mutant study vitro flow cytometry assay analyze imatinib nilotinib-induced apoptosis cml cell develop drug induce significant apoptosis cd34 cell 36 cml bone marrow sample p 10 -4 whereas cd34 cell bcr-abl negative sample unaffected experiment carry presence cocktail cytokine nilotinib imatinib-induced apoptosis inhibit differential inhibition confirm k562 cell block anti-cd117 antibody alleviate antiapoptotic effect cytokine nilotinib moreover use short hairpin rna bcr-abl show k562 cell dependent bcr-abl signaling long stem cell factor scf receptor pathway activate conclude c-kit pathway may substitute bcr-abl tyrosine kinase activate survival signal c-kit must inhibit besides bcr-abl allow apoptosis cml cell 
study evaluate mechanistic difference pralatrexate methotrexate pemetrex inhibition dihydrofolate reductase dhfr quantify use recombinant human dhfr cellular uptake folylpolyglutamate synthetase fpgs activity determine use radiolabele pralatrexate methotrexate pemetrex nci-h460 non-small cell lung cancer nsclc cell tumor growth inhibition tgi assess use mv522 nci-h460 human nsclc xenograft apparent k value dhfr inhibition 45 26 200 nm pralatrexate methotrexate pemetrex respectively significantly greater percentage radiolabele pralatrexate enter cell polyglutamylatate relative methotrexate pemetrex vivo pralatrexate show superior anti-tumor activity nsclc model effective dose-dependent tgi rapidly grow nci-h460 xenograft pralatrexate demonstrate distinct mechanistic anti-tumor activity profile relative methotrexate pemetrex pralatrexate exhibit enhance cellular uptake increase polyglutamylation correlate increase tgi nsclc xenograft model 
pemetrex docetaxel show clinical activity variety solid tumor include lung cancer identify optimal schedule combination cytotoxic interaction pemetrexed docetaxel study various schedule use three human lung cancer cell line a-549 lu-99 sbc-5 vitro cell incubate pemetrexed docetaxel simultaneously 24 120 h. cell also incubate pemetrex 24 h follow 24 h exposure docetaxel vice versa growth inhibition determine use 3 4,5-dimethylthiazol-2-yl -2,5-diphenyltetrazolium bromide mtt assay cell cycle analysis cytotoxic interaction evaluate isobologram method simultaneous exposure pemetrexed docetaxel 24 120 h produce antagonistic effect three cell line pemetrex 24 h follow docetaxel 24 h produce additive effect a-549 cell synergistic effect lu-99 sbc-5 cell docetaxel follow pemetrex produce additive effect a-549 lu-99 cell antagonistic effect sbc-5 cell result cell cycle analysis fully consistent isobologram analysis provide molecular basis sequence-dependent difference cytotoxic interaction two agent sequential administration pemetrexed follow docetaxel may provide greatest anti-tumor effect combination treatment lung cancer 
increase resistance imatinib emerge problem patient chronic myeloid leukemia cml aim study ass mechanism relate cellular drug resistance imatinib-resistant derivate chronic myeloid leukemia k-562 cell line parental k-562 imatinib-resistant derivate cell line use cell line test cytotoxicity imatinib cytarabine busulfan etoposide mtt assay cytotoxicity express ic50 inhibitory concentration 50 cell multidrug resistance protein expression rhodamine retention daunorubicin accumulation measure cell line continuous exposition k-562 cell line 0.01-0.02 mm imatinib result development resistance exposition 0.1 microm imatinib increase cell sensitivity drug high correlation pgp mrp1 lrp expression ic50 value imatinib etoposide test cell line highly resistant cytarabine rhodamine retention alone presence cyclosporine lowest imatinib-resistant k-562r-0.1 cell line suggest high pgp activity cell line highest daunorubicin accumulation observe parental k-562 cell line lower imatinib-resistant cell line datum suggest imatinib substrate multidrug resistance protein increase expression pgp mrp1 lrp play role resistance imatinib cml imatinib multidrug resistance protein chronic myeloid leukemia pgp mrp1 lrp 
previously synthesize series hydrazide class compound examine cytotoxicity number cancer cell line among analogue sc144 exhibit potent cytotoxicity panel drug-sensitive drug-resistant cancer cell line explore therapeutic potential combination setting evaluate synergy sc144 select conventional chemotherapeutic agent in-vitro cancer cell model sc144 show synergism 5-fluorouracil oxaliplatin cotreate colorectal cancer ht29 cell pretreatment sc144 oxaliplatin-resistant htoxar3 cell effective oxaliplatin pretreatment addition combination sc144 paclitaxel exhibit synergism mda-mb-435 cell schedule-dependent block cell cycle mda-mb-435 mouse xenograft model coadministration sc144 paclitaxel delay tumor growth sc144 dose-dependent manner evaluation pharmacokinetic sc144 reveal intraperitoneal administration sc144 show two-compartmental pharmacokinetic elimination profile observe oral dosing summary study validate sc144 novel anticancer agent provide insight develop combination therapy drug-sensitive drug-resistant cancer 
aurora kinase play key role regulate centrosome maturation mitotic spindle formation cytokinesis cell division consider promising drug target due frequent overexpression variety human cancer sns-314 selective potent pan aurora inhibitor currently dose escalation phase 1 clinical trial treatment patient advanced solid tumor report antiproliferative effect sns-314 combination common chemotherapeutic cell culture xenograft model hct116 colorectal carcinoma cell line intact deplete p53 protein level treat sns-314 cytotoxic chemotherapeutic panel comprise gemcitabine 5-fluorouracil 5-fu carboplatin daunomycin sn-38 active metabolite irinotecan docetaxel vincristine combination administer either concurrent sequential schedule sns-314 predominantly additive effect administer concurrently commonly use anticancer agent sequential administration sns-314 chemotherapeutic compound show additive antiproliferative effect carboplatin gemcitabine 5-fu daunomycin sn-38 synergy observe combination gemcitabine docetaxel vincristine profound antiproliferative effect observe sequential administration sns-314 follow docetaxel vincristine vivo sns-314 potentiate antitumor activity docetaxel xenograft vitro synergy observe sns-314 agent target mitotic spindle potentiation see docetaxel vivo consistent mechanism action aurora inhibition bypass mitotic spindle assembly checkpoint prevent cytokinesis augment subsequent spindle toxin-mediated mitotic catastrophe cell death 
previously demonstrate abl kinase highly active invasive breast cancer cell line contribute survival response nutrient deprivation invasion proliferation determine whether abl kinase inhibitor sti571 gleevec imatinib mesylate sensitize breast cancer cell chemotherapeutic agent treat three breast cancer cell line bt-549 mda-mb-231 mda-mb-468 active abl kinase sti571 combination several conventional chemotherapeutic drug frequently use treat breast cancer assess effect cell viability proliferation apoptosis find sti571 synergistic effect cisplatin bt-549 extent mda-mb-468 cell synergize camptothecin use alternate dosing regimen mda-mb-231 cell sti571 synergistically sensitize mda-mb-468 cell paclitaxel high dose 5-fluorouracil significantly sti571 increase ability cisplatin inhibit constitutive activation pi3k/akt bt-549 cell synergize camptothecin increase stability ikappab mda-mb-231 cell mda-mb-468 cell camptothecin 5-fluorouracil inhibit sti571-dependent activation stat3 cell line/drug combination sti571 additive antagonistic effect indicate ability sti571 sensitize breast cancer cell chemotherapeutic agent cell type-dependent significantly unlike cisplatin paclitaxel camptothecin mechloroethamine strongly antagonistic sti571 effect cell line-dependent take together datum indicate cellular milieu govern response breast cancer cell sti571/chemotherapeutic combination regimen suggest treatment combination require individualization 
src signaling implicate several malignancy include melanoma prevalence src activation human melanoma effect newer src inhibitor dasatinib bosutinib ski-606 single agent combination melanoma cell line well establish melanoma cell line a-375 sk-mel-5 sk-mel-28 activity src inhibitor assess alone combination standard chemotherapy agent 50 growth inhibitory concentration determine mts assay immunoblotting use measure src activation downstream signaling stain src activation measure src-phosphotyrosine 416 immunohistochemistry perform primary cutaneous mucosal metastatic melanoma src inhibitor block growth melanoma cell line furthermore src inhibitor treatment synergize cisplatin temozolomide paclitaxel treatment dasatanib increase level ps473 akt a-375 melanoma cell two cell line forty-eight percent 17 35 melanoma stain weakly moderately strongly py416 src cutaneous 61 eight 13 mucosal 31 four 13 metastatic 55 five nine positive biopsy stain weakly one metastatic melanoma specimen stain strongly src-phosphotyrosine 416 py416 src express cutaneous mucosal metastatic melanoma various degree src inhibitor may promising therapy melanoma either combination chemotherapy especially platinum compound inhibitor akt/pi3k pathway 
gene methylthioadenosine phosphorylase mtap lie 9p21 close gene cdkn2a encode tumor suppressor protein p16 p14arf mtap cdkn2a homozygously co-deleted frequency 35 70 lung pancreatic cancer glioblastoma osteosarcoma soft-tissue sarcoma mesothelioma t-cell acute lymphoblastic leukemia normal cell tumor cell lack mtap mtap cleave natural substrate 5 deoxy-5 methylthioadenosine mta adenine 5-methylthioribose-1-phosphate mtr-1-p convert adenine nucleotide methionine distinct difference normal mtap-positive cell tumor mtap-negative cell lead several proposal therapy offer novel strategy mta toxic adenine analog 2,6-diaminopurine dap 6-methylpurine mep 2-fluoroadenine f-ade administer mtap-positive cell abundant adenine generate supply mta competitively block conversion analog adenine phosphoribosyltransferase aprt active nucleotide form mtap-negative tumor cell supply mta generate adenine hence conversion analog block show combination treatment -- adenine analog plus mta -- kill mtap-negative a549 lung tumor cell mtap-positive human fibroblast hf protect co-culture breast tumor cell line mcf-7 hf cell mcf-7 inhibit kill hf cell proliferate robustly 5-fluorouracil 5-fu 6-thioguanine 6-tg may also use strategy though neither analog activate aprt mtap-positive cell adenine produce supply mta block conversion 5-fu 6-tg toxic nucleotide form compete 5-phosphoribosyl-1-pyrophosphate prpp combination mta 5-fu 6-tg treatment mtap-negative tumor may produce significantly improve therapeutic index describe selective strategy kill tumor cell lack mtap 
human interferon-beta ifn-beta know exhibit pleiotropic biological activity include antitumor effect hand temozolomide tmz oral bioavailable alkylating agent excellent tolerability demonstrate efficacy become key therapeutic agent patient malignant glioma however survival benefit remain unsatisfactory recent study indicate might favorable therapeutic interaction ifn-beta tmz although therapeutic advantage combination yet fully explore main aim present study determine whether antitumor effect potentiate combination ifn-beta tmz antitumor effect cell sensitivity ifn-beta tmz synergistic potential ifn-beta tmz combination evaluate six malignant glioma cell line correlation among mgmt methylation status quantitative level mgmt mrna mgmt protein expression antitumor effect agent also evaluate since one prominent resistance mechanism tmz involve dna repair protein mgmt cell growth inhibitory effect ifn-beta tmz tumor cell line observe dose-dependent manner human malignant glioma-derived cell line differ sensitivity tmz mgmt status include promoter hypermethylation quantitative mrna expression protein expression strongly correlate tmz sensitivity synergistic cell growth inhibitory effect down-regulate mgmt mrna level significantly observe clinically achievable cns dose ifn-beta combine tmz compare treatment ifn-beta tmz alone tmz-resistant t98g cell furthermore significant amount endogenous ifn-beta protein detect tmz-treated t98g cell elisa result suggest clinical therapeutic efficacy tmz might improve combination ifn-beta malignant glioma unmethylate mgmt gene datum provide experimental basis future strategy tmz chemotherapy although study need determine detailed role combined ifn-beta tmz chemotherapy increase tumor sensitivity 
triphenyltin iv complex composition ph 3 snl 1 h n 1 ph 3 snl 2 h n 2 l 1 h = 2 e -2 3-formyl-4-hydroxyphenyl -1-diazenyl benzoate l 2 h = 2 e -2 4-hydroxy-5-methylphenyl -1-diazenyl benzoate synthesize characterize spectroscopic 1 h 13 c 119 sn nmr ir 119 sn mössbauer technique combination elemental analysis molecular structure geometry complex 1 2 fully optimize use quantum mechanical method pm3 complex 1 2 find exhibit stronger cytotoxic activity vitro across panel human tumour cell line viz. a498 evsa-t h226 igrov m19 mel mcf-7 widr test compound 1 2 exhibit comparable result compound find far superior ccdp cisplatin 5-fu 5-fluorouracil eto etoposide across panel cell line activity pronounced a498 22 fold h226 33 fold cell line compare ccdp a498 13 fold h226 39 fold mcf-7 33 fold cell line compare eto test compound even 23 fold active magnitude term id 50 value least h226 cell line compare mtx methotrexate mechanistic role cytotoxic activity test compound 1 2 discuss relation theoretical result docking study key enzyme ribonucleotide reductase thymidylate synthase thymidylate phosphorylase topoisomerase ii 
polyamine analogue demonstrate significant activity human breast cancer cell line single agent well combination cytotoxic drug study evaluate ability polyamine analogue n 1 n 11 bis ethyl norspermine benspm synergize six standard chemotherapeutic agent 5-fluorouracil fu fluorodeoxyuridine cis-diaminechloroplatinum ii c-ddp paclitaxel docetaxel vinorelbine four human breast cancer cell line mda-mb-231 mcf-7 hs578t t47d one immortalize non-tumorigenic mammary epithelial cell line mcf-10a use vitro combination study benspm cytotoxic drug xenograft mouse model generate mda-mb-231 cell use vivo study benspm paclitaxel benspm exhibit synergistic inhibitory effect cell proliferation combination 5-fu paclitaxel human breast cancer cell line mda-mb-231 mcf-7 either antagonistic less effective non-tumorigenic mcf-10a cell line synergism highest 120 h concomitant treatment pre-treatment benspm 24 h follow concomitant treatment 96 additional hour since cytotoxic effect many polyamine analogue cytotoxic agent believe act part induction polyamine catabolic enzyme ssat smo role enzyme synergistic response evaluate mda-mb-231 mcf-7 treat benspm 5-fu paclitaxel combination treatment benspm 5-fu paclitaxel result induction ssat mrna activity cell line compare either drug alone smo mrna activity increase mda-mb-231 cell induction greater benspm/paclitaxel combination benspm/5-fu rnai study demonstrate ssat smo play significant role response mda-mb-231 cell treatment benspm 5-fu paclitaxel mcf-7 cell ssat appear involve response treatment effort translate combination study vitro vivo form basis clinical setting vivo therapeutic efficacy benspm alone combination paclitaxel tumor regression evaluate xenograft mouse model generate mda-mb-231 cell intraperitoneal exposure benspm taxol singly combination 4 week result significant inhibition tumor growth finding help elucidate mechanism involve synergistic drug response support combination polyamine analogue chemotherapeutic agent potentially use treatment breast cancer 
investigate various combination treatment regimen employ nilotinib established chemotherapeutic agent daunorubicin mitoxantrone etoposide cytarabine imatinib-sensitive resistant bcr-abl-positive cell mitoxantrone cytarabine show synergism ci 1 combination nilotinib imatinib-sensitive lama84 cell whereas imatinib-resistant lama84-r cell synergistic effect assess daunorubicin mitoxantrone etoposide combine nilotinib imatinib-sensitive resistant k562 cell daunorubicin mitoxantrone etoposide demonstrate synergism combination nilotinib moreover daunorubicin mitoxantrone lead synergistic antiproliferative effect combine nilotinib imatinib-resistant ba/f3 cell carry point mutation abl tk domain e255k e255v t315i annexin v/propidium iodide staining reveal significant enhancement nilotinib-induced apoptosis imatinib-resistant ba/f3t315i lama84-r cell upon combination daunorubicin mitoxantrone respectively result demonstrate efficacy combination treatment regimen employ nilotinib established chemotherapeutic agent improve antileukemic effect imatinib-sensitive imatinib-resistant cell may foundation study potential apply combination clinical setting 
growth-inhibitory effect fluoropyrimidine combine short-term exposure leucovorin pattern polyglutamylation folate compare parental ccrf-cem cell cell line impaired ability form polyglutamate ccrf-cem/p combination leucovorin 5-fluorouracil 5-fluorodeoxyuridine increase growth inhibition ccrf-cem cell compare fluoropyrimidine alone parent cell line ccrf-cem/p cell addition leucovorin produce significant increase inhibition intracellular thymidylate synthase activity cause 5-fluorouracil 5-fluorodeoxyuridine compare drug alone ccrf-cem cell increase inhibition produce single drug alone observe ccrf-cem/p cell although level 5,10-methylene tetrahydrofolate leucovorin administration similar cell line polyglutamylation coenzyme decrease ccrf-cem/p cell line inability ccrf-cem/p cell form significant level polyglutamate n5,n10-methylenete-trahydrofolate may responsible lack enhance cell kill observe short exposure leucovorin use fluoropyrimidine 
plant use drug century however limited research great potential source new therapeutic agent purpose study evaluate physalis peruviana cytotoxic activity cell line ht-29 pc-3 k-562 vero ht-29 cell line pc-3 k-562 vero expose four concentration p. peruviana ethanolic leave stem extract also different concentration cisplatin 5-fluorouracil 5-fu use positive control find rate growth within 48 hour determine inhibitory concentration 50 ic50 use linear regression analysis index selectivity sample p. peruviana ethanolic leave stem extract show cytotoxic activity ic50 g/ml leaf stem 0.35 r = -0.95 p 0.025 0.37 r = 0.90 p 0.05 ht-29 0.87 r = -0.98 p 0.01 1.01 r = -0.95 p 0.025 pc-3 0.02 r = -0.98 p 0.01 0.03 r = -0.98 p 0.01 k-562 4.9 r = -0.95 p 0.025 6.2 r = -0.98 p 0.01 vero ic50 antineoplastic cisplatin 4.2 r = -0.96 p 0.025 10.3 r = -0.97 p 0.025 0.15 r = -0.98 p = 0.01 1.1 r = 0.98 p = 0.01 5-fu 2.3 r = -0.97 p 0.025 17.9 r = -0.95 p 0.025 0.15 r = -0.98 p = 0.01 1.1 r = -0.94 p = 0.05 ht-29 pc-3 k562 vero respectively leaf stem extract selectivity index 5.6 245 tumor cell line evaluate contrast cisplatin 5-fu show value 0.11 7.3 p. peruviana leave steam ethanolic extract cytotoxic cisplatin 5 fu line ht-29 pc-3 k562 furthermore p. peruviana cytotoxic effect less cisplatin 5-fu vero control cell line 
endothelin-1 et-1 endothelin receptor etar contribute development progression breast carcinoma modulate cell proliferation angiogenesis anti-apoptosis investigate antitumoral effect specific etar antagonist zd4054 breast cancer cell xenograft assess antitumoral efficacy combination zd4054 aromatase inhibitor fulvestrant gene expression change assess quantitative real-time pcr cell proliferation measure use alamarblue migration invasion assay perform use modify boyden chamber evaluate antitumoral efficacy zd4054 vivo different breast cancer model employ use nude mouse xenograft zd4054 reduce et-1 etar expression mcf-7 mda-mb-231 mda-mb-468 breast cancer cell concentration-dependent manner zd4054 inhibit invasion 37.1 p = 0.022 combination zd4054 either anastrozole letrozole produce significant reduction migration aromatase-overexpressing mcf-7aro cell p 0.05 combination zd4054 fulvestrant reduce mcf-7 cell migration invasion 36.0 p = 0.027 56.7 p 0.001 respectively effect significantly exceed see either compound alone regard tumor volume reduction vivo zd4054 10 mg/kg equipotent fulvestrant 200 mg/kg exhibit additive effect anastrozole 0.5 mg/kg datum first indicate selective etar antagonism zd4054 display antitumoral activity breast cancer cell vitro vivo datum strongly support rationale clinical use zd4054 combination endocrine therapy 
bypass resistance due limited entry cell derivative cytarabine cp-4055 elacytarabine gemcitabine cp-4126 contain fatty acid chain 5 position nucleoside develop cp-4055 show increase retention active metabolite triphosphate characteristic suppose favor combination tubulin antagonist docetaxel platinum oxaliplatin antifolate pemetrexed role cell cycle effect cp-4055 cp-4126 efficacy combination docetaxel pemetrexed determine combination cp-4055 oxaliplatin docetaxel also evaluate mouse xenograft model cp-4055 induce g2/m s phase accumulation cp-4126 s phase accumulation analog induce dose-dependent cell kill apoptosis necrosis none docetaxel combination induce synergistic effect combination docetaxel cp-4055 cp-4126 induce g2/m accumulation a549 lung cancer cell line g0/g1 accumulation widr colon cancer cell line preincubation docetaxel induce increase cell kill cell line combination oxaliplatin show synergistic effect cell line combination pemetrex antagonistic cell line a549 cell line pemetrex cp-4055 lead increase g0/g1 phase s phase widr combination pemetrex cp-4055 increase g0/g1 phase increase cell kill pemetrex cp-4126 induce increase g0/g1 phase s phase a549 cell line xenograft study colon cancer lung metastasis model combination cp-4055 docetaxel show best result treatment cp-4055 follow docetaxel 4 h result reduction metastasis lung metastasis model favorable toxicity profile observe conclusion combination oxaliplatin show synergistic effect combination study although combination docetaxel show enhance effect vitro study combination reveal increase effect xenograft model 
study phenomenon human erythroid leukemia k-562 cell sensitive cytotoxic effect antimetabolite culture serum-free medium conventional medium contain fetal calf serum fcs cytotoxic effect methotrexate azaserine 5-fluorouracil estimate access lactate dehydrogenase ldh activity viable tumor cell protein fcs separate use two-dimensional electrophoresis follow mass spectrometry analysis addition 10 fcs attenuate anti-tumor activity methotrexate azaserine k-562 cell compare serum-free medium activity fcs different serum lot comparison protein active serum lot active one use two-dimensional electrophoresis show active serum protein 150 kda absent active serum lot mass spectrometry indicate protein amino acid sequence albumin sera one healthy volunteer two patient thyroid cancer also attenuate activity agent several lot fcs human serum demonstrate ability attenuate cytotoxic effect methotrexate vitro possibly due formation albumin dimers/mtx complex 
chronic myeloid leukemia cml hematological malignancy characterize high level immature white blood cell cml cause translocation chromosome 9 22 result formation philadelphia chromosome create bcr-abl fusion protein imatinib nilotinib chemotherapeutic drug specifically bind bcr-abl inhibit cancer cell nilotinib effective respect imatinib show nilotinib induce apoptosis imatinib-resistant k562 cml cell wild-type bcr-abl fusion gene almost extent parental sensitive cell increase caspase-3 enzyme activity decrease mitochondrial membrane potential effect nilotinib even low concentration may indicate efficacy usage nilotinib imatinib-resistant cml less risk undesired cytotoxic effect remain cell body 
study aim investigate reversal effect tyrosine kinase inhibitor tki imatinib nilotinib multidrug-resistant cell line k562/a02 expression level mdr-1 mrna bcr-abl mrna assay rt-pcr protein level p-glycoprotein p-gp p210 detect western blot daunorubicin dnr accumulation k562/a02 cell analyze flow cytometry fcm result show 0.0625 micromol/l imatinib 5 nmol/l nilotinib alone cytotoxic effect inhibition k562/a02 cell k562/a02 cell treat imatinib nilotinib alone 48 hour expression mdr-1 mrna der/abl mrna p-gp p210 protein down-regulate furthermore effect nilotinib stronger imatinib detection fluorescence intensity reveal dnr concentration k562/a02 cell treat imatinib nilotinib alone 48 hour 7.85 12.02 k562 cell respectively conclude tyrosine kinase inhibitor show great effect reverse drug resistance cell moreover effect nilotinib stronger imatinib 
chronic myeloid leukemia cml bcr/abl-mediated oncogenic signaling target bcr/abl-inhibitor imatinib nilotinib dasatinib however agent may also affect anti-tumor immunity analyze effect 3 bcr/abl-inhibitor natural killer nk cell reactivity exposure cml cell k562 meg-01 pharmacological concentration imatinib nilotinib dasatinib diminish expression ligand activate immunoreceptor nkg2d similar extent result comparably reduce nk cell cytotoxicity ifn-gamma production direct effect nk cell response k562 primary cml cell well activate cytokine study dasatinib find abrogate nk cytotoxicity cytokine production nilotinib alter cytotoxicity high level impaired nk cytokine production imatinib direct influence nk cell reactivity note nilotinib bcr/abl-inhibitor increase cell death within preferentially cytokine-secreting cd56 bright cd16 nk cell subset may least part serve explain effect nilotinib nk cytokine production analysis nk cell signaling reveal dasatinib inhibit proximal signaling event lead decrease phosphorylation pi3k erk crucial nk cell reactivity imatinib nilotinib contrast show relevant effect nk cell pi3k erk activity light potential role nk cell immunesurveillance residual leukemia future combinatory immunotherapeutic approach datum indicate choice dosing suitable bcr/abl-inhibitor give patient require careful consideration 
patient chronic myeloid leukemia cml disease keep control use bcr/abl kinase inhibitor imatinib nevertheless resistance intolerance imatinib bcr/abl inhibitor may occur therapy therefore cml research focus novel target target drug polo-like kinase 1 plk1 serine/threonine kinase play essential role mitosis study examine expression plk1 cml cell potential role therapeutic target plk1 find express phosphorylated form cml cell line k562 well primary cml cell patient test inhibition bcr/abl imatinib nilotinib amn107 lead decrease expression plk1 protein cml cell suggest bcr/abl promote plk1 generation silencing plk1 cml cell small interfere rna approach follow cell cycle arrest apoptosis furthermore plk1-targeting drug bi 2536 find inhibit proliferation imatinib-sensitive imatinib-resistant cml cell include leukemic cell carry t315 mutation bcr/abl reasonable ic 50 value 1-50 nmol/l growth-inhibitory effect bi 2536 cml cell find associate cell cycle arrest apoptosis moreover bi 2536 find synergize imatinib nilotinib produce growth inhibition cml cell conclusion plk1 express cml cell may represent novel interesting target imatinib-sensitive imatinib-resistant cml 
microrna mirna noncoding rna regulate multiple cellular process include proliferation apoptosis use microarray technology identify mirna upregulate non-small cell lung cancer nsclc a549 cell response cisplatin cddp corresponding synthetic mirna precursor pre-mirna per se lethal transfect a549 cell yet affect cell death induction cddp c2-ceramide cadmium etoposide mitoxantrone inducer-specific fashion whereas synthetic mirna inhibitor anti-mirna target mir-181a mir-630 fail modulate response a549 cddp pre-mir-181a pre-mir-630 enhance reduce cddp-triggered cell death respectively pre-mir-181a pre-mir-630 consistently modulate mitochondrial/postmitochondrial step intrinsic pathway apoptosis include bax oligomerization mitochondrial transmembrane potential dissipation proteolytic maturation caspase-9 caspase-3 addition pre-mir-630 block early manifestation dna damage response include phosphorylation ataxia-telangiectasia mutate atm kinase two atm substrate histone h2ax p53 pharmacologic genetic inhibition p53 corroborate hypothesis pre-mir-630 pre-mir-181a block upstream signaling pathway ignite dna damage converge p53 activation pre-mir-630 arrest a549 cell g0-g1 phase cell cycle correlate increase level cell cycle inhibitor p27 kip1 well reduce proliferation rate result greatly diminish sensitivity a549 cell late s-g2-m cell cycle arrest mediate cddp altogether result identify mir-181a mir-630 novel modulator cddp response nsclc 
purpose low-molecular-weight cyclin e lmw-e breast cancer cell induce genomic instability resistance inhibition p21 p27 fulvestrant therapy seek determine lmw-e render breast cancer cell unresponsive aromatase inhibitor ai elucidate mechanism resistance ascertain inhibitor lmw-e-associated kinase activity overcome resistance experimental design antiproliferative effect ai examine aromatase-overexpressing mcf-7 / ac1 cell presence absence full-length cyclin e lmw-e inhibition lmw cyclin e kinase activity roscovitine cyclin-dependent kinase cdk inhibitor examine letrozole-unresponsive mcf-7 / ac1 cell role lmw-e cdk2 mediate recurrence follow ai treatment also assess breast cancer patient result overexpression lmw-e postmenopausal patient associate poor prognosis letrozole exemestane anastrozole mediate pronounced g 1 arrest mcf-7 / ac1 cell androstenedione-induced g 1 exit correlate increase cyclin e-associated kinase activity increase cdk2 level letrozole treatment inhibit cyclin e-cdk2 kinase activity prevent androstenedione-induced increase cdk2 lmw-e bypass effect render cell resistant letrozole inhibition roscovitine block androstenedione-induced increase cdk2 lmw-e overexpression bypass effect lastly breast cancer patient whose tumor overexpress lmw-e responsive ai treatment conclusion roscovitine treatment reverse intrinsic acquire resistance letrozole due lmw-e expression breast cancer cell datum support clinical investigation cdk2 inhibitor therapy postmenopausal woman estrogen receptor-positive lmw-e-expressing breast cancer 
curcumin diferuloylmethane discernible toxicity inhibit initiation promotion progression carcinogenesis 5-fluorouracil 5-fu 5-fu plus oxaliplatin folfox remain backbone colorectal cancer chemotherapeutic produce incomplete response result survival cell chemo-surviving cell may lead cancer recurrence present investigation therefore undertake examine whether addition curcumin folfox superior therapeutic strategy chemo-surviving cell forty-eight-hour treatment colon cancer hct-116 ht-29 cell folfox result 60-70 survival accompany marked activation insulin like growth factor-1 receptor igf-1r minor moderate increase epidermal growth factor receptor egfr v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 her-2 well v-akt murine thymoma viral oncogene homolog 1 akt cyclooxygenase-2 cox-2 cyclin-d1 however inclusion curcumin continue folfox treatment another 48 h greatly reduce survival cell accompany concomitant reduction activation egfr her-2 igf-1r akt well expression cox-2 cyclin-d1 importantly egfr tyrosine kinase inhibitor gefitinib attenuation igf-1r expression corresponding si-rna cause 30-60 growth inhibition chemo-surviving hct-116 cell however curcumin alone find effective gefitinib igf-1r si-rna mediate growth inhibition chemo-surviving hct-116 cell addition folfox curcumin increase growth inhibitory effect curcumin datum suggest inclusion curcumin conventional chemotherapeutic regimen effective strategy prevent emergence chemoresistant colon cancer cell 
low-dose metronomic chemotherapy show promising activity many preclinical phase ii clinical study involve various tumor type evaluate potential therapeutic impact metronomic chemotherapy ovarian cancer develop preclinical model advanced human ovarian cancer test various low-dose metronomic chemotherapy regimen alone concurrent combination antiangiogenic drug pazopanib clone skov-3 human ovarian carcinoma cell line express secretable beta-subunit human choriogonadotropic beta-hcg protein firefly luciferase generate evaluate growth orthotopic i.p. injection severe combined immunodeficient mouse highly aggressive clone skov-3-13 select study mouse treat begin 10 14 day injection cell evidence carcinomatosis-like disease peritoneum establish assess imaging analysis chemotherapy drug test initial experiment include oral cyclophosphamide inject irinotecan paclitaxel alone doublet combination cyclophosphamide result indicate metronomic cyclophosphamide antitumor activity whereas metronomic irinotecan potent activity therefore test oral topoisomerase-1 inhibitor oral topotecan optimal biological dose 1 mg/kg/d metronomic oral topotecan show excellent antitumor activity extent significantly enhance concurrent pazopanib modest activity 100 survival value drug combination six month continuous therapy conclusion oral topotecan may ideal agent consider clinical trial assessment metronomic chemotherapy ovarian cancer especially combine antiangiogenic drug target vascular endothelial growth factor pathway pazopanib mol cancer ther 9 4 996-1006 c 2010 aacr 
alteration tyrosine kinase expression functionality link tumor growth detailed analysis tyrosine kinase pathway lead development novel anticancer drug base inhibition aim present work examine cytotoxicity cellular alteration correlate multidrug resistance mechanism induce three tyrosine kinase inhibitor lapatinib sorafenib gefitinib study perform three breast cancer cell line brc-230 mcf-7 skbr3 drug-induced growth inhibition detect sulforhodamine b analysis apoptosis cytosolic calcium alteration extrusion pump activity mitochondrial membrane depolarization assess flow cytometry drug efflux-related gene expression analyze rt-pcr drug target protein expression evaluate western blot lapatinib gefitinib induce cytotoxic effect mitochondrial membrane depolarization brc-230 skbr3 cell sorafenib induce apoptosis high rapid dissipation mitochondrial potential cell line moreover three drug produce rapid cytosolic calcium mobilization endoplasmic reticulum store investigate cell line strong decrease multidrug transporter activity brc-230 mcf-7 cell mitochondrial membrane depolarization inhibition multidrug transporter activity induce tyrosine kinase inhibitor independent cytosolic calcium mobilization datum suggest investigate drug possess mechanism action independent drug target expression open possibility development new therapeutic strategy 
malignant glioma highly lethal neoplasm cure currently available therapy temozolomide tmz recently introduce alkylating agent yield significant benefit become key agent treatment high-grade glioma however survival benefit remain unsatisfactory understand molecular basis tmz sensitivity/resistance necessary improve treatment outcome devise strategy able circumvent primary drug resistance therefore combine vitro tmz response microarray gene expression datum identify gene potentially use predict response malignant glioma tmz therapy first obtain individual ic50 value tmz seven malignant glioma cell line a-172 am-38 t98g u-87mg u-138mg u-251mg yh-13 identify gene whose expression correlate highly tmz sensitivity employ cdna microarray present list highly up-regulate down-regulate gene may involve confer tmz sensitivity/resistance malignant glioma although gene implicate causal factor tmz response except mgmt also demonstrate confirm mgmt methylation status quantitative mgmt mrna level mgmt protein expression level tmz resistant glioma cell vitro result thus consistent previous study suggest dominant mechanism confer sensitivity/resistance tmz exist malignant glioma cell although present study dose several limitation report candidate gene represent potential molecular marker tmz sensitivity/resistance also chemotherapy target furthermore present study provide foundation alternative therapeutic strategy include novel combination treatment incorporate additional reagent direct overcome resistance tmz 
dna methylation play important role regulation gene expression increasingly recognize determinant chemosensitivity human cancer aim improve chemotherapeutic efficacy breast carcinoma effect dna methyltransferase inhibitor 5-aza-2 deoxycytidine 5-aza-cdr chemosensitivity anticancer drug investigate cytotoxicity paclitaxel ptx adriamycin adr 5-fluorouracil 5-fu analyze human breast cancer cell line mda mb 231 mcf 7 cell line use mtt assay synergy 5-aza-cdr agent determine drewinko fraction method effect single agent combined treatment cell cycle arrest analyze flow cytometric analysis also investigate effect single agent combined treatment anticancer drug 5-aza-cdr methylation status select gene methylation specific pcr mda mb 231 cell synergistic antiproliferative effect observe combination 10 microm 5-aza-cdr three anticancer drug mcf 7 cell semiadditive effect observe treatment 5-aza-cdr anticancer drug result partial demethylation panel gene include rarbeta2 slit2 gstp1 mgmt base finding propose 5-aza-cdr enhance chemosensitivity anticancer drug breast cancer cell may promising approach increase chemotherapeutic potential anticancer agent effective management breast carcinoma 
replication-selective oncolytic adenovirus prove safety record promising clinical outcome however strategy improve efficacy still require report greatly improve antitumor efficacy attenuate dl1520 highly potent dl922 -- 947 oncolytic mutant combination current standard care late-stage hormone-independent prostate cancer mitoxantrone docetaxel agreement previous report dl922 -- 947 superior potency compare dl1520 single agent combination cytotoxic drug dl922 -- 947 mutant cause significant synergistic cell killing drug-insensitive sensitive prostate cancer cell line pc3 du145 respectively combine docetaxel mitoxantrone magnitude synergistic response greatest dl1520 whereas overall efficacy greatest dl922 -- 947 latter also efficacious vivo prostate cancer model du145 pc3 cell increase viral uptake 9 8-fold respectively e1a expression altered cell cycle progression contribute synergistic cell killing similar trend also detect lncap cell potent e1a expression essential response murine xenograft model du145 pc3 tumor growth inhibition improve suboptimal dose docetaxel viral mutant combine finding demonstrate efficacy highly potent oncolytic mutant dl922 -- 947 target retinoblastoma protein prb pathway enhance even low drug dose support deletion e1acr2 region future candidate adenovirus treatment hormone-independent prostate cancer 
thiopurine include mercaptopurine mp 6-thioguanine s g azathioprine widely use treatment many human disease include acute lymphoblastic leukemia exert cytotoxic effect prodrug need metabolically activate s g nucleotide incorporate nucleic acid s g dna methylate spontaneously s 6 methylthioguanine s 6 mg presence s-adenosyl-l-methionine propose s 6 mg owe high miscoding potential pair preferentially thymine may induce cell death trigger postreplicative mismatch repair pathway understand implication pathway cytotoxic effect thiopurine drug necessitate accurate measurement level s 6 methylthio-2 deoxyguanosine s 6 mdg dna cell treat thiopurine drug develop sensitive hplc couple tandem mass spectrometry lc-ms/ms method measure level 6-thio-2 deoxyguanosine s dg s 6 mdg genomic dna four human leukemia cell line one human colorectal carcinoma cell line result reveal upon treatment 3 mum s g 24 h approximately 10 7.4 7 3 guanine replace s g jurkat t hl-60 ccrf-cem k-562 cell respectively however less 0.02 s dg convert s 6 mdg cell line hct-116 cell lowest level 0.2 guanine replace s g dna approximately 5 10 4 s g convert methylate counterpart first report simultaneous accurate quantification s dg s 6 mdg genomic dna culture human cell treat s g addition result suggest dna s g might trigger mismatch repair mmr pathway without convert s 6 mg 
serine/threonine kinase akt lie critical signaling node downstream phosphatidylinositol-3-kinase important promote cell survival inhibit apoptosis akt inhibitor may particularly useful cancer increase akt signaling associate reduce sensitivity cytotoxic agent receptor tyrosine kinase inhibitor evaluate effect novel allosteric akt inhibitor mk-2206 combination several anticancer agent vitro mk-2206 synergistically inhibit cell proliferation human cancer cell line combination molecular target agent erlotinib epidermal growth factor receptor inhibitor lapatinib dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor complementary inhibition erlotinib-insensitive akt phosphorylation mk-2206 one mechanism synergism synergistic effect find even erlotinib-insensitive cell line mk-2206 also show synergistic response combination cytotoxic agent topoisomerase inhibitor doxorubicin camptothecin antimetabolite gemcitabine 5-fluorouracil anti-microtubule agent docetaxel dna cross-linker carboplatin lung nci-h460 ovarian a2780 tumor cell synergy docetaxel depend treatment sequence schedule mk-2206 dose docetaxel effective mk-2206 suppress akt phosphorylation induce carboplatin gemcitabine vivo mk-2206 combination agent exert significantly potent tumor inhibitory activity agent monotherapy setting finding suggest akt inhibition may augment efficacy exist cancer therapeutics thus mk-2206 promising agent treat cancer patient receive cytotoxic and/or molecular target agent 
previously demonstrate prolonged treatment raloxifene ral vitro will result phase ii ral resistance ral-induced tumor growth clinical interest prompt re-examine ral resistance vivo particularly effect long-term treatment decade evolution ral resistance study address question reproducible phenomenon wild-type estrogen receptor er positive human breast cell line mcf-7 mcf-7 cell culture estrogen-deprived condition presence 1 microm ral year develop ral resistance result independent cell line mcf7-ral mcf7-ral cell grow response estradiol e2 ral fulvestrant ful block ral e2-mediated growth transplantation mcf7-ral cell athymic ovariectomized mouse treatment physiologic dose e2 cause early e2-stimulated tumor growth contrast continuous treatment implant animal daily oral ral 1.5 mg daily cause growth small tumor within 15 week continuous re-transplantation tumor grow ral-treated mouse indicate ral stimulate tumor growth tumor untreated mouse grow bi-transplantation mcf7-e2 mcf7-ral tumor oppose mammary fat pad ovariectomized animal demonstrate mcf7-e2 grow e2 stimulation ral conversely mcf7-ral tumor grow ral e2 characteristic phase ii resistance establish phase ii resistance mcf7-ral tumor confirm follow 7 year serial transplantation ral-treated athymic mouse eralpha retain tumor cyclical nature ral resistance confirm extend 2-year evolution resistant phase mcf7-ral tumor mcf7-ral tumor initially inhibit e2 grow presence e2 subsequently grow either ral e2 ral remain major grow stimulus ral enhance e2-stimulated growth subsequent transplantation e2 stimulate tumor evaluation action ral demonstrate robust e2-stimulated growth block ral characteristic anti-estrogenic action ral e2-stimulated breast cancer growth minor component phase ral resistance continuous transplantation phase ral-stimulated tumor 8 month cause reversion phase ii resistance datum literature report cyclical nature anti-androgen/androgen responsiveness prostate cancer growth illustrate generality evolution anti-hormonal resistance sex steroid-sensitive target tissue 
familial breast ovarian cancer often defective homologous recombination hr due mutation brca1 brca2 gene cisplatin chemotherapy poly adp-ribose polymerase parp inhibitor test tumor clinical trial screen novel drug selectively kill brca2-defective cell identify 6-thioguanine 6tg induce dna double-strand break dsb repair hr furthermore show 6tg efficient parp inhibitor selectively kill brca2-defective tumor xenograft model spontaneous brca1-defective mammary tumor gain resistance parp inhibitor increase p-glycoprotein expression show 6tg efficiently kill brca1-defective parp inhibitor-resistant tumor also show 6tg kill cell tumor gain resistance parp inhibitor cisplatin genetic reversion brca2 gene although hr reactivate parp inhibitor-resistant brca2-defective cell fully restore repair 6tg-induced lesion likely due several recombinogenic lesion form 6tg show brca2 also require survival mismatch repair-independent lesion form 6tg include dsb suggest hr involve repair 6tg-induced dsb well mismatch repair-independent 6tg-induced dna lesion altogether datum show 6tg efficiently kill brca2-defective tumor suggest 6tg may effective treatment advanced tumor develop resistance parp inhibitor platinum-based chemotherapy 
background prognosis advanced recurrent colorectal cancer still poor dye-effluxing side population sp colon cancer cell reportedly resistant chemotherapeutic agent sporadic colorectal cancer involve constitutive activation wnt signaling pathway study examine effect wnt signaling sp cell possibility inhibition wnt signaling may decrease resistance chemotherapeutic drug human colon cancer cell material method drug resistance sp cell 5-fluorouracil 5-fu irinotecan decrease sp cell wnt signaling inhibition activation wnt signaling sort sp cell examine use sw480 colon cancer cell line mrna expression atp-binding cassette abc transporter wnt signaling inhibit evaluate real-time pcr use colon cancer cell line sw480 dld-1 hct116 ht29 lovo sensitivity irinotecan paclitaxel wnt signaling inhibit investigate use sw480 inhibition wnt signaling perform sirna beta-catenin result sp cell show resistance 5-fu irinotecan higher activation wnt signaling pathway non-sp cell silencing beta-catenin decrease significantly sp cell non-sp cell expression abc transporter gene abcb1 abcg2 significantly higher sp cell non-sp cell silencing beta-catenin decrease transcription abc transporter gene beta-catenin-silenced cell become relatively sensitive paclitaxel irinotecan conclusion result indicate inhibit wnt signaling pathway may fruitful strategy target chemotherapy-resistant colon cancer cell include sp cell 
prognosis advanced recurrent colorectal cancer still poor dye-effluxing side population sp colon cancer cell reportedly resistant chemotherapeutic agent sporadic colorectal cancer involve constitutive activation wnt signaling pathway study examine effect wnt signaling sp cell possibility inhibition wnt signaling may decrease resistance chemotherapeutic drug human colon cancer cell drug resistance sp cell 5-fluorouracil 5-fu irinotecan decrease sp cell wnt signaling inhibition activation wnt signaling sort sp cell examine use sw480 colon cancer cell line mrna expression atp-binding cassette abc transporter wnt signaling inhibit evaluate real-time pcr use colon cancer cell line sw480 dld-1 hct116 ht29 lovo sensitivity irinotecan paclitaxel wnt signaling inhibit investigate use sw480 inhibition wnt signaling perform sirna beta-catenin sp cell show resistance 5-fu irinotecan higher activation wnt signaling pathway non-sp cell silencing beta-catenin decrease significantly sp cell non-sp cell expression abc transporter gene abcb1 abcg2 significantly higher sp cell non-sp cell silencing beta-catenin decrease transcription abc transporter gene beta-catenin-silenced cell become relatively sensitive paclitaxel irinotecan result indicate inhibit wnt signaling pathway may fruitful strategy target chemotherapy-resistant colon cancer cell include sp cell 
comparative efficacy pure diastereoisomer leucovorin natural 6s unnatural 6r form compare racemic form 6rs protective effect methotrexate-treated ccrf-cem cell obtain 6s concentration 100-fold higher methotrexate 6rs concentration 2-fold greater 6s however low concentration methotrexate 6s effective 6rs prevent cytotoxicity methotrexate opposite 6r exhibit protective effect concentration 10 4 higher methotrexate cell line 6s show enhance cytotoxic effect 5 fluorouracil exactly 6rs 6r exhibit enhancing effect cell expose 5 fluorouracil 
angiogenesis inhibitor may enhance effect low dose metronomic chemotherapy however wide range novel angiogenesis inhibitor must test combination oral chemotherapy agent assess anti-endothelial anti-cancer effect preliminary testing suit high throughput vitro model rather clinical trial aim establish vitro model test anti-endothelial anti-cancer effect multi-kinase inhibitor sorafenib use single agent combination oral chemotherapy agent use low concentration micro-vascular endothelial cell 3 cancer cell line utilise extended treatment strategy 96 h employ order mimic continuous low dose anti-angiogenic chemotherapy regimen sorafenib significantly enhance anti-endothelial effect low dose etoposide paclitaxel temozolomide sorafenib also significantly enhance anti-cancer effect low dose etoposide paclitaxel temozolomide sk-mel-2 melanoma cell produce additive effect inhibition cell growth case combination appear promising vivo pre-clinical study view testing melanoma patient continuous dosing strategy due vitro additive inhibitory effect growth see endothelial cancer cell 
lapatinib specific her1 2 target tyrosine kinase inhibitor now widely use combination chemotherapy clinical setting work investigate interaction lapatinib specific chemotherapy agent cisplatin sn-38 topotecan panel cell line breast n = 2 lung n = 2 testis n = 4 high-sensitivity cell proliferation/cytotoxicity atp assay flow cytometry use determine cell viability apoptosis effect drug cell-cycle distribution calcusyn analysis employ formally identify synergistic interaction drug intracellular concentration sn-38 measure use novel high-performance liquid chromatography hplc technique flow cytometry hplc technique use identify effect lapatinib drug influx efflux pump use specific substrate inhibitor pump result show significant synergy sn-38 lapatinib majority cell line combination index 0.75 associate increase apoptosis synergy universal observe susa s/r h1975 h358 mda-mb-231 cell line relate sn-38 intracellular accumulation 2.2 4.8-fold increase p 0.05 attributable inhibition breast cancer-related protein bcrp efflux pump lapatinib flow cytometry analysis show lapatinib 10 μmol/l inhibit efflux mitoxantrone specific substrate bcrp pump manner similar fumitremorgin c known bcrp inhibitor confirm lapatinib bcrp inhibitor work show lapatinib direct inhibitory effect bcrp accounting synergistic finding synergy cell line dependent related activity specific efflux pump 
aim determine potential allosteric mammalian target rapamycin inhibitor everolimus act combination cytotoxic anticancer compound vitro vivo concomitant combination vitro show evidence antagonism enhance antiproliferative effect additive synergistic cisplatin doxorubicin 5-fluorouracil gemcitabine paclitaxel patupilone everolimus 1-5 mg/kg/d orally evaluate antitumor activity vivo alone combination suboptimal cytotoxic dose use athymic nude mouse bear subcutaneous human h-596 lung kb-31 cervical hct-116 colon tumor xenograft everolimus monotherapy well tolerate cause inhibition tumor growth rather regression associate dose-dependent decline tumor ps6 level key downstream protein mammalian target rapamycin dose use cytotoxic inhibit tumor growth cause tolerable body-weight loss concomitant combination cisplatin doxorubicin paclitaxel patupilone everolimus produce cooperative antitumor effect case produce regression without clinically significant increase toxicity contrast combination gemcitabine 5-fluorouracil less well tolerate alternative administration schedule test cisplatin gemcitabine paclitaxel combine everolimus dramatically affect cisplatin gemcitabine activity tolerability antagonistic paclitaxel everolimus show promising maintenance activity treatment doxorubicin paclitaxel cease overall result confirm everolimus effective well-tolerated suppressor experimental human tumor growth although show strong potentiation efficacy antitumor activity vivo increase without marked increase toxicity support clinical use everolimus partner conventional cytotoxic 
series novel quinoxalinyl-piperazine compound 1 5 6-substituted alkoxyquinoxalinyl aminocarbonyl -4 hetero arylpiperazine derivative synthesize evaluate anticancer agent screening quinoxalinyl-piperazine compound library identify many compound inhibit proliferation various human cancer cell nanomolar concentration among one fluoro quinoxalinyl-piperazine derivative show ic 50 value range 11 21nμ growth inhibition cancer cell compound also display potent effect paclitaxel paclitaxel resistant hct-15 colorectal carcinoma cell potency novel compound confirm synergistic cytotoxic effect several known cancer drug paclitaxel doxorubicin cisplatin gemcitabine 5-fluorouracil cancer cell strong cell killing effect derive induction apoptosis mechanistic study show quinoxalinyl-piperazine compound g2/m-specific cell cycle inhibitor inhibit anti-apoptotic bcl-2 protein p21 induction thus result suggest compound potential use growth inhibition drug resistant cancer cell combination therapy clinically approve anticancer agent well 
investigate therapeutic action f8-il2 fusion protein consist f8 antibody specific alternatively splice extradomain-a fibronectin diabody format human interleukin-2 caki-1 atcc ® model human renal cell carcinoma graft subcutaneously nude mouse f8-il2 clone express cho cell purify homogeneity immunocytokine administer alone combine 3 standard drug commonly use therapy kidney cancer include sunitinib sorafenib interferon-α 2 set dose treatment schedule neither f8-il2 therapeutic agent cure tumor bearing mouse use single agent best therapeutic result observe combination sunitinib f8-il2 continuous administration schedule yield 28 cure rate substantial tumor growth retardation consider recombinant interleukin-2 base immunocytokine now investigate several clinical trial patient cancer alone combine chemotherapy preclinical result provide motivation study f8-il2 combine sunitinib clinical trial patient kidney cancer 
combined effect pirarubicin thp various antitumor drug hela s3 human uterine cervix carcinoma k562 human myelocytic leukemia cell determine enhancement cytotoxic activity combination 0.15 microgram/ml thp cisplatin cddp mitomycin c mmc peplomycin pep 5-fluorouracil 5-fu methotrexate mtx enocitabine bh-ac etoposide show synergistic effect hela s3 cell also combination 0.01 microgram/ml thp cddp bh-ac etoposide show synergistic effect k562 cell especially combined effect thp mmc mtx remarkable combination almost concentration mmc mtx show synergistic effect hela s3 cell hand combination adriamycin adm mmc mtx show remarkable effect hela s3 cell 
recently new di-gold organometallic complex 1,3 ph 3 pau 2 c 6 h 4 kf0101 synthesise find exhibit cytotoxic activity vitro subsequently demonstrate kf0101 show little cross-resistance number cisplatin resistant ovarian cancer cell line vitro suggest different mode action drug study syncrotron radiation infrare microspectroscopy sr-irms use drug treat single a2780 cell order determine different mode action identify spectroscopically aim study establish single cell sr-irms use give insight cellular response treatment different cytotoxic agent relative non-treated cell control ii cytotoxic drug elicit different biochemical response response distinguish striking feature obtain principal components analysis pca resonant mie scattering rmies correct single cell spectrum drug treat ovarian a2780 cell spectrum obtain control quite heterogeneous several hundred spectrum require adequately define nature control ii drug treatment ic50 level 24 h cisplatin kf0101 methotrexate paclitaxel 5-fluorouracil cell spectrum represent pca score plot generally concentrate certain well define area control however small number spectrum fall outside area define control iii differentiation cell spectrum obtain treatment different drug observe fit well different vitro cell culture behaviour flow cytometry cell cycle analysis control drug treated cell inspection load plot show pc1 essentially plot reflect change cell biochemistry related cell cycle pc2 however comparison control versus cisplatin cisplatin versus kf0101 indicative difference induce drug treatment term cell cycle-plus behaviour datum show consistent obtain use bench-top irm average number single cell spectrum carry pca sr-irms offer insight drug affect cell population importantly approach enable influence cell cycle control drug treat sample take consideration evaluate drug-cell interaction 
bcr/abl positive cell know resistant dna damage induce chemotherapy sensitive imatinib tyrosine kinase inhibitor tki evaluate whether drug increase activity cytotoxic drug bcr/abl positive cell measure toxicity cytosine arabinoside ara-c hydroxyurea hu melphalan mel pretreatment 24 h k562 cell line highest cytotoxic effect see tki follow mel result indicate inhibition bcr/abl activity increase cytotoxicity mel favor dna damage induce drug shorten time dna repair g2/m checkpoint stronger activation gene involve intrinsic extrinsic apoptotic pathway also observe im/mel combination compare mel alone drug association test type baf3 cell tonb .210 bcr-abl expression inducible doxycycline model confirm reduction bcr/abl activity result increase susceptibility cytotoxic effect mel furthermore study effect im/mel treatment proliferative potential myeloid progenitor six cml patient diagnosis analysis cfu-gm bfu-e colony demonstrate im/mel combination effective alone reduce overall number colony number copy bcr/abl conclusion work show inhibition bcr/abl activity increase toxicity mel allow efficient killing leukemic cell suggest clinical development approach therapeutic advantage cml patient 
explore activity dasatinib alone combination paclitaxel carboplatin ovarian cancer cell determine dasatinib activity predict base evaluation src pathway microarray analysis perform igrov1 ovcar3 a2780 skov3 ovarian cancer cell status genomic src signature pathway determine cell treat carboplatin paclitaxel dasatinib individually combination pre post-treatment phospho-src psrc src protein expression determine dose-response curve construct drug interaction assess combination index ci method src protein expression level reflect src pathway genomic signature cell line lowest skov3 highest igrov1 pathway expression intermediate expression ovcar3 a2780 dasatinib treatment cause loss psrc cell line 50 growth inhibition igrov1 70 nm ovcar3 34 nm a2780 4.1 μm skov3 530 nm dasatinib combine cytotoxic yield synergistic effect ci = 0.46 0.79 cell line except skov3 dasatinib combination standard chemotherapeutic agent appear interact synergistic manner ovarian cancer cell line research need evaluate tumor cell characteristic predict response dasatinib 
limited efficacy chemotherapeutic drug solid tumor attribute poor drug penetration tumor tissue multicellular layer mcl culture recapitulate barrier drug penetration distribution use successfully production clinically relevant datum present study evaluate characteristic paclitaxel ptx 5-fluorouracil 5-fu penetration effect tissue penetration use mcl human colorectal cancer cell dld-1 ht-29 grow transwell insert drug concentration condition media mcl penetration estimate use survival cell expose condition media penetration rate calculate drug concentration relative expect concentration penetration cell-free mcl ptx show limited penetration mcl contrast full penetration see 5-fu penetration rate measure 24 h cytotoxicity condition media 40 38 dld-1 20 μm ht-29 mcl 1 μm respectively concentration condition media produce 50 growth inhibition monolayer penetration profile obtain use 14c paclitaxel also show slow limited penetration concentration cell line-dependency ht-29 mcl full penetration ptx obtain 10 μm 48 h whereas 80 obtain 1 μm dld-1 mcl penetration ptx minimal especially 1 μm show penetration rate low 10 20 24 96 h respectively ptx 5-fu allow penetrate sequential combination effect penetration rate observe overall result demonstrate limited penetration ptx human colorectal cancer mcl along concentration time cell line-dependency assessment penetration use cytotoxicity condition media use present study may useful early stage screening anticancer agent potential tissue penetration 
determine whether treatment response aurora b kinase inhibitor azd1152 monitor early course therapy noninvasive 18 f label fluoro-2-deoxyglucose 18 f fdg and/or 3 deoxy-3 18 f fluorothymidine 18 f flt pet imaging azd1152-treated control hct116 sw620 xenograft-bearing animal monitor tumor size 18 f fdg 18 f flt pet imaging additional study assess endogenous exogenous contribution thymidine synthesis two cell line xenograft show significant volume-reduction azd1152 contrast 18 f fdg uptake demonstrate treatment response 18 f flt uptake decrease less 20 control value azd1152-treated hct116 xenograft whereas 18 f flt uptake near background level treat untreated sw620 xenograft ec 50 azd1152-hqpa approximately 10 nmol/l sw620 hct116 cell contrast sw620 cell much sensitive methotrexate mtx 5-fluorouracil 5fu hct116 cell immunoblot analysis demonstrate marginally lower expression thymidine kinase sw620 compare hct116 cell aforementioned result suggest sw620 xenograft higher dependency de novo pathway thymidine utilization hct116 xenograft azd1152 treatment show antitumor efficacy colon cancer xenograft although 18 f fdg pet inadequate monitor treatment response 18 f flt pet effective monitor response hct116 xenograft sw620 xenograft observation suggest de novo thymidine synthesis limitation confounding factor 18 f flt pet imaging quantification tumor proliferation may apply clinical study well 
thiopurine 6-mercaptopurine 6-mp 6-thioguanine 6-tg use treatment leukemia incorporation deoxythioguanosine nucleotide dg s dna thiopurine-treated cell cause cell death also evidence thiopurine metabolite particularly 6-mp metabolite methylthioinosine monophosphate metimp inhibit de novo purine synthesis dnps toxicity dnps inhibitor influence methylthioadenosine phosphorylase mtap gene frequently delete cancer growth mtap-deleted tumor cell dependent dnps hypoxanthine salvage predict cell show differential sensitivity 6-mp 6-tg test hypothesis sensitivity 6-mp 6-tg compare relation mtap status use cytotoxicity assay two mtap-deficient cell line transfect express mtap t-cell acute lymphoblastic leukemic cell line jurkat transfect mtap cdna control tetracycline-inducible promoter lung cancer cell line a549-mtap transfect express mtap constitutively a549-mtap sensitivity 6-mp methyl mercaptopurine riboside convert intracellularly metimp markedly higher cell line mtap condition measurement thiopurine metabolite support hypothesis dnps inhibition major cause cell death 6-mp whereas dg s incorporation main cause cytotoxicity 6-tg datum suggest thiopurine particularly 6-mp may effective patient delete mtap 
subset primary breast cancer breast cancer cell line express hypermethylation defect characterize dnmt hyperactivity dnmt3b overexpression contribute chemotherapy resistance provide target development new treatment strategy objective current study determine target epigenome enhance sensitivity breast cancer cell cytotoxic chemotherapy hypermethylator breast cancer cell line mda-mb-453 bt549 hs578t treat 250 500 nm 5-aza-2 deoxycytidine 5-aza and/or subject rnai-mediated dnmt3b knockdown kd test sensitivity doxorubicin hydrochloride dox paclitaxel pax 5-fluorouracil 5-fu mda-mb-453 cell dnmt3b kd reduce ic 50 dox 0.086 0.048 μm 44 reduction pax 0.497 0.376 nm 24 5-fu 0.817 0.145 mm 82 treatment 250 nm 5-aza 7 day increase efficacy dox pax 5-fu 7-day treatment 500 nm 5-aza sensitize cell reduce ic 50 dox 0.035 μm 60 pax 0.311 nm 37 5-fu 0.065 mm 92 5-aza treatment dnmt3b kd cell reduce ic 50 dox 0.036 μm 59 pax 0.313 nm 37 5-fu 0.067 92 similar trend enhancement cell kill see bt549 13-60 hs578t 29-70 cell rnai-mediated dnmt3b kd and/or treatment 5-aza effectiveness dox pax 5-fu enhance target and/or pharmacological inhibition dnmt3b strongly suggest combine epigenetic cytotoxic treatment will improve efficacy breast cancer chemotherapy 
background caveolin-1 protein display promotive versus preventive role cancer progression accord circumstance temozolomide tmz standard chemotherapeutic treat glioma patient present work aim characterizetmz-induced effect caveolin-1 expression glioma cell method human astroglioma u373 t98g oligodendroglioma hs683 cell line use vitro well vivo orthotopic xenograft hs683 u373 brain immunocompromisedmice vitro tmz-induced effect protein expression cellular localization determine western blot analysis actin cytoskeleton organization means immunofluorescence approach vivo tmz-induced effect caveolin-1 expression human glioma xenograft monitor means immunohistochemistry result tmz modify caveolin-1 expression localization vitro vivo administration schedule slightly impaired cell growth characteristic vitro caveolin-1 100-ng/ml concentration able significantly reduce invasiveness boyden chamber three human glioma cell line tmz-inducedmodification caveolin-1 expression flotation/raft compartment parallel altered cyr61 beta 1 integrin expression two element already report collaborate caveolin-1 regulate glioma cell biology feature lead profound reorganization actin cytoskeleton experimental src kinase inhibitor azd0530 almost completely antagonize tmz-induced modulation caveolin-1 expression conclusion tmz modify caveolin-1 expression vitro vivo glioma cell feature directly affect glioma cell migration property 
lung cancer one lethal tumor although standard chemotherapy produce clinical response little improvement prognosis therefore research effort focus target-specific agent sorafenib block raf/mek/erk signalling pathway receptor involve neovascularization tumor progression include vegfr-2 c-kit investigate whether sorafenib synergistic gemcitabine nsclc cell line human lung cancer cell a549 calu-1 calu-6 h23 hcc 827 treat sorafenib gemcitabine alone combination cytotoxicity assess celltiter 96 non-radioactive cell proliferation kit cell cycle apoptosis investigate flow cytometry fluorescence microscopy respectively moreover effect drug akt s473 c-kit y823 erk ptpy185/187 phosphorylation study elisa finally quantitative pcr analysis perform assess whether sorafenib gemcitabine modulate expression gene relate drug activity gemcitabine sorafenib synergistically interact inhibition cell proliferation assessment apoptosis demonstrate drug association increase apoptotic index sorafenib reduce c-kit erk activation gemcitabine inhibit akt phosphorylation moreover quantitative pcr show sorafenib modulate expression target relate gemcitabine activity gemcitabine induce expression rkip datum demonstrate sorafenib gemcitabine synergistically interact nsclc cell suppression akt c-kit erk phosphorylation induction apoptosis modulation dck rrm1 rrm2 rkip gene expression association traditional cytotoxic agent new target-specific agent sorafenib challenge clinical preclinical future investigation lung cancer treatment 
mechanism cell death apoptosis necrosis determine morphologically dna gel electrophoresis 3 human leukaemic t-cell line ccrf-cem f2 ccrf-hsb molt .4 treatment cytotoxic drug include one hormone dexamethasone dxm dna damaging agent melphalan cisplatin bleomycin mitomycin c mithramycin inhibitor dna synthesis aphidicolin cytosine arabinoside ara-c methotrexate mtx 5-fluoro-2 deoxyuridine fudr 5-fluorouracil 5-fu metabolic inhibitor bromo-2 deoxy-2 uridine budr actinomycin d 5-azacytidine 5-ac cycloheximide vincristine etoposide adriamycin cell death assess morphologically apoptotic cell death apparent three cell line 48 hour drug treatment however distinct pattern dna breakdown observe cell line smear dna agarose gel see ccrf-cem f2 5-fu mithramycin treatment whilst ccrf-hsb cell show similar dna profile 5-fu mtx treatment drug treatment molt .4 cell produce necrotic pattern dna degradation cycloheximide inhibitor protein synthesis reduce dna fragmentation ccrf-cem f2 cell treat dxm mtx fudr indicate protein synthesis require cytotoxicity apoptosis however extent dna fragmentation cause 5-fu significantly affect cycloheximide result indicate least morphological electrophoretic criterion use avoid differ conclusion mode cell death 
breast cancer resistance protein bcrp/abcg2 confer resistance anticancer drug 7-ethyl-10-hydroxycamptothecin sn-38 active metabolite irinotecan mitoxantrone topotecan study examine reverse effect yho-13177 novel acrylonitrile derivative water-soluble diethylaminoacetate prodrug yho-13351 bcrp-mediated drug resistance yho-13177 potentiate cytotoxicity sn-38 mitoxantrone topotecan bcrp-transduced human colon cancer hct116 hct116/bcrp cell sn-38-resistant human lung cancer a549 a549/sn4 cell express bcrp little effect parental cell addition yho-13177 potentiate cytotoxicity sn-38 human lung cancer nci-h460 nci-h23 myeloma rpmi-8226 pancreatic cancer aspc-1 cell intrinsically express bcrp contrast effect p-glycoprotein-mediated paclitaxel resistance mdr1-transduced human leukemia k562 cell multidrug resistance-related protein 1-mediated doxorubicin resistance mrp1-transfected human epidermoid cancer kb-3-1 cell yho-13177 increase intracellular accumulation hoechst 33342 substrate bcrp 30 minute partially suppress expression bcrp protein 24 hour treatment hct116/bcrp a549/sn4 cell mouse yho-13351 rapidly convert yho-13177 oral intravenous administration coadministration irinotecan yho-13351 significantly increase survival time mouse inoculate bcrp-transduced murine leukemia p388 cell suppress tumor growth hct116/bcrp xenograft model whereas irinotecan alone little effect tumor model finding suggest yho-13351 prodrug yho-13177 clinically useful reverse bcrp-mediated drug resistance cancer chemotherapy 
drug resistance major problem cancer therapy mcf-7 / cddp cell line subline mcf-7 human breast carcinoma cell line resistant cis-diamminedichloroplatinum ii also resistant carboplatin d-tetraplatin lesser degree melphalan thiotepa bcnu compare mcf-7 parental cell line resistance persist normally oxygenate condition 2 h exposure hypoxic condition prior exposure antitumor alkylating agent normally oxygenate condition mcf-7 parental cell mcf-7 / cddp cell treat sr-4233 20 mum etanidazole 5 mm 2 h prior exposure antitumor alkylating agent change sensitivity resistance pattern cell line however mcf-7 parental cell mcf-7 / cddp cell expose sr-4233 20 mum etanidazole 5 mm 2 h hypoxic condition follow release hypoxia exposure antitumor alkylating agent 1 h normally oxygenate condition resistance mcf-7 / cddp reverse mcf-7 parental mcf-7 / cddp cell line essentially equally sensitive six antitumor alkylating agent result indicate non-cytotoxic concentration modulator sr-4233 etanidazole may useful reverse resistance 
human epidermal growth factor receptor 2 her2/neu also know erbb2 overexpression correlate poor prognosis chemoresistance cancer breast cancer resistance protein bcrp abcg2 drug efflux pump responsible multidrug resistance mdr variety cancer cell her2 bcrp associate poor treatment response breast cancer patient although relationship her2 bcrp expression clear show transfection her2 mcf7 breast cancer cell mcf7/her2 result up-regulation bcrp via phosphatidylinositol 3-kinase pi3k / akt nuclear factor-kappa b nf-κb signaling treatment mcf/her2 cell pi3k inhibitor ly294002 iκb phosphorylation inhibitor bay11-7082 dominant negative mutant iκbα inhibit her2-induced bcrp promoter activity furthermore find her2 overexpression lead increase resistance mcf7 cell multiple antitumor drug paclitaxel taxol cisplatin ddp etoposide vp-16 adriamycin adm mitoxantrone mx 5-fluorouracil 5-fu moreover silence expression bcrp selectively inhibit activity akt nf-κb sensitize mcf7/her2 cell chemotherapy agent least part take together up-regulation bcrp pi3k/akt/nf-κb signaling pathway play important role her2-mediated chemoresistance mcf7 cell akt nf-κb bcrp pathway might serve potential target therapeutic intervention 
exposure molt4 human t-cell leukemia cell 6-mercaptopurine 6-mp 6-thioguanine 6-tg result acquire resistance associate attenuate expression gene encode concentrative nucleoside transporter 3 cnt3 equilibrative nucleoside transporter 2 ent2 identify alteration rna dna level associate 6-mp 6-tg resistance compare pattern gene expression dna copy number profile resistant subline parental wild-type cell mrna level two nucleoside transporter down-regulate thiopurine-resistant subline moreover cell line express gene encode enzyme purine nucleotide composition synthesis include adenylate kinase 3-like 1 guanosine monophosphate synthetase significantly lower level wild-type cell addition expression mrna specialize dna polymerase human terminal transferase encode terminal deoxynucleotidyl transferase dntt gene 122 93-fold higher 6-tg 6-mp-resistant cell respectively vary response 6-mp 6-tg observe may help identify novel cellular target modality resistance thiopurine well indicate new potential approach individualization therapy drug 
recq helicase play essential role maintenance genome stability human loss recq helicase function link predisposition cancer and/or premature ageing current datum show specific depletion human recq1 helicase lead mitotic catastrophe cancer cell inhibition tumor growth mouse show recq1 highly express various type solid tumor however case brain glioma high expression recq1 glioblastoma tissue parallel lower expression control sample due poor expression recq1 non-dividing tissue conclusion validate immunohistochemical analysis tissue microarray contain 63 primary glioblastoma 19 perilesional tissue sample control also show acute depletion recq1 rnai result significant reduction cellular proliferation perturbation s-phase progression spontaneous γ-h2ax focus formation t98g u-87 glioblastoma cell moreover recq1 deplete t98g u-87 cell hypersensitive hu temozolomide treatment collectively result indicate recq1 unique important role maintenance genome integrity result also suggest recq1 might represent new suitable target anti cancer therapy aim arrest cell proliferation brain glioma 
synthesize superparamagnetic paclitaxel nanoparticle modify chitosan tangle around fe3o4 ferrofluid taxol observe nanoparticle transmission electronic microscopy tem evaluate paramagnetism particle vibration specimen magnetometer vsm test cytotoxicity flow cytometry fcm prepared nanoparticle solution black without floccule sediment appear transparent dilute nanoparticle spherical dispersed water mean diameter 15 nm tem show superparamagnetic character fcm test show nanoparticle significant toxic effect malignant astrocytoma u251 cell line equal taxol alone result show superparamagnetic nanoparticle enhance solubility paclitaxel water also superparamagnetic cytotoxic make suitable tool magnetic target chemotherapy brain glioma 
multidrug resistance mdr cancer phenomenon administration single chemotherapeutic agent cause cross-resistance cancer cell variety therapy even different mechanism action development mdr standard therapy major challenge treatment cancer previously demonstrate unique ability cxl017 5 selectively target mdr cancer cell synergize mitoxantrone mx hl60/mx2 mdr cell expand scope demonstrate 5 synergize vincristine paclitaxel three different mdr cell line hl60/dnr k562/hht300 ccrf-cem/vlb100 also demonstrate 5 potent cytotoxicity nci-60 panel cell line average ic 50 1.04 mum addition 5 unique mechanism action comparison standard agent nci database base compare analysis structure-activity relationship study lead development potent analogue compound 7d ic 50 640 nm hl60/mx2 additionally one enantiomer 5 13-fold active less active enantiomer take together study lead discovery series analogue selectively target drug-resistant cancer cell potential treatment drug-resistant cancer 
series novel self-assembled hyaluronic acid derivative ha-c 18 graft hydrophobic octadecyl moiety dual target folic acid-conjugated ha-c 18 fa-ha-c 18 synthesize increase degree substitution octadecyl group 12.7 19.3 critical micellar concentration ha-c 18 copolymer decrease 37.3 10.0 μg/ml paclitaxel ptx successfully encapsulate hydrophobic core ha-c 18 fa-ha-c 18 micelle encapsulation efficiency high 97.3 physicochemical property polymeric micelle measure dls tem dsc moreover vitro release behavior ptx investigate dialysis bag method ptx release micelle near zero-order sustained manner vitro antitumor activity test suggest ptx-loaded ha-c 18 fa-ha-c 18 micelle exhibit significantly higher cytotoxic activity mcf-7 a549 cell compare taxol lower ptx concentration cellular uptake experiment conduct quantitative assay ptx cellular accumulation confocal laser scanning microscopy imaging coumarin-6 label ha-c 18 fa-ha-c 18 micelle folate receptor overexpress mcf-7 cell folate cd44 receptor competitive inhibition study perform fluorescence microscopy imaging suggest intracellular delivery ha-c 18 fa-ha-c 18 micelle efficiently take via cd44 receptor-mediated endocytosis folate receptor-mediated endocytosis enhance internalize amount fa-ha-c 18 micelle mcf-7 cell compare ha-c 18 micelle internalization pathway ptx-loaded ha-c 18 fa-ha-c 18 micelle might include clathrin-mediated endocytosis caveolae-mediated endocytosis macropinocytosis therefore present study suggest ha-c 18 fa-ha-c 18 copolymer biodegradable biocompatible cell-specific targetable nanostructure carrier promising nanosystem cellular intracellular target delivery hydrophobic anticancer drug 
study investigate effect combine lenalidomide docetaxel vitro vivo model prostate cancer potential strategy treatment castrate resistant prostate cancer crpc effect combine lenalidomide docetaxel proliferation apoptosis invasive potential anchorage independent growth p53 activation pc3 du145 prostate cell line investigate effect lenalidomide docetaxel combination lncap prostate cancer cell growth invasiveness vitro also study combination two agent finally test xenograft model pc3 tumor growth nude mouse lenalidomide decrease ic 50 docetaxel 50 p 0.05 also decrease invasion pc3 lncap du145 cell anchorage independent growth pc3 cell p 0.01 apoptosis lenalidomide/docetaxel-treated cell increase 2.2-fold single agent docetaxel corresponding increase p53 p38 bad activation observe western blot p 0.001 pc3 challenge mouse treat lenalidomide docetaxel median survival increase 48 59 day rate tumor growth significantly reduce p 0.05 lenalidomide may promising candidate combination docetaxel treatment crpc 
mycophenolic acid mpa deplete intracellular gtp block de novo guanine nucleotide synthesis gtp use ubiquitously dna/rna synthesis signaling molecule make surprising discovery anti-proliferative activity mpa act synergistically specific chemotherapeutic agent cell type-dependent manner mda-mb-231 cell mpa show extremely potent synergy 5-fu doxorubicin etoposide synergy 5-fu mpa work effectively highly tumorigenic mammary tumor cell compare less tumorigenic one work non-breast cancer cell type test exception pc3 cell contrary mpa show highest synergy paclitaxel 5-fu scc-25 cell derive oral squamous cell carcinoma mechanistically synergistic effect mpa 5-fu mda-mb-231 cell recapitulate inhibit rna polymerase-i activity require expression nucleostemin work reveal synergy mpa anti-proliferative agent determine cell type-dependent factor 
anaphase promote complex cofactor cdh1 play critical role tumor suppression genomic stability cancer however role chronic myeloid leukemia cml remain unclear treat wild-type imatinib-resistant k562 cell imatinib nilotinib bortezomib respectively sirnas cdh1 skp2 design transiently transfect hiperfect transfection reagent cml cell expression cdh1-skp2-p27 pathway protein detect western blotting cell cycle cell apoptosis cellular morphology detect flow cytometry wright staining study reveal cdh1 express lower level imatinib-resistant cml blast crisis bc patient imatinib-sensitive one moreover imatinib bortezomib induce cell cycle quiescence arrest upregulation nuclear relocation cdh1 cml cell furthermore nilotinib bortezomib result upregulation cdh1 imatinib-resistant cml cell conversely cdh1 silencing result stabilization skp2 cdc20 subsequently promote g1-s transition formation multinucleated cell study show tki bortezomib regulate cell cycle cell apoptosis via regulation expression redistribution cdh1 cml-bc shed light orchestration crosstalk tki bortezomib imatinib-resistant cml-bc additionally cdh1 tend play important role maintenance genomic stability detailed mechanism deserve study 
recent clinical evidence reveal use beta-blocker propranolol prior diagnosis concurrently chemotherapy increase relapse-free overall survival breast cancer patient therefore hypothesize propranolol may able increase efficacy chemotherapy either direct effect cancer cell via anti-angiogenic mechanism vitro proliferation assay show propranolol 50-100 μm induce dose-dependent anti-proliferative effect panel 9 human cancer normal cell line matrigel assay reveal propranolol display potent anti-angiogenic property non-toxic concentration less 50 μm exert vascular-disrupting activity combine chemotherapeutic drug 5-fluorouracil 5-fu paclitaxel propranolol lowest effective concentration result synergistic additive antagonistic effect cell proliferation vitro depend cell type dose chemotherapy use interestingly breast cancer vascular endothelial cell among responsive combination furthermore matrigel assay indicate low concentration propranolol 10 50 μm potentiate anti-angiogenic effect 5-fu paclitaxel use orthotopic xenograft model triple-negative breast cancer base s.c injection luciferase-expressing mda-mb-231 cell mammary fat pad nude mouse show propranolol use alone induce transient anti-tumor effect increase median survival however combination propranolol chemotherapy result profound sustained anti-tumor effect significantly increase survival benefit induce chemotherapy alone +19 +79 median survival combination compare 5-fu alone paclitaxel alone respectively p less 0.05 collectively result show propranolol potentiate anti-angiogenic effect anti-tumor efficacy chemotherapy current study together retrospective clinical datum strongly suggest use propranolol concurrently chemotherapy may improve outcome breast cancer patient thus provide strong rationale evaluation drug combination prospective clinical study 
combination chemotherapy treat cancer often superior clinical efficacy monotherapy aim study investigate schedule-dependent effect 5-fluorouracil 5-fu platinum derivative cisplatin oxaliplatin colorectal cancer crc cell line explore factor affect two human crc-derived cell line dld-1 hct116 use three treatment schedule test growth inhibitory effect evaluate wst-1 assay combined effect assess isobolograms combination index cellular accumulation dna-binding platinum measure inductively couple plasma mass spectrometry exposure 5-fu follow cisplatin produce synergistic effect dld-1 cell amount platinum bind dna substantially increase compare schedule 5-fu oxaliplatin also tend synergistic 5-fu give first significant change cellular kinetics platinum observe hand hct116 cell combined effect 5-fu platinum derivative comparable among three schedule exposure 5-fu follow cisplatin synergistic effect dld-1 cell suggest amount platinum bind dna contribute result also effect dependent type platinum derivative cell 
mesenchymal stromal cell msc consider suitable vehicle cellular therapy various condition expression reporter and/or effector protein s enable identification msc within organism exploitation target tumor therapy aim study evaluate cellular change induce retrovirus-mediated transgene expression msc vitro human adipose tissue-derived msc at-msc transduce express enhance green fluorescent protein egfp reporter transgene ii fusion yeast cytosine deaminase uracil phosphoribosyltransferase cdy uprt enzyme along expression dominant positive selection gene neor iii selection marker neor alone mock cdy uprt expression result increase proliferation cdy uprt-msc versus naïve at-msc mock-msc egfp-msc furthermore cdy uprt-msc significantly sensitive 5-fluorouracil 5fu cisplatin cyclophosphamide cytosine arabinoside determine increase caspase 3/7 activation and/or decrease relative proliferation cdy uprt-msc direct coculture breast cancer cell mda-mb-231 increase tumor cell killing induce low concentration 5fu datum demonstrate change proliferation chemoresistance engineer msc express transgene enzymatic function suggest possibility augmentation target msc-mediated antitumor therapy 
cancer cell acquire resistance therapy hypoxic condition aim investigate mechanism regulate chemoresistance induce hypoxia human colorectal cancer cell ht-29 sw480 culture hypoxic condition sensitivity 5-fluorouracil fu oxaliplatin sn-38 active metabolite irinotecan test cell cycle evaluate flow cytometry staining cell propidium iodide pi hypoxia-inducible factor 1α hif-1α expression evaluate western blot analysis hypoxia induce strong g 0 / g 1 cell cycle arrest cancer cell abrogate cytotoxic effect 5-fu oxaliplatin sn-38 effect dependent significant inhibition accumulation hif-1α cancer cell culture hypoxia sn-38 neither 5-fu oxaliplatin affect hif-1α expression sn-38 inhibition hif-1α overcome chemoresistance hypoxic condition colon cancer cell 
glioblastoma multiforme gbm common intracranial tumor dismal prognosis although temozolomide tmz base chemotherapy follow neurosurgery prove effective patient benefit clinically tmz resistance give protein expression o 6 methylguanine-dna-methyltransferase mgmt important determinant tmz resistance great effort make suppress regulate mgmt-related transcription factor study present demonstrate resveratrol natural polyphenol able reverse tmz resistance glioblastoma t98g cell relatively high mgmt activity datum show combination treatment tmz resveratrol result enhance antitumor potential tmz decrease 50 inhibit concentration ic50 tmz increase induction apoptosis tmz-resistant t98g cell hoechst 33258 staining reveal increase apoptotic morphology chromatin aggregation nuclear cytoplasmic condensation cell receive combination treatment western blot analysis manifest significant decrease intracellular content nuclear translocation nf-κb increase cleavage caspase-3 cell expose combination treatment compare cell treat tmz alone addition recombinant expression nf-κb subunit p65 remarkably promote nuclear translocation nf-κb abolish tmz-resistance reversal induce combination treatment suggest underlie nf-κb-dependent mechanism study improve knowledge mechanism tmz resistance suggest novel strategy tmz-based chemotherapy glioblastoma patient 
elafin report abundantly express human epithelial ovarian carcinoma eoc however function poorly understand evaluate role elafin modulate sensitivity human eoc cell chemotherapeutic drug elafin expression determine elisa 9 establish human eoc cell line lentivirus encode elafin-specific shrna use down-regulate elafin expression ovcar3 ov433 cell plasmid encode elafin use ectopically express elafin elafin-negative skov3 cell sensitivity cisplatin genotoxic agent paclitaxel inhibitor microtubule depolymerization examine ovcar3 ov433 skov3 subline cell viability determine mtt assay apoptosis annexin v/7-aad staining caspase activation fluorimetric assay knockdown elafin gene decrease cisplatin ic50 least 2-fold ovcar3 ovcar433 cell p 0.01 affect paclitaxel ic50 sensitivity genotoxic agent carboplatin cyclophosphamide 5-fluorouracil also increase silence expression elafin apoptosis caspase-3 activation significantly augmented cisplatin-treated ovcar3 cell silence elafin overexpression elafin skov3 cell make resistant cisplatin decrease cisplatin-induced apoptosis caspase activation p 0.01 expression elafin decrease sensitivity human eoc cell several genotoxic agent may important implication predict response patient eoc chemotherapy clinic 
high-linear energy transfer radiation offer superior biophysical property conventional radiotherapy may great potential treat radioresistant tumor glioblastoma however little pre-clinical datum exist effect high-let radiation glioblastoma cell line concomitant application chemotherapy study investigate vitro effect temozolomide combination low-energy proton α particle cell survival dna damage repair cell growth examine four human glioblastoma cell line ln18 t98g u87 u373 treatment either x ray proton let 12.91 kev/μm α particle let 99.26 kev/μm without concurrent temozolomide clinically-relevant dose 25 50 μm relative biological effectiveness 10 survival rbe 10 increase let increase 1.17 1.06 proton 1.84 1.68 α particle ln18 u87 cell line respectively temozolomide administration increase cell killing o 6 methylguanine dna methyltransferase-methylated u87 u373 cell line contrast temozolomide provide therapeutic enhancement methylguanine dna methyltransferase-unmethylated ln18 t98g cell line addition residual number γ-h2ax focus 24 h treatment radiation concomitant temozolomide find lower equal expect dna damage either individual treatment kinetics focus disappearance x-ray proton irradiation follow similar time course whereas loss γ-h2ax focus α particle irradiation occur slower rate low-let radiation half-life 12.51-16.87 h combination temozolomide different radiation type cause additive rather synergistic cytotoxicity nevertheless particle therapy combine chemotherapy may offer promising alternative additional benefit superior biophysical property also possible new fractionation schedule design exploit change dna repair kinetics mgmt-methylated cell respond high-let radiation 
malignant pleural mesothelioma mpm aggressive tumor poor prognosis effective therapy remain establish study investigate therapeutic potential gene delivery use suppressor cytokine signaling 1 socs-1 endogenous inhibitor intracellular signaling pathway treatment mpm infected mpm cell meso-4 h28 h226 adenovirus-expressing socs-1 vector examine effect socs-1 overexpression mpm cell evaluate antitumor effect socs-1 gene delivery combine cisplatin plus pemetrex cell proliferation apoptosis invasion assay also investigate regulation nf-κb stat3 signaling related apoptotic pathway furthermore evaluate inhibition tumor growth socs-1 gene delivery combine cisplatin plus pemetrex vivo socs-1 gene delivery cooperate cisplatin plus pemetrex inhibit cell proliferation invasiveness induction apoptosis mpm cell socs-1 regulate nf-κb stat3 signaling induce apoptosis meso-4 h226 cell furthermore socs-1 gene delivery cooperate cisplatin plus pemetrex regulate nf-κb signaling significantly inhibit tumor growth mpm vivo result suggest socs-1 gene delivery potent antitumor effect mpm potential clinical use combination cisplatin plus pemetrexed 
il-6 / 6r signaling closely associate tumor growth poor prognosis although evidence interleukin-6 receptor il-6r mediate signaling promote growth malignancy cancer role il-6r cancer stem cell csc poorly define study investigate role il-6r proliferation csc sphere-forming cell isolate h460 non-small cell lung cancer nsclc cell line identify csc use confocal microscopy rt-pcr wst-1 assay h460 sphere demonstrate typical characteristic csc include cd133 expression upregulation nanog self-renewal drug resistance methotrexate mtx fluorouracil 5-fu release il-6r ligand il-6 quantitatively determine compare csc non-csc concentration soluble il-6r sil-6r remarkably high csc compare non-cscs furthermore significant upregulation il-6r gene also observe csc growth csc significantly inhibit transfection il-6r small-interfering rna sirna well il-6r monoclonal antibody mab addition block il-6r il-6 use sirna mab intensify inhibition csc proliferation finding indicate il-6r present csc important role proliferation csc h460 lung cancer cell line therefore suggest il-6r viable target development csc-directed lung cancer therapeutics potential csc marker nsclc 
current study undertake characterize effect anti-metabolite induce cxcl8 signaling determine whether constitutive and/or drug-induced cxcl8 signaling metastatic prostate cancer cap cell modulate sensitivity class agent response metastatic cap cell 5-fluorouracil 5-fu pemetrexed tomudex determine use cell count assay flow cytometry parp cleavage analysis quantitative-pcr elisa immunoblot employ determine effect drug cxcl8 administration target gene/protein expression administration 5-fu pemetrexed potentiate cxcl8 secretion increase cxcr1 cxcr2 gene expression metastatic pc3 cell consistent inhibition cxcl8 signaling use cxcr2 antagonist az10397767 increase cytotoxicity 5-fu 4-fold p 0.001 increase 5-fu-induced apoptosis pc3 cell p 0.01 contrast administration az10397767 effect sensitivity pemetrexed cxcr2 antagonist exert greatest effect increase sensitivity pc3 cell tomudex direct thymidylate synthase ts inhibitor subsequent experiment confirm administration recombinant human cxcl8 increase ts expression response mediate part cxcr2 receptor moreover sirna-mediated knockdown cxcl8-target gene bcl-2 increase sensitivity pc3 cell 5-fu cxcl8 signaling provide selective resistance metastatic prostate cancer cell specific anti-metabolite promote target-associated resistance addition underpin evasion treatment-induced apoptosis 
introduction clinically available small-molecule kinase inhibitor multi-targeted inhibit multiple kinase drive hypothesis one multi-targeted tyrosine kinase inhibitor tki antiproliferative activity ros1 translocate non-small-cell lung cancer nsclc method select nsclc cell line -- a549 kras g12s nci-h3255 egfr l858r nci-h3122 eml4-alk e13 a20 hcc78 slc34a2-ros1 evaluate antiproliferative effect submicromolar concentration multitargeted tki imatinib sorafenib erlotinib crizotinib result imatinib sorafenib unable significantly inhibit proliferation aforementioned cell line erlotinib inhibit egfr mutate nci-h3255 expect crizotinib display dose-dependent inhibition anaplastic lymphoma kinase translocate nci-h3122 also ros1 -- translocate hcc78 slc34a2-ros1 translocate hcc78 cell line phosphorylate level ros1 akt erk inhibit submicromolar dose crizotinib subsequently undergo apoptosis conclusion ros1-translocated hcc78 cell line sensitive inhibition multitargeted alk/met/ron / ros1 inhibitor crizotinib preclinical datum support clinical development crizotinib ros1-translocated nsclc 
many effective drug cancer treatment poorly water-soluble combination chemotherapy need excipient additive formulation often toxic restrict application clinical intervention report amphiphilic poly 2-oxazoline s pox micelle promising high capacity delivery platform multidrug cancer chemotherapy variety binary ternary drug combination paclitaxel ptx docetaxel dtx 17-allylamino-17-demethoxygeldanamycin 17-aag etoposide eto bortezomib btz solubilize define polymeric micelle achieve unprecedented high total load capacity 50 wt drug per final formulation multidrug loaded pox micelle show enhance stability comparison single-drug loaded micelle drug ratio dependent synergistic cytotoxicity micellar eto/17-aag observe mcf-7 cancer cell micellar btz/17-aag mcf-7 pc3 mda-mb-231 hepg2 cell 
sorafenib sunitinib multi-kinase inhibitor antitumor activity patient advanced renal cell carcinoma rcc several study evaluate effect sorafenib/sunitinib combination chemotherapeutic agent different type tumor however study address activity fluorinate pyrimidine combination sorafenib/sunitinib study examine potential combination therapy 5fu sorafenib/sunitinib human rcc cell line three human rcc cell line achn caki-1 caki-2 use assess sensitivity 5-fluorouracil 5fu sorafenib sunitinib alone combination use vitro cell survival assay caki-2 cell demonstrate significantly higher resistance 5fu sorafenib compare achn caki-1 additive antitumor effect combination therapy observe vitro study tendency positive correlation sensitivity sunitinib platelet-derived growth factor beta pdgfr-beta expression level examine reverse transcription polymerase chain reaction caki-1 xenograft model prepare inoculate cell subcutaneously nude mouse divide randomly six group control 5fu 8 mg/kg/day intraperitoneally sorafenib 15 mg/kg/day orally sunitinib 20 mg/kg/day orally 5fu sorafenib sunitinib treatment administer 5 day week tumor growth monitor 42 day follow inoculation cell synergistic antitumor effect combination therapy observe vivo study resected tumor evaluate use ki-67 labeling index microvessel density ki-67 labeling index microvessel density decrease tumor treat combination therapy compare treat sorafenib/sunitinib alone finding suggest combination therapy 5fu sorafenib/sunitinib may effective therapeutic modality advanced rcc patient 
effect combined administration multi-targeted receptor tyrosine kinase rtk inhibitor sorafenib chemotherapy pemetrexed still unknown cytotoxicity optimal combined modality mechanism underlie cytotoxic synergism sorafenib pemetrex egfr tki-resistant nsclc cell line investigate a549 egfr wild-type kras mutation h1975 egfr mutation kras wild-type cell line treat pemetrexed and/or sorafenib vitro ic50 value ci combination index cell cycle distribution phospho-p44 / 42mapk assess cell line cytotoxic interaction sorafenib pemetrex dose dependent egfr tki-resistant nsclc cell line administration pemetrexed-sorafenib sequence synergistic effect advantage sorafenib-pemetrexed sequence concomitant administration cell line cell cycle analysis show sorafenib arrest cell mainly g1 phase pemetrexed arrest cell mainly s phase exposure sorafenib first induce g1 arrest subsequently prevent cytotoxicity s phase specific drug pemetrex exposure pemetrexed result increase phospho-p44 / 42mapk level inhibit subsequent exposure sorafenib u0126 inhibitor mapk kinase also enhance cytotoxicity pemetrex sequence dependent manner tki-resistant cell line likewise pemetrexed-activated mapk signaling pathway subsequently inhibit u0126 sequence pemetrexed follow sorafenib synergistic effect advantage sequence egfr tki-resistant nsclc cell line synergistic mechanism due sorafenib subsequently inhibit pemetrexed-activated mapk signaling pathway result may provide molecular evidence support clinical treatment strategy patient egfr tki-resistant lung cancer 
series acrylamide analogue design synthesize imatinib nilotinib novel bcr-abl inhibitor application principle nonclassical electronic isostere new compound evaluate inhibitory effect activity bcr-abl kinase proliferation k562 leukemia cancer cell vitro acrylamide analogue substituent c ring trifluoromethyl group identify highly potent bcr-abl kinase inhibitor compound 13f exhibit ic 50 value low 20.6 nm abl kinase inhibition ic 50 value 32.3 nm antiproliferative activity 10.5-fold 12-fold lower imatinib respectively result suggest compound 13f promising candidate novel bcr-abl kinase inhibitor development 
chemoresistance represent major obstacle successful treatment malignant glioma temozolomide n 7 methyl-g n 3 methyl-a adduct comprise 80 dna lesion induce temozolomide process base excision repair suggest cellular resistance cause part efficient repair pathway although study focus subject aim study evaluate cellular response temozolomide treatment associate methoxyamine blocker base excision repair glioblastoma cell line order test hypothesis blockage base excision repair pathway might sensitize glioblastoma cell temozolomide test cell line t98g show significant difference temozolomide temozolomide plus methoxyamine treatment observe reduce survival rate enhance level dna damage induce arrest g2-phase addition ~ 10 apoptotic cell sub-g1 fraction observe 48 h. western blot analysis demonstrate ape1 fen1 present slightly reduce expression level combined treatment probably due ap site blockade methoxyamine thus cause minor requirement base excision repair pathway downstream ap removal ape1 hand pcna expression temozolomide plus methoxyamine-treated cell rule possibility alteration might relate blockage cell cycle g2-phase observe 24 h recovery time result obtain present study demonstrate efficiency methoxyamine overcome glioblastoma resistance temozolomide treatment 
chromosomal instability key feature cancer progression recently report brca1 regulate transcription several gene prostate cancer include atm ataxia telangiectasia mutate although well accept atm pivotal mediator genotoxic stress unknown whether atm transcription regulate molecular response dna damage investigate atm transcription regulation human prostate tumor pc3 cell line find doxorubicin mitoxantrone repress atm transcription pc3 cell etoposide methotrexate affect atm expression demonstrate brca1 bind atm promoter doxorubicin exposure release brca1 overexpression increase atm transcription enhancement abolish brca1 depletion moreover brca1-brct domain loss impair ability brca1 regulate atm promoter activity strongly suggest brct domain essential atm regulation brca1 brca1-overexpressing pc3 cell expose ku55933 atm kinase inhibitor show significant decrease atm promoter activity compare untreated cell suggest atm transcriptional regulation brca1 partially mediate atm kinase activity addition demonstrate e2f1 binding atm promoter doxorubicin exposure e2f1 overexpression diminish atm transcription doxorubicin exposure impair e2f1 dominant negative mutant finally co-regulator transcription ctip increase atm transcription ctip increase atm transcription altogether brca1/e2f1/ctip binding atm promoter activate atm transcription doxorubicin exposure release brca1 ctip atm promoter still keep e2f1 recruit turn repress atm expression 
imatinib nilotinib interact abcb1 abcg2 however whether substrate inhibitor source conjecture vitro bcr-abl kinase inhibition use elucidate impact abcb1/abcg2 overexpression imatinib nilotinib transport high level abcb1 protein k562-dox cell result significantly increase 50 inhibitory concentration ic 50 compare parental k562 cell imatinib ic 50 9 µm 19 µm p = 0.002 nilotinib ic 50 nil 345 nm 620 nm p = 0.013 difference abrogate abcb1 inhibitor however overexpression abcg2 significantly increase ic 50 ic 50 nil significantly decrease ic 50 upon abcg2 inhibition inhibition abcb1 abcg2 result substantial increase intracellular nilotinib use 150 nm increase use 2 µm imatinib nilotinib appear transport abcb1 interact strongly abcg2 furthermore abcb1 efflux nilotinib may concentration-dependent transport occur clinically relevant concentration 
o 6 methylguanine-dna methyltransferase mgmt dna-repair protein promote resistance tumor cell alkylate chemotherapeutic agent glioma cell particularly resistant class drug include temozolomide tmz carmustine bcnu previous study use rna microarray technique show decrease mgmt mrna stand among alteration gene expression cause cell growth-depressing transfection t98g glioma cell line liver-type glutaminase lga szeliga et al. 2009 glia 57 1014 show stably lga-transfected cell tlga exhibit decrease mgmt protein expression activity compare non-transfected mock transfect cell control however decrease expression occur absence change methylation promoter region indicate lga circumvent yet unknown route common mechanism mgmt silencing tlga turn significantly sensitive treatment 100-1000 μm tmz bcnu acute cell growth inhibition assay mtt clonogenic survival assay tlga cell display increase sensitivity even 10 μm tmz bcnu result indicate enrichment lga addition inhibit glioma growth may facilitate chemotherapeutic intervention 
thiarabine undergo clinical trial support effort combination therapy thiarabine plus six clinical anticancer agent evaluate use various human tumor xenograft model antitumor activity thiarabine combination appear greater additive irinotecan dld-1 colon paclitaxel pc-3 prostate cisplatin pc-3 prostate cyclophosphamide rl lymphoma additive irinotecan nci-h460 nsclc cisplatin nci-h460 nsclc methotrexate ccrf-cem leukemia less additive irinotecan ht29 colon paclitaxel nci-h460 nsclc cisplatin nci-h23 nsclc combine thiarabine irinotecan paclitaxel cisplatin cyclophosphamide receive consideration clinical treatment cancer 
addition primary culturing cancer stem cell csc tumor tissue csc find established tumor cell line however unclear culture condition affect csc enrichment additionally differentiation potential cell line-derived csc well study study glioblastoma cell line ln229 t98g u251n u87 culture sphere serum-containing medium serum sphere serum-free medium serum-free sphere find ln229 u251n cell express multiple stem cell marker nestin sox2 musashi-1 cd44 serum sphere express even higher level nestin sox2 musashi-1 compare monolayer cell serum‑free sphere ln229 u251n cell show higher migration colony formation potential compare t98g u87 cell express nestin sox2 musashi-1 serum sphere ln229 u251n cell also exhibit higher resistance temozolomide compare serum-free sphere tumor cell line show neuronal differentiation tuj-1 positive u251n serum sphere exhibit astrocytic gfap‑positive neuronal differentiation conclude sphere culture serum-containing medium provide efficient enrichment cancer stem cell u251n cell distinguish tumor cell due potential multilineage differentiation 
design short hairpin rna shrna interference sequence silence glutathione s-transferase p1 gstp1 gene androgen independent prostate cancer cell line du145 explore effect proliferation sensitivity chemotherapeutic target sequence pick form shrna 3 shrna expression vector shrna255 shrna554 shrna593 dna template clone plasmid pgpu6/gfp/neo shrna identify enzyme digest gene sequencing screening experiment pick shrna expression vector highest transfection ratio best gene silencing result du145 cell divide blank plasmid group shrna transfect group accord chemotherapeutic du145 cell divide fluorouracil fu group paclitaxel pa group 2 group subdivide 4 subset accord chemotherapeutic concentration fu 30 60 120 240 μg/ml pa 0.2 2 10 20 μg/ml meanwhile blank control group include respectively 3 4,5-dimethylthiazol-2-yl -2,5-diphenyl tetrazolium bromide mtt assay use evaluate proliferation transfection mtt terminal de-oxynucleotidyl transferase-mediated dutp nick end labeling tunel assay use detect inhibition effect different concentration 5-fu pa proliferation induction apoptosis du145 transfection ratio 3 shrna expression vector shrna255 shrna554 shrna593 63.30 ± 1.04 76.20 ± 0.68 72.70 ± 0.33 transfection ratio shrna554 highest significant difference among 3 shrna expression vector p 0.01 transfection mrna 128.31 ± 2.50 43.24 ± 4.30 85.62 ± 6.30 gstp1 protein 163.92 ± 12.40 65.38 ± 9.30 114.25 ± 16.70 transfection shrna554 mrna protein gstp1 lowest level significant difference among 3 shrna expression vector p 0.01 mtt analysis show transfection survival ratio cell different concentration fu 30 60 120 240 μg/ml 95.60 ± 2.11 90.20 ± 0.86 83.10 ± 3.12 74.60 ± 1.32 however transfection survival ratio cell 91.30 ± 1.43 84.60 ± 2.13 73.20 ± 1.52 65.5 ± 0.942 tunel assay show transfection apoptosis ratio cell different concentration fu 30 60 120 240 μg/ml 5.50 ± 0.88 10.20 ± 1.64 15.20 ± 2.39 25.10 ± 2.59 however transfection apoptosis ratio cell 10.8 ± 0.62 15.7 ± 1.32 20.4 ± 1.89 34.9 ± 2.54 transfection cell survival ratio decrease concentration fu apoptosis ratio increase statistical significance p 0.01 mtt analysis show transfection survival ratio cell different concentration pa 0.2 2 10 20 μg/ml 98.50 ± 2.34 95.20 ± 1.32 89.40 ± 0.68 82.70 ± 1.73 transfection survival ratio cell 94.20 ± 0.78 86.50 ± 2.13 78.70 ± 1.34 70.10 ± 0.76 tunel assay show transfection apoptosis ratio cell different concentration pa 0.2 2 10 20 μg/ml 2.40 ± 1.07 5.20 ± 1.33 10.50 ± 2.41 20.70 ± 1.92 transfection apoptosis ratio cell 5.46 ± 2.13 13.80 ± 1.24 21.20 ± 2.39 29.20 ± 2.21 transfection cell survival ratio decrease pa concentration apoptosis ratio increase statistical significance p 0.01 gene gstp1 silence via shrna transfection androgen independent prostate cancer cell line du145 inhibit proliferation time dependent manner induce apoptosis raise sensitivity chemotherapeutic 
study combination therapy use oral fluoropyrimidine tegafur-gimeracil-oteracil s-1 several target agent antibody evaluate first effect tyrosine kinase inhibitor erlotinib hydrochloride sorafenib tosilate sunitinib malate human non-small cell lung cancer nsclc breast cancer colorectal cancer evaluate vivo effect combination s-1 target antibody bevacizumab cetuximab human colorectal cancer also evaluate vivo s-1 epidermal growth factor receptor egfr tyrosine kinase inhibitor erlotinib show significant inhibition growth human nsclc lu-99 pc-9 cell line antitumor activity combination s-1 erlotinib lu-99 pc-9 cancer cell line significantly superior either monotherapy p 0.05 combination therapy use multi-tyrosine kinase inhibitor sorafenib sunitinib s-1 breast cancer mx-1 cell line nsclc nci-h460 cell line significantly superior either monotherapy p 0.01 combination anti-vascular endothelial growth factor antibody bevacizumab anti-egfr antibody cetuximab s-1 human colorectal cancer col-1 km20c bevacizumab dld-1 cetuximab cell line 5-fluorouracil 5-fu resistant cell line km12c/5-fu significantly superior either monotherapy p 0.01 particular growth col-1 cell completely inhibit combination s-1 bevacizumab toxic mortality significant difference body weight change animal treat s-1 combine target agent mono-therapy observe therefore treatment appear well-tolerated preclinical finding indicate combination therapy s-1 target agent promising treatment option 
chemoprotection haematopoietic stem cell hsc gene therapeutic transfer drug-resistance gene represent encouraging approach prevent myelosuppression one severe side effect tumor therapy thus clone evaluate six different bicistronic lentiviral sin vector encode two transgene mgmt p140k o 6 benzylguanine-resistant mutant methylguanine-dna methyltransferase mdr1 multidrug resistance 1 use various linker sequence iresemcv iresfmdv 2a-element fmdv f2a expression transgene hl-60 k562 cell assay quantitative real-time pcr combination therapy acnu plus paclitaxel hl-60 cell carmustin bcnu plus doxorubicin k562 cell result significant survival advantage cell transduce lentiviral vector hr sin-mgmt p140k f2a-mdr1 compare untransduced cell human hsc overexpression transgene vector also cause significantly increase survival enrichment transduce cell treatment bcnu plus doxorubicin temozolomide plus paclitaxel summary show significant chemoprotection overexpression mdr1 mgmt p140k lentiviral vector use f2a linker element two different haematopoietic cell line human primary hsc various combination regimen consequently convince vitro investigation will help improve combination chemotherapy regimen reduce myelotoxic side effect increase therapeutic efficiency 
treatment colon cancer antagonist growth hormone-releasing hormone ghrh jmr-132 result cell cycle arrest s-phase tumor cell thus investigate effect jmr-132 combination s-phase-specific cytotoxic agent 5-fu irinotecan cisplatin vitro vivo growth ht-29 hct-116 hct-15 human colon cancer cell line vitro every compound inhibit proliferation hct-116 cell dose-dependent manner treatment jmr-132 5 μm combine 5-fu 1.25 μm irinotecan 1.25 μm cisplatin 1.25 μm result additive growth inhibition hct-116 cell vitro show mts assay cell cycle analysis reveal treatment hct-116 cell jmr-132 accompany cell cycle arrest s-phase combination treatment use jmr-132 plus cytotoxic drug lead significant increase sub-g 1 fraction suggest apoptosis vivo daily treatment ghrh antagonist jmr-132 decrease tumor volume 40-55 p 0.001 ht-29 hct-116 hct-15 tumor xenograft athymic nude mouse combined treatment jmr-132 plus chemotherapeutic agent 5-fu irinotecan cisplatin result additive tumor growth suppression ht-29 hct-116 hct-15 xenograft 56-85 observation indicate jmr-132 enhance antiproliferative effect s-phase-specific cytotoxic drug cause accumulation tumor cell s-phase 
glioblastoma multiforme common malignant central nervous system tumor also among difficult treat due lack response chemotherapeutic new method counter mechanism confer chemoresistance malignant glioma lead significant advance quest identify novel drug combination target drug delivery system cancer therapy study investigate use target nitric oxide donor pretreatment sensitize glioma cell chemotherapy protein chlorotoxin ctx show preferentially target glioma cell develop ctx-no glioma-specific no-donating ctx derivative pretreatment cell ctx-no follow 48-h exposure either carmustine bcnu temozolomide tmz common chemotherapeutic use glioma treatment result increase efficacy therapeutics ctx-no exposure t98g u-87mg human malignant glioma cell show increase sensitivity bcnu tmz investigation reveal consequence combination therapy reduction active level cytoprotective enzyme mgmt altered p53 activity essential dna repair tumor cell resistance chemotherapy combination ctx-no chemotherapeutic also lead decrease cell invasion study indicate target donor invaluable tool development novel approach treat cancer 
objective evaluate efficacy combination navitoclax carboplatin paclitaxel ovarian cancer method 8 ovarian cancer cell line treat either doublet triplet combination navitoclax carboplatin paclitaxel interaction assess determine combination index measure caspase activity effect combination also evaluate measure inhibition cell grow spheroid result navitoclax exhibit modest ic 50 = 3-8 mum single agent potency antagonism carboplatin paclitaxel evident ovcar-4 ovcar-8 skov-3 cell drug combination include navitoclax carboplatin and/or paclitaxel show significantly less antagonism even synergy several cell line carboplatin/paclitaxel alone navitoclax enhance activation caspase 3/7 induce carboplatin and/or paclitaxel igrov-1 cell combination navitoclax carboplatin paclitaxel show additive activity igrov-1 spheroid conclusion navitoclax improve activity combination carboplatin paclitaxel vitro observation take publish datum provide rationale clinical trial navitoclax ovarian cancer combination chemotherapy 
constitutive expression bcr-abl kinase chronic myelogenous leukaemia cml know produce elevated level reactive oxygen species ros enhance cell survival well generate genomic instability laboratory previously demonstrate nadph oxidase nox activity contribute intracellular-ros level bcr-abl-positive cell induce increase pro-survival signalling pi3k/akt pathway bcr-abl signalling regulate nox activity still remain elucidate study use k562 cml cell line show inhibition bcr-abl signalling either imatinib nilotinib lead significant reduction ros level concurrent gsk-3β dependent post-translational down-regulation small membrane-bound protein p22phox essential component nox complex furthermore sirna knockdown p22phox cell establish importance ros production proliferation take together believe result provide possible link bcr-abl signalling ros production nox activity demonstrate novel mechanism action associate imatinib nilotinib treatment cml 
treatment malignant glioma generally consist cytoreductive surgery follow radiotherapy chemotherapy study intend investigate effect 2-propylpentanoic acid vpa histone deacetylase inhibitor chemosensitivity radiosensitivity human glioma cell line human glioma cell line t98-g sf295 treat temozolomide tmz irradiation ir without vpa 1.0 mmol/l cytotoxicity clonogenic survival assay perform cell cycle stage apoptosis autophagy also detect use flow cytometry dansyl monocadaverin mdc incorporation assay one-way analysis variance anova t-test use analyze difference among variant group mild cytotoxicity vpa reveal cell line t98-g sf295 50 inhibit concentration ic50 value 3.85 ± 0.58 mmol/l 2.15 ± 0.38 mmol/l respectively ic50 value tmz 0.20 ± 0.09 mmol/l t98-g 0.08 ± 0.02 mmol/l sf295 moreover combine vpa 1.0 mmol/l 96 hour sensitivity glioma cell tmz significant increase p 0.05 survive fraction 2 gy sf2 t98-g sf295 cell expose ir alone 0.52 0.58 however vpa combine ir sf2 t98-g sf295 drop 0.39 p = 0.047 0.49 p = 0.049 respectively treatment vpa plus tmz ir also result significant decrease proportion cell g2 phase increase apoptotic rate well autophagy t98-g sf295 cell line p 0.01 vpa may enhance activity tmz ir glioma cell possibly cell cycle block promote autophagy thus potential sensitizer glioma treatment 
favorable outcome chemotherapy glioblastoma unequivocally link promoter hypermethylation o6-methylguanine-dna methyltransferase mgmt gene encode dna repair enzyme associate resistance alkylating agent indicate molecular mechanism determine mgmt expression yet fully elucidate show glioblastoma capable downregulate mgmt expression independently promoter methylation elongation 3 utr mrna render alternatively polyadenylated transcript susceptible mirna-mediated suppression elongate transcript poorly express normal brain abundance human glioblastoma specimen inversely correlate mgmt mrna expression use bioinformatically guide experimental approach identify mir-181d mir-767-3p mir-648 significant post-transcriptional regulator mgmt glioblastoma first two mirna induce mgmt mrna degradation latter affect mgmt protein translation regression model include two mirna influence mgmt mrna expression mgmt methylation status reliably predict cancer genome atlas mgmt expression datum responsivity mgmt express t98g glioma cell temozolomide significantly enhance transfection mir-181d mir-767-3p mir-648 take together result uncovered alternative polyadenylation mgmt 3 utr mirna targeting new mechanism mgmt silencing 
three new triphenyltin iv complex viz. triphenylstannyl 2 e 4-hydroxy-3 e 4 methoxycarbonyl phenyl imino methyl phenyl diazenyl benzoate ph 3 snl 2 h 2 methyl 2 e 4-hydroxy-3 e 4 triphenylstannyl oxy carbonyl phenyl imino methyl phenyl diazenyl benzoate ph 3 snl 3 h 3 triphenylstannyl 2 e 4-hydroxy-3 e 4 triphenylstannyl oxy carbonyl phenyl imino methyl phenyl diazenyl benzoate ph 3 sn 2 l 4 h 4 synthesize characterize spectroscopic 1 h 119 sn nmr ir technique combination elemental analysis 119 sn nmr spectral datum record non-coordinating solvent indicate tetrahedral coordination geometry solution solid state single-crystal x-ray diffraction analysis dinuclear complex ph 3 sn 2 l 4 h 4 reveal monocapped tetrahedral coordination geometry anisobidentate coordination mode carboxylate group average bond angle around sn atom 113.5 112.2 respectively vitro cytotoxicity study perform three complex 2-4 along previously report parent aquatriphenylstannyl complex 2 3-formyl-4-hydroxyphenyl diazenyl benzoate ph 3 snl 1 h.oh 2 1 across panel human tumor cell line viz. a498 evsa-t h226 igrov m19 mel mcf-7 widr screening result compare related triphenyltin iv carboxylate contain imino 11-16 ii diazenyl framework 1 5-10 general complex 2-4 exhibit good cytotoxic activity among compound 4 find best performer particularly evsa-t mcf-7 cell line additionally 4 score better activity cisplatin 2-15 fold 5-fluorouracil etoposide across panel cell line docking study indicate diazenyl imino nitrogen atom oxygen atom triphenyltin ester methyl ester phenolic group play important role complexation organotin compound active site enzyme ribonucleotide reductase pdb id 4r1r thymidylate synthase pdb id 2g8d thymidylate phosphorylase pdb id 1brw topoisomerase ii pdb id 1qzr 
metronomic use chemotherapeutic drug presume anti-angiogenic effect current study aim test effect lower dose cytotoxic agent vegf secretion tumor cell line test cytotoxic effect widely use chemotherapeutic drug include 5-florouracil irinotecan oxaliplatin paclitaxel docetaxel tumor cell line mcf-7 human breast cancer cell line ht-29 human colon cancer cell line primary gastric cancer cell line calculate ic50 value also assay effect lower dose chemotherapeutic drug level vegf secrete tumor cell vitro human primary gastric cancer cell resistant 5-fu oxaliplatin ht29 mcf-7 cell line p 0.001 significant difference notice term ic50 value irinotecan docetaxel paclitaxel among study tumor cell line p 0.05 test drug yield significant decrease vegf level dose -2 log ic50 value mcf-7 primary gastric cancer cell line 5-florouracil inhibit vegf secretion ht-29 cell line irinotecan oxaliplatin docetaxel paclitaxel significantly decrease level secrete vegf result suggest lower dose chemotherapeutic drug decrease vegf secretion tumor cell without cause substantial cell killing datum suggest occurrence kind selective drug-tumor cell type relationship 
cytotoxin family cobra venom protein also call cardiotoxin activate necrotic apoptotic cell death pathway cancer cell cytotoxin 1 ctx1 naja atra cantor venom 60 amino acid 6698 da protein yet untested anticancer efficacy cell selectivity test toxicity ctx1 number cancer cell line mcf-7 p388 k562 h22 one normal human cell line 16hbe rank order cytotoxicity mcf-7 p388 ≈ k562 h22 ≈ 16hbe indicate effect ctx1 certain cancer cell type relatively selective.treatment ctx1 greatly prolong survival p388 ascite tumor bear km mouse compare cyclophosphamide treatment cell viability apoptosis lysosomal permeability assay demonstrate ctx1 induce dose time-dependent cell death cell exhibit morphological biochemical feature late apoptosis necrosis mitochondrial membrane potential lose ctx1-treated p388 cell addition ctx1 induce increase lysosomal membrane permeability cathepsin b protease activity analysis reveal ctx1 possess significant selective anticancer activity likely induce program cell death mitochondrial and/or lysosomal pathway 
atg7 key autophagy-promoting gene play critical role regulation cell death survival various cell type report microrna mirna class endogenous 22-24 nucleotide noncoding rna molecule able affect stability translation mrna may represent novel mechanism regulate atg7 expression therefore autophagy demonstrate atg7 potential target mir-17 mirna negatively regulate atg7 expression result modulation autophagic status t98g glioblastoma cell treatment tumor cell mir-17 mimic decrease antagomir increase expression atg7 protein dual luciferase reporter assay confirm specific mir-17 binding sequence 3 utr atg7 contribute modulation expression gene mir-17 interestingly result show anti-mir-17 administration activate autophagy autophagosome formation result lc3b atg7 protein expression increase analysis gfp-lc3 positive autophagosome vesicle living cell furthermore autophagy activation anti-mir-17 result decrease threshold resistance temozolomide dose t98g cell mir-17 modulation u373-mg glioblastoma cell result sensitization low ionize radiation dose study role mir-17 regulate atg7 expression autophagy reveal novel function mirna sequence critical cellular event significant impact cancer development progression treatment 
thiopurine antimetabolite 6-mercaptopurine 6-mp 6-thioguanine 6-tg inactive pro-drug require intracellular metabolism activation cytotoxic metabolite thiopurine methyltransferase tpmt one important enzyme process metabolize 6-mp 6-tg different methylate metabolite include methylthioinosine monophosphate metimp methylthioguanosine monophosphate metgmp respectively different suggest pharmacological cytotoxic property metimp potent inhibitor de novo purine synthesis dnps significantly contribute cytotoxic effect 6-mp metgmp add much effect 6-tg cytotoxicity 6-tg seem dependent incorporation thioguanine nucleotide tgn dna rather inhibition dnp order investigate role tpmt metabolism thus cytotoxic effect 6-mp 6-tg knock expression gene encode tpmt enzyme use specifically design small interference rna sirna human molt4 leukemia cell knock-down confirm rna protein enzyme function level apoptosis determine use annexin v propidium iodide staining facs analysis result show 34 increase sensitivity molt4 cell 1μm 6-tg treatment tpmt-targeting sirna compare cell transfect non-targeting sirna sensitivity cell toward 6-mp affect significantly down-regulation tpmt gene differential contribution enzyme tpmt cytotoxicity two thiopurine probably due role formation metimp cytotoxic methylate metabolite 6-mp case 6-tg methylation tpmt substantially deactivate drug 
retrospectively compare primary treatment weekly carboplatin/paclitaxel pc-w standard 3-weekly carboplatin/paclitaxel pc-3 w woman advanced epithelial ovarian cancer tubal carcinoma primary peritoneal carcinoma medical record assess age stage disease tumor histology grade brca mutation status platinum sensitivity patient treat either paclitaxel 175 mg/m 2 carboplatin auc 6 every three week pc-3 w 133 patient weekly paclitaxel 80 mg/m 2 weekly carboplatin auc 2 day 1 8 15 every 28 day pc-w 267 patient patient baseline characteristic similar group median overall survival os similar pc-w pc-3 w 64.5 month vs. 61.5 month pc-w longer median progression-free survival pfs 27.4 month 95 ci 22.7-31.4 vs. 19.5 month 95 ci 15.6-22.2 pc-3 w p = 0.0024 longer median platinum-free interval pfi 22.1 month 95 ci 16.0-24.5 vs. 14.2 month 95 ci 10.7-17.2 pc-3 w p = 0.0075 pc-w show significantly higher response rate 86.4 vs. 77.9 pc-3 w p = 0.0435 multivariate analysis include age diagnosis stage disease optimal debulking histology brca status pretreatment ca-125 pfi reveal pc-w woman lower risk death hr = 0.587 95 ci 0.402-0.857 p = 0.0058 lower risk disease progression hr = 0.494 95 ci 0.359-0.680 p 0.0001 higher 2 3-year survival rate decrease grade ii hair loss neuropathy thrombocytopenia compare pc-3 w woman pc-w protocol improve pfs similar os pc-3w 
glioblastoma gbm highly lethal primary brain tumour treatment malignant glioma remain ineffective extremely resistant chemotherapeutic application furthermore combination therapy cancer treatment become popular generate synergistic anticancer effect reduce individual drug-related toxicity associate side effect currently magnetic nanoparticle mnp base drug delivery system attract much attention owing intrinsic magnetic property drug loading capacity present study mnp base drug delivery approach co-delivering potent chemotherapeutic drug curcumin herbal drug temozolomide dna methylating agent implement dual drug load mnp formulation evaluate two-dimensional 2-d monolayer culture three-dimensional 3-d tumour spheroid culture t-98g cell understand therapeutic discrepancy dual drug load mnp formulation demonstrate higher cytotoxic effect single drug load mnp formulation compare corresponding native drug 2-d 3-d culture combination index ci analysis reveal synergistic mode action dual drug load mnp formulation confirm cell death induction assay mediate acridine orange ao / propidium iodide pi staining illustrate higher efficacy formulation towards gbm therapy 
report gne-783 novel checkpoint kinase-1 chk1 inhibitor enhance activity gemcitabine disable s g2 cell-cycle checkpoint follow dna damage use focused library 51 dna-damaging agent undertake systematic screen use three different cell line determine chemotherapeutic activity enhance combine gne-783 find gne-783 effective enhance activity antimetabolite-based dna-damaging agent however surprisingly wide range activity within class agent next select six different therapeutic agent screen combination gne-783 across panel cell line reveal preference enhance chemopotentiation select agent within tumor type instance gne-783 preferentially enhance activity temozolomide melanoma cell line additionally although p53 mutant status important overall response combination agent datum indicate alone insufficient predict synergy finally compare ability structurally related chk1 inhibitor gne-900 enhance vivo activity gemcitabine cpt-11 temozolomide xenograft model gne-900 significantly enhance activity gemcitabine vivo suggest strong chemopotentiation vitro translate chemopotentiation vivo conclusion result show selection appropriate agent combine chk1 inhibitor need carefully evaluate context genetic background tumor type will use 
cardiomyocyte represent one useful model conduct cardiac research single adult heart yield million cardiomyocyte cell survive long isolation aim determine whether inhibition myosin ii atpase essential muscle contraction may preserve fully differentiate adult cardiomyocyte use inhibitor myosin ii atpase blebbistatin n-benzyl-p-toluene sulphonamide bts preserve freshly isolate fully differentiate adult primary cardiomyocyte store refrigerated temperature specifically preserved cardiomyocyte stay viable 2-week period stable expression cardiac gene retain expression key marker characteristic cardiomyocyte furthermore voltage-clamp action potential calcium transient contractility study confirm preserved cardiomyocyte comparable freshly isolate cell long-term exposure preserved cardiomyocyte four tyrosine kinase inhibitor sunitinib malate dasatinib sorafenib tosylate imatinib mesylate reveal potential induce cardiac toxicity manifest decrease contractility induction cell death toxicity observe acute experiment conduct time course amenable freshly prepared cardiomyocyte study introduce concept inhibition myosin ii atpase safeguard structure function fully differentiate adult cardiomyocyte fact preserved cardiomyocyte use numerous day preparation make robust versatile tool cardiac research allow investigation long-term exposure novel drug cardiomyocyte function 
previously show innately resistant tumor silencing estrogen receptor er reverse treatment histone deacetylase hdac inhibitor entinostat tumor responsive aromatase inhibitor ai letrozole investigate whether er acquire letrozole-resistant tumor restore entinostat ovariectomize athymic mouse inoculate mcf-7ca cell supplement androstenedione delta 4 aromatizable substrate tumor reach 300 mm 3 mouse treat letrozole initial response letrozole tumor eventually become resistant double initial volume mouse group receive letrozole exemestane 250 mug/d entinostat 50 mug/d combination entinostat letrozole exemestane 26 week growth rate tumor mouse treat combination entinostat letrozole exemestane significantly slower single agent p 0.05 analysis letrozole-resistant tumor show entinostat increase eralpha expression aromatase activity downregulate her-2 p-her-2 p-mapk p-akt however mechanism action entinostat reverse acquire resistance involve epigenetic silencing rather include posttranslational well transcriptional modulation her-2 entinostat treatment reduce association her-2 protein hsp-90 possibly reduce stability her-2 protein addition entinostat also reduce her-2 mrna level stability result suggest hdac inhibitor may reverse letrozole resistance cell tumor modulate her-2 expression activity 
thiopurine efficacy partly reflect genetic polymorphism thiopurine methyltransferase tpmt enzyme responsible variation metabolism toxicity therapeutic efficacy thiopurine azathioprine aza 6-mercaptopurine 6-mp 6-thioguanine 6-tg determination tpmt activity administration thiopurine thus crucial individualized dosing order prevent toxicity tpmt deficient individual individual must treat markedly lower eg 5-10 standard dose prescribe medication paper describe comparison three different method quantification tpmt activity red blood cell rbc culture human cell line succeed perform measurement tpmt activity minimum amount 1 × 10 6 culture cell hplc-uv system modify optimize laboratory tpmt activity linearly correlate cell concentration culture cell line range 1-10 × 10 6 cell significant correlation determination tpmt activity rbc radiometric detection hplc classic radiochemical detection uv detection hplc observe correlation coefficient r 0.72 0.73 respectively within-day day-to-day coefficient variation hplc-uv-based method 8 16 respectively evaluation method demonstrate study tpmt activity rbc isolate 198 patient well molt4 leukemic cell line sub-cell line acquire resistance 6-mp 6-tg 
although cd138 expression hallmark plasma cell myeloma cell reduce cd138 expression occasionally find however mechanism underlie cd138 downregulation myeloma cell remain unclear previous report suggest bone marrow microenvironment may contribute cd138 downregulation among various factor tumor microenvironment hypoxia associate tumor progression poor clinical outcome dedifferentiation formation cancer stem cell niche solid tumor since recent finding show progression multiple myeloma mm deliver hypoxia within bone marrow hypothesize cd138 expression may regulate hypoxia present study examine whether expression cd138 transcription factor occur myeloma cell hypoxic condition mm cell line kms-12bm rpmi 8226 culture normoxic hypoxic condition 30 day change phenotype expression surface antigen transcription factor analyze use flow cytometry rt-pcr western blotting all-trans retinoic acid atra use examine phenotypic change hypoxic condition expression level cd138 cs1 plasma cell-specific transcription factor decrease hypoxic condition cd20 cxcr4 b cell-specific transcription factor increase compare normoxic condition stem cell-specific transcription factor upregulate hypoxic condition difference observe aldh activity reduce cd138 expression hypoxic condition recover cell treat atra even hypoxic condition along decrease expression stem cell-specific transcription factor interestingly atra treatment sensitize mm cell bortezomib hypoxia propose hypoxia induce immature stem cell-like transcription phenotype myeloma cell take together previous observation decrease cd138 expression correlate disease progression present datum suggest hypoxic microenvironment affect phenotype mm cell may correlate disease progression 
triple-negative breast cancer tnbc define tumor lack expression estrogen receptor progesterone receptor human epidermal growth factor receptor 2 clinically tnbc patient treat cytotoxic drug include 5-fluorouracil 5-fu however tnbc develop resistance drug series treatment elucidate mechanism drug resistance establishment drug-resistant cancer cell line one useful model system however 5-fu-resistant tnbc cell line previously report study establish 5-fu-resistant cell line mda-mb-231 / 5-fu human tnbc cell line mda-mb-231 repeat exposure stepwise increase concentration 5-fu ic50 value 5-fu mda-mb-231 / 5-fu 5.5-fold parental cell mda-mb-231 / 5-fu cell line acquire resistance 5-fu also vinorelbine paclitaxel gemcitabine additionally perform itraq-based quantitative proteomic mda-mb-231 / 5-fu cell parental cell order characterize mda-mb-231 / 5-fu protein upregulate newly establish cell mainly classify category dna recombination cell cycle complex assembly cytoskeleton organization transport negative regulation cell death protein may relate mechanism drug resistance tnbc establish mda-mb-231 / 5-fu cell line useful tool identify new mechanism drug resistance new drug target tnbc 
synthesis methotrexate mtx polyglutamate investigate human leukemia cell line ccrf-cem increase either extracellular mtx concentration 0.1-10 microm exposure time 4-24 h allow greater accumulation polyglutamate derivative species predominate di tri tetraglutamate also time concentration dependent derivative pentaglutamate readily detectable hexaglutamate present condition polyglutamate derivative preferentially retain cell transfer drug-free medium mtx rapidly exit cell condition absence extracellular mtx perform intracellular mtx polyglutamate continue elongate accumulation mtx polyglutamate particularly triglutamate longer species positively correlate cytotoxicity ccrf-cem cell measure clonogenic assay investigation methotrexate-fluorouracil interaction reveal effect 5-fluorouracil mtx polyglutamate accumulation various condition widely different degree cytotoxicity find synergy observe mtx precede fluorouracil treatment therefore effect mtx polyglutamylation mtx polyglutamate may however play indirect role synergy 
investigate effect epigenetic modifier dna methyltransferase dnmt histone deacetylase hdac inhibitor cytotoxicity induce 3 anticancer drug 5-fluorouracil 5-fu irinotecan cpt-11 active form sn38 oxaliplatin l-ohp human colorectal cancer crc cell cytotoxicity 4 crc cell line ht29 sw480 sw48 hct116 examine colorimetric assay drug treatment 72 h effect drug combination analyze isobologram method sw480 cell show lowest sensitivity cytotoxicity induce anticancer drug among 4 crc cell line sw480 cell dnmt inhibitor decitabine dac azacytidine zebularine zeb show synergic effect cytotoxicity induce anticancer drug except sn-38 plus zeb hdac inhibitor trichostatin suberoylanilide hydroxamic acid valproic acid show antagonistic effect dac show potent synergic effect among epigenetic modifier study thus examine whether synergic effect dac observe different crc cell line ht29 sw48 hct116 cell 4 crc cell line cytotoxicity l-ohp enhance synergic manner co-treatment dac however synergic effect dac 5-fu cpt-11 sn-38 observe 4 crc cell line 
investigate effect epigenetic modifier dna methyltransferase dnmt histone deacetylase hdac inhibitor cytotoxicity induce 3 anticancer drug 5-fluorouracil 5-fu irinotecan cpt-11 active form sn38 oxaliplatin l-ohp human colorectal cancer crc cell cytotoxicity 4 crc cell line ht29 sw480 sw48 hct116 examine colorimetric assay drug treatment 72 h effect drug combination analyze isobologram method sw480 cell show lowest sensitivity cytotoxicity induce anticancer drug among 4 crc cell line sw480 cell dnmt inhibitor decitabine dac azacytidine zebularine zeb show synergic effect cytotoxicity induce anticancer drug except sn-38 plus zeb hdac inhibitor trichostatin suberoylanilide hydroxamic acid valproic acid show antagonistic effect dac show potent synergic effect among epigenetic modifier study thus examine whether synergic effect dac observe different crc cell line ht29 sw48 hct116 cell 4 crc cell line cytotoxicity l-ohp enhance synergic manner co-treatment dac however synergic effect dac 5-fu cpt-11 sn-38 observe 4 crc cell line 
fulvestrant faslodex pure antiestrogen effective treat estrogen receptor er positive breast cancer tumor resistant selective estrogen receptor modulator tamoxifen clinical trial investigate utility add fulvestrant therapeutics show affect cytochrome p450-mediated metabolism effect phase ii metabolism drug resistance explore study demonstrate fulvestrant regulate expression udp glucuronosyltransferase 1a4 ugt1a4 2.5 3.5-fold mcf7 hepg2 cell respectively regulation occur time concentration-dependent manner inhibit sirna silencing eralpha fulvestrant also regulate multidrug resistance-associated protein mrp regulation mrp2 1.5 3.5-fold mrp3 5.5 4.5-fold mcf7 hepg2 cell line respectively regulation mrp1 4-fold mcf7 cell ugt1a4 mrna regulation significantly correlate ugt1a4 protein expression anastrozole glucuronidation eralpha mrna expression mrp mrna expression eralpha protein expression genetic variant ugt1a4 promoter -163 -217 g -219 t reduce basal activity ugt1a4 40-60 silico analysis indicate transcription factor c-myb binding capacity may affect variation luciferase activity assay demonstrate silencing c-myb abolish ugt1a4 regulation fulvestrant promoter common genotype -163 g -217 t -219 c mcf7 cell datum indicate fulvestrant influence disposition ugt1a4 substrate finding suggest clinically significant role ugt1a4 mrp drug efficacy 
tyrosine kinase inhibitor tki use treatment chronic myeloid leukemia substrate efflux transport protein atp-binding cassette subfamily g member 2 abcg2 variation abcg2 activity might influence pharmacokinetic therapeutic outcome tki role abcg2 single-nucleotide polymorphism snp tki treatment clear functional in-vitro study lack aim study investigate consequence abcg2 snp transport efficacy tki imatinib n-desmethyl imatinib cgp74588 dasatinib nilotinib bosutinib abcg2 snp 34g 421c 623t c 886g c 1574t g 1582g construct abcg2 wild-type cdna transduce k562 cell retroviral gene transfer variant abcg2 expression cell membrane evaluate effect abcg2 snp transport efficacy tki measure ability abcg2 variant protect tki cytotoxicity wild-type abcg2 protective effect cytotoxicity investigate compound except bosutinib find abcg2 expression provide better protection cgp74588 parent compound imatinib abcg2 421c 623t c 886g c 1574t g reduce cell membrane expression abcg2 protective effect abcg2 imatinib cgp74588 dasatinib nilotinib cytotoxicity finding show abcg2 snp 421c 623t c 886g c 1574t g increase efficacy investigate tki indicate reduce transport function might influence tki pharmacokinetic vivo furthermore active imatinib metabolite cgp74588 influence abcg2 expression greater extent parent compound 
design short hairpin rna shrna interference sequence silence glutathione s-transferase p1 gstp1 gene androgen-independent prostate cancer cell line du145 explore effect sensitivity chemotherapeutic target sequence pick form shrna du145 cell divide five group accord shrna add transfection shrna255 shrna554 shrna593 negative-shrna blank group fluorescence microscope use pick shrna highest transfection ratio western blotting rt-pcr take pick shrna best gene silencing result 3 4,5-dimethylthiazol-2-yl -2 5-diphenyl tetrazolium bromide assay terminal de-oxynucleotidyl transferase-mediated dutp nick end-labeling assay use detect survival ratio apoptosis ratio du145 administer fluorouracil 5-fu paclitaxel pa different concentration shrna transfection three different shrna oligonucleotide shrna255 shrna554 shrna593 target code sequence gstp1 mrna one negative control shrna construct transfection ratio shrna554 76.2 ± 0.68 higher shrna255 63.3 ± 1.04 p 0.01 shrna593 72.7 ± 0.33 p 0.01 transfection shrna554 mrna protein level lowest p 0.01 survival ratio du145 administer 5-fu different concentration 30 60 120 240 μg/ml decline transfection p 0.01 besides apoptosis ratio increase transfection p 0.01 similarly survival ratio du145 administer pa different concentration 0.2 2 10 20 μg/ml decline p 0.01 apoptosis ratio increase p 0.01 transfection gene gstp1 silence via shrna transfection androgen-independent prostate cancer cell line du145 enhance sensitivity chemotherapeutic 
classical drug use today destroy cancer cell lead development acquire resistance cell limit cellular entry drug export efflux pump result higher dose drug usually require kill cancer cell affect normal cell cause numerous side effect accumulation therapeutic level drug inside cancer cell thus require adequate period time get drug complete therapeutic efficacy minimize side effect normal cell order improve efficacy chemotherapeutic drug nanoparticle carbonate apatite strontium sr 2 substitute derivative use study make complex three classical anticancer drug methotrexate cyclophosphamide 5-flurouracil binding affinity drug apatite evaluate absorbance hplc analysis therapeutic efficacy drug-apatite complex determine cell viability assay carbonate apatite demonstrate significant binding affinity towards methotrexate cyclophosphamide lead cellular toxicity free drug mcf-7 4t1 breast cancer cell moreover sr 2 substitution carbonate apatite result tiny particle less 100 nm diameter promote binding methotrexate nanocarrier indicate sr 2 substitute apatite nanoparticle high potential load substantial amount anti-cancer drug eventual therapeutic effectiveness 
cisplatin commonly use chemotherapeutic associate ototoxicity renal toxicity neurotoxicity thus identify means increase therapeutic index cisplatin may allow improve outcome snp rs4343077 within eps8 discover genome wide association study cisplatin-induced cytotoxicity apoptosis lymphoblastoid cell line lcl provide impetus study gene purpose work evaluate role eps8 cellular susceptibility cisplatin cancerous non-cancerous cell use eps8 rna interference determine effect decrease eps8 expression lcl a549 lung cancer cell sensitivity cisplatin eps8 knockdown lcls result 7.9 increase cisplatin-induced survival p = 1.98 × 10 -7 8.7 decrease apoptosis p = 0.004 compare control contrast reduce eps8 expression lung cancer cell result 20.6 decrease cisplatin-induced survival p = 5.08 × 10 -5 investigate eps8 inhibitor mithramycin potential agent increase therapeutic index cisplatin mithramycin decrease eps8 expression lcl result decrease cellular sensitivity cisplatin evidence lower caspase 3/7 activation follow cisplatin treatment 42.7 ± 6.8 relative control p = 0.0002 5 non-small-cell lung carcinoma nsclc cell line mithramycin also result decrease eps8 expression add mithramycin 4 nsclc cell line bladder cancer cell line result increase sensitivity cisplatin significantly pronounced tumor cell line lcl line p 0.0001 egfr mutant nsclc cell line h1975 show significant change sensitivity cisplatin addition mithramycin treatment therefore inhibitor eps8 mithramycin improve cisplatin treatment increase sensitivity tumor relative normal cell 
mtor inhibitor temsirolimus antitumor antiangiogenic activity several carcinoma yet report document efficacy temsirolimus malignant pleural mesothelioma mpm therefore evaluate efficacy temsirolimus antiangiogenic effect temsirolimus treatment mpm examine efficacy temsirolimus alone efficacy combination temsirolimus cisplatin pemetrex four mpm cell line use 3 4,5-dimethylthiazol-2-yl -2,5-diphenyl tetrazolium bromide mtt assay effect temsirolimus production proangiogenic cytokine mpm cell line examine enzyme-linked immunosorbent assay elisa expression mtor proangiogenic cytokine clinical specimen mpm patient determine immunohistochemistry temsirolimus inhibit cell viability suppress cell proliferation mpm cell line combined treatment temsirolimus cisplatin inhibit viability mpm cell line effectively temsirolimus alone temsirolimus strongly inhibit phosphorylation p70s6k downstream molecule mtor mpm cell line lead increase level cleave caspase-3 h226 y-meso14 cell temsirolimus also inhibit production vascular endothelial growth factor vegf platelet-derived growth factor-aa pdgf-aa phosphorylate mtor high expression vegf pdgf detect 2 3 respectively 5 mpm specimen result suggest temsirolimus activity mpm cell inhibition cell proliferation angiogenesis may beneficial subset mpm patient high mtor expression 
give importance complementary alternative medicine cam cancer patient increase need learn possible interaction cam anticancer drug mistletoe viscum album l. belong medicinal herb use supportive care chemotherapy vitro study present effect standardized mistletoe preparation cytostatic cytotoxic activity several common conventional chemotherapeutic drug investigate use different cancer cell line human breast carcinoma cell line hcc1937 hcc1143 treat doxorubicin hydrochloride pancreas adenocarcinoma cell line pa-tu-8902 gemcitabine hydrochloride prostate carcinoma cell line du145 docetaxel mitoxantrone hydrochloride lung carcinoma cell line nci-h460 treat docetaxel cisplatin dose respective chemotherapeutic drug combine viscum album extract vae clinically relevant concentration proliferation apoptosis measure vae inhibit chemotherapy induce cytostasis cytotoxicity experimental setting higher concentration vae show additive inhibitory effect vitro result suggest risk safety herb drug interaction expect exposition cancer cell chemotherapeutic drug vae simultaneously 
despite aggressive treatment radiation therapy concurrent adjuvant temozolomide tmz glioblastoma multiform gbm still dismal prognosis aim identify strategy improve therapeutic outcome combined radiotherapy tmz gbm target pro-survival signaling epidermal growth factor receptor egfr glioma cell line u251 t98g use colony formation dna damage repair mode cell death invasion migration vasculogenic mimicry well protein expression determine u251 cell show low level methyl guanine transferase mgmt highly responsive radiosensitizing effect tmz compare t98g cell high level mgmt treatment dual inhibitor class pi3k/mtor pi103 hsp90 inhibitor 17-dmag hdac inhibitor lbh589 increase cytotoxic effect radiation therapy plus tmz u251 cell t98g cell however treatment mtor inhibitor rapamycin discernibly potentiate radiosensitizing effect tmz either cell line mechanism enhance radiosensitizing effect tmz multifactorial involve impaired dna damage repair induction autophagy apoptosis reversion emt epithelial-mesenchymal transition result suggest possible strategy counteract pro-survival signaling egfr improve therapeutic outcome combined radiotherapy tmz high-grade glioma 
effect extracellular folate concentration intracellular folate phosphoribosylpyrophosphate prpp level cytotoxicity methotrexate 5-fluorouracil study human kb cell grow fetal bovine serum-supplemented eagle minimum essential medium contain standard high folic acid level 2.3 microm standard s medium folic acid-free serum-supplemented medium contain approximately 4 nm 5-methyltetrahydrofolate physiological p medium folate level form comparable normal human serum macrocytosis prolongation double time 150 observe 5-10 serial pass p medium 10-15 serial pass kb cell become adapt p medium size double time value indistinguishable cell maintain s medium cellular folate level fall marked elevation prpp level 68 / 43 642 / 287 pmol/mg cell protein mean / sd observe kb cell serially pass p medium human leukemia hl-60 k562 cell mjy-alpha mouse mammary tumor cell serially pass p medium also exhibit 10 20-fold elevation prpp level glucose consumption glucose decarboxylation thymidine adenosine specific uptake thymidine incorporation dna 5-fluorouracil uptake study kb cell elevated control prpp level determine clonal assay despite elevated prpp level kb cell culture p medium less sensitive 5-fluorouracil cell culture s medium unless exogenous folate add datum support concept endogenous folate level may inadequate optimal 5-fu pharmacological action kb cell modulate increase prpp level 
present several drug treatment advanced renal cell carcinoma arcc main objective work perform systematic review sr meta-analysis ma clinical randomized study compare target cell therapy tct sr identify clinical randomize trial compare tct versus interferon-alpha treatment patient arcc order analyze efficiency evaluate free-survival progression fsp total survival ts response rate rr relation first line treatment seven study tct identify use sunitinib sorafenib bevacizumab temsirolimus two study sorafenib everolimus second line treatment relative risk rri ma fsp first line therapy 0.83 ci = 0.78-0.87 i2 = 94 p 0.00001 best result rr specific fsp among study 0.38 sunitinib ci = 0.25-0.58 bevacizumab 0.62 ci = 0.47-0.83 temsirolimus 0.78 ci = 0.70-0.87 ma show benefit regard ts first line treatment analyze drug rr significant result sunitinib 3.83 ci = 2.86-5.12 bevacizumab 2.52 ci = 1.78-3.57 bevacizumab 1.97 ci = 1.43-2.71 first line treatment sunitinib effective tct relation fps alteration ts rr small significant sunitinib bevacizumab available study conclude result second line treatment 
report upregulate sirt1 nad dependent class iii histone deacetylase deacetylate p53 protein repress function allow tumor cell growth various cancer investigate antitumor effect tenovin-6 small-molecule inhibitor sirt1 sirt2 various colon cancer cell line tenovin-6 induce apoptosis five colon cancer cell line investigate two cell line wild-type p53 three mutant p53 regardless p53 mutation status effect accompany accumulation death receptor 5 dr5 cell line dr5 silencing hct116 cell strongly attenuate tenovin-6-induced apoptosis investigate effect combine tenovin-6 conventional anticancer agent 5-fluorouracil 5-fu sn-38 active metabolite irinotecan oxaliplatin synergistic antitumor effect tenovin-6 observe combination either 5-fu oxaliplatin vitro combination tenovin-6 oxaliplatin exhibit potent growth inhibition hct116 xenograft tumor vivo conclusion tenovin-6 induce apoptosis human colon cancer cell activation dr5 signaling pathway enhance antitumor property 5-fu oxaliplatin result may help develop novel treatment option colorectal cancer use sirt inhibitor 
although inhibition cyclooxygenase-2 cox-2 vascular endothelial growth factor receptor vegfr show promising antitumor strategy non-small cell lung cancer nsclc therapeutic efficacy limit due inherent tumor resistance present study select sorafenib sor vegfr inhibitor combination celecoxib cxb cox-2 inhibitor suppress tumor growth simultaneously reduce dose drug treatment nsclc effect sor combine cxb examine a549 cell nsclc cell line assay proliferation apoptosis cell cycle distribution receptor signaling perform find treatment combination low concentration sor cxb significantly suppress proliferation a549 tumor cell vitro suppress tumor growth vivo compare action either agent alone result also show combination sor cxb significantly increase induction apoptosis decrease expression inhibitor apoptosis gene survivin bcl-2 p 0.01 furthermore combination treatment significantly suppress constitutive phosphorylation mek erk may contribute inhibition tumor growth take together finding reveal additive combination sor cxb potential drug candidate treatment nsclc 
incomplete chemotherapeutic eradication leukemic cd34 ⁺ cd38 ⁻ stem cell likely result disease relapse purpose study evaluate effect nilotinib eradicate leukemia stem cell enhance efficacy chemotherapeutic agent result show abcb1 abcg2 preferentially express leukemic cd34 ⁺ cd38 ⁻ cell nilotinib significantly enhance cytotoxicity doxorubicin mitoxantrone cd34 ⁺ cd38 ⁻ cell lead increase apoptosis moreover nilotinib strongly reverse multidrug resistance increase intracellular accumulation rhodamine 123 primary leukemic blast overexpress abcb1 and/or abcg2 study abc transporter-overexpressing carcinoma cell model confirm nilotinib effectively reverse abcb1 abcg2-mediated drug resistance show significant reversal effect abcc1 abcc4-mediated drug resistance result cytotoxicity assay show cd34 ⁺ cd38 ⁻ cell exhibit moderate resistance 2.41-fold nilotinib compare parental k562 cell furthermore nilotinib less effective block phosphorylation bcr-abl crkl substrate bcr-abl kinase cd34 ⁺ cd38 ⁻ cell take together datum suggest nilotinib particularly target cd34 ⁺ cd38 ⁻ stem cell mdr leukemia cell effectively enhance efficacy chemotherapeutic drug block efflux function abc transporter 
aldehyde dehydrogenase 3a1 aldh3a1 play important role many cellular oxidative process include cancer chemoresistance metabolize activate form oxazaphosphorine drug cyclophosphamide cp analogue mafosfamide mf ifosfamide ifm 4-hydroperoxycyclophosphamide 4-hpcp compound selectively target aldh3a1 permit delineation role process restore chemosensitivity cancer cell express isoenzyme report detailed kinetic structural characterization aldh3a1-selective inhibitor cb29 previously identify high-throughput screen kinetic crystallographic study demonstrate cb29 bind within aldehyde substrate-binding site aldh3a1 cellular proliferation aldh3a1-expressing lung adenocarcinoma a549 glioblastoma sf767 cell line well aldh3a1 non-expressing lung fibroblast ccd-13lu cell unaffected treatment cb29 analogue alone however sensitivity toward anti-proliferative effect mafosfamide enhance treatment cb29 analogue tumor cell contrast sensitivity ccd-13lu cell toward mafosfamide unaffected addition compound cb29 chemically distinct previously report small-molecule inhibitor aldh isoenzyme inhibit aldh1a1 aldh1a2 aldh1a3 aldh1b1 aldh2 isoenzyme concentration 250 mum thus cb29 novel small molecule inhibitor aldh3a1 might useful chemical tool delineate role aldh3a1 numerous metabolic pathway include sensitize aldh3a1-positive cancer cell oxazaphosphorine 
glioblastoma multiforme gbm common primary brain tumor adult despite multimodal therapy consist resection follow fractionate radiotherapy rt combine chemotherapeutic agent ct temozolomide tmz recurrence almost inevitable since immune system capable eliminate small tumor mass therapy also aim stimulate anti-tumor immune response induction immunogenic cell death form histone deacetylase inhibitor valproic acid vpa might foster reflect therapy standard apply vitro model fractionate rt single dose 2gy clinically relevant concentration ct. impact rt and/or ct tmz and/or vpa clonogenic potential cell cycle glioblastoma cell line t98g u251mg u87mg analyze also result cell death form release danger signal heat-shock protein70 hsp70 high-mobility group protein b1 hmgb1 clonogenic assay reveal t98g u251mg mutate tumor suppressor protein p53 resistant rt ct u87mg wild type wt p53 glioblastoma cell line fractionate rt induce g2 cell cycle arrest case u87mg tmz and/or vpa alone result cell cycle block fractionate rt significantly increase number apoptotic necrotic tumor cell three cell line however u87mg treatment tmz and/or vpa alone combination fractionate rt induce significantly cell death compare untreated irradiated control necrotic glioblastoma cell present vpa tmz especially lead significantly increase amount u87mg cell radiosensitive g2 cell cycle phase ct impact release hsp70 fractionate rt result significantly increase extracellular concentration hsp70 p53 mutate wt glioblastoma cell result indicate fractionate rt main stimulus induction glioblastoma cell death form immunogenic potential generate tumor cell microenvironment might beneficial include immune therapy gbm future 
glioblastoma gbm remain aggressive lethal brain tumor due molecular heterogeneity high motility invasion capability cell result high resistance current standard treatment surgery follow ionize radiation combine temozolomide chemotherapy administration locus amplification gene overexpression genetic mutation epidermal growth factor receptor egfr hallmark gbm ectopically activate downstream signaling oncogenic cascade pi3k/akt/mtor pathway importantly alteration pathway involve also regulation autophagy process improve radioresistance gbm cell thus promote aggressive phenotype tumor work endogenous egfr expression profile autophagy modulate increase radiosensitivity behavior human t98g u373mg gbm cell result primarily indicate egfr interfere induce radiosensitivity accord decrease clonogenic capability investigate cell effective reduction vitro migratory feature moreover egfr interfere result increase temozolomide tmz cytotoxicity t98g tmz-resistant cell order elucidate involvement autophagy process pro-death pro-survival role cell subject egfr interfere key autophagic gene atg7 silence thereby produce transient block autophagy process autophagy inhibition rescue clonogenic capability irradiated egfr-silenced t98g cell suggest pro-death autophagy contribution confirm functional interplay egfr autophagy pathway rapamycin-mediated autophagy induction egfr modulation promote impairment irradiated cell term clonogenic migration capability take together result might suggest novel combined egfr-autophagy modulation strategy overcome intrinsic gbm radioresistance thus improve efficacy standard treatment j. cell physiol 229 1863-1873 2014 © 2014 wiley periodicals inc. 
several clinical trial demonstrate effectiveness bortezomib combination various anti-myeloma agent however definitive information available regard drug best suit use combination bortezomib use isobologram analysis investigate combined effect bortezomib four key anti-myeloma drug melphalan cyclophosphamide doxorubicin lenalidomide represent component major bortezomib-based regimen corticosteroid three myeloma cell line u266 rpmi8226 kms-12bm various condition melphalan show best performance bortezomib culture condition test liquid culture fibronectin-coated plate co-culture bone marrow stromal cell whereas cyclophosphamide antagonistic bortezomib especially presence stromal cell doxorubicin show additive effect stroma-free condition contact fibronectin rather antagonistic presence stromal cell contrast lenalidomide exert favorable effect bortezomib contact stromal cell consistent result caspase-3 activate strongly melphalan agent combination bortezomib moreover bortezomib-induced up-regulation chop readily enhance lenalidomide contact stromal cell present finding may provide fundamental information selection bortezomib-based regimen myeloma patient 
oestrogen influence pathophysiology development hormone-sensitive cancer breast cancer tissue factor pathway inhibitor tfpi serine protease inhibitor extrinsic coagulation pathway recently associate breast cancer cell development moreover reduce tfpi level report plasma healthy post-menopausal woman receive hormone replacement therapy indicate possible link oestrogen tfpi study aim examine effect oestrogen oestrogen analogue tfpi expression breast cancer cell identify underlie mechanism s oestrogen receptor alpha erα positive mcf7 negative mda-mb-231 cell treat 17-β-oestradiol 17-β-ethinyloestradiol raloxifene fulvestrant tfpi mrna protein measure use qrt-pcr elisa respectively transient erα knockdown achieve use sirna erα express mcf7 cell mda-mb-231 cell tfpi mrna protein level significantly downregulate 50 four six hour incubation 17-β-ethinyloestradiol 17-β-oestradiol respectively moreover significant increase fxa generation detect response oestrogen breast tissue er antagonist raloxifene fulvestrant affect tfpi mrna however fulvestrant block oestrogen mediated reduction tfpi mrna transient knockdown erα abolish oestrogenic effect tfpi co-treatment mcf7 cell protein synthesis inhibitor cycloheximide 17-β-oestradiol also lead reduction tfpi mrna datum establish direct time dependent regulation tfpi expression oestrogen erα transcriptional level 
breast cancer evolution tumor progression control complex interaction steroid receptor growth factor receptor signaling aberrant growth factor receptor signaling augment suppress estrogen receptor function hormone-dependent breast cancer cell thus aim investigate antitumor effect sorafenib lapatinib alone combination mcf-7 breast cancer cell cytotoxicity sorafenib lapatinib test mcf-7 cell xtt assay 50 25 12.5 6.25 μm concentration sorafenib 200 100 50 25μm concentration lapatinib administer alone combination result evaluate absorbance 450nm ic50 value calculate accord absorbance datum sorafenib lapatinib show concentration dependent cytotoxic effect mcf-7 cell sorafenib exert cytotoxic effect ic50 value 32.0 μm contrast lapatinib ic50 136.6 μm sorafenib lapatinib combine lapatinib increase cytotoxic effect sorafenib ineffective concentration also concentration drug cytotoxic effect combination show strong anticancer effect kill approximately 70 percent breast cancer cell combination tyrosine kinase inhibitor cytotoxic agent molecular target therapy successful many type cancer present study show sorafenib lapatinib alone effective treatment breast cancer also combination two agent may promising therapeutic option treatment breast cancer 
purpose effective sensitize strategy potentially extend benefit temozolomide tmz therapy patient glioblastoma gbm previously demonstrate robust tmz-sensitizing effect poly adp-ribose polymerase parp inhibitor veliparib abt-888 restricted tmz-sensitive gbm xenograft focus study provide understanding differential sensitization paired tmz-sensitive resistant gbm model experimental design impact veliparib tmz-induced cytotoxicity dna damage evaluate vitro vivo model acquire tmz resistance gbm12tmz-mgmt high gbm12tmz-mgmt low u251tmz inherent tmz resistance t98g tmz-sensitive u251 gbm12 vivo drug efficacy pharmacokinetic pharmacodynamic analyze use clinically relevant dosing regimen result veliparib enhance tmz cytotoxicity dna-damage signaling gbm model vitro pronounced effect tmz-resistant line 3 10 mumol/l veliparib vivo combine tmz/veliparib compare tmz alone significantly delay tumor growth enhance dna-damage signaling gammah2ax level sensitive gbm12 xenograft line resistant gbm12tmz line pharmacokinetic profile veliparib similar gbm12 gbm12tmz tumor cmax ~ 1.5 mumol/l tissue significantly lower concentration associate optimal vitro sensitize effect resistant tumor contrast robust suppression parp-1 expression shrna significantly increase tmz sensitivity u251tmz vitro vivo conclusion vitro cytotoxicity assay adequately model therapeutic index parp inhibitor concentration veliparib tmz require sensitize tmz-resistant cancer cell vivo achieve use tolerable dosing regimen 
fibroblast growth factor receptor 2 fgfr2 think mediate important signaling pathway prostate epithelial cell stromal cell maintenance homeostasis normal prostate tissue abnormality fgfr2 show advanced prostate cancer prostate cancer cell line previously demonstrate tumor-suppressive effect restoration fgfr2iiib prostate cancer cell aim present study determine whether fgfr2iiib play role chemosensitivity castration-resistant prostate cancer cell clonal line pc-3 cell express fgfr2iiib pc-3r2iiib establish transfection iresneo2-expressing vector bearing fgfr2iiib cdna effect chemotherapeutic agent docetaxel cisplatin 5-fluorouracil zoledronic acid cell viability apoptosis examine mtt assay western blot analysis respectively expression level molecule marker epithelial-to-mesenchymal transition chemosensitivity-related protein assess western blot analysis viability pc-3r2iiib cell significantly lower control pc-3 cell transfect vector alone pc-3neo viability suppress treatment chemotherapeutic agent particularly docetaxel induce expression caspase-3 evident pc-3r2iiib cell enhance treatment docetaxel expression n-cadherin vimentin survivin xiap lower pc-3r2iiib cell pc-3neo cell contrast expression p21 higher pc-3r2iiib cell control pc-3neo cell datum indicate restoration fgfr2iiib castration-resistant prostate cancer cell may reverse epithelial-to-mesenchymal cell property characteristic tumor cell induce part mesenchymal-to-epithelial transition property together enhancement apoptotic pathway involve caspase-3 may enhance chemosensitivity particularly docetaxel widely use treatment castration-resistant prostate cancer 
effect abcb1 p-gp p-glycoprotein mdr1 abcg2 bcrp1 breast cancer resistance protein 1 expression cell resistance daunorubicin drn imatinib nilotinib study human leukemia cell use set cell derive parental k562 cell line express various level abcb1 abcg2 respectively function abcb1 abcg2 confirm use calcein pheophorbide accumulation assay respectively assay indicate distinct difference activity abcb1 abcg2 correspond expression level observe resistance drn imatinib proportional expression level abcb1 similarly resistance nilotinib imatinib proportional expression level abcg2 importantly k562/doxdr05 k562/abcg2-z cell lowest expression abcb1 abcg2 respectively fail reduce intracellular level imatinib provide significant resistance drug however k562/doxdr05 k562/abcg2-z cell significantly decrease intracellular level drn nilotinib respectively thereby mediate significant resistance drug cell expression abcb1 abcg2 exceed certain level exhibit significantly decrease intracellular level imatinib effect accompany significantly increase resistance drug result clearly indicate resistance anticancer drug mediate main abc transporter abcb1 abcg2 strongly depend expression protein level importantly resistance one drug might maintain resistance one might become undetectable low transporter expression level 
despite numerous therapy effectively inhibit estrogen signaling breast cancer significant proportion patient estrogen receptor er positive malignancy will succumb disease herein demonstrate long-term estrogen deprivation lted therapy among er-positive breast cancer cell result adaptive increase er expression subsequent activation multiple tyrosine kinase combination therapy er down-regulator fulvestrant dasatinib broad kinase inhibitor exhibit synergistic activity lted cell reduction cell proliferation cell survival cell invasion mammary acinar formation screening kinase phosphorylation use protein array functional proteomic analysis demonstrate combination fulvestrant dasatinib inhibit multiple tyrosine kinase cancer-related pathway constitutively activate lted cell lted cell display increase insulin receptor insr / insulin-like growth factor 1 receptor igf-1r signaling add ant-igf-1 antibody combination fulvestrant dasatinib effort increase inhibition however add mk0646 modestly increase inhibition cell growth monolayer culture neither suppress acinar formation inhibit cell migration vitro invasion vivo therefore combination fulvestrant dasatinib mk0646 may benefit patient tyrosine-kinase-activated endocrine therapy-resistant breast cancer 
nilotinib second-generation tyrosine kinase inhibitor tki approve first-line chronic myeloid leukemia cml treatment improve clinical response nilotinib first generation tki imatinib think result high potency inhibition bcr-abl kinase study aim characterize difference nilotinib imatinib intracellular accumulation cytotoxic effect cml cell line k562 accumulation nilotinib k562 cell 4.7 9.0-fold higher imatinib cytotoxic effect nilotinib k562 cell 14.2-fold higher imatinib inhibition experiment k562 cell examination cellular uptake use influx transporter-transfected human embryonic kidney hek 293 cell suggest influx transporter oct1 oatp1a2 report mediate accumulation imatinib cml cell contribute little uptake nilotinib nilotinib find accumulate imatinib-resistant k562 k562/im cell overexpress efflux transporter p-glycoprotein p-gp although cytotoxic assay show k562/im cell display 20000-fold greater resistance nilotinib parent k562 cell conclusion present finding suggest intracellular accumulation nilotinib cml cell contribute clinical response efficacy cml patient although nilotinib report effective imatinib-resistant abl kinase mutant drug overcome imatinib resistance acquire p-gp-overexpression result imply classification mechanism drug resistance important suitable strategy treat imatinib-resistant cml patient 
success chemo radiotherapy glioblastoma multiforme common lethal primary brain tumour rely induction immunogenic tumour cell death induction anticancer immune response study investigate cell survival single treatment combination x-ray temozolomide glioblastoma cell line t98g u251mg attempt identify danger signal hmgb1 hsp70 release die cell microenvironment activate antitumour immunity contribute therapeutic efficacy conventional treatment datum suggest hsp70 translocate cytoplasm extracellular environment increase radiation dose hmgb1 translocate nucleus cytoplasm subsequently release extracellular space confirm role protein signal release radiation-induced damage glioblastoma cell also state tmz limit effectiveness activate hmgb1 hsp70 signalling instead adjuvant effect observe combined treatment depend schedule cell line timing big challenge tumour therapy therefore identify beneficial combination chronology multiple treatment option contribute improvement therapeutic outcome 
cyclic peptide compose five tryptophan four arginine one cysteine w5r4c synthesize peptide evaluate generate cyclic peptide-capped selenium nanoparticle cp-senp situ physical mix cyclic peptide seo3 -2 solution water generate w5r4c senp via combination reduce cap property amino acid peptide structure transmission electron microscopy tem image show w5r4c senp size range 110-150 nm flow cytometry datum reveal fluorescence-labeled phosphopeptide f pepylgld f = fluorescein anticancer drug f dasatinib exhibit approximately 25 9-time higher cellular uptake presence w5r4c senp f pepylgld dasatinib alone human leukemia ccrf-cem cell 2 h incubation respectively confocal microscopy also exhibit higher cellular delivery f pepylgld f dasatinib presence w5r4c senp compare parent fluorescence-labeled drug alone human ovarian adenocarcinoma sk-ov-3 cell 2 h incubation 37 c antiproliferative activity several anticancer drug doxorubicin gemcitabine clofarabine etoposide camptothecin irinotecan epirubicin fludarabine dasatinib paclitaxel improve presence w5r4c senp 50 mum 38 49 36 36 31 30 30 28 24 17 respectively 48 h incubation sk-ov-3 cell result indicate cp-senp potentially use nanosized delivery tool negatively charge biomolecule anticancer drug 
glioblastoma multiforme gbm difficult treat conventional anti-cancer/anti-apoptotic drug test hypothesis inhibition na / k atpase cause mixed hybrid form concurrent apoptosis necrosis therefore enhance anti-cancer effect chemotherapy glioblastoma cell human ln229 drug-resistant t98g glioblastoma cell culture cell death signal pathway measure use immunocytochemistry western blotting fluorescent dye apply measure intracellular ca2 na k change specific na / k atpase blocker ouabain 0.1 10 μm induce cell death disruption k homeostasis time concentration-dependent manner annexin-v translocation caspase-3 activation indicate apoptotic component ouabain cytoxicity accompany reduce bcl-2 expression mitochondrial membrane potential ouabain-induced cell death partially attenuate caspase inhibitor z-vad 100 μm consistently k ionophore valinomycin initiate apoptosis ln229 cell k efflux-dependent manner ouabain cause initial cell swell follow sustained cell volume decrease electron microscopy reveal ultrastructural feature apoptotic necrotic alteration cell finally human t98g glioblastoma cell resistant chemotherapy drug temozolomide tmz show unique high expression na / k atpase α2 α3 subunit compare tmz-sensitive cell line ln229 normal human astrocyte low concentration ouabain selectively kill t98g cell knock α3 subunit sensitize t98g cell tmz cause cell death study suggest inhibition na / k atpase trigger hybrid cell death serve underlying mechanism enhance chemotherapy effect glioblastoma cell 
photodynamic therapy pdt induce selective cell death neoplastic tissue connect vasculature combine photosensitizer light previously report pdt induce apoptotic cell death glioma cell photosensitizer talaporfin sodium npe6 use investigate combined effect npe6-pdt temozolomide dna-alkylating drug use glioma therapy human glioblastoma t98g cell human glioma u251 cell use glioma cell cell viability evaluate wst-8 assay apoptosis evaluate measurement caspase-3 activity dna-fragmentation intracellular reactive oxygen species evaluate dihydrorhodamine assay degree npe6-pdt induce cell death unchanged t98g u251 cell temozolomide treatment adjuvant dose-dependently increase concomitant treatment temozolomide concomitantly administer temozolomide dose-dependently increase caspase-3 activity dna-fragmentation adjuvant-temozolomide result suggest concomitantly administer temozolomide potentiate effect npe6-pdt facilitate apoptotic cell death additionally concomitantly administer temozolomide increase intracellular npe6-fluorescence reactive oxygen species suggest augmentation effect combined treatment may due increase intracellular accumulation npe6 result suggest concomitant treatment npe6-pdt temozolomide potentially useful therapy glioma 
merm1/wbscr22 novel metastasis promoter show involve tumor metastasis viability apoptosis best knowledge currently study suggest possible correlation expression merm1/wbscr22 tumor cell chemosensitivity antitumor agent present study two human non-small cell lung cancer cell line h1299 h460 use investigate whether merm1/wbscr22 affect chemosensitivity antitumor agent include cisplatin cddp doxorubicin adm paclitaxel ptx mitomycin mmc 7-ethyl-10-hydroxycamptothecin sn-38 active metabolite camptothecin 5-fluorouracil 5-fu merm1/wbscr22 knockdown cell line h1299-shrna h460-shrna negative control cell line h1299-nc h460-nc establish stable transfection efficiency merm1/wbscr22 knockdown confirm western blotting immunofluorescence microscopy quantitative polymerase chain reaction result demonstrate shrna-mediated knockdown merm1/wbscr22 affect cell proliferation vitro vivo h460 cell harbor wild type p53 markedly sensitive six antitumor agent compare p53-null h1299 cell downregulation merm1/wbscr22 affect h1299 sensitivity six antitumor agent whereas attenuate h460 sensitivity sn-38 5-fu without significant alteration p53 mrna protein level identify reduce h460 sensitivity sn-38 confirm vivo sn-38 demonstrate significant tumor growth inhibitory activity h460 h460‑nc tumor xenograft model marginally suppress h460-shrna xenograft tumor growth furthermore cddp 4 10 15 µg/ml resistant human non-small lung cancer cell a549 a549-cddpr-4 10 15 express significant amount merm1/wbscr22 protein compare parental a549 cell conclusion shrna-mediated knockdown merm1/wbscr22 attenuate h460 sensitivity sn-38 5-fu suggest merm1/wbscr22 involve chemosensitivity sn-38 5-fu h460 cell direct correlation p53 expression level altered chemosensitivity identify 
novel series n-substituted-4-phenylphthalazin-1-one 14a-g bear different aniline n-2 phthalazin-1-one scaffold via acetyl-flexible linker design synthesize development potential anticancer agent compound 19a-g synthesize insertion methylene ch2 bridge c4-position 14a-g provide flexibility phenyl group newly synthesize compound 14a-g 19a-g evaluate anti-proliferative activity three human tumor cell line hepg2 hepatocellular carcinoma ht-29 colon cancer mcf-7 breast cancer particular hepg2 ht-29 cancer cell line susceptible synthesize derivative compound 19d ic50 = 1.2 ± 0.09 μm find potent derivative hepg2 2.9 time active doxorubicin ic50 = 3.45 ± 0.54 sorafenib ic50 = 3.5 ± 1.04 μm compound 14e 14g 19d 19g ic50 = 3.29 ± 0.45 3.50 ± 0.846 1.20 ± 0.09 3.52 ± 0.70 μm respectively find active candidate hepg2 cancer cell compound 14e 14g 19d 19g able induce apoptosis hepg2 assure significant increase percentage annexin v-fitc-positive apoptotic cell ur lr down-regulation anti-apoptotic protein bcl-2 up-regulation pro-apoptotic protein bax addition boost caspase-3 level moreover cytotoxicity evaluation newly synthesize compound ht-29 reveal compound 14e 14f 19e 19f ic50 = 3.05 ± 0.78 4.02 ± 1.18 3.68 ± 0.79 2.98 ± 0.47 μm respectively potent doxorubicin ic50 = 7.70 ± 1.78 μm 
liposomal formulation irinotecan irinophore c ™ irc ™ efficacious panel tumor model normalize tumor vasculature increase accumulation second drug tumor now show irinophore c ™ also effective patient derive xenograft pdx colon cancer examine kinetics vascular normalization ht-29 tumor model assess change might use 5-fu sequentially rag2m mouse bear ht-29 tumor treat irc ™ 25mg/kg q7d × 3 three week group tumor harvest analysis 7 14 21day start treatment drug lipid level tumor evaluate use hplc scintillation count respectively change tumor morphology h&e vasculature cd31 perfusion hoechst 33342 apoptosis tunel quantify use microscopy accumulation second drug 14 c -5-fu 40mg/kg give 3h sacrifice determine use liquid scintillation efficacy irc ™ q7d × 3 follow 5-fu treatment q7d × 3 assess mouse bear established ht-29 tumor efficacy irc ™ also evaluate primary human colorectal tumor grow orthotopically nod-scid mouse follow single dose irc ™ active lactone form irinotecan metabolite sn-38 measurable ht-29 tumor 7day treatment reduce tumor cell density increase apoptosis hoechst 33342 perfusion accumulation 14 c -5-fu treated tumor increase significantly day 7 14 accompany increase number endothelial cell relative total nucleus tumor section pre-treatment irc ™ q7d × 3 follow 5-fu q7d × 3 delay time take tumor reach 1 cm 3 9day p 0.05 irc ™ just effective free irinotecan use patient derive xenograft colorectal cancer treatment irc ™ reduce tumor cell viability appear normalize vascular function tumor single treatment cycle concomitant increase accumulation second drug 5-fu tumor observe tumor irc ™ treat animal correlate change vascular structure consistent normalization treatment effect sequential 5-fu dosing follow irc ™ additive additional toxicity contrast previous study concurrent 5-fu irc ™ treatment exacerbate 5-fu toxicity study pdx tumor also indicate irc ™ just effective free irinotecan pdx tumor even though deliver dose halve 
since cancer stem cell exhibit embryonic-like self-renewal characteristic malignant behavior include drug resistance metastasis may origin tumorigenesis cancer recurrence cancer cell stemness also highly relevant cancer hypoxic environment study use cobalt dichloride cocl2 create hypoxic environment lung adenocarcinoma a549 cell cisplatine-resistant cell line a549/ddp cancer stem-like cd166 positive population cell stemness detect flowcytometry quantitative real-time pcr separation use magnetic antibody drug resistance cisplatine docetaxel pemetrexed also measure finally tissue array use analyze relationship hypoxia-induced stemness overall survival radical surgery datum show chemical-induced hypoxia change cell stemness enhance stem cell transcription factor marker chemotherapeutic drug resistance cd166-positive cancer stem cell-like population show greater drug resistance cd166-negative cell tissue array study also suggest poorer prognosis patient whose tissue express higher cd166 level finding indicate chemical hypoxia may augment cancer cell stemness drug resistance cd166-positive stem cell therefore target stem-like cell population especially cd166-positive cell may represent novel therapeutic strategy treat lung cancer 
present study investigate ability carboplatin paclitaxel sensitize human non-small-cell lung cancer nsclc cell carbon-ion beam irradiation nsclc h460 cell treat carboplatin paclitaxel irradiate x-ray carbon-ion beam radiosensitivity evaluate clonogenic survival assay cell proliferation determine count number viable cell use trypan blue apoptosis senescence evaluate terminal deoxynucleotidyl transferase-mediated dutp nick-end labeling tunel staining senescence-associated β-galactosidase sa-β-gal staining respectively expression cleave caspase-3 bax p53 p21 analyze western blotting clonogenic survival assay demonstrate synergistic radiosensitizing effect carboplatin paclitaxel carbon-ion beam sensitizer enhancement ratio ser dose give 10 survival fraction d10 1.21 1.22 respectively similarly carboplatin paclitaxel show radiosensitizing effect x-ray ser 1.41 1.29 respectively cell proliferation assay validate radiosensitizing effect carboplatin paclitaxel carbon-ion beam x-ray irradiation carboplatin paclitaxel treatment combine carbon-ion beam increase tunel-positive cell expression cleave caspase-3 bax indicate enhancement apoptosis combined treatment also increase sa-β-gal-positive cell expression p53 p21 indicate enhancement senescence summary carboplatin paclitaxel radiosensitize h460 cell carbon-ion beam irradiation enhance irradiation-induced apoptosis senescence 
aromatase inhibitor ai treatment first-line systemic treatment majority postmenopausal breast cancer patient estrogen receptor er positive primary tumor although many patient benefit treatment will develop resistance model mimic acquire resistance will valuable tool unravel resistance mechanism find new treatment biomarker cell culture model acquire resistance three clinically relevant ai letrozole anastrozole exemestane develop selection expansion colony mcf-7 breast cancer cell survive long-term ai treatment condition endogenous aromatase-mediated conversion androgen estrogen require growth four cell line resistant ai establish characterize maintenance er expression function general finding er loss see one twelve cell line receptor expression increase particular egfr expression letrozole-resistant cell line ai-resistant cell line acquire ability grow without aromatase-mediated conversion testosterone estradiol upon withdrawal ai treatment testosterone induce minor growth stimulation letrozole exemestane tamoxifen able abrogate testosterone stimulation reduce growth level standard growth medium ai demonstrate cross-resistance letrozole exemestane tamoxifen contrast fulvestrant totally block growth ai resistant cell line withdrawal ai ai treatment datum show er main driver growth ai-resistant cell line indicate ligand-independent activation er fulvestrant efficient treatment option ai-resistant breast cancer cell cell line will useful tool disclose underlie molecular mechanism resistance different ai 
become recognize screening oncology drug platform use two-dimensionally 2d culture cell line unable precisely select clinically active drug therefore three-dimensional 3d culture system emerge show potential better simulate vivo tumor microenvironment purpose study reveal differential effect chemotherapeutic drug 2d 3d-culture explore underlying mechanism evaluate difference 2d 3d-cultured breast cancer cell line assess drug sensitivity oxygen status expression ki-67 caspase three cell line bt-549 bt-474 t-47d develop dense multicellular spheroid mcss 3d-culture show greater resistance paclitaxel doxorubicin compare 2d-cultured cell additional three cell line mcf-7 hcc-1954 mda-mb-231 develop loose mcss 3d show drug sensitivity similar find 2d-culture treatment paclitaxel result greater increase cleaved-parp expression 2d-culture compare 3d-culture cell line form dense 3d-mcss suggest mcs formation protect cell paclitaxel-induced apoptosis hypoxia observe dense 3d-mcss bt-549 fewer cell positive ki-67 3d 2d-culture suggest greater g0-dormant subpopulation responsible drug resistance 3d-culture bt-474 lower level caspase-3 3d 2d-culture suggest 3d-environment anti-apoptotic finally compare staining ki-67 caspase 2d 3d-primary-cultured cell originate patient-derived xenograft pdx fresh pdx tumor patient original tumor 2d-cultured cell show greater proportion ki-67-positive caspase-3-positive cell agreement view 3d-primary culture better represent characteristic tumor vivo conclusion 3d-cultured cell form dense mcss may better 2d-cultured cell simulate important tumor characteristic vivo namely hypoxia dormancy anti-apoptotic feature result drug resistance 
become recognize screening oncology drug platform use two-dimensionally 2d culture cell line unable precisely select clinically active drug therefore three-dimensional 3d culture system emerge show potential better simulate vivo tumor microenvironment purpose study reveal differential effect chemotherapeutic drug 2d 3d-culture explore underlying mechanism evaluate difference 2d 3d-cultured breast cancer cell line assess drug sensitivity oxygen status expression ki-67 caspase three cell line bt-549 bt-474 t-47d develop dense multicellular spheroid mcss 3d-culture show greater resistance paclitaxel doxorubicin compare 2d-cultured cell additional three cell line mcf-7 hcc-1954 mda-mb‑231 develop loose mcss 3d show drug sensitivity similar find 2d-culture treatment paclitaxel result greater increase cleaved-parp expression 2d-culture compare 3d-culture cell line form dense 3d-mcss suggest mcs formation protect cell paclitaxel-induced apoptosis hypoxia observe dense 3d-mcss bt-549 fewer cell positive ki-67 3d 2d-culture suggest greater g0-dormant subpopulation responsible drug resistance 3d-culture bt-474 lower level caspase-3 3d 2d-culture suggest 3d-environment anti-apoptotic finally compare staining ki-67 caspase 2d 3d-primary‑cultured cell originate patient-derived xenograft pdx fresh pdx tumor patient original tumor 2d-cultured cell show greater proportion ki-67-positive caspase-3-positive cell agreement view 3d-primary culture better represent characteristic tumor vivo conclusion 3d-cultured cell form dense mcss may better 2d-cultured cell simulate important tumor characteristic vivo namely hypoxia dormancy anti-apoptotic feature result drug resistance 
trifluridine ftd key component novel oral antitumor drug tas-102 consist ftd thymidine phosphorylase inhibitor like 5-fluoro-2 deoxyuridine fdurd deoxynucleoside form 5-fluorouracil metabolite ftd sequentially phosphorylate inhibit thymidylate synthase activity also incorporate dna although tas-102 effective treatment refractory metastatic colorectal cancer clinical trial mechanism ftd-induced cytotoxicity completely understand show ftd well fdurd induce transient phosphorylation chk1 ser345 follow accumulation p53 p21 protein p53-proficient human cancer cell line particular ftd induce p53-dependent sustained arrest g2 phase associate proteasome-dependent decrease cyclin b1 protein level suppression ccnb1 cdk1 gene expression addition p53-dependent increase p21 protein associate ftd-induced decrease cyclin b1 protein although numerous ssdna dsdna break induce fdurd dna strand break detect ftd-treated hct-116 cell despite massive ftd misincorporation genomic dna suggest antiproliferative effect ftd due induction dna strand break distinctive effect ftd provide insight cellular mechanism underlie antitumor effect may explain clinical efficacy tas-102 
breast cancer major form cancer high mortality rate woman crucial achieve efficient safe anticancer drug recent development medical nanotechnology result novel advance cancer drug delivery cisplatin doxorubicin 5-fluorouracil three important anti-cancer drug poor water-solubility study use cisplatin doxorubicin 5-fluorouracil-loaded polycaprolactone-polyethylene glycol pcl-peg nanoparticle improve stability solubility molecule drug delivery system nanoparticle prepare double emulsion method characterize fourier transform infrared ftir spectroscopy hydrogen-1 nuclear magnetic resonance 1 hnmr cell treat equal concentration cisplatin doxorubicin 5-fluorouracil-loaded pcl-peg nanoparticle free cisplatin doxorubicin 5-fluorouracil 3 4,5-dimethylthiazol-2yl -2,5-diphenyl tetrazolium bromide mtt assay confirm cisplatin doxorubicin 5-fluorouracil-loaded pcl-peg nanoparticle enhance cytotoxicity drug delivery t47d mcf7 breast cancer cell however ic50 value doxorubicin lower ic50 value cisplatin 5-fluorouracil difference statistically consider significant p˂0 .05 however ic50 value drug t47d lower mcf7 
patient highly malignant glioblastoma short median survival time mainly due aggressive relapse therapeutic treatment beside achieve progressive character via epithelial-to-mesenchymal transition emt however comprehensive investigation emt paired primary-recurrent glioblastoma pair presently available thus present study examine expression profile different emt-marker 17 match primary recurrent glioblastoma qpcr double-immunofluorescence staining identify emt marker express cell type additionally analyze influence temozolomide emt marker expression vitro comparison primary tumor expression β-catenin p 0.05 snail1 p 0.05 snail2/slug p 0.05 biglycan p 0.05 twist1 p 0.01 downregulate recurrence whereas l1cam show upregulation p 0.05 qpcr expression desmoplakin vimentin fibronectin tgf-β1 receptor tgf-βr1 tgf-βr2 almost unchanged compare individual pair five different 'em t group within glioblastoma collective identify accord regulation mrna expression gfap desmoplakin snail1 snail2 twist1 vimentin additionally double-staining emt marker combination cell specific marker glial fibrillary acidic protein cd11b von willebrand factor reveal emt marker express complex pattern three cellular type possible source temozolomide treatment significantly induce mrna expression nearly investigate emt marker t98g glioma cell thus emt seem involve glioma progression complex way require individualized analysis influence commonly use therapeutic option glioma therapy 
many anti-cancer drug fail human trial despite show efficacy preclinical model clear vitro assay involve 2d monoculture reflect complex extracellular matrix chemical cellular microenvironment tumor tissue may explain failure 2d model predict clinical efficacy first optimize vitro microtumor model use tumor-aligned ecm tumor-aligned medium mcf-7 mda-mb-231 breast cancer spheroid human umbilical vein endothelial cell human stromal cell recapitulate tissue architecture chemical environment cellular organization grow invade tumor assay microtumor cell proliferation invasion tumor-aligned extracellular matrix exhibit collagen deposition acidity glucose deprivation hypoxia find maximal proliferation invasion multicellular spheroid culture tumor-aligned medium low ph low glucose 10 fetal bovine serum hypoxic condition 7-day assay vary dose fluorouracil paclitaxel differential effect proliferation mcf-7 mda-mb-231 tumor spheroid microtumor compare 2d 3d monoculture microtumor exhibit tumor morphology drug response similar publish xenograft datum thus demonstrate physiologically predictive vitro model 
trifluridine ftd 2 deoxy-5-fluorouridine fdurd derivative 5-fluorouracil 5-fu antitumor agent inhibit thymidylate synthase activity nucleotide incorporate dna however evident several difference occur underlie antitumor mechanism associate nucleoside analogue recently tas-102 compose ftd tipiracil hydrochloride tpi show prolong survival patient colorectal cancer receive median 2 prior therapy include 5-fu tas-102 recently approve clinical use japan datum suggest antitumor activity tas-102 5-fu proceed via different mechanism thus analyze property term thymidine salvage pathway utilization involve membrane transporter nucleoside kinase nucleotide-dephosphorylating enzyme dna polymerase alpha ftd incorporate dna higher efficiency fdurd ftd fdurd transport cell ent1 ent2 phosphorylate thymidine kinase 1 show higher catalytic activity ftd fdurd deoxyutpase dut recognize dttp ftd-triphosphate f3dttp whereas deoxyuridine-triphosphate dutp fdurd-triphosphate fdutp efficiently degrade dut dna polymerase alpha incorporate f3dttp fdutp dna site align adenine opposite strand ftd-treated cell show differ nuclear morphology compare fdurd-treated cell finding indicate ftd fdurd incorporate dna different efficiency due difference substrate specificity tk1 dut cause abundant ftd incorporation dna 
investigate effectiveness combination 6-thioguanine 6-tg pralatrexate pdx methylthioadenosine phosphorylase mtap deficient t-cell acute lymphoblastic leukemia t-cell ccrf-cem mtap / molt4 mtap / t-cell cell line treat 6-tg pdx evaluate efficacy 72 h later nod/scid gamma mouse bear cem molt4 xenograft treat 6-tg pdx alone combination evaluate antitumor effect cem cell sensitive 6-tg pdx vitro molt4 vivo cem cell sensitive pdx 6-tg whereas molt4 cell highly resistant 6-tg well-tolerated combination pdx 6-tg achieve significant tumor regression cem xenograft loss mtap expression may therapeutically exploit t-cell combination 6-tg pdx inclusion leucovorin rescue allow safe effective regimen mtap-deficient t-cell 
chemoresistance cancer therapy unfavorable prognostic factor non-small cell lung cancer nsclc elevation intracellular calcium level multidrug resistant mdr subline lead sensitization mdr subline cell death demonstrate fungal protein ganoderma microsporum gmi elevate intracellular calcium level reduce growth mdr subline via autophagy apoptosis regardless p-glycoprotein p-gp overexpression mouse xenograft tumor addition examine role autophagy death mdr a549 lung cancer subline gmi thapsigargin tg tunicamycin tm vitro cytotoxicity tg inhibit overexpressed p-gp however tm-induced death mdr subline independent p-gp level combination tg tm either docetaxel vincristine show additional cytotoxic effect mdr subline tg tm-mediated apoptosis mdr subline demonstrate annexin-v assay western blot repress pan-caspase inhibitor z-vad-fmk treatment mdr subline tg tm also augment autophagy accumulation lc3-ii protein breakdown p62 formation acidic vesicular organelle avo inhibition atg5 shrna silencing significantly reduce autophagy cell death apoptosis follow tg tm treatment gmi treatment inhibit phosphorylation akt/s473 p70s6k/t389 interestingly phosphorylation erk associate gmi-induced autophagy conclude autophagy play pro-death role acquire mdr upregulation autophagy gmi via akt/mtor inhibition provide potential strategy overcome mdr treatment lung cancer 
recently porous carbon show great potential many area study tio2-doped mesoporous carbonaceous tio2 @c nanoparticle obtain simple one-pot hydrothermal treatment folic acid fa conjugate tio2 @c amide bond mitoxantrone hcl mtx adsorb onto tio2@c-fa drug delivery system tio2@c-fa / mtx obtain tio2@c-fa / mtx show much faster mtx release ph 4.5 ph 6.0 ph 7.4 furthermore compare free mtx drug delivery system show dose-dependent cytotoxicity vary irradiance afford higher antitumor efficacy culture pc3 cell vitro ability tio2@c-fa / mtx combine chemotherapy photodynamic activity enhance cancer cell killing effect vitro demonstrate tio2@c-fa / mtx great potential cancer therapy future 
non-small cell lung cancer commonly see higher morbidity mortality high-mobility group protein 1 hmgb1 highly conserve nuclear protein involve multiple human disease include cancer however mechanism hmgb1 non-small cell lung cancer remain unclear goal present study identify relationship hmgb1 progresssion non-small cell lung cancer investigate molecular mechanism hmgb1 non-small lung cancer cell line firstly detect expression level hmgb1 real-time pcr western blotting analysis result demonstrate hmgb1 much higher express non-small cell lung cancer cell line include a549 spc-1-1 nci-2170 sk-mes-1 nci-h1299 compare wi-38 next 5 μm adriamycin amd 20 μm cisplatin ddp 50 μm methotrexate mtx use treat a549 cell spc-a-1 cell 48 h result show treatment chemotherapy drug significantly increase level hmgb1 a549 cell spc-a-1 cell moreover expression level hmgb1 increase time-dependent manner treat ddp endogenous hmgb1 expression successfully interfer shrna specific hmgb1 a549 spc-a-1 cell detect western blotting analysis cisplatin-sensitive a549 cell cisplatin-resistant a549/ddp cell treat increase concentration cisplatin 24 48 72 h cell viability analyze mtt assay ic50 value calculate result demonstrate expression level hmgb1 a549/ddp cell much higher a549 cell moreover transfection hmgb1 shrna a549/ddp cell decrease ic50 value cisplatin a549/ddp cell expression level autophagy-related protein beclin-1 lc3-ii significantly higher a549/ddp cell a549 cell treat chemotherapeutic drug compare a549 cell however interference endogenous hmgb1 obviously suppress autophagy-related protein increase cell apoptosis rate expression cleave caspase-3 a549/ddp cell datum suggest interference endogenous hmgb1 significantly inhibit cell autophagy increase cell apoptosis a549/ddp cell thus study resistance chemotherapy drug provide theoretical reference clinical treatment non-small cell lung cancer 
peloruside microtubule-stabilizing agent isolate new zealand marine sponge peloruside prevent growth panel cancer cell line low nanomolar concentration include cell line resistant paclitaxel three xenograft study athymic nu/nu mouse perform assess efficacy peloruside compare standard anticancer agent paclitaxel docetaxel doxorubicin first study examine effect 5 10 mg/kg peloruside qd × 5 growth h460 non-small cell lung cancer xenograft peloruside cause tumor growth inhibition tgi 84 95 respectively whereas standard treatment paclitaxel 8 mg/kg qd × 5 docetaxel 6.3 mg/kg q2d × 3 much less effective tgi 50 18 respectively second xenograft study use a549 lung cancer cell vary schedule dosing activity peloruside superior compare taxane inhibition range 51 74 compare 44 50 two taxane third xenograft study p-glycoprotein-overexpressing nci/adr-res breast tumor model show peloruside better tolerate either doxorubicin paclitaxel conclude peloruside highly effective prevent growth lung p-glycoprotein-overexpressing breast tumor vivo therapeutic development warrant mol cancer ther 14 8 1816-23 © 2015 aacr 
glioblastoma multiforme gbm tumor associate poor prognosis know resistant radiotherapy alkylating agent temozolomide tmz beta-elemene monomer find chinese traditional herb extract curcuma wenyujin currently use antitumor drug different type tumor include gbm present study investigate role beta-elemene radiosensitivity chemosensitivity gbm cell human gbm cell line u87-mg t98g u251 ln229 rat c6 cell treat beta-elemene combine radiation tmz use mtt colony form assay evaluate proliferation survival cell comet assay observe dna damage expression protein analyze immunoblotting present study find beta-elemene inhibit proliferation survival different gbm cell line combine radiotherapy tmz via inhibition dna damage repair treatment gbm cell beta-elemene decrease phosphorylation ataxia telangiectasia mutate atm akt erk follow radiotherapy chemotherapy result reveal beta-elemene significantly increase radiosensitivity chemosensitivity gbm beta-elemene may use potential drug combination radiotherapy chemotherapy gbm 
evaluate suggest metastasis-related microrna mirna association disease-free survival dfs overall survival os triple-negative breast cancer tnbc cohort 456 tnbc case systematically evaluate 57 previously report metastasis-related mirna tumor tissue use nanostring ncounter assay cox regression apply evaluate mirna expression association dfs os vitro assay use tnbc cell line mda-mb-231 also conduct validate epidemiological study finding median follow-up 5.3 year 112 death 97 recurrence document high level mir-374b-5p mir-218-5p mir-126-3p low level mir-27b-3p independently associate favorable tnbc outcome p 0.01 composite score base level four mirna associate dfs hazard ratio 95 confidence interval 0.70 0.43-1.15 0.51 0.29-0.90 0.18 0.09-0.37 second third fourth compare lowest quartile incorporate mirna score known tnbc outcome predictor i.e. age diagnosis tumor stage basal-like subtype increase c-index predict dfs 0.68 0.74 additionally mir-126-3p correlate basal-like breast cancer mir-374b-5p modify therapeutic effect 5-fluorouracil cyclophosphamide treatment basal-like breast cancer patient restore mir-126-3p mir-218-5p mir-374b-5p inhibit mir-27b-3p mda-mb-231 cell reduce cell proliferation mir-374b-5p suppress cell invasion mir-218-5p inhibit colonization study provide strong evidence expression level mir-374b-5p mir-27b-3p mir-126-3p mir-218-5p tumor tissue predict tnbc outcome 
previous study demonstrate sulfate conjugation involve metabolism three commonly use breast cancer drug tamoxifen raloxifene fulvestrant current study design systematically identify human cytosolic sulfotransferase sult capable sulfate raloxifene fulvestrant two active metabolite tamoxifen afimoxifene endoxifen systematic analysis use 13 known human sult reveal sult1a1 sult1c4 major sult responsible sulfation afimoxifene endoxifen raloxifene fulvestrant kinetic parameter two human sult catalyze sulfation drug compound determine sulfation afimoxifene endoxifen raloxifene fulvestrant metabolic condition examine use hepg2 human hepatoma cell mcf-7 breast cancer cell moreover human intestine kidney liver lung cytosol examine verify presence afimoxifene/endoxifen/raloxifene / fulvestrant-sulfating activity 
high grade glioma hgg grade iii iv common primary brain tumor adult malignant nature rank fourth incidence cancer death standard treatment glioblastoma gbm involve surgical resection follow radiation chemotherapy temozolomide tmz anti-angiogenic therapy bevacizumab substantially improve overall survival new therapeutic agent desperately need devastate disease study potential therapeutic agent ag119 pre-clinical model glioma ag119 possess anti-angiogenic rtk inhibition antimicrotubule cytotoxic activity single molecule gl261 glioma-bearing mouse either treat ag119 anti-vegf vascular endothelial growth factor antibody anti c-met antibody tmz compare untreated tumor-bearing mouse animal survival assess tumor volume vascular alteration monitor morphological magnetic resonance imaging mri perfusion-weighted imaging respectively percent survival gl261 hgg-bearing mouse treat ag119 significantly higher p 0.001 compare untreated tumor tumor volume 21-31 day follow intracerebral implantation gl261 cell find significantly lower ag119 p 0.001 anti-vegf p 0.05 anti-c-met p 0.001 antibody treatment tmz-treated p 0.05 mouse compare untreated control perfusion datum indicate ag119 tmz able reduce effect decrease perfusion rate significantly p 0.05 compare untreated tumor also find ic50 value ag119 much lower tmz t98g u251 cell datum support exploration anticancer activity ag119 hgg compound able increase animal survival decrease tumor volume mouse gl261 glioma model ag119 also subject methyl guanine transferase mgmt mediated resistance case tmz indicate ag119 may potentially useful treat resistant glioma 
platinum-based chemotherapeutic drug widely use component combination chemotherapy treatment cancer one drug oxaliplatin exert synergistic effect advanced colorectal cancer combination 5-fluorouracil 5-fu leucovorin p53-proficient colorectal cancer cell line hct116 oxaliplatin repress expression deoxyuridine triphosphatase dutpase ubiquitous pyrophosphatase catalyze hydrolysis dutp dump inhibit dutp-mediated cytotoxicity however underlie mechanism activity completely elucidate remain unclear whether factor downregulation dutpase contribute synergistic effect 5-fu oxaliplatin study find oxaliplatin dachplatin platinum-based drug contain 1,2-diaminocyclohexane dach carrier ligand repress expression nuclear isoform dutpase dut-n whereas cisplatin carboplatin oxaliplatin induce early p53 accumulation upregulation primary mir-34a transcript expression subsequent downregulation e2f3 e2f1 nutlin-3a activate p53 nongenotoxically similar effect introduction mir-34a mimic also repress e2f1 dut-n expression indicate mirna play causative role addition dut-n oxaliplatin repress p53-dependent manner expression gene encode enzyme involve thymidylate biosynthesis consequently oxaliplatin significantly decrease level dttp dntp pool p53-dependent manner datum indicate dach carrier ligand oxaliplatin trigger signaling via p53-mir-34a-e2f axis lead transcriptional regulation ultimately result accumulation dutp reduce dttp biosynthesis potentially enhance 5-fu cytotoxicity 
mtt assay less degree mts xtt wst widely exploit approach measure cell viability/drug cytotoxicity mtt reduction occur throughout cell significantly affect number factor include metabolic energy perturbation change activity oxidoreductase endo / exocytosis intracellular trafficking over/underestimation cell viability mtt assay may due adaptive metabolic mitochondrial reprogramming cell subject drug treatment-mediated stress inhibitor off-target effect previously imatinib rottlerin ursolic acid verapamil resveratrol genistein nanoparticle polypeptide show interfere mtt reduction rate result inconsistent result mtt assay alternative assay test under/overestimation viability mtt assay compare result derive mtt assay trypan blue exclusion assay treatment glioblastoma u251 t98g c6 cell three widely use inhibitor known direct side effect energy metabolic homeostasis temozolomide tmz dna-methylating agent temsirolimus tem inhibitor mtor kinase u0126 inhibitor mek1/2 kinase inhibitor apply shortly ic50 evaluate study long study focus drug resistance acquisition show over/underestimation cell viability mtt assay significance depend cell line time point viability measurement experimental parameter furthermore provide comprehensive survey factor account mtt assay avoid result misinterpretation supplementation tetrazolium salt-based assay non-metabolic assay recommend 
background colorectal cancer crc major health problem china around world one lead cause cancer-related death research group thus search novel efficient anti-crc agent result demonstrate abc294640 novel sphk2 inhibitor induce growth inhibition apoptosis transform primary crc cell sphk activity remarkably inhibit abc294640 accompany sphingosine-1-phosphate s1p depletion ceramide incensement crc cell exogenously-added s1p inhibit abc294640-induced ht-29 cell lethality c6 ceramide sphk1 inhibitor ski-ii facilitate abc294640-induced cytotoxicity ht-29 cell abc294640 inhibit akt-s6k1 activate jnk signaling transform primary crc cell jnk inhibitor sp600125 jnki-ii alleviate abc294640-induced crc cell apoptosis moreover low concentration abc294640 sensitize activity 5-fu cisplatin vitro vivo abc294640 oral administration dramatically inhibit ht-29 xenograft growth nude mouse conclusion targeting sphk2 abc294640 potently inhibit crc cell growth vitro vivo abc294640 develop novel therapeutic treatment crc 
solanum incanum extract sr-t100 contain active ingredient solamargine induce apoptosis via upregulation tumor necrosis factor receptor expression activation mitochondrial apoptosis pathway therapeutic effect patient actinic keratosis evaluate novel molecular mechanism underlie sr-t100-regulated stemness chemoresistance concentration sr-t100 inhibit 50 cell viability ic50 lower ovarian cancer cell nonmalignant cell furthermore sr-t100 ic50 chemoresistant cell similar ic50 chemosensitive cell additionally sr-t100 increase cisplatin paclitaxel sensitivity chemoresistant cell sr-t100 downregulate expression stem cell marker include aldehyde dehydrogenase 1 aldh1 notch1 foxm1 reduce sphere formation ovarian cancer cell use microarray analysis immunoblotting luciferase activity chromatin immunoprecipitation chip assay show sr-t100 suppress expression c/ebpbeta col11a1 promoter activity resistant cell sensitive cell sr-t100 paclitaxel cisplatin inhibit growth a2780cp70 cell mouse xenograft compare vehicle control combination cisplatin sr-t100 effective either treatment alone sr-t100 may represent potential therapeutic adjunct chemotherapy ovarian cancer treatment 
mesoporous silica nanoparticle msnp 100 nm size incorporate cy5 fluorophore within silica framework synthesize load anti-cancer drug temozolomide tmz use treatment glioma surface particle decorate use electrostatic interaction polyarginine-peptide nucleic acid r8-pna conjugate target mir221 microrna multi-functional nanosystem thus obtain rapidly internalize glioma c6 t98g cell anti-mir activity pna retain confirm reverse transcription polymerase chain reaction rt-pcr measurement induction apoptosis observe temozolomide-resistant cell line tmz-loaded msnp show enhance pro-apoptotic effect combined effect tmz r8-pna msnp show effective induction apoptosis 70.9 apoptotic cell thus far achieve temozolomide-resistant t98g cell line 
temozolomide tmz widely use patient glioblastoma gbm however tumor cell frequently exhibit drug-resistance base excision repair ber identify possible mediator tmz resistance attractive approach sensitize cell chemotherapy human apurinic/apyrimidinic endonuclease/redox factor-1 ape1 essential enzyme role ber pathway repair abasic site also act reduction factor maintain transcription factor active reduce state thus aim investigate whether down-regulation ape1 expression sirna interfere resistance gbm tmz evaluate several cellular molecular parameter demonstrate ape1 knockdown associate tmz treatment efficiently reduce cell proliferation clonogenic survival resistant cell t98g appear consequence increase dna damage s-phase arrest h2ax phosphorylation result apoptosis induction contrary assay sensitization effect ape1 silencing plus tmz treatment occur tmz-sensitive cell line u87mg interestingly tmz-treatment ape1 knockdown significantly reduce cell invasion cell line tmz alone reduce invasion capacity u87mg cell observe t98g also find vegf expression down-regulate tmz treatment t98g cell regardless ape1 knockdown u87mg show different response since ape1 silencing counteract vegf induction promote tmz suggest ape1-redox function may play indirect role depend cell line present result support contribution ber gbm resistance tmz greater effect tmz-resistant compare tmz-sensitive cell emphasize ape1 promising target modify tmz tolerance furthermore genetic characteristic tumor cell consider critical information select appropriate therapeutic strategy 
investigate mechanism action immuno-modulatory drug lenalidomide protein expression cereblon crbn therapeutic target multiple myeloma cell line rpmi8226 multiple myeloma cell line rpmi8226 culture treat different concentration lenalidomide bortezomib determine proliferation inhibition rate apoptosis rate protein expression crbn result reveal lenalidomide bortezomib inhibit proliferation rpmi8226 promote cell apoptosis however protein expression crbn decrease signifi-cantly treatment lenalidomide bortezomib effect expression crbn confirm crbn may target lenalidomide 
accumulate gene mutation cancer suggest multi-targeted suppression affected signaling network promising strategy cancer treatment present study report 7-o-succinyl macrolactin sma suppress tumor growth stabilize beta-catenin destruction complex achieve inhibition regulatory component associate complex sma significantly reduce activity pi3k/akt correspond decrease gsk3beta phosphorylation increase beta-catenin phosphorylation reduction nuclear beta-catenin content ht29 human colon cancer cell time activity tankyrase inhibit beta-catenin destruction complex destabilizing axin level suppress sma despite low potency sma tankyrase activity ic50 50.1 mum 15.5 mum tankyrase 1 2 respectively compare xav939 ic50 11 nm tankyrase 1 selective potent tankyrase inhibitor sma strong inhibitory effect beta-catenin-dependent tcf/lef1 transcriptional activity ic50 39.8 nm similar xav939 ic50 28.1 nm addition suppress colony form ability colon cancer cell vitro sma significantly inhibit tumor growth ct26 syngenic ht29 xenograft mouse tumor model furthermore treat mouse sma combination 5-fu colon cancer xenograft model cisplatin a549 lung cancer xenograft model result greater anti-tumor activity treatment drug alone xenograft tumor tissue sma dose-dependently inhibit nuclear beta-catenin along reduction gsk3beta phosphorylation increase axin level result suggest sma possible candidate effective anti-cancer agent alone combination cytotoxic chemotherapeutic drug 5-fu cisplatin mode action sma involve stabilization beta-catenin destruction complex inhibition tankyrase pi3k/akt signaling pathway 
nilotinib amn induce apoptosis various cancer cell however effect amn human ovarian cancer cell still unclear reduction cell viability associate occurrence apoptotic characteristic observe human skov-3 ovarian cancer cell amn sorafenib sora imatinib sti stimulation activation apoptotic pathway include increase caspase casp -3 poly adp-ribose polymerase 1 parp1 protein cleavage amn detect disrupt mitochondrial membrane potential mmp accompany decrease bcl-2 protein increase cytosolic cytochrome cyt c/cleaved casp-9 protein expression find amn-induced cell death inhibit peptidyl casp inhibitor vad devd lehd increase phosphorylated c-jun n-terminal kinase jnk protein expression detect amn sora sti-treated skov-3 cell jnk inhibitor sp600125 jnki show slight significant enhancement amn-induced cell death skov-3 cell intracellular peroxide level elevated amn h2o2 n-acetylcysteine nac prevent h2o2 amn-induced peroxide production apoptosis skov-3 cell amn induction apoptosis increase intracellular peroxide production jnk protein phosphorylation also identify human a2780 ovarian cancer cell cisplatin-resistant a2780cp cell clear es-2 cell evidence support amn effectively reduce viability human ovarian cancer cell via mitochondrion-dependent apoptosis provide 
recurrence colorectal cancer crc may arise due persistence drug-resistant cancer-initiating cell survive exposure chemotherapy protein responsible recurrence include chemokine receptor cxcr4 know enable crc metastasis well cancer-initiating cell marker peptidase cd26 terminate activity chemokine cxcl12 evaluate expression function cxcr4 cd26 colon cancer cell line xenograft follow treatment common chemotherapy use radioligand binding flow cytometry immunofluorescence enzymatic assay 5-fluorouracil oxaliplatin sn-38 active metabolite irinotecan well cisplatin methotrexate vinblastine cause decrease cell-surface cxcr4 concomitant increase cd26 ht-29 t84 hrt-18 sw480 sw620 crc cell line flow cytometry indicate decline cxcr4 associate significant loss cxcr4 / cd26 cell elevation cd26 parallel increase intrinsic dipeptidyl peptidase activity cd26 well capacity bind extracellular adenosine deaminase orthotopic ht-29 xenograft treat standard crc chemotherapeutic 5-fluorouracil irinotecan oxaliplatin show dramatic increase cd26 compare untreated tumor consistent loss cxcr4 gain cd26 migratory response exogenous cxcl12 eliminate cell pretreat cytotoxic agent although cell retain basal motility analysis cancer-initiating cell cd44 cd133 subset reveal drug-dependent response cd26/cd44/cd133 population suggest benefit combine standard chemotherapy 5-fluoruracil oxaliplatin may derive complementary elimination cell population result indicate conventional anticancer agent may act inhibit chemokine-mediated migration eradication cxcr4 cell attenuation chemokine gradient elevation cd26 activity 
aim study lal 17/84 reduce number relapse intensify initial treatment patient classify high hr standard-risk sr group follow established risk index early response 2 week treatment also consider sr protocol include ten-week induction cns prophylaxis phase first 5 week prednisolone pred vincristine vcr daunorubicin dauno asparaginase aspar give last 5 week two intravenous infusion ara-c three intermediate dose id methotrexate mtx administer simultaneously 5 injection drug cns prophylaxis complete 5 injection one beginning 4 monthly interval 3rd 6th month hr protocol initial phase last 16 week first 5 drug sr use dose pred aspar higher cns prophylaxis include holocranial radiotherapy 18 gy 2 iv infusion ara-c 2 mtx id 6 dose mtx ara-c finally consolidation phase pred vcr 3 dose tenoposide 3 dose cyclophosphamide give complementary chemotherapy protocol consist daily mercaptopurine weekly mtx 2 year moreover randomize half patient receive monthly reinforcement pred vcr dauno hr group 4 month oct. 83 nov. 87,87 patient age 3 month 15 year enrol 86 evaluable achieve remission abstract truncate 250 word 
chronic myeloid leukemia myeloproliferative syndrome characterize presence philadelphia chromosome ph generate reciprocal translocation occur chromosome 9 22 t 9 22 q34 q11 consequence fusion gene bcr-abl encode constitutively active kinase generate first-line treatment consist bcr-abl inhibitor imatinib nilotinib dasatinib nevertheless treatment may lead selection resistant cell therefore find molecule enhance anti-proliferative effect first-line drug value hyaluronan oligomer oha know able sensitize several tumor cell chemotherapy previously demonstrate oha revert vincristine resistance mouse lymphoma human leukemia cell line however little know role oha hematological malignancy aim work determine whether oha able modulate anti-proliferative effect imatinib chronic myeloid leukemia cml cell line effect apoptosis senescence well involvement signaling pathway also evaluate purpose human cml cell line k562 kv562 resistant use demonstrate oha sensitize cell line anti-proliferative effect imatinib increase apoptosis senescence moreover effect accomplish down-regulation pi3k signaling pathway finding highlight potential oha use co-adjuvant therapy chronic myeloid leukemia 
cytotoxicity monofunctional alkylator temozolomide tmz know mediate mismatch repair mmr trigger o6-alkylguanine contrast cytotoxicity bifunctional alkylator include carmustine bcnu melphalan mel depend interstrand crosslink form o6-alkylguanine repair nucleotide excision repair recombination o6-alkylguanine remove o6-methylguanine-dna methyltransferase mgmt aim present study evaluate cytotoxicity tmz bcnu mel two different leukemic cell line hl-60 molt-4 context dna repair transcript level mgmt ercc1 hmlh1 hmsh2 determine use reverse transcription-quantitative polymerase chain reaction addition proliferation measure use trypan blue exclusion assay drug sensitivity find vary two cell line treatment cell tmz bcnu mel combination o6-benzylguanine mgmt inhibitor demonstrate sensitize two cell line agent however extent sensitization find correlate expression level mgmt transcript furthermore drug sensitivity also associate transcript level ercc1 hmlh1 hmsh2 thus leukemic cell sensitize alkylating agent inhibition mgmt 
chemotherapy often result cognitive impairment neuroprotective drug now available study aim understand underlie neurotoxicological mechanism anticancer drug evaluate neuroprotective effect pan-811 primary neuron different concentration antioxidant ao insult 3 day methotrexate mtx 5-fluorouracil 5-fu cisplatin cddp absence presence pan-811 · cl · h2o effect pan-811 anticancer activity test drug also examine use mouse human cancer cell bnlt3 h460 assess negative interference cell membrane integrity survival death intramitochondrial reactive oxygen species ros measure test anticancer drug elicit neurotoxicity low level ao elicit ros increase result suggest ros mediate neurotoxicity test anticancer drug pan-811 dose-dependently suppress increase ros block neurotoxicity neuron insult test anticancer drug pan-811 interfere anticancer activity anticancer drug bnlt3 cell pan-811 inhibit mtx-induced death h460 cell interestingly demonstrate synergistic effect 5-fu cddp reduce cancer cell viability thus pan-811 potent drug candidate chemotherapy-induced cognitive impairment 
microtubule fundamental component mitotic spindle play essential role cell division well know purify microtubule affect static magnetic field smf vitro diamagnetic anisotropy tubulin however whether effect lead cell division defect unknown find 1t smf induce abnormal mitotic spindle increase mitotic index synchronization experiment show smf delay cell exit mitosis cause mitotic arrest mimic cellular effect microtubule-targeting drug paclitaxel taxol frequently use combination 5-fluorouracil 5-fu cisplatin cancer treatment use four different human cancer cell line hela hct116 cne-2z mcf7 find smf increase antitumor efficacy 5-fu 5-fu/taxol cisplatin indicate smf-induced combinational effect chemodrug drug-specific study reveal effect smf microtubule cause abnormal mitotic spindle delay cell exit mitosis also imply potential application smf combination chemotherapy drug 5-fu 5-fu/taxol cisplatin cancer treatment 
evofosfamide th-302 hypoxia-activated prodrug cytotoxin bromo-isophosphoramide hypoxic condition br-ipm release alkylate dna ifosfamide chloro-isophosphoramide prodrug activate hepatic cytochrome p450 enzyme compound use treatment cancer ifosfamide approve fda evofosfamide currently late stage clinical development purpose study compare efficacy safety profile evofosfamide ifosfamide preclinical non-small cell lung cancer h460 xenograft model immunocompetent cd-1 mouse h460 tumor-bearing immunocompromised nude mouse use investigate safety profile efficacy evofosfamide ifosfamide alone combination docetaxel sunitinib compare ectopic intrapleural othortopic h460 xenograft model animal expose ambient air different oxygen concentration breathing condition equal body weight loss level evofosfamide show greater comparable efficacy ectopic orthotopic h460 xenograft model evofosfamide ifosfamide exhibit controlled oxygen concentration breathing condition-dependent antitumor activity however equal body weight loss level ifosfamide yield severe hematologic toxicity compare evofosfamide monotherapy combination docetaxel equal hematoxicity level evofosfamide show superior antitumor activity result indicate evofosfamide show superior comparable efficacy favorable safety profile compare ifosfamide preclinical human lung carcinoma model finding consistent multiple clinical trial evofosfamide single agent combination therapy demonstrate anti-tumor activity safety profile without severe myelosuppression 
aim investigate role large intergenic noncoding rna regulator reprogramming linc-ror chemotherapy resistance human breast cancer bc cell mechanism total 142 patient diagnose bc first affiliated hospital zhejiang university january 2012 january 2014 enrol study bc tissue adjacent normal tissue 5 cm away tumor tissue enrol patient select human bc cell line mcf10a sk-br-3 mcf-7 bcap-37 mda-mb-231 t47d also select quantitative real-time polymerase chain reaction qrt-pcr western blot 3 4 5-dimethylthiazol-2-yl -5 3-carboxymethoxyphenyl -2 4-sulfophenyl -2 h-tetrazolium inner salt mts assay transwell apply study expression level linc-ror messenger rna mrna bc tissue clearly higher adjacent normal tissue significant difference find expression level linc-ror mrna lymph node metastasis p 0.05 linc-ror highly express bc cell line compare immortalize mammary epithelial cell mec mcf10a p 0.05 mda-mb231 cell present higher expression p 0.001 different concentration 5-fu paclitaxel mda-mb231 cell e-cadherin mrna protein expression increase gradually increase concentration vimentin n-cadherin mrna protein expression decrease gradually decrease concentration p 0.05 compare shctrl group mda-mb231 cell shror group present higher sensibility 5-fu paclitaxel increase e-cadherin expression decrease vimentin n-cadherin expression invasion ability p 0.05 compare vector cell overexpress linc-ror cell present decrease sensibility 5-fu paclitaxel decrease e-cadherin expression increase vimentin n-cadherin expression invasion ability p 0.05 study demonstrate linc-ror important marker multidrug resistance bc up-regulation important chemotherapy tolerance invasion bc 
background use dietary polyphenol chemosensitizing agent enhance efficacy conventional cytostatic drug recently gain attention scientist clinician plausible approach overcome limitation chemotherapy e.g. drug resistance cytotoxicity aim study investigate whether naturally occur diet-based flavonoid fisetin physiologically attainable concentration act synergistically clinically achievable dose paclitaxel produce growth inhibitory and/or pro-death effect a549 non-small cell lung cancer cell mechanism might involve method drug-drug interaction analyze base combination index method chou talalay datum mtt assay provide insight mechanism underlie synergistic action fisetin paclitaxel select morphological biochemical molecular parameter examine include morphology cell nucleus mitotic spindle pattern lc3-ii immunostaining formation autophagic vacuole electron fluorescence microscopic level disruption cell membrane asymmetry/integrity cell cycle progression expression level lc3-ii bax bcl-2 caspase-3 mrna result report first experimental evidence existence synergism fisetin paclitaxel vitro model non-small cell lung cancer synergism least partially ascribe induction mitotic catastrophe switch cytoprotective autophagy autophagic cell death also implicate mechanism synergistic action fisetin paclitaxel a549 cell addition reveal synergism fisetin paclitaxel cell line-specific well fisetin synergize arsenic trioxide mitoxantrone methotrexate a549 cell conclusion result provide rationale testing fisetin combination paclitaxel arsenic trioxide obtain detailed insight mechanism synergistic action well evaluate toxicity towards normal cell animal model vivo conclude study potentially interesting development novel chemotherapeutic approach non-small cell lung cancer 
lung cancer lead cause cancer-related mortality new therapeutic option urgently need non-small cell lung cancer nsclc account approximately 85 lung cancer current standard regimen care nsclc include chemotherapy pemetrex single agent combination platinum-based agent e.g. cisplatin pemetrexed folic acid antagonist inhibit synthesis precursor nucleotide whereas cisplatin directly induce dna adduct repair dependent sufficiently high nucleotide level clinical setting pemetrexed-cisplatin combination therapy administer concomitantly hypothesize prolonged pretreatment pemetrex beneficial prior depletion nucleotide pool sensitize cancer cell subsequent treatment cisplatin nsclc a549 h460 cell treat pemetrex 72 h addition 24 h cisplatin treatment initiate day 1 2 3 result either simultaneous pemetrexed application pemetrexed pretreatment 24 48 h respectively cell growth colony formation well senescence induction quantify treatment cell cycle distribution phosphorylation histone variant h2ax surrogate marker dna damage quantify flow cytometry relative change gene expression determine quantitative real time pcr prolonged pemetrexed pretreatment 48 h prior cisplatin treatment maximally delay long-term cell growth significantly reduce number recover clone moreover apoptosis senescence augmented recovery treatment-induced dna damage delay interestingly cell population identify display epithelial-to-mesenchymal transition emt stem cell phenotype population highly resistant concomitant pemetrexed-cisplatin treatment sensitize pemetrexed pretreatment adaptation standard treatment schedule include pretreatment pemetrex optimize anticancer efficiency pemetrexed-cisplatin combination therapy correlate persistence treatment-induced dna damage therefore study warrant investigation elucidate whether adaptation enhance effectiveness standard clinical treatment regimen addition subpopulation therapy resistant cell emt cancer stem cell feature identify resistant standard treatment regimen sensitive pemetrexed pretreatment combine cisplatin 
glioblastoma multiforme gbm malignant invasive human brain tumor characterize poor prognosis short survival time current treatment strategy gbm use surgery chemotherapy and/or radiotherapy ineffective pi3k/akt/pten signaling pathway frequently deregulate cancer connect regulation cell cycle apoptosis autophagy current study undertake examine effect small interfere rna sirna target akt3 pik3ca gene susceptibility t98g cell temozolomide tmz carmustine bcnu t98g cell transfect akt3 pi3kca sirna transfection efficiency assess use flow cytometry fluorescence microscopy influence akt3 pi3kca sirna combination tmz bcnu t98g cell viability proliferation apoptosis autophagy evaluate well alteration messenger rna mrna expression apoptosis-related autophagy-related gene analyze use quantitative reverse transcription polymerase chain reaction qrt-pcr transfection t98g cell akt3 pi3kca sirna exposure tmz bcnu lead significant reduction cell viability accumulation subg1-phase cell reduction cell s g2/m phase well induction apoptosis necrosis regulation autophagy sirna-induced akt3 pi3kca mrna knockdown combination tmz bcnu inhibit proliferation induce apoptosis autophagy t98g cell thus knockdown gene combination tmz bcnu may offer novel therapeutic strategy effectively control growth human gbm cell study necessary confirm positive phenomenon treatment gbm 
synthesis structure activity relationship four series novel 2-imino-2h-chromene-3 n-aryl carboxamide v-viii describe bioisosteric replacement usually present ketone 2nd position coumarin imine various substitutent introduce aryl chromene ring iminocoumarin investigate effect lipophilicity electronic property substituent cytotoxic activity four human cancer cell line novel 2-imino-2h-chromene-3 n-aryl carboxamide v-viii synthesize reaction substitute 2 cyanoacetamide different salicyaldehyde presence sodium acetate glacial acetic acid compound via show potent activity mcf-7 ic50 = 8.5 μm pc-3 ic50 = 35.0 μm a-549 ic50 = 0.9 μm caco-2 ic50 = 9.9 μm cell line anticancer result reveal synthesize compound show equipotent activity standard 5-fluorouracil docetaxel caco-2 mcf-7 cell line respectively 
background present study focus biodistribution profile pharmacokinetic parameter egfr-targeted chitosan nanoparticle tg cs nanoparticle sirna/cisplatin combination therapy lung cancer material method mad2 sirna encapsulate egfr target nontargeted ntg cs nanoparticle electrostatic interaction biodistribution nanoparticle assess qualitatively quantitatively cisplatin ddp sensitive resistant lung cancer xenograft model result tg nanoparticle show consistent preferential tumor target ability rapid clearance plasma infiltrate sustain within tumor 96 h exhibit sixfold higher tumor target efficiency compare ntg nanoparticle conclusion tg nanoparticle present attractive drug delivery platform rnai therapeutics nsclc 
series novel benzimidazole-2-subsituted phenyl pyridine propyl ketene derivative design synthesize biological activity derivative evaluate potential antitumour agent compound assay growth-inhibitory activity hct116 mcf-7 hepg2 cell line vitro ic50 value compound a1 a7 cancer cell 0.06-3.64 mum 0.04-9.80 mum respectively antiproliferative activity significantly better 5-fluorouracil ic50 56.96-174.50 mum close paclitaxel ic50 0.026-1.53 mum activity derivative 100 time effective report structure chalcone analogue licochalcone preliminary mechanistic study suggest compound inhibit p53-mdm2 binding compound a1 a7 a9 effectively inhibit tumour growth balb/c mouse colon carcinoma hct116 cell group administer 200 mg/kg compound a7 show 74.6 tumour growth inhibition sign toxicity high dose similar inhibition achieve 12.5 mg/kg irinotecan positive control 70.2 therefore class benzimidazole-2-subsituted phenyl pyridine propyl ketene derivative represent promising lead structure development possible p53-mdm2 inhibitor new antitumour agent 
new series 2-amino-4-oxo-6-substituted pyrrolo 2,3-d pyrimidine isosteric replacement side chain amide moiety sulfur atom design synthesize multitargeted antifolate well potential antitumor agent start previously synthesize 2-amino-4-oxo-pyrrolo 2,3-d pyrimidin-6-yl-acetic acid reduction lithium triethylborohydride successive mesylation afford key mesylate nucleophilic substitution mercaptoacetic mercaptopropionic acid methyl ester follow hydrolysis condensation pyridinyl-methylamine provide nonclassical compound 1-6 whereas condensation glutamic acid diethyl ester hydrochloride saponification afford classical analog 7-8 target compound exhibit inhibitory activity toward kb sw620 a549 tumor cell line potent compound series 7 8 better inhibitor a549 cell methotrexate mtx pemetrexed pmx nucleoside protection assay establish compound 8 dual inhibitor thymidylate synthase ts 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase aicarftase target de novo thymidylate purine nucleotide biosynthesis verify molecular modeling study analogous pmx target compound 8 alternate cell cycle sw620 cell s-phase accumulation induce apoptosis lead cell death 
chronic myeloid leukemia cml patient relapse imatinib due acquire abl1 kinase domain mutation successfully treat second-generation abl1-tyrosine kinase inhibitor abl-tki dasatinib nilotinib ponatinib however ~ 40 relapsed patient uncharacterized bcr-abl1 kinase-independent mechanism resistance identify mechanism resistance potential treatment option generate abl-tki-resistant k562 cell prolonged sequential exposure imatinib dasatinib dual-resistant k562 cell lack bcr-abl1 kinase domain mutation acquire genomic aberration characterize next-generation sequencing copy number analysis proteomic show dual-resistant cell elevated level foxo1 phospho-erk bcl-2 dasatinib longer inhibit substrate pi3k/akt pathway contrast parental cell resistant cell sensitive growth inhibition apoptosis induce class pi3k inhibitor gdc-0941 pictilisib also induce foxo1 nuclear translocation foxo1 elevated subset primary specimen relapse cml patient lack bcr-abl1 kinase domain mutation sample responsive gdc-0941 treatment ex vivo conclude elevated foxo1 contribute bcr-abl1 kinase-independent resistance experience cml patient pi3k inhibition couple bcr-abl1 inhibition may represent novel therapeutic approach 
k-ras currently accept frequently mutate oncogene non-small cell lung cancer nsclc include squamous carcinoma adenocarcinoma large cell carcinoma nsclc patient k-ras mutation appear refractory majority systemic therapy present study vitro antitumor effect correlate molecular mechanism sorafenib combine gemcitabine pemetrex explore k-ras mutation-positive nsclc a549 cell line sorafenib see exhibit dose-dependent growth inhibition a549 cell sorafenib combine pemetrexed demonstrate greater synergism compare sorafenib combine gemcitabine sorafenib arrest cell cycle g1 phase gemcitabine pemetrexed cause arrest s phase molecular mechanism synergism due downstream signalling pathway efficiently suppress sorafenib therefore increase incidence entry chemotherapeutic drug apoptotic pathway moreover sorafenib pemetrexed demonstrate stronger synergism demonstrate inhibit ras/raf/mek / erk ras/pi3k/akt pathway concurrently may achieve improved antitumor effect 
v 4 q 5 ddavp novel 2nd generation vasopressin analogue robust antitumour activity metastatic breast cancer recently report act vasopressin v2r membrane receptor present tumour cell microvascular endothelium v 4 q 5 ddavp inhibit angiogenesis metastatic progression disease without overt toxicity despite chemotherapy remain primary therapeutic option aggressive breast cancer use limit low selectivity associate adverse effect regard evaluate potential combinational benefit add v 4 q 5 ddavp standard-of-care chemotherapy vitro combination v 4 q 5 ddavp sub-ic50 concentration paclitaxel carmustine result cooperative inhibition breast cancer cell growth comparison single-agent therapy vivo antitumour efficacy v 4 q 5 ddavp addition chemotherapy first evaluate use triple-negative mda-mb-231 breast cancer xenograft model tumour-bearing mouse treat i.v. injection v 4 q 5 ddavp 0.3 μg/kg thrice weekly combination weekly cycle paclitaxel 10 mg/kg i.p. 6 week treatment combination regimen result greater tumour growth inhibition compare monotherapy v 4 q 5 ddavp addition also associate reduction local aggressiveness impairment tumour invasion infiltration skin benefit combined therapy confirm hormone-independent metastatic f3ii breast cancer model combine v 4 q 5 ddavp carmustine 25 mg/kg i.p. interestingly v 4 q 5 ddavp plus cytotoxic agent severely impaired colony form ability tumour cell inhibit breast cancer metastasis lung present study show v 4 q 5 ddavp may complement conventional chemotherapy modulate metastatic progression early stage microtumour establishment thus support preclinical testing compound management aggressive breast cancer 
chemotherapy resistance present difficult challenge treat epithelial ovarian cancer patient particularly tumor exhibit resistance multiple chemotherapeutic agent study show elevated serum level ovarian cancer biomarker he4 correlate tumor chemoresistance response treatment survival seek confirm previous result he4 contribute collateral resistance cisplatin paclitaxel vitro uncover factor may contribute he4-mediated chemoresistance mts assay western blot cleave parp use assess resistance he4-overexpressing skov3 ovcar8 clone cisplatin paclitaxel crispr/cas technology use knockdown he4 he4-overexpressing skov3 cell microarray conduct determine differential gene expression skov3 null vector-transfected he4-overexpressing clone upon cisplatin exposure result validate quantitative rt-pcr regulation mitogen activate protein kinase mapk tubulin assess western blot he4-overexpressing skov3 ovcar8 clone display increase resistance cisplatin paclitaxel knockdown he4 he4-overexpressing skov3 cell partially reverse chemoresistance microarray analysis reveal he4 overexpression result suppression cisplatin-mediated upregulation egr1 mapk-regulated gene involve promote apoptosis upregulation p38 mapk activate response cisplatin suppress he4-overexpressing clone difference extracellular signal-regulated kinase erk activation note he4-overexpressing clone treat 25 μm cisplatin erk activation partially suppress he4-overexpressing clone treat 80 μm cisplatin furthermore treatment cell recombinant he4 dramatically affect erk activation skov3 ovcar8 wild type cell recombinant he4 also upregulate α-tubulin β-tubulin level skov3 ovcar8 cell microtubule associate protein tau mapt gene expression increase skov3 he4-overexpressing clone overexpression he4 promote collateral resistance cisplatin paclitaxel downregulation he4 partially reverse chemoresistance multiple factor involve he4-mediated chemoresistance include deregulation mapk signaling well alteration tubulin level stability 
dna damaging agent cause rapid shrinkage tumor form basis chemotherapy sarcoma despite significant toxicity drug superior efficacy wider therapeutic window need improve patient outcome use cell proliferation apoptosis assay sarcoma cell line benign cell gamma-h2ax expression comet assay immunoblot analysis drug combination study vitro patient derive xenograft pdx model bo-1055 cause apoptosis cell death concentration time dependent manner sarcoma cell line bo-1055 potent activity submicromolar ic50 ewing sarcoma rhabdomyosarcoma intermediate activity dsrct ic50 = 2-3mum weak activity osteosarcoma ic50 10mum cell line bo-1055 exhibit wide therapeutic window compare dna damaging drug bo-1055 induce dna double strand break gammah2ax expression cancer cell compare benign cell bo-1055 show inhibition tumor growth a673 xenograft cause tumor regression cyclophosphamide resistant patient-derived ewing sarcoma xenograft a204 xenograft combination bo-1055 irinotecan demonstrate synergism ewing sarcoma pdx model potent activity sarcoma cell relative lack toxicity present strong rationale development bo-1055 therapeutic agent 
glucose regulate protein 78 grp78 recently suggest associate drug resistance breast cancer patient however precise role grp78 drug resistance involved signaling pathway clearly understand present study show among panel drug namely paclitaxel tax doxorubicin dox 5-fluorouracil 5-fu ucn-01 tamoxifen tam use tam alone up-regulate expression grp78 significantly induce apoptosis mcf-7 mda-mb-231 cell interestingly inhibition grp78 specific pharmacological inhibitor ver-155008 augment tam-induced apoptosis overexpression grp78 render cell resistant tam-induced cell death suggest role grp78 tam-induced cytotoxicity mechanistically expression phosphorylate akt determine western blot analysis reveal tam selectively upregulate phosphorylation akt thr308 ser473 sirna silencing grp78 result inhibition akt phosphorylation thr308 ser473 grp78 inhibitor ver155008 inhibit tam-induced phosphorylation gsk3β downstream substrate akt result thus suggest role grp78 tam-induced akt activation additionally co-localization study immunofluorescence immunoprecipitation experiment demonstrate complex formation akt grp78 furthermore glucose-free medium cell sensitize tam-induced cell death associate reduce akt phosphorylation thr308 thus strengthen association akt regulation drug response collectively finding identify role grp78 akt regulation response tam breast cancer cell 
abcb1 p-glycoprotein implicate multidrug-resistance phenotype include resistance toward anticancer drug tyrosine kinase inhibitor tki purpose study evaluate vitro influence abcb1 1199g snp abcb1 transport activity toward select tki imatinib nilotinib dasatinib currently use chronic myelogenous leukemia two different cell line hek293 k562 stably transfect abcb1 1199g wild-type abcb1 1199a variant allele impact polymorphism accumulation antiproliferative effect imatinib nilotinib dasatinib evaluate k562 model expression asn400 variant protein associate lower antiproliferative effect imatinib nilotinib dasatinib compare ser400 wild-type protein moreover hek293 cell imatinib nilotinib intracellular accumulation lower variant compare wild-type model imatinib nilotinib dasatinib transport efficiently abcb1 variant asn400 compare wild-type ser400 protein impact abcb1 1199g snp tki response investigate chronic myelogenous leukemia patient 
three novel series 1,2-benzisothiazole derivative develop inhibitor carbonic anhydrase isoform ix compound 5c 5j test vitro human colon cell line ht-29 block growth cell culture chemically induce hypoxic condition display specific activity cancer cell characterize caix up-regulation moreover synergistic activity 5c sn-38 active metabolite irinotecan 5-fluorouracil cell proliferation hypoxic condition demonstrate 
despite effectiveness endocrine therapy estrogen receptor positive er breast cancer approximately 40 patient relapse previously identify focal-adhesion kinase canonical pathway major contributor resistance estrogen deprivation cellular-sarcoma kinase c-src dominant gene pathway dasatinib pan-src inhibitor recently use clinical trial treat er patient show mixed success follow study use isogenic cell line model provide potential explanation finding suggest sub-group may benefit panel isogenic cell line model resistance aromatase inhibitor lted tamoxifen tamr assess response dasatinib endocrine therapy dasatinib cause dose-dependent decrease proliferation mcf7-tamr cell resensitize tamoxifen fulvestrant hcc1428-tamr contrast estrogen-deprived condition dasatinib increase proliferation rate parental-mcf7 cell effect mcf7-lted hcc1428-lted treatment dasatinib cause decrease src-phosphorylation inhibition downstream pathway include akt erk1/2 cell line test mcf7-tamr show concomitant decrease marker cell cycle progression inhibition src also cause significant decrease cell migration mcf7-lted mcf7-tamr cell finally show mcf7-tamr cell contrast tamoxifen sensitive cell line er express throughout cell rather restricted nucleus treatment dasatinib result nuclear shuttling er associate increase er-mediated transcription datum suggest src differential effect endocrine-resistant cell line particularly tamoxifen resistant model low er genomic activity provide evidence importance patient selection clinical trial test dasatinib utility er breast cancer 
current study vitro biological feature imatinib-loaded silver nanoparticle imab-agnp human breast cancer cell line investigate formation synthesize silver nanoparticle agnp characterize uv-visible spectroscopy eds tem imaging sem ftir dls zeta potentiometer develop imab-agnp maximum percentage load efficiency demonstrate average 130 nm mostly spherical additionally vitro drug release study show slow continuous release imatinib period 80 h demonstrate synthesize imab-agnp exhibit dose-dependent cytotoxicity mcf-7 cell line real-time pcr method also apply investigation bax bcl-2 gene expression cell compare imab-agnp agnps imatinib reveal ability imab-agnp up-regulate bax/bcl -2 ratio induction apoptosis evidence annexin-v/pi detection assay base current obtain datum imab-agnp exhibit inhibitory effect viability regulation apoptosis mcf-7 cancer cell provide influence evidence green synthesize agnp promising sustained drug delivery system 
glioblastoma multiforme gbm often associate poor survival prognostic patient main reason seem acquire inherent resistance chemotherapeutic agent use treat tumor temozolomide tmz day recognize pathway resistance dna direct repair pathway means protein o6 methylguanine dna-methyltransferase mgmt design synthesize series mgmt inhibitor sensitize gbm cell tmz twenty-five o6-alkyl o6-aryl o6-substituted-aryl guanine analog include nine novel compound synthesize characterize analyze molecular docking test t98g gbm cell viability follow molecular modeling mgmt newly design compound 19 22 24 emerge promising mgmt ligand display modest cytotoxicity guanine analog 19 bear p-nitrobenzyl moiety reduce considerably o6-methylguanine dnamethyltransferase expression level combine tmz 1 use first line treatment brain tumor compound 19 22 24 decrease t98g cell proliferation 32 68 50 respectively tmz 1 display negligible effect proliferation cell support notion cell model resistant alkylating agent overall result notably highlight group mgmt inhibitor warrant exploration development therapeutic option circumvent tmz resistance brain tumor 
human nucleoside transporter hnt mediate cellular influx anticancer nucleoside drug include cytarabine cladribine fludarabine bcr-abl tyrosine kinase inhibitor tki imatinib dasatinib inhibit fludarabine cytarabine uptake assess interaction bosutinib dasatinib imatinib nilotinib ponatinib recombinant hnt hent1 2 hcnt1 -2 -3 produce individually yeast saccharomyces cerevisiae nilotinib inhibit hent1-mediated uridine transport potently ic50 value 0.7 μm follow ponatinib bosutinib dasatinib imatinib imatinib inhibit hcnt2 ic50 value 2.3 μm ponatinib inhibit five hnt greatest effect see hent1 ic50 value 9 μm tki inhibit 3 h uridine uptake competitive manner study yeast mutant two amino acid residue hent1 l442i l442t m33a m33a/l442i previously show involve uridine dipyridamole binding suggest bcr-abl tki interact met 33 tm1 leu 442 tm11 residue hent1 culture human cem lymphoblastoid cell possess single hnt type hent1 accumulation 3 h cytarabine 3 h cladribine 3 h fludarabine reduce five tki also cause reduction cell surface expression hent1 protein conclusion bcr-abl tki variously inhibit five different hnt cause decrease cell surface hent1 expression decrease uridine accumulation present together uridine give uridine experiment mutant hent1 show first time interaction met 33 involve dipyridamole binding bcr-abl inhibitor reduce interaction m33a mutant hent1 
study pattern resistance extreme nevertheless clinically relevant drug concentration develop series methotrexate-selected ccrf-cem subline highly resistant antifolate relative resistance 10 2 greater 10 5 fold least methotrexate-resistant subline completely sensitive drug associate multidrug resistance phenotype however highly methotrexate-resistant subline significantly cross-resistant vincristine vinblastine dactinomycin maximum relative resistance 40-fold subline cross-resistant doxorubicin daunorubicin teniposide regression analysis indicate relative resistance methotrexate correlate relative resistance vincristine r = 0.96 vinblastine r = 0.99 cross-resistance highly methotrexate-resistant cell may important clinical implication 
nanodiamond nd 5 nm crystalline structure recognize emerge carbon delivery vehicle due biocompatible inertness high surface-to-volume ratio energy absorbance property study carboxylate nanodiamond nd-cooh reduce hydroxylate nanodiamond nd-oh stable ph-independent colloidal dispersity poorly water-soluble paclitaxel ptx physically load nd-oh cluster form amorphous ptx nanostructure interparticle nanocage nd substrate stable physical ptx load onto nd substrate stable colloidal stability show enhance ptx release nd-oh/ptx complex retain sustained release ptx 97.32 70 h compare 47.33 release bare crystalline ptx enhance ptx release nd substrate show low cell viability hela mcf-9 a549 cancer cell due sustained release stable dispersity biological aqueous environment especially ic50 value nd-oh/ptx complex ptx hela cell 0.037 μg/ml 0.137 μg/ml respectively well-dispersed cellular uptake suprastructure nd-oh/ptx nanocomplex directly observe tem image nd-oh/ptx nanocomplex assimilate cell might provide convective diffusion high ptx concentration induce initial necrosis study suggest poorly water-soluble drug formulate suprastructure nd act highly concentrated drug reservoir directly within cell 
body epidemiological evidence implicate exposure endocrine disrupt chemical edc increase susceptibility breast cancer evaluate physiological effect suspect edc vivo expose mcf-7 breast cancer cell patient-derived xenograft pdx estrogen receptor positive physiological level methylparaben mepb commonly use personal care product preservative mepb pellet 4.4 μg per day lead increase tumor size mcf-7 xenograft er pdx tumor mepb think xenoestrogen however vitro exposure 10 nm mepb fail increase mcf-7 cell proliferation induction canonical estrogen-responsive gene ps2 progesterone receptor contrast 17β-estradiol e2 treatment mcf-7 pdx-derived mammosphere exhibit increase size up-regulation canonical stem cell marker aldh1 nanog oct4 sox2 expose mepb effect observe mda-mb-231 er mammosphere tumor-initiating cell tic also believe responsible chemoresistance mammosphere treat either tamoxifen pure anti-estrogen fulvestrant presence mepb block estrogenic response sufficient block nanog expression mammosphere point non-classic estrogen response er-independent mechanism mepb promotion mammosphere activity overall result suggest mepb increase breast cancer tumor proliferation enhance tic activity part via regulation nanog mepb may play direct role chemoresistance modulate stem cell activity copyright © 2016 john wiley sons ltd. 
study aim elucidate mechanism underlie resistance breast cancer eribulin seven eribulin-resistant breast cancer cell line mcf7/e bt474/e zr75-1 / e skbr3/e mda-mb-231 / e hs578t/e mda-mb-157 / e establish mrna protein expression atp-binding cassette subfamily b member 1 abcb1 subfamily c member 11 abcc11 increase eribulin-resistant cell line compare parental cell line abcb1 abcc11 expression inhibit small interfere rna mcf7/e bt474/e mda-mb-231 / e cell eribulin sensitivity partially restore moreover eribulin resistance attenuate additively inhibit abcb1 abcc11 mcf7/e cell additionally overexpression exogenous abcb1 abcc11 hek293t cell confer resistance eribulin mcf7/e mda-mb-231 / e cell show cross-resistance paclitaxel doxorubicin fluorouracil inhibition abcb1 partially restore paclitaxel doxorubicin sensitivity partial restoration fluorouracil sensitivity induce inhibit abcc11 mcf7/e mda-mb-231 / e cell abcb1 abcc11 involve development eribulin resistance breast cancer cell vitro regardless breast cancer subtype thus abcb1 abcc11 expression may use biomarker predict response eribulin patient breast cancer concomitant inhibition abcb1 abcc11 might help enhance antitumor effect eribulin 
triple negative breast cancer tnbc express progesterone estrogen her2/neu receptor aggressive difficult treat paclitaxel tubulin stabilize agent one frequently prescribe anticancer agent breast cancer include tnbc residual disease occur due resistance partial resistance cancer cell tumor anticancer agent important issue oncology present study mda-mb-231 cell tnbc cell line treat 30 microm paclitaxel slightly higher concentration gi50 value 6 day small number cell different morphology survive among survive cell small round cell isolate clone name mda-mb-231-jyj cell mda-mb-231-jyj cell observe highly proliferative tumorigenic addition signal transduction molecule involve proliferation survival malignancy stemness cancer cell c-src c-met notch 1 c-myc sox2 oct3/4 nanog e-cadherin highly express activate study require mda-mb-231-jyj cell appear characteristic cancer precursor cell although mda-mb-231-jyj cell isolate cell survive continuous presence paclitaxel resistant paclitaxel develop resistance dasatinib bcr-abl src kinase family inhibitor activate state src notch 1 expression level c-myc cyclin mda-mb-231-jyj cell less affect mda-mb-231 cell treatment dasatinib may explain resistance mda-mb-231-jyj cell dasatinib result suggest cancer cell become resistant dasatinib process paclitaxel therapy patient may appear caution require design clinical trial use two agent 
colorectal cancer chemotherapy current standard care include combination therapy 5-fluorouracil 5-fu leucovorin lv however factor determine lv-mediated enhancement 5-fu antitumor activity fully understand therefore investigate role thymidine synthase tyms folate receptor 1 folr1 dihydrofolate reductase dhfr phosphoribosylglycinamide formyltransferase gart methylenetetrahydrofolate dehydrogenase mthfd1 methylenetetrahydrofolate reductase mthfr lv-mediated enhancement 5-fluoro-2 deoxyuridine fdurd cytotoxicity vitro model 5-fu antitumor activity gene downregulate dld-1 hct116 human colorectal cancer cell use small-interfering rna reduce expression tyms mrna significantly increase fdurd cytotoxicity 100 8.3-fold dld-1 hct116 cell respectively contrast reduce expression folr1 dhfr gart mthfd1 mthfr decrease fdurd cytotoxicity 2.13 12.91-fold dld-1 cell 3.52 10.36-fold hct116 cell result demonstrate folate metabolism important efficacy fdurd overall result indicate important clarify relationship folate metabolism-related molecule 5-fu treatment order improve prediction effectiveness 5-fu lv combination therapy 
although drug resistance often observe metastatic recurrence breast cancer little know intrinsic drug resistance metastase present study find first time mda-mb-231br brain metastatic variant human breast cancer cell line refractory treatment 5-fluorouracil 5-fu even without chronic drug exposure compare parent cell line mda-mb-231 bone metastatic variant mda-mb-231scp2 mrna protein level cox-2 bcl2a1 mda-mb-231br significantly higher mda-mb-231 mda-mb-231scp2 neither cox-2 inhibitor celecoxib nf-κb inhibitor bay11-7082 sensitize mda-mb-231br 5-fu indicate cox-2 play little role resistance mda-mb-231br 5-fu although bcl2-family inhibitor abt-263 fail sensitize mda-mb-231br 5-fu dose abt-263 consider bind bcl2 bcl2-xl bcl2-w bcl2a1 abt-263 sensitize mda-mb-231br 5-fu level comparable mda-mb-231 dose 5 μm abt-263 may disrupt intracellular bcl2a1 protein interaction importantly bcl2a1 sirna sensitize mda-mb-231br 5-fu whereas overexpression bcl2a1 confer 5-fu-resistance mda-mb-231 result indicate bcl2a1 key contributor intrinsic 5-fu-resistance mda-mb-231br interesting note drug sensitivity mda-mb-231br distinct mda-mb-231scp2 even though origin mda-mb-231 investigation pertinent present finding may provide valuable insight breast cancer brain metastasis 
treatment pulsed electromagnetic field pemf emerge interesting therapeutic option patient cancer literature demonstrate low-frequency/low-energy electromagnetic field cause predictable effect dna however epigenetically act gene expression aim present work study possible epigenetic effect pemf mediate mirna human glioblastoma cell line t98g test pemf maximum magnetic induction 2 mt frequency 75 hz demonstrate induce autophagy glioblastoma cell particular study effect pemf expression gene involve cancer progression promising synergistic effect temozolomide frequently use drug treat glioblastoma multiforme find electromagnetic stimulation combination temozolomide elicit epigenetic pro-apoptotic effect chemo radioresistant t98g glioblastoma cell line 
drug-induced dna hypermethylation observe constitute one component response human tumor cell toxic concentration commonly use cancer chemotherapy agent human lung adenocarcinoma cell htb-54 human rhabdomyosarcoma cell ccl-136 pulse exposure topoisomerase ii inhibitor etoposide nalidixic acid antibiotic doxorubicin microtubule inhibitor vincristine vinblastine colchicine dna cross-linking agent cisplatinum hydroxyurea antimetabolite 1-beta-d-arabinofuranosylcytosine 5-fluorouracil 5-fluorodeoxyuridine methotrexate associate profound drug-induced dna hypermethylation exposure human t-lymphocyte molt-4 toxic pulse dose 3 azidodideoxythymidine associate similar drug-induced dna hypermethylation every case drug-induced dna hypermethylation observe degree dna synthesis inhibition cause drug exceed 90 drug level duration exposure sufficient kill 90-100 expose cell drug-induced dna hypermethylation show represent tissue culture phenomenon since occur vivo high-dose 1-beta-d-arabinofuranosylcytosine hydroxyurea treatment two leukemic patient drug-induced alteration dna methylation frequently biphasic hypomethylation occur drug concentration produce mild dna synthesis inhibition kill less 50 expose cell exposure alkylating agent 1,3-bis 2-chloroethyl -1-nitrosourea cyclophosphamide antimetabolite 5-azadeoxycytidine 6-thioguanine associate dna hypomethylation study concentration htb-54 cell drug-induced dna hypermethylation block preexposure hypomethylating agent administer nontoxic mildly toxic concentration drug-induced dna hypermethylation may capable create drug-resistant phenotype inactivate gene product require drug cytotoxicity perhaps paradoxically drug-induced dna hypermethylation may also produce second class drug-resistant tumor cell characterize overexpression particular gene product potentiate process gene amplification 
high dose multiple alkylating agent chemotherapy employ conjunction autologous marrow transplantation clinic investigate scheduling several alkylate drug effort optimize antitumor effect vitro modeling continuous 72 h versus bolus 1 h exposure mcf-7 cell show n n n triethylenethiophosphoramide thiotepa cis-diamminedichloroplatinum ii cddp 4-hydroperoxycyclophosphamide carboplatin l-phenylalanine mustard l-pam continuous exposure yield essentially killing kinetics bolus exposure n n bis 2-chloroethyl n-nitrosourea bcnu however even fresh drug addition every 30 min bolus exposure produce superior cytotoxicity vivo modeling continuous three i.p. injection 9 h versus bolus single dose administration alkylating agent cyclophosphamide bcnu thiotepa melphalan cddp carboplatin conduct mouse bear emt6 tumor tumor cell killing measure tumor cell survival vitro compare killing bone marrow cfu-gm measure culture representative sensitive normal tissue cyclophosphamide considerable increase therapeutic index killing tumor cells/killing cfu-gm total dose drug administer multiple injection versus single injection bcnu thiotepa smaller increase therapeutic index observe l-pam cddp advantage multiple versus single dose administration observe carboplatin decrease therapeutic index see conclusion six alkylating agent examine multiple dose schedule least effective tumor single dose schedule dose level 
glioblastoma associate poor overall survival despite new treatment advance antiangiogenic strategy target vegf base tyrosine kinase inhibitor tki currently undergo extensive research treatment glioma.herein demonstrate tki axitinib induce dna damage response ddr characterize γ-h2ax phosphorylation chk1 kinase activation lead g2/m cell cycle arrest mitotic catastrophe u87 t98 u251 glioma cell line moreover find p21 waf1/cip1 increase level correlate induction ros senescence-associated cell death u87 t98 cell line revert n-acetyl cysteine pretreatment conversely u251 cell line show resistant phenotype response axitinib treatment evidence cell cycle arrest sign cell death.the combinatorial use axitinib therapy aim inhibit multiple signaling pathway involve tumor growth increase efficiency tki thus address combined effect axitinib toxic dose proteasome inhibitor bortezomib growth u87 t98 axitinib-sensitive axitinib-resistant u251 cell line compare single treatment combined exposure effective inhibit cell viability glioma cell line although different cell death modality regulation key ddr cell cycle protein include chk1 γ-h2ax p21 waf1/cip1 also study glioma cell lines.collectively finding provide new perspective use axitinib combination bortezomib overcome therapy resistance glioma 
mk-8776 recently describe inhibitor highly selective checkpoint kinase 1 chk1 weaken dna repair capacity cancer cell achieve chemo-sensitization number study show mk-8776 enhance cytotoxicity hydroxyurea gemcitabine without increase normal tissue toxicity thus far evidence mk-8776 use radiotherapy sensitization agent study investigate effect mk-8776 radiosensitivity 3 human triple-negative breast cancer tnbc cell line mda-mb-231 bt-549 cal-51 mk-8776 dose-dependently inhibit proliferation mda-mb-231 bt-549 cal-51 cell ic50 value 9.4 17.6 2.1 μmol/l respectively compare irradiation-alone treatment pretreatment low dose mk-8776 100-400 nmol/l significantly increase irradiation-induced γh2a.x focus 3 tnbc cell line suggest enhance dna damage mk-8776 inhibit cell proliferation increase radiosensitivity 3 tnbc cell line similar result obtain mda-mb-231 xenograft tumor nude mouse receive mk-8776 15 40 mg/kg ip 26 d irradiation explore mechanism underlie radio-sensitization mk-8776 use tem find irradiation significantly increase number autophagosome 3 tnbc cell line moreover irradiation markedly elevate level atg5 promote transformation lc3-i lc3-ii cell pretreatment low dose mk-8776 suppress effect result suggest mk-8776 increase human tnbc radiosensitivity inhibit irradiation-induced autophagy mk-8776 may potential agent radiosensitization human tnbc 
lung cancer one prevalent type cancer world surgery chemotherapy radiotherapy use clinically treatment numerous cancer due appearance drug resistance remission rate limit 40-50 docetaxel pemetrex two drug commonly use effect single-phase cell culture well know pharmacological point view appear rational hypothesize sequential therapy effect show better outcome compare traditional single-phase experiment consider present study aim establish first-line second-line adenocarcinoma treatment model use combination cisplatin docetaxel pemetrex vitro different sequential therapy timing test human lung cancer a549 cell line use inhibitory effect determine add docetaxel follow treatment cisplatin pemetrexed pem-doc group compare group pemetrexed add subsequent treatment cisplatin docetaxel doc-pem group additionally difference gene protein expression level excision repair cross-completion gene 1 ercc1 gene promote drug resistance cisplatin compare two group present result show inhibitory effect cell proliferation pem-doc group increase compare doc-pem group gene expression protein level ercc1 pem-doc group decrease compare doc-pem group pem-doc treatment plan effective inhibit cell proliferation lower expression ercc1 gene therefore pem-doc may effective adenocarcinoma treatment 
aim present study investigate potential application 3,6-o o dimyristoyl chitosan dmch amphiphilic derivative chitosan improve oral bioavailability paclitaxel ptx water insoluble anticancer drug o-acylation chitosan myristoyl chloride carry employ high 13.3 low 2.0 molar excess chitosan result sample dmch07 dmch12 respectively successful o-acylation chitosan confirm ftir 1h nmr spectroscopy latter allow also determination average degree substitution ds critical aggregation concentration cac sample dmch07 ds 6.8 dmch12 ds 12.0 8.9x10-3mg / ml 13.2 x103mg/ml respectively observe tem dmch micelle show spherical shape dls measurement allow determination average size 287nm-490nm zeta potential +32 mv +44 mv dmch micelle able encapsulate paclitaxel high drug encapsulation efficiency ee confirm hplc analysis study cytotoxicity dmch07 micelle toward caco-2 ht29-mtx cell show regardless ptx load dmch07 micelle slightly decrease cellular viability low micelle concentration = 1mug/ml high concentration 10mug/ml ptx-loaded dmch07 micelle less toxic toward caco-2 cell compare free ptx ptx permeation across caco-2 monoculture caco-2 / ht29-mtx co-culture model confirm potential dmch micelle improve intestinal absorption ptx result suggest dmch micelle may promising carrier encapsulate ptx aim cancer therapy 
ovarian cancer lethal disease among gynecological malignancy effective therapy require counter high recurrence rate chemotherapy resistance investigate efficacy molecular mechanism three combine treatment tct novel histone deacetylase hdac inhibitor obp-801 / ym753 5-fluorouracil 5-fu paclitaxel ptx human ovarian cancer skov-3 ovcar-3 cell inhibition cell growth stronger tct single agent two combined treatment tct significantly induce g2 phase arrest cell line analyze molecular mechanism find tct increase phosphorylation p38 thr180/tyr182 decrease expression cdc25c increase phosphorylation cdc2 tyr15 inactive form cdc2 examine responsibility p38 pathway g2 phase arrest induce tct employ p38 inhibitor sb203580 sb203580 inhibit g2 phase arrest suppression cdc25c phosphorylation cdc2 tyr15 induce tct result suggest tct induce g2 phase arrest activation p38 signaling pathway therefore believe combination promising novel therapeutic strategy ovarian cancer 
glioblastoma multiforme gbm among lethal human tumor frequently occur malignant primary brain tumor adult current standard care soc gbm initial surgical resection follow treatment combination temozolomide tmz ionize radiation ir however gbm dismal prognosis survivor compromise quality life owing adverse effect radiation gbm characterize overt activity phosphoinositide 3-kinase pi3k signaling pathway gdc-0941 highly specific pi3k inhibitor promising anti-tumor activity human solid tumor evaluate phase ii clinical trial treatment breast non-squamous cell lung cancer hypothesize gdc-0941 may act antitumor agent potentiate effect tmz ir study gdc-0941 alone induce cytotoxicity pro-apoptotic effect moreover combine standard gbm therapy tmz ir suppress cell viability show enhance pro-apoptotic effect augment autophagy response attenuate migratory/invasive capacity three glioma cell line protein microarray analysis show treatment tmz+gdc -0941 ir induce higher level p53 glycogen synthase kinase 3-beta gsk3-β expression shg44gbm cell induce treatment verify cell line western blot analysis furthermore combination tmz gdc-0941 without ir reduce level p-akt o6-methylguanine dna methyltransferase mgmt t98g cell result study suggest combination tmz ir gdc-0941 promising choice future treatment gbm 
aim study establish paclitaxel ptx load mixed micelle delivery system ptx-tp-m vitamin e-tpgs tpgs plasdone ® s-630 copovidone pvps630 carrier improve solubility oral absorption anti-tumor activity ptx lung cancer study ptx-tp-m prepare use ethanol thin-film dispersion method follow characterization binary mixed micelle system average size ptx-tp-m 83.5 ± 1.8 nm polydispersity index 0.265 ± 0.007 drug loading dl entrapment efficiency ee 3.09 ± 0.09 95.67 ± 2.84 respectively contribute high solubility ptx 24947-fold increase water 4.78 ± 0.14 mg/ml addition tem analysis show ptx-tp-m appear spherical structure well disperse without aggregation adhesion vitro release study show ptx-tp-m display sustained release compare free ptx dialysis bag efflux ratio ptx reduce 44.83 3.52 formulate ptx-tp-m 92.15 reduction study use caco-2 monolayer model oral bioavailability ptx also improve 4.35-fold suggest ptx-tp-m markedly promote absorption gastrointestinal tract use vitro mtt assay observe cytotoxicity markedly increase ic50 value ptx-tp-m 3.14 ± 0.85 8.28 ± 1.02 μg/ml lower ptx solution 5.21 ± 0.93 14.53 ± 1.96 μg/ml a549 lewis cell respectively vivo anti-tumor study show ptx-tp-m achieve higher anti-tumor efficacy compare ptx lewis bare c57bl/6 mouse furthermore gastrointestinal safety assay also prove safety ptx-tp-m result demonstrate ptx-tp-m exhibit great potential deliver ptx increase solubility oral bioavailability anti-cancer activity binary mixed micelle drug delivery system potential use clinically 
bevacizumab combination chemotherapeutic show significant survival benefit clinical study patient non-small cell lung cancer nsclc since bevacizumab administer standard treatment disease progression importance bevacizumab maintenance phase prospectively investigate study three human nsclc cell line xenograft model use investigate antitumor effect bevacizumab tumor microvessel density mvd analyze a549 nci-h292 model bevacizumab maintenance follow combination paclitaxel exhibit stronger tumor suppression absence nci-h292 model bevacizumab maintenance continuously inhibit increase mvd nci-h2228 model follow induction treatment pemetrexed bevacizumab maintenance 
expression breast cancer resistant protein bcrp lung cancer correlate development multidrug resistance mdr therefore lead lower response chemotherapy zm323881 previously develop selective vegfr-2 inhibitor find inhibitory effect bcrp-mediated mdr investigation zm323881 significantly decrease cytotoxic dose mitoxantrone sn-38 bcrp-overexpressing nci-h460 / mx20 cell mechanistic study reveal zm323881 effect inhibit bcrp-mediated drug efflux lead intracellular accumulation bcrp substrate significant alteration expression level localization pattern bcrp observe bcrp-overexpressing cell expose zm323881 stimulated bell-shaped atpase activity observe molecular docking suggest zm323881 bind modulator site bcrp binding pose stable validate 100n molecular dynamic simulation overall result indicate zm323881 reverse bcrp-related mdr inhibit efflux function finding might useful develop combination chemotherapy mdr cancer treatment 
chronic myeloid leukemia cml hematopoietic malignancy cause constitutive activation bcr-abl tyrosine kinase bcr-abl inhibitor imatinib second-generation tyrosine kinase inhibitor dasatinib nilotinib remarkable efficacy cml treatment however gene mutation-mediated drug resistance remain critical problem among point mutation bcr-abl t315i mutation confer resistance bcr-abl inhibitor previously synthesize compound 1-methyl-1h-indol-5-yl 3,4,5-trimethoxy-phenyl methanone mpt0b002 novel microtubule inhibitor study evaluate effect proliferation cell cycle apoptosis k562 cml cell baf3 cell express either wild-type bcr-abl baf3/p210 t315i-mutated bcr-abl baf3/t315i mpt0b002 inhibit cell viability dose-dependent manner cell affect proliferation human umbilical vein endothelial cell disrupt tubulin polymerization arrest cell cycle g2/m phase treatment mpt0b002 induce apoptosis induction associate increase level cleave caspase-3 cleave parp furthermore mpt0b002 downregulate bcr-abl bcr-abl-t315i mrna expression protein level downstream signaling pathway take together finding suggest mpt0b002 may consider promising compound downregulate wild type bcr-abl also t315i mutant overcome bcr-abl-t315i mutation-mediated resistance cml cell 
ovarian cancer lead cause death gynecological cancer 6th cause woman cancer death developed country late stage detection peritoneal dissemination acquisition resistance carboplatin main reason explain poor prognosis strengthen need alternative treatment improve management ovarian cancer and/or sensitize tumor platinum salt epidermal growth factor receptor egfr hepatocyte growth factor receptor met cellular src kinase c-src crucial kinase imply ovarian tumor growth survival invasion resistance carboplatin expression increase advanced ovarian cancer correlate poor prognosis despite clear potential inhibit protein ovarian cancer single agent combination carboplatin treatment need target kinase tandem capacity trigger compensatory pathway synergize promote drug resistance target egfr c-src met individually combination carboplatin use gefitinib dasatinib crizotinib respectively panel carboplatin-sensitive ovcar-3 igrov-1 a2780 carboplatin-resistant cell skov-3 efo-21 study ability potent combination induce apoptosis regulate migration invasion modulate activation proliferation survival protein crizotinib dasatinib gefitinib alone combination carboplatin show cell-specific cytotoxic synergy ovarian cancer cell dasatinib plus gefitinib combination synergistic ovcar-3 skov-3 igrov-1 cell high concentration combination unable induce apoptosis suppress cell migration invasion activation egfr erk c-src akt compare single treatment combine carboplatin kinase inhibitor lead synergistic interaction cell-specific manner unlike platinum-based combination mix dasatinib gefitinib lead cytotoxic activity inhibition cell migration invasion thus dasatinib gefitinib combination present anti-tumour property superior platinum-based combination indicate may well represent promising new treatment modality test clinic 
malignant pleural mesothelioma mpm difficult-to-treat global disease pegylate arginase bct-100 recently show anti-tumor effect hepatocellular carcinoma acute myeloid leukemia melanoma study aim investigate effect peg-bct-100 mpm panel 5 mesothelioma cell line h28 211h h226 h2052 h2452 use study vitro effect bct-100 crystal violet staining vivo effect bct-100 study use 211h h226 nude mouse xenograft protein expression argininosuccinate synthetase ornithine transcarbamylase cleave parp cleave caspase 3 cyclin a2 d3 e1 h cdk4 ki67 arginine concentration evaluate western blot elisa respectively cellular localization bct-100 detect immunohistochemistry immunoflorescence tunel assay use identify cellular apoptotic event argininosuccinate synthetase express h28 h226 h2452 cell well 211h h266 xenograft ornithine transcarbamylase undetectable cell line xenograft model bct-100 reduce vitro cell viability ic50 value 13-24 mu/ml 72 h across different cell line suppress tumor growth 211h h226 xenograft model bct-100 60 mg/kg significantly suppress tumor growth p 0.01 prolonged median survival p 0.01 xenograft model combine bct-100 pemetrexed cisplatin confer additional benefit single agent serum intratumoral arginine level effectively decrease bct-100 associate cytosolic accumulation bct-100 within tumor cell apoptosis parp cleavage 211h xenograft bcl-2 downregulation cleavage parp caspase 3 h226 xenograft positive tunel staining g1 arrest downregulation cyclin a2 d3 e1 cdk4 211h xenograft suppression cyclin a2 e1 h cdk4 h226 xenograft evident bct-100 treatment furthermore proliferative factor ki67 downregulate bct-100 treatment arm bct-100 suppress tumor growth prolonged median survival partially mediate intratumoral arginine depletion result apoptosis g1 arrest mesothelioma xenograft model finding provide scientific evidence support clinical development bct-100 treatment mpm 
glioblastoma multiforme gbm malignant tumor central nervous system high mortality rate curativetreatment presently available commonly use chemiotherapeutic drug alkylating agent temozolomide tmz able increase life expectancy often associate drugresistance therefore urgent need exist novel drug aim treat glioma present study obtain three major result use corliagin demonstrate inhibit growth u251 glioma cell activation apoptotic pathway b demonstrate also active temozolomideresistant t98g glioma cell c demonstrate use combination temozolomide t98g glioma cell higher level pro-apototic antiproliferative effect observe study indicate corilagin investigate detail order determine develop potential therapeutic agent addition result suggest corilagin use combination low dosage standard anticancer chemotherapeutic drug glioma temozolomide aim obtain enhance anticancer effect 
role glioma stem cell gsc cancer progression currently debate however hypothesise subpopulation partially responsible therapeutic resistance observe glioblastoma multiforme gbm recent study show current treatment fail eliminate gsc population even promote gsc reprogramming glioma non-stem cell stem cell since standard gbm treatment often require supplementation adjuvant drug antidepressant role regulation heterogeneous nature gsc need evaluation examine effect imipramine amitriptyline fluoxetine mirtazapine agomelatine escitalopram temozolomide phenotypic signature cd44 ki67 nestin sox1 sox2 expression gsc isolate human t98g cell line drug examine several model hypoxia 1 oxygen 2.5 oxygen hypoxia-reoxygenation model compare standard laboratory condition 20 oxygen report antidepressant drug particularly imipramine amitriptyline modulate plasticity silence gsc profile partially reverse malignant phenotype gbm moreover observe contrast temozolomide tricyclic antidepressant stimulate viability mitochondrial activity normal human astrocyte ability phenotype switching gsc non-gsc stimulate antidepressant primarily imipramine amitriptyline shed new light heterogeneous nature gsc well role antidepressant adjuvant gbm therapy 
thalidomide derivative lenalidomide pomalidomide imid effective treatment haematologic malignancy show imid impart gain-of-function property cul4-rbx1-ddb1-crbn crl4crbn ubiquitin ligase enable binding ubiquitination degradation key therapeutic target ikzf1 ikzf3 csnk1a1 substrate implicate efficacy target multiple myeloma mm 5q deletion associate myelodysplastic syndrome del 5q mds target likely exist use pulse-chase silac mass spectrometry-based proteomic approach demonstrate lenalidomide induce ubiquitination degradation zfp91 establish zfp91 bona fide imid-dependent crl4crbn substrate show zfp91 harbour zinc finger znf motif related ikzf1/3 znf critical imid-dependent crbn binding finding demonstrate single time point pulse-chase silac mass spectrometry-based proteomic psilac ms sensitive approach target identification small molecule induce selective protein degradation 
glioblastoma multiforme gbm malignant brain cancer cause high mortality human respond poorly common cancer treatment surgery chemo radiation therapy temozolomide tmz alkylating agent widely use treat gbm resistance drug often find one unexplored possibility overcome resistance treatment base concomitant exposure electromagnetic field emf tmz indeed many evidence show emf affect cancer cell drug performance study evaluate potential synergistic effect 100μm tmz emf 100hz 100g two human glioma cell line i.e. u87 t98g single treatment tmz emf co-treatment synergistically enhance apoptosis u87 t98g cell increase expression p53 bax caspase-3 decrease bcl-2 cyclin-d1 also observe increase reactive oxygen species ros production overexpression heme oxygenase-1 ho-1 gene comparison control conclusion since emf enhance apoptotic effect tmz possibly redox regulation mechanism tmz/emf combination may effective glioma cancer treat study need reveal action mechanism possible novel therapeutic approach 
jak protein link survival proliferation multiple myeloma mm cell therefore jak inhibition therapeutic strategy mm evaluate jak1 jak2 expression mm patient effect jak/stat pathway inhibition apoptosis cell cycle gene protein expression rpmi-8226 u266 mm cell line 57 patient present overexpression jak2 27 jak1 treatment ruxolitinib bortezomib rpmi-8226 u266 present 50 cell late apoptosis reduction anti-apoptotic gene expression higher number cell subg0 phase co-culture stromal cell protect rpmi-8226 cell apoptosis reverse lenalidomide addition combination ruxolitinib bortezomib lenalidomide induce 72 cell death equivalent bortezomib lenalidomide dexamethasone combination use clinical practice many jak/stat pathway gene treatment expression reduce mainly rpmi-8226 insignificant change u266 scenario jak/stat pathway pose new therapeutic target exploit since constitutively active contribute survival mm tumor cell 
chemoresistance non-small cell lung cancer nsclc occur docetaxel doc chemotherapy substantially decrease survival patient overcome doc-induced chemoresistance establish doc-selected a549 lung cancer subline a549/d16 a549/d32 reveal subline cross-resistant vincristine vcr doxorubicin dxr notably subline sensitive pemetrexed pem parental cell accord mtt clonogenic assay expression level thymidylate synthase ts γ-glutamyl hydrolase ggh downregulate doc-resistant subline exogenous ts overexpress a549/d16 cell pem sensitivity significantly decrease however decrease overexpression exogenous ggh pem treatment induce apoptotic sub-g1 cell doc-resistant subline vivo pem sensitivity a549/d16 cell finding confirm xenografted tumor model unmask mediator ts downregulation investigate human lung cancer cell line various tp53 status use doc treatment level ts protein significantly decrease wild-type tp53-containing cell doc treatment ts expression level affect mutant-tp53 tp53‑null cell condition furthermore expression tp53 inhibit a549 cell expression level ts increase datum indicate doc activate wild-type tp53 suppress ts expression continuous doc exposure therefore expression ts remain low level doc-resistant a549 cancer cell datum reveal lung cancer doc resistance wild‑type tp53 status administration pem second-line agent overcome doc-resistance may benefit patient 
present study evaluate retinoic acid ra enhancement temozolomide tmz effect human glioma cell u251 explore underlying molecular mechanism cell growth detect use mtt assay cell cycle assess flow cytometry cell apoptosis analyze annexin v/propidium iodide staining cell morphology evaluate use transmission electron microscopy tem additionally reverse transcription-pcr western blot analysis apply detect mrna protein level ra treatment combination tmz human u251 cell inhibit cell growth arrest cell cycle progression g0/g1 phase significantly induce apoptosis u251 cell ra+tmz treatment u251 cell autophagy associate protein beclin 1 lc3b significantly increase tem analysis consistent autophagy protein level moreover keap1/nrf2/are expression downregulate significantly indicate involvement mechanism ra treatment enhance tmz effect u251 cell ra treatment combination tmz may provide experimental evidence possible effect ra+tmz growth proliferation glioma cell therefore ra+tmz administration may potential utility glioblastoma treatment 
glioblastoma gbm common type primary tumor central nervous system poor prognosis need development new therapeutic drug study focus sodium selenite ss effect cancer cell culture multicellular tumor spheroid mct 3d closer vivo tumor investigate ss anticancer effect three human gbm cell line culture 3d ln229 u87 o 6 methyguanine-dna-methyltransferase mgmt negative t98g mgmt positive ss absorption evaluate cytotoxicity ss temozolomide tmz standard drug use gbm compare ss impact proliferation cell death invasiveness evaluate well epigenetic modification focus histone deacetylase hdac activity dimethyl-histone-3-lysine-9 methylation h3k9m2 24h 72h ss exposition ss absorb spheroid cytotoxic tmz i.e. ln229 ic50 38 fold-more elevated tmz ss 72h ss induce cell cycle arrest s phase apoptosis via caspase-3 ss decrease carbonic anhydrase-9 ca9 expression invasion matrigel matrix modulate e n-cadherin transcript expression ss decrease hdac activity modulate h3k9m2 level 3d model provide relevant strategy screen new drug ss promising drug gbm now test gbm animal model 
aberrant ras-mapk signaling receptor tyrosine kinase rtk include epidermal growth factor receptor egfr human epidermal growth factor receptor-2 her2 hallmark triple negative breast cancer tnbc thus provide rationale target ras-mapk pathway components egfr/her2-ras-raf mek-erk pathway co-target mda-mb-231 mda-mb-468 human tnbc cell line vitro effect signaling cytotoxicity well vivo effect xenograft tumor growth metastasis assess dual egfr/her2 inhibitor lapatinib lpn display greater cytotoxic potency mapk signaling inhibition egfr inhibitor erlotinib suggest egfr her2 contribute mapk signaling tnbc model raf inhibitor sorafenib sfn mek inhibitor u0126 suppress mapk signaling greater extent lpn correlate greater cytotoxic potency sfn u0126 however u0126 potentiate cytotoxic efficacy lpn sfn additive synergistic manner respectively in-series raf-mek co-targeting synergy recapitulate orthotopic mouse xenograft sfn mek inhibitor selumitinib azd6244 inhibit primary tumor growth pulmonary metastasis raf mek co-inhibition exhibit synergy tnbc model represent promising combination therapy aggressive breast cancer type 
thymidylate synthase ts inhibitor include fluoropyrimidine e.g. 5-fluorouracil 5-fu 5-fluorodeoxyuridine 5-fdu floxuridine antifolate e.g. pemetrex widely use solid tumor previously report shrna-mediated knockdown kd uracil dna glycosylase udg sensitize cancer cell 5-fdu p53 also show critical determinant sensitivity ts inhibitor interrogate 5-fdu cytotoxicity udg depletion regard p53 status analyze panel human cancer cell know p53 status determine p53-mutated deficient cell highly resistant 5-fdu udg depletion resensitize 5-fdu p53-mutant deficient cell whereas p53 wild-type wt cell affect similar condition utilize paired hct116 p53 wt p53 knockout ko cell show loss p53 improve cell survival 5-fdu udg depletion significantly sensitize p53 ko cell sensitization also recapitulate udg depletion cell p53 kd shrna addition sensitization also observe pemetrex p53 ko cell 5-fu likely due rna incorporation importantly p53 wt cell apoptosis pathway induce 5-fdu activate independent udg status however p53 ko cell apoptosis compromise udg-expressing cell dramatically elevated udg-depleted cell collectively result provide evidence loss udg catalyze significant cell death signal cancer cell mutant deficient p53.implications study reveal udg depletion restore sensitivity ts inhibitor chemotherapeutic potential context mutant deficient p53 mol cancer res 16 2 212-21 2017 aacr 
multidrug resistance mdr one major obstacle successful chemotherapy combination chemotherapy drug multidrug-resistant reverse agent treat mdr tumor good strategy overcome mdr work prepare simple redox-responsive micelle base mpeg-ss-c18 co-delivery system load paclitaxel ptx dasatinib das treatment mcf-7 / adr cell co-loaded micelle good dispersity spherical shape uniform size distribution quickly disassemble rapidly release drug reduction environment compare mcf-7 cell das ptx co-loaded redox-sensitive micelle ss-pdnps show stronger cytotoxicity improve intracellular drug concentration drug formulation mcf-7 / adr cell summary result suggest simple co-delivery micelle ptx das possess significant potential overcome drug resistance cancer therapy 
combine multikinase inhibitor sorafenib platinum-based chemotherapy solid tumor expect improve treatment outcome however many clinical trial benefit sorafenib addition platinum-containing regimen demonstrate moreover study decrease survival ovarian cancer patient well non-small cell lung cancer patient squamous cell histology observe aim study investigate cellular mechanism pharmacological interaction platinum drug sorafenib different cancer cell line interaction characterize combination index analysis platinum accumulation dna platination determine use flameless atomic absorption spectrometry protein expression assess western blot sensitive a2780 ovarian carcinoma h520 squamous cell lung carcinoma cell line sorafenib induce downregulation na k atpase a2780 cell kinase inhibitor also decrease expression copper transporter 1 ctr1 result sorafenib treatment lead diminish cellular accumulation cisplatin carboplatin decrease dna platination cell line case cisplatin-resistant a2780cis ovarian carcinoma h522 lung adenocarcinoma cell line feature lower basal expression above-mentioned transporter cell line study antagonistic interaction platinum drug sorafenib find result suggest sorafenib impair cisplatin carboplatin uptake downregulation ctr1 and/or na k atpase result reduction dna platination effect observe cancer cell defect platinum accumulation 
background/aims valproic acid vpa anticonvulsant mood-stabilizing drug use treat epileptic seizure glioblastoma patient besides antiepileptic activity vpa attribute function improve clinical outcome glioblastoma patient comprise inhibition histone deacetylase hdac isoform reportedly may result radiosensitization retrospective analysis patient datum however unequivocally confirm prolonged survival glioblastoma patient receive vpa present study aim identify potential vpa target cellular level method end effect vpa metabolism ca2 biochemical electro-signaling cell-cycling clonogenic survival transfilter migration analyze three human glioblastoma line t98g u-87mg u251 mtt assay ca2 imaging immunoblotting patch-clamp recording flow cytometry delay plate colony formation modify boyden chamber assay respectively addition effect vpa clonogenic survival primary glioblastoma spheroid culture treat temozolomide fractionate radiation assess limited dilution assay result 2 3 glioblastoma line clinical relevant concentration vpa slightly slow cell cycle progression decrease clonogenic survival furthermore vpa induce ca2 signaling accompany pronounced k channel activity transfilter cell migration vpa affect metabolic nad p h formation radioresistance glioblastoma line finally vpa impair clonogenic survival radioresistance temozolomide-treated primary spheroid culture conclusion combine vitro datum propose general use vpa radiosensitizer anti-glioblastoma therapy 
establish platform possibility effective safe delivery temozolomide tmz brain via surface engineer polyamidoamine pamam dendrimer treatment glioblastoma present study aim investigate efficacy pamam-chitosan conjugate base tmz nanoformulation pct glioma vitro well vivo prepared nanoconjugated formulation characterize 1h nmr ft-ir spectroscopy surface morphological parameter report approach also design way ensure toxicity vivo delivery conduct hemolytic study surface morphology find per nanoformulation via size pdi zeta potential measurement pct efficacious term ic50 value compare pure tmz u-251 t-98g glioma cell line vivo pharmacokinetic parameter prove sustained release fashion half-life t1/2 22.74 h pct rather than15 .35 h tmz higher concentration find heart brain bio-distribution study study exhibit potential applicability dendrimer cs improve anticancer activity delivery tmz brain attractive ex vivo cytotoxicity two glioma cell line u-251 t-98g phase solubility study tmz reveal remarkable result vivo study prepared nanoformulation significant promising explore double concentration tmz brain due surface functionality dendrimer report work novel non obvious none approach use chitosan anchor dendrimer tmz delivery report earlier 
rna-binding protein lin28b play important role development stem cell biology tumorigenesis lin28b two isoform lin28b-long short isoform although study reveal function lin28b-long isoform tumorigenesis role lin28b-short isoform remain unclear represent major gap field lin28b-long short isoform express subset human colorectal cancer adjacent normal colonic mucosa respectively elucidate functional mechanistic aspect isoform colorectal cancer cell caco-2 lovo generate either express lin28b short long isoform interestingly long isoform suppress let-7 expression activate canonical ras/erk signaling whereas short isoform lin28b-long isoform-expressing cell demonstrate increase drug resistance 5-fluorouracil cisplatin upregulation ercc1 dna repair gene let-7-dependent manner lin28b-short isoform preserve ability bind pre-let-7 without inhibit maturation let-7 compete lin28b-long isoform bind pre-let-7 coexpression short isoform lin28b-long isoform-expressing cell rescue phenotype induce lin28b-long isoform.implications study demonstrate differential antagonistic function lin28b-short isoform lin28b-long isoform inability degrade let-7 lead novel premise short isoform may serve counterbalance long isoform normal colonic epithelial homeostasis downregulation colonic carcinogenesis may reveal protumorigenic effect long isoform mol cancer res 16 3 403-16 2018 aacr 
glioblastoma multiforme gbm highly malignant brain tumor tumor stem cell major influence tumor malignancy immunological escape mechanism involve natural killer group 2 member d nkg2d receptor-ligand-system key element tumor immuno-surveillance analyze expression profile localization nkg2d ligand nkg2dl embryonic neural stem cell marker solid human gbm stem-like cell isolate glioma cell line qrt-pcr immunohistochemistry include quantitative analysis also evaluate effect temozolomide tmz standard chemotherapeutic agent use gbm therapy nkg2dl expression nkg2dl-positive cell mostly find scatter isolate detectable glial fibrillary acidic protein gfap positive tumor region partly penumbra tumor vessel nkg2dl find distinct tumor stem-like cell subpopulation broadly costain quantitative analysis reveal dependent individual nkg2dl investigate cell portion costain different stem cell marker vary small musashi-1 high klf-4 amount however costaining nkg2dl cd3γ typically find t cell also observable whereas cd11b marker tumor micoglia cell rarely costain nkg2dl stem-like cell derive glioma cell line t98g u251mg show distinct expression pattern nkg2dl stem cell marker seem balance cell line-specific way differentiation t98g display less nkg2dl whereas u251mg expression stem cell marker decrease addition stimulation tmz lead significant upregulation nkg2dl stem-like cell line stem-like glioma cell tend show higher expression nkg2dl differentiate tumor cell tmz treatment support upregulation nkg2dl nkg2d system might play important role tumor stem cell survival gbm therapy 
inhibitory effect combined 5-methyltetrahydrofolate 5-ch3-thf physiological circulate folate species fluoropyrimidine 5-fluorouracil fura 5-fluoro-2 deoxyuridine fdurd growth human leukemia cell ccrf-cem determine function time dose sequence exposure exposure ccrf-cem cell exponential growth 5-ch3-thf 1-100 microm 4 h fura 250 microm fdurd 0.5 microm last 2 h result synergistic inhibitory effect cell growth synergy dependent 5-ch3-thf dose 100 greater 10 greater 1 microm occur 0.1 microm clear dependency synergy sequence observe fura 5-ch3-thf combination 4 h exposure 5-ch3-thf -- fura 5-ch3-thf fura fura -- 5-ch3-thf 5-ch3-thf fdurd combination synergy dependent sequence exposure 5-ch3-thf -- fdurd 5-ch3-thf fdurd synergistic fdurd -- 5-ch3-thf thymidine 0.1 microm add drug treatment substantially rescue ccrf-cem cell 5-ch3-thf-fura cytotoxicity l-methionine 1500 mg/l completely protect ccrf-cem cell toxicity combination 5-ch3-thf-fdurd result consistent hypothesis mechanism 5-ch3-thf potentiate fluoropyrimidine cytotoxicity enhancement ternary complex formation thymidylate synthase 5-fluorodeoxyuridylate active metabolite fluoropyrimidine consequence increase intracellular level 5-10-methylenetetrahydrofolate generate 5-ch3-thf 
nf-e2-related factor 2 nrf2 regulate transcription battery metabolic cytoprotective gene nrf2 epidermal growth factor receptor egfrs/hers regulator cellular proliferation determinant cancer initiation progression nrf2 confer cancer resistance several therapeutic agent nevertheless limited understanding regulation expression activation link nrf2 signalling pathway show nrf2 regulate basal inducible expression her1 treatment ovarian cancer cell peo1 ovcar3 skov3 nrf2 activator tbhq induce her1 inhibition nrf2 sirna knockdown retinoid repress her1 furthermore treatment cell tbhq increase total phosphorylated nrf2 her1 akt level compromise cytotoxic effect lapatinib erlotinib treatment sirna retinoid antagonise effect tbhq nrf2 her1 level enhance sensitivity ovarian cancer cell lapatinib erlotinib pharmacological genetic inhibition nrf2 and/or treatment lapatinib erlotinib elevated cellular ros deplete glutathione extend understanding nrf2 regulation family receptor open strategic target improve cancer therapy 
background use alkylating agent temozolomide association radiotherapy rt therapeutic standard glioblastoma gbm regimen modestly prolong overall survival also light still dismal prognosis improvement desperately need especially patient o6-methylguanine-dna-methyltransferase mgmt unmethylated tumor benefit standard treatment less tinostamustine edo-s101 first-in-class alkylating deacetylase inhibitor ak-daci molecule fuse dna damaging effect bendamustine fully functional pan-histone deacetylase hdac inhibitor vorinostat completely new chemical entity method tinostamustine test model gbm use 13 gbm cell line seven patient-derived gbm proliferating/stem cell line vitro u87mg u251mg mgmt negative well t98g mgmt positive subcutaneously inject nude mouse whereas luciferase positive u251mg cell patient-derived gbm stem cell line cscs-5 evaluate orthotopic intra-brain vivo experiment result demonstrate tinostamustine possess stronger antiproliferative pro-apoptotic effect observe vorinostat bendamustine alone similar combination irrespective mgmt expression addition observe stronger radio-sensitization single treatment temozolomide use control due reduce expression increase time disappearance gammah2ax indicative reduce signal dna repair associate higher caspase-3 activation reduction rt-mediated autophagy vivo tinostamustine increase time-to-progression ttp additive/synergistic rt. tinostamustine significant therapeutic activity suppression tumor growth prolongation dfs disease-free survival os overall survival orthotopic intra-brain model superior bendamustine rt temozolomide show stronger radio sensitivity conclusion datum suggest tinostamustine deserve investigation patient glioblastoma 
inhibitory effect leucovorin lv combine 5-fluorouracil fura floxuridine fdurd growth human t-lymphoblast leukemia cell ccrf-cem determine function time dose sequence exposure exposure ccrf-cem cell exponential growth lv 1-100 microm 4 hour fura 100 microm fdurd 0.5 microm last 2 hour result synergistic inhibitory effect cell growth synergism dependent lv dose 100 greater 10 greater 1 microm occur 0.1 microm clear dependence synergy sequence observe fura lv combination lv fdurd combination synergism dependent sequence exposure lv fdurd lv -- fdurd synergistic fdurd -- lv thymidine 0.1 microm add drug treatment substantially rescue ccrf-cem cell lv -- fura cytotoxicity concomitant hypoxanthine 100 microm partially protect ccrf-cem cell toxicity combination result consistent hypothesis mechanism lv potentiate fluoropyrimidine cytotoxicity enhancement complex formation thymidylate synthase 5-fluorodeoxyuridylate presumably consequence increase intracellular level 5,10-methylenetetrahydrofolate generate lv also enhance stability complex presence high level folate coenzyme may contribute synergy observe datum also provide rationale use fura especially fdurd lv treatment lymphoid malignancy man 
growth inhibitory effect 5-fluorouracil fura 5-fluoro-2 deoxyuridine fdurd combine 5-methyltetrahydrofolate 5-ch3-h4pteglu determine function time dose sequence exposure human t-lymphoblast leukemia cell ccrf-cem synergistic inhibitory effect cell growth obtain exponentially grow ccrf-cem cell expose 5-ch3-h4pteglu 1-100 microm 4 hr fura 250 microm fdurd 0.5 microm last 2 hr synergism dependent 5-ch3-h4pteglu dose 100 greater 10 greater 1 microm occur 0.1 microm clear dependence synergism sequence observe fura 5-ch3-h4pteglu combination 5-ch3-h4pteglu -- fura,5-ch3-h4pteglu fura fura -- 5-ch3-h4pteglu 5-ch3-h4pteglu fdurd combination synergism dependent sequence exposure 5-ch3-h4pteglu fdurd 5-ch3-h4pteglu -- fdurd synergistic fdurd -- 5-ch3-h4pteglu thymidine 0.1 microm add drug treatment substantially rescue ccrf-cem cell 5-ch3-h4pteglu -- fura cytotoxicity l-methionine 1500 mg/l completely protect ccrf-cem cell enhance cytotoxicity combination 5-ch3-h4pteglu-fdurd result consistent hypothesis mechanism 5-ch3-h4pteglu potentiate fluoropyrimidine cytotoxicity enhancement complex formation thymidylate synthase 5-fluorodeoxyuridylate consequence increase intracellular level 5,10-methylenetetrahydrofolate generate 5-ch3-h4pteglu also enhance stability complex presence high level folate coenzyme may contribute synergism observe datum provide rationale basis trial folate coenzyme fluoropyrimidine combination clinic 
glioblastoma multiforme gbm malignant form brain tumor dismal prognosis despite treatment surgery combine radiotherapy chemotherapy neuropeptide substance p sp physiological ligand neurokinin-1 receptor highly express glioblastoma cell thus sp represent potential ligand target alpha therapy study protocol synthesis sp label alpha emitter 225 ac develop bind affinity property determine effect 225 ac-dota-sp investigate human glioblastoma cell line t98g u87mg u138mg well gbm stem cell significant dose-dependent reduction cell viability detect 6 day treatment also colony-forming capacity inhibit lower dose test comparison treatment conventional agent temozolomide show higher cell viability colony-forming capacity 225 ac-dota-sp treatment cause induction late apoptosis pathway cell arrest g2/m-phase upon treatment increase dose treatment time cause additional s-phase arrest similar result obtain use human glioblastoma stem cell know show radioresistance datum suggest 225 ac-dota-sp promising compound treatment gbm 
lenalidomide immunomodulatory drug possess anti-angiogenic immunomodulatory activity multiple myeloma present study assess vitro effect lenalidomide combine cisplatin mda-mb-231 triple-negative breast cancer tnbc cell line explore underlie molecular mechanism combination cell viability apoptosis protein expression phosphorylate p total extracellular signal-regulated kinase erk b-cell lymphoma-2 bcl-2 caspase-3 cleave poly-adenosine diphosphate-ribose polymerase cparp vascular endothelial growth factor vegf basic fibroblast growth factor bfgf measure mda-mb-231 cell treat different concentration lenalidomide cisplatin combination use different biochemical assay lenalidomide demonstrate significant effect cell viability mda-mb-231 cell even high concentration whereas lenalidomide combination cisplatin significantly reduce cisplatin ic50 7.8 3.0 microm mda-mb-231 cell addition lenalidomide cisplatin combination significantly induce cell apoptosis 1.6 1.38-fold respectively compare lenalidomide cisplatin alone p 0.05 expression level vegf bfgf bcl-2 protein significantly reduce p 0.01 whereas caspase-3 cleave parp expression significantly increase mda-mb-231 cell treat combination compare treat single agent p 0.01 lenalidomide treatment alone significantly reduce p-erk level compare control p 0.05 cisplatin treatment alone significantly increase p 0.01 however treatment combination significantly reduce p-erk level mda-mb-231 cell compare cisplatin treatment alone p 0.05 conclusion present study provide basis use lenalidomide combination cisplatin tnbc therapy 
angiogenesis play significant role pathogenesis multiple myeloma mm microvesicle mv type extracellular vesicle know important player cell-to-cell communication mm-derived mv exhibit activity promote angiogenesis bortezomib lenalidomide important drug treat myeloma therefore aim present study investigate whether mv secrete human myeloma cell expose bortezomib lenalidomide affect angiogenesis rpmi-8226 human myeloma cell human umbilical vein endothelial cell huvec use mv isolate drug-treated rpmi-8226 cell number mv analyze flow cytometry expression pro-angiogenic factor analyze pcr elisa angiogenic potential huvec examine nf-κb activation analyze use pcr immunofluorescent staining western blotting assay show bortezomib treatment induce increase number mvs shed myeloma cell number mv significantly alter lenalidomide expression level vascular endothelial growth factor vegf interleukin 6 il-6 basic fibroblast growth factor bfgf reduce mv rpmi-8226 cell expose bortezomib lenalidomide consequently mv exhibit reduce angiogenic potential evaluate wound healing test boyden chamber assay tube formation assay co-culturing huvec drug-treated mv inhibit nf-κb activation huvec reduce secretion pro-angiogenic factor conclusion bortezomib lenalidomide treatment culture myeloma cell block mv-induced angiogenesis hence provide another mechanism anti-angiogenic therapy 
glioma common brain tumor diverse biological behaviour glioblastoma gbm aggressive worst prognosis characterize intense aberrant angiogenesis distinguish low-grade glioma lgg benign expansive lesion meningioma mng increase evidence importance vascularization tumor biology focus isolation characterization endothelial cell ec primary gbm lgg mng gene expression analysis real-time pcr immunofluorescence flow cytometry analysis tube-like structure formation vascular permeability assay perform result show higher efficiency ec form complex vascular architecture well greater impairment brain blood barrier model overexpression pro-angiogenic mediator gbm lgg mng furthermore administration temozolomide bevacizumab sunitinib trigger different proliferative apoptotic angiogenic response dose time-dependent manner increase resistance temozolomide observe t98g cell co-culture gbm-ec condition media therefore develop novel platform reproduce tumor vascularization disease dish allow perform screening sensitivity/resistance drug order optimize target approach gbm therapy 
resistance chemotherapy substantially hinder successful glioblastoma gbm treatment contribute almost 100 mortality rate resistance frontline chemotherapy temozolomide tmz arise numerous signaling pathway deregulate gbm include hedgehog hh signaling investigate suppression hh signaling adjuvant tmz use u87-mg t98g cell line vitro model gbm find silencing gli1 sirna reduce cell metabolic activity 30 combination tmz reduce multidrug efflux activity 2.5-fold additionally pharmacological gli inhibition modulate nuclear p53 level decrease mgmt expression combination tmz surprisingly find silencing gli1 induce apoptosis absence tmz co-treatment discover silencing gli1 without tmz co-treatment induce senescence evidence significant 2.3-fold increase senescence associate beta-galactosidase staining occur loss pten-dependent manner finally show gli inhibition increase apoptosis glioma stem-like cell 6.8-fold combination tmz reduce size number neurosphere grow glioma stem-like cell aggregate datum warrant continued investigation hh pathway inhibitor adjuvant tmz chemotherapy highlight importance identify signaling pathway determine whether co-treatment will successful 
background natural killer cell line nk-92mi cytotoxic various type cancer aim study develop chimeric antigen receptor-modified car nk-92mi cell target carcinoembryonic antigen-expressing cea tumour increase kill efficacy pharmacologically modify cea-expression result generate anti-cea-car nk-92mi cell retroviral vector transduction genetically-modified cell line recognise lyse high cea-expressing tumour cell line ls174t 47.54 12.60 moderate cea-expressing tumour cell line widr 31.14 16.92 5:1 effector target e/t ratio cell line lyse low cea-expressing tumour cell hct116 parental cell nk-92mi cell histone deacetylase-inhibitor hdac sodium butyrate nab methylation-inhibitor 5-azacytidine 5-aza epigenetic modifier induce cea-expression hct116 widr cell although ic50 5 fluorouracil 5-fu increase cell line show collateral sensitivity anti-cea-car nk-92mi cell cytolytic function anti-cea-car nk-92mi cell increase 22.99 2.04 lysis background 69.20 11.92 nab treatment 69.70 9.93 5-aza treatment 10:1 e/t ratio hct116 cell widr cell show similar trend 22.99 4.01 lysis background 70.69 10.19 nab treatment 59.44 10.92 5-aza treatment 10:1 e/t ratio conclusion datum indicate effector-ability anti-cea-car nk-92mi increase cea-dependent manner combination epigenetic-modifier like hdac-inhibitor methylation-inhibitor adoptive-transfer ex vivo-expanded allogeneic-nk cell may clinically applicable patient 5-fu resistant condition 
aim present study investigate antiproliferative proapoptotic action n 5-benzyl-1,3-thiazol-2-yl -3,5-dimethyl-1-benzofuran-2-carboxamide derivative compound 5 glioma cell comparison action temozolomide tmz doxorubicin dox use positive control antiproliferative activity compound 5 tmz dox human glioblastoma u251 human glioblastoma multiform t98g cell measure use mtt test western blot analysis fluorescent microscopy agarose gel retardation assay flow cytometric analysis dna comet assay alkaline condition carry study effect compound 5 u251 cell compound show ~ 20 time higher cytotoxicity toward u251 t98g cell compare effect tmz approximately two time higher activity dox compound 5 induce apoptosis u251 cell parp1 caspase 3 cleavage mechanism also induce increase level bax bim proapoptotic protein decrease level phosho-erk1 / 2 kinase cytotoxicity compound 5 associate increase production hydrogen peroxide formation dna single-strand break compound 5 intercalate dna molecule thus novel thiazole derivative compound 5 prove potential antiglioma drug show much higher cytotoxic action human glioma cell compare effect tmz dox cytotoxicity associate apoptosis induction production reactive oxygen species formation dna single-strand break without significant dna intercalation 
efficiency colorectal carcinoma treatment chemotherapy diminish resistance develop time patient hold true 5-fluorouracil drug use first line chemotherapy colorectal carcinoma chemoresistant derivative ht-29 cell prepare long-term culturing increase concentration 5-fluorouracil cell characterize viability assay flow cytometry gene expression array kinetic imaging immunomagnetic separation use isolation subpopulation positive cancer stem cells-related surface marker aldehyde dehydrogenase expression attenuate sirna vivo study perform scid/bg mouse prepared chemoresistant cell line label ht-29 / egfp/fur assign different morphology decrease proliferation rate 135-fold increase ic50 value 5-fluorouracil comparison parental counterpart ht-29 / egfp capability chemoresistant cell form tumor xenograft inject subcutaneously scid/bg mouse strongly compromise however form distant metastase mouse lung spontaneously derived cell preserve resistance vitro vivo even without 5-fluorouracil selection pressure importantly resistant cisplatin oxaliplatin cyclophosphamide exhibit high cross-resistance along alteration expression cancer-stem cell marker cd133 cd166 cd24 cd26 cxcr4 cd271 cd274 also detect increase aldehyde dehydrogenase aldh activity associate overexpression specific aldh isoform 1a3 inhibition sirna approach partially sensitize cell various agent thus link first time aldh1a3 chemoresistance colorectal cancer study demonstrate acquire chemoresistance go along metastatic migratory phenotype accompany increase activity aldehyde dehydrogenase describe valuable model study molecular link resistance chemotherapy metastatic dissemination 
exosome derive mesenchymal stem cell msc evaluate potential use drug delivery vehicle synthetically personalize exosome mimetic em alternative vesicle drug delivery study aim isolate em human msc cell mix paclitaxel ptx ptx-loaded em ptx-msc-em isolate evaluate anticancer effect breast cancer em isolate human bone marrow-derived msc msc 4 x 106 cells/ml mix without ptx different concentration phosphate-buffered saline pbs serially extrude 10 5 1-mum polycarbonate membrane filter use mini-extruder msc centrifuge remove debris supernatant filter 0.22-mum filter follow ultracentrifugation isolate em drug-loaded em em without encapsulate drug msc-ems encapsulate ptx ptx-msc-ems characterize western blotting nanoparticle tracking analysis nta transmission electron microscopy tem anticancer effect msc-em ptx-msc-em assess breast cancer mda-mb-231 cell vitro vivo use optical imaging em isolate extrusion method ultracentrifugation isolate vesicle positive membrane marker alix cd63 negative golgi gm130 endoplasmic calnexin marker protein nta reveal size msc-em around 149 nm tem confirm morphology ptx-msc-em significantly p 0.05 decrease viability mda-mb-231 cell vitro increase concentration em vivo tumor growth significantly inhibit ptx-msc-em compare control and/or msc-em thus msc-em successfully isolate use simple procedure drug-loaded msc-em show therapeutically efficient treatment breast cancer vitro vivo msc-em may use drug delivery vehicle breast cancer 
background lgals3 promote tumor progression diverse cancer however involvement lgals3 glioblastoma yet broadly illuminate method microarray perform detect gene expression profile radioresistance t98g cell identify universally upregulate gene lgals3 impact lgals3 survival glioblastoma cell face ionize irradiation temozolomide investigate cell count kit-8 cck-8 total 120 glioblastoma case collect analyze relationship lgals3 expression patient prognosis another 961 patient glioma 1,351 healthy control recruit study association snp across lgals3 gene glioblastoma susceptibility functional snp site also study cellular experiment result effective protection lgals3 ionize irradiation temozolomide-induced cell death t98g u251 cell find addition high expression lgals3 work independent risk factor survival patient glioblastoma two snp site rs4644 rs4652 across lgals3 gene associate increase risk glioblastoma c allele rs4652 allele rs4644 enhance glioblastoma resistance radio-chemotherapy cell proliferation conclusion result suggest lgals3 important biomarker influence glioblastoma risk prognosis potential target treat malignancy especially one resistance standard therapy impact lgals3 promote glioblastoma cell resistance ionize irradiation temozolomide predict poor prognosis targeting lgals3 may limit therapeutic resistance glioblastoma increase patient survival 
series polymer-drug conjugate base 2-methacryloyloxyethyl phosphorylcholine mpc prepare glioblastoma drug temozolomide tmz pendent group random block copolymer synthesize reversible addition-fragmentation chain-transfer raft polymerization use tmz-containing methacrylate monomer solution property polympc-tmz copolymer investigate dynamic light scattering transmission electron microscopy reveal well-defined nanostructure block copolymer conjugation tmz polympc enhance drug stability decomposition half-life value range 2 19-time longer free tmz cytotoxicity polympc-tmz evaluate chemosensitive u87mg chemoresistant t98g glioblastoma cell line furthermore polympc-tmz platform expand considerably preparation redox-sensitive polympc-tmz copolymer utilize disulfide polymer-to-drug linker 
drug combination represent one accredited strategy cancer therapy able improve drug efficacy possibly overcome drug resistance among agent use complement conventional chemotherapy carbonic anhydrase ix caix inhibitor appear one suitable marker hypoxic acidic cancer cell respond chemo radiotherapy perform preclinical vitro assay evaluate whether slc-0111 caix inhibitor co-operate potentiate cytotoxic effect conventional chemotherapeutic drug a375-m6 melanoma cell mcf7 breast cancer cell hct116 colorectal cancer cell demonstrate slc-0111 caix inhibitor potentiate cytotoxicity dacarbazine temozolomide currently use advanced melanoma treatment slc-0111 also increase breast cancer cell response doxorubicin enhance 5-fluorouracil cytostatic activity colon cancer cell finding disclose possibility extend use caix inhibitor combination therapy various cancer histotype 
combination chemotherapy widely exploit suppress drug resistance achieve synergistic anticancer efficacy clinic paper nanostructured target methotrexate mtx plus pemetrexed pmx chitosan nanoparticle cnp develop modify methoxy polye thylene glycol mpeg pegylation cnp use stealth nanocarrier pcnp mtx employ targeting ligand chemotherapeutic agent well study undertake human lung adenocarcinoma epithelial a549 lewis lung carcinoma llc cell line reveal anti-tumor efficacy nanoparticle drug delivery system co-delivery nanoparticle mtx-pmx-pcnp well-dispersed sustained release behavior cell counting kit-8 cck8 use measure a549 cell viability research show mtx-pmx-pcnp much effective free drug come inhibition growth proliferation cell cycle assay flow cytometry manifest mtx-pmx-pcnp exhibit stronger intracellular take ability free drug concentration vivo anticancer effect result indicate mtx-pmx-pcnp exhibit significantly prolong blood circulation tumoral location accumulation result robust synergistic anticancer efficacy lung cancer mouse result clearly demonstrate unique synergistic anticancer efficacy co-delivery mtx pmx via stealth nanocarrier provide prospective strategy lung cancer treatment 
malignant melanoma highly lethal disease advance stage melanoma prove resistant many chemotherapeutic drug include temozolomide paclitaxel cancer stem cell csc identify isolate different cancer include melanoma prove play important role drug resistance retinoic acid ra promising anticancer agent induce differentiation csc main purpose present study evaluate possible ra-induced differentiation melanoma csc sensitization melanoma csc paclitaxel result show csc human melanoma a375 cell tolerant paclitaxel non-cscs melanoma cell contrary ra stronger inhibitory effect melanoma csc non-csc time ra arrest cell cycle csc reduce expression sox-2 oct-4 csc melanoma thereby induce differentiation csc increase sensitivity paclitaxel study conclude ra increase anticancer effect paclitaxel induce differentiation cancer stem cell melanoma combined application ra paclitaxel may effective treatment melanoma 
tumor cell binding microenvironment component collagen type 1 col1 attenuate sensitivity cytotoxic drug like cisplatin cddp mitoxantrone mx refer cell adhesion mediate drug resistance cam-dr cam-dr consider onset resistance mutation underlie mechanism remain elusive evaluate cam-dr target sensitization strategy analyze signaling pathway human estrogen-positive mcf-7 triple-negative mda-mb-231 breast cancer cell western blot proteome profiler array top-flash assay presence col1 beta1-integrin know bind col1 appear key mediate col1-related resistance cell line primarily follow fak/pi3k/akt pathway mcf-7 mapk pathway mda-mb-231 cell notably pcreb highly elevated cell line consequently block pathway sensitize cell evidently cddp mx treatment wnt signaling relevant context beta1-integrin knockdown mcf-7 cell mcf-7-beta1-kd reveal signaling shift fak/pi3k/akt mapk pathway thus creb emerge promising primary target sensitization mda-mb-231 secondary target mcf-7 cell conclude provide evidence importance cam-dr breast cancer cell identify intracellular signaling pathway target sensitize cell cytotoxicity treatment regime 
temozolomide tmz therapeutic dna alkylator cause lethal dna damage cancer cell widely use standard chemotherapy glioblastoma however long-term treatment tmz often cause drug resistance poor prognosis mechanism remain largely unclear study aim investigate possible role mir-222 / gas5 axis dna damage cytotoxic effect induce tmz glioblastoma cell t98g datum suggest dna comet tail length t98g positively correlate level mir-222 r2 = 0.9808 p 0.05 negatively correlate level gas5 r2 = 0.8903 p 0.05 optical density value t98g negatively correlate level mir-222 r2 = 0.7848 p 0.05 positively correlate level gas5 r2 = 0.6886 p 0.05 furthermore comet tail length optical density value negatively positively correlate level o-6-methylguanine-dna methyltransferase respectively r2 = 0.8462 p 0.05 r2 = 0.7018 p 0.05 conclusion mir-222 / gas5 involve dna damage cytotoxic effect induce tmz mean mir-222 / gas5 may great potential use biomarker screening chemotherapeutic alkylator 
cancer cell resistance drug remain important problem affect cancer treatment strategy previously study nicotinamide phosphoribosyltransferase nampt inhibitor fk866 resistance mechanism human colorectal cancer hct116 cell establish acquire fk866-resistant cell line hct116rfk866 study investigate gene mutation parental hct116 hct116rfk866 cell use exome sequencing technology result indicate cluster gene relate nad biosynthesis include nampt dna repair atp-binding cassette transporter differentially alter cell interestingly hct116rfk866 cell resistant class nampt inhibitor sensitive anticancer 5-fluorouracil cisplatin gamma-ray irradiation compare parental hct116 cell higher sensitivity appear cause genetic change identify gene cluster resistance nampt inhibitor fk866 collectively novel finding provide better understanding anticancer candidate nampt inhibitor regard resistance mechanism cancer chemotherapy strategy 
global physiological function specifically express gene mitoxantrone mtx resistant prostate cancer pca unclear study gene expression pattern microarray datum investigate identify differentially express gene deg mtx-resistant pca xenograft human pca cell line du145 pc3 culture vitro xenograft severe combined immunodeficiency scid mouse treat mtx intragastrically three time week mouse relapse gene expression profile xenograft castrated mouse perform affymetrix human whole genomic oligonucleotide microarray cytoscape software use investigate relationship protein signalling transduction network total 355 overlap gene differentially express mtx-resistant du145r pc3r xenograft 16 gene select validate quantitative real-time pcr qrt-pcr xenograft test set formalin-fixed paraffin-embedded optimal cut temperature oct clinical tumour sample functional pathway enrichment analysis reveal deg closely related cellular activity androgen synthesis dna damage repair also involve erk/mapk pi3k/serine-threonine protein kinase also know protein kinase b pkb akt apoptosis signalling pathway exploratory analysis provide information potential candidate gene may bring new insight molecular cascade involvement mtx-resistant pca 
colorectal cancer crc one prevalent neoplastic disease worldwide effective treatment remain challenge find macrolide antibiotic brefeldin bfa exhibit considerable antitumor activity vitro vivo induction complete autophagic flux characterize key event bfa-induced crc suppression mechanistically bfa provoke endoplasmic reticulum stress-mediated binding immunoglobulin protein bip expression lead increase bip/akt interaction resultant decrease akt phosphorylation thereby activate autophagy autophagy inhibition bip suppression relieve bfa-induced cell death suggest key role bip-regulated autophagy antitumor property bfa moreover bfa act synergistically paclitaxel 5-fluorouracil crc suppression collectively study provide important molecular basis bfa-induced autophagy suggest antibiotic bfa reposition potential anticancer drug crc treatment.-zhou l. gao w. wang k. huang z. zhang l. zhang z. zhou j. nice e. c. huang c. brefeldin inhibit colorectal cancer growth trigger bip/akt-regulated autophagy 
current study cytocompatible situ cross-linkable ph/thermo-dual responsive injectable hydrogel prepared base poly n-isopropylacrylamide carboxymethyl chitosan i.e. poly cmcs-g-nipaam prepared formulation aim use drug depot 5-fluorouracil 5-fu subcutaneous administration vivo phase transition sol-gel state physiologic temperature range analyze confirm tube title optical transmittance measurement viscoelastic property gel formulation confirm rheology determination via time sweep temperature continuous ramp test oscillatory swell cycle confirm temperature effect structural change ph temperature sensitivity dual responsive gel analyze different ph temperature program vitro drug release profile display develop formulation highest release acidic ph 25 c safety blank gel formulation evaluate l929 cell line via mtt assay confirm cytocompatibility detectable toxicity vitro cytotoxic potential drug-loaded gel hela mcf-7 cancer cell line confirm 5-fu control cytotoxic potential depot form comparison free 5-fu solution ic50 value free 5-fu 21 05 mug/ml 18 66 mug/ml find higher comparison loaded form copolymer structure formation confirm nmr ftir spectroscopic analysis tg dsc analysis prove thermal stability phase transition temperature pure copolymer sample sem analysis show porous nature situ form hydrogel conclude result develop formulation ph/temperature sensitivity potential systemic intratumoral control drug delivery property 
glioblastoma lead malignant glioma poor prognosis study aim investigate antitumor effect natural killer cell combination temozolomide standard chemotherapeutic agent glioblastoma use simple feeder-less chemically define culture method expand human peripheral blood mononuclear cell assess receptor expression natural killer cell activity regulatory t cell frequency expand cell next use standard human glioblastoma cell line temozolomide-sensitive u87mg temozolomide-resistant t98g ln-18 assess ligand expression receptor natural killer cell furthermore antitumor effect combination expand natural killer cell temozolomide assess use growth inhibition assay apoptosis detection assay senescence-associated beta-galactosidase activity assay glioblastoma cell line novel culture system sufficient attain highly purify 98 expand 440-fold cd3 / cd56 peripheral blood-derived natural killer cell designate expand population genuine induced natural killer cell genuine induce natural killer cell exhibit high natural killer activity low regulatory t cell frequency compare lymphokine-activated killer cell growth inhibition assay reveal genuine induced natural killer cell inhibit glioblastoma cell line growth enhance temozolomide-induced inhibition effect u87mg apoptosis detection assay reveal genuine induced natural killer cell induce apoptosis glioblastoma cell line furthermore senescence-associated beta-galactosidase activity assay reveal temozolomide induce senescence u87mg genuine induce natural killer cell induce apoptosis temozolomide-sensitive temozolomide-resistant glioblastoma cell enhance temozolomide-induced antitumor effect different mechanism hence combination genuine induced natural killer cell temozolomide may prove promising immunochemotherapeutic approach patient glioblastoma antitumor effect vivo demonstrate 
investigate effect pretreatment difluoromethylornithine dfmo ornithine decarboxylase inhibitor cytocidal response four human adenocarcinoma cell line two alkylate crosslink agent chlorambucil n n n triethylenethiophosphoramide thiotepa cell line study include hutu-80 duodenum ht-29 colon me-180 cervix a-427 lung 48 72-h pretreatment dfmo reduce intracellular putrescine spermidine contents less 10 less 1 control level treatment also cause 30 -70 decline spermine content survival control dfmo-pretreated cell treatment chlorambucil thiotepa measure plate efficiency assay three four line study dfmo-induced partial polyamine depletion significantly protect cell lethal effect chlorambucil me-180 culture alone dfmo pretreatment alter cytocidal efficacy chlorambucil addition exogenous putrescine culture hutu-80 ht-29 a-427 24 h dfmo addition 24 h treatment chlorambucil reverse polyamine depletion protective effect chlorambucil-induced cell kill contrast observation dfmo partial polyamine depletion effect cell survival thiotepa treatment cell line investigate 
aim study evaluate effect related pharmacological mechanism switch schedule antiangiogenic chemotherapeutic drug beyond progression first-line treatment colorectal cancer preclinical model vivo study perform nude mouse subcutaneously transplant colon cancer cell treatment include drug combination switch chemotherapeutic i.e. irinotecan 5-fluorouracil and/or antiangiogenic drug i.e. anti-vegf antibody sunitinib time tumor progression proliferation assay also achieve vitro different colon cancer cell line expose sn-38 sunitinib alone combination abcg2 gene expression perform real-time pcr sn-38 intracellular concentration measure switch combined treatment time tumor progression chemotherapeutic irinotecan 5-fluoruracil antiangiogenic drug anti-vegf antibody sunitinib drug induce new response immunohistochemistry stromal pdgf-c plgf sd1-alpha tie-2 vegfr-2 show statistical difference tumor time relapse switch therapy moreover combination sn-38 sunitinib cause synergism colon cancer cell significant inhibition abcg2 gene expression increase sn-38 intracellular concentration observation may clinical relevance suggest switch single chemotherapeutic antiangiogenic drug beyond progression disease obtain new tumor response due modulation angiogenic factor direct effect tumor cell possible variation intracellular drug concentration 
background high-dose chemotherapy follow autologous peripheral blood stem-cell transplantation standard therapy patient diagnose multiple myeloma purge process remove contaminate residual myeloma cell improve patient outcome study purge method human multiple myeloma cell peripheral blood mononuclear cell evaluate materials method human myeloma cell line rpmi-8226 seoul korea treat bortezomib selleck chemicals houston tx usa lenalidomide sigma aldrich st. louis mo usa mixture human peripheral blood mononuclear cell line pcs-800-011 atcc usa rpmi-8226 treat bortezomib lenalidomide 24 hour efficacy purge myeloma cell evaluate 8-color flow cytometric analysis result cytotoxicity bortezomib 10-160 nmol/l lenalidomide 200-3,200 nmol/l investigate rpmi-8226 myeloma cell line 24-hour incubation bortezomib 10 20 40 80 160 nmol/l induce 5.45 -0.07 47.15 -1.20 57.15 -0.21 72.35 -0.07 84.75 -0.49 growth inhibition rpmi-8226 cell respectively 24-hour incubation lenalidomide 200 400 800 1,600 3,200 nmol/l induce 5.45 -0.07 7.55 -0.07 9.75 -0.35 18.25 -0.21 39.75 -0.78 growth inhibition rpmi-8226 cell respectively bortezomib 40 nmol/l 24 hour lenalidomide 3,200 nmol/l 24 hour effectively remove cd38 cd138 cell peripheral mononuclear cell rpmi-8226 cell show abberant phenotype cd56 / cd45 conclusion result present study demonstrate bortezomib lenalidomide treatment rpmi-8226 multiple myeloma cell effectively remove contaminate plasma cell 
interaction high-mobility group box 1 protein hmgb1 receptor advanced glycation end product rage important tumor cell growth investigate tumor biological effect hmgb1 rage interaction previously identify inhibitor hmgb1/rage interaction papaverine non-narcotic opium alkaloid use unique drug design system drug reposition approach present study examine anticancer effect papaverine human glioblastoma gbm temozolomide tmz first-line anticancer medicine sensitive u87mg tmz-resistant t98g cell hmgb1 supplementation culture medium promote tumor cell growth t98g cell effect cancel papaverine addition papaverine t98g cell suppress cancer cell migration hmgb1/rage inhibitor papaverine also significantly inhibit cell proliferation u87mg t98g cell effect papaverine evaluate vivo u87mg xenograft mouse model determine tumor growth delay result indicate papaverine smooth muscle relaxant potential anticancer drug may useful gbm chemotherapy 
thermo ph-responsive poly-n-isopropylacrylamide pnipam polymer gain interest due microenvironment target potential toward cancer cell exceptional potential phase transition body temperature 37 c make biologically relevant drug delivery biosensing optimum drug loading particle size controlled release specific site essential critical process parameter cpp study investigate formulation optimization anastrozole anst load pnipam nanoparticle np prepare solvent evaporation method ph thermo-responsive drug delivery box-behnken design bbd implement observe effect select process parameter quality attribute product include particle size 110.15 nm zeta potential 11.02 mv pdi 0.175 drug load 8.35 dl statistical datum find fit quadratic model p value less 0.005 thermo-responsive behavior pnipam evaluate dls uv-visible spectroscopy elevated temperature 60 c show increment turbidity show aggregation nanoparticle tem afm reveal spherical smooth surface anst-pnipam np formulation show controlled release anst 48 h ph 7.4 trigger release simulated tumor microenvironment ph 5.0 vitro cytotoxicity formulation higher free anst show dose-dependent cell viability higher cell uptake observe np 12-h incubation mcf-7 cell line use confocal microscopy apoptotic evaluation anst-pnipam np exhibit 22.67 comparison free anst 6 analyze flow cytometer 
rationale characterization new genetic alteration essential assign effective personalized therapy non-small cell lung cancer nsclc furthermore find stratification biomarker essential successful personalized therapy molecular alteration yes1 member src family kinase sfk find significant subset lung cancer patient objective evaluate yes1 genetic alteration therapeutic target predictive biomarker response dasatinib nsclc method functional significance evaluate vivo model nsclc metastasis patient-derived xenograft pdx efficacy pharmacological genetic crispr/cas9 yes1 abrogation also evaluate vitro functional assay signaling survival invasion also perform association yes1 alteration prognosis evaluate clinical sample measurement main result demonstrate yes1 essential nsclc carcinogenesis furthermore yes1 overexpression induce metastatic spread preclinical vivo model yes1 genetic depletion crispr/cas9 technology significantly reduce tumor growth metastasis yes1 effect mainly drive mtor signaling interestingly cell line pdx model yes1 gene amplification present high sensitivity dasatinib sfk inhibitor point yes1 status stratification biomarker dasatinib response moreover high yes1 protein expression independent predictor poor prognosis lung cancer patient conclusion yes1 promising therapeutic target lung cancer result provide support clinical evaluation dasatinib treatment select subset patient use yes1 status predictive biomarker therapy 
show nuclear factor kappa-b nf-kappab constitutively activate glioblastoma gbm suggest pathway therapeutic target glycyrrhetic acid ga compound isolate licorice glycyrrhiza glabra show decrease cell viability increase apoptosis human cancer cell line nf-kappab signaling pathway suppression dipotassium glycyrrhizinate dpg dipotassium salt ga anti-inflammatory property without toxicity current study examine effectiveness dpg anti-tumor u87mg t98g gbm cell line additionally assess dpg candidate combinational therapy gbm temozolomide tmz result demonstrate viability u87mg t98g cell significantly decrease time dose-dependent manner dpg treatment apoptotic ratio dpg-treated group significantly higher control group addition dpg combination tmz reveal synergistic effect furthermore expression nf-kappab-luciferase-reporter transfect gbm cell line remarkably reduce dpg exposure up-regulate mir16 mir146a down-regulate target gene irak2 traf6 reduce neuro-sphere formation also observe dpg gbm cell conclusion dpg present anti-tumoral effect gbm cell line decrease proliferation increase apoptosis addition datum also suggest dpg anti-tumoral effect relate nf-kappab suppression irak2 traf6-mediating mir16 mir146a respectively might potential therapeutic target dpg 
novel series 6-substituted pyrrolo 2,3-d pyrimidine reversed amide moiety lead compound 1a design synthesize nonclassical antifolate potential antitumor agent target compound 1-9 successfully obtain two sequential condensation reaction key intermediate 2-amino-6 2-aminoethyl -3,7-dihydro-4h-pyrrolo 2,3-d pyrimidin-4-one preliminary antiproliferation assay compound demonstrate submicromolar nanomolar inhibitory effect kb tumor cell whereas compound 1-3 also exhibit nanomolar antiproliferative activity toward sw620 a549 cell particular compound 1-3 significantly potent positive control methotrexate mtx pemetrexed pmx a549 cell growth inhibition induce cell cycle arrest g1-phase s-phase suppression along result nucleoside protection assay inhibition assay dihydrofolate reductase dhfr clearly elucidate intracellular target design compound dhfr molecular modeling study suggest two binding mode target compound dhfr 
background deregulated phosphoinositide 3-kinase pi3k / mtor signaling commonly exist glioblastoma gbm make axis attractive target therapeutic manipulation recent dual inhibitor pi3k/mtor pathway xl765 exhibit attractive suppression effect gbm tumor growth however exact functional mechanism tumor suppression mediate xl765 yet fully characterize purpose study take effort assess effect pi3k/mtor blockade xl765 gbm growth vitro vivo method analyze cytotoxicity xl765 three different gbm cell line a172 u87mg t98g use hoechst 33258 invitrogen annexin v/propidium iodide pi well cell count kit -8 cck-8 assay also use a172 xenograft model study effect xl765 vivo result find xl765 inhibit gbm viability wide range potency importantly xl765 suppress gbm cell growth induce endoplasmic reticulum er stress dependent apoptosis activation chop/dr5 pathway xl765 induce er stress responsible induction apoptosis moreover inhibition mtor signal xl765 major source er stress rather inhibition pi3k last demonstrate combination xl765 gmb chemotherapeutic drug temozolomide tmz achieve better therapy effect vitro vivo conclusion overall datum show target pi3k/mtor xl765 promising therapeutic strategy relieve tumor burden gbm patient 
temozolomide alkylating agent use first line treatment glioblastoma however chemoresistance temozolomide common glioma patient addition likely many unknown mechanism anti-tumor effect temozolomide know alkylating agent sulfur mustard activate cytosolic phospholipase a2 cpla2 release arachidonic acid suppress tumor present study perform elucidate involvement cpla2 anti-tumor mechanism temozolomide three glioblastoma cell line gl261 u251mg t98g perform several evaluation include cell viability cell migration apoptosis study temozolomide-induced anti-tumor effect evaluate tumor size murine orthotropic glioblastoma model oral administration temozolomide finally investigate phosphorylation cpla2 gl261 cell treat temozolomide clarify whether phosphorylation cpla2 affect cell growth temozolomide suppress cell growth cell migration glioblastoma cell vitro show anti-tumor effect murine orthotopic glioblastoma model vivo furthermore temozolomide increase phosphorylation cpla2 associate suppression cell growth however mgmt high-expressing glioblastoma t98g cell temozolomide suppress cell growth cause phosphorylation cpla2 finding indicate temozolomide suppress cell growth partly phosphorylation cpla2 glioblastoma cell addition temozolomide cause phosphorylation cpla2 mgmt high-expressing glioblastoma t98g cell phosphorylation cpla2 may cause dna alkylation temozolomide 
background endocrine therapy clinically administer hormone-responsive breast cancer combination fluoropyrimidine s-1 aromatase inhibitor anti-estrogen consider beneficial japan herein assess new combination s-1 fulvestrant patient method cytotoxicity fulvestrant 5-fluorouracil 5-fu assess hormone-responsive mcf-7 non-responsive mda-mb-231 breast cancer cell culture fulvestrant s-1 evaluate antitumor activity mouse effect estrogen receptor er alpha progesterone receptor pgr level mcf-7 xenograft use immunohistochemical method result fulvestrant inhibit growth mcf-7 mda-mb-231 xenograft combination 5-fu fulvestrant superior monotherapy vitro vivo antitumor activity s-1 / fulvestrant combination therapy significantly p 0.05 enhance compare monotherapy fulvestrant partially down-regulate expression eralpha pgr combination s-1 almost completely block expression conclusion chemo-endocrine combination therapy use s-1 fulvestrant beneficial estrogen-responsive breast cancer 
sb365 saponin d extract root pulsatilla koreana report show cytotoxicity several cancer cell line investigate effect sb365 u87-mg t98g glioblastoma multiforme gbm cell efficacy combination temozolomide treat gbm sb365 exert cytotoxic effect gbm cell induce apoptosis cancer cell line trigger caspase-independent cell death inhibition autophagic flux neutralization lysosomal ph occur rapidly application sb365 follow deterioration mitochondrial membrane potential cathepsin b inhibitor n-acetyl cysteine antioxidant partially recover cell death induce sb365 sb365 combination temozolomide exert additive cytotoxic effect vitro vivo conclusion sb365 inhibit autophagic flux induce caspase-independent cell death gbm cell manner involve cathepsin b mainly reactive oxygen species use combination temozolomide show promise treatment gbm 
metronomic chemotherapy use 5-fu prodrug uracil-tegafur uft cyclophosphamide ctx previously show modestly delay primary tumor growth nevertheless markedly suppress development micro-metastasis orthotopic breast cancer xenograft model use metastatic variant mda-mb-231 cell line 231/lm2 4 furthermore remarkable prolongation survival toxicity observe model postsurgical advanced metastatic disease question remain unanswered seemingly selective anti-metastatic mechanism action responsible treatment assess vivo effect metronomic uft ctx combination vascular density collagen deposition c-met cell mediator modulator tumor cell invasion dissemination via histochemistry/immunohistochemistry primary tumor section also assess effect continuous exposure low non-toxic dose active drug metabolite 5-fluorouracil 5-fu 4-hydroperoxycyclophosphamide 4-hc combination 231/lm2 4 cell invasiveness vitro vivo study significant reduction vascular density p-met y1003 level associate uft+ctx treatment treatment reduce intratumoral collagen deposition vitro study significant reduction collagen iv invasion treatment observe 3d structure form 231/lm2 4 matrigel show predominantly mass phenotype treated condition stellate phenotype untreated culture take together result suggest low-dose metronomic chemotherapy regimen test suppress several mediator tumor invasiveness highlight new perspective anti-metastatic efficacy metronomic chemotherapy 
glioblastoma gbm one deadliest primary brain malignant tumor bleak prognosis craniotomy surgical resection follow radiotherapy chemotherapy still standard therapeutic strategy gbm target alkylate agent temozolomide tmz utilize therapy gbm decade however effective treatment gbm stymie rapid acquire resistance bone marrow suppression synthesize tetrahedral framework nucleic acid tfna nanoparticle carry tmz enhance lethality four glioblastoma cell line via activate cell apoptosis autophagy pathway nanoparticle namely tfna-tmz show obvious efficacy kill tmz-sensitive cell a172 u87 single agent tmz besides tfna-tmz able attenuate drug resistance tmz-resistant cell t98g ln-18 via downregulate expression o6-methylguanine-dna-methyltransferase mgmt furthermore modify tfna gs24 dna aptamer specially bind transferrin receptor trf cerebral vascular endothelial cell mouse enable tfna nanoparticle cross blood brain barrier summary result demonstrate tfna-tmz promising role nanoscale vehicle deliver tmz enhance efficacy glioblastoma 
background lncrna show play essential role cancer therapeutic response however detailed mechanism lncrna temozolomide tmz resistance glioblastoma gbm remain elucidate method elucidate mechanism maintain tmz resistance construct two tmz-resistant gbm cell line t98g-r/u118-r lncrna four public dataset reanalyze candidate lncrna adamts9-as2 evaluate tmz-treated gbm patient vitro cell line result reanalysis lncrna expression profile identify adamts9-as2 significantly overexpress tmz-resistant gbm cell positively associate ic50 tmz gbm cell overexpression adamts9-as2 also significantly associate poor tmz response shorter progression-free survival pfs tmz-treated gbm patient knockdown adamts9-as2 inhibit proliferation attenuate ic50 tmz well mitigating invasion migration tmz-resistant gbm cell subsequent investigation indicate reduce expression adamts9-as2 significantly suppress expression fus protein predict direct substrate adamts9-as2 expression trend fus directly correlate adamts9-as2 show increase concentration prolonged treatment tmz rna pull-down rip assay indicate endogenous exogenous adamts9-as2 directly bind rrm znf _ ranbp2 domain fus consequently increase fus protein expression knockdown adamts9-as2 reduce half-life fus decrease fus protein stability via k48 ubiquitin degradation moreover e3 ubiquitin-protein ligase mdm2 interact regulate fus rrm znf _ ranbp2 domain fus facilitate binding mdm2 adamts9-as2 decrease interaction mdm2 fus mediate fus k48 ubiquitination additionally knockdown adamts9-as2 / fus signaling axis significantly alleviate progression metastasis tmz-resistant cell conclusion adamts9-as2 possess novel function promote tmz resistance via upregulate fus/mdm2 axis gbm cell rrm znf _ ranbp2 domain fus facilitate combination adamts9-as2 fus competitively inhibit mdm2-dependent fus k48 ubiquitination result enhance fus stability tmz resistance result suggest adamts9-as2 / fus/mdm2 axis may represent suitable prognostic biomarker potential target tmz-resistant gbm therapy 
introduction lung breast colorectal cancer lead cause cancer-related death despite many therapeutic option include target therapy immunotherapy method investigate impact ptc-209 small-molecule bmi-1 inhibitor human cancer cell viability alone combination anticancer drug namely cisplatin oxaliplatin 5-fluorouracil camptothecin frondoside-a impact cellular migration colony growth vitro tumor growth ovo result demonstrate ptc-209 cause concentration time-dependent decrease cellular viability lung cancer cell lnm35 a549 breast cancer cell mda-mb-231 t47d colon cancer cell ht-29 hct8/s11 hct-116 similarly treatment ptc-209 significantly decrease growth lnm35 a549 mda-mb-231 ht-29 clone colony vitro lnm35 a549 tumor growth ovo tumor xenograft model ptc-209 non-toxic concentration significantly reduce migration lung lnm35 a549 breast mda-mb-231 cancer cell moreover show ptc-209 concentration 1 mum enhance anti-cancer effect frondoside-a lung breast colon cancer cell well effect camptothecin breast cancer cell effect cisplatin lung cancer cell vitro however ptc-209 fail enhance anti-cancer effect oxaliplatin 5-fluorouracil colon cancer cell treatment lung breast colon cancer cell ptc-209 1 2.5 mum 48 h show caspase-3 activation decrease cell number seeding level suggest ptc-209 reduce cellular viability probably inhibition cell proliferation induction cell death via caspase-3-independent mechanism molecular mechanism analysis reveal ptc-209 significantly inhibit stat3 phosphorylation decrease expression level gp130 early 30 min post-treatment conclusion finding identify ptc-209 promising anticancer agent treatment solid tumor either alone and/or combination standard cytotoxic drug cisplatin camptothecin natural product frondoside-a 
introduction glioblastoma aggressive cancer begin within brain clinic temozolomide use anti-tumor drug glioblastoma chemotherapy show limited effect therefore improve effect temozolomide glioblastoma urgently need method cell viability t98g cell detect cell counting kit-8 cck-8 assay apoptosis detect use annexin-v-fitc pi apoptosis kit assess flow cytometry expression level bax b cell lymphoma 2 bcl-2 phos-jun n-terminal kinase jnk phos-extracellular signal-regulated kinase erk phos-p38 determine western blot effect ultrasound temozolomide combination mouse determine survival analysis result compare temozolomide treatment alone ultrasound temozolomide combination inhibit cell viability promote apoptosis human glioblastoma t98g cell bax level increase bcl-2 level decrease combination group mechanically combination treatment promote apoptosis via jnk p38 pathway mouse glioblastoma model combination treatment improve overall survival conclusion ultrasound enhance anti-tumor effect temozolomide glioblastoma cell via jnk p38 pathway 
background temozolomide tmz commonly use chemotherapeutic agent use treat glioblastoma gbm cause significant dna damage highly proliferative cell observation add accumulate evidence tmz induce stress-responsive cellular program know promote cell survival include autophagy target survival pathway may represent new vulnerability gbm treatment tmz method use t98g human glioma cell line assess molecular signaling associate tmz treatment cellular consequence use pan-pi3k inhibitor px-866 perform clonogenic assay determine effect sequential treatment tmz px-866 colony formation additionally also use subcutaneous gbm patient derive xenograft pdx tumor show relative lc3 protein expression correlation survival pathway molecular marker dictate clinical responsiveness tmz result report tmz induce autophagic flux t98g glioma cell gbm patient-derived xenograft pdx tumor treat tmz also display increase autophagosome marker lc3 ii additionally o6-methylguanine-dna-methyltransferase mgmt expression correlate pi3k/akt activity suggest patient inherent resistance tmz mgmt-high benefit pi3k/akt inhibitor addition tmz accordingly identify blood-brain barrier bbb penetrant pan-pi3k inhibitor px-866 early-stage inhibitor autophagic flux maintain ability inhibit pi3k/akt signaling glioma cell lastly due induction autophagic flux tmz provide evidence sequential treatment tmz follow px-866 rather combined co-treatment means shut autophagy-induced survival gbm cell enhance apoptosis conclusion understanding tmz induce survival pathway autophagy may offer new therapeutic vulnerability opportunity use sequential inhibition alternate pro-survival pathway regulate autophagy identification additional way inhibit tmz-induced autophagy enhance efficacy tmz 
acknowledge cancer cell able undergo senescence response clinically use chemotherapeutic moreover recent year provide evidence drug selectively remove senescent cell therefore essential properly identify characterize senescent cell especially come cancer senescence induce various cancer cell line a549 sh-sy-5y hct116 mda-mb-231 mcf-7 following treatment doxorubicin irinotecan methotrexate 5-fluorouracil oxaliplatin paclitaxel treatment test chemotherapeutic result upregulation p21 proliferation arrest without cytotoxicity comparative analysis use common senescence marker i.e. morphology sa-beta-galactosidase granularity secretory phenotype level double-stranded dna damage reveal large diversity response chemotherapeutic use strongest senescence inducer doxorubicin irinotecan methotrexate paclitaxel intermediate effect oxaliplatin 5-fluorouracil induce senescence addition different susceptibility cancer cell senescence observe statistical analysis aim find relationship senescence marker apply show clear correlation moreover increase sa-beta-gal activity couple p21 expression prove unequivocal senescence marker point need simultaneously analyze multiple marker give individual limitation 
background glioblastoma gbm aggressive type primary malignant brain tumour interaction high-mobility group box 1 hmgb1 receptor advanced glycation end-product rage important tumour cell growth previously identify anticancer candidate papaverine inhibit hmgb1-rage interaction material method study assess anticancer effect papaverine alone combination temozolomide u87mg t98g human gbm cell use clonogenicity assay well u87mg xenograft mouse model radiosensitize efficacy papaverine measure base clonogenicity t98g cell result papaverine significantly inhibit clonogenicity u87mg t98g cell compare single treatment combination papaverine temozolomide highly suppress clonogenicity t98g cell delay tumour growth u87mg xenograft mouse model furthermore papaverine increase radiosensitivity t98g cell conclusion papaverine potential anticancer drug gbm treatment 
serine-arginine protein kinase 2 srpk2 aberrantly express human malignancy include colorectal cancer crc however little know molecular mechanism role srpk2 chemosensitivity remain unexplored crc recently show srpk2 promote pancreatic cancer progression downregulate numb p53 therefore investigate cooperation srpk2 numb p53 cell migration invasion chemosensitivity crc vitro show srpk2 expression higher crc tumor nontumor tissue srpk2 expression positively associate clinicopathological characteristic crc patient include tumor differentiation t stage n stage uicc stage additionally srpk2 association mutant p53 mtp53 sw480 sw620 cell negatively regulate numb wild-type p53 wtp53 response 5-fluorouracil cisplatin treatment hct116 cell moreover srpk2 numb p53 coimmunoprecipitate triple complex without treatment 5-fluorouracil hct116 cell p53 knockdown reverse upregulation wtp53 induce srpk2 silencing chemical agent treatment furthermore overexpression srpk2 increase cell migration invasion decrease chemosensitivity 5-fluorouracil cisplatin hct116 cell conversely srpk2 silencing decrease cell migration invasion increase chemosensitivity 5-fluorouracil cisplatin yet effect reverse p53 knockdown chemical agent treatment result thus reveal novel role srpk2-numb-p53 signaling progression crc demonstrate srpk2 potential therapeutic target crc clinical therapy 
new series 1,2,3-triazole-chalcone hybrid synthesize screen vitro panel 60 human cancer cell line accord nci usa protocol compound 4d 3 4-dimethoxyphenyl chalcone moiety potent derivative inhibit growth rpmi-8226 sr leukemia cell line 99.73 94.95 10 mum respectively also inhibit growth m14 melanoma k-562 leukemia mcf7 breast cancer cell line 80 test concentration 4d show ic50 value less 1 mum six type tumor cell high selectivity index reach 104 fold mcf7 compound 4d show superior activity methotrexate gefitinib sensitive leukemia cell line addition higher comparable activity rest sensitive cell line flow cytometry analysis rpmi-8226 cell reveal compound 4d cause cell cycle arrest g2/m phase induce apoptosis dose dependant manner mechanistic evaluation refer apoptosis induction trigger mitochondrial apoptotic pathway induce ros accumulation increase bax/bcl -2 ratio activation caspase 3 7 9 
molecular interaction tumor cell microenvironment regard onset chemotherapy resistance refer cell adhesion mediate drug resistance cam-dr elucidate mechanism cam-dr breast cancer cell vitro show human mcf-7 mda-mb-231 breast cancer cell decrease sensitivity towards cisplatin doxorubicin mitoxantrone cytotoxicity upon bind collagen type 1 col1 fibronectin fn intracellular concentration doxorubicin mitoxantrone decrease upon cell cultivation col1 cellular cisplatin level remain unaffected since doxorubicin mitoxantrone transporter substrate refer atp binding cassette abc efflux transporter activity activation transporter bcrp p-gp mrp1 show fluorescence assay distinguish individual input transporter resistance presence col1 related expression level western blot abc transporter inhibitor able re-sensitize col1-treated cell doxorubicin mitoxantrone toxicity antibody-blocking beta1-integrin itgb1 induce sensitization towards indicate cytostatic drug attenuate increase abc efflux activity refer key role itgb1 matrix binding subsequent transporter activation downregulation alpha2beta1 integrin follow col1 binding appear clear indication relationship itgb1 abc transporter regulate resistance formation knockdown itgb1 lead significant upregulation three transporter datum provide evidence role cam-dr breast cancer via itgb1 transporter axis offer promising therapeutic target cancer sensitization 
cisplatin main chemotherapeutic drug use treat non-small-cell lung cancer patient however patient commonly face cisplatin resistance role underlying mechanism gemcitabine irinotecan pemetrex docetaxel use single agent combine cisplatin overcome cisplatin-resistant non-small-cell lung cancer explore study mtt assay show gemcitabine alone exhibit stronger cytotoxicity cisplatin-resistant a549 cell irinotecan pemetrex docetaxel meanwhile gemcitabine combine cisplatin show synergistic inhibitory effect cisplatin-resistant cell rna sequencing gene ontology/kyoto encyclopedia gene genome analysis show cell cycle signaling pathway trx-interacting protein factor efficacy cotreatment flow cytometry western blot result show cisplatin-resistant a549 cell cotreate gemcitabine cisplatin g0/g1 phase arrest occur trx-interacting protein upregulate silencing trx-interacting protein attenuate response resistant cell drug combination trx-interacting protein agonist together cisplatin show additive cytotoxic effect resistant cell compare cisplatin alone gemcitabine cisplatin combination compare gemcitabine pbs alone markedly suppress growth cisplatin-resistant a549 tumor vivo accompany increase trx-interacting protein decrease ki67 expression therefore conclude gemcitabine cisplatin fda-approved combination viable therapy cisplatin-resistant non-small-cell lung cancer ex vivo vivo 
background glioblastoma gbm malignant primary brain tumor relapse occur regularly clinical behavior seem due therapy-resistant subpopulation glioma-initiating cell belong group cancer stem cell aldehyde dehydrogenase aldh identify marker cell population show previously aldh1a3-positive gbm cell resistant temozolomide tmz treatment however still unclear aldh expression mediate chemoresistance material method aldh1a3 expression analyze 112 specimen primary secondary surgical resection 56 patient gbm grade iv patient receive combined adjuvant radiochemotherapy experimental analysis crispr-cas9-induced knockout cell three establish gbm cell line ln229 u87mg t98g two glioma stem-like cell line investigate tmz treatment result aldh1a3 knockout cell sensitive tmz oxidative stress seem molecular process aldh1a3 exert role resistance tmz oxidative stress lead lipid peroxidation yield active aldehyde detoxify aldh enzymatic activity metabolic process autophagy induce lead downregulation enzyme aldh1a3 upregulate even higher expression level finish tmz therapy vitro recurrent gbm show significantly higher aldh1a3 expression respective sample primary tumor patient suffer gbm high aldh1a3 expression show shorter median survival time 12 month vs 21 month p .05 conclusion oxidative stress important clinically relevant component tmz-induced therapeutic effect cytotoxicity seem mediate aldehyde result lipid peroxidation aldh1a3 able reduce number toxic aldehyde therefore present molecular explanation role aldh1a3 therapeutic resistance human gbm cell 
structural maintenance chromosome protein 2 smc2 central component condensin complex involve dna supercoiling essential process embryonic stem cell survival smc2 over-expression relate tumorigenesis cancer malignancy inhibition regard potential therapeutic strategy even though drug currently available propose inhibit smc2 intracellular delivery specific antibody smc2 protein strategy aim reduce cancer malignancy target cancer stem cell csc tumoral subpopulation responsible tumor recurrence metastasis order prevent degradation improve cellular internalization anti-smc2 antibody ab-smc2 deliver polymeric micelle pm base pluronic f127 amphiphilic polymer importantly scaffolding ab-smc2 onto nanoparticle allow cellular internalization highly increase efficacy term cytotoxicity inhibition tumorsphere formation mda-mb-231 hct116 breast colon cancer cell line respectively moreover case hct116 cell line g1 cell-cycle arrest also observe contrast effect free ab-smc2 detect case combination therapy anti-smc2 micelle paclitaxel ptx 5-fluorouracil 5-fu also explore ptx 5-fu respectively load anti-smc2 decorate pm efficacy encapsulated drug higher free form hct116 mda-mb-231 cell line remarkably micelle load ab-smc2 ptx show highest efficacy term inhibition tumorsphere formation hct116 cell accordingly datum clearly suggest effective intracellular release antibody target smc2 cell model strong cytotoxicity csc alone combined treatment standard-of-care drug 
aromatase inhibitor ai letrozole femar / femara exemestane aromasin widely use treat estrogen receptor er positive breast cancer postmenopausal patient setting metastatic breast cancer drug may use another cause new response select patient progress first choice precise explanation lack cross resistance still miss neoletexe neoadjuvant randomize open-label cross-over trial postmenopausal patient er-positive her-2 negative locally advanced breast cancer enrol patient randomize treatment start either letrozole exemestane least 2 month follow another 2 month alternative ai total estrogenic activity blood sample determine use aroer tri-screen assay develop chen laboratory use highly sensitive assay estrogenic activity detect three time point patient importantly significantly higher total estrogenic activity find therapy exemestane compare letrozole 21 26 patient letrozole include aroer tri-screen assay estrogenic activity sample collect exemestane treatment reduce suggest low level androgen remain specimen obtain exemestane treatment result suggest aroer tri-screen sensitive method estimate overall estrogen-mediated activity human sample even therapy highly potent aromatase inhibitor present study serum estrogen activity significantly higher exemestane therapy compare letrozole therapy 
basic clinical study small bowel adenocarcinoma sba limit due rare nature cancer establish patient-derived xenograft pdx model tumor tissue advanced sba patient liver peritoneal metastasis cell line pdx pdx model compare control group 5-fluorouracil 5-fu treatment result statistically significant tumor growth inhibition tgi oxaliplatin ohp irinotecan significant inhibitory effect combination 5-fu ohp show highest rate tgi ic50 ohp significantly lower paclitaxel gemcitabine trifluorothymidine pdx-derived cell line compare ht29 colon cancer cell line genetic analysis patient tumor pdx tumor cell line demonstrate consistency microsatellite status mutation tp53 apc hras csf1r fgfr3 flt3 pdgfra ret gene however pdx tumor alone additional mutation indicate pdx-derived cell line may support unstable genetic status pdx finding confirm effectiveness combination ohp 5-fu common treatment advanced sba advance colorectal cancer preclinical model preclinical model sba help understand biology sba 
epithelial ovarian carcinoma eoc lethal gynecological malignancy herein seek determine efficacy phosphoinositide 3-kinase pi3k / akt inhibition use three azd compound nod-scid xenograft mouse model akt regulation panel eight ovarian cancer cell line elevated akt phosphorylation ser473 thr308 cancerous tissue correlate short progression-free survival pfs overall survival os death azd8835 azd8186 inhibit akt phosphorylation azd5363 augment phosphorylation ser473 add compound inhibit akt downstream effector 4e-bp1 p70s6 kinase azd8835 azd5363 sensitize chemoresistant ovarian cancer cell cisplatin paclitaxel treatment azd5363 inhibit col11a1 mrna promoter activity important factor akt regulation chemoresistance ovarian cancer use mouse xenograft model azd8835 azd5363 azd8186 cause significant reduction tumor formation azd compound change mrna expression brca1/brca ovarian cancer cell azd8835 inhibit brca1/brca2 mrna expression p-erk protein expression ovcar-8 cell kras mutation study highlight importance pi3k/akt ovarian tumor progression chemoresistance potential application azd compound especially azd8835 azd5363 therapeutic agent treatment ovarian cancer 
spindle poison chemotherapeutic drug use treatment malignant tumor however numerous patient develop resistance follow chemotherapy present study aim induce polyploidy breast cancer cell use spindle poison nocodazole investigate mechanism polyploid-induced tumor resistance reveal spindle poison nocodazole induce apoptosis hcc1806 cell also induce polyploidy mda-mb-231 cell drug sensitivity polyploid mda-mb-231 cell paclitaxel docetaxel epirubicin 5-fluorouracil oxaliplatin lower original tumor cell however polyploid mda-mb-231 cell sensitive etoposide original tumor cell expression f-box wd repeat domain contain 7 fbw7 decrease expression mcl1 apoptosis regulator bcl2 family member mcl-1 bcl-2 increase caspase-3 / 9 bax express mda-mb-231 cell resistance docetaxel etoposide reverse sensitivity paclitaxel change follow bcl-2 silencing formation polyploidy tumor may one molecular mechanism underlie tumor resistance spindle poison expression bcl-2 family member example fbw7 mcl-1 play key role apoptosis cell escape process form polyploid cell however bcl-2 silencing different reversal effect different anti-tumor drug require investigation 
activate macrophage primary target rheumatoid arthritis ra management report efficacious dual-functional methotrexate mtx loaded folate-conjugated ph-responsive glycol-chitosan nanoparticle mfgcn prepare nano-precipitation zero-order cross-linking reaction target inflamed arthritic tissue physical characterization dls sem tem indicate spherical smooth morphology diameter ~ 300 nm 1h nmr ftir indicate folic acid conjugation gc zero-order cross-linker vitro release kinetics pbs show ph-responsive sustained release behaviour mfgcn enhance cellular uptake cytotoxicity mfgcn lps raw activate peritoneal macrophage mphus observe compare lps raw cell mfgcn-induced mitochondrial membrane potential mmp perturbation indicate apoptosis oxidative stress evident significant increase ros rn 4 h post incubation mfgcn negligible hemolysis fgcn mfgcn rat rbc indicate biocompatibility vivo biodistribution mfgcn adjuvant-induced arthritis aia rat indicate ra targetability prolonged blood circulation couple higher concentration 99mtc-mfgcn arthritic site observe post 24 h injection gamma scintigraphic image confirm accumulation radiolabelled mfgcn arthritic paw compare non-inflamed paw confirm selective uptake 99mtc-mfgcn folate-overexpressing macrophage arthritic synovium thereby prove target efficacy theranostic potential aia rat mfgcn lower arthritic sign improve antioxidant response decrease pro-inflammatory cytokine suggest potential target activate macrophage synovium graphical abstract 
purpose paclitaxel cytotoxic chemotherapy commonly use patient triple negative breast cancer tnbc however resistance paclitaxel cause poor response patient aim study examine role protein phosphatase 1h ppm1h paclitaxel resistance breast cancer patient method investigate function ppm1h paclitaxel treatment conduct vitro assay molecular experiment use stable cell line mda-mb-231 ppm1h overexpress also perform molecular analysis patient tissue sample molecular expression related ppm1h breast cancer patient analyze use tcga datum result investigate whether ppm1h associate paclitaxel resistance breast cancer ppm1h expression upregulate breast cancer cell treat paclitaxel also observe overexpression ppm1h breast cancer cell result increase sensitivity paclitaxel vitro additionally paclitaxel treatment induce dephosphorylation cyclin-dependent kinase cdk inhibitor p27 p27 evident ppm1h-overexpressing cell understand upregulation ppm1h increase paclitaxel sensitivity determine level p27 phospho-p27 cdk2 since cdk2 exert antagonistic effect ppm1h p27 phosphorylation patient-derived xenograft pdx tumor respond paclitaxel show increase level cdk2 phospho-p27 decrease level total p27 compare breast tumor tissue use dinaciclib selective cdk inhibitor significantly inhibit tumor growth pdx model conclusion cdk2 kinase activity significantly upregulate basal breast cancer tumor negatively correlate p27 protein level tcga breast cancer dataset suggest target cdk2 may effective treatment strategy tnbc patient 
background tamoxifen metabolite z-endoxifen demonstrate promising antitumor activity endocrine-resistant estrogen receptor-positive er breast cancer compare antitumor activity z-endoxifen tamoxifen letrozole letrozole-sensitive mcf7 aromatase express model mcf7ac1 well tamoxifen fulvestrant exemestane exemestane plus everolimus letrozole-resistant mcf7 model mcf7lr method mcf7ac1 tumor-bearing mouse randomize control drug letrozole 10 mug/day tamoxifen 500 mug/day z-endoxifen 25 75 mg/kg treatment letrozole arm continue resistance develop mcf7lr tumor-bearing mouse randomize z-endoxifen 50 mg/kg tamoxifen 4 week tumor harvest microarray immunohistochemistry analysis antitumor activity z-endoxifen mcf7lr tumor compare second vivo study exemestane exemestane plus everolimus fulvestrant result mcf7ac1 tumor z-endoxifen dose significantly superior control tamoxifen reduce tumor volume 4 week additionally 75 mg/kg z-endoxifen dose additionally superior letrozole prolonged letrozole exposure result resistance 25 week mcf7lr tumor-bearing mouse z-endoxifen significantly reduce tumor volume compare tamoxifen letrozole exemestane significant difference compare exemestane plus everolimus fulvestrant additionally compare tamoxifen z-endoxifen markedly inhibit eralpha target gene ki67 akt expression vivo conclusion endocrine-sensitive letrozole-resistant breast tumor z-endoxifen result robust antitumor antiestrogenic activity compare tamoxifen aromatase inhibitor monotherapy datum support ongoing development z-endoxifen 
treatment hormone sensitive breast cancer tumor endocrine therapy antiestrogen aromatase inhibitor improve outcome significantly study include show downregulation eralpha pure antiestrogen fulvestrant combination aromatase inhibitor may prolong responsiveness tumor endocrine therapy fulvestrant study second line first line treatment post-menopausal hormone receptor positive breast cancer single agent combination ai study also suggest escalation dose may improve benefit however dose escalation fulvestrant administer via intramuscular injection difficult due poor solubility overcome shortcoming injectable drug novel orally active antiestrogen azd9496 develop addition orally active azd9496 design selective eralpha downregulator serd current study compare effect azd9496 fulvestrant growth mcf-7ca human estrogen receptor positive mcf-7 cell stably transfect human placental aromatase gene xenograft grow ovariectomized athymic nude mouse azd9496 also compare fulvestrant vitro single agent combination anastrozole current study show azd9496 equally effective fulvestrant control growth hormone sensitive human breast cancer tumor similar fulvestrant azd9496 inhibit cellular aromatase activity eralpha mediated signaling however unlike fulvestrant combination azd9496 anastrozole produce increase tumor inhibition result show azd9496 significantly better inhibit cellular aromatase contribute anticancer activity next measure effect azd9496 mouse uterus uterine weight mouse treat azd9496 significantly lower mouse treat androstenedione reduction uterine weight due azd9496 mediate inhibition aromatase activity direct effect uterine eralpha expression also observe anti-cancer efficacy azd9496 depend ability inhibit cellular aromatase result suggest azd9496 may better alternative fulvestrant due selectivity mammary er ability inhibit aromatase addition downregulate eralpha obtain upon oral administration azd9496 may prove better option fulvestrant treatment hormone sensitive human breast cancer 
novel series 5 4-methoxybenzylidene thiazolidine-2,4-dione derivative 5a-g 7a-f design synthesize evaluate anticancer activity hepg2 hct116 mcf-7 cell hepg2 hct116 sensitive cell line influence new derivative particular compound 7f 7e 7d 7c find potent derivative test compound hepg2 hct116 mcf-7 cancer cell line compound 7f ic50 = 6.19 0.5 5.47 0.3 7.26 0.3 microm respectively exhibit higher activity sorafenib ic50 = 9.18 0.6 8.37 0.7 5.10 0.4 microm respectively hepg2 mcf-7 cell lower activity hct116 cancer cell respectively also compound display higher activity doxorubicin ic50 = 7.94 0.6 8.07 0.8 6.75 0.4 microm respectively hepg2 mcf-7 cell nearly activity hct116 cell respectively derivative 5a-g 7a-f evaluate inhibitory activity vascular endothelial growth factor receptor-2 vegfr-2 among compound 7f find potent derivative inhibit vegfr-2 ic50 value 0.12 0.02 microm nearly sorafenib ic50 = 0.10 0.02 microm compound 7e 7d 7c 7b exhibit highest activity ic50 value 0.13 0.02 0.14 0.02 0.14 0.02 0.18 0.03 microm respectively half sorafenib furthermore molecular docking perform investigate binding mode affinity toward vegfr-2 receptor datum obtain docking study highly correlate obtain biological screening 
background mitoxantrone mtx synthetic compound use second line chemotherapeutic drug prostate cancer report trigger immunogenic cell death icd animal model study underlie mechanism fully understand yet especially prostate cancer cell method icd determine assess release damage-associated molecular pattern damp prostate cancer-derived cell line lncap 22rv1 pc-3 short hairpin rna shrna use knock target gene expression phagocytosis assess use dual labeling technology dendric cell co-culture cancer cell perk gene promoter clone dual luciferase assay chromatin immunoprecipitation chip use determine p53 protein-dna binding activity immunocompetent mouse murine rm-1 prostate cancer cell use vaccination experiment result mtx treatment induce typical characteristic damp release include increase cell surface exposure calreticulin calr extracellular release atp high mobility group box-1 hmgb1 protein mtx also enhance phagocytosis dendritic cell moreover mtx treatment increase eukaryotic initiation factor 2alpha eif2alpha s51 phosphorylation reduce perk gcn2 silence use shrna addition perk gcn2 silencing significantly reduce mtx-induced release damp vitro anti-tumor immunity vivo mtx treatment also result dendritic cell activation mouse attenuate perk gcn2 silence cancer cell use vaccination analysis reveal perk gcn2 expression enhance mtx treatment perk gcn2 enhance via p53-dependent mechanism conclusion mtx trigger icd activate eif2alpha via perk/gcn2 upregulation prostate cancer cell mtx-induced perk expression upregulation depend p53 pathway gcn2 require investigation 
order develop potential anticancer agent stimulate apoptosis novel 3,4-isoxazolediamide 4,5,6,7-tetrahydro-isoxazolo 4,5-c pyridine derivative synthetize original structure geldanamycin radicicol know natural heat shock protein hsp inhibitor deeply modify exhibit several drawback poor solubility hepatotoxicity intrinsic chemical instability deprivation vivo activity novel class synthetic compound contain isoxazole nucleus exhibit potent selective inhibition hsp90 previous study biological assay focus vitro antiproliferative effect pro-apoptotic activity human erythroleukemic k562 cell model system refer tumor cell grow suspension glioblastoma u251-mg glioblastoma temozolomide tmz resistant t98g cell line two model system refer tumor cell grow attach flask perform almost isoxazole derivative demonstrate significant antiproliferative pro-apoptotic activity show induction early late apoptosis k562 cell different effect observe glioma u251-mg t98g cell depend structure analogue antiproliferative pro-apoptotic activity k562 cell associate activation erythroid differentiation program present study demonstrate 3,4-isoxazolediamide 4,5,6,7-tetrahydro-isoxazolo 4,5-c pyridine derivative consider vivo study focus development anticancer drug act least partially via activation apoptosis 
objective hepatocellular carcinoma hcc frequently diagnose patient late-stage disease ineligible curative surgical therapy majority patient become resistant sorafenib approved first-line therapy advanced cancer underscore need newer effective drug purpose study expedite identification novel drug sorafenib resistant sr hcc method employ transcriptomics-based drug repurpose method term connectivity mapping use gene signature vitro-derived sr huh7 hcc cell proof concept validation focus drug fda-approved clinical investigation prioritize two anti-neoplastic agent dasatinib fostamatinib target associate hcc also prospectively validate predict gene expression change drug-treated sr huh7 cell well identify validate target fostamatinib hcc result dasatinib specifically reduce viability sr-hcc cell correlate up-regulate activity src family kinase target sr-hcc model however fostamatinib able inhibit parental sr hcc cell vitro xenograft model ingenuity pathway analysis fostamatinib gene expression signature lincs predict jak/stat pi3k/akt erk/mapk pathway potential target fostamatinib validate western blot analysis fostamatinib treatment reverse expression gene deregulate sr hcc conclusion provide proof concept evidence validity drug repurpose approach sr-hcc implication personalized medicine 
anticancer activity novel thiazolidine-2,4-dione evaluate hepg2 hct-116 mcf-7 cell mcf-7 sensitive cell line cytotoxicity new derivative particular compound 18 12 17 16 find potent derivative test compound cancer cell line hepg2 hct116 mcf-7 ic50 = 9.16 0.9 8.98 0.7 5.49 0.5 microm 9.19 0.5 8.40 0.7 6.10 0.4 microm 10.78 1.2 8.87 1.5 7.08 1.6 microm 10.87 0.8 9.05 0.7 7.32 0.4 microm respectively compound 18 12 nearly activity sorafenib ic50 = 9.18 0.6 5.47 0.3 7.26 0.3 microm respectively hepg2 cell slightly lower activity hct116 cell slightly higher activity mcf-7 cancer cell line also compound display lower activity doxorubicin hepg2 hct-116 cell higher activity mcf-7 cell ic50 = 7.94 0.6 8.07 0.8 6.75 0.4 microm respectively contrast compound 17 16 exhibit lower activity sorafenib hepg2 hct116 cell nearly equipotent activity mcf-7 cancer cell line also compound display lower activity doxorubicin three cell line synthesize derivative 7-18 evaluate inhibitory activity vegfr-2 test compound display high medium inhibitory activity ic50 value range 0.17 0.02 0.27 0.03 microm compound 18 12 17 16 potently inhibit vegfr-2 ic50 value 0.17 0.02 0.17 0.02 0.18 0.02 0.18 0.02 microm respectively nearly half ic50 value sorafenib 0.10 0.02 microm 
background/aim glioma malignant tumour human brain still lack effective treatment modality betulin pentacyclic triterpene abundantly find birch bark show demonstrate interesting anti-cancer activity towards many cancer cell determine effect acetylenic synthetic betulin derivative asbd anti-tumour agent glioma cell vitro material method t98g c6 glioma cell viability proliferation determine mtt 3 4,5-dimethylthiazol-2-yl -2,5-diphenyl tetrazolium bromide assay brdu bromo deoxyuridine test respectively cell-cycle progression induction apoptosis investigate flow cytometry result asbd significantly decrease glioma cell viability/survival inhibit proliferation dose-dependent manner vitro moreover asbd cytotoxic clinically use chemotherapeutic temozolomide cisplatin conclusion asbd may consider study potent anti-tumour agent glioma treatment 
current treatment option glioblastoma include chemotherapy limited surgical resection temozolomide tmz current therapeutic choice chemotherapy still severe limitation due development resistance occur genetic modification constitutive activation several cell signaling pathway therefore essential develop combination therapy tmz novel compound prevent development chemo-resistance study use two inhibitor ica inhibitor pkc-iota zeta-stat inhibitor pkc-zeta t98g u87mg glioblastoma cell treat either ica zeta-stat tmz monotherapy well tmz combine either ica zeta-stat five consecutive day vitro result exhibit ica combine tmz significantly decrease viability cancerous cell compare untreated tmz ica monotherapy additionally glioblastoma cell remarkably undergo apoptosis combination treatment tmz ica nucleotide compare untreated control cell suggest annexin-v/pi flow cytometric analysis moreover combination tmz ica also decrease invasion glioblastoma cell line act fak/paxillin pathway evidence scratch assay transwell invasion assay western blot immunoprecipitation analysis furthermore vivo datum present combination ica tmz also reduce glioblastoma tumor growth volume mouse datum suggest atypical pkc particularly pkc-iota might important therapeutic target adjuvant therapy treatment glioblastoma 
glioblastoma multiforme gbm primary brain tumor high degree malignancy classify glioma iv present treatment patient suffer gbm base surgical resection tumor maximal protection surround tissue follow radio pharmacological therapy use temozolomide frequently recommend drug strategy however guarantee success devastating consequence test new substance therapy potential treatment gbm well detection side effect human animal model disease usually use purpose one possibility implantation human tumor cell rodent brain solution use present study purpose comparison elemental anomaly appear brain result implantation different glioblastoma cell line two commercially available cell line u87mg t98g well tumor cell take directly patient diagnose gbm use total reflection x-ray fluorescence determine contents p s k ca fe cu zn se implanted-left intact-right brain hemisphere number elemental anomaly register hemisphere positively correlate invasiveness gbm cell highest animal subject u87mg cell implantation present significant decrease p k cu level increase se concentration within left hemisphere abnormality common three group animal subject glioma cell implantation increase fe level brain may result higher blood supply presence hemorrhaging region case intact hemisphere elevated fe concentration may also indicate higher neuronal activity cause take function left hemisphere impair result tumor growth 
objective aim study identify specific chemosensitivity drug various molecular subtype breast tumor chinese woman detect expression drug resistance gene use drug sensitivity test different molecular subtype breast cancer method expression drug resistance gene include topo ii gst-pi p-gp lrp cd133 detect immunohistochemistry tissue microarray drug sensitivity test include paclitaxel epirubicin carboplatin vinorelbine fluorouracil conduct primary cancer tissue cell cell line include t47d bt-474 mda-mb-231 cell human breast cancer xenograft nude mouse result different drug resistant gene topo ii gst-pi p-gp lrp differentially express among different molecular subtype breast cancer p 0.05 positive expression cd133 highest basal-like breast cancer p 0.05 kaplan-meier survival analysis show positive expression topo ii cd133 correlate shorter disease-free survival dfs p 0.05 overall survival p 0.05 positive expression lrp correlate shorter dfs p 0.05 bt-474 show chemosensitivity paclitaxel epirubicin mda-mb-231 show chemosensitivity paclitaxel epirubicin carboplatin fluorouracil t/c = 50 basal-like her2 breast cancer primary cell show chemosensitivity paclitaxel epirubicin significant difference compare luminal breast cancer primary cell p 0.05 conclusion differential expression drug resistance gene differential chemosensitivity drug different molecular subtype breast cancer suggest individual treatment give type breast cancer 
standard prognostic marker multiple myeloma mm patient revise international staging system r-iss however room improvement guide treatment apply particularly older patient benefit/risk ratio reduce comorbidity subsequent side effect hypothesize add gene-expression datum r-iss generate stronger marker test combine r-iss sky92 classifier sky-riss hovon-87 / nmsg-18 trial eudract 2007-004007-34 compare melphalan-prednisone-thalidomide follow thalidomide maintenance mpt-t melphalan-prednisone-lenalidomide follow lenalidomide maintenance mpr-r trial 168 patient available r-iss status gene-expression profile analyze r-iss stage ii iii assign 8 75 7 patient respectively 3-year overall survival os rate 80 65 33 p = 8 x 10-3 use sky92 classifier 13 patient high risk hr 3-year os rate standard risk sr 70 hr 28 p .001 combine sky92 r-iss result 3 risk group sky-riss sky-sr r-iss-i 15 sky-riss iii sky-hr r-iss-ii/iii 11 sky-riss ii patient 74 3-year os rate sky-riss ii iii 88 66 26 respectively p = 6 x 10-7 sky-riss model validate older patient commpass dataset moreover sky-riss demonstrate predictive potential hr patient appear benefit mpr-r mpt-t median os 55 14 month respectively combine sky92 r-iss classify patient accurately additionally benefit observe mpr-r mpt-t sky92-riss hr patient 
breast cancer heterogeneous disease tumor microenvironment include extracellular component play crucial role tumor progression potentially modulate treatment response different approach use develop three-dimensional model able recapitulate complexity extracellular matrix use cell-free patient-derived scaffold pdss generate breast cancer sample recellularize cancer cell line vivo-like culture system drug testing show pds culture mcf7 cancer cell increase resistance front-line chemotherapy drug 5-fluorouracil doxorubicin paclitaxel comparison traditional two-dimensional cell culture gene expression environmentally adapt cancer cell modulate different way depend drug concentration use high dose doxorubicin reduce cancer stem cell feature whereas 5-fluorouracil increase stemness decrease proliferative phenotype use pdss repopulate breast cancer cell line t-47d mda-mb-231 observe general cell line specific drug response summary pdss use examine extracellular matrix influence cancer drug response testing novel compound vivo-like microenvironment 
glioblastoma multiforme gbm highly lethal aggressive tumor brain carry poor prognosis temozolomide tmz widely use first-line treatment gbm however poor brain targeting side effect drug resistance limit application treatment gbm design temozolomide-conjugated gold nanoparticle functionalize antibody ephrin type-a receptor 3 anti-epha3-tmz@gnps target gbm therapy via intranasal administration system bypass blood-brain barrier target active glioma cell improve glioma targeting tmz enhance treatment efficacy reduce peripheral toxicity drug resistance prepared anti-epha3-tmz@gnps 46.12 2.0 nm suitable intranasal administration demonstrate high safety nasal mucosa toxicity assay vitro study show anti-epha3-tmz@gnps exhibit significantly enhance cellular uptake toxicity higher cell apoptosis ratio see compare tmz 54.9 14.1 respectively toward glioma cell c6 result experiment tmz-resistant glioma cell t98g demonstrate ic50 anti-epha3-tmz@gnps 64.06 0.16 mum 18.5-fold lower tmz addition western blot analysis also reveal anti-epha3-tmz@gnps effectively down-modulate expression o6-methylguanine-dna methyltransferase increase chemosensitivity t98g tmz antiglioma efficacy vivo investigate orthotopic glioma-bearing rat result demonstrate anti-epha3-tmz@gnps prolong median survival time 42 day increase tumor-cell apoptosis dramatically compare tmz conclusion anti-epha3-tmz@gnps serve intranasal drug delivery system efficacious treatment gbm 
background palbociclib selective cyclin-dependent kinase cdk 4/6 inhibitor use combination aromatase inhibitor fulvestrant patient hormone receptor-positive hr human epidermal growth factor receptor 2 her2 negative advanced/metastatic breast cancer abc/mbc palbociclib first cdk 4/6 inhibitor approve hr / her2 abc/mbc treatment canada combination letrozole p+l initial endocrine-based therapy approve march 2016 fulvestrant p+f follow disease progression prior endocrine therapy approve may 2017 ibrance real world insights iris study nct03159195 collect real-world outcome datum palbociclib-treated patient several country include canada method retrospective chart review include woman hr / her2 abc/mbc receive p+l p+f canada physicians review medical record 14 patient abstract demographic clinical characteristic treatment pattern clinical outcome progression-free rate pfr survival rate sr 6 12 18 24 month estimate via kaplan-meier analysis result thirty-three physician examine medical record 247 patient p+l n = 214 p+f n = 33 median follow-up 8.8 month p+l 7.0 month p+f patient initiate palbociclib 125 mg/d p+l 90.2 p+f 84.8 dose reduce 16.6 p+l 14.3 p+f patient initiate palbociclib 125 mg/d pfr p+l 90.3 12 month 78.2 18 month corresponding sr 95.6 93.0 p+f 6-month pfr 91.0 12-month sr 100.0 conclusion dose reduction rate low pfr sr high canadian real-world assessment p+l p+f treatment suggest palbociclib combination well tolerate effective 
new series sulfonamide endowed hydrazone couple dimethyl and/or diethyl malonate prepare various sulfa drug diazotize follow coupling active methylene dimethyl and/or diethyl malonate afford new intermediate hydrazone 3a-c 4a-c reactivity hydrazone derivative towards hydrazine investigate thus novel series 3,5-dioxopyrazolidine7a-cwere obtain treatment hydrazine hydrate hydrazone allow react phenyl hydrazine alkyl 2 4 n substitute sulfamoyl phenyl diazenyl -3-oxo-3 2-phenylhydrazinyl propanoateswere obtain 8a-c and/or 10a-c anticancer activity evaluate hepg2 hct-116 mcf-7 hepg2 sensitive one particular compound 7c 7b 10c find potent derivative ic50 = 6.43 0.5 9.66 0.8 10.57 0.9 microm 8.65 0.7 7.49 0.6 14.29 1.3 microm 8.97 0.7 10.13 0.9 13.82 1.1 microm respectively sorafenib doxorubicin use reference drug potent derivative 7a 7b 7c 8c 10c test cytotoxicity normal vero cell line compound 7a 7b 7c 8c 10c respectively 2.41 4.85 4.08 3.23 5.89 fold time toxic hct116 vero normal cell moreover active anti-proliferative derivative 7a 7b 7c 8c 10c subject biological study evaluate inhibitory potential vegfr-2 test compound display high good inhibitory activity ic50 value range 0.14 0.02 0.23 0.03 microm among compound 7c 7b 10c find potent derivative inhibit vegfr-2 ic50 value 0.14 0.02 0.15 0.02 0.15 0.02 microm respectively sorafenib use reference drug furthermore admet profile evaluate four active compound comparison doxorubicin reference drug datum obtain docking study highly correlate obtain biological screening 
three new human cell line establish biopsy specimen ovarian cystadenocarcinoma line ja-1 derive primary solid tumour untreated patient whilst line derive ascite patient previously treat chlorambucil plus either cyclophosphamide tr175 cisplatin tr170 vitro characteristic compare established sk-ov-3 line similar origin line distinct morphology express unique isozyme profile karyotype 4 line comparable population double time 28-38 hr 3 line reproducibly form colony soft agar ja-1 line fail clone readily produce xenograft nude mouse drug sensitivity testing use clonogenic growth-inhibition assay show line express wide range sensitivity cisplatin greater 20-fold tr175 cell prove particularly sensitive narrower range sensitivity less equal 10-fold adriamycin follow 6 24-hr pulsed exposure vitro drug concentration ic50 ic90 value significant resistance develop adriamycin line test contrast cisplatin treatment line retain original sensitivity except tr170 cell expose highest concentration express cisplatin resistance 
lethal non-lethal effect l-buthionine-sr-sulfoximine bso sulfhydryl-dependent anticancer agent shdaa investigate mouse agent study include carmustine bcnu cyclophosphamide ctx doxorubicin dox melphalan lpam show normal mouse bso nontoxic give ip po dose 5 g/kg pharmacodynamic study two different dose bso cd-1 mouse liver kidney heart demonstrate diurnal variation thiol content dose-dependent depression tissue non-protein sulfhydryl npsh level acute lethal survival study mouse treat ctx bso exhibit increase lethality seizure possible cause death effect see bcnu dox lpam evaluation organ-specific biochemical marker show slight elevation ldh enzyme level bone marrow suppression enhance use vivo spleen colony assay vitro colony form unit myelotoxicity assay result show addition bso shdaa enhance acute lethality agent ctx may also increase non-myelosuppressive toxicity agent recommend bso use caution combination shdaa monitoring hepatic enzyme routinely perform 
five human glioma tumor line transplant subcutaneously athymic nude mouse three line d-54 mg u-118 mg u-251 mg derive permanent human glioma cell line two line n-456 n-519 establish direct xenograft mouse growth rate vary among line treat common average tumor volume 200-300 mm3 three drug known clinical activity human anaplastic glial tumor test system procarbazine pcb produce significant response five tumor line carmustine produce significant growth delay two mithramycin produce slight growth delay one carmustine-pcb combination produce greater therapeutic effect either agent alone d-54 mg combination effective pcb alone u-118 mg result parallel clinical experience indicate useful model test agent potential activity brain tumor therapy 
effect treatment ethinyl-estradiol tamoxifen prednisolone cyclophosphamide methotrexate 5-fluorouracil adriamycin activity pfk 6pgdh alpha-gpdh alpha-gpdh/6pgdh ratio investigate mcf-7 cell monolayer culture follow finding record ethinyl-estradiol prednisolone fail induce alteration activity enzyme tamoxifen increase activity pfk alpha-gpdh alpha-gpdh/6pgdh ratio whereas ethinyl-estradiol inhibit tamoxifen-induced rise activity pfk treatment cyclophosphamide alone without effect combination either methotrexate 5-fluorouracil induce increase activity 6pgdh alpha-gpdh adriamycin lower dose increase activity 6pgdh alpha-gpdh alpha-gpdh/6pgdh ratio decrease activity pfk higher dose level reduce activity enzyme whilst increase alpha-gpdh/6pgdh ratio datum encourage undertake project test sensitivity individual tumour drug vitro thereby enable selection appropriate drug adjuvant therapy 
effect methotrexate 5-fluorouracil 5-fluoro-2 deoxyuridine growth human leukemic t-lymphoblast ccrf-cem determine function drug concentration exposure time substantial inhibition cell growth greater equal 90 obtain short duration exposure 4 h mtx ed90 = 4.3 microm 5-fluorouracil relatively ineffective cytotoxic agent exposure short duration 4 h exposure 24 72 h result cell growth inhibition greater equal 90 drug term ed90 5-fluoro-2 deoxyuridine 190 1300-fold active 5-fluorouracil 24 72 h exposure respectively 0.4 vs 75 microm 0.01 vs 26 microm sequential exposure methotrexate 4 h 5-fluorouracil last 2 h methotrexate exposure result synergistic inhibitory effect cell growth antagonistic inhibitory effect cell growth methotrexate 5-fluoro-2 deoxyuridine combination observe independently drug concentration pretreatment 4h 5-methyltetrahydrofolate reduce folate leucovorin rapidly convert vivo potentiate cell growth inhibitory effect subsequently administer 5-fluorouracil 5-fluoro-2 deoxyuridine result provide information scheduling methotrexate reduce folate fluoropyrimidine might potential importance development clinical trial design patient leukemia lymphoma 
twenty patient postsurgical modify stage ii t2 n1 m0 t1 n1 m0 non-small cell bronchogenic carcinoma see 1974 1981 evaluate retrospective manner fifteen patient t2 n1 m0 lesion 5 patient t1 n1 m0 disease eight patient treat surgical resection alone seven die median survival 12.0 month four patient receive surgical resection postoperative radiation therapy two die median survival reach 37 month eight patient treat surgical resection radiation therapy adjuvant chemotherapy include cyclophosphamide c doxorubicin methotrexate m procarbazine p six patient alive free disease median survival yet reach 72 month significant survival advantage 12 patient treat combined modality therapy surgical resection radiation therapy surgical resection radiation therapy chemotherapy compare eight patient treat sr alone p less 0.01 eight patient receive chemotherapy versus 12 patient p less 0.01 spite thorough clinical surgical staging patient t1 t2 primary tumor n1 disease high relapse rate predominantly metastatic site adjuvant radiation therapy chemotherapy appear benefit patient modify stage ii non-small cell bronchogenic carcinoma 
study effect various immunosuppressive drug growth human-derived t molt-4 b mgl-8 lymphoblast addition examine whether lymphotoxic effect drug attribute inhibition either adenosine deaminase ada purine nucleoside phosphorylase pnp result indicate 1-beta-d-arabinofuranosylcytosine ara-c methotrexate chlorambucil four seven time toxic t b cell azathioprine 6-thioguanine 6-mercaptopurine 5-fluorouracil highly toxic t b cell cyclophosphamide oxisuran lymphotoxic concentration exceed 300 microm deoxyadenosine 50 microm deoxyguanosine 10 microm deoxycoformycin 10 microm fail enhance t cell toxicity individually combine drug none drug test inhibit t b lymphoblast ada pnp activity exception ara-c neither datp dgtp accumulate t lymphoblast incubate presence drug conclude cell culture system use investigation useful identify lymphotoxic t cell-specific immunosuppressive agent however none drug study appear function inhibitor competitive substrate either ada pnp 
one hundred eight child acute lymphocytic leukemia admit prospective therapeutic regime remission induction achieve 94 case vincristine l-asparaginase adriamycine prednisone one hundred one patient receive three intermediate dose methotrexate mtx infusion combine intrathecal mtx follow l-asparaginase 24 h later high risk hr patient n = 50 treat addition high dose cyclophosphamide ara-c 3 week one hundred one patient receive cranial irradiation 1,800 rad standard risk sr patient 2,400 rad hr-patient intrathecal mtx maintenance therapy perform usual two drug combination daily 6 mercaptopurine 6 mp weekly mtx orally base phenotype 67 patient common type pre-t t-cell type 18 six per cent patient leukemic blast express common t-cell marker c/t-type 9 acute undifferentiated leukemia aul 108 101 achieve complete remission 6 patient die induction therapy 1 non-responder 9 patient relapse four patient die continuous complete remission ccr 101 patient 30 month probability ccr 0.85 / 0.05 51 patient standard risk ccr probability 0.98 / 0.03 50 patient high risk index 0.65 / 0.11 patient c-all ccr survival 0.85 / 0.07 t pre-t-all 0.88 / 0.09 5 patient c/t-all alive ccr study pediatric aul patient unfavourable prognosis 
methotrexate daunomycin chlorambucil independently conjugate immune goat gamma-globulin specifically raise ph1 chronic myelogenous leukemia cell line k-562 drug-antibody conjugate test myelosarcoma make k-562 cell grow nude mouse efficacy compare drug alone gamma-globulin mixture two conjugate drug normal goat gamma-globulin conjugation method methotrexate daunomycin abrogate antibody activity indicate absence complement-mediated cytotoxicity conjugate vitro lack effect myelosarcoma vivo simultaneous administration either drug antibody partially abrogate development myelosarcoma chlorambucil-antibody conjugate however retain cytotoxicity vitro find effective vivo first successful attempt covalently bind chlorambucil gamma-globulin without loss drug antibody biological activity although simultaneous administration chlorambucil gamma-globulin conjugate drug gamma-globulin reduce growth myelosarcoma considerably immune gamma-globulin alone either reduce weight larger degree eliminate growth completely result study indicate myelosarcoma make k-562 cell grow nude mouse good reproducible model testing various therapeutic agent advantage use human cell proliferate vivo environment bring experimental therapy one step closer clinical trial 
miso substantially enhance cell killing action variety cytotoxic drug large intramuscular lewis lung tumor normal bone marrow differential response explain hypoxic environment necessary requirement miso enhancement test hypothesis directly determine enhancement factor cytotoxicity melphalan cyclophosphamide cyc 5-fluorouracil 5-fu administer simultaneously miso 750 mg/kg melphalan cyc 1000 mg/kg 5-fu four experimental system know differ oxygenation status 250 mg intramuscular i.m. lewis lung tumor less 2 mg lung tumor single tumor cell trap pulmonary capillary normal bone marrow clonogenic cell assay use produce dose response curve enhancement factor express survival curve slope ratio sr drug alone versus drug miso hypoxic i.m. tumor sr 1.6 1.9 wee obtain whereas better oxygenate test system sr range 1.0 1.3 although result consistent proposal hypoxia might important miso enhancement cytotoxic drug action exclude possibility factor may responsible 
ht-29 human colon tumor cell grow spheroid evaluate model system measure response human colon tumor cell antineoplastic agent ht-29 cell capacity form spheroid 1 mm diameter grow spinner culture multicellular ht-29 spheroid develop hypoxic center reflect cellular condition find human cancer treatment i.e. nutritionally deficient hypoxic cell feel significant source radiation chemotherapy clinical treatment failure spheroid increase size radiate disperse single cell colony survival assay compare irradiated single cell suspension spheroid cell demonstrate significant increase radioresistance grow spheroid develop complex radiation survival curve variable respect size spheroid drug 5-fu study examine preliminary fashion interaction resistant cell fraction direct cytotoxicity assay 5-fluorouracil 5-fu exhibit cytotoxic cytostatic effect drug present concentration greater 0.4 microgram/ml interaction 5-fu x-rays ht-29 spheroid complex dependent type assay employ spheroid size versus clonogenicity effect allopurinol agent protect cell 5-fu toxicity examine allopurinol concentration 100 microgram/ml find protect human colonic carcinoma cell cytotoxic effect 5-fu condition resemble find vivo overall ht-29 spheroid system appear b interesting model study variety drug/x-ray interaction vitro may prove capable answer specific question preclinical clinical relevance 
effect prolonged exposure 2 10 microm 6-mercaptopurine 6mp human lymphoblastic t-cell line molt-4 study respect cell-kinetic parameter phosphoribosyl pyrophosphate prpp purine ribonucleotide level formation 6mp-nucleotide especially methyl-thio-imp me-timp dna rna synthesis 32p incorporation 8-14c 6mp incorporation newly synthesize dna rna result provide new insight complex mechanism action 6mp human malignant lymphoblast exposure 2 microm 6mp result rapid inhibition purine de novo synthesis pdns increase level me-timp result increase prpp level decrease purine ribonucleotide affect cell growth clonal growth less cell death dna synthesis decrease associate increase delay cell s phase incorporation thioguanine nucleotide newly synthesize dna result increase arrest cell g2 m phase rna synthesis initially decrease recover partially associate recovery purine ribonucleotide new formation 6mp-nucleotide timp detect within first 24 hr 6mp level culture medium already undetectable 6 hr exposure 2 microm indicate high rate incorporation complete conversion 6mp within period incorporation 6mp-nucleotide dna 5 time high incorporation rna exposure 10 microm 6mp result early cytotoxicity 24 hr associate complete inhibition pdns large pool me-timp lower level purine ribonucleotide compare 2 microm 6mp severe delay cell s phase associate inhibition dna synthesis 14 control within first 24 hr arrest g2 m phase increase level me-timp cause arrest cell late cytotoxicity s phase 48 hr prevent progression g2 m phase datum suggest inhibition pdn due me-timp crucial event mechanism 6mp cytotoxicity responsible decrease rna synthesis decrease availability natural deoxyribonucleotide cause delay dna synthesis s phase enhance incorporation 6mp thioguanine nucleotide dna s phase subsequent late cytotoxicity g2 phase however high concentration 6mp large pool me-timp cause severe reduction natural deoxyribonucleotide lymphoblast active pdns abstract truncate 400 word 
angiogenesis inhibitor o chloroacetyl-carbamoyl fumagillol tnp-470 show antitumor activity three human cancer xenograft system tnp-470 potently inhibit tumor growth hormone-independent prostate cancer pc-3 cell breast cancer mda-mb-231 cell dose dependently weekly s.c. dose 50-200 mg/kg maximum inhibition 96 88 tumor growth 4 12 respective control experiment combination therapy chemotherapeutic agent combination tnp-470 100 mg/kg cisplatin 5 mg/kg show additive antitumor effect treat versus control 38 22 5 pc-3 carcinoma 5-fluorouracil adriamycin alone significantly inhibit mda-mb-231 tumor growth treat versus control 131 64 respectively tnp-470 also inhibit tumor growth widr colon cancer although inhibition less marked treated versus control 39 observe hormone-independent cancer use study vitro study cell line test considerably insensitive tnp-470 monolayer culture 50 inhibitory concentration approximately 5 micrograms/ml whereas tnp-470 inhibit anchorage-independent growth pc-3 mda-mb-231 cell 50 inhibitory concentration 0.05 470 ng/ml respectively inhibitory activity tnp-470 anchorage-independent growth correlate well vivo antitumor activity among cell line test thus inhibitory action may partly contribute potent antitumor activity angiogenesis inhibitor tnp-470 least case pc-3 mda-mb-231 result suggest hormone-independent prostate breast cancer may appropriate target disease tnp-470 clinical trial 
use mercaptopurine mp rather thioguanine tg treatment childhood acute lymphoblastic leukemia occur historical reason pharmacologic basis purpose study begin address whether tg efficacious mp treatment childhood preclinical cytotoxicity study perform use human leukemic cell line leukemic cell patient first concentration-survival curve mp tg three human leukemic cell line molt-4 ccrf-cem wilson determine second group experiment determine concentration-time dependence cytotoxicity mp tg final group experiment compare vitro cytotoxicity mp tg leukemic cell patient thiopurine display classical anti-metabolite cytotoxicity profile exhibit cytotoxicity threshold concentration demonstrate increase cell kill prolongation exposure drug mp cytotoxicity threshold approximately 1 microm maximum cytotoxicity occur 10 microm concentration tg threshold 0.05 microm maximum cytotoxicity occur 0.5 microm exposure mp 8 h necessary produce cytotoxicity whereas exposure short 4 h require tg leukemic cell child also sensitive tg mp median ic50 tg 20 microm significantly lower mp = 206 microm datum present provide strong rationale evaluate tg place mp treatment childhood direct intracellular activation pathway higher potency shorter duration drug exposure necessary cytotoxicity suggest tg may advantage mp 
bivariate flow cytometric analysis proliferate cell nuclear antigen pcna perform prostate carcinoma cell line pc-3 du-145 cell line 100 methanol fixation provide optimal fluorescence intensity pcna ratio pcna/dna increase late g1 early s/phase follow decrease mid late s enhancement g2/m phase pcna expression increase g2/m phase cell treat 48 h vinblastine slight decrease pcna expression observe cyclohexamide treatment hydroxyurea induce increase s-phase fraction along enhance pcna expression methotrexate adriamycin little effect cell cycle compartment pc-3 du-145 however methotrexate decrease pcna expression adriamycin enhance cisplatin increase s-phase cell line increase pcna expression pc-3 decrease du-145 cell datum effect drug treatment point dissociation pcna expression s-phase fraction calculate dna distribution case e.g. cisplatin study different effect obtain two different cell line treat drug whether change pcna expression will provide useful information s-phase fraction evaluation potential antitumor drug know 
response dld-1 hct-15 human colon adenocarcinoma cell hyperthermia 5-fluorouracil 5-fu / leucovorin carboplatin tumor necrosis factor-alpha singly multiple combination evaluate clonogenic assay combination hyperthermia lower dose combination result survival fraction 0.005 0.001 cell type whereas estimate additive interaction alone result survival fraction 0.5 dld-1 0.05 hct-15 survival fraction 0.00001 greater observe higher dose level combine hyperthermia whereas additive interaction alone achieve decrease 0.001 0.0001 survive fraction combination three modality either dose level condition hyperthermia normothermia achieve statistically significant apparently supra-additive loss clonogenicity hct-15 cell similar result obtain lower dose level dld-1 cell result suggest human colon tumor cell markedly sensitive combination modality use clinically achievable dose level 
march 1984 may 1988 212 child acute lymphoblastic leukemia enrol protocol tcl-842 68 patient classify standard risk sr 56 intermediate risk ir 88 high risk hr group remission induction three group consist vincristine vcr prednisolone pred l-asparaginase l-asp one consolidation course cyclophosphamide cp cytarabine arac use sr ir group two course give patient hr group central nervous system prophylaxis randomize use either cranial irradiation 18 gy 5 intrathecal methotrexate mtx triple maintenance reinforcement cycle employ periodically maintenance therapy basically 6-mercaptopurine mtx vary among three group four-week oral pred every 16 week sole reinforcement agent sr. two-week vcr dexamethasone dex adriamycin cp cycle use reinforce ir hr different interval five third-form cycle vcr+dex+a rac use hr treatment discontinue three year patient achieve continuous complete remission ccr eight patient die induction phase eight fail achieve complete remission cr cr rate sr 97 ir 98 hr 83.3 overall rate 91.8 30 june 1991 33 patient drop 12 die remission 52 relapse twenty-eight sr 26 ir 29 hr patient remain ccr median follow-up duration 66 month 38-88 month abstract truncate 250 word 
anthracenedione mitoxantrone mtx examine activity toward ryanodine-sensitive ca release channel i.e. ryanodine receptor ryr rat cardiac sr singly combination doxorubicin dxr mtx dxr exhibit antithetical activity toward ryr condition promote channel closure dxr enhance binding 3h ryanodine ec50 = 44 microm whereas mtx higher affinity ec50 = 25 microm 10-fold lower activity towards activate ryr unlike dxr mtx assay condition promote channel activation inhibit binding 3h ryanodine ic50 = 3.3 microm alter potency ca activate ryr presence absence mg presence mg mtx alter kob slow k-1 3h ryanodine binding whereas dxr accelerate kob little change k-1 antithetical behavior mtx dxr ryr raise possibility mtx antagonize ability dxr activate ryr drug present combination consonance hypothesis mtx inhibit dxr 60 microm sensitize 3h ryanodine-binding site dose-dependent manner ic50 = 8.4 microm shift ec50 dxr-activated 3h ryanodine-binding without reduce maximum occupancy attain high dxr concentration reveal competitive nature interaction dxr mtx mtx singly alter active ca accumulation sr show fully inhibit dxr-induced ca release result suggest mtx antagonize dxr-activated ryr bind mutually exclusive site may provide rational basis combination therapy aim extend current dose limit dxr 
glutathione gsh glutathione s-transferase gst play important role protection cell toxic effect many electrophilic drug chemical modulation cellular gsh and/or gst activity level provide potentially useful approach sensitize tumor cell electrophilic anti-cancer drug study describe interaction four representative alkylating agent aa melphalan 4-hydroperoxy-cyclophosphamide 4hc activate form cyclophosphamide 1,3-bis 2-chloroethyl -1-nitrosourea bcnu cisplatin gsh gst human breast cancer cell line mcf-7 depletion cellular gsh pool approximately 80 treatment cell gsh synthesis inhibitor buthionine sulfoximine bso sensitize tumor cell aa different extent dose-modifying factor 2.39 2.21 1.64 1.27 observe melphalan 4hc cisplatin bcnu respectively treatment cell gst inhibitor ethacrynic acid ea fail show significant effect cytotoxicity aa however ea potentiate cytotoxicity melphalan give combination bso effect may due complete depletion cellular gsh level combined modulator treatment follow 1-hr exposure cytotoxic-equivalent concentration aa gsh level decrease substantially case 4hc bcnu increase 30-50 case cisplatin melphalan bso pretreatment largely block effect cisplatin melphalan cellular gsh enhance gsh-depleting activity 4hc bcnu basis result conclude gsh affect cytotoxicity different aa different extent b basal gst expression mcf-7 cell play major role aa metabolism c ea potentiate enhancing effect bso melphalan cytotoxicity mcf-7 cell d depletion cellular gsh pretreatment bcnu cyclophosphamide may correspond useful strategy enhance anti-tumor activity aa give sequential combination 
methotrexate analog edatrexate show greater antitumor activity improve therapeutic index compare parent compound preclinical system study suggest edatrexate may broad role treatment solid tumor information regard edatrexate combination chemotherapeutic agent limit evaluate interaction edatrexate cisplatin vitro assess median-effect analysis a549 human lung-cancer cell line effect dose exposure time schedule dependence assess cytotoxicity evaluate use tetrazolium-based colorimetric mtt assay inhibitory concentration produce 50 absorbance ic50 edatrexate 1 h exposure 1.4 microm combination experiment edatrexate dose fix 0.2 microm ic10 whereas cisplatin cddp concentration vary 1 3 24-h exposure either edatrexate treatment drug interaction assess use combination-index method define median-effect analysis synergistic interaction document experiment edatrexate apply prior cddp combination index 1 combination study edatrexate use prior cddp result significant reduction three cddp ic50 value 1-h ic50 30.0 3.9 microm 3-h ic50 21.3 1.4 microm 24-h ic50 1.7 0.03 microm contrast synergism observe experiment edatrexate treatment occur cisplatin exposure median-effect analysis useful method determine drug interaction present study combination edatrexate cddp demonstrate schedule-dependent synergism synergism observe setting edatrexate treatment cddp exposure due potential broad spectrum activity edatrexate plus cddp study warrant determine mechanism responsible synergism investigate combination variety tumor model 
background active isomer leucovorin lv lv-6s compare racemic form lv-6r s inactive form lv-6r material method pharmacokinetic study lv-6s 6r s perform normal volunteer patient growth pediococcus cerevisiae pc lv-dependent strain measure 3 form lv ccrf-cem leukemic human cell line use compare effect lv-6s 6r s 6r rescue methotrexate mtx cytotoxicity 5-fluorouracil 5-fu result lv-6s exhibit pharmacokinetic pattern similar obtain lv-6r s whatever route use oral intravenous growth pc similar active isomer racemic form unnatural isomer lv-6r promote growth cell expose mtx 10 -7 10 -5 m rescue mtx cytotoxicity lv-6s lv-6r s concentration 100 200 fold higher whereas lv-6r reverse toxic effect mtx enhancement cytotoxicity induce 5-fu 10 -4 m obtain preexposure cell lv-6s lv-6r s lv-6r exhibit synergistic effect conclusion lv-6s similar effect lv-6r s vitro vivo half dose clinical use prevent possible interference inactive isomer especially patient receive high dose lv 
major mechanism underlie cytotoxicity fluoropyrimidine analog 5-fluorouracil 5-fluoro-2 deoxyuridine fdurd occur via formation 5-fluoro-2 deoxyuridylate fdump tight-binding inhibitor thymidylate synthase ts genetic variation structure ts molecule important determinant response fluoropyrimidine variation may affect binding fdump enzyme previous study show colonic tumor cell line hct116 express two structurally distinct ts polypeptide differ presence tyrosine histidine residue 33 compare tyr-33 form his-33 form confer 3-4-fold level fdurd resistance cell postulate derive reduce affinity enzyme fdump n5,n10-methylenetetrahydrofolate ligand require formation stable inhibitory complex present study tyr-33 his-33 form purify homogeneity property compare detail km value dump n5,n10-methylenetetrahydrofolate ts reaction significantly different two enzyme contrast catalytic efficiency kcat 8-fold lower his-33 form kinetic equilibrium binding measurement demonstrate dissociation constant fdump binding ternary complex 3-4-fold higher his-33 form show due decrease rate fdump association enzyme increase rate fdump dissociation ternary complex ts form contain phenylalanine residue 33 create site-directed mutagenesis show similar tyr-33 enzyme regard kcat ph/activity profile effect fdurd response thus presence histidine residue 33 rather absence tyrosine responsible alteration catalytic ligand-binding function exhibit his-33 form possible mechanism histidine residue perturb structure ts active site discuss 
study metastatic behavior five human colon tumor cell line ls174t widr caco-2 sw 620 sw 480 use intrasplenic-nude mouse isms intravenous-nude mouse ivms model system ls174t highly metastatic system ivms system ls174t cell produce lung metastasis also grow skin cell inject subcutaneously also study anti-metastatic activity three anticancer drug 5-fluorouracil 5-fu doxorubicin dx 1,3-bis 2-chloroethyl -1-nitrosourea bcnu use ls174t cell ism ivm system drug give intravenously day 19 26 tumor cell injection mouse sacrifice organ observe metastatic growth 4-6 week cell injection result show isms system bcnu 5-fu inactive liver metastasis primary growth spleen dx inhibit metastatic growth primary growth ivms system bcnu inactive whereas 5-fu dx active metastatic growth thus dx may activity blood-borne human colon tumor metastasis 
glutathione gsh glutathione-s-transferase gst implicate resistance tumor cell certain alkylating agent include melphalan glutathione level gst activity determine melphalan-resistant subline human prostate carcinoma cell line du 145 pc-3 lncap produce serial treatment melphalan progressively increase concentration resistant subline m4 .5 du145 m5du145 m6du145 m6pc-3 m6lncap 27 7 3 6 2-fold resistant melphalan parental line melphalan-resistant du 145 pc-3 line show cross-resistance cisplatin tetraplatin retain sensitivity vinblastine colchicine etoposide interestingly subline also resistant methotrexate adriamycin melphalan-resistant lncap line show slight resistance cisplatin adriamycin remain sensitive tetraplatin methotrexate line also retain sensitivity vinblastine develop resistance colchicine intracellular gsh level increase 2.8 fold m5du145 1.7 fold m6pc-3 2.1 fold m6lncap compare parental line whereas gst activity use chlorodinitro-benzene substrate comparable line cumene hydroperoxide use substrate increase gst activity note m6pc-3 line compare parent line western blot analysis show change gst isozyme profile parent resistant du 145 line however mu class isoenzyme detect resistant parent pc-3 line use yb1 antibody m5du145 cell maintain absence melphalan seven month maintain resistance melphalan depletion gsh buthionine sulfoximine control level reverse melphalan resistance control level 
characteristic cell death investigate exposure ccrf-cem f2 cell five drug broad concentration range glucocorticoid dexamethasone dxm mitotic inhibitor vincristine vin three antimetabolite methotrexate mtx 5 fluoro-2 deoxyuridine fudr 5 fluorouracil 5-fu drug-treated cell monitor cell death mechanism different time examine pattern dna degradation cell morphology flow cytometric profile together effect cell growth 72 h growth-inhibitory drug concentration first change cell cycle perturbation detectable 4-6 h drug exposure appearance feature characteristic apoptotic cell death note drug treatment ccrf-cem f2 cell line pattern kinetics vary considerably vin induce apoptotic change 12 h dxm treatment cause apoptosis 48 h. mtx fudr induce morphological change characteristic apoptosis least 24 h internucleosomal dna cleavage detectable 48 h contrast 5-fu cause internucleosomal dna cleavage 48 h concentration despite presence morphologically apoptotic cell 24 h earlier datum suggest disruption cell cycle cause drug treatment may common trigger initiate drug-specific apoptotic sequence die cell 
interleukin-11 rhil-11 cytokine show enhance recovery bone marrow intestinal crypt cell cytotoxic insult radiation anticancer drug current study examine effect rhil-11 response cem human lymphoblastic leukemia cell emt-6 murine mammary carcinoma vivo cytotoxic anticancer therapy exposure cem cell rhil-11 24 hr alter cytotoxicity melphalan radiation increase cytotoxicity cddp 100 mum 4-hydroperoxycyclophosphamide 50 betam decrease cytotoxicity 5-fluorouracil ara-c toward cell treatment mouse bear emt-6 tumor rhil-11 twice daily 4 day prior day cytotoxic therapy result significant change tumor cell killing bone marrow cfu-gm killing melphalan cyclophosphamide thiotepa cddp radiation 5-fluorouracil ara-c administration rhil-11 twice per day day 7-18 emt-6 tumor bearing animal receive high dose chemotherapy melphalan thiotepa cyclophosphamide single dose day 7 follow mobilize peripheral blood cell day 8 rhg-csf day 8-20 tend prolong tumor growth delay produce drug rhil-11 treatment also result rapid recovery white blood cell granulocyte animal furthermore animal treat rhil-11 improve survival rate compare animal receive normal tissue support without rhil-11 
fluoroglutamate-containing analog folate methotrexate mtx altered capacity poly gamma-glutamate metabolism synthesize probe biological role polyglutamate compare folic acid dl-e t-gamma-fluorofolic acid compound poor substrate polyglutamylation approximately 25-fold less potent promote growth folate-depleted h35 rat hepatoma cell dl-beta beta-difluorofolic acid compound form diglutamate readily folic acid least equivalent folic acid potency leucovorin lv reduce folate 30-fold potent folic acid promote growth whereas analogous form dl-e t-gamma-fluorofolate dl-e t-gamma-fluoroleucovorin dl-e t-gamma-flv 4-fold potent folic acid lv dl-e t-gamma-flv protect rescue cell growth inhibitory effect mtx however 37 46-fold higher concentration fluoro analog require folic acid dl-e t-gamma-fluorofolic acid lv dl-e t-gamma-flv potentiate growth inhibitory effect 5-fluoro-2 deoxyuridine ccrf-cem human leukemia cell higher concentration fluorinate analog require stereochemically pure l-t-gamma-fluoromethotrexate l-t-gamma-fmtx poor substrate polyglutamylation evaluate cell growth inhibitor continuous exposure l-t-gamma-fmtx 7-fold less potent mtx inhibitor ccrf-cem growth result fluorinate folate mtx analog offer insight importance polyglutamate metabolism biological pharmacological effect 
originally design antitumor agent zidovudine azt exhibit marginal tumor growth inhibitory activity recently three abstract describe positive clinical outcome small number patient advanced breast cancer treat weekly infusion either methotrexate cisplatin azt consequently conduct preclinical study anti-breast cancer anti-mammary tumor activity azt demonstrate azt alone preferential vitro vivo effect breast mammary cancer cell 1000 time potent inhibitor vitro growth human breast cancer cell line mcf-7 ic50 = 10 / 5 nm growth t-cell leukemia cell line cem ic50 = 14 / 2 microm novel mechanism preferential effect growth indicate 3-4-fold increase production phosphorylate azt mono di triphosphate mcf-7 relative cem extend vitro observation vivo study rat find azt potent vivo inhibitor growth methylnitrosourea-induced rat mammary tumor without apparent toxic effect internal organ preclinical result demonstrate first time azt significant anti-breast cancer activity strongly suggest clinical usefulness drug worthy investigation 
purpose test number established human tumor cell line early passage breast cancer uacc2150 melanoma cell uacc1273 growth scid mouse tumor response conventional chemotherapeutic drug method establish melanoma a375 c81-61 colon sw480 lung a549 lymphomoblastoid leukemia lcl-b promyelocytic leukemia hl60 prostate pc-3 du145 breast mcf7 cell line inject subcutaneous s.c. intraperitoneal i.p. mammary fat pad mfp site tumor volume growth curve survival curve establish various tumor cell line carmustine bcnu cisplatin cddp cyclophosphamide cpa doxorubicin dacarbazine dtic tamoxifen vincristine inject s.c. i.p. chemotherapeutic drug effect tumor volume survival determine result tumor growth occur cell type i.p. injection 90 mortality occur within 26 60 day except early passage melanoma cell line uacc1273 mortality occur within approximately 90 day mcf7 breast model treatment tamoxifen p 0.001 cpa p 0.0001 result significant tumor growth delay compare control group bcnu cddp result significant tumor growth delay relative control sw480 colon cancer p 0.0014 a375 melanoma p 0.0001 model respectively cpa doxorubicin improve survival hl60 leukemia model p = 0.0018 conclusion scid mouse human tumor model appear reflect clinical situation clinically active chemotherapeutic drug similarly active scid mouse model therefore scid mouse model may useful test new chemotherapeutic agent various human cancer type 
test number established human tumor cell line early passage breast cancer uacc2150 melanoma cell uacc1273 growth scid mouse tumor response conventional chemotherapeutic drug establish melanoma a375 c81-61 colon sw480 lung a549 lymphomoblastoid leukemia lcl-b promyelocytic leukemia hl60 prostate pc-3 du145 breast mcf7 cell line inject subcutaneous s.c. intraperitoneal i.p. mammary fat pad mfp site tumor volume growth curve survival curve establish various tumor cell line carmustine bcnu cisplatin cddp cyclophosphamide cpa doxorubicin dacarbazine dtic tamoxifen vincristine inject s.c. i.p. chemotherapeutic drug effect tumor volume survival determine tumor growth occur cell type i.p. injection 90 mortality occur within 26 60 day except early passage melanoma cell line uacc1273 mortality occur within approximately 90 day mcf7 breast model treatment tamoxifen p 0.001 cpa p 0.0001 result significant tumor growth delay compare control group bcnu cddp result significant tumor growth delay relative control sw480 colon cancer p 0.0014 a375 melanoma p 0.0001 model respectively cpa doxorubicin improve survival hl60 leukemia model p = 0.0018 scid mouse human tumor model appear reflect clinical situation clinically active chemotherapeutic drug similarly active scid mouse model therefore scid mouse model may useful test new chemotherapeutic agent various human cancer type 
investigate chemotherapy agent interact leukemic cell death pathway examine apoptosis human lymphoblastic leukemia cell nalm-6 molt-4 treat various anticancer drug etoposide vp-16 camptothecin cpt adriamycin adr cytosine arabinoside ara-c methotrexate mtx 6 mercaptopurine 6mp cyclophosphamide cpm vincristine vcr prednisolone prd flow cytometric procedure proportion apoptotic cell estimate presence cell fractional dna content dna histograms incubation drug-treated cell dna extraction buffer treatment ara-c cpt vp-16 adr result rapid apoptosis 40-60 apoptotic cell 8 h. treatment mtx vcr 6mp prd induce apparent apoptosis 12 h treatment drug result apoptosis 50 mtx 20-30 6mp vcr 5-10 prd apoptotic cell respectively 24 h. cpm induce apoptosis 10-20 apoptotic cell 10 -6 m higher dose 10 -5 m cause rapid cell death necrosis cell cycle position apoptotic cell assess terminal deoxynucleotidyl transferase tdt assay dna strand break combine dna staining mtx ara-c cpt vp-16 adr preferentially induce apoptosis s phase prd 6mp induce apoptosis g1 phase g1 s phase respectively cpm show cell cycle phase specificity finding suggest susceptibility cell apoptosis sole determinant cellular sensitivity cytotoxic drug 
paclitaxel docetaxel series new analog synthesize 14beta-hydroxy-10-deacetylbaccatin iii 14-oh-dab natural diterpene closely related core synthon 2 prototype test vitro growth-inhibitory activity different human cancer cell line include express classic multidrug-resistant mdr phenotype mcf-7 adrr cem vblr 14-oh-dab derivative show enhance anti-proliferative activity compare parent compound mdr-positive cancer cell line particularly idn 5109 show 25 30-fold higher activity paclitaxel fold change activity paclitaxel analog ic50 paclitaxel/ic50 analog mdr-positive cell line calculate significant correlation observe far mdr-negative mda-mb 231 cell concern docetaxel idn 5109 exhibit potent activity paclitaxel basis datum obtain cell growth inhibition select active compound study effect cell cycle cell cycle analysis show compound test able induce cell cycle block g2/m concentration-dependent manner amount cell block measure g1/g2 ratio correlate significantly p 0.001 apoptosis evaluate sub-g1 region dna fragmentation thereby suggest g2/m-blocked cell undergo apoptosis confirm occurrence apoptosis system dna gel agarose electrophoresis perform show typical ladder pattern 
oxaliplatin classical 5-fluorouracil 5-fu non-classical ag337 thymidylate synthase inhibitor show promising activity treatment cancer study investigate cytotoxic effect oxaliplatin combination 5-fu ag337 culture human colon ht29 caco2 breast mcf-7 mda-mb-231 ovarian 2008 cancer cell line derive counterpart select resistance 5-fu ht29-5-fu doxorubicin mcf-7mdr cisplatin 2008c13 therapeutic experiment conduct mouse bear colon-ht29 xenograft gr hormone-independent mammary carcinoma model vitro oxaliplatin show potent cytotoxic activity colon ic50 2.1 / 1.1 5.9 / 1.7 microm ovarian ic50 = 10 / 1.6 microm breast cancer cell ic50 7.4 / 2.7 17.9 / 7.1 microm oxaliplatin potent inhibitor dna synthesis bind cellular dna surprisingly overall amount oxaliplatin dna binding significantly inferior induce isocytotoxic concentration cisplatin ht29 p = 0.026 vitro synergistic antiproliferative effect observe oxaliplatin add 5-fu ag337 synergistic effect combination maintain colon ht29-5-fu cancer cell vivo 5-fu increase significantly antitumor activity oxaliplatin ht29 xenograft p = 0.0036 similarly 5-fu ag337 increase activity oxaliplatin gr tumor model p = 0.0012 datum may encourage clinical investigation oxaliplatin combination classical non-classical thymidylate synthase inhibitor treatment human cancer 
theoretical pharmacologic benefit regional vs. systemic chemotherapy define concentration response behavior cytostatic drug optimal exposure time describe human cancer cell line ht29 nmg64/84 fresh human tumor cell suspension human tumor colony assay htca theoretical pharmacological advantage 5.8 6 adriamycin adm 8 cisplatinum cddp 6.3 epidoxorubicin epi 22 58 5-fluorouracil 5fu 4.6 mitomycin c mmc 6.3 mitoxantrone nov drug differ cytotoxic potency vitro thus also potential efficacy regional chemotherapy however 5-fluorodeoxyuridine 5fudr exert cytotoxicity dependent exposure time concentration average elevation test concentration 1 lg double response fresh human tumor cell suspension result clinical consideration optimal time define regional chemotherapy strategy hepatic artery infusion intraperitoneal instillation chemoembolisation perform institution 
effect methotrexate mtx 6-mercaptopurine 6-mp metabolism study four human leukemic cell line vitro ccrf-cem wi-l2 tbj hl-60 express thiopurine methyltransferase tpmt activity cell grow horse serum-supplemented rpmi 1640 medium add 4 microm 6-mp 4 microm 6-mp 20 nm mtx presence mtx result 2.1 1.7 2.4 8-fold increase concentration methylmercaptopurine ribonucleotide mmprp cem wi-l2 tbj hl-60 cell respectively p 0.0008 concentration 6-thioguanine nucleotide 6 tgn increase 1.9 1.4 2.4 1.9-fold cell line p 0.02 four cell line differ respect effect mtx consumption 6-mp medium cem consume 6-mp wi-l2 less 6-mp media contain mtx media contain 6-mp p = 0.005 0.02 respectively mtx affect consumption 6-mp tbj cell p = 0.17 media hl-60 cell grow contain detectable amount 6-mp end experiment simultaneous increase methylate 6-mp metabolite 6-tgn represent possible explanation synergism mtx 6-mp however clinical importance increase mmprp remain elucidate 
paclitaxel irinotecan important new anticancer agent combination two agent consider use variety advanced solid tumor since schedule-dependent effect combination may crucial use study interaction paclitaxel sn-38 active metabolite irinotecan various schedule four human cancer cell line culture cell growth inhibition 5 day determine use mtt assay effect drug combination ic80 level analyze isobologram method simultaneous exposure paclitaxel sn-38 24 h produce antagonistic subadditive protective effect human lung cancer cell line a549 breast cancer cell line mcf7 colon cancer cell line widr produce additive effect ovarian cancer cell line pa1 sequential exposure paclitaxel 24 h follow sn-38 24 h reverse sequence produce additive effect four cell line finding suggest sequential administration simultaneous administration may appropriate schedule therapeutic combination paclitaxel irinotecan continue preclinical clinical study provide insight assist determine optimal schedule combination clinical use 
report previously expression e. coli dutpase dute protect ht29 cell 5-fluorodeoxyuridine fdurd induce dna fragmentation cytotoxicity study report characterize ability dute expression one ht29 clone dute7 alter effect treatment fdurd thymidylate synthase ts inhibitor addition develop two hutu80 dute-expressing clone use plncx-dute retroviral construct test sensitivity fdurd-induced dna fragmentation cytotoxicity dute retroviral expression system dute antibody develop facilitate generation screening dute-expressing clone ht29 hutu80 clone express dute test drug-induced dna damage either alkaline elution pulsed field gel electrophoresis drug-induced loss clonogenicity follow 24-h treatment 100 microm cb3717 500 nm methotrexate mtx dute7 cell significantly less sensitive drug-induced loss clonogenicity con3 cell dute7 cell also resistant cb3717-induced dna fragmentation 24 h. however follow 48-h treatment cb3717 mtx difference survival con3 dute7 cell even though dna damage still greatly attenuate dute7 cell line addition expression dute two hutu80 clone 80 c 80 k protect cell fdurd-induced dna damage cytotoxicity conclude role uracil misincorporation subsequent dna damage cytotoxicity induce ts inhibitor ht29 cell time dependent cytotoxicity cause long-term exposure drug largely independent resultant dna damage cell line inability dute protect hutu80 cell fdurd suggest significance uracil misincorporation result ts inhibition vary among cell line 
platinum agent frequently combine ifosfamide mesna originally coadminister protect ifosfamide side effect might also react platinum agent combination malignant glioma cell incubate cisplatin carboplatin mesna cell number measure count mtt-test cell free solution mesna turn mtt blue farmazan product mesna effect cell cell-line specific penetrate u87 cell without effect growth reduce cell number c6 t98g cell alter u251 cell concentration cisplatin killing 50 cell 7 x 10 -7 c6 9.7 x 10 -6 t98g 1.2 x 10 -5 u251 2.4 x 10 -4 u87 cell effect carboplatin require 3-10 time higher concentration mesna protect cell line cytotoxicity platinum agent clinical study specify detail infusion schedule mesna platinum agent 
